0001178913-25-00031420-F InMode Ltd. 20250204202502040704320704340704340434 0 0001178913-25-000314 20-F 106 20241231 20250204 20250204 InMode Ltd. 0001742692 3845 000000000 L3 1231 20-F 34 001-39016 25585279 TAVOR BUILDING, SHA?AR YOKNEAM POB 533 YOKNEAM L3 2069200 972-4-9097470 TAVOR BUILDING, SHA?AR YOKNEAM POB 533 YOKNEAM L3 2069200 20-F 1 zk2532597.htm 20-F InMode Ltd. - 1742692 - 2025 In U.S. dollars per Ordinary Share Including, for 2022, payments amounting $12 million for Amendment to the Investments Law and settlements with the Israeli tax authority. See note 13a(2)(b). falseFY20240001742692P7Y4MRevenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Companyâ€™s total revenues, or Companyâ€™s net accounts receivable, in any fiscal year presented. As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029. Consists of non-current accounts receivable, net and other investments Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission. http://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2024#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrent 0001742692inmd:TwoThousandsEighteenIncentivePlanMember 2024-12-31 0001742692 2023-12-31 0001742692 2024-01-01 2024-12-31 0001742692 2024-12-31 0001742692inmd:ExercisePriceRangeOneMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeOneMember 2024-12-31 0001742692inmd:ExercisePriceRangeTwoMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeTwoMember 2024-12-31 0001742692inmd:ExercisePriceRangeThreeMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeThreeMember 2024-12-31 0001742692inmd:ExercisePriceRangeFourMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeFourMember 2024-12-31 0001742692inmd:ExercisePriceRangeFiveMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeFiveMember 2024-12-31 0001742692inmd:ExercisePriceRangeSixMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeSixMember 2024-12-31 0001742692inmd:ExercisePriceRangeSevenMember 2024-01-01 2024-12-31 0001742692inmd:ExercisePriceRangeSevenMember 2024-12-31 0001742692us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0001742692us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001742692us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001742692us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001742692us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001742692us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001742692us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-12-31 0001742692us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001742692us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001742692 2022-01-01 2022-12-31 0001742692us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001742692us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001742692us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001742692us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001742692inmd:EmployeesMemberinmd:TwoThousandsEighteenIncentivePlanMember 2024-01-01 2024-12-31 0001742692inmd:EmployeesMemberinmd:TwoThousandsEighteenIncentivePlanMember 2023-01-01 2023-12-31 0001742692inmd:EmployeesMemberinmd:TwoThousandsEighteenIncentivePlanMember 2022-01-01 2022-12-31 0001742692us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001742692inmd:TwoThousandsEighteenIncentivePlanMember 2024-01-01 2024-12-31 0001742692us-gaap:IPOMember 2020-09-01 2020-09-30 0001742692 2024-05-01 2024-05-31 0001742692 2024-09-01 2024-09-30 0001742692us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001742692us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001742692us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001742692 2023-01-01 2023-12-31 0001742692inmd:TwoThousandsEighteenIncentivePlanMemberus-gaap:SubsequentEventMember 2025-01-01 2025-01-24 0001742692inmd:ShareRepurchaseProgramMember 2024-01-01 2024-12-31 0001742692 2022-12-31 0001742692 2021-12-31 0001742692inmd:InmodeLtdAndIsraeliSubsidiariesMember 2024-01-01 2024-12-31 0001742692inmd:InmodeLtdAndIsraeliSubsidiariesMember 2023-01-01 2023-12-31 0001742692inmd:InmodeLtdAndIsraeliSubsidiariesMember 2022-01-01 2022-12-31 0001742692inmd:SubsidiariesOutsideIsraelMember 2024-01-01 2024-12-31 0001742692inmd:SubsidiariesOutsideIsraelMember 2023-01-01 2023-12-31 0001742692inmd:SubsidiariesOutsideIsraelMember 2022-01-01 2022-12-31 0001742692country:IL 2024-01-01 2024-12-31 0001742692country:IL 2023-01-01 2023-12-31 0001742692country:IL 2022-01-01 2022-12-31 0001742692inmd:RegulationsMember 2024-01-01 2024-12-31 0001742692 2021-11-15 0001742692inmd:AmendmentAdvantageExemptionMember 2021-11-15 0001742692inmd:IsraeliTaxAuthorityMember 2023-12-31 0001742692srt:MinimumMemberinmd:SubsidiariesOutsideIsraelMember 2024-01-01 2024-12-31 0001742692srt:MaximumMemberinmd:SubsidiariesOutsideIsraelMember 2024-01-01 2024-12-31 0001742692inmd:SubsidiaryInUnitedStatesMember 2024-12-31 0001742692inmd:SubsidiaryInStateMember 2024-12-31 0001742692srt:MinimumMember 2024-01-01 2024-12-31 0001742692srt:MaximumMember 2024-01-01 2024-12-31 0001742692srt:MinimumMember 2023-01-01 2023-12-31 0001742692srt:MaximumMember 2023-01-01 2023-12-31 0001742692srt:ScenarioForecastMember 2025-01-01 2025-12-31 0001742692srt:MinimumMemberus-gaap:ComputerEquipmentMember 2024-12-31 0001742692srt:MaximumMemberus-gaap:ComputerEquipmentMember 2024-12-31 0001742692srt:MinimumMemberus-gaap:ToolsDiesAndMoldsMember 2024-12-31 0001742692srt:MinimumMemberus-gaap:EquipmentMember 2024-12-31 0001742692srt:MaximumMemberus-gaap:ToolsDiesAndMoldsMember 2024-12-31 0001742692srt:MaximumMemberus-gaap:EquipmentMember 2024-12-31 0001742692us-gaap:ComputerEquipmentMember 2024-12-31 0001742692us-gaap:ComputerEquipmentMember 2023-12-31 0001742692us-gaap:OfficeEquipmentMember 2024-12-31 0001742692us-gaap:OfficeEquipmentMember 2023-12-31 0001742692us-gaap:ToolsDiesAndMoldsMember 2024-12-31 0001742692us-gaap:ToolsDiesAndMoldsMember 2023-12-31 0001742692us-gaap:LeaseholdImprovementsMember 2024-12-31 0001742692us-gaap:LeaseholdImprovementsMember 2023-12-31 0001742692us-gaap:CommonStockMember 2021-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001742692us-gaap:RetainedEarningsMember 2021-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001742692us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001742692us-gaap:CommonStockMember 2022-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001742692us-gaap:RetainedEarningsMember 2022-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001742692us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001742692us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001742692us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001742692us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001742692us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001742692us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001742692us-gaap:CommonStockMember 2024-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001742692us-gaap:RetainedEarningsMember 2024-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001742692us-gaap:TreasuryStockCommonMember 2024-12-31 0001742692us-gaap:TreasuryStockCommonMember 2021-12-31 0001742692us-gaap:TreasuryStockCommonMember 2022-12-31 0001742692us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001742692us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001742692us-gaap:TreasuryStockCommonMember 2023-12-31 0001742692us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001742692us-gaap:RetainedEarningsMember 2023-12-31 0001742692us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001742692us-gaap:CommonStockMember 2023-12-31 0001742692dei:BusinessContactMember 2024-01-01 2024-12-31 0001742692inmd:LeaseAgreementMember 2018-05-01 2018-05-31 0001742692srt:WarehouseMemberinmd:LeaseAgreementMember 2018-05-01 2018-05-31 0001742692srt:OfficeBuildingMemberinmd:LeaseAgreementMember 2020-08-01 2020-08-31 0001742692srt:OfficeBuildingMemberinmd:LeaseAgreementMember 2022-07-01 2022-07-31 0001742692srt:OfficeBuildingMemberinmd:LeaseAgreementMember 2022-07-01 0001742692us-gaap:VehiclesMemberinmd:LeaseAgreementMember 2018-05-31 0001742692srt:OfficeBuildingMemberinmd:LeaseAgreementMember 2020-08-31 0001742692country:US 2024-01-01 2024-12-31 0001742692country:US 2023-01-01 2023-12-31 0001742692country:US 2022-01-01 2022-12-31 0001742692inmd:OtherCountryMember 2024-01-01 2024-12-31 0001742692inmd:OtherCountryMember 2023-01-01 2023-12-31 0001742692inmd:OtherCountryMember 2022-01-01 2022-12-31 0001742692inmd:MinimalInvasiveMember 2024-01-01 2024-12-31 0001742692inmd:MinimalInvasiveMember 2023-01-01 2023-12-31 0001742692inmd:MinimalInvasiveMember 2022-01-01 2022-12-31 0001742692inmd:HandsFreeMember 2024-01-01 2024-12-31 0001742692inmd:HandsFreeMember 2023-01-01 2023-12-31 0001742692inmd:HandsFreeMember 2022-01-01 2022-12-31 0001742692inmd:NonInvasiveMember 2024-01-01 2024-12-31 0001742692inmd:NonInvasiveMember 2023-01-01 2023-12-31 0001742692inmd:NonInvasiveMember 2022-01-01 2022-12-31 0001742692country:IL 2024-12-31 0001742692country:IL 2023-12-31 0001742692country:US 2024-12-31 0001742692country:US 2023-12-31 0001742692inmd:OtherCountryMember 2024-12-31 0001742692inmd:OtherCountryMember 2023-12-31 0001742692srt:EuropeMember 2022-01-01 2022-12-31 0001742692srt:EuropeMember 2023-01-01 2023-12-31 0001742692srt:EuropeMember 2024-01-01 2024-12-31 0001742692inmd:CapitalEquipmentMember 2024-01-01 2024-12-31 0001742692inmd:CapitalEquipmentMember 2023-01-01 2023-12-31 0001742692inmd:CapitalEquipmentMember 2022-01-01 2022-12-31 0001742692inmd:ConsumablesAndServiceRevenuesMember 2022-01-01 2022-12-31 0001742692inmd:ConsumablesAndServiceRevenuesMember 2023-01-01 2023-12-31 0001742692inmd:ConsumablesAndServiceRevenuesMember 2024-01-01 2024-12-31 0001742692srt:AsiaMember 2022-01-01 2022-12-31 0001742692srt:AsiaMember 2023-01-01 2023-12-31 0001742692srt:AsiaMember 2024-01-01 2024-12-31 0001742692srt:ChiefExecutiveOfficerMember 2024-01-01 2024-12-31 0001742692srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0001742692us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001742692us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001742692us-gaap:MunicipalBondsMember 2024-12-31 0001742692us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0001742692us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001742692us-gaap:CertificatesOfDepositMember 2024-12-31 0001742692us-gaap:CertificatesOfDepositMember 2023-12-31 0001742692us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001742692us-gaap:FairValueInputsLevel2Member 2024-12-31 0001742692us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001742692us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001742692us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember 2023-12-31 0001742692us-gaap:FairValueInputsLevel2Member 2023-12-31 0001742692us-gaap:MunicipalBondsMember 2023-12-31 0001742692us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember 2023-12-31 0001742692inmd:HomeSkinnovationsLtdMember 2024-01-01 2024-12-31 0001742692inmd:HomeSkinnovationsLtdMember 2023-01-01 2023-12-31 0001742692inmd:HomeSkinnovationsLtdMember 2022-01-01 2022-12-31 0001742692inmd:ExpensesIncomeMemberinmd:SubsidiaryOfHomeSkinnovationsLtdMember 2024-01-01 2024-12-31 0001742692inmd:ExpensesIncomeMemberinmd:SubsidiaryOfHomeSkinnovationsLtdMember 2023-01-01 2023-12-31 0001742692inmd:ExpensesIncomeMemberinmd:SubsidiaryOfHomeSkinnovationsLtdMember 2022-01-01 2022-12-31 0001742692inmd:SpaMedicalInternationalLsrlMember 2021-01-01 2021-12-31 0001742692inmd:SpaMedicalInternationalLsrlMember 2023-01-01 2023-12-31 0001742692inmd:SpaMedicalInternationalLsrlMember 2022-01-01 2022-12-31 0001742692inmd:HimalayaFamilyOfficeConsultingLtdMember 2024-01-01 2024-12-31 0001742692inmd:HimalayaFamilyOfficeConsultingLtdMember 2023-01-01 2023-12-31 0001742692inmd:HimalayaFamilyOfficeConsultingLtdMember 2022-01-01 2022-12-31 0001742692inmd:HomeSkinnovationsLtdMember 2024-12-31 0001742692inmd:HomeSkinnovationsLtdMember 2023-12-31 0001742692inmd:HimalayaFamilyOfficeConsultingLtdMember 2024-12-31 0001742692inmd:HimalayaFamilyOfficeConsultingLtdMember 2023-12-31 0001742692inmd:SubsidiaryOfHomeSkinnovationsLtdMember 2024-12-31 0001742692inmd:SubsidiaryOfHomeSkinnovationsLtdMember 2023-12-31 0001742692inmd:MedimorMemberinmd:SharePurchaseAndShareholdersAgreementMember 2019-11-30 0001742692inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:SharePurchaseAndShareholdersAgreementMember 2019-11-30 0001742692inmd:MedimorMemberinmd:SharePurchaseAndShareholdersAgreementMember 2023-11-30 0001742692inmd:MedimorMemberinmd:TwoPurchaseAndShareholdersAgreementsMember 2024-12-31 0001742692inmd:MedimorMemberinmd:TwoPurchaseAndShareholdersAgreementsMember 2023-12-31 0001742692inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:TwoPurchaseAndShareholdersAgreementsMember 2024-12-31 0001742692inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:TwoPurchaseAndShareholdersAgreementsMember 2023-12-31 iso4217:ILSxbrli:shares xbrli:pure xbrli:shares iso4217:USD iso4217:USDxbrli:shares iso4217:ILS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â FORM 20-F Â Â (Mark One) Â â˜Â Â Â Â Â Â Â Â Â Â REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934â€‰â€‰ Â OR Â â˜’Â Â Â Â Â Â Â Â Â Â ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‰â€‰ Â For the fiscal year endedÂ December 31, 2024 Â OR Â â˜Â Â Â Â Â Â Â Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‰â€‰ Â OR Â â˜Â Â Â Â Â Â Â Â Â Â SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‰â€‰ Â Date of event requiring this shell company report Â For the transition period from _____ to _____ Â Commission file number 001-39016 Â Â InMode Ltd. (Exact name of Registrant as specified in its charter) Â N/A (Translation of Registrantâ€™s name into English) Â Israel (Jurisdiction of incorporation or organization) Â Tavor Building, Shaâ€™ar Yokneam, P.O. Box 533 Yokneam, 2069206, Israel (Address of principal executive offices) Â Moshe Mizrahy +972-4-9096313 Tavor Building, Shaâ€™ar Yokneam, P.O. Box 533 Yokneam, 2069206, Israel (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Â Securities registered or to be registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Ordinary shares, par value NIS 0.01 per ordinary share Â INMD Â Nasdaq Global Select Market Â Securities registered or to be registered pursuant to Section 12(g) of the Act. Â None (Title of Class) Â Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. Â None (Title of Class) Â Â Indicate the number of outstanding shares of each of the issuerâ€™s classes of capital or common stock as of the close of the period covered by the annual report: 69,558,670 Ordinary Shares, par value NIS 0.01 per share. Â Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Â Yes â˜’ No â˜ Â If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Â Yes â˜ No â˜’ Â Note â€” Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections. Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Â Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Â Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filerÂ â˜’ Accelerated filer â˜ Non-accelerated filer â˜ Â Â Emerging growth company â˜ Â If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â The above number of Ordinary Shares outstanding does not include a total of 18,025,003 Ordinary Shares held at December 31,

2024, as treasury shares, all of which were repurchased by InMode Ltd. Â â€ The term â€œnew or revised financial accounting standardâ€ refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. Â Indicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. â˜´ Â If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. â˜ Â Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§240.10D-1(b). â˜ Â Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: Â U.S. GAAP â˜´ International Financial Reporting Standards as issued by the International Accounting Standards Board â˜ Â Â Â Â Â Â Â Â Â Other â˜ Â If â€œOtherâ€ has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. N/A Â â˜ Item 17 â˜ Item 18 Â If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Â Yes â˜ No â˜´ Â (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) Â Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Â Yes â˜ No â˜ Â TABLE OF CONTENTS Page PART I Â 1 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 1 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3. KEY INFORMATION 1 ITEM 4. INFORMATION ON THE COMPANY 31 ITEM 4A. UNRESOLVED STAFF COMMENTS 66 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 66 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 73 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 91 ITEM 8. FINANCIAL INFORMATION 93 ITEM 9. THE OFFER AND LISTING 93 ITEM 10. ADDITIONAL INFORMATION 94 ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 105 Â ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 105 PART II 106 ITEM 13. DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES 106 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 106 ITEM 15. CONTROLS AND PROCEDURES 106 ITEM 16. [RESERVED] 107 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 107 ITEM 16B. CODE OF ETHICS 107 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 107 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 107 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 108 ITEM 16F. CHANGE IN REGISTRANTâ€™S CERTIFYING ACCOUNTANT 108 ITEM 16G. CORPORATE GOVERNANCE 108 ITEM 16H. MINE SAFETY DISCLOSURE 110 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 110 Â ITEM 16J. INSIDER TRADING POLICIES 111 Â ITEM 16K. CYBERSECURITY 111 PART III 111 ITEM 17. FINANCIAL STATEMENTS 111 ITEM 18. FINANCIAL STATEMENTS 111 ITEM 19. EXHIBITS 112 SIGNATURES 113 - i - Certain Definitions Â In this Annual Report on Form 20-F, unless the context otherwise requires: Â â€¢ references to â€œInMode,â€ the â€œCompany,â€ â€œus,â€ â€œweâ€ and â€œourâ€ refer to InMode Ltd., an Israeli company, and its consolidated subsidiaries; Â â€¢ references to â€œordinary shares,â€ â€œour sharesâ€ and similar expressions refer to the Companyâ€™s ordinary shares; Â â€¢ references to â€œdollars,â€ â€œU.S. dollarsâ€ and â€œ$â€ are to U.S. Dollars; Â â€¢ references to â€œNISâ€ are to New Israeli Shekels, the Israeli currency; Â â€¢ references to the â€œCompanies Lawâ€ are to Israelâ€™s Companies Law, 5759-1999, as amended; Â â€¢ references to the â€œSECâ€ are to the U.S. Securities and Exchange Commission; and Â â€¢ references to â€œU.S. GAAPâ€ are to U.S. generally accepted accounting principles. Forward-Looking Statements Â The sections entitled â€œItem 3. Key Information â€“ D. Risk Factorsâ€ â€œItem 4. Information on the Companyâ€ and â€œItem 5. Operating and Financial Review and Prospectsâ€ and elsewhere in this Annual Report on Form 20-F contain forward-looking statements that are subject to substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Annual Report on Form 20-F regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œpredict,â€ â€œproject,â€ â€œwill,â€ â€œwouldâ€ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Unless otherwise indicated in this Annual Report on Form 20-F, the basis for any statements regarding our competitive position is based on our own assessment and knowledge of the market in which we operate. Â These forward-looking statements include, among other things, statements about: Â â€¢ our ability to identify and penetrate new markets for our products and technology; Â â€¢ our ability to innovate, develop and commercialize our existing and new products and to expand beyond our traditional customer base; Â â€¢ our ability to obtain and maintain regulatory clearances; Â â€¢ the impact of the political, economic and military instability in Israel and the ongoing Israel-Hamas war on our ability to operate and develop, manufacture and deliver products and components; Â â€¢ our expectation regarding the safety and efficacy of our products; Â â€¢ the commercial experience of our management team; Â â€¢ our commercialization, marketing and manufacturing capabilities and strategy; Â â€¢ our estimates regarding the potential market opportunity for our products; Â â€¢ developments and projections relating to our competitors or our industry; Â â€¢ our ability to differentiate and distinguish our products from those of our competitors; Â â€¢ our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Â â€¢ our sales and marketing capabilities and strategy in the United States and internationally; Â â€¢ the implementation of our business model, strategic plans for our business, products and technology; Â â€¢ our ability to attract or retain key personnel; Â â€¢ the impact of climate-related events and increasing regulatory requirements and security on our operating costs and business operations; Â â€¢ our intellectual property portfolio and position and our ability to protect our intellectual property rights; and Â â€¢ our assessment of the impact to us of any third-party litigation claiming patent infringement. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Forward-looking statements are based on our managementâ€™s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our managementâ€™s beliefs and assumptions, are not guarantees of future performance or development, and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 20-F, particularly in the section entitled â€œItem 3. Key Information â€“ D. Risk Factors,â€ which could cause actual results or events to differ materially from the forward-looking statements that we make. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements. Readers are encouraged to consult the Companyâ€™s reports made on Form 6-K, which are periodically filed with or furnished to the SEC. Â - ii - PART I Â ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Â Not applicable. Â ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Â Not applicable. Â ITEM 3. KEY INFORMATION Â A.Â Â Â Â Â Â Â [Reserved] Â B.Â Â Â Â Â Â Â Capitalization and Indebtedness Â Not applicable. C.Â Â Â Â Â Â Â Reasons for the Offer and Use of Proceeds Â Not applicable. Â D.Â Â Â Â Â Â Â Risk Factors Â Our business faces significant risks. You should carefully consider all of the information set forth in this Annual Report on Form 20-F and in our other filings with the SEC, including the following risk factors that we face and that are faced by our industry. Our business, financial condition or results of operations could be materially and adversely affected by any of these risks. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may have similar adverse effects on us. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors, including the risks described below and elsewhere in this Annual Report on Form 20-F and our other SEC filings. See â€œForward-Looking Statementsâ€ above. Â Summary Risk Factors Â Our business is subject to a number of risks of which you should be aware of before making an investment decision. These risks are discussed more fully in the â€œRisk Factorsâ€ section of this annual report. These risks include, but are not limited to, the following: Â â€¢ our success depends upon market acceptance of our products; Â â€¢ if there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, resulting in unfavorable operating results; Â â€¢ the success and continued development of our products depends, in part, upon maintaining strong relationships with physicians and other healthcare professionals; Â â€¢ we rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability; Â â€¢ the failure to attract and retain key personnel could adversely affect our business; Â â€¢ the impact of the political, economic and military instability in Israel and the ongoing Israel-Hamas war and other conflicts in the region could impede our ability to operate and develop, manufacture and deliver products and components and harm our financial results; Â â€¢ the impact of actual or threatened tariffs imposed on our products or their respective components; Â â€¢ if we do not continue to develop and commercialize new products and identify new markets for our products and technologies, we may not remain competitive or expand beyond our traditional customer base, and our revenues and operating results could suffer; Â 1 â€¢ product liability suits could be brought against us due to defective material or design or misuse of our products and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates; Â â€¢ our products and operations are subject to extensive and continuing regulatory compliance obligations in the United States and other countries, and failure to meet those obligations could adversely harm our business; Â â€¢ we outsource almost all of the manufacturing of our products to a small number of manufacturing subcontractors. If our subcontractorsâ€™ operations are interrupted or if our orders exceed our subcontractorsâ€™ manufacturing capacity, we may not be able to deliver our products on time; Â â€¢ our operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security; Â â€¢ if we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology; Â â€¢ third parties have commenced and may in the future commence litigation against us claiming that our products infringe upon their patents or other intellectual property rights; Â â€¢ if we fail to obtain and maintain necessary FDA clearances for our products, if clearances for future products and proposed indications are delayed or not issued, if we or any of our third-party suppliers or manufacturers fail to comply with applicable regulatory requirements, or if there are regulatory changes, our commercial operations could be harmed; and Â â€¢ as a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and Nasdaq corporate governance rules and are permitted to file less information with the SEC than U.S. domestic public companies, which may limit the information available to holders of our ordinary shares. Â Risks Related to Our Business and Industry Â Our success depends upon market acceptance of our products. Â We design, develop, manufacture and commercialize innovative, minimally invasive and non-invasive surgical/medical products. We have developed products that apply our minimally invasive technology in plastic surgery, dermatology, gynecology and ophthalmology. We were established in 2008 and have expanded our product offerings to include fourteen product platforms: BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke,Â Morpheus8, EmpowerRF, Define, Envision, IgniteRFÂ andÂ OptimasMAX.Â In 2024 we introduced two new platforms, IgniteRFÂ andÂ OptimasMAX.Â If we fail to significantly penetrate current or new markets with our products or fail to properly manage the manufacturing and distribution of multiple products, our business, financial condition and results of operations could be negatively impacted. The success of our products depends on adoption and acceptance of our technology by user doctors. The rate of adoption and acceptance may be affected adversely by perceived issues relating to quality and safety, doctorsâ€™ reluctance to invest in new technologies, the cost of competitive treatments and widespread acceptance of other technologies. Our business strategy is based, in part, on our expectation that we will continue to make novel product introductions and upgrades that we can sell to new and existing users of our products and that we will be able to identify new markets for our existing technologies. Â To increase our revenues, we must: Â â€¢ continue to further penetrate our existing traditional customer base, including plastic and facial surgeons, aesthetic surgeons, dermatologists and obstetricians/gynecologists, or OB/GYNs, and drive recurring revenues by demonstrating to our customers that our products or product upgrades would be an attractive revenue-generating addition to their practices; Â â€¢ expand our customer base to include non-traditional customers, such as ear, nose and throat physicians, or ENTs, ophthalmologists, general practitioners and aesthetic clinicians; Â â€¢ leverage our existing technology to expand into new minimally invasive and non-invasive applications that either add to or significantly improve our current products; Â â€¢ increase our sales presence to target and expand our market globally; Â 2 â€¢ actively pursue business development opportunities, including potential acquisitions and strategic partnerships to augment our product and technology portfolio; and Â â€¢ expand and maintain our intellectual property and patent portfolio. Â In addition, the surgical aesthetic solutions market is highly competitive and dynamic and marked by rapid and substantial technological development and product innovations. Demand for our products could be diminished by equivalent or superior products and technologies offered by competitors. Â If there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, resulting in unfavorable operating results. Â Continued expansion of the global market for energy-based aesthetic procedures is a material assumption of our business strategy. Most procedures performed using our products are not reimbursable through government or private health insurance and are therefore elective procedures, the cost of which must be borne by the patient. The decision to utilize our products may therefore be influenced by a number of factors, including: Â â€¢ consumer disposable income and access to consumer credit; Â â€¢ the cost of procedures performed using our products; Â â€¢ the cost, safety and effectiveness of alternative treatments, including treatments which are not based upon laser or other energy-based technologies and treatments which use pharmaceutical products; Â â€¢ the success of our sales and marketing efforts; Â â€¢ the education of our customers and patients on the benefits and uses of our products compared to competitorsâ€™ products and technologies; and Â â€¢ consumer confidence, which may be impacted by economic and political conditions. Â If, as a result of these factors, there is not sufficient demand for the procedures performed with our products, practitioner demand for our products could decline, which could have a material adverse effect on our results of operations. Â The success and continued development of our products depends, in part, upon maintaining strong relationships with physicians and other healthcare professionals. Â If we fail to maintain our working relationships with physicians and other ancillary healthcare professionals, our products may not be developed and marketed in line with the needs and expectations of the professionals who use and support our products. If we are unable to maintain these strong relationships or form new relationships with physicians and other healthcare professionals beyond our traditional customer base, the development and marketing of our products could suffer, which could have a material adverse effect on our business, financial condition and results of operations. Â We rely heavily on our sales professionals to market and sell our products worldwide. If we are unable to hire, effectively train, manage, improve the productivity of and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability. Â Our success largely depends on our ability to hire, train, manage and improve the productivity levels of our sales professionals worldwide. We train our existing and recently recruited sales professionals to better understand our existing and new product technologies and how they can be positioned against our competitorsâ€™ products and increase the revenue of our customers. It may take time for the sales professionals to become productive, and there can be no assurance that recently recruited sales professionals will be adequately trained in a timely manner, that our direct sales productivity will improve or that we will not experience significant levels of attrition in the future. Â 3 Product liability suits could be brought against us due to defective material or design or misuse of our products and could result in expensive and time-consuming litigation, payment of substantial damages and an increase in our insurance rates. Â Our systems are inherently complex in design and require ongoing scheduled maintenance. Our products may malfunction when used by our customers. Additionally, if our products are alleged to be defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to substantial and costly litigation by our customers or their patients. Misusing our products or failing to adhere to operating guidelines could cause burns, scarring and tissue irregularities. In addition, if our operating guidelines are found to be inadequate, we may be subject to liability. Furthermore, our products are sold in jurisdictions that vary as to the specific qualifications or training required for purchasers or operators of the products. There is a risk that our products may be purchased or operated by physicians with varying levels of training and, in some cases, by practitioners, such as nurses, chiropractors and technicians, who may not be adequately trained. The purchase and use of our products by non-physicians or persons who lack adequate training may result in the misuse of our products, which could give rise to adverse treatment outcomes. If we are unable to prevent product malfunctions or misuse, or if we fail to do so in a timely manner, we could also experience, among other things, delays in the recognition of revenues or loss of revenues, particularly in the case of new products; legal actions by customers, patients and other third parties, which could result in substantial judgments against us or settlement costs; action by regulatory bodies; and diversion of development, engineering and management resources. Â Product liability claims could divert managementâ€™s attention from our core business, be expensive to defend and

result in sizable damage awards against us. In addition, such potential adverse effects may cause a significant increase in the premiums under our insurance policies. Further, the coverage limits of our product liability insurance policies may not be adequate to cover future claims. A successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations. Even if unsuccessful, such a claim could nevertheless have an adverse impact on us, due to damage to our reputation and diversion of management resources. Â We may have difficulty managing our growth, which could limit our ability to increase sales and cash flow. Â Since inception, we have experienced significant growth in our operations, and the number of our employees has significantly increased since inception. This growth has placed significant demands on our management, as well as our financial and operational resources. In order to achieve our business objectives, we will need to continue to grow our business. Continued growth would increase the challenges involved in: Â â€¢ implementing appropriate operational and financial systems; Â â€¢ expanding our sales and marketing infrastructure and capabilities; Â â€¢ ensuring compliance with applicable Food and Drug Administration, or FDA, and other regulatory requirements; Â â€¢ providing adequate training and supervision to maintain high quality standards; and Â â€¢ preserving our culture and values. Â If our growth continues, it will require that we continue to develop and improve our operational, financial and other internal controls. If we cannot scale and manage our business appropriately, we will not realize our projected growth and our financial results will suffer. Â The failure to attract and retain key personnel could adversely affect our business. Â Our success also will depend in large part on our ability to continue to attract, retain and motivate qualified and highly skilled personnel. Competition for highly skilled employees is intense. We may be unable to continue to attract and retain sufficient numbers of highly skilled employees. Our inability to attract and retain additional key employees or the loss of one or more of our current key employees could adversely affect our business, financial condition and results of operations. Â Our financial results may fluctuate from quarter to quarter. Â We base our production, inventory and operating expenditure levels on anticipated orders. If orders are not received when expected in any given quarter, expenditure levels could be disproportionately high in relation to sales for that quarter. A number of additional factors, over which we have limited control, may contribute to fluctuations in our financial results, including: Â â€¢ customer adoption of our products; Â â€¢ the willingness of individuals to pay directly for aesthetic medical procedures in light of the lack of reimbursement by third-party payors; Â 4 â€¢ continued availability of attractive equipment leasing terms for our customers, which may be negatively influenced by interest rate increases; Â â€¢ the impact of the political, economic and military instability in Israel and the ongoing Israel-Hamas war; Â â€¢ changes in our ability to obtain and maintain regulatory approvals and maintain compliance with applicable regulatory requirements; Â â€¢ actual or perceived breaches of, or failures relating to, privacy, data protection or data security; Â â€¢ positive or negative coverage in the media or clinical publications of our products or products of our competitors or industry; Â â€¢ increases in the length of our sales cycle; Â â€¢ performance of our independent distributors; Â â€¢ delays in, or failure of, product and component deliveries by our subcontractors and suppliers; Â â€¢ the impact on our operating costs and business operations by climate-related events and increasing regulatory requirements and security; and Â â€¢ the impact of global health crises on our business and general economic conditions. Â We rely on a limited number of suppliers, contract manufacturers and logistics partners for our products. A loss of any of these partners or delays at transition points such as harbors, straights and ports could negatively affect our business. Â We rely on a limited number of contract manufacturers, suppliers and logistics providers to manufacture and transport our products. Our reliance on a limited number of contract manufacturers for our products increases our risks, since we do not currently have alternative or replacement contract manufacturers beyond these key parties. In the event of interruption from any of our contract manufacturers or suppliers, we may not be able to increase capacity from other sources or develop alternate or secondary sources without incurring material additional costs and substantial delays. Furthermore, our primary facilities are located in Israel. Thus, our business could be affected if one or more of our suppliers, manufacturers or logistics partners are impacted by a natural disaster, an epidemic, the ongoing Israel-Hamas war and other conflicts in the region, or other interruption at a particular location. Interruptions in the development, manufacturing, and shipment of our products, could adversely impact our revenue, gross margins and operating results. Such interruptions may be due to, among other things, temporary closures of the facilities our contract manufacturers, and other vendors in ourÂ supplyÂ chain; restrictions or delays on transport or the import/export of goods and services from certain ports and harbors that we and our logistics partners use; and local quarantines or work stoppages. Â Competition among providers of energy-based devices for the medical aesthetics market is characterized by rapid innovation. If we do not continue to develop and commercialize new products and identify new markets for our products and technologies and expand beyond our traditional customer base, we may not remain competitive, and our revenues and operating results could suffer. Â The industry in which we operate is subject to continuous technological development and product innovation. If we do not continue to be innovative in the development of new products and applications, our competitive position will likely deteriorate as other companies successfully design and commercialize new products and applications. While we attempt to protect our products through patents and other intellectual property, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that compete directly with ours. We expect that any competitive advantage we may enjoy from our current and future innovations may diminish over time, as companies successfully respond to our, or create their own, innovations. Accordingly, our success depends in part on developing new and innovative applications of laser and other energy-based technology and identifying new markets for and applications of existing products to new customers and technology. Our future growth also depends, in part, on our ability to expand beyond our traditional customer base to ENTs, ophthalmologists, general practitioners and aesthetic clinicians. If we are unable to develop and commercialize new products and identify and penetrate new markets for our products and technology, our products and technology could become obsolete and our revenues and operating results could be adversely affected. Â 5 Our long-term growth depends on our ability to enhance our products, expand our indications, and develop and commercialize additional products. Â It is important to our business that we continue to enhance our products and develop and introduce new products. Developing products is expensive and time-consuming. The success of any new product offering or product enhancement to our current products will depend on several factors, including our ability to: Â â€¢ properly identify and anticipate physician and patient needs; Â â€¢ develop and introduce new products and product enhancements in a timely manner; Â â€¢ avoid infringing upon the intellectual property rights of third parties; Â â€¢ demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials; Â â€¢ obtain the necessary regulatory clearances or approvals for expanded indications, new products or product modifications; and Â â€¢ be fully FDA-compliant with marketing of new devices or modified products. Â If we are not successful in expanding our indications and developing and commercializing new products and product enhancements, our ability to increase our revenue may be impaired, which could have a material adverse effect on our business, financial condition and results of operations. Â Our inability to compete effectively with our competitors may prevent us from achieving significant market penetration or improving our operating results. Â Our products compete against products offered by public companies, including AbbVie Inc., Cutera, Inc., Apyx Medical Corporation, Venus Concept Inc. and Sisram Medical Ltd, as well as by private companies, such as Cynosure LLC, Lumenis Ltd., BTL Aesthetics, Inc. and Candela Medical Inc. Competition with these companies could result in reduced prices and profit margins and loss of market share, any of which could harm our business, financial condition and results of operations. We also face competition from medical aesthetic products, including BotoxÂ®, hyaluronic acid injections and collagen injections, and aesthetic procedures, such as face lifts, liposuction, sclerotherapy, electrolysis, chemical peels and laser procedures, which may offer a broader range of medical and non-medical products and technologies that are more readily available to customers at a lower cost. Our ability to compete effectively depends upon our ability to distinguish the Company and our products from our competitors and their products and includes the following factors: Â â€¢ product performance; Â â€¢ product pricing; Â â€¢ product safety; Â â€¢ intellectual property protection; Â â€¢ quality of customer support; Â â€¢ success and timing of new product development and introductions; and Â â€¢ development of successful distribution channels. Â Furthermore, potential customers also may need to recoup the cost of expensive products that they already have purchased from our competitors and may decide not to purchase our products or to delay such purchases. If we are unable to achieve continued market penetration, we will be unable to compete effectively, and our business will be harmed. Â The introduction of disruptive technological breakthroughs, whether pharmaceutical or other newer therapeutic solutions, may present an additional threat to our success in our target markets. Â The medical technology industry is intensely competitive. Pharmaceutical alternative treatments compete vigorously with traditional laser and other energy-based procedures, such as those carried out with our products. Some pharmaceutical companies, academic and research institutions or others may develop new, non-invasive or minimally invasive therapies that are more effective, more convenient or less expensive than our current or future products. The introduction of new technologies, along with these potential new therapies, could result in increased competition or make our products obsolete. Moreover, we could expand our business to include new, non-invasive or minimally invasive therapies which may compete with our current product offerings. We may not be able to respond effectively to technological changes and emerging industry standards or to successfully identify, develop or support new technologies or enhancements to existing products in a timely and cost-effective manner. Any such developments could have a material adverse effect on our business, financial condition and results of operations. Â 6 Our markets are characterized by evolving technological standards and changes in customer requirements, and we may not be able to react to such changes and introduce new products in a timely manner. Â The aesthetics market is characterized by extensive research and development, technological change, frequent modifications and enhancements, innovations, new applications, evolving industry standards, and changes in customer requirements. Our future growth depends, in part, on our ability to introduce new products on a timely basis, as well as to introduce other product enhancements that address the evolving customer needs. This requires us to design, develop, manufacture, assemble, test, market and support these new products or product enhancements on a timely and cost-effective basis. It also requires continued substantial investment in research and development. Â During each stage of the research and development process, we may encounter obstacles that could delay development and consequently increase our expenses. This may ultimately force us to abandon a potential product in which we have already invested substantial time and resources. Technologies in development could prove to be more complex than initially understood or not scientifically or commercially viable. Even if we develop new products and technologies ahead of our competitors, we will still need to obtain the requisite regulatory approvals for such products, including from public agencies, such as the FDA, before we can commercially distribute them. We cannot assure you that we will successfully identify new technological opportunities, develop and bring new or enhanced products to market, obtain sufficient patent or other intellectual property protection for such new or enhanced products, or obtain the necessary regulatory approvals in a timely and cost-effective manner, or, if such products are introduced, that those products will achieve market acceptance. Our failure to do so, or to address the technological changes and challenges in our markets, could have a material adverse effect on our business, financial condition and results of operations. Â We rely on our own direct sales force to sell our products in certain territories, which may result in higher fixed costs than our competitors and may slow our ability to reduce costs in the face of a sudden decline in demand for our products. Â We rely on our own direct sales force to market and sell our products in certain territories. Some of our competitors rely predominantly on independent sales agents and third-party distributors. A direct sales force may subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we will bear associated with employee benefits, and training and managing sales personnel. As a result, we could be at a competitive disadvantage. Additionally, these fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products, which could have a material adverse effect on our business, financial condition and results of operations. Â To successfully market and sell our products internationally, we must address many issues with which we have little or no experience. Â International (non-U.S.) sales accounted for approximately 38% of our total revenue for the year ended December 31, 2024. We believe that an increasing percentage of our future revenue will come from international sales as we continue to expand our operations and develop opportunities in additional international territories. We currently depend on third-party distributors and a direct sales team in certain regions to sell our products internationally. If these distributors or direct sales personnel underperform, we may be unable to increase or maintain our level of international revenue. We will need to attract additional distributors to grow our business and expand the territories in which we sell our products. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations. If current or future distributors do not perform adequately, or we are unable to locate distributors in particular geographic areas, we may not realize expected international revenue growth. Additionally, we expect to expand our direct sales force in the United States, Canada, Europe and Asia. If we are unable to do so successfully, our revenue and revenue growth from international operations will be adversely affected. Â International sales are subject to a number of risks, including: Â â€¢ difficulties in staffing and managing our foreign operations; Â â€¢ difficulties in penetrating markets in which our competitorsâ€™ products are more established; Â 7 â€¢ reduced protection for intellectual property rights in some countries; Â â€¢ export restrictions, trade regulations and foreign tax laws; Â â€¢ fluctuating foreign currency exchange rates; Â â€¢ obtaining and maintaining foreign certification and compliance with other regulatory requirements; Â â€¢ customs clearance and shipping delays; and Â â€¢ political and economic instability. Â If one or more of these risks were realized, it could require us to dedicate significant resources to remedy the situation, and if we are unsuccessful at finding a solution, our revenue may decline. Â The impact of the ongoing Israel-Hamas war could impede our ability to operate and develop, manufacture and deliver products and components and harm our business and financial results. Â In October of 2023, Hamas terrorists infiltrated Israelâ€™s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attacks, Israelâ€™s security cabinet declared war against Hamas and commenced a military campaign. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During November 2024, a ceasefire in Lebanon was declared. During January 2025, Israel and Hamas have agreed to a Gaza three-phase ceasefire agreement and partial hostage release, the first six-week phase of such ceasefire began on January 19, 2025. It is possible that these hostilities will escalate in the future into a greater regional conflict, and that additional terrorist organizations and countries will actively join the hostilities. The ongoing and revived hostilities in the region, could prevent or delay shipments of our products, harm our operations and product development and cause our sales to decrease. In the event that the hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies and products, our operations may be materially adversely affected. The conflict could cause situations where applicable foreign regulatory bodies, such as the FDA, could not be able to visit our third-party manufacturing facilities in Israel in order to review, causing delays. The war could also result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. Â Further, there have been travel advisories imposed as related to travel to Israel, and restriction on travel, or delays and disruptions as related to imports and exports may be imposed in the future. An inability to receive supplies and materials, shortages of materials or difficulties in procuring our materials, among others, may adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause a number of delays and/or issues for our operations, including delay of the review of our product candidates by regulatory agencies, which in turn would have a material adverse impact on our ability to commercialize our product candidates. Although the resulting sanctions and any related market disruptions are impossible to predict, they could be substantial, particularly if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations on a global scale. See â€œItem 3. Key Information â€“ D. Risk Factors â€“ Risks Related to our Operations in Israelâ€. Â We have limited business in Russia which pose some degree of sanctions risk that cannot be entirely eliminated. Â We have a long-standing distribution contract with a Russian distributer which distributes our products in the country and other neighboring countries. Given the nature of our products and our end customers in Russia (typically physicians), our Russia-related business falls within a category of activities with respect to which the sanctions regimes have been historically more permissive and with respect to which there is a relatively lower incidence of sanctions exposure. Furthermore, we are committed, and take measures, to ensure compliance with any applicable Sanctions. However, the sanctions against Russia across various key jurisdictions, including the United States, are extremely dynamic and complex and usually apply on a strict liability basis and sometimes may expose non-U.S. parties to liability or imposition of market restrictions even in the absence of jurisdictional grounds or touchpoints with the country of the governmental authority imposing the sanctions. Accordingly, in the current environment, Russia-related dealings may entail some degree of exposure to sanctions risks that cannot be entirely eliminated. Â 8 We outsource almost all of the manufacturing of our products to a small number of manufacturing subcontractors. If our subcontractorsâ€™ operations are interrupted or if our orders exceed our subcontractorsâ€™ manufacturing capacity, we may not be able to deliver our products on time. Â We outsource almost all of the manufacturing of our products to three subcontractors located in Israel, two of which we are substantially dependent on, while we manufacture our laser and intense pulsed light, or IPL, handpieces in-house in Israel. These subcontractors have limited manufacturing capacity that may be inadequate if our customers place orders for unexpectedly large quantities of our products. In addition, because our subcontractors are located in Israel, they on occasion may feel the impact of potential economic or political instability in the region, including the ongoing Israeli-Hamas war. If the operations of

one or more of our subcontractors were halted or limited, even temporarily, or if they were unable or unwilling to fulfill large orders, we could experience business interruption, increased costs, damage to our reputation and loss of our customers. In addition, finding new subcontractors that meet our manufacturing requirements, comply with regulatory requirements, and are ISO certified could take several months. Â Future changes to U.S. income tax or trade policies impacting multi-national companies could materially affect our financial condition and results of operations. Â In recent years, the U.S. government has instituted or proposed changes to international trade policy through the renegotiation, and potential termination, of certain existing bilateral or multilateral trade agreements and treaties with, and the imposition of tariffs on a wide range of products and other goods from China and other countries. Given our contract manufacturing and logistic providers in those countries, policy or regulations changes in the United States or other countries present particular risks for us. Â New or increased tariffs could adversely affect many of our products. There also are risks associated with retaliatory tariffs and resulting trade wars. We cannot predict future trade policy and regulations in the United States and other countries, the terms of any renegotiated trade agreements or treaties, or tariffs and their impact on our business. An escalated trade war could have a significant adverse effect on world trade and the world economy. To the extent that trade tariffs and other restrictions imposed by the United States or other countries increase the price of, or limit the amount of, our products or components or materials used in our products imported into the United States or other countries, or create adverse tax consequences, the sales, cost, or gross margin of our products may be adversely affected and the demand from our customers for products and services may be diminished. Uncertainty surrounding international trade policy and regulations as well as disputes and protectionist measures could also have an adverse effect on consumer confidence and spending. If we deem it necessary to alter all or a portion of our activities or operations in response to such policies, agreements, or tariffs, our capital and operating costs may increase. Â Components used in our products are complex in design, and defects may not be discovered prior to shipment to customers, which could result in warranty obligations, reducing our revenue and increasing our costs. Â In manufacturing our products, we and our subcontractors depend upon third-party suppliers for various components. Many of these components require a significant degree of technical expertise to produce. If our suppliers fail to produce components to specification, or if the suppliers, our subcontractors, or we, use defective materials or workmanship in the manufacturing process, the reliability and performance of our products will be compromised. Â If our products contain defects that cannot be repaired easily and inexpensively, we may experience: Â â€¢ loss of customer orders and delay in order fulfillment; Â â€¢ damage to our brand reputation; Â â€¢ increased cost of our warranty program due to product repair or replacement; Â â€¢ inability to attract new customers; Â â€¢ diversion of resources from our manufacturing and research and development departments into our service department;â€‰â€‰ Â â€¢ product recalls; and Â â€¢ legal action. Â The occurrence of any one or more of the foregoing could materially harm our business, financial condition and results of operations. Â 9 We and our manufacturing subcontractors depend upon third-party suppliers, making us vulnerable to supply shortages, price fluctuations or other degradations in performance of these suppliers, which could harm our business and financial condition. Â Many of the components that comprise our products are currently manufactured by a limited number of suppliers. Although each of our components can be obtained from more than one supplier, we do not have the ability to manufacture the components we outsource. Additionally, our subcontractors rely on a limited number of suppliers, or in some cases, one supplier, for some of the materials and components used in our products. If our subcontractors were to lose such suppliers, there can be no assurance that they will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all, which could cause interruptions in their operations. If any of these third-party suppliers fails to adequately perform, our revenue and profitability could be adversely affected. A supply interruption or an increase in demand beyond current suppliersâ€™ capabilities could harm our ability to manufacture our products until we identify and qualify a new source of supply, which could take several months. Â There is a risk that our suppliers will not always act consistent with our best interests, and may not always supply goods that meet our requirements. Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers, which would have an adverse effect on our business, financial condition and results of operations. Â Transitioning to a new supplier could be time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our products or could require that we modify the design of certain product systems. If a change in manufacturer results in a significant change to any product, a new 510(k) clearance from the FDA or similar international regulatory authorization may be necessary before we implement the change, which could cause substantial delays. Â Disruptions or interruptions to our suppliers could occur for many reasons, including fire, floods, hurricanes, typhoons, droughts, tsunamis, volcanoes, earthquakes, disease or other similar natural disasters, unplanned maintenance or other manufacturing problems, labor shortages, power outages or shortages, telecommunications failures, strikes, transportation interruption, government regulation, economic or political instability, terrorism or other extraordinary events, including epidemics and related travel restrictions. Such disruptions may continue over a sustained period and could cause direct injury or damage to our supplierâ€™s employees and property with significant indirect consequences to us. Alternative facilities with sufficient capacity or capabilities may not be available, may cost substantially more or may take a significant time to start manufacturing, each of which could negatively affect our ability to fill customer orders and our business and financial performance. Â There exists potential for misuse of our products, over which we have very little to no control, which could harm our reputation and our business. Â In the United States, federal regulations allow us to sell our products to or on the order of â€œlicensed practitionersâ€. The definition of â€œlicensed practitionersâ€ varies from state to state. As a result, depending on state law, our products may be purchased or operated by physicians or other licensed practitioners, including nurse practitioners, chiropractors and technicians. Outside the United States, many jurisdictions do not require specific qualifications or training for purchasers or operators of our products. Although we offer training on the use of our products, we do not supervise the treatments performed. Purchase and use of our products by non-physicians may result in product misuse. The potential misuse of our products by physicians and non-physicians may result in adverse treatment outcomes, which could harm our reputation and expose us to costly product liability litigation. Â Our products include a limited time warranty which could result in substantial additional costs to us should we fail to monitor product quality effectively. Â We generally provide a 12-month warranty on our products. After the warranty period, maintenance and support is provided on a service contract basis. If our products malfunction, warranty claims may become significant, which could cause a significant drain on our resources and materially adversely affect our results of operations. Â We forecast sales to determine requirements for our products and if our forecasts are incorrect, we may experience either shipment delays or increased costs. Â Our subcontractors keep limited materials and components on hand. To help them manage their manufacturing operations and minimize inventory costs, we forecast anticipated product orders to predict our inventory needs up to six months in advance and enter into purchase orders on the basis of these forecasts. If our business expands, our demand will increase and our suppliers may be unable to meet our demand. If we overestimate our requirements, our subcontractors will have excess inventory, and may transfer to us any increase in costs. If we underestimate our requirements, our subcontractors may have inadequate components and materials inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance and the level of satisfaction our customers have with our business. Â 10 Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. Â We generally enter into non-competition agreements with our professional employees, in most cases within the framework of their employment agreements. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under applicable employment laws, we may be unable to enforce these agreements, in whole or in part, and it may be difficult for us to restrict our competitors from gaining the expertise our former employees gained while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a companyâ€™s confidential commercial information or its intellectual property. If we cannot demonstrate that harm would be caused to us, we may be unable to prevent our competitors from benefiting from the expertise of our former employees, which could materially adversely affect our business, results of operations and ability to capitalize on our proprietary information. Â The expense and potential unavailability of insurance coverage for our customers and the Company could adversely affect our ability to sell our products and our financial condition. Â Some of our customers and prospective customers are required to maintain liability insurance to cover their operations and use of our products. Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our products and, industry-wide, potential customers may opt against purchasing light, laser or radio frequency-based products due to the cost or inability to procure insurance coverage. Â Outbreaks of contagious disease or similar public health threats could materially and adversely affect our business, financial condition and results of operations. Â Outbreaks of contagious disease or other adverse public health developments worldwide could have a material adverse effect on our business, financial condition and results of operations. Outbreaks of contagious disease or other adverse public health developments could affect our business in a number of ways, including but not limited to: Â â€¢ Disruptions or restrictions on our employeesâ€™ ability to work effectively due to illness. Â â€¢ Temporary closures or disruptions at our facilities or the facilities of our customers or suppliers could reduce demand for our products or affect our ability to timely meet our customerâ€™s orders and negatively impact our supply chain. Â â€¢ Outbreaks of contagious disease could cause delays or disruptions in our supply chain. Â â€¢ The failure of third parties on which we rely to meet their respective obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, could have an adverse impact on our business, financial condition or results of operations. Â â€¢ The impact of contagious disease or other adverse public health developments could also exacerbate other risks discussed elsewhere in this section of this report, any of which could have a material adverse effect on us. Â Global economic and social conditions may adversely affect our business, financial condition and results of operations. Â Any negative conditions in the national and global economic environments may adversely affect our business, financial condition and results of operations. During uncertain economic times and in tight credit markets, many of our customers may experience financial difficulties or be unable or unwilling to borrow money to fund their operations, including obtaining credit lines for purchasing our products, and may delay or reduce purchases or reduce the extent of their operations. The market for aesthetic procedures and the market for our premium products can be particularly vulnerable to economic uncertainty, since the end-users of our products may decrease the demand for our products when they have less discretionary income or determine not to spend their discretionary income on aesthetic procedures. In addition, in many instances, the ability of our customers to purchase our products depends in part upon the availability of obtaining financing at acceptable interest rates. Â 11 These factors could result in reductions in revenues from sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies and increased price competition. Payment by our customers of our receivables is dependent upon the financial stability of the economies of certain countries. In light of the current economic state of many countries outside of the United States, we continue to monitor the creditworthiness of our customers because weakness in the end-user market could negatively affect the cash flows of our customers who could, in turn, delay paying their obligations to us. This would increase our credit risk exposure and cause delays in our recognition of revenues on current and future sales to these customers. Â Exchange rate fluctuations may decrease our earnings if we are not able to hedge our currency exchange risks successfully. Â A majority of our revenues and a substantial portion of our expenses are denominated in U.S. dollars. However, a portion of our revenues and a portion of our costs, including personnel and some marketing and facilities expenses, are incurred in NIS, Canadian dollars and Euros. Inflation in Israel or Europe may have the effect of increasing the U.S. dollar cost of our operations in that country. If the U.S. dollar declines in value in relation to one or more of these currencies, it will become more expensive for us to fund our operations in the countries that use those other currencies. To date, we have not found it necessary to hedge the risks associated with fluctuations in currency exchange rates. In the future, if we do not successfully engage in hedging transactions, our results of operations may be subject to losses from fluctuations in foreign currency exchange rates. Â Cyber-attacks as well as improper disclosure or control of personal information could result in liability and harm our reputation, which could adversely affect our business and results of operations. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential customer information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards. Â Our business is heavily dependent on the security of our IT networks. Internal or external attacks on any of those could disrupt the normal operations of our engagements and impede our ability to provide services to our customers, thereby subjecting us to liability under our contracts. Additionally, our business involves the use, storage and transmission of information about our employees, our customers and clients of our customers. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we take measures to protect the security of, and unauthorized access to, our systems, as well as the privacy of personal and proprietary information, it is possible that our security controls of our systems, as well as other security practices we follow or those systems of our customers which we rely upon, may not prevent the improper access to or disclosure of personally identifiable or proprietary information. Such disclosure could harm our reputation and subject us to liability under our contracts and laws that protect personal data, resulting in increased costs or loss of revenue. Â Further, the global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect about individuals in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business. Â 12 As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. We are subject to U.S. federal and state laws regarding data privacy and security including Section 5 of the Federal Trade Commission Act, or FTC Act, the California Consumer Privacy Act, or the CCPA and the California Privacy Rights Act, or the CPRA. Further, the Health Insurance Portability and Accountability Act of 1996, as amended, and regulations implemented thereunder, or HIPAA, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumersâ€™ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of the Federal Trade Commission Act. The FTC expects a companyâ€™s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Federal and state consumer protection laws are increasingly being applied by the FTC, and statesâ€™ attorneys general to regulate the collection, use, storage and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content. Â Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. For example, the CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. Both the CCPA and CRPA are generally more stringent than similar U.S. federal regulations. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Â We are also subject to foreign data privacy and security laws, including the Israeli Protection of Privacy Law of 1981 and the Privacy Protection Regulations (Data Security) 5777-2017, the European Union General Data Protection Regulation, or GDPR, and the United Kingdom GDPR, or UK GDPR. The GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European

Economic Area, or the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and significant penalties for non-compliance, including potential fines for noncompliance of up to â‚¬20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The UK GDPR mirrors the fines under the GDPR, e.g., fines up to the greater of â‚¬20 million (Â£17.5 million) or 4% of global turnover. Â As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. Â Our failure to adhere to or successfully implement processes in response to changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations. Â In the course of providing services to our customers, we may have access to confidential customer information, including nonpublic personal data. We are bound by certain agreements to use and disclose this information in a manner consistent with the privacy standards under regulations applicable to our customers and are subject to numerous U.S. and foreign jurisdiction laws and regulations designed to protect this information, such as the GDPR and various U.S. federal and state laws governing the protection of health or other individually identifiable information. If any person, including a team member of ours, misappropriates customer confidential information, or if customer confidential information is inappropriately disclosed due to a security breach of our computer systems, system failures or otherwise, we may have substantial liabilities to our customers or our customersâ€™ clients and may incur substantial liability and penalties in connection with any violation of applicable privacy laws and/or criminal prosecution. In addition, in the event of any breach or alleged breach of our confidentiality agreements with our customers, these customers may terminate their engagements with us or sue us for breach of contract, resulting in the associated loss of revenue and increased costs and damaged reputation. We may also be subject to civil or criminal liability if we are deemed to have violated applicable regulations. We cannot assure you that we will adequately address the risks created by the regulations to which we may be contractually obligated to abide. Â 13 Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations. Â We may become subject to numerous foreign, federal, and state healthcare statutes and regulations and our failure to comply could result in a material adverse effect to our business and operations. Â Although none of our products or procedures using our products are currently covered by any state or federal government healthcare programs, or any private commercial payor, we may become subject to foreign, federal, and state laws intended to prevent healthcare fraud and abuse, including those that apply to all payors. These laws could include state anti-kickback and false claims laws, which may extend to services reimbursable by any payor, as well as state consumer protection laws. Although we currently are not subject to transparency laws, we may become subject to such laws in the future. Such laws could include requirements to disclose payments to certain healthcare professionals and healthcare entities or disclosures related to sales and marketing, or that could require healthcare professionals to provide notice to their patients of ownership or financial arrangements with manufacturers. Â Efforts to ensure that our internal operations and business arrangements with third parties comply with future applicable healthcare laws and regulations may involve substantial costs. These laws and regulations, among other things, could constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including financing programs, we may have with physicians or other potential purchasers of our products. It is possible that governmental authorities may conclude that our business practices, including our arrangements with physicians, some of whom received stock options as compensation for services provided, as well as fees for marketing to other physicians, are subject to and do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our current or future operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties which could adversely affect our ability to operate our business and pursue our strategy. Â We are subject to anti-bribery, and corruption and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. Â As we continue to grow our international presence and global operations, we will be increasingly exposed to trade and economic sanctions and other restrictions imposed by the United States, the European Union, the State of Israel and other governments and organizations. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that â€œfails to prevent briberyâ€ by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented â€œadequate proceduresâ€ to prevent bribery. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations. Â We have implemented policies and procedures designed to ensure compliance by us and our directors, officers, employees, representatives, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. We cannot assure you, however, that our policies and procedures are or will be sufficient or that directors, officers, employees, representatives, consultants and agents have not engaged and will not engage in conduct for which we may be held responsible, nor can we assure you that our business partners have not engaged and will not engage in conduct that could materially affect their ability to perform their contractual obligations to us or even result in our being held liable for such conduct. Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our business, financial condition and results of operations. Â 14 Our operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security. Â The effects of climate change (such as drought, flooding, heat waves, wildfires, increased storm severity, and sea level rise, etc.) could affect our ability to continue our operations and cause delays in our product development, manufacturing and shipment, all of which could cause reputational harm or otherwise have an adverse effect on our business and operating results. In addition, the impacts of climate change on the global economy and our industry are rapidly evolving. Changing market dynamics, global policy developments and the increasing frequency and impact of extreme weather events on critical infrastructure across different countries could have the potential to disrupt our business, the business of our third-party suppliers and the business of our customers, and may cause us to experience higher attrition, losses and additional costs to maintain or resume operations. We also expect to face increasing regulatory requirements and regulatory scrutiny related to climate matters, resulting in higher associated compliance costs. Failure to uphold, meet or make timely forward progress against our public commitments and goals related to climate action could adversely affect our reputation with suppliers and customers, financial performance or the ability to recruit and retain talent. Â Risks Related to Our Intellectual Property Â If we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology. Â Our success and ability to compete depends in large part upon our ability to protect our proprietary technology. We rely primarily upon a combination of patents and trademarks, as well as nondisclosure, confidentiality and other contractual agreements to protect the intellectual property related to our brands, products and other proprietary technologies. Â We generally apply for patents only in those countries where we intend to make, have made, use, offer for sale, or sell products. To date, we have issued patents in the United States, which we consider to be our main target market, and one issued patent in South Korea. Most of our revenues for the years ended December 31, 2024, 2023 and 2022 were derived from the United States where we have patent protection. We do not seek protection in all countries where we sell products and we may not accurately predict all the countries where patent protection would ultimately be desirable. At this time, the countries in which we have not sought patent protection, but intend to offer our products for sale, are not our main target markets. We acknowledge that competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we do not have patent protection. Such activity may prevent us from protecting our proprietary technology, and thus, may harm our competitive position. Â Our patent portfolio consists of fifteen issued U.S. patents, one issued Korean patent and eleven pending patent applications in the United States relating to our technology and products Our pending and future patent applications may not issue as patents or, even if issued, may not issue in a form that will be advantageous to us. Any issued patents may be challenged, invalidated or legally circumvented by third parties. We cannot be certain that our patents will be upheld as valid, proven enforceable or prevent the development of competitive products. Other companies may also design around technologies we have patented. Third parties may have blocking patents that could prevent us from marketing our products or practicing our own patented technology. In addition, competitors could purchase one of our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, or develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected against competitorsâ€™ products and methods, our competitive position could be adversely affected, as could our business and financial results. Â The U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Â 15 We rely on a combination of patent and other intellectual property laws and confidentiality, non-disclosure and assignment of inventions agreements, as appropriate, with our employees and consultants, to protect and otherwise seek to control access to, and distribution of, our proprietary information. These measures may not be adequate to protect our technology from unauthorized disclosure, third-party infringement or misappropriation. Parties may breach these agreements, and we may not have adequate remedies for any breach. Also, the laws of certain countries in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as the laws of the United States or Israel. Â The aesthetics industry is highly competitive and marked by frequent litigation. New patent applications may be pending or may be filed in the future by third parties covering technology that we currently use or may ultimately use. Third parties have claimed, and may in the future claim, that our current or future products infringe their patent or other intellectual property rights and may seek to prevent, limit or interfere with our ability to make, use, sell or import our products. Moreover, if such a claim were to be decided adversely to us or if we settled such a claim on adverse terms, we could be forced to pay substantial damages, to license the technology in question at high rates or to redesign or modify our products so as to avoid any infringement. Any of those results could adversely affect our sales, margins and results of operations. Â If it appears necessary or desirable, we may try to obtain licenses for those patents or intellectual property rights that we are allegedly infringing, may infringe, or desire to use. Although holders of these types of intellectual property rights commonly offer these licenses, we cannot assure you that licenses will be offered or that the terms of any offered licenses will be acceptable to us. Our failure to obtain a license for key intellectual property rights from a third party for technology used by us could cause us to incur substantial liabilities and to suspend the manufacturing and selling of products utilizing the technology. Â Alternatively, we could be required to expend significant resources to develop non-infringing technology. We cannot assure you that we would be successful in developing non-infringing technology. Â Third parties have and may in the future commence litigation against us claiming that our products infringe upon their patents or other intellectual property rights. Â From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our products, components of our products, services, and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include: Â â€¢ we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third partiesâ€™ patents; Â â€¢ we or our collaborators may participate at substantial cost in International Trade Commission proceedings to abate importation of products that would compete unfairly with our products; Â â€¢ if our competitors file patent applications that claim technology also claimed by us, we may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; Â â€¢ if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; Â â€¢ if third parties initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product, service, or technology does not infringe our patents or patents licensed to us, we will need to defend against such proceedings; Â â€¢ we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our products; and Â â€¢ if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate its patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. Â 16 These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force us to do one or more of the following: Â â€¢ incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the product, service, or technology at issue infringes or violates the third partyâ€™s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third partyâ€™s attorneysâ€™ fees; Â â€¢ pay substantial damages to our customers or end users to discontinue use or replace infringing technology with non-infringing technology; Â â€¢ stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the product or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such product, service, or technology; Â â€¢ obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all; Â â€¢ redesign our products, services, and technology so they do not infringe or violate the third partyâ€™s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; Â â€¢ enter into cross-licenses with our competitors, which could weaken our overall intellectual property position; Â â€¢ lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others; Â â€¢ find alternative suppliers for non-infringing products and technologies, which could be costly and create significant delay; or Â â€¢ relinquish rights associated with one or more of our patent claims, if our claims are held invalid or otherwise unenforceable. Â On February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action (the â€œSecurities Class Actionâ€) in the United States District Court for the Central District of California, captioned Cement Masons and Plasterers Local No. 502 Pension Fund v. InMode Ltd. et al., Case No. 2:24-cv-01219, against the Company and certain of its officers and directors. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Companyâ€™s business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. On April 16, 2024, multiple shareholders moved to be appointed lead plaintiff. On December 4, 2024, the Court entered an order appointing a group of shareholder funds as the lead plaintiffs. On January 31, 2025, the lead plaintiffs filed an amended complaint. The amended complaint purportedly brings claims on behalf of purchasers of the Companyâ€™s common stock between February 18, 2020 and December 6, 2023, inclusive. The Companyâ€™s deadline to respond to the amended complaint is April 1, 2025. The Securities

Class Action is in the preliminary stages, and the Company has not yet responded to the amended complaint. As of the date of this filing, the Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in the Securities Class Action, and an estimated liability has not been recorded in the Companyâ€™s financial statements. The defendants intend to deny the allegations of wrongdoing and vigorously defend against the claims in the Securities Class Action. Â Although we may try to resolve any potential future claims or actions, we may not be able to do so on reasonable terms, if at all. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate, and could divert managementâ€™s attention from our core business. If we lose this kind of litigation, a court could require us to pay substantial damages and could prohibit us from using technologies essential to our products, either of which would have a material adverse effect on our business, results of operations and financial condition. Â 17 We may become involved in litigation to protect the trademark rights associated with the Company name or the names of our products. If we have to change the name of the Company or products, we may experience a loss in goodwill associated with our brand name, customer confusion and a reduction in sales. Â Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our products, services and technology. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows. Â In addition, we may indemnify our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related to our products. Third parties may assert infringement claims against our customers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors, or may be required to obtain licenses for the products or services they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services. Â Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ordinary shares. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares. Â If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Â Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Â We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. Â We do and may employ individuals who were previously employed at universities or other pharmaceutical or medical device companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, and we are not currently subject to any significant claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Â Intellectual property rights do not necessarily address all potential threats to our business. Â The degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: Â â€¢ others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue; Â 18 â€¢ we or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; Â â€¢ we or any future strategic partners might not have been the first to file patent applications covering certain of our inventions; Â â€¢ others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; Â â€¢ it is possible that our pending patent applications will not lead to issued patents; Â â€¢ issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; Â â€¢ our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; Â â€¢ third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license; Â â€¢ parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; Â â€¢ we may not develop or in-license additional proprietary technologies that are patentable; Â â€¢ we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and Â â€¢ the patents of others may have an adverse effect on our business. Â Should any of these events occur, they could significantly harm our business and results of operations. Â Risks Related to Government Regulation Â Our business is subject to extensive and continuing regulatory compliance obligations.Â If we fail to obtain and maintain necessary FDA clearances for our products, if clearances for future products and proposed indications are delayed or not issued, if we or any of our third-party suppliers or manufacturers fail to comply with applicable regulatory requirements, or if there are regulatory changes, our commercial operations could be harmed. Â Our products are medical devices subject to extensive regulation by the applicable regulatory authorities where our products are or will be sold prior to their marketing for commercial use. In the United States, our products are subject to extensive regulation by the FDA for developing, testing, manufacturing, labeling, sale, marketing, advertising, promotion, distribution, import, export, shipping, establishment registration and device listing, inspections and audits, record keeping, recalls and field safety corrective actions and post-market surveillance, including reporting of certain events. Â Before a new medical device, or a new use of, or claim for, an existing product can be marketed in the United States, it must first receive marketing authorization from the FDA unless it is exempt. The FDA marketing authorizations include a 510(k) clearance or premarket approval. A relatively small number of devices may be exempt from 510(k) clearance or may receive marketing authorization through the de novo classification pathway. These processes can be expensive and lengthy. The FDAâ€™s 510(k) clearance process usually takes from 3 to 12 months, but it can last longer. The process of obtaining premarket approval is much more costly and uncertain than the 510(k)-clearance process and it generally takes from one to three years, or even longer, from the time the application is filed with the FDA. Our future products and enhancements or changes to products may require new 510(k) clearance or premarket approval from the FDA. All products that we currently market in the United States that require an FDA marketing authorization have received 510(k) clearance for the uses for which they are marketed. Â Medical devices may be marketed only for the indications for which they are approved or cleared. We have obtained 510(k) clearance for the current treatments for which we offer our products. However, our clearances can be revoked under certain circumstances. If the FDA disagrees with us concerning the scope or applicability of a clearance or exemption with respect to a device, we may be required to change our promotional and/or labeling materials and/or stop marketing that device. Changes or modifications to an FDA-cleared device that could significantly affect its safety or effectiveness or that constitute a major change or modification in its intended use would require a new 510(k) clearance or possibly premarket approval. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, our existing products in a timely fashion, or at all. Delays in obtaining future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our revenue and future profitability. Â 19 We have made modifications to our devices in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees, and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing the modified devices. We also are subject to the FDAâ€™s Medical Device Reporting regulations, which require us to report to the FDA if our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. Â The FDA or the applicable foreign regulatory bodies can delay, limit or deny clearance or approval of a device for many reasons, including: Â â€¢ our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory bodies that our products are safe or effective for their intended uses; Â â€¢ the disagreement of the FDA or the applicable foreign regulatory bodies with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials; Â â€¢ serious and unexpected adverse device effects experienced by participants in our clinical trials; Â â€¢ the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; Â â€¢ our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; Â â€¢ the manufacturing process or facilities we use may not meet applicable requirements; and Â â€¢ the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval. Â In addition, the FDA or applicable foreign regulatory bodies may change their clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the Food, Drug and Cosmetic Act of 1938, as amended (the â€œFDCAâ€). Among other things, the FDA announced that it plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals include possible plans to sunset certain older devices that were used as predicates under the 510(k)-clearance pathway, and to publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA also announced that it intends to finalize guidance to establish a premarket review pathway for â€œmanufacturers of certain well-understood device typesâ€ as an alternative to the 510(k) clearance pathway and that such premarket review pathway would allow manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. These proposals have not yet been finalized or adopted, and the FDA announced that it would seek public feedback prior to publication of any such proposals, and may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business. Â Additionally regulatory clearances or approvals to market a product can contain limitations on the indicated uses for such product. Product clearances and approvals can be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial clearance or approval. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect our operations. We and our manufacturers may be inspected by the FDA from time to time to determine whether we or our manufacturers are in compliance with applicable laws, including the cGMP regulations set forth in the FDAâ€™s Quality System Regulation/Medical Device Current Good Manufacturing Practices, or QSR, including those relating to specifications, development, documentation, validation, testing, quality control and product labeling. A determination that we are in violation of FDA or other applicable foreign regulations or any of our product clearances or approvals could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions. Â 20 The use, misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. Â The use, misuse or off-label use of our products may harm our reputation or the image of our products in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in legal sanctions if we are deemed or alleged to have engaged in off-label promotion. Â A medical device may be authorized by the FDA for marketing through several regulatory mechanisms. The FDA classifies medical devices as Class I, Class II, or Class III, in increasing order of risk. Most of our products are Class I or Class II medical devices. As such, they are either exempt from premarketing authorization requirements or are subject to the 510(k)-clearance process, and all are listed with the FDA pursuant to FDAâ€™s medical device listing requirements. Â Under FDA regulations, for each of our products we must only use labeling, including advertising and promotional materials, that is consistent with the specific indication(s) for use included in the FDA exemption regulation, clearance, or approval, which is applicable to the specific product. If the FDA or other authorities determine that our promotional or training materials constitute the unlawful promotion of an off-label use, they could request that we modify our training or promotional materials and/or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, seizure, injunction or criminal fines and penalties. Other federal, state or foreign governmental authorities might also take action if they consider our promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In each event, our reputation could be damaged and the use of our products in the marketplace could be impaired, or our business could face significant hardship. Â In addition, there may be increased risk of injury if physicians or others attempt to use our products off-label. The FDA does not restrict or regulate a physicianâ€™s use of a medical product within the practice of medicine, and we cannot prevent a physician from using our products for an off-label use. The use of our products for indications other than those for which our products have been approved or cleared by the FDA may not effectively treat the conditions not referenced in product indications, which could harm our reputation in the marketplace among physicians and patients. Physicians may also misuse our products or use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of product liability. Product liability claims are expensive to defend and could divert managementâ€™s attention from our primary business and result in substantial damage awards against us. Any of these events could harm our business, results of operations and financial condition. Â We are subject to ongoing regulatory obligations and a failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market. Â Even after we have obtained the proper regulatory clearance or approval to market a product, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Â Our products and/or their use are also subject to state regulations and additional regulations in other foreign jurisdictions outside of the United States, which may change at any time. We cannot predict the impact or effect of future legislation or regulations and any changes in regulations may impede sales. Â 21 Furthermore, the FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions: Â â€¢ warning letters or untitled letters, fines, injunctions, consent decrees and civil penalties; Â â€¢ repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizure of our products; Â â€¢ operating restrictions or partial suspension or total shutdown of production; Â â€¢ refusing our requests for 510(k) clearance or premarket approval of new products, new intended uses, or modifications to existing products; Â â€¢ withdrawing 510(k) clearances or premarket approvals or foreign regulatory approvals that have already been granted, resulting in prohibitions on sales of our products; and Â â€¢ criminal prosecution. Â The occurrence of any of these events could harm our business, financial condition and results of operations. Â If we or our subcontractors fail to comply with federal and state regulation, including the FDAâ€™s Quality System Regulation/Medical Device Good Manufacturing Practices and performance

standards, our or our subcontractorsâ€™ manufacturing operations could be halted, and our business would suffer. Â We and our subcontractors currently are required to demonstrate and maintain compliance with the QSR. The QSR is a complex regulatory scheme that covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. Because our products use optical energy, including lasers, our products also are covered by a performance standard for lasers set forth in FDA regulations. The laser performance standard imposes specific record-keeping, reporting, product testing and product labeling requirements. These requirements include affixing warning labels to laser products, as well as incorporating certain safety features in the design of laser products. The FDA enforces the QSR and laser performance standards through periodic announced or unannounced inspections. We and our subcontractors are subject to such inspections. Although we place our own quality control employee at each of our subcontractorâ€™s facilities, we do not have complete control over our subcontractorâ€™s compliance with these standards. Â Any failure by us or our subcontractors to take satisfactory corrective action in response to an adverse QSR inspection or to comply with applicable laser performance standards could result in enforcement actions against us or our subcontractors, including warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals or clearances; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDAâ€™s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us or our employees. Any of these actions could significantly and negatively impact the supply of our products, and could cause our sales and business to suffer. In addition, we are subject to standards imposed on our activities outside of the United States, such as obtaining CE mark certification in Europe (by our notified body DEKRA) and the Standards Institution of Israel (imposed on our activities in Israel), and failure to comply with such standards could adversely impact our business. Â Our products may cause or contribute to adverse medical events or other undesirable side effects that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. Â We are subject to the FDAâ€™s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance, seizure of our products or delay in clearance of future products. Â 22 The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Depending on the corrective action we take to redress a productâ€™s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals or clearances for the product before we may market or distribute the corrected product. Seeking such approvals or clearances may delay our ability to replace the recalled products in a timely manner. Moreover, if we do not adequately address problems associated with our products, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. Â Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Â We may be unable to obtain or maintain international regulatory qualifications or approvals for our current or future products and indications, which could harm our business. Additionally, obtaining and maintaining regulatory approval in one jurisdiction does not mean we will be successful in obtaining regulatory approvals for our products in other jurisdictions. Â Sales of our products outside the United States are subject to foreign regulatory requirements that vary widely from country to country, including some regulatory requirements that we may not be fully aware of, or that may change in ways that affect our ability to sell our products in those jurisdictions. Complying with international regulatory requirements can be an expensive and time-consuming process and approval is not certain. The regulatory process in foreign jurisdictions includes all the risks associated with obtaining FDA clearance, as well as additional risks not present in the FDA process. For example, the time required to obtain foreign clearance or approvals may be longer than that required for FDA clearance or approvals, and requirements for such clearances or approvals may significantly differ from FDA requirements, adding costs and variability. Foreign regulatory authorities may not approve our product for the same uses cleared by the FDA. Although we have obtained regulatory clearances to sell our products in the European Union and other countries outside the United States, we may be unable to maintain regulatory qualifications, clearances or approvals in these countries or to obtain approvals in other countries. We also may incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals, clearances or qualifications. Â If we experience delays in receiving necessary qualifications, clearances or approvals to market our products outside the United States, or if we fail to receive those qualifications, clearances or approvals, we may be unable to market some of our products or enhancements in certain international markets effectively, or at all. Since the enactment of the Israeli Medical Equipment Law, 2012, or the Medical Equipment Law, the manufacturing and marketing of medical and certain aesthetic devices, including our products, in Israel requires registration with the Israeli Ministry of Health. The Medical Equipment Law offers a fast-track registration process for devices that received approval from certain non-Israeli regulatory agencies, including FDA clearance or CE marks. We have taken advantage of such fast-track registration process in the past. If we are unable to obtain and maintain the necessary registration for any of our products in Israel, we may have to move the manufacturing of such unregistered products to a location outside of Israel and stop selling these products in Israel until the products are registered. We may also suffer harm to our reputation as a result. Â Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. Â The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Â 23 Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or cleared by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Â New regulations may limit our ability to sell to non-physicians in the future. Â Currently, we sell our products solely to physicians. However, where permitted under applicable laws, we intend to introduce certain of our products in the developing medical spa market, where aesthetic procedures are being performed at dedicated facilities by non-physicians under physician supervision. U.S., state and international regulations could change at any time, disallowing sales of our products to aestheticians, and/or limiting the ability of aestheticians and non-physicians to operate our products. We cannot predict the impact or effect of changes in U.S., state or international laws or regulations. Â Risks Related to Our Ordinary Shares Â The price of our ordinary shares may be volatile, and you may lose all or part of your investment. Â The price of our ordinary shares has historically fluctuated and has experienced volatility in the past. The market price for our ordinary shares may fluctuate as a result of a number of factors, many of which are beyond our control, including: Â â€¢ fluctuations in our operating results or the operating results of our competitors; Â â€¢ changes in the estimates of the future size and growth rate of our market opportunities; Â â€¢ changes in the general economic, industry and market conditions; Â â€¢ success of competitive technologies and procedures; Â â€¢ recruitment or departure of key personnel; Â â€¢ the announcement of new products or enhancements by us or our competitors; Â â€¢ the commencement or outcome of litigation against us, or involving our general industry or both; Â â€¢ new laws or regulations or new interpretations of existing laws or regulations applicable to our business; Â â€¢ changes in earnings estimates, investorsâ€™ perceptions, recommendations by securities analysts or our failure to achieve analystsâ€™ earnings estimates; Â â€¢ developments in our industry, including the announcement of significant new technologies, procedures or acquisitions by us or our competitors; Â â€¢ actual or expected sales of our ordinary shares by the holders of our ordinary shares; and Â â€¢ the trading volume of our ordinary shares. Â In addition, the stock prices of companies in the medical device industry have experienced wide fluctuations that often have been unrelated to the operating performance of those companies. These fluctuations may be attributed, among other reasons, to the general global economic environment and the instability in markets. These factors and price fluctuations may materially and adversely affect the market price of our ordinary shares. Â Future sales of our ordinary shares could reduce the price of our ordinary shares. Â Sales by shareholders of substantial amounts of our ordinary shares, or the perception that these sales may occur in the future, could materially and adversely affect the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities and our ability to acquire other companies by using our ordinary shares as consideration. Â 24 As of December 31, 2024, there are 69,558,670 ordinary shares outstanding (not including a total of 18,025,003 ordinary shares held at that date as treasury shares). Sales of these shares, or the perception that these sales may occur in the future, into the market could cause the market price of our ordinary shares to drop significantly. In addition, we have registered all ordinary shares that we may issue under our equity compensation plans, and, as such, these shares can be freely sold in the public market upon issuance. Â We have not paid dividends in the past and may not pay dividends in the future, and any return on investment may be limited to the value of our ordinary shares. Â We have never declared or paid cash dividends on our ordinary shares and may not distribute cash or other dividends on our ordinary shares in the foreseeable future. The distribution of dividends on our ordinary shares will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. We may only distribute dividends out ofâ€‰â€œprofits,â€ as defined by the Companies Law and provided that the distribution is not reasonably expected to impair our ability to fulfill our outstanding and anticipated obligations as they become due. If we do not distribute dividends, our ordinary shares may be less valuable because a return on your investment will only occur if the price of our ordinary shares appreciates. Â We incur significant costs operating as a public company in the United States, and our management is required to devote substantial time to compliance matters. Â As a public company whose ordinary shares are listed in the United States, we are subject to an extensive regulatory regime, requiring us, among other things, to maintain various internal controls and facilities and to prepare and file periodic and current reports and statements. Complying with these requirements is costly and time consuming. In the event that we are unable to demonstrate ongoing compliance with our obligations as a public company, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities and investors may lose confidence in our operating results, and the price of our ordinary shares could decline. As of December 31, 2020, we became a â€œlarge accelerated filerâ€ beginning from December 31, 2020. We have incurred significant management time and cost complying with the more stringent reporting requirements applicable to â€œaccelerated filers,â€ including complying with auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. Â We are subject to legal proceedings that may adversely affect our business, financial condition or results of operations. Â We are subject to various litigation claims and legal proceedings including securities class actions and potential derivative claims and proceedings based thereon, personal injury, customer contract, environmental and employment claims. Certain of these lawsuits or potential future lawsuits, if decided adversely to us or settled by us, may result in liability and expense material to our consolidated financial condition and consolidated results of operations. Â We may be subject to shareholder activism, including proposals or demands by our shareholders to effect changes in our governance, corporate structure or business strategy. Â Activist shareholders may seek to influence or control decisions regarding matters such as our operations, distributions, management, compensation or other key aspects of our business or operations.Â Such activism could result in significant costs and management distraction, diverting resources away from our strategic priorities. Shareholder activism could give rise to perceived uncertainties as to our future prospects and adversely affect our business, operations, financial condition and stock price.Â Additionally, increased activist activity may lead to volatility in our stock price and potentially adversely impact our relationship with investors, customers, employees, and other stakeholders. Â U.S. investors in the Company could suffer adverse tax consequences if we are characterized as a passive foreign investment company. Â We believe that we were not a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for our taxable year ended December 31, 2024, and we do not expect to be classified as a PFIC for the current year ending December 31, 2025 or the foreseeable future. However, the determination of whether we are a PFIC is a factual determination made annually based on all the facts and circumstances and thus is subject to change. The relevant rules for determining whether or not we are a PFIC as applied to our business are not entirely clear and certain aspects of the relevant tests will be outside our control. Therefore, no assurance can be given that we will not be a PFIC for any taxable year. Â 25 If we are determined to be a PFIC at any time during which a U.S. Holder (as defined in â€œItem 10E. Additional Informationâ€“Taxationâ€“Material U.S. Federal Income Tax Considerations to U.S. Holdersâ€) holds our shares, such U.S. Holder may be subject to materially adverse tax consequences, including additional U.S. federal income tax liability and tax filing obligations. See â€œItem 10E. Additional Informationâ€“Taxationâ€“Material U.S. Federal Income Tax Considerations to U.S. Holdersâ€“Passive Foreign Investment Company Considerations.â€ U.S. Holders are strongly urged to consult their tax advisors as to whether or not we will be a PFIC. Â If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares. Â Effective internal control over financial reporting is necessary for us to provide reliable financial reports. As a â€œlarge accelerated filerâ€ we are responsible for establishing and maintaining internal controls and procedures that will allow our management to report on, and our independent registered public accounting firm to attest to, our internal controls over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404. Although our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 and our management is required to report on our internal controls over financial reporting under Section 404, any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ordinary shares. Â We are a â€œforeign private issuerâ€ and have disclosure obligations that are different from those of U.S. domestic reporting companies. Â We are a foreign private issuer and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we are not required to issue quarterly reports or proxy statements that comply with the requirements applicable to U.S. domestic reporting companies. Furthermore, although under regulations promulgated under the Companies Law, as an Israeli public company listed on the Nasdaq, we are required to disclose the compensation of our five most highly compensated officers on an individual basis, this disclosure will not be as extensive as that required of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file our annual report with the SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore, our officers, directors and principal shareholders are exempt from the requirements to report transactions and short-swing profit recovery required by Section 16 of the Exchange Act. Also, as a â€œforeign private issuer,â€ we are not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. Even though we may voluntarily elect to comply with Regulation FD and have done so in the past, these exemptions and leniencies reduce the frequency

and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting company. Â We would lose our foreign private issuer status if, as of June 30 in any calendar year, a majority of our outstanding shares are held of record by U.S. residents and a majority of our directors or executive officers are U.S. citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we lose our foreign private issuer status, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. Â 26 As a â€œforeign private issuer,â€ we are permitted to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers. Â As a â€œforeign private issuer,â€ we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. For instance, we follow our home country law instead of the listing rules of Nasdaq that require that we obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity-based compensation plans, an issuance that will result in a change of control of us, certain transactions other than a public offering involving issuances of a 20% or greater interest in the Company, and certain acquisitions of the stock or assets of another company. Under the Companies Law as currently applicable to us, there is no requirement to receive shareholder approval for the issuance of securities for such dilutive events, and under our amended and restated articles of association our board of directors is authorized to issue securities, including ordinary shares, warrants and convertible notes. Additionally, under the Companies Law, unless the articles of association otherwise provide, the quorum required for an ordinary meeting of shareholders must consist of at least two shareholders who hold at least 25% of the voting rights (instead of the 33 and 1/3% required under Nasdaq rules), and we are not required to have a nominating committee consisting solely of independent directors for the nomination of directors. See â€œItem 16G. Corporate Governanceâ€ for details on the differences between Israeli corporate governance practices and comparable U.S. requirements and other home country practices we follow instead of the listing rules of Nasdaq. We may in the future elect to follow home country corporate governance practices in Israel with regard to other matters. Following our home country corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection to you than what is accorded to investors under the listing rules of Nasdaq applicable to domestic U.S. issuers. Â Risks Related to Our Operations in Israel Â The impact of political, economic and military conditions in Israel, including the ongoing Israel-Hamas war, and the surrounding region could directly affect our business. Â Our principal executive offices and research and development facilities as well as our third-party manufacturers are located in Israel. In addition, all of our subcontractors are located in Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region could directly affect our business. Â On the military front, since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors, Hamas (an Islamist militia and political group that controls the Gaza Strip), Hezbollah (an Islamist militia and political group that controls large portions of southern Lebanon), and with Iranian-backed military forces in Syria and the region. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip, Lebanon and Syria against civilian targets in various parts of Israel, including areas in which our employees and third-party manufacturers are located. Any hostilities involving Israel, regional political instability or the interruption or curtailment of trade between Israel and its trading partners could materially and adversely affect our operations and results of operations. Â In particular, in October 2023, Hamas terrorists infiltrated Israelâ€™s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers. These attacks resulted in extensive deaths, injuries, and kidnapping of civilians and soldiers, as well as evacuations of tens of thousands of civilians from their homes. Following the attacks, Israelâ€™s security cabinet declared war against Hamas and commenced a military campaign and the Israel Defense Force (the â€œIDFâ€), the national military of Israel, began to call-up reservists for active duty. During January 2025, Israel and Hamas have agreed to a Gaza three-phase ceasefire agreement and partial hostage release, the first six-week phase of such ceasefire began on January 19, 2025. There is no certainty that the subsequent phases of this ceasefire will be agreed and consummated and that the ceasefire will last in the long term. Â Several of our employees are subject to military reserve service in the IDF and have been and may be called to serve. Since the war with Hamas broke out and as of the date of this Annual Report, 12 of our employees served in active duty. Military reserve service call ups that result in absences of personnel for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations. Â In addition, since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran who joined the hostilities against Israel by firing hundreds of drones, ballistic missiles and guided missiles to Israel causing further uncertainty in the region. During November 2024, a ceasefire agreement was reached between Israel and Hezbollah with sporadic breaches. It is possible that these hostilities will escalate in the future into a greater regional conflict, and that additional terrorist organizations, including Hezbollah, the rebels in Syria, Palestinian military organizations in the West Bank, as well as other hostile countries, such as Iran, will actively join or escalate the hostilities. Â 27 In addition, in Syria, a country bordering Israel, a civil war is taking place and during December 2024, Syrian Islamist rebel forces seized control of Syria, and the Assad regime collapsed, adding additional instability to the region. Â Such hostilities may include terror and missile attacks. In the event that our facilities are damaged as a result of hostile actions, or hostilities otherwise disrupt our ongoing operations, our ability to deliver or provide products and services in a timely manner to meet our contractual obligations towards customers and vendors could be materially and adversely affected. Â The scope, intensity and duration of Israelâ€™s current war against Hamas is difficult to predict, as are such warâ€™s economic implications on our business and operations and on Israelâ€™s economy in general. For example, these events may be intertwined with wider macroeconomic indications of a deterioration of Israelâ€™s economic and political standing, which may involve, for instance, a downgrade in Israelâ€™s credit rating by rating agencies (such as the recent downgrade by Moodyâ€™s of its credit rating of Israel from A1 to A2, as well as the downgrade of its outlook rating from â€œstableâ€ to â€œnegativeâ€, followed by additional downgrade from A2 to Baa1 while maintaining â€œnegativeâ€ outlook. Any of these implications on Israelâ€™s economy or financial conditions may have a material adverse effect on us and our ability to effectively conduct our business and operations. Â Further, as an Israeli company, there is a heightened risk of cyberattacks on our and our supply chainâ€™s IT networks by our adversaries in general, and more so as a result of the ongoing war with Hamas and other conflicts in the region. Although the current war has not materially impacted our business or operations as of the date of this report, any escalation or expansion of the war could have a negative impact on both global and regional conditions and may adversely affect our business, financial condition and results of operations. Â Furthermore, following Hamasâ€™ attack on Israel and Israelâ€™s security cabinet declaration of war against Hamas, the Houthi movement, which controls parts of Yemen, launched a number of attacks on marine vessels traversing the Red Sea, which marine vessels were thought to either be in route towards Israel or to be partly owned by Israeli businessmen. The Red Sea is a vital maritime route for international trade traveling to or from Israel. As a result of such disruptions, we may experience in the future delays in supplier deliveries, extended lead times, increased cost of freight, increased insurance costs, and increased materials and manufacturing labor costs. The risk of ongoing supply disruptions may further result in delayed deliveries of our products. Â Moreover, political uprisings and conflicts in various countries in the Middle East are affecting the political stability of those countries. This instability has raised concerns regarding security in the region and the potential for armed conflict. Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and certain other countries. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may be disinclined to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary, in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. Â In addition, the potential of further escalation of Israel-Hamas conflict and other conflicts in the region could cause disruptions to our operations, and a delay in the development, production and shipment of our products and the heightened tension in our relations with various Middle Eastern countries could adversely affect our customer relationships as well as our sales and performance of existing or future contracts, which in turn could adversely affect our operating results, financial conditions and the expansion of our business.Â Furthermore, the ongoing Israel-Hamas war and other conflicts in the region and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies.Â Although the length and impact of this ongoing conflict are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices and supply chain disruptions. For more information about the impact of the Israel-Hama war on our operations and financial results, please see â€œItem 3. Key Information â€“ D. Risk Factorsâ€“Risks to Our Business and Industryâ€. Â 28 Finally, on the political front, Israel has held five general elections between 2019 and 2022, and prior to the Hamas attack in October 2023, the Israeli government had been pursuing legislative changes, which, if adopted, will alter the current state of separation of powers among the three branches of government and, as a result, have sparked a considerable political debate. Many individuals, organizations and institutions, within and outside of Israel, voiced concerns over the potential negative impacts of such changes and the controversy surrounding them on the business and financial environment in Israel. Such negative impacts may include, among other things, increased interest rates, currency fluctuations, inflation, civil unrest and volatility in the securities markets, which could adversely affect the conditions in which we operate and potentially deter foreign investors and organizations from investing or transacting business with Israeli-based companies. To date, these initiatives have been substantially put on hold, but if such changes to Israelâ€™s judicial system are again pursued by the government and approved by the parliament, or if any of the foregoing negative impacts were to materialize, it may have an adverse effect on our business, our results of operations and our ability to raise additional funds. Â Our commercial insurance may leave us subject to a risk of a loss if a terrorist attack or act of war occurs. Â Our insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East or for any resulting disruption in our operations. Although the Israeli government has in the past covered the reinstatement value of direct damages that were caused by terrorist attacks or acts of war, we cannot be assured that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully for damages incurred and the government may cease providing such coverage or the coverage might not suffice to cover potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions generally and could harm our results of operations. Â Boycotts and various Middle Eastern business restrictions in the region may adversely impact our ability to operate and sell our products. Â Several countries, principally in the Middle East, restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of the ongoing and revived hostilities in the region, the ongoing Israel-Hamas war or otherwise. In addition, there have been increased efforts by activists to cause companies and consumers to boycott Israeli goods based on Israeli government policies. Although Israel had signed bilateral peace agreements with several Middle Eastern countries for forging new economic ties with them, the performance of such bilateral peace agreements could be adversely affected by the going and revived hostilities in Israel region, which has caused a substantial strain on Israelâ€™s regional relations with a number of Middle Eastern countries, such as Egypt and Jordan whose relations with Israel had long been cold but worsened since the outbreak of the war.Â The restrictive laws and policies and the actions by boycott activists, if become more widespread and successful, and the fast-moving changes to Israelâ€™s geopolitical relations as a result of the war, may seriously limit our ability to sell our products in these countries and may have an adverse impact on our operating results, financial conditions or the expansion of our business. Â We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business. Â We have entered into assignment of invention agreements with our employees pursuant to which such individuals agree to assign to us all rights to any inventions created during their employment or engagement with us. A significant portion of our intellectual property has been developed by our employees in the course of their employment with us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company and as a result thereof are regarded as â€œservice inventions,â€ which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no agreement between an employer and an employee with respect to the employeeâ€™s right to receive compensation for such â€œservice inventions,â€ and to what extent and under which conditions, the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his or her service inventions and the scope and conditions for such remuneration. The Patent Law further provides criteria for assisting the Committee in making its decisions. Case law clarifies that the right to receive consideration for â€œservice inventionsâ€ can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework between the parties, applying interpretation rules of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration, nor the criteria or circumstances under which an employeeâ€™s waiver of his right to remuneration will be disregarded. Similarly, it remains unclear whether waivers by employees in their employment agreements of the alleged right to receive consideration for service inventions should be declared as void being a depriving provision in a standard contract. Although our employees have agreed to assign to us service invention rights and have specifically waived their right to receive any special remuneration for such service inventions beyond their regular salary and benefits, as a result of uncertainty under Israeli law with respect to the efficacy of waivers of service invention rights, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business. Â 29 Our operations may be affected by negative economic conditions or labor unrest in Israel. Â General strikes or work stoppages, including at Israeli ports, have occurred periodically or have been threatened in the past by Israeli trade unions due to labor disputes. These general strikes or work stoppages may have an adverse effect on the Israeli economy and on our business, including our ability to deliver products to our customers and to receive raw materials from our suppliers in a timely manner and could have a material adverse effect on our results of operations. Â You may have difficulties enforcing a U.S. judgment against us, our executive officers and directors and Israeli experts named in this Annual Report on Form 20-F in Israel or the United States, asserting U.S. securities laws claims in Israel or serving process on our officers and directors and these experts in Israel. Â We are incorporated in Israel and our corporate headquarters is located in Israel. Many of our executive officers and directors reside outside of the United States, and a significant portion of our assets and the assets of certain of our directors and executive officers are located outside the United States. Therefore, a judgment obtained against us or any of them in the United States, including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. Further, if a foreign judgment is enforced by an Israeli court, it will be payable in Israeli currency. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. Â Moreover, among other reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel. Â Provisions of our amended and restated articles of association and Israeli law may delay, prevent or make

difficult a merger with, or an acquisition of, the Company, which could prevent a change of control even when the terms of such transaction are favorable to us and our shareholders and, therefore, could depress the price of our ordinary shares. Â As a company incorporated under the laws of the State of Israel, we are subject to Israeli corporate law. Israeli corporate law regulates mergers, requires tender offers for acquisitions of ordinary shares above specified thresholds, requires special approvals for transactions involving directors, officers or certain significant shareholders and regulates other matters that may be relevant to these types of transactions. In addition, our amended and restated articles of association contain provisions that may make it more difficult to acquire us, such as classified board provisions. Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax obligations. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including, in some cases, a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are subject to certain restrictions. See â€œItem 10E. Additional Informationâ€“Taxationâ€“Israeli Material Tax Considerationsâ€ for additional information. These provisions of our amended and restated articles of association and Israeli law may delay, prevent or make difficult an acquisition of us, which could prevent a change of control and therefore depress the price of our ordinary shares. Â 30 In addition, as a corporation incorporated under the laws of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988, and the regulations promulgated thereunder (formerly known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances to obtain the approval of the Israel Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or substantially all of our assets. Â Your rights and responsibilities as a holder of our ordinary shares will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. Â Since we are incorporated under Israeli law, the rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law, including the Companies Law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law, a shareholder of an Israeli company has certain duties, including to act in good faith and fairness and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power in the company including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to the companyâ€™s articles of association, an increase of the companyâ€™s authorized share capital, a merger of the company, and approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholdersâ€™ vote or to appoint or prevent the appointment of an officer of the company has a duty to act in fairness towards the company with regard to such vote or appointment. See â€œItem 6C. Directors, Senior Management and Employeesâ€“Board Practicesâ€“Approval of Related Party Transactions under Israeli Lawâ€ for additional information. There is limited case law available to assist in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. Â Â ITEM 4. INFORMATION ON THE COMPANY Â A. History and Development of the Company Â We were incorporated as a limited liability company in the State of Israel on January 2, 2008, and operate under its laws. In November 2017, our corporate name was changed from Invasix Ltd. to InMode Ltd. Our registered office is located at Tavor Building, Shaâ€™ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel. The phone number of our registered office is +972-4-9096313. Our whollyâ€‘owned subsidiary, Invasix Inc., a Delaware corporation, acts as our agent for service of process in the United States and is located at 17 Hughes Irvine, California 92618. The phone number for Invasix Inc. is 949-387-5711. Â In August 2019, we completed our initial public offering of 10,000,000 of our ordinary shares at an initial public offering price of $7.00 per ordinary share. The effective date of the registration statement on Form F-1 (File No. 333-232615) was August 7, 2019. Also, during August 2019, the underwriters partially exercised their over-allotment option and purchased an additional 1,000,000 ordinary shares at the same price per share. Our ordinary shares commenced trading on Nasdaq on August 8, 2019, under the symbol â€œINMDâ€. Â Our capital expenditures for the years ended December 31, 2024, 2023 and 2022 amounted to approximately $$0.7 million, $0.8 and $1.6 million, respectively. Our capital expenditures consist principally of the purchase of molds for manufacturing. We anticipate our capital expenditures in 2025 to be up to $1 million and to be financed from our existing cash and cash equivalents. Â The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers, including InMode, that file electronically with the SEC. The address of that site is www.sec.gov. We maintain a corporate website at www.inmodemd.com. Our periodic filings are available, free of charge (other than an investorâ€™s own Internet access charges), on our website soon as reasonably practicable after we electronically file or furnish such material with the SEC. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this Annual Report on Form 20-F, and the reference to our website in this Annual Report on Form 20-F is an inactive textual reference only. Â 31 B. Business Overview Â Overview Â We are a leading global provider of innovative, energy-based, minimally invasive surgical medical treatment solutions. Within the global aesthetics market, our products and solutions are primarily designed to address three energy-based treatment categories comprised of: (i) face and body contouring; (ii) medical aesthetics; and (iii) womenâ€™s wellness. We have developed and commercialized products utilizing medically accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. We believe our RF energy-based proprietary technologiesâ€“(i) Radio Frequency Assisted Lipolysis, or RFAL; (ii) Deep Subdermal Fractional RF; (iii) Simultaneous Fat Destruction and Skin Tightening; and (iv) Deep Heating Collagen Remodeling for skin and human natural openings â€“ represent a paradigm shift in the minimally invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures including liposuction with simultaneous skin tightening, face and body contouring, ablative skin rejuvenation treatments and treatment of Genitourinary Syndrome of Menopause (GSM). Our products, developed with our proprietary RF energy-based technologies, overcome many of the shortcomings of other surgical options by delivering surgical-grade results under local anesthetics while significantly minimizing risks of scarring, downtime, pain and other complications typically accompanying surgical procedures. In addition to our minimally invasive solutions, we design, develop, manufacture and market differentiated, non-invasive medical aesthetic products that target a wide array of procedures. These include simultaneous fat destruction and skin tightening, permanent hair reduction through the use of our innovative dual wavelength technology and other treatments targeting skin appearance and texture through the use of our high-power IPL technology. Our products, which we market and sell traditionally to plastic and facial surgeons, aesthetic surgeons, dermatologists and OB/GYNs may be used on a variety of body parts including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. Â In addition to the existing group of patients who currently undergo full surgical aesthetic procedures, we believe our minimally invasive solutions satisfy an unmet market demand in two incremental groups of patients: (i) those whose skin laxity or other physical attributes have previously precluded them from undergoing surgical aesthetic procedures and (ii) those who would entertain the idea of surgical or minimally invasive aesthetic procedures, but are averse to the associated costs, downtime and potential safety risks. We believe these patient populations will continue to represent a significant opportunity for our differentiated minimally invasive aesthetic solutions. Â We believe our products have consistently been at the forefront of technological development in the aesthetic solutions market. Since 2010, we have launched fourteen product platforms: BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, Morpheus8, EmpowerRF, Define, Envision, IgniteRF and OptimasMAX. Each product consists of the following components: a platform that incorporates multiple energy sources, one or more handpieces or hands-free applicators, our proprietary software and a simple user interface with touch screen. Our platforms have a small footprint and are lightweight compared to our competitorsâ€™ systems, which are typically larger and heavier. Our products can be upgraded easily by the user in order to perform additional treatments by adding handpieces, hands-free applicators and/or installing software in the existing platform. The ease of upgrades enables our customers to meet demand for aesthetic solutions through additional service offerings. Â Our focus on innovation has resulted in a strong track record of sustained new and next-generation product development. We believe our ability to bring new products to market and continuously innovate is a distinct competitive advantage. Â We expect that the new product platforms will complement our existing portfolio of products, allowing us to increase our offerings to existing customers and attract new customers. We believe that introducing new product platforms is important in order to satisfy consumer demand and respond to evolving technological developments and consumer needs. Â In response to customersâ€™ desires to enhance and expand their offering of our aesthetic and wellness office-based procedures, we are developing additional RF energy-based platforms, handpieces and applicators targeted towards several medical specialties. Â â€¢ For ENTs, we are in the initial stage of developing a new platform and handpieces that we believe will provide patients with a medical treatment solution for snoring and rhinitis. The handpiece for treatment of turbinates is based on our Deep Subdermal Fractional RF technology and is expected to contract the turbinate to enable free breathing. This platform and handpiece is in the concept design phase. Â â€¢ For urologists, we bring to the market a device using RF energy to treat ED (Erectile Dysfunction). We registered a patent application to protect our technological concept, and we believe that our technological concept will work well for this indication but much more research and development is needed. Â 32 We are focused on establishing and using clinical evidence to support and broaden our marketing claims and drive customer awareness and acceptance of our products. Traditionally, the aesthetic solutions market has relied heavily on marketing efforts and â€œbefore-and-afterâ€ pictures in an attempt to distinguish products. We believe our focus on establishing clinical evidence for the efficacy of our products has been important for adoption by our surgically trained customers, who are accustomed to seeing extensive clinical data in their non-aesthetic practices. To date, Â 95 third-party clinical studies have been completed and ten third-party clinical studies are in the process of being conducted using our products. We also have a portfolio of over 100 peer-reviewed publications. While we did not have any involvement in the clinical studies mentioned above, such studies provide qualitative results that we believe are meaningful. However, because these were third-party studies, we do not have access to any raw data to conduct any quantitative analyses. Â To complement our surgical aesthetic and medical treatment solutions, we offer post-sales training and support services. We provide physicians with training focused on the most beneficial ways to utilize our products, including safety and instructional videos to expand procedural offerings and hands-on, personalized marketing support. We believe that we provide one of the most extensive training and ongoing support programs available to physicians throughout the aesthetic solutions market. Â Our revenue decreased to approximately $394.8 million for the year ended December 31, 2024, from approximately $492.0 million for the year ended December 31, 2023 and from approximately $454.3 million for the year ended December 31, 2022. For the years ended December 31, 2024, 2023 and 2022, we recorded a gross margin of approximately 80%, 84% and 84%, respectively, and net income of approximately $181.3 million, $197.9 million and $161.5 million, respectively. Our principal market is in the U.S., where our revenue decreased to approximately $244.8 million for the year ended December 31, 2024, from approximately $307.8 million for the year ended December 31, 2023 and from approximately $298.6 million for the year ended December 31, 2022. Outside of the U.S., our revenue decreased to approximately $150.0 million for the year ended December 31, 2024, from approximately $184.2 million for the year ended December 31, 2023 and from approximately $155.7 million for the year ended December 31, 2022. Â Regarding U.S. revenues for the years ended December 31, 2024, 2023 and 2022, we derived approximately $223.7 million, or 92%, $264.7 million, or 86% and $253.8 million, or 85%, of our total U.S. revenues from the sale of minimally invasive platforms. We derived approximately $15.2 million, or 6%, $33.9 million, or 11% and $35.8 million, or 12%, respectively, of our total U.S. revenues from the sale of hands-free platforms, and approximately $5.9 million, or 2%, $9.2 million, or 3% and $8.9 million, or 3%, respectively, of our total U.S. revenues from the sale of non-invasive platforms. Â We have 35 FDA clearances and, in addition to the United States, where we have an installed base of over 11,860 product platforms, we are permitted to sell our products in most countries. As of December 31, 2024, we sell and market our products in the United States, Canada, United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxembourg, Italy, Germany, Austria, Japan, Australia and India through a direct sales force (including distributor sales managers) of approximately 267Â representatives. We also sell and market our products through over 60 distributors in over 85 countries. As of December 31, 2024, we had a global installed base of approximately 27,090 product platforms capable of running various multi-use applicators and utilizing minimally invasive consumables. Â Our Solution Â Key benefits of our minimally invasive surgical aesthetic and medical treatment solutions include: Â â€¢ Small to no incisions, which reduces the drawbacks and risks typically associated with surgical procedures such as significant pain, local or widespread scarring, infection, perforation and hemorrhage. Â â€¢ Outpatient procedures that typically do not require general anesthesia, which can decrease patient downtime, discomfort and other potential complications and typically reduces cost. Â â€¢ Minimally invasive procedures with similar efficacy to surgical procedures that have the ability to expand the addressable patient population for aesthetics procedures. Â â€¢ Effective and long-lasting aesthetic solutions, many of which are supported by compelling clinical data, including over 100 peer-reviewed publications. Â â€¢ Differentiated, RF energy-based technology simultaneously destroys fat and tightens skin, overcoming the many shortcomings of traditional surgical, minimally and non-invasive aesthetic procedures. Â â€¢ Innovative dual wavelength laser technology that allows for permanent hair reduction on a wider range of skin types and hair textures than other aesthetic solutions currently on the market, reducing the number of treatments required. Â â€¢ Typically less expensive than other aesthetic solutions on the market that provide comparable results as a result of less required physician time and training required. Â 33 Leader in RF Energy Â We believe we are the leader in using RF energy for both minimally invasive and subdermal ablative aesthetic purposes. RF energy is different from optical energy because it is not absorbed by the epidermis and is able to be targeted to penetrate deep into the tissue. The application of RF energy in medicine is a well-established practice. For example, RF energy is the basis of magnetic resonance imaging, or MRI, and surgical diathermy, used to cauterize blood vessels to prevent excessive bleeding, both commonplace applications administered regularly in medical practice. RF energy is also used in cardiology for ablative interventions and in oncology surgery for tumor/metastasis ablation. Â RF energy can be delivered to the skin in a variety of ways, the most common being monopolar delivery, whereby RF energy is delivered through a single probe placed on the skin with a grounding pad distant to the probe site. Alternatively, in bipolar delivery, RF energy is delivered from a probe with two electrodes placed over the treatment area. Bipolar delivery has an important advantage over monopolar delivery: depth of penetration of the RF energy is not dependent on the tissue impedance, or electrical resistance, which varies from person to person, or the cross-sectional area of the probe. That is not the case with monopolar delivery. Instead, in bipolar delivery, depth of penetration of the RF energy depends on the distance between the two electrodes on the probe, with increasing distance resulting in increased depth of penetration. We believe we are the leader in the development, design and commercialization of bipolar RF energy devices for minimally invasive and subdermal ablative aesthetic purposes. Â Radio-Frequency Assisted Lipolysis Â Using our expertise in bipolar RF energy delivery, we developed what we believe is the next generation of lipolysis and adipose tissue remodeling technology, a new category that delivers a thermal response to the adipose tissue, skin and subdermal matrix. Our RFAL products deliver directional RF energy into the subcutaneous fat to coagulate, liquefy and remodel adipose tissue and heat the subcutaneous fibrous septa, or partitions, resulting in substantial collagen contraction of subdermal space. We believe we are the first company to utilize bipolar radio frequency in a minimally invasive manner. Our RFAL products generate a higher power and more efficient energy transfer than laser energy systems and allow the treatment of larger volumes of the subcutaneous tissue with optimal thermal profiles, facilitating the significant tightening of the tissue. The shrinkage of tissue is significant and can reach double-digit percentages of the heated tissue volume. The thermal energy is delivered by an innovative handpiece comprised of two electrodes: the internal electrode is inserted into the fat layer while the other larger electrode is applied externally to the skin surface above the cannula tip. The internal cannula is passed through the subcutaneous fat while the external electrode is moved above and over the skinâ€™s surface. The small, conductive tip of the cannula delivers RF energy into the subcutaneous fat, liquefying it and simultaneously contracting fibrous septa. The liquefied fat can then be removed from the body through a suction cannula. Our RFAL products also apply gentle uniform heating of the dermis, thereby promoting skin tightening. Figure 1 below shows how the RF energy is delivered through the handpiece to simultaneously liquefy fat and tighten the skin. Â 34 Our BodyTite, EmbraceRF and IgniteRF platforms, and the BodyTite,Â FaceTite and QuantumRF handpieces rely on our proprietary RFAL technology. To date, there have been more than 280,000 successful RFAL procedures conducted with positive clinical results using our BodyTite, EmbraceRF and IgniteRF platforms, and the BodyTite, FaceTite and QuantumRF handpieces.Â We have demonstrated that RFAL has the potential to elicit three-dimensional soft tissue contraction reliably and predictably to both serve otherwise non-traditional liposuction candidates, as well as to improve outcomes in patients for whom liposuction is an option. Â Â Â Figure 1: RFAL mechanism of action. Â Deep Subdermal Fractional RF Â Our Deep Subdermal Fractional RF delivers RF energy into the subdermal fat tissue to depths of up to four millimeters, or mm. Deep Subdermal Fractional RF provides skin tightening and adipose tissue remodeling directly under the dermal layer. Our Deep Subdermal Fractional RF products deliver RF energy under the dermis through an array of pins producing localized heat and small micro-lesion dots in the treatment area. The heat generated by the pins in the

subdermal tissue promotes collagen restructuring and tissue reshaping. Physicians can offer a versatile fractional treatment creating a three-dimensional matrix of coagulation volumes inside the tissue. Deep Subdermal Fractional RF is used for wrinkle reduction, skin tightening and treatment of cellulite appearance. Our deep subdermal fractional RF can be applied to both face and body. Our Morpheus8, Morpheus8 Body, Morpheus Burst and Morpheus8 V handpieces rely on our proprietary Deep Subdermal Fractional RF technology and are used in conjunction with our BodyTite, Embrace RF, Optimas, IgniteRF, OptimasMAX , EmpowerRF, Envision and Define platforms. Figure 2 below shows how the RF energy is delivered through the coated pins on the handpiece to reshape tissue under the dermal layer. Â â€‰Â Figure 2: Deep Subdermal Fractional RF mechanism of action. Â Simultaneous Fat Destruction and Skin Tightening Â Our Simultaneous Fat Destruction and Skin Tightening proprietary technology combines vacuum and bipolar RF energy with high and low amplitudes to both permanently destroy adipose tissue and contract the skin. We believe our Simultaneous Fat Destruction and Skin Tightening technology is the first and only RF-based, non-invasive body contouring technology that permanently destroys adipose tissue. Our BodyFX handpiece and MiniFX handpiece utilize our Simultaneous Fat Destruction and Skin Tightening technology to address problematic fatty tissue in larger body areas such as the abdomen, back and thighs. Â Deep Heating Collagen Remodeling for Skin and Human Natural Openings Â Our Deep Heating Collagen Remodeling propriety technology delivers heat in a uniform and volumetric form targeting deep into tissue while providing collagen remodeling with real-time control of the deviceâ€™s temperature. The versatility of this technology allows the operator to provide a customized solution to address a variety of womenâ€™s wellness concerns that occur due to aging, hormonal stress or physical damage. Our Forma,Â FormaV, and Morpheus8V handpieces utilize Deep Heating Collagen Remodeling technology while harnessing continuous bipolar RF energy with real-time temperature measurement. RF energy generated heat is delivered uniformly to vaginal tissue through a consumable applicator to provide vaginal and labia contraction with patients often seeing effects of the procedure immediately. Â 35 Pulse/Continuous Bipolar RF Â Continuous Bi-polar RF is electrical energy in the RF spectrum (1 MHz) that results from the flow of an electric charge between two electrodes. This conducted energy increases ion movement in the tissue and generates kinetic energy that is transformed to thermal energy (heating). In turn, this thermal energy causes controlled damage to the tissue and triggers a natural healing mechanism and tissue-renewal resulting in tissue tightening and remodeling. The distance between the electrodes allows for control of the depth of penetration of the bi-polar RF energy into the tissue. The distance between the electrodes is chosen based on the particular treatment and according to the tissue to be treated (generally varies between a few millimeters to 3-4 centimeters). Bi-polar RF can be delivered to the tissue in one of two modes: either pulse or continuous. In pulse mode, pulse duration is pre-determined and RF energy automatically stops. In continuous mode, the RF energy is delivered uninterrupted into the tissue for as long as the operator deems appropriate. As part of the design, continuous bi-polar RF energy allows real-time measurement of the patientâ€™s skin temperature. This allows our products to provide real-time feedback to the operator throughout the treatment process and enhances overall safety and efficiency. All of our RF platforms (both existing and expected) and RF handpieces (both minimally and non-invasive) have both pulse bi-polar RF and continuous bi-polar RF capabilities. Our proprietary RFAL-based products (such as our BodyTite and IngiteRF platforms with BodyTite, FaceTite and QuantumRF handpiece) and Deep Heating Collagen Remodeling based products (such as our Forma and Plus handpieces) primarily utilize the continuous bipolar RF feature. Our proprietary Deep Subdermal Fractional RF based products (such as our Morpheus8 and Mopheus8 Burst handpieces) and Simultaneous Fat Destruction and Skin Tightening products (such as our BodyFX and Mini FX handpieces) primarily utilize the pulse feature depending on the procedure and target result. Figure 3 below shows how RF energy is delivered through the handpiece by an electric charge between two electrodes continuously into the tissue. Â â€‰Â Figure 3: Pulse/Continuous Bi-polar RF mechanism of action. Â Non-invasive Medical Aesthetic Technologies Â In addition to our proprietary minimally invasive solutions, we continue to develop innovative non-invasive medical aesthetic solutions, including: Â â€¢ Simultaneous non-invasive fat destruction and skin tightening. We believe our technology is the first and only RF-based, noninvasive body contouring technology that permanently destroys adipose tissue while simultaneously contracting the skin. This technology addresses problematic fatty tissue in large body areas such as the abdomen, back and thighs. Customers use this technology with the Contoura platform and the BodyFX and MiniFX handpieces. Â â€¢ Dual wavelength for permanent hair reduction. Our single-pulse, dual wavelength product for permanent hair reduction, Triton, combines two wavelengths in one platform, overcoming certain limitations of standard lasers. This optimal mix of wavelengths allows the highest efficiency and safety. We believe Triton is the only FDA-cleared, single-pulse, dual wavelength product for permanent hair reduction. Customers use this technology with the Triton DuoÂ Light and Triton DuoÂ Dark handpieces. Â â€¢ High-power Intense Pulsed Light. Our high-power IPL is a breakthrough technology that delivers up to three times more energy than typical IPL devices within the 500 to 600 nanometers, or nm, range to improve efficacy for vascular and pigmented lesions. It is optimized to treat a variety of skin types and conditions in a single session. Customers use this technology with the Optimas and the OptimasMAX platforms and the Lumecca handpiece. Â â€¢ Controlled continuous RF heating. We believe our controlled continuous RF technology is the first auto-adjusting non-invasive thermal skin treating technology for deep and uniform tissue stimulation. This technology uses bipolar RF energy delivery that allows uniformity between the electrodes to provide a comfortable thermal effect with immediate and subsequent contraction. Customers use this technology with the Optimas, OptimasMAX, Votiva, Define, Contoura, Evoke and EvolveX hands-free platforms and EmpowerRF for womenâ€™s wellness, as well as the Envision. Â 36 Differentiated and Comprehensive Post-Sales Support Â To complement our innovative aesthetic solutions, we offer post-sales training and support services. We provide physicians training focused on the most beneficial ways to utilize our products, including a disciplined focus on safety. Our clinical training and support program consists of three key components: Â i. A visit by a new physician to one of our many highly qualified plastic surgery facilities for instruction followed by a live patient demonstration; Â ii. A visit to the new physicianâ€™s office by a trained registered nurse or physicianâ€™s assistant to attend the first day of treatments to in-service; and iii. Open house workshops organized by us, wherein a new physician invites this patient base and we assist them in â€œkick startingâ€ marketing efforts. These events typically secure significant procedural revenues for the physician. Â In addition, we offer ongoing livestream classes for customers where they can observe and interact in real-time with both our training staff and highly qualified physician instructors on a regular basis. Advanced training is also available for physicians who choose to expand their education on highly skilled procedures, including non-excisional breast lifting or brachioplasty. We are continuing to build a library of on-line instructional videos as both a reference tool and to expand physiciansâ€™ procedural offerings. We also provide support to help customers educate and engage patients about the new minimally invasive procedures available to them through our In-Practice program. This program provides hands-on, personalized marketing support for customersâ€™ practices including signage, educational collateral, digital marketing and advertising assets. We believe that we provide one of the most extensive training and ongoing support programs available to physicians throughout the aesthetics industry. Â Our Competitive Strengths Â We attribute the growing commercial success of our various platforms and products to the following: Â â€¢ Pioneer of the minimally invasive aesthetic solutions market. We believe our proprietary technologies represent a paradigm shift in the minimally invasive and surgical aesthetic solutions market. We believe our technologies and products demonstrate numerous performance advantages over other aesthetic options and enable physicians and patients to obtain results that previously could only be generally achieved with more expensive and invasive surgical procedures. Our RF proprietary energy-based technology simultaneously destroys fat and tightens skin, overcoming many of the limitations of other surgical, minimally and non-invasive procedures, positioning us to address unmet patient needs and expand the addressable patient population for aesthetic solutions. Unlike many of our competitors, our technology is not exclusively laser-based or limited to superficial treatment of the skin. Instead, we have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. Â â€¢ Strong brand recognition. Our brand is associated with product leadership, significant technological advances and extensive clinical data, which has led to strong customer loyalty. We believe our brand is synonymous throughout the physician and patient communities with having the broadest RF energy-based portfolio in the minimally invasive aesthetics market for fat destruction and remodeling, face and body contouring and skin tightening. Â â€¢ Provide comprehensive solutions for physicians and patients. We have an extensive product portfolio that includes solutions for a wide range of both minimally and non-invasive procedures across the aesthetic solutions market. Although each of our product platforms has a primary handpiece or applicator that is either minimally or non-invasive, our platforms are designed to be modular, which enables the user to provide complementary treatments using a single platform by attaching different handpieces or applicators. For each of our products, we offer post-sales support services including training, installation, practice growth consulting and repair support that minimizes product downtime and associated lost revenues to physicians. Â 37 â€¢ Broad regulatory approvals supported by extensive clinical data. We have 35 FDA clearances and in addition to the United States, are permitted to sell in United States, Canada, United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxembourg, Italy, Germany, Austria, Japan, Australia and India. To date, we also have a portfolio of over 100 peer-reviewed publications and there are over 95 completed and 10 ongoing third-party clinical studies on a number of our products (BodyTite, FaceTite, NeckTite, Optimas, Fractora, Morpheus8, Forma, Lumecca, DiolazeXL, Votiva, Morpheus8V, FormaV, Contoura, BodyFX, MiniFX, Evoke, EvolveX, Morpheus8, AccuTite and QuantumRF). While we did not have any involvement in the clinical studies mentioned above, such studies provide qualitative results that we believe are significant. However, because these were third-party studies, we do not have access to any raw data to conduct any quantitative analyses. We believe our focus on demonstrated clinical data and effectiveness differentiates us from our competition and helps to validate our technology with surgically-trained physicians, who we believe are typically the most difficult segment of the market to penetrate. Â â€¢ Strong management team with proven track record. Our management team has significant expertise in the medical aesthetics industry with a proven track record of successfully developing and commercializing innovative technologies. Moshe Mizrahy and Dr. Michael Kreindel, our co-founders, previously founded Syneron Medical Ltd. Our senior executive team has an average of over 15 years of medical aesthetics industry experience and has served in various leadership positions at Syneron Medical Ltd. and Cynosure, Inc. Â Our Growth Strategy Â Our objective is to expand our technological leadership in the surgical solutions market and to leverage our RF proprietary technologies to expand into additional medical solutions markets. We intend to achieve this goal by implementing the following strategies: Â â€¢ Increase our sales presence to target and expand our addressable market globally. We plan to continue to expand our direct sales organization and our distribution network and seek to recruit and train exceptionally talented sales representatives in existing and new markets to help us broaden the adoption of our products, drive further market penetration and expand beyond our traditional customer base. Â â€¢ United States: We have a direct sales presence in United States and plan to keep expanding our direct sales team. Â â€¢ Canada: We have a direct sales presence in Canada and plan to keep expanding our direct sales team. Â â€¢ Europe: We intend to establish sales and marketing organizations and a network of exclusive European distributors in addition to our subsidiaries network in the United Kingdom, Spain, Italy, France and Germany. Â â€¢ Latin America: We plan to strengthen our network of exclusive distributors in all countries in Latin America. Â â€¢ Asia-Pacific: In addition to our direct sales presence in India, Australia and Japan, we may also establish direct sales presence in China through our fully-owned subsidiary in China, Guangzhou InMode Medical Technology Ltd., as well as enhance our network of exclusive distributors in all other countries in Asia. Â â€¢ Continue to further penetrate our existing customer base and drive recurring revenues. We believe that there are opportunities for us to generate additional revenue from existing customers who are already familiar with our products. Since inception, we have sold over 3.4 million consumables. We expect that as our customer base grows, the percentage of our revenues attributable to consumables will increase. We also expect that certain customers will be candidates for technology upgrades to enhance the capabilities of their existing InMode products. In addition, as we continue to grow our support services program, we expect to seek to increase the number of customers that enter into extended warranties, which would provide us with additional recurring revenues. Â 38 â€¢ Leverage our existing technology to expand into new minimally and non-invasive applications. We have an active research and development pipeline focused on additional solutions targeted to our traditional customer base. Our near-term product development portfolio consists of new and second generation solutions for various conditions, including wearable, noninvasive face and body reshaping products, cellulite, large area lipolysis, fractional RF treatment of SUI (stress urinary incontinence), vaginal laxity pelvic floor muscle restoration, labiaplasty procedures, post-partum treatments and other GSM symptoms, snoring and rhinitis treatments, dry eye and eyelid treatments, TMJ (Temporomandibular Joint Disorders) and ED (Erectile Dysfunction). Â â€¢ Expand our customer base beyond traditional customers. We intend to develop products that leverage our minimally and non-invasive technologies to address the unmet market needs of a new customer base, which includes OB/GYNs, ENTs, ophthalmologists, general practitioners and aesthetic clinicians. We intend to adapt our products to the expertise and skill level of these providers, further expanding our addressable market. Â â€¢ Actively pursue business development opportunities. We may seek to engage in targeted business development activities, including acquisitions of technologies and strategic partnerships, in order to augment our product and technology portfolio in our existing and potentially adjacent markets. We believe we can leverage our global infrastructure and existing relationships to implement a disciplined tuck-in acquisition strategy. Â â€¢ Expand our intellectual properly and patent portfolio. We intend to expand our existing intellectual property and patent portfolio as we develop additional applications and continue to aggressively defend against potential infringement by our competitors. Â Our Products Â We offer a broad portfolio of aesthetic and medical treatment solutions that consist of a variety of platforms providing minimally and non-invasive applications. The following tables provide information concerning our product platforms and their applications. Â Minimally Invasive and Ablative Platforms Product Platform Energy Source(s) Year Introduced Handpiece(s) Primary (not Exclusive) Applications* BodyTite Bipolar RF 2010 BodyTite Body Contouring (MI) Â Â Â FaceTite Face Contouring (MI) Â Â Â NeckTite Neck Contouring (MI) Â Â Â AccuTite Face/Body Contouring (MI) Optimas Laser Bipolar RF IPL 2016 Morpheus8 Skin Rejuvenation (MI) Â Optimas MAX Â Â 2024 Forma Lumecca DiolazeXL VasculazeÂ Skin Rejuvenation (NI) Â Â Â Skin Rejuvenation & Pigmentation (NI) Â Â Â Hair Removal (NI) Â Â Â Vascular Lesion (NI) Â Â Â Facial Wrinkles and Texture (MI) Â Â Â Â Â EmbraceRF Bipolar RF 2018 FaceTite Face Remodeling (MI) Â Â Â Morpheus8 Facial Wrinkles and Texture (MI) Â Â Â AccuTite Face/Body Contouring (MI) Votiva Bipolar RF 2017 FormaV Womenâ€™s Wellness (MI) Â Â Â Â Womenâ€™s Wellness (NI) Morpheus8 Bipolar RF 2021 Morpheus8 Face and body fractional RF treatment (MI) Â Â Â Morpheus8 Body Â Envision Bipolar RF and IPL 2023 Forma i Lumecca I Morpheus8 Treatment of dry eyes Facial Rejuvenation Morpheus8 Burst Bipolar RF 2024 Morpheus8 Burst Morpheus8 Burst Deep Face and body fractional RF treatment (MI) EmpowerRF Bipolar RF and EMS 2021 FormaV, Morpheus8V, VTone, Aviva Womenâ€™s Wellness (MI) IgniteRF Bipolar RF 2024 QuantumRF Body and face contouring (MI) Â 39 Non-Invasive Platforms Â ProductÂ Platform EnergyÂ Source(s) YearÂ Introduced Handpiece(s) Primary (not Exclusive) Applications* Contoura Bipolar RF 2017 BodyFX Body Contouring Â Â Â MiniFX Face/Neck Contouring Â Â Â Plus Skin Tightening Triton Laser 2018 Triton Duo Light Hair Removal Â Â Â Triton Duo Dark Hair Removal Â Hand-Free Platforms Â ProductÂ Platform EnergyÂ Source(s) YearÂ Introduced Handpiece(s) Primary (not Exclusive) Applications* EvolveX Bipolar RF EMS 2021 Tite (HF) Skin Tightening Â Â Â Transform (HF) Body Contouring Â Â Â Tone (HF) EMS Evoke Bipolar RF 2020 Cheek (HF) Skin Rejuvenation Â Â Â Chin (HF) Skin Rejuvenation Define Bipolar RF 2023 Cheek (HF) Chin (HF) Skin Rejuvenation Skin Rejuvenation Â Â Â Â Â

energy for RFAL treatments using needle-size cannula and external electrodes to apply RF energy to the subcutaneous adipose tissue. The tissue is heated to 50Â°C to 70Â°C to destroy fat and contract connective tissue, simultaneously remodeling the dermis at external temperatures of up to 42Â°C. This handpiece allows tissue treatment using a 17cm cannula that provides treatment depth up to 50mm. Â Facerite/NeckTiteÂ â€“ The minimally invasive, consumableÂ FaceTiteÂ andÂ NeckTiteÂ handpieces, introduced in 2012, utilize directional RF energy for RFAL treatments using cannula with diameters of 1.8mm and 2.2mm and external electrodes to apply RF energy to the subcutaneous adipose tissue. The tissue is heated to 50Â°C to 70Â°C to destroy fat and contract connective tissue, simultaneously remodeling the dermis at external temperatures up to 42Â°C. This handpiece allows tissue treatment using a 10cm cannula that provides treatment depth up to 25mm. Â AccuTiteÂ â€“ The minimally invasiveÂ AccuTiteÂ handpiece, introduced in 2019, utilizes directional RF energy for RFAL treatments using sub-millimeter cannula with diameters of 0.9mm and external electrodes to apply RF energy to subcutaneous adipose tissue. The tissue is heated to 50Â°C to 70Â°C to destroy fat and contract connective tissue, simultaneously remodeling the dermis at external temperatures of up to 42Â°C. This handpiece allows tissue treatment using a 60mm cannula that provides treatment depth up to 25mm. Additionally, in 2019, we began marketingÂ AccuTiteÂ forÂ Aviva,Â a minimally invasive procedure that restores the function and appearance of the vulva by offering a non-excisional alternative to a labiaplasty.Â AvivaÂ is powered byÂ AccuTiteÂ to deliver safe and uniform heat to the entire soft tissue matrix of the labia minora, labia majora, clitoral hood, vaginal introitus and perineal body. Â QuantumRF 10 and QuantumRF25 â€“ The minimally invasive disposable handpieces for minimally invasive treatment of face and body for simultaneous treatment of destroying fat and skin tightening. The QuantumRF handpieces are operated on the IgniteRF platform. Â FractoraÂ â€“ The minimally invasiveÂ FractoraÂ handpiece, introduced in 2011, uses customizable fractional energy and superficial fractional resurfacing for subdermal adipose tissue remodeling. The handpiece offers two treatment depths (skin surface and subdermal) and is safe on all skin types including type IV. The consumable applicator tip contains 24-coated pins with a length of up to 4mm. Â Morpheus8/Morpehus8 Body/mopheus8 Burst/Nopheus8 Deep/Morpheus8VÂ â€“ The minimally invasiveÂ Morpheus8 and Morpheus8 BodyÂ handpieces use RF energy for subdermal adipose tissue remodeling, which is programmable by the user according to treatment area. The handpieces offer treatment depth up to 7mm. The upper part of the needle and external electrodes are coated with a polymer to prevent skin surface thermal damage while delivering RF energy into the subdermal space. Â Non-Invasive Â BodyFX/MiniFXÂ â€“ The non-invasiveÂ BodyFXÂ and MiniFX handpieces, introduced in 2013, combine vacuum and bipolar RF energy with high and low amplitudes to both permanently destroy adipose tissue and contract the skin. The BodyFX handpiece, intended for use on various parts of the body, comprises a vacuum cavity with a size of 1.36in x 1.2in. The MiniFX handpiece, better suited to address problematic fatty tissue in smaller areas, comprises a vacuum cavity with a size of 1.24in x 0.87in. Â DiolazeXL (810nm)Â â€“ The non-invasiveÂ DiolazeXL (810nm)Â handpiece, introduced in 2017, is a high-speed, gold standard 810nm (diode) laser indicated for permanent hair reduction.Â DiolazeXLâ€™sÂ differentiated triple contact cooling technology (pre, parallel and post), or 3PC technology, provides for a safe and comfortable patient experience. The handpiece covers a spot size of 12mm x 26mm to allow for the removal of a variety of hair colors and thickness. This handpiece offers short and long pulse durations and repetition rates that enable treatment times up to 6cm2/second. Â Triton Duo Light (755nm & 810nm)Â â€“ The non-invasiveÂ Triton Duo LightÂ handpiece, introduced in 2017, combines two wavelengths for optimal treatment of light skin patients. The handpiece utilizes a blend of 755nm (Alexandrite) and 810nm (diode) laser wavelengths that have been optimized for hair removal on patients with skin types I to IV. We believe theÂ TritonÂ platform is the only FDA-cleared device capable of firing two wavelengths in one pulse. The handpiece covers a spot size of 12mm x 26mm and provides two pulse durations and high repetition rates. Â 41 Triton Duo Dark (810nm & 1064nm)Â â€“ The non-invasiveÂ Triton Duo DarkÂ handpiece, introduced in 2017, combines two wavelengths for optimal treatment of dark skin patients. The handpiece utilizes a blend of 810nm (diode) and 1064nm (Nd:YAG) laser wavelengths that have been optimized for hair removal on patients with skin types Ito IV. We believe theÂ TritonÂ platform is the only FDA-cleared device capable of firing two wavelengths in one pulse. The handpiece covers a spot size of 12mm x 26mm and provides two pulse durations and high repetition rates. Â FormaÂ â€“ The non-invasive Forma handpiece, introduced in 2013, uses our ACE technology to deliver auto-adjusting uniform RF energy-generated heat (up to 43Â°C) for collagen remodeling and skin contraction of the face and neck. We believeÂ FormaÂ is the first thermal face and neck skin tightening device to have both temperature monitoring and automatic, user programmable, RF on/off control. This handpiece has an RF energy output power of up to 65 watts and covers a spot size of 22mm x 20mm. Â Forma I â€“ The non-invasive handpiece introduced in 2022 for treatment of peri-orbital and meibomian glands, and for dry eye indication by Health Canada. The energy level is similar to Forma, and the spot size is 10 sq. millimeters. Â FormaVÂ â€“ The non-invasiveÂ FormaV handpiece, introduced in 2017, uses our ACE technology to deliver auto-adjusting uniform RF energy generated heat (up to 43Â°C) to vaginal tissue through a consumable applicator. Â VToneÂ â€“ Intervaginal EMS device to treat SUI and pelvic floor muscle restorations. Â PlusÂ â€“ The non-invasiveÂ PlusÂ handpiece, introduced in 2013, uses our ACE technology to deliver auto-adjusting uniform RF generated heat (up to 43Â°C) for collagen remodeling and skin contraction of the body. We believeÂ PlusÂ is the first thermal body skin tightening device to have both temperature monitoring and automatic, user programmable, RF on/off control. This handpiece has an RF energy output of up to 65 watts and covers a spot size of 45mm x 45mm. Â LumeccaÂ Peak â€“ The non-invasiveÂ LumeccaÂ and Lumecca Peak handpiece, introduced in 2015 and 2024, are IPL handpieces optimized for both light and dark skin that uses a xenon flash lamp to deliver filtered optical energy in the 515nm to 1200nm range for light skin treatment and 580nm to 1200nm range for darker skin.Â LumeccaÂ is intended for treatment of superficial vascular and pigmented lesions. The handpiece covers a spot size of 30mm x 10mm with a peak optical power of 10,000 watts. Â VasculazeÂ â€“ The non-invasiveÂ VasculazeÂ handpiece, introduced in 2018, is a 1064nm wavelength diode laser intended for use in the coagulation and hemostasis of benign vascular legions such as, but not limited to, reticular leg veins, spider veins, hemangiomas, port wine stains and venous lakes.Â VasculazeÂ is optimized with high peak power, strong contact cooling and an ergonomic head intended to maximize treatment efficiency. The handpiece covers a spot size of 3mm x 4mm and has pulse duration of 20 to 100 milliseconds, or msec. Â Hands-Free Â TransformÂ â€“ The non-invasiveÂ Transform,Â introduced in 2021, is a set of six hands-free applicators for theÂ EvolveXÂ platform. The mechanism of action is a combination of Bipolar RF and EMS. TheÂ TransformÂ is mounted on a belt and works automatically without the assistance of a physician orÂ technician. Â TiteÂ â€“ The non-invasiveÂ Tite, introduced in 2019, is a set of eight hands-free applicators for theÂ EvolveXÂ platform. The mechanism of action is similar to theÂ PlusÂ handpiece. TheÂ TiteÂ is mounted on a belt for treatment of different body parts and areas without the assistance of a physician or technician. Â ToneÂ â€“ The non-invasiveÂ Tone, introduced in 2019, is a set of four hands-free electro-muscle stimulation applicators. TheÂ ToneÂ is designed to be used on theÂ EvolveXÂ platform for muscle stimulation and improving skin tone. Â CheekÂ â€“ The non-invasiveÂ Cheek, introduced in 2020, is a hands-free device containing eight applicators that is mounted on the face and designed to be used with theÂ EvokeÂ platform or Define platform. The mechanism of action is similar to theÂ FormaÂ handpiece, but works automatically on both sides of the face without the assistance of a physician or technician. Â ChinÂ â€“ The non-invasiveÂ Chin, introduced in 2020, is a hands-free device containing two applicators that is mounted on the chin and designed to be used with theÂ EvokeÂ platform or Define platform. The mechanism of action is similar to theÂ FormaÂ handpiece, but works automatically on the chin without the assistance of a physician or technician. Â 42 Proprietary Software Â Our software permits the user to define treatment parameters to be communicated to the electronic modules in the platform and deliver RF or optical energy through the handpiece or hands-free applicator to the patient. In addition, our software controls and manages proper system performance and automatic temperature control, system self-calibration, system setup and detection of any malfunction of the system. We believe our softwareâ€™s automotive capabilities allow physicians to dedicate their attention and focus to patient treatment rather than system monitoring. Our users upgrade their products through the purchase of additional treatment applicators and corresponding software plugs. All of our software complies with applicable medical specifications and regulations. Â Applications and Procedures Â Our products provide our customers with a broad range of applications among both traditional procedures and emerging applications. Â Face and Body Contouring Â Minimally Invasive Â Generally performed by a physician, RFAL delivers directional RF energy into a patientâ€™s subcutaneous fat to coagulate and liquefy adipose tissue and heat the subcutaneous fibrous septa, resulting in substantial collagen contraction of the subdermal space. RF energy is delivered through an innovative handpiece comprised of two electrodes. The internal electrode is inserted into the fat layer, while the other larger electrode is applied externally to the skin surface above the cannula tip. The internal cannula passes through the subcutaneous fat, while the external electrode slides over the skinâ€™s surface. The small conductive tip of the cannula concentrates RF energy in the subcutaneous fat, liquefying it and simultaneously contracting the fiber septa. This liquefied fat can then be removed from the body. Our RFAL technology can be administered on all regions of the body and typical treatments are approximately 30 to 90 minutes each under local anesthesia. We received 510(k) FDA clearance for our RFAL technology in 2016. Users conduct minimally invasive face and body contouring using RFAL technology with theÂ BodyTiteÂ andÂ EmbraceÂ platforms andÂ BodyTite, FaceTiteÂ andÂ AccuTiteÂ handpieces. In 2024, we introduced the IgniteRF platform with the QuantumRF handpiece which is also based on RFAL technology and received 510 K FDA clearance for the QuantumRF in 2024. Â Generally performed by a physician, Deep Subdermal Fractional RF, delivers RF energy into the subcutaneous adipose tissue to depths of up to 4mm through an array of coated needles producing localized heat and matrix of small lesions in the subcutaneous fat. The heat generated by the pins in the subdermal tissue promotes connective tissue restructuring. As a result, physicians can offer a versatile fractional treatment creating a three-dimensional collagen contraction and subdermal fat coagulation. The deep fractional remodeling is used when fat layer is not thick enough to use RFAL technology or when patient wants only superficial result. Deep Subdermal Fractional RF can be used for wrinkle reduction, skin tightening and treatment of cellulite appearance. In addition to reshaping, Deep Subdermal Fractional RF provides long-term results for inflammatory acne by coagulating enlarged sebaceous glands. The most common areas of treatment are the face and neck. Patients generally receive between one to three treatments for approximately 30 minutes each. Treatments are typically spaced two to three weeks apart. We received two 510(k) FDA clearances forÂ FractoraÂ in 2011 and 2016, and 510(k) FDA clearance for theÂ Morpheus8Â in 2019. In addition, we received 510K clearance for Morpheus8soft tissue coagulation/contraction in 2024.Â Customers use this technology with theÂ BodyTite,Â Embrace, IgniteRF, Votiva, Empower,Â Optimas and OptimasMAX Â platforms. Â Non-Invasive Â Handpieces:Â Administered by physicians and other aesthetic practitioners, our differentiated fat reduction solution is based on skin shaping using a vacuum and delivering both low amplitude bipolar RF energy for gentle deep tissue heating and high amplitude RF energy to simultaneously destroy fat and tighten skin. The handpiece is placed over the desired area of the body and vacuum energy shapes the skin into the cavity for safe and effective RF energy delivery allowing greater volumes of fat to be treated (up to 2.5cm in depth). Subsequently, temperature-controlled RF energy is applied to preheat the tissue and fat uniformly to 42Â°C to 43Â°C. High amplitude RF energy delivered in ultra-short pulse duration is then administered via electrodes causing apoptosis of adipose tissue and resulting in simultaneous skin contraction. Our technology can be administered on all regions of the body. Patients generally receive six treatments for approximately 10 to 20 minutes each. Treatments are typically spaced one to two weeks apart. We received 510(k) FDA clearance for this technology in 2013. Users conduct non-invasive face and body contouring with theÂ ContouraÂ platform using theÂ BodyFX orÂ MiniFX handpieces. Â 43 Hands-Free Â Hands-Free Applicators: Applied by physicians and other aesthetic practitioners, our differentiated skin tightening, fat reduction and muscle stimulation solution is based on bipolar RF and EMS technologies, delivered through a set of hands-free applicators mounted or placed over the body or face. The setup of the parameters is determined by a doctor. Subsequently, temperature-controlled RF energy is applied to preheat the tissue and fat uniformly to 42Â°C to 43Â°C. High amplitude RF energy delivered in ultra-short pulse duration is then administered via electrodes causing apoptosis of adipose tissue and resulting in simultaneous skin contraction. Our technology can be administered on all regions of the body and face. Patients generally receive three to six treatments for approximately 30 minutes each. Treatments are typically spaced one to two weeks apart. We received 510(k) FDA clearance for theÂ EvokeÂ andÂ EvolveÂ in 2019. In 2021 we received 510(k) FDA clearance for the EvolveX which replace the Evolve platform. Users conduct hands-free face and body contouring with theÂ EvokeÂ andÂ EvolveXÂ platforms using theÂ Transform,Â TiteÂ andÂ ToneÂ hands-free applicators for theÂ EvolveX, andÂ CheekÂ andÂ ChinÂ hands-free applicators for theÂ Evoke and Define. Â Medical Aesthetics Â Skin Rejuvenation/Vascular & Pigmented Lesion Treatment Â Generally performed by a physician or other aesthetic professional, different types of energy and treatments are provided depending on the handpiece. The application of JPL energy enables the improvement of photo damage, as well as other pigmented abnormalities and superficial vascular lesions. A 1064nm laser is used for the treatment of larger and deeper veins. Patients often see results after a single treatment but typically two to three treatments of approximately 15 minutes each are recommended. Treatments are typically spaced two to four weeks apart. We received 510(k) FDA clearance for superficial vascular and pigmented lesion treatments in 2013 and for hair removal and permanent hair reduction in 2017 and 2018, respectively. Users rejuvenate the skin with theÂ OptimasÂ and OptimasMAX platforms using theÂ Vasculaze,Â Lumecca and Lumecca Peak Â handpieces. Â Sub-Necrotic Thermal Tissue Remodeling Â Administered by physicians and other aesthetic practitioners, the application is based on uniform and deep heating of the skin and subdermal layer using bipolar RF energy. The handpiece is moved over the desired area of the treatment area, while maintaining the designated temperature for the predetermined time for safe and effective collagen remodeling. Subsequently, temperature-controlled RF energy is applied automatically to heat tissue uniformly to 42Â°C to 43Â°C. TheÂ FormaÂ handpiece is utilized to target fat and heats the tissue to depths of up to 4.5mm while theÂ PlusÂ handpiece is used for larger body areas and provides effect up to 6mm in depth. Patients generally receive six treatments for approximately 10 to 20 minutes each. Treatments are typically spaced one to two weeks apart. We received three 510(k) FDA clearances for this technology in 2014, 2016 and 2017. Users conduct facial treatment with theÂ Optimas and OptimasMAXÂ platforms using theÂ FormaÂ handpiece and body contouring with the Contoura platform using theÂ PlusÂ handpiece. Â Permanent Hair Reduction Â Administered by a user, who is not necessarily a physician, our differentiated dual wavelength technology incorporated in theÂ TritonÂ platform fires two wavelengths in a single pulse destroying the hair follicles located in the dermis and subdermal layers. This procedure is continued over the target area and can last from a few minutes to 90 minutes depending on the size of the treatment area. In general, permanent hair reduction requires four to six treatments spaced four to eight weeks apart. More sessions may be required for stubborn hairs. Due to our unique dual wavelength technology, ourÂ TritonÂ platform allows practitioners to address all skin types and tones. We received 510(k) FDA clearance for ourÂ OptimasÂ and dual wavelengthÂ TritonÂ platforms for permanent hair reduction treatments in 2016 and 2018, respectively. Users perform permanent hair reduction procedures with ourÂ OptimasÂ andÂ TritonÂ platforms using theÂ DiolazeXLÂ andÂ Triton Duo LightÂ andÂ Triton Duo DarkÂ handpieces, respectively. Â Womenâ€™s Wellness Â We have two platforms for womenâ€™s wellness: the Votiva and the EmpowerRF. Procedures with these platforms are performed by a physician. Depending on the handpiece, the administration of bipolar RF energy or subdermal heating is applied to gently warm and massage the internal vaginal tissueÂ (FormaV),Â the external vaginal tissueÂ (Morpheus8V),Â or to deliver uniform heat to the entire soft tissue matrix of the labia minora, labia majora, clitoral hood, vaginal introitus and perineal bodyÂ (AvivaÂ procedure administered by theÂ AccuTiteÂ handpiece), and pelvic floor muscle restoration (with VTone). Depending on the treatment type, patients typically receive between two to three treatments of approximately 15 minutes each. Treatments are typically spaced two to three weeks apart. We received 510(k) FDA clearance forÂ FormaVÂ for certain indications in 2017. In July 2018, we received a letter from the FDA seeking information as to the regulatory basis for marketing of ourÂ FormaVÂ handpiece based on our promotion and labeling of this device for use in certain womenâ€™s wellness conditions and procedures. We timely responded to the FDA by immediately altering the wording of our promotional and labeling materials, and we submitted a response letter in August 2018 answering the FDAâ€™s questions and advising the agency that we had modified our promotional and labeling materials to remove certain statements regarding uses of our products for conditions and procedures that were questioned by the FDA in the agencyâ€™s informational request letter. The FDA responded in September 2018 by stating that the agency had reviewed our response letter and verified the changes in terminology made to our website. Moreover, the FDA further responded in November 2018 and confirmed we addressed all items raised by the agency in its letter, and that the FDA continues to expect us to conduct a review of our marketing and promotional materials to make appropriate changes and remove materials containing uncleared claims. We have received no further communications from the agency regarding this matter. Â 44 Sales and Marketing Â Our primary strategy to increase market penetration relies on selling directly to our traditional customer base of plastic and facial surgeons, aesthetic surgeons, dermatologists and OB/GYNs. We believe we are the only company commercializing minimally invasive aesthetic solutions specifically targeting the surgical community and believe our products represent a significant opportunity for these practitioners to deliver improved patient treatment results and significantly increase their ability to generate additional revenue. We are also targeting newer market opportunities consisting of OB/GYNs, ENTs, ophthalmologists, general practitioners and aesthetic clinicians as an incremental growth opportunity. Â We target potential customers through office visits, trade shows, professional journals and various forms of paid and unpaid media. We also conduct clinical workshops featuring recognized expert panelists and key opinion leaders to promote existing and new treatment techniques using our products. We believe that these workshops enhance customer loyalty and provide us with new sales opportunities. We plan to continue to offer a large number of workshops spanning from single-day workshops to three-day

workshops. We also use direct mail programs to target specific segments of the market that we seek to access, such as members of medical societies and attendees at meetings sponsored by medical societies or associations. In addition, we maintain an active public relations program that has resulted in treatments based on our products being featured in various televised and printed media outlets includingÂ InStyle, Shape,Â The DoctorsÂ andÂ Harperâ€™s Bazaar. In September 2022, international actress and producer, Eva Longoria, agreed to join us as our brand ambassador to share her positive experience with ourÂ EvolveXÂ andÂ Morpheus8Â technologies, replacing our previous brand ambassador, international pop icon, Paula Abdul. Â We currently sell and market our products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia and India, through a direct sales force of approximately 260 representatives. We also sell and market our products through over 60 distributors in over 85 countries. Our U.S. sales efforts are headquartered in Irvine, California. To support the continued roll-out of our products and further penetrate the market, we anticipate that our direct salesforce in the United States will continue to increase. Â In international markets, to complement our direct sales force in Canada, the United Kingdom, Spain, Portugal, France, Belgium, Luxemburg, Italy, Australia and India, we sell our products through a network of distributors. Our Canadian sales efforts are headquartered in Toronto, Canada. As of December 31, 2024, we had an international sales management team of seven employees supporting over 60 independent distributors. The percentage of our revenues from customers located outside of the United States for each of the years ended December 31, 2024 and 2023 was 38%, and 37%, respectively. We intend to continue to increase penetration of our customer base in international markets and expand into attractive new international markets by identifying and training qualified distributors. In addition, we may opportunistically hire a direct sales force and expand our marketing campaigns in select international markets. We require our distributors to provide customer training, to invest in service and demonstration equipment and marketing, and to attend certain exhibitions and industry meetings. Â Service and Support Â We support our customers with a range of services, including business and practice development consulting and product service and maintenance. Â We service our products in three service centers: (1) the U.S. market is serviced through our facility in Irvine, California, (2) the Canadian market is serviced through our facility in Toronto, Canada, and (3) the rest of the world is serviced through our distributors and our facility in Yokneam, Israel. In the event of a technical malfunction, our customers first contact us (if in the United States or Canada) or our distributors (if outside of the United States or Canada) telephonically. If a product requires service or repair that cannot be addressed telephonically, we or our distributors ship a temporary â€œloanerâ€ system to the customer as soon as possible, often overnight. This unique â€œloanerâ€ system reduces any product downtime and associated lost revenues for the physician. We then arrange for shipment of the out-of-order product to one of our service centers in the United States or Canada. Outside the United States or Canada, the product is sent to our distributors or our facility in Israel. Either we or our distributors quickly repair the product and ship it back to the customer. We have designed our products in a lightweight, modular fashion to enable quick and efficient service and support. Specifically, we build our platforms to be less than 35 kilograms in weight to ensure acceptance by traditional, commercial third-party logistics providers for next-day delivery of replacement products without requiring specialized shipping procedures. We believe our depot service and support model provides for more efficient and less costly operations. Â 45 Our standard warranty term is 12 months, however, certain products are sold with multi-year warranties. Our standard warranty covers parts, labor, participation in our loaner program and a white glove, door-to-door, shipping service for expedited repair service, and can be extended for an additional charge. We believe that we have a significant opportunity to increase our recurring customer revenue by increasing the number of our customers that enter into service contracts and extended warranties for our systems. All of our distributors have a service department and are required by us to maintain a full inventory of spare parts. All service staff is trained by our service department in Israel. Â Manufacturing and Supply Â We rely primarily on outsourced manufacturing to produce our devices while maintaining control over the production process. Outsourcing allows us to carry lower inventory levels and maintain fixed unit costs without incurring significant capital expenditures than would be in place if products were self-manufactured. We outsource almost all of the manufacturing of our products to three subcontractors located in Israel, two of which we are substantially dependent on as part of our business. Through our strategic arrangement with Flextronics (Israel) Ltd., or Flex, and (BY) Medimor Ltd., or Medimor, we maintain dedicated manufacturing lines supervised by us in Flex and Medimorâ€™s medical-grade manufacturing facilities in Migdal Haemek and Poriya, Israel. Within the Flex and Medimor facilities, all proprietary manufacturing, testing and assembly equipment has been built and is owned by us. We also use a separate manufacturer in addition to Flex and Medimor to produce our handpieces and disposables. Â We believe our outsourced manufacturersâ€™ processes comply with all applicable U.S. and international quality and safety standards, such as ISO 13485:2016, CE and the FDA quality system regulations. We conduct in-house prototype development and present detailed manufacturing documents to our subcontractors, who then purchase most of the necessary components and manufacture the product. These manufacturing subcontractors provide us fully assembled, or â€œturn-key,â€ services. We control and monitor the quality of our products by having one of our quality control employees at each of our subcontractorâ€™s facilities. Â The contracts we have withÂ our main manufacturing subcontractors (Flex and Medimor) do not have minimum purchase requirements and allow us to purchase end products entered into on a purchase order basis. Under these contracts, our manufacturing subcontractors provide manufacturing services pursuant to our written specifications. These manufacturing services include labor, materials, testing, packaging and delivery, as well as allocating production and storage space within their facilities for our products. Pricing under these contracts is reviewed between us and the manufacturing subcontractors every three months. These contracts typically have one-year terms that automatically renew for successive one-year terms unless either we or the manufacturing subcontractor provide three months written notice prior to the expiration of the term. To date, we have not experienced any significant manufacturing delays.Â These contracts can be terminated by either party, without cause, with four to six months prior written notice. Â We manufacture all laser and IPL handpieces in our facility in Yokneam, Israel and procure other major components of our products on behalf of our third-party manufacturers from a limited number of suppliers. We have flexibility to adjust the number of lasers and other components that we either manufacture or procure as well as the delivery schedules. The forecasts that we use are based on historical demands and expected future plans. Lead times may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components. We intend to reduce any potential for delays of supply by maintaining relationships with multiple suppliers of major components. To date, we have not experienced significant delays in obtaining our major components. Â In November 2019, we signed a Share Purchase and Shareholders Agreement, or the SPA, with Medimor, one of our turnkey manufacturing subcontractors. Pursuant to the SPA, we have invested an aggregate of $600,000, in consideration for 1,369,863 ordinary shares of Medimor (which reflected a 10.34% ownership interest in Medimor at the signing date, on a fully diluted basis), at a price per share of $0.438, of which 414,384 ordinary shares were issued upon consummation of the initial closing on December 31, 2019, and the remaining 955,479 ordinary shares were issued in July 2020 following Medimor achieving certain pre-defined milestone events. In November 2023, we signed an additional Share Purchase and Shareholders Agreement (the â€œPurchase Agreementâ€) in which we invested an additional $100,000 in consideration of 117,440 ordinary shares of Medimor. Â As of December 31, 2024, we hold 14.78% ownership interest on an as-issued basis and 11.23% ownership interest on a fully diluted basis of Medimor. Â 46 Research and Development Â Our research and development activities are conducted internally by a team of 43 research and development staff based mainly in Israel. Our research and development efforts are focused on the development of new products, as well as on the extension of our existing products to introduce new applications in the minimally and non-invasive and medical aesthetic markets. We have a number of new projects and products under development. We expect to concentrate our research and development efforts in the coming years on developing procedures and platforms based on our proprietary technologies: (i) RFAL, (ii) Deep Subdermal Fractional RF, (iii) Simultaneous Fat Destruction and Skin Tightening, and (iv) Deep Heating Collagen Remodeling, and developing new technologies. Â Our research and development expenditures for the years ended December 31, 2024 and 2023 were approximately $13.1 million and $13.4, respectively. Â Seasonality Â Our business is not significantly impacted by seasonality; however, our fourth quarter has historically generated slightly stronger operating results. We have historically experienced stronger sales in the fourth quarter in correlation with our customersâ€™ spending patterns and budget cycles. Most physicians operate on an annual budget cycle with a fiscal year that begins on January 1. It is not uncommon to experience a higher level of purchasing activity from physicians in the final months and weeks of their fiscal year. Consequently, our fourth quarter revenues may be greater than other quarters. Our business is also impacted by general economic conditions, which may impact future seasonal variations. Â Intellectual Property Â We rely on a combination of patent, trademark and copyright laws to protect our intellectual property rights. Â Patents and Patent Applications Â As of February 4, 2025, we own fifteen issued U.S. patents and one issued Korean patent. As of February 4, 2025, we have filed eleven patent applications that are pending in the United States Patent and Trademark Office. Our issued U.S. patents are projected to expire between 2027 and 2042 (assuming pending U.S. patent applications are approved). These patents and patent applications cover the technologies described herein, and contribute to the protection of our rights to our proprietary technology. Our patents relate to radio frequency (RF) based technology that may be used for minimally invasive aesthetic solutions, such as fat destruction, and fractional skin ablation relating to skin tightening and fat destruction, among others, and cover our existing products. Without these patents, we cannot guarantee that we can prevent others from manufacturing similar products that are covered by our patent rights. We also rely on our issued patents to make, use, sell, and distribute our products. The term of the patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. We also rely upon trademarks in various jurisdictions covering the InMode brand and our product lines, as well as upon U.S. copyright law for protection of the software programs associated with our products. Â We cannot assure you that patents will issue from any of our pending applications or that, if patents issue, they will be of sufficient scope or strength to provide meaningful protection for our technology. Our policy is to obtain patents and to seek to operate without infringing on the intellectual property rights of third parties. Loss or invalidation of our patents, or a finding of unenforceability or limitation of scope of our patents, could have a material adverse effect on us. The patent position of many inventions in the areas related to our business is highly uncertain, involves many complex legal, factual and technical issues and has recently been the subject of litigation industry-wide. There is no certainty in predicting the breadth of allowable patent claims or the degree of protection afforded under any issued patents. Â Notwithstanding the scope of the patent protection available to us, a competitor could develop treatment methods or devices that are not covered by our patents. Furthermore, numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products. Because patent applications can take many years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or proprietary technologies may be alleged to infringe. Third parties may also obtain patents that we may need to license from them in order to conduct our business. Â 47 It is possible that patents issued to us will be successfully challenged or that patents issued to others may preclude us from commercializing our products under development. Litigation to establish or challenge the validity of patents, to defend against infringement, unenforceability or invalidity claims or to assert infringement, invalidity or unenforceability claims against others, if required, can be lengthy and expensive, and may result in determinations materially adverse to us. We cannot assure you that the products currently marketed or under development by us will not be found to infringe patents issued or licensed to others. Â Patent Litigation Â We have received, and we may in the future receive, allegations from third parties contending that we are infringing their patents. If such third parties were to commence infringement suits against us, and such third-party patents were found by a court to be valid, enforceable and infringed upon by us, then we could be required to pay damages and/or make royalty payments, and we could also be enjoined from continuing the infringing activity. Depending on the nature of the patent found to be infringed upon by us, a court order requiring us to cease such infringement could have a material adverse effect on us. We might be unable to design around such patents or continue offering the products or services found to be infringing, or we could suffer other adverse consequences. Â On October 11, 2023, we filed a complaint of patent infringement against BTL Industries Ltd. (â€œBTLâ€) in the United States District Court, Central District of California, alleging that BTL infringed our U.S. patent no. 8961511. In December 2024, the litigation was transferred to the District of Massachusetts, and BTL has filed an answer to our complaint.Â On April 10, 2024, BTL filed a petition for inter partes review (IPR) before the Patent Trial and Appeal Board of the United States Patent Office, and the Board instituted review of the patent on October 8, 2024. BTL has filed a motion to stay the district court case pending the IPR proceeding, which motion currently is pending. Â Although we may try to resolve any potential future claims or actions, we may not be able to do so on reasonable terms, if at all. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate, and could divert managementâ€™s attention from our core business. If we lose this kind of litigation, a court could require us to pay substantial damages and could prohibit us from using technologies essential to our products, either of which would have a material adverse effect on our business, results of operations and financial condition. See â€œItem 3. Key Information â€“ D. Risk Factors-Risks Related to Our Intellectual Property â€“ If we are unable to protect our intellectual property rights, our competitive position could be harmed. Our success and ability to compete depends in large part upon our ability to protect our proprietary technology.â€ Â Copyrights, Trademarks and Trade Secrets Â The software programs associated with our products are protected by U.S. copyright law. Â We also filed for protection available under trademark law. As of December 31, 2024, we own 16 registered trademarks in the United States and we own at least 38 registered trademarks in various jurisdictions outside the United States, including for the marks â€œInModeâ€ and â€œRFALâ€ and certain key product names, in particular,Â BodyTite, ContouraÂ byÂ InMode, FaceTite, InMode, OptimasÂ byÂ InMode, TritonÂ byÂ InMode, VotivaÂ byÂ InMode, TritonÂ byÂ InMode, AccuTite, Morpheus, BodyFX, Diolaze, FractoraÂ andÂ Lumecca.Â We also have at least 6 pending foreign trademark applications. We also have 9 trademark applications in the United States pending for â€œDefine by InModeâ€, â€œFusion Darkâ€, Fusion Lightâ€, and â€œQuantumRFâ€. Â We also rely upon know-how and continuing technological innovation, and may pursue licensing opportunities in the future, to develop and maintain our competitive position. We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to proprietary information, under which they are bound to assign to us inventions made during the term of their employment or term of service. Â All professional employees and technical consultants are required to execute confidentiality agreements in connection with their employment and consulting relationships with us. We also require them to agree to disclose and assign to us all inventions conceived in connection with their services to us. However, there can be no assurance that these confidentiality and invention assignment agreements will be enforceable or that they will provide us with adequate protection. Â 48 Competition Â Our industry is subject to intense competition, subject to rapid change and highly sensitive to the introduction of new products or other market activities of industry participants. We compete against products offered by public companies, including AbbVie, Cutera, Inc., Apyx Medical Corporation, Venus Concept Inc. and Sisram Medical Ltd., as well as by private companies, such as Cynosure LLC/Lutronic, Lumenis Ltd., BTL Aesthetics, Inc. and Candela Medical Inc. In the past few years, several large pharmaceutical and medical device companies have also entered the aesthetic device market, including Valeant Pharmaceuticals International Inc. and Merz Pharma Group. Our products compete against conventional medical products, including BotoxÂ®, hyaluronic acid injections and collagen injections, and aesthetic procedures, such as face lifts, liposuction, sclerotherapy, electrolysis, chemical peels and microdermabrasion, which are unrelated to laser, light and RF-based technologies. Our products also compete against laser and other light and radio frequency-based products. Â Competition among providers of laser and other light and radio frequency-based products for the aesthetic medical market is characterized by extensive research efforts and rapid technological progress. While we attempt to protect our products through patents and other intellectual property rights, there are few barriers to entry that would prevent new entrants or existing competitors from developing products that would compete directly with ours. There are many companies, both public and private, that are developing innovative devices that use laser and other energy-based and alternative technologies. Many of these competitors have significantly greater financial and human resources than we do and have established reputations, greater brand name recognition, broader product lines, and larger customer bases, as well as worldwide distribution channels that are more effective than ours. Additional competitors may enter the market, and we are likely to compete with new companies in the future. Any business combinations or mergers among our competitors that result in larger competitors with greater resources or distribution networks, or the acquisition of a competitor by a major medical or technology corporation seeking to enter this business, could further result in increased competition. Â To compete effectively, we have to demonstrate that our products are attractive alternatives to other devices and treatments by differentiating our products on the basis of performance, brand name, reputation and price. We have encountered and expect to continue to encounter potential customers who, due to existing relationships with our competitors, are committed to, or prefer the products offered by, these competitors. We expect that competitive pressures may over time result in price reductions and reduced margins for our products. Â Other medical companies, academic and research institutions, or others, may develop new technologies or therapies, including medical devices, surgical procedures or pharmacological treatments and obtain regulatory approval for products utilizing such techniques that are more effective in treating the conditions that we target or are less expensive than

our current or future products. Our technologies and products could be rendered obsolete by such developments. Â Government Regulation Â Our products and operations are subject to extensive and rigorous regulation by the relevant governmental authorities in the countries where we market and sell or products. These governmental authorities include the FDA, which enforces, the FDCA as well as other similar laws, and regulatory bodies worldwide. In addition, the Federal Trade Commission, or FTC, regulates the advertising of our products in the United States. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training and other practices to government scrutiny. Â In some jurisdictions, such as the United States, Canada, South Korea and Israel, we must complete an application process with the relevant regulator, which includes submitting the results of clinical trials for their review. Â In addition to the requirements regarding product clearance, many countries also impose product standards, packaging requirements, environmental requirements, labeling requirements and import and export restrictions on our devices. Each country also has its own tariff regulations, duties and tax requirements. Failure to comply with applicable regulatory requirements may result in fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, criminal prosecution, or other consequences. Â In the United States, the FDCA and its implementing regulations govern the following activities that we perform and will continue to perform to help ensure that medical products distributed within the United States are safe and effective for their intended uses: Â â€¢ product design and development; Â â€¢ product testing; Â 49 â€¢ product manufacturing; Â â€¢ product safety; Â â€¢ product labeling; Â â€¢ product storage; Â â€¢ record-keeping; Â â€¢ premarket clearance or approval; Â â€¢ advertising and promotion; Â â€¢ manufacturing and production; Â â€¢ product sales and distribution; Â â€¢ import, export and shipping; Â â€¢ establishment registration and device listing; and Â â€¢ recalls, field-safety corrective actions and post-market surveillance. Â Each of our currently marketed products has received 510(k) clearance for the uses for which they are being marketed. Â FDAâ€™s Premarket Clearance and Approval Requirements Â Unless an exemption applies, each medical device we wish to commercially distribute in the United States requires 510(k) clearance or premarket approval. The FDA classifies medical devices into one of three classes â€“ Class I, Class II or Class III â€“ depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDAâ€™s General Controls for medical devices, which include compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDAâ€™s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDAâ€™s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. All of our current products are Class II devices subject to the 510(k) clearance requirements. Â Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a premarket approval application, or PMA. Some pre-amendment devices are unclassified, but are subject to the FDAâ€™s premarket notification and clearance process in order to be commercially distributed. Â 510(k) Clearance Pathway Â When a 510(k) clearance is required, we must submit a premarket notification demonstrating that our proposed device is â€œsubstantially equivalent,â€ as defined in the statute, to a previously cleared 510(k) device or a device that was in commercial distribution in the United States before May 28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, for which the FDA has not yet called for the submission of premarket approval applications. Â After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, if the FDA requires additional information, clearance often takes far longer, and clearance is never assured. Although most 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. Â 50 If the FDA determines that the device is not â€œsubstantially equivalentâ€ to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. A manufacturer can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. Â After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application orÂ de novoÂ classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturerâ€™s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturerâ€™s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite PMA(s). Â Over the last several years, the FDA has proposed reforms to its 510(k)-clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k)-clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FFDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k)-clearance pathway and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Â In September 2019, the FDA finalized guidance describing an optional â€œsafety and performance basedâ€ premarket review pathway for manufacturers of â€œcertain, well-understood device typesâ€ to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the â€œsafety and performance basedâ€ pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. Â Laser devices used for aesthetic procedures, such as hair removal, have generally qualified for clearance under 510(k) procedures. Â The table below presents the specific FDA 510(k) clearances, dates and summary of cleared indications for ourÂ BodyTite (InmodeÂ RF/IgniteRF), Optimas, Votiva, Contoura, Triton, EmbraceRF, Morpheus8, EvolveX,Â Define and EvokeÂ platforms: Â Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications Define Radiofrequency (RF) Cheek Chin Forma MiniFX Morpheus8 K242598 (11/24/2024) The Define System with the Cheek and Chin Applicators is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. The Define System with the Forma Applicator is intended for the relief of minor muscle aches and pain, relief of muscle spasm, and for the temporary improvement of local blood circulation. Â The Define System with the MiniFX Applicator is intended for the relief of minor muscle aches and pain, relief of muscle spasm, for the temporary improvement of local blood circulation and for the temporary reduction in the appearance of cellulite. Â The Define System with the Morpheus8 Applicator is intended for use in dermatologic procedures where coagulation/contraction of soft tissue or hemostasis is needed. At higher energy levels greater than 62 mJ/pin, the use of the Morpheus8 Applicator is limited to Skin Types I-IV. 51 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications InMode RFÂ /Â IgniteRF Radiofrequency (RF) QuantumRF 25 minimally invasive handpiece QuantumRF 10 minimally invasive handpiece K240780 (07/24/2024) InMode RF/IgniteRFÂ platform with the FaceTite or BodyTite is indicated for use in dermatologic procedures where coagulation/contraction of soft tissue or hemostasis is needed. InMode system with Morpheus8 90 applicators (coagulation/contraction of software tissue) Radiofrequency (RF) â€¢Â Â The standard Morpheus 8 90 Applicator is limited to use with the Morpheus8 90 tip head. K240017 (06/13/2024) The InMode System with the Morpheus8 90 Applicator is intended for use in dermatological procedures where coagulation/contraction of soft tissue or hemostasis is needed. At higher energy levels greater than 62 mJ/pin, the use of the Morpheus8 Applicator is limited to Skin Types I-IV. InMode RFÂ /Â IgniteRF Radiofrequency (RF) BodyTite Turbo minimally invasive handpiece FaceTite Turbo minimally invasive handpiece K233642 (03/20/2024) Â InMode RF/IgniteRFÂ platform with the FaceTite or BodyTite is indicated for use in dermatologic procedures where coagulation/contraction of soft tissue or hemostasis is needed. Â Evolve system with the Transform applicator Sequential RF/EMS Â Transform K231495 (10/13/2023) The Evolve System with the Transform Applicator employs RF technology and EMS-TENS technology for the treatment of selected medical conditions. The Transform Applicator in RF mode is intended for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. The Transform Applicator in EMS mode is intended for: â€¢Â Â Â Â Â Relaxation of muscle spasms â€¢Â Â Â Â Prevention or retardation of disuse atrophy â€¢Â Â Â Â Â Increasing local blood circulation â€¢Â Â Â Â Â Muscle re-education â€¢Â Â Â Â Â Maintaining or increasing range of motion â€¢Â Â Â Â Â Immediate postsurgical stimulation of calf muscles to prevent venous thrombosis The Transform Applicator in TENS mode is intended for: â€¢Â Â Â Â Â Symptomatic relief and management of chronic, intractable pain â€¢Â Â Â Â Â Post-surgical acute pain â€¢Â Â Â Â Â Post-trauma acute pain Additionally, the Transform Applicator in sequential RF/EMS mode is intended for: â€¢Â Â Â Â Â Â Non-invasive lipolysis (breakdown of fat) of the abdomen. â€¢Â Â Â Â Â Â Reduction in circumference of the abdomen 52 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications InMode system with Morpheus8 applicators (coagulation/contraction of software tissue) Radiofrequency (RF) â€¢Â Â Â Â The standard Morpheus 8 Applicator is limited to use with the 12, 24 & T tip heads. â€¢Â Â The Morpheus 8 Body Applicator is limited to use with the 40-tip head. K231790 (07/20/2023) The InMode System with the Morpheus8 Applicators is intended for use in dermatological procedures where coagulation/contraction of soft tissue or hemostasis is needed. At higher energy levels greater than 62 mJ/pin, the use of the Morpheus8 Applicator is limited to Skin Types I-IV. 53 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications InMode Multi System (interface screen was slightly enlarged from 10 inch to 12 inch) Radiofrequency (RF), Laser, IPL Laser Applicators: â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diolaze XL 810nm â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diolaze XL 755/810nm â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diolaze XL 810/1064nm â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â VLaze (Vasculaze) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â IPL Applicator: â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â SR IPL (Lumecca 580, Lumecca 515) Non-Invasive RF Applicators: â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Forma (Plus) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Plus (Plus Plus) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Plus90 â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â i-Forma â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â BodyFXâ„¢ (WMBody) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â MiniFXâ„¢ â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â WMFace Fractional RF Applicators: Fractora â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â 24 pins tip (FRF) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â 60 pins tip â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â Morpheus8â„¢ â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12 pins tip (Prime Tip) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â 24 pins tip)Fractora 3D) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â 40 pins tip (Body Tip) â€¢Â Â Â Â Â Â Â Â Â Â Â Â Â Â T tip K221571 (05/26/2022) The InMode Multi System with the Diode laser Applicators is indicated for: â€¢Â Â Â Â Diolaze XL 810nm Applicator is intended for hair removal and permanent hair reduction defined as the stable, long-term reduction in hair counts at 6, 9, or 12 months following a treatment regime. â€¢Â Â Â Â Diolaze XL 755/810nm & 810/1064nm Applicators are intended for hair removal. â€¢Â Â Â Â VLaze Applicator is intended for the treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, port wine stains, leg veins and other benign vascular lesions. The InMode Multi System with the IPL Applicator is indicated for: â€¢Â Â Â Â IPL Applicator with wavelengths (515-l200nm) is indicated for use for the following treatments: The treatment of benign pigmented epidermal lesions, including dyschromia, hyperpigmentation, melasma, ephelides (freckles); The treatment of benign cutaneous vascular lesions, including port wine stains, facial, truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikiloderma of Civatte, superficial leg veins and venous malformations. The InMode Multi System with the non-invasive RF Applicators is indicated for: â€¢Â Â Â Â BodyFX (WMBody) and MiniFX Applicators are intended for the treatment of the following medical conditions: Relief of minor muscle aches and pains, relief of muscle spasm, temporary improvement of local blood circulation; and temporary reduction in the appearance of cellulite. â€¢Â Â Â Â Plus/ Plus90/Plus-Plus (Forma) and i-Forma Applicators are indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. â€¢Â Â Â Â FaceFX (WMFace) Applicator is intended for use in dermatologic procedures, for noninvasive treatment of mild to moderate facial wrinkles and rhytids. The InMode Multi System with the Fractional RF Applicators is indicated for: â€¢Â Â Â Â Â FRACTORA 60 pin Applicator is intended for use in dermatological procedures requiring ablation and resurfacing of the skin. â€¢Â Â Â Â FRF 24 pin Applicator is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. Fractora3D and Morpheus8 Applicators are intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62 mJ/pin, use is limited to Skin Types I-IV. 54 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications InMode RF MultiÂ Platform â€“ Contoura Radiofrequency (RF) Forma(Plus), Plus90,Â Plus(Plus-Plus) BodyFX, MiniFX, Wmface, Fractora 24 pins tip Fractora 60 pins tip Morpheus8 24 Pin Applicator Morpheus8 40 PinÂ treatment tip â€¢Â Â Â Â Â Â Â Â Â Â Â Â Morpheus8 12 Pin treatment tip â€¢Â Â Â Â Â Â Â Â Â Â Â Â Morpheus8 T Pin treatment tip K201150 (07/21/2020) The InMode RF Multi-System with the Non-invasive RF Applicators employs RF energy for various applications: â€¢Â Â Â Â Forma (Plus), Plus (Plus Plus) and Plus90 for relief of minor muscle aches and pain, relief of muscle spasm, and temporary improvement of local blood circulation. â€¢Â Â Â Â Â WMface is intended for use in dermatologic procedures for non-invasive treatment of mild to moderate facial wrinkles and rhytids. â€¢Â Â Â Â Â BodyFXâ„¢ (WMBody)/MiniFXâ„¢ for relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation and temporary reduction in the appearance of cellulite. The InMode RF Multi-System with the Fractional Applicators employs RF energy for various applications: â€¢Â Â Â Â Â Â Fractora Applicator with 60 pins tip is designed for use in dermatological procedures requiring ablation and resurfacing of the skin. â€¢Â Â Â Â Â Â Â Fractora Applicator with 24 pins tip is intended for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62mJ/pin, use of the applicator is limited to skin types I-IV. â€¢Â Â Â Â Â Morpheus8â„¢ for dermatological and general surgical procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62mJ/pin, use of the applicator is limited to skin types I-IV. Inmode Powered muscle stimulator Tone K192249 (12/17/2019) The Evolve platform is used in EMS mode for: â€¢Â Â Â Â Â prevention or retardation of disuse atrophy; â€¢Â Â Â Â Â maintaining or increasing range of motion; â€¢Â Â Â Â Â muscle re-education; â€¢Â Â Â Â Â relaxation of muscle spasms; â€¢Â Â Â Â Â increasing local blood circulation; and â€¢Â Â Â Â Â immediate postsurgical stimulation of calf muscles to prevent venous thrombosis. And in TENS mode for: â€¢Â Â Â Â Â symptomatic relief and management of chronic, intractable pain; â€¢Â Â Â Â Â post-surgical acute pain; and â€¢Â Â Â Â Â post-traumatic acute pain. InModeÂ Powered muscle stimulatorÂ vToneÂ K200293 (05/05/2020) The InMode System with the vTone Applicator is intended to provide electrical stimulation and neuromuscular re-education for the purpose of rehabilitation of weak pelvic floor muscles for the treatment of stress, urge, and mixed urinary incontinence in women. 55 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications EmFace (Evoke) Radiofrequency (RF) Cheek Chin K191855 (10/29/2019) TheÂ EmFaceÂ (Evoke) device with theÂ CheekÂ andÂ ChinÂ applicators is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. EmBody (Evolve) Radiofrequency (RF) EMBodyPlus â€“ Tite EmBodyFX â€“ Trim K183450 (06/20/2019) TheÂ EmBody (Evolve)Â platform with its designated applicators is intended for the treatment of the following medical conditions: TheÂ EmBodyPlus (Tite)Â hands-fee applicator is intended for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. TheÂ EmBodyFX(Tite)Â hands-free applicator is intended for the treatment of the following medical conditions using RF combined with massage: â€¢Â Â Â Â Â relief of minor muscle aches and pain, relief of muscle spasm, and temporary improvement of local blood circulation; and â€¢Â Â Â Â Â temporary reduction in the appearance of cellulite. InMode RF /Â BoditeÂ /Â EmbraceRF Radiofrequency (RF) BodyriteÂ minimally invasive handpiece for thick body areas (>20mm) K171593 (10/10/2017) TheÂ InMode RFIBodyTitel EmbraceRFÂ platform with the minimally invasiveÂ BodyriteÂ handpiece for thick body areas is indicated for use in

dermatological and general surgical procedures for electrocoagulation and hemostasis. InMode RFÂ /Â BodyriteÂ /Â EmbraceRF Radiofrequency (RF) BodyriteÂ minimally invasive handpiece for thin body areas (<20mm) or for large specialty areasÂ K163190 (12/12/2016) TheÂ InMode RFIBodyTitel EmbraceRFÂ platform with the minimally invasiveÂ BodyriteÂ handpiece for thin body and large specialty areas is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. InMode RFÂ /Â EmbraceRF Radiofrequency (RF) FaceTite K151793 (02/19/2016) TheÂ InMode RF/EmbraceRFÂ platform with theÂ FaceTiteÂ handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. Optimas / InMode RF Radiofrequency (RF) FractoraÂ (60 pin tip) K102461 (06/02/2011) TheÂ Optimas/InModeÂ RF platform with theÂ FractoraÂ 60 pin tip handpiece is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin. 56 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications OptimasÂ /Â InMode RFÂ /Â EmbraceRF Radiofrequency (RF) FractoraÂ (24 pin tip)Â FractoraV K151273 (01/04/2016) TheÂ OptimaslInMode RFI EmbraceRFÂ platform with theÂ FractoraÂ 24 pin tip handpiece is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. Optimas Radiofrequency (RF) Morpheus8 K180189 (06/01/2018) TheÂ OptimasÂ platform with theÂ Morpheus8Â handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and homeostasis. InMode RF Radiofrequency (RF) Morpheus8 24 PinÂ Applicator Morpheus8 40 PinÂ treatment tip (New tip) Â â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 12 PinÂ treatment tip (New tip) â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 T PinÂ treatment tip (New tip) (maximal treatmentÂ depth 4.00 mm) K192695 (12/27/2019) The InMode System with the Morpheus8Â (Fractora)Â Applicators is intended for use in dermatological procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62 mJ/pin, use of the Morpheus8 (Fractora) Applicator is limited to Skin Types I-IV. InMode Radiofrequency (RF) Morpheus8 24 PinÂ Applicator Â Morpheus8 40 PinÂ treatment tip (New tip) â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 12 PinÂ treatment tip (New tip) â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 T PinÂ treatment tip (New tip) maximal treatment depthÂ 7.00 mm) K200947 (06/12/2020) The InMode System with the Morpheus8 Applicators is intended for use in dermatological procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62 mJ/pin, use of the Morpheus8 (Fractora) Applicator is limited to Skin Types I-IV. 57 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications EmBody (Evolve) Radiofrequency (RF) Tone K201285 (03/05/2021) TheÂ EmBody (Evolve)Â platform with its designated applicators is intended for the treatment of the following medical conditions:Â The EmBody (Evolve) System with Tone Applicator is designed to operate in two modes â€“ EMS and TENS. In EMS mode it is used for: â€¢Â Â Â Â Â Relaxation of muscle spasms â€¢Â Â Â Â Â Prevention or retardation of disuse atrophy â€¢Â Â Â Â Â Increasing local blood circulation â€¢Â Â Â Â Â Muscle re-education â€¢Â Â Â Â Â Maintaining or increasing range of motion â€¢Â Â Â Â Â Immediate postsurgical stimulation of calf muscles to prevent venous thrombosis And in TENS mode is intended for: â€¢Â Â Â Â Â Symptomatic relief and management of chronic, intractable pain â€¢Â Â Â Â Â Post-surgical acute pain â€¢Â Â Â Â Â Post-trauma acute pain EmBody (Evolve) Radiofrequency (RF) EMBodyPlus â€“ Tite Â T3-Transform K210877 (07/19/2021) The EvolveX System with the T3 Applicator employs RF technology or EMS-TENS technology for the treatment of selected medical conditions. The T3 Applicator in RF mode is intended for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. The T3 Applicator in EMS mode is intended for: â€¢Â Â Â Â Â Relaxation of muscle spasms â€¢Â Â Â Â Â Prevention or retardation of disuse atrophy â€¢Â Â Â Â Â Increasing local blood circulation â€¢Â Â Â Â Â Muscle re-education â€¢Â Â Â Â Â Maintaining or increasing range of motion â€¢Â Â Â Â Â Immediate postsurgical stimulation of calf muscles to prevent venous thrombosis The T3 Applicator in TENS mode is intended for: â€¢Â Â Â Â Â Symptomatic relief and management of chronic, intractable pain â€¢Â Â Â Â Â Post-surgical acute pain â€¢Â Â Â Â Â Post-trauma acute pain The RF treatment mode and EMS/TENS mode should not be used in combination or sequentially. 58 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications InMode RF ProÂ Platform â€“ Empower Radiofrequency (RF) i-Forma Forma(Plus), Plus90,Â Plus(Plus-Plus) BodyFX, MiniFX, Wmface, Fractora 24 pins tip Fractora 60 pins tip Morpheus8 24 Pin Â Applicator Morpheus8 40 Â PinÂ treatment tip â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 12 PinÂ treatment tip â€¢Â Â Â Â Â Â Â Â Â Â Â Morpheus8 T PinÂ treatment tip K201150 (07/21/2021) The InMode RFÂ Pro System with the Non-invasive RF Applicators employs RF energy for various applications: â€¢Â Â Â i-Forma, Forma (Plus), Plus (Plus Plus) and Plus90 for relief of minor muscle aches and pain, relief of muscle spasm, and temporary improvement of local blood circulation. â€¢Â Â Â Â WMface is intended for use in dermatologic procedures for non-invasive treatment of mild to moderate facial wrinkles and rhytids. â€¢Â Â Â Â BodyFXâ„¢ (WMBody)/MiniFXâ„¢ for relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation and temporary reduction in the appearance of cellulite. The InMode RF Multi-System with the Fractional Applicators employs RF energy for various applications: â€¢Â Â Â Â Fractora Applicator with 60 pins tip is designed for use in dermatological procedures requiring ablation and resurfacing of the skin. â€¢Â Â Â Â Â Fractora Applicator with 24 pins tip is intended for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62mJ/pin, use of the applicator is limited to skin types I-IV. â€¢Â Â Â Â Â Morpheus8â„¢ for dermatological and general surgical procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62mJ/pin, use of the applicator is limited to skin types I-IV. InMode RFÂ /Â EmbraceRF Radiofrequency (RF) AccuTite K182325 (08/27/2018) TheÂ InMode RFI EmbraceRFÂ platform with the AccuTite handpiece is indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. Contoura / Optimas Radiofrequency (RF) Plus Plus90 Plus-Plus K172302 (12/08/2017) TheÂ Contoura/OptimasÂ platform with theÂ FormaÂ Plus,Â Plus90,Â Plus-PlusÂ handpieces is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. Optimas Intense Pulsed Light (IPL) Lumecca 515 Lumecca 580 K123860 (04/02/2013) TheÂ OptimasÂ platform with theÂ Lumecca 515Â andÂ Lumecca 580Â handpieces is indicated for: â€¢Â Â Â Â the treatment of benign pigmented epidermal lesions, including dyschromia, hyperpigmentation, melasma, ephelides (freckles); and â€¢Â Â Â Â the treatment of benign cutaneous vascular lesions, including port wine stains, facial truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikiloderma of civatte, superficial leg veins and venous malformations. 59 Product Platform Energy Source Handpiece FDA 510(k) Clearance and Cleared Indications Triton / Optimas Laser DiolazeXL K170738 (08/07/2017) TheÂ Triton/OptimasÂ platform with theÂ DiolazeXLÂ handpiece is indicated for hair removal and permanent hair reduction defined as stable, long-term reduction in hair counts at six, nine or 12 months following a treatment regime. Triton / Optimas Powered Laser Vasculaze K173677 (02/23/2018) TheÂ Triton/OptimasÂ platform with theÂ VasculazeÂ handpiece is indicated for the treatment of vascular lesions, including angiomas, hemangiomas, telangiectasia, port wine stains, leg veins and other benign vascular lesions. Votiva Radiofrequency (RF) FormaV f (07/12/2016)* TheÂ InMode Plus90 (Votiva)Â platform with theÂ FormaÂ V handpiece is indicated for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation. Contoura / Optimas Radiofrequency (RF) BodyFX K131362 (10/08/2013) TheÂ Contoura/OptimasÂ platform with theÂ BodyFXÂ handpiece is indicated for the treatment of: â€¢Â Â Â Â relief of minor muscle aches and pains, muscle spasms and temporary improvement of blood circulation; and â€¢Â Â Â Â temporary reduction in the appearance of cellulite. Contoura / Optimas Radiofrequency (RF) MiniFX K160329 (08/19/2016) TheÂ Contoura/OptimasÂ platform with theÂ MiniFXÂ handpiece is indicated for the treatment of: â€¢Â Â Â Â relief of minor muscle aches and pain, muscle spasms, and temporary improvement of local blood circulation; and â€¢Â Â Â Â temporary reduction in the appearance of cellulite. Triton / Optimas Laser Triton Duo Light/Â TritonÂ Duo DarkÂ InModeÂ Diolaze XLÂ 755/810nmÂ InMode Diolaze XLÂ 810/1064nmÂ InMode DiolazeÂ XLÂ 810nm K180719 (06/14/2018) TheÂ Triton/OptimasÂ platform with theÂ Triton DuoÂ LightÂ andÂ Triton Duo DarkÂ handpieces is indicated for hair removal and permanent hair reduction. InMode Laser Diolaze K142952 (11/24/2014) The InMode Diolaze device is indicated for use for hair removal and for permanent reduction in hair regrowth, defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime InMode Laser Diolaze K123682 (27/02/2013) The InMode Diolaze device is indicated for use for hair removal InMode Radiofrequency (RF) WMface k140926 (12/03/2014) The InMode WMface device is intended for use in dermatologic procedures for noninvasive treatment of mild to moderate facial wrinkles and rhytids. * In addition to the 510(k) clearance, we also market the FormaV for use with the Votiva platform pursuant to a classification regulation for â€œgenital vibrators for therapeutic useâ€ under 21 C.F.R. 884.5960, which permits â€œelectronically operated devices intended and labeled for therapeutic use in the treatment of sexual dysfunction or as an adjunct to Kegelâ€™s exercise (tightening of the muscles of the pelvic floor to increase muscle tone)â€ to be marketed without a 510(k) clearance. Â Premarket Approval Pathway Â A PMA must be submitted to the FDA if the device cannot be cleared through the 510(k) process. A PMA must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling, to demonstrate the safety and effectiveness of the device to the FDAâ€™s satisfaction. Â No device that we have developed has required premarket approval, nor do we currently expect that any future device or indication will require premarket approval. Â Pervasive and Continuing Regulation Â After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: Â â€¢ QSR, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process; Â â€¢ clearance or approval of product modifications to 510(k)-cleared or PMA-approved devices that could affect safety or effectiveness; 60 â€¢ labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or â€œoff-labelâ€ uses; Â â€¢ advertising and promotion requirements; Â â€¢ medical device reporting regulations, which require that manufacturers report to the FDA if their devices may have caused or contributed to deaths or serious injuries or malfunctioned in ways that would likely cause or contribute to deaths or serious injuries if the malfunctions were to recur; Â â€¢ medical device correction and removal reporting regulations, which require the manufacturers to report to the FDA corrections and removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; and Â â€¢ post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the devices. Â We may be subject to similar foreign laws that may include applicable post-marketing requirements such as safety surveillance. Our manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, our facilities, records and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR or other applicable regulatory requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls. Â The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the facilities of our manufacturing subcontractors. Â We also are regulated under the Radiation Control for Health and Safety Act, which requires laser products to comply with performance standards, including design and operation requirements, and manufacturers to certify in product labeling and in reports to the FDA that their products comply with all such standards. The law also requires laser manufacturers to file new product and annual reports, maintain manufacturing, testing and sales records, and report product defects. Various warning labels must be affixed and certain protective devices installed, depending on the class of the product. Â Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: Â â€¢ warning or untitled letters, fines, injunctions, consent decrees and civil penalties; Â â€¢ unanticipated expenditures, repair, replacement, refunds, recalls, administrative detention or seizure of products; Â â€¢ operating restrictions, partial suspension or total shutdown of production; Â â€¢ refusing requests for 510(k) clearance or PMAs of new products or new intended uses; Â â€¢ withdrawing 510(k) clearance or PMAs that have already been granted; and Â â€¢ criminal prosecution. Â The FDA also has the authority to require us to repair, replace or refund the cost of any medical device that we have manufactured or distributed. If any of these events were to occur, they could have a material adverse effect on our business. Â We are also subject to a wide range of federal, state and local laws and regulations, including those related to the environment, health and safety, land use, and quality assurance. We believe that we are in compliance with these laws and regulations as currently in effect, and our compliance with such laws will not have a material adverse effect on our capital expenditures, earnings, and competitive and financial position. Â 61 Federal Communications Commission and other U.S. governmental agencies governing the use of radio frequency energy Â Our products generate and use radio frequency energy and therefore may be subject to technical equipment authorization and other regulatory requirements in the countries and regions where they are marketed or distributed. In the United States, our products are subject to the Federal Communications Commissionâ€™s equipment verification procedures, under which the manufacturer is required to determine or verify that the equipment complies with the applicable technical standards and to keep a record of test measurements demonstrating compliance before the equipment can be marketed or sold in the United States. Any modifications to our products may require reverification before we are permitted to market and distribute the modified devices. Â We obtain regulatory approvals in countries requiring advance clearance of our products before they are marketed or distributed in those countries. Our failure to comply with the technical, equipment authorization or other regulatory requirements of a specific country or region could impair our ability to commercially market and distribute our products in that country or region. Â Other Healthcare Laws Â Although none of our products or procedures using our products are currently covered by any state or federal government healthcare programs, or any private commercial payor, we may be subject to a number of foreign, federal, and state laws and regulations that may restrict our business practices, including, without limitation, anti-kickback, false claims, physician payment transparency and data privacy and security laws. The government has interpreted these laws broadly as they apply to the marketing and sales activities of manufacturers and distributors. Companies targeted in such prosecutions and in civil litigation have paid substantial fines, penalties, and settlements in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans, can be excluded from federal health care programs, and have often become subject to consent decrees, settlement agreements or corporate integrity agreements severely restricting the manner in which they conduct their business. Many U.S. states and countries outside the United States have similar fraud and abuse statutes or regulations that may be broader in scope than the U.S. federal laws, and may apply regardless of payor, in addition to items and services reimbursed under government programs. Â International Regulations Â International manufacturing and sales of medical devices are subject to foreign governmental regulations, which vary substantially from country to country. The time required to obtain clearance or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may be different. For example, the European Union has adopted numerous specific directives regulating the design, manufacture, clinical investigations, conformity assessment, labeling and adverse event reporting for medical devices that do not necessarily have an exact equivalent under U.S. law. Â Devices that comply with the essential requirements of the EU Medical Devices Directive (Directive 93/42/EEC) will be entitled to bear CE conformity marking, indicating that the device conforms with the essential requirements of the EU Medical Devices Directive and, accordingly, can be commercially distributed throughout the member states of the European Union, the member states of the European Economic Area, or EEA (which is comprised of the 27 EU countries, plus Norway, Liechtenstein, and Iceland), and countries that have entered into a Mutual Recognition Agreement. The method of assessing conformity varies depending on the type and (risk) class of the product but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a notified body, an independent organization designed by an EU country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturerâ€™s quality system and specific testing of the manufacturerâ€™s device. An assessment by a notified body in one member state of the European Union, the EEA or a country that has entered into a Mutual Recognition Agreement is required in order for a manufacturer to commercially distribute the product throughout these countries. European Standardization Committees and the International Organization for Standardization, or ISO, have promulgated voluntary harmonized standards. Compliance with applicable standards establishes the presumption of conformity with the essential requirements for a CE Marking. Â As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system, incidents must be reported to the relevant authorities of the Member States of the EEA, and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An

incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. Â 62 On May 25, 2017, the EU passed the Medical Devices Regulation (Regulation 2017/745) (â€œMDRâ€) entered into force, which repeals and replaces the EU Medical Devices Directive. The MDR allows devices lawfully placed on the market prior to May 26, 2021 pursuant to the EU Medical Devices Directive (discussed above), to generally continue to be made available on the market or put into service until May 26, 2025. Once the MDR phase-in period is complete after May 26, 2025, some of our products that entered the market prior to May 26, 2021 may come out of service. Â The Medicines and Healthcare Products Regulatory Agency of the United Kingdom (â€œMHRAâ€) is responsible for monitoring the UK medical device market. The MHRA requires that medical devices sold in the U.K. be required with the MHRA. Manufacturers based outside the UK need to appoint a UK Responsible Person to register devices with the MHRA in line with the grace periods. From July 1, 2023, all medical devices sold in the UK were required to carry a UKCA (UK Conformity Assessed) mark. However, UKCA marking alone will not be recognized in the EU. The rules for placing medical devices on the Northern Ireland market differs from those in the UK. All of our platforms and applicators require UKCA marking. Â Several member states of the EEA have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the marketing of medical devices that meet European Union requirements. Â In Israel, the Medical Equipment Law generally governs the regulatory process and authorizations required for the manufacture, marketing and use of medical and certain aesthetic products in Israel. Under the Medical Equipment Law, we are required to register our products with the Israeli Ministry of Health. The Medical Equipment Law offers a fast-track approval process for devices that received approval from certain non-Israeli regulatory agencies, including FDA clearance or CE marks. The registration process under this fast-track process involves submitting an application to the Israeli Ministry of Health which includes, among other things, documentation confirming receipt of the necessary regulatory approvals, such as 510(k) clearance or CE mark certification. In addition, we must provide details regarding the approval, including the period for which the applicable device was authorized for marketing in the applicable country, registration terms, any limitations, and any instructions given with respect to the labeling and packaging of such device. If approved, the registration of the device in Israel will be valid for the same period that such device was authorized to be marketed in the applicable non-Israeli country (but in any event not more than five years from the date of registration in Israel), and the device will be subject to the terms and conditions imposed by the relevant non-Israeli regulatory agency, if any. We have taken advantage of such fast-track approval in the past. Most of our products that we currently sell in Israel are registered with the Israeli Ministry of Health, with registrations that are set to expire on June 10, 2029. Our new products are in the process of being registered with the Israeli Ministry of Health. As necessary, we applied for extensions as required to maintain active registrations, and such registrations expired on January 31, 2024. Â Data Protection Â Our business involves the use, storage and transmission of information about our employees, our customers and, to a certain extent, clients of our customers. In the course of our operations, we may gain access to confidential customer information, including nonpublic personal data. We are bound by certain agreements to use and disclose this information in a manner consistent with the privacy standards under regulations applicable to our customers and are subject to numerous U.S. and foreign jurisdiction laws and regulations designed to protect this information. With the increase in publicity regarding data breaches resulting in improper dissemination of consumer information, many states have passed laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers, governmental entities, and the media. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. We intend to protect all personal information and to comply with all applicable laws regarding the protection of such information. Â 63 As an Israeli headquartered company, we are subject to the Israeli Protection of Privacy Law of 1981 and the Privacy Protection Regulations (Data Security) 5777-2017. Further, in the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy laws and consumer protection and advertising laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. Â In the European Union and the EEA, the GDPR imposes several stringent requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data and additional obligations when we contract third-party processors in connection with the processing of the personal data. The GDPR provides that EU and EEA member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU and EEA member states may result in fines of up to â‚¬20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. To comply with the new data protection rules imposed by GDPR, we may be required to put in place additional mechanisms ensuring compliance. Further, since January 1, 2021, we are subject to the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g., fines up to the greater of â‚¬20 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. It is not clear whether (and when) an adequate decision may be granted by the European Commission enabling data transfers from European Union member states to the United Kingdom long-term without additional measures. These changes will lead to additional costs and increase our overall risk exposure. Â Corporate and Social Responsibility Â Our management continues to participate in Corporate Social Responsibility (â€œCSRâ€) Reporting on our website to respond to increased awareness of the importance of environmental and sustainability topics and non-material company activities towards the long-term success of the company. As a manufacturer of medical devices, we already adhere to strict quality and safety requirements dictated by regulatory bodies such as the FDA, CE, Health Canada, TGA (Australia), Brazil, Japan, Chinaâ€™s National Medical Products Administration (â€œNMPAâ€), ISO, as well as international GMP standards. We successfully completed all audits conducted by the regulatory bodies in 2024, including a physical audit of our facilities and the facilities of our Tier 1 subcontractors â€“ Medimor, Flex, and Resonetics.Â Â Â Our mission is to develop and produce innovative, life-changing technologies to enable patients to become their â€˜best possible selfâ€™, in the safest and most effective manner. Our commitment to CSR topics complements InModeâ€™s core values to provide the ultimate in customer care and support. Â Management Discussion of Corporate and Social Responsibility Â In 2023, we completed reporting on all six topics defined by The SASB (Sustainability Accounting Standards Board) Sustainability Accounting Standard for Medical Equipment and Supplies. These topics were: Affordability & Pricing, Ethical Marketing, Product Design & Lifecycle Management, Business Ethics, Product Safety and Supply Chain Management. Â Our CSR Reporting also highlights our impact on the local economies in government-designated development areas in the periphery where we work with contract suppliers and subcontractors (https://inmodemd.com/investors/corporate-social-responsibility/). Â The CSR Reporting specifically focuses on our primary assembly and manufacturing facilities in Israel, the location of the Companyâ€™s headquarters. Further information on our corporate social responsibility efforts and SASB data reporting is available on our website. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this Annual Report on Form 20-F, and the reference to our website in this Annual Report on Form 20-F is an inactive textual reference only. Â 64 Community Involvement in the Periphery Â Robotics Mentoring in Dimona Â Since 2017, Moshe Mizrahy and InMode engineers have been involved with the FIRST Robotics Group at Amit Zinman High School in Dimona. Dimona is located in southern Israel and is an area in the lower rungs of the socioeconomic scale. Â InMode supports the robotics team of Amit Zinman High School with more than just financial resources. Our engineers provide ongoing mentoring and opportunities to design electromechanical devices. One of the programâ€™s goals is to introduce STEM subjects into the community through projects and our outreach programs and activities for kindergartens and elementary schools. We continue to support the high schoolâ€™s robotics team with mentoring, resources, and funds and will continue in 2025. Â Technology Project at ORT Maale Tiberias High School Â InMode, together with Medimor, our Tier 1 supplier, has established a partnership with ORT Maale Tiberias school to create a sustainable technology project. We have earmarked one hundred thousand dollars to this educational project. Tiberias is inÂ an economically depressed area of Israel and there have been few industry or business partnerships with Tiberias. We are proud to sponsor such an exciting and impactful project. Â C. Organizational Structure Â Our subsidiaries, the countries of their incorporation/residence and proportion of ownership interest are as follows: Â Name Jurisdiction of Incorporation Â Percentage Ownership Invasix Inc.Â Â Â Â Â Â Â Â Â Â Â Delaware, USA Â 100% Invasix Corp.Â Â Â Â Â Â Â Â Â Â Â Canada Â 100% InMode M.D. Ltd.Â Â Â Â Â Â Â Â Â Â Â Israel Â 100% Invasix UK Ltd.Â Â Â Â Â Â Â Â Â Â Â United Kingdom Â 100% InMode Japan KKÂ Â Â Â Â Â Â Â Â Â Â Japan Â 100% Invasix Iberia S.L.Â Â Â Â Â Â Â Â Â Â Spain Â 100% Guangzhou InMode Medical Technology Ltd. China Â 100% InMode Asia Limited.Â Â Â Â Â Â Â Â Â Â Hong Kong Â 100% InMode India Private LimitedÂ Â Â Â Â Â Â Â Â Â Â India Â 100% InMode Australia Pty LtdÂ Â Â Â Â Â Â Â Â Â Â Australia Â 100% IMD France EURLÂ Â Â Â Â Â Â Â Â Â Â France Â 100% InMode Innovations Ltd.Â Â Â Â Â Â Â Â Â Â Â Israel Â 100% InMode Italy S.r.lÂ Â Â Â Â Â Â Â Â Â Â Italy Â 100% InMode Germany GmbHÂ Â Â Â Â Â Â Â Â Â Â Germany Â 100% D. Property, Plants and Equipment Â We lease our main office, manufacturing and research and development facilities, located in the Industrial Zone in Yokneam, Israel, pursuant to a lease that expires in December 2027. The original agreement was signed in May 2018.Â In January 2019, February 2020, March 2021, May 2023, June 2024 and July 2024, we signed supplemental lease agreements, further expanding our headquarters in Israel. Â We currently lease approximately 44.4 thousand square feet in the Israeli facility. Our current monthly rent payment is approximately $76.7 thousand. In addition, we currently lease a warehouse in Zarzir, Israel with approximately 10.1 square feet and our current monthly rent payment for such warehouse is approximately $8.9 thousand. Â In August of 2020, our U.S. subsidiary, signed a new leasing agreement, for an approximately 24-thousand-square-foot facility located in Orange County, California, to support our expanding operations in the U.S. The new lease agreement is for seven years and four months and occupation of the new facility commenced in the middle of April of 2021. The current monthly rent payment is approximately $28 thousand. Â 65 Our Canadian subsidiary has signed a new lease agreement in April 2022 for an approximately 12-thousand-square-foot facility in Richmond Hill, Ontario. The new lease agreement is for three years which began in July 2022. The current monthly rent payment is approximately $17 thousand. Â From time to time, we also lease small properties, mainly for offices for our subsidiaries around the world, for periods that generally last up to three years. Â We believe our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. Â ITEM 4A. UNRESOLVED STAFF COMMENTS Â None. Â ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS Â The following discussion should be read in conjunction with our consolidated financial statements and related notes for the years ended DecemberÂ 31, 2024, 2023 and 2022, which are included elsewhere in this 2024 Annual Report. Â Overview Â We design, develop, manufacture and commercialize innovative, energy-based, non-invasive, minimally invasive surgical aesthetic and medical treatment solutions. Since 2010, we have launched 14 product platformsÂ (BodyTite, Optimas, Votiva, Contoura, Triton,Â EmbraceRF, EvolveX, Evoke,Â Morpheus8, EmpowerRF, Define,Â Envision, IgniteRF and OptimasMAX)Â that we market and sell traditionally to plastic and facial surgeons, aesthetic surgeons, medical spas, dermatologists and OB/GYNs. Â As of December 31, 2024, we had a global installed base of approximately 27,090 product platforms capable of running various multi-use applicators and minimally invasive consumables. Â We anticipate that our quarterly results of operations may fluctuate from quarter to quarter due to several factors, including seasonality, unexpected delays in the introduction and market acceptance of our products, unexpected delays in our manufacturing operations, introduction of new and improved products by our competitors and the performance of our direct sales organization. Â Components of Our Operating Results Â Revenues Â We generate our revenues primarily from the sale of energy-based medical aesthetic products, which consist of platforms and non-consumable handpieces and hands-free applicators. To a lesser extent, we generate revenue from the sale of consumables and from the sale of extended warranties. For the year ended December 31, 2024, we derived approximately 80% of our revenues from the sale of medical aesthetic products and approximately 20% of our revenues from the sale of consumables and extended warranties. We expect our revenues from the sale of consumables and extended warranties to increase over time as our installed base continues to grow. we expect continued growth in sales of consumables as a result of, increased patient and physician awareness of our medical aesthetic products and additional sales representatives. We have expanded our sales and marketing organization as well as our number of platforms, to help us drive and support revenue growth and intend to continue this expansion. Â For the years ended December 31, 2024 and 2023 we derived approximately $344.0 million, or 87% and $406.6 million, or 83%, respectively, of our total revenues from the sale of minimally invasive platforms, and we derived approximately $20.1 million, or 5% and $43.1 million, or 8%, respectively, of our total revenues from the sale of hands-free platforms and approximately $30.7 million, or 8% and $42.4 million, or 9%, respectively, of our total revenues from the sale of non-invasive platforms. This resulted in the year ended December 31, 2024 a decrease of approximately $62.6 million, or 15%, $23.0 million, or 53% and $11.7 million, or 28% in revenues from the sale of minimally invasive platforms, hands-free platforms and non-invasive platforms, respectively. The decrease in the total revenues for the year ended December 31, 2024 was primarily generated by a decrease in the volume of medical aesthetic products sold by us as a result of the economic situation. Â In the future, we expect that revenues from the sale of minimally invasive platforms will continue to be a major contributor to our revenues. Â 66 We sell our products directly in the United States, Canada, United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia and India, and indirectly through third-party distributors in other countries. Â The following table provides information regarding the breakdown of our revenue by geographic region for the years ended December 31, 2024, 2023 and 2022: Â Â Â Years Ended December 31, Â Geographic region Â 2024 Â Â 2023 Â Â 2022 Â United StatesÂ Â Â Â Â Â Â Â Â Â Â Â Â 244,774 Â Â 307,818 Â Â 298,612 Â EuropeÂ Â Â Â Â Â Â Â Â Â Â Â Â 63,441 Â Â 62,532 Â Â 49,274 Â Asia Â 42,974 Â Â 47,744 Â Â 36,492 Â OtherÂ Â Â Â Â Â Â Â Â Â Â Â Â 43,629 Â Â 73,954 Â Â 69,893 Â TotalÂ Â Â Â Â Â Â Â Â Â Â Â Â 394,818 Â Â 492,048 Â Â 454,271 Â We believe that there are opportunities for us to generate additional revenue from existing customers who are already familiar with our products. We intend to continue to invest in research and development activities, increase the number of sales representatives in our sales and marketing organization and introduce innovative next-generation pipeline products to our customers. As a result, we expect that certain existing customers will be candidates for technology upgrades to enhance the capabilities of their existing InMode products. In addition, as we continue to grow our support services program, we expect to increase the number of customers that enter into service contracts and extended warranties with us, which would result in additional recurring revenues. We also plan to expand our current product line in order to reach non-traditional customers, such as ENTs, ophthalmologists, general practitioners and aesthetic clinicians, and generate additional revenue. Â Cost of Revenues Â Our cost of revenues consists primarily of the expenses we incur to have our products manufactured and assembled by third parties and the direct costs we incur in order to obtain the materials, labor and overhead that are needed to manufacture and assemble our products. Â Our cost of revenues also includes shipping, handling, service and warranty expenses, as well as salaries and personnel-related expenses, including share-based compensation expenses, for our operations management team, which is comprised of subcontractor supervisors and purchasing and quality control employees. We expect our cost of revenues to increase in absolute dollars primarily as, and to the extent, our revenue grows. Â Our cost of revenues as a percentage of revenues has been, and we expect it to continue to be, affected by a variety of factors, including the average selling price of our products, promotional prices being offered to existing customers for our new products, manufacturing costs, the maturity of our existing products, and to a lesser extent the sales mix between the United States and the rest of the world as our average selling price in the United States tends to be higher than in the rest of the world after accounting for differences in currency value. We expect our gross margin to be maintained at current levels over time to the extent we are successful in maintaining our average selling prices, as well as, offsetting increased material and shipping costs with reducing manufacturing costs as our sales volume increases. However, our gross margin may fluctuate from period to period. Â Research and Development Expenses Â Our research and development expenses consist of salaries and personnel-related expenses, including share-based compensation expenses, for our employees that are primarily engaged in research, development and engineering activities. Our research and development expenses also include regulatory-related costs and expenses, external engineering fees, materials used and other overhead expenses that are incurred in connection with the design and development of our products. For further details with

respect to government regulations we are subject to, see â€œItem 4B. Information on the Company-Business Overview-Government Regulations.â€ We expense all of our research and development costs as incurred. While we do not track our research and development spending by technology, product or application, we do expect that our overall research and development costs will increase in absolute dollars in the future as we develop more products and technologies. We expect research and development expenses as a percentage of our total revenue to vary over time depending on the level and timing of initiating new product development efforts. Â 67 Sales and Marketing Expenses Â Our sales and marketing expenses consist primarily of salaries, commissions and personnel-related expenses, including share-based compensation expenses, for our employees that are engaged in sales and marketing activities, which include marketing and public support of our products, participation in trade shows and industry events, promotional and public relations activities, and administrative functions in support of sales and marketing. We expect sales and marketing expenses to continue to increase in absolute dollars as we continue to expand our marketing organization to both drive and support our planned growth in revenue. Â General and Administrative Expenses Â Our general and administrative expenses consist primarily of salaries and personnel-related expenses, including share-based compensation expenses, for executive, accounting and administrative personnel, professional fees and other general corporate expenses. We expect general and administrative expenses to grow at a steady state as our operations will continue to expand. However, general and administrative expenses may vary over time, due to increasing legal and insurance premium costs and involvement in IP related litigations. Â Income Taxes Â We are subject to income taxes in Israel, the United States and numerous foreign jurisdictions. Â Our facilities in Israel were previously granted the status of â€œBenefited Enterpriseâ€ which provided us with a ten-year corporate tax exemption for undistributed income from 2012 to 2021. From 2022, our corporate tax rate under the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 and our Israeli subsidiary is expected to be approximately 7.5%. See â€œItem 10E. Additional Information-Taxation.â€ Â Critical Accounting Policies and Estimates Â Our discussion and analysis of our financial condition and results of our operations is based upon our audited consolidated financial statements as of and for the years ended December 31, 2024, 2023 and 2022, which have been prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, sales and expenses and related disclosure of contingent assets and liabilities. We base our estimates on historical experience, authoritative pronouncements and various other assumptions that we believe to be reasonable under the circumstances. On a periodic basis, we evaluate our estimates. Actual results could differ from those estimates. Â The following are our critical accounting policies and the significant judgments and estimates affecting the application of those policies in our consolidated financial statements. Â Revenue Recognition Â Product revenue, Net Â Revenues from product sales are recognized when the customer obtains control over our product, typically upon shipment to the customer. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. Â Variable consideration includes price concessions related to installment sales contracts. We estimate variable consideration using the most likely outcome amount. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Â We do not grant any right of return, refund, cancelation or termination. From time to time, we participate in our customersâ€™ marketing activities and deduct costs related to such activities from revenue. Â Service Revenue Â We also generate revenues from long-term maintenance contracts or extended warranties. Revenue from extended warranties is recognized ratably, on a straight-line basis, over the period of the applicable service contract. Revenue from repairs performed in the absence of extended warranties is recognized when the related services are performed. Â More information regarding revenue recognition is discussed in Note 2q in our consolidated financial statements. Â 68 Income Taxes Â The provision for income tax is calculated based on our assumptions as to our entitlement to various benefits under the applicable tax laws in the jurisdictions in which we operate. The entitlement to such benefits depends upon our compliance with the terms and conditions set out in these laws. We are subject to income taxes in Israel, the U.S. and other foreign jurisdictions. Our effective tax rate is primarily impacted by the geographical mix of taxable income and loss. We record a tax provision for the anticipated tax consequences of our reported operating results. Changes in tax laws, regulations, agreements and treaties, currency exchange restrictions or the level of operations or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balances and hence our net income. Â We estimate the degree to which deferred tax assets will result in a benefit, after consideration of all positive and negative evidence, and provide a valuation allowance for deferred tax assets that we believe more likely than not will not be realized. In situations in which we are able to determine that our deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. Significant judgment required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. Â During the year ended DecemberÂ 31, 2024, we determined that the positive evidence overcame any negative evidence, primarily due to cumulative income in recent years, including the effect of permanent adjustments, and the expectation of profitability in future periods, and concluded that it was more likely than not that the United States net deferred tax assets were realizable. As a result, we released the valuation allowance of $60.1 millionÂ related to the United States net deferred tax assets during the year ended DecemberÂ 31, 2024, with $5.4 millionÂ used during 2024, and $54.7 millionÂ recorded as defer tax assets. As of DecemberÂ 31, 2024, we concluded that the deferred tax assets for certain jurisdictions would not be realized and therefore reserved valuation allowance in the amount of $4.2 millionÂ with respect to these deferred tax assets. Â Significant judgment is required in evaluating our uncertain tax positions. In evaluating the exposure associated with our various tax filing positions, we record reserves for uncertain tax positions in accordance with US GAAP, based on the technical support for the positions and our past audit experience with similar positions. For those tax positions where it is more likely than not that a tax benefit will be sustained, we record the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. We believe our tax positions comply with applicable tax laws and we intend to defend our positions, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax reserves and accruals. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate. The liability for these unrecognized tax benefits totaled $3.4 million on DecemberÂ 31,Â 2024Â (see Note 13Â to our consolidated financial statementsÂ for additional information). Â Operating Results Â The following table summarizes the results of our operations for the periods presented: Â Â Â Years Ended December 31, Â Â Â 2024 Â Â 2023 Â Â Â ($) Â Â (% of Revenues) Â Â ($) Â Â (% of Revenues) Â Â Â (in thousands) Â RevenuesÂ Â Â Â Â Â Â Â Â Â Â Â 394,818 Â Â Â 100 Â Â Â 492,048 Â Â Â 100 Â Cost of revenuesÂ Â Â Â Â Â Â Â Â Â Â Â 77,752 Â Â Â 20 Â Â Â 80,708 Â Â Â 16 Â Gross profitÂ Â Â Â Â Â Â Â Â Â Â Â 317,066 Â Â Â 80 Â Â Â 411,340 Â Â Â 84 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â Â Â Â Â Â Â Â Â Â Â 13,137 Â Â Â 3 Â Â Â 13,410 Â Â Â 3 Â Sales and marketingÂ Â Â Â Â Â Â Â Â Â Â Â 181,366 Â Â Â 46 Â Â Â 193,042 Â Â Â 39 Â General and administrativeÂ Â Â Â Â Â Â Â Â Â Â Â 10,032 Â Â Â 3 Â Â Â 9,228 Â Â Â 2 Â Total operating expensesÂ Â Â Â Â Â Â Â Â Â Â Â 204,535 Â Â Â 52 Â Â Â 215,680 Â Â Â 44 Â Operating incomeÂ Â Â Â Â Â Â Â Â Â Â Â 112,531 Â Â Â 28 Â Â Â 195,660 Â Â Â 40 Â Finance income, netÂ Â Â Â Â Â Â Â Â Â Â Â 30,938 Â Â Â 8 Â Â Â 21,607 Â Â Â 4 Â Income before income taxesÂ Â Â Â Â Â Â Â Â Â Â Â 143,469 Â Â Â 36 Â Â Â 217,267 Â Â Â 44 Â Income taxes benefit (expenses)Â Â Â Â Â Â Â Â Â Â Â 37,806 Â Â Â 10 Â Â Â (19,348) Â Â 4 Â Net incomeÂ Â Â Â Â Â Â Â Â Â Â Â 181,275 Â Â Â 46 Â Â Â 197,919 Â Â Â 40 Â 69 Comparison of the Year Ended December 31, 2024 to the Year Ended December 31, 2023 Â Revenues Â Our revenues decreased by approximately $97.2 million, or 20%, to approximately $394.8 million for the year ended December 31, 2024, compared to approximately $492.0 million for the year ended December 31, 2023. This decrease was attributable to a decrease in sales of our minimal invasive platforms worldwide in the amount of $62.6 million, a decrease in the sales of our hand free platforms worldwide in the amount of $23.0 million, and a decrease of $11.7 decrease from non-invasive. The decrease in the total revenues for the year ended December 31, 2024 as compared to the prior year was primarily generated by an decrease in the volume of medical aesthetic products sold by us during the period as a result of decrease in patient and physician demand due to economic situation. Our revenues in the United States decreased by approximately $63.0 million, or 20%, to approximately $244.8Â million for the year ended December 31, 2024, compared to approximately $307.8 million for the year ended December 31, 2023. This decrease was primarily attributable to the overall slowdown in the demand for aesthetic procedures, in addition to challenging financing market in the United States. Â Our revenues outside of the United States decreased by approximately $34.2, or 19%, to approximately $150.0 million for the year ended December 31, 2024, compared to approximately $184.2 million for the year ended December 31, 2023. This decrease was primarily due to global slowdown in demand for aesthetic procedures and capital equipment sales. Â Our revenues from the sale of consumables and extended warranties for the year ended December 31, 2024, decreased by approximately 1% compared to the year ended December 31, 2023. This decrease was primarily attributable to slowdown in demand for aesthetic procedures. Â Cost of revenues Â Our cost of revenues decreased by approximately $2.9 million, or 4%, to approximately $77.8 million for the year ended December 31, 2024, compared to approximately $80.7 million for the year ended December 31, 2023. This decrease was primarily due to decrease in sales. Our gross margin decreased to 80% for the year ended December 31, 2024, compared to approximately 84% for the year ended December 31, 2023. This decrease was primarily attributable to an increase of material costs and a different sales mix between the United States and rest of the world.. Â Research and development expenses Â Our research and development expenses decreased to approximately $13.1 million for the year ended December 31, 2024, compared to approximately $13.4 million for the year ended December 31, 2023. This decrease was primarily attributable to a decrease in share-based compensation in the amount of $0.5 million. Â Sales and marketing expenses Â Our sales and marketing expenses decreased by approximately $11.6 million, or 6%, to approximately $181.4 million for the year ended December 31, 2024, compared to approximately $193.0 million for the year ended December 31, 2023. This decrease was primarily attributable to decrease in commission for sales in the amount of $11.4 million, decrease in share-based compensation in the amount of $5.8 million which was offset with increase in salaries in the amount of $1.8 million, related expenses in the amount of $1.2 million and, trade show and other marketing expenses in amount of $2.2 million. Â General and administrative expenses Â Our general and administrative expenses increased by approximately $0.8 million, or 9%, to approximately $10.0 million for the year ended December 31, 2024, compared to approximately $9.2 million for the year ended December 31, 2023. This increase was primarily attributable to the increase in professional services in the amount of $0.9 million, increase in product liability provision in the amount of $0.5 million which was offset with decrease in share-based compensation in the amount of $0.5 million. Â 70 Finance income, net Â Our finance income, net was approximately $30.9 million for the year ended December 31, 2024, compared to approximately $21.6 million for the year ended December 31, 2023. This increase in finance income, net was primarily attributable to increase in interest income from our portfolio of investments in bonds and corporate debt securities and short-term bank deposits in the amount of $12.5 million. Â Income taxes benefit (expenses) Â Our income taxes decreased by approximately $57.1 million, or -295%, to result in a benefit of approximately $37.8 million for the year ended December 31, 2024, compared to expenses of approximately $19.3 million for the year ended December 31, 2023. This decrease was primarily attributable to recognition of a NOL deferred tax asset in amount of $55.6 million . See â€œItem 10E. Additional Informationâ€“Taxationâ€. Â Liquidity and Capital Resources Â Historically, we have funded our operations primarily from cash flows from operations, from private placements of our ordinary shares, from our initial public offering in August 2019 and from exercise of options. Since inception in January 2008, we have not received any debt financing from banks or issued any preferred or debt securities. We have received aggregate net proceeds of approximately $109.8 million from issuances of our ordinary shares, including approximately $69.8 million from our initial public offering. Â In May 2024, we approved a share repurchase program of up to 8.37 million ordinary shares, to be purchased out of our cash reserve. In September 2024, we approved a share repurchase program of up to 7.68 million ordinary shares, to be purchased out of our cash reserve. As of December 31, 2024, we purchased 16.05 million ordinary shares in the amount of $285.4 million under these repurchase programs. Â As of December 31, 2024, we had working capital of approximately $644.6 million, and our primary source of liquidity was approximately $596.5 million in cash and cash equivalents, marketable securities and short-term bank deposits. Our major cash requirements are obligations to support our ongoing operations which consist primarily of salary and commissions expenses for employees, and contractual obligations for our subcontractors and lease agreements. We expect our working capital to be sufficient for the Companyâ€™s present requirements. Â If existing cash and cash generated from operations are insufficient to satisfy our liquidity requirements, we may seek to sell equity or debt securities or obtain a credit facility. If we raise funds by issuing equity securities, our shareholders would experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or equity that we raise may contain terms that are not favorable to us or our shareholders. Financing may not be available at all, or in amounts or on terms unacceptable to us. If we are unable to obtain financing, we may be required to delay the development, commercialization and marketing of our aesthetic medical products. Â Cash Flows Â The following table represents a summary of our cash flow for the periods indicated Â Â Â Years ended December 31, Â Â Â 2024 Â Â 2023 Â Net cash provided by (used in): Â (in thousands) Â Operating activitiesÂ Â Â Â Â Â Â Â Â Â Â Â $ 132,664 Â Â $ 176,826 Â Investing activitiesÂ Â Â Â Â Â Â Â Â Â Â Â 162,206 Â Â Â (136,064) Financing activitiesÂ Â Â Â Â Â Â Â Â Â Â Â (282,771) Â Â 5,504 Â Effects of exchange rate changes on cashÂ Â Â Â Â Â Â Â Â Â Â Â (1,181) Â Â 605 Â Net increase in cash and cash equivalentsÂ Â Â Â Â Â Â Â Â Â Â Â $ 10,918 Â Â $ 46,871 Â Â Net Cash Provided by Operating Activities Â For the year ended December 31, 2024, our net cash provided by operating activities was $132.7 million. The primary reason for net cash provided by operating activities was the net profit of $181.3 million, decrease in accounts receivable of $5.9 million and increase in contract liabilities of $5.4 million. The outflow from deferred tax income in the amount of $55.2 million was primarily due to release of valuation allowance in the U.S. and increase in inventory of $14.5 million and other receivables of $5.7 million. Additionally, our net profit for the year ended December 31, 2024, included $16.6 million in non-cash expenses primarily comprised of share-based compensation expense. Â 71 For the year ended December 31, 2023, our net cash provided by operating activities was $176.8 million. The primary reason for net cash provided by operating activities was the net profit of $197.9 million. The outflow from operating assets and liabilities in the amount of $41.4 million was primarily due to an increase of $16.1 million in accounts receivable due to an increase in sales through distributors, and an increase in other liabilities of $12.6 million, primarily in income tax due to one-time payments of the Company to the Israeli tax authority discussed above, and an increase of $5.2 million in inventories to meet growth in anticipated sales. As we expect our revenues to continue to grow, we anticipate our accounts receivables, inventory and accounts payable will similarly continue to grow, including our available working capital. Â Net Cash Used in Investing Activities Â For the year ended December 31, 2024, net cash provided in investing activities was $162.2 million, which primarily related to investment of short-term bank deposits and marketable securities of $504.4 million. These outflows were partially offset by inflows of $667.3 million related to proceeds from short-term bank deposits and marketable securities. Â For the year ended December 31, 2023, net cash used in investing activities was $136.1 million, which primarily related to short-term bank deposits and marketable securities of $478.6 million. These outflows were partially offset by inflows of $343.3 million related to proceeds from short-term bank deposits and marketable securities. Â Net Cash Used in Financing Activities Â For the year ended December 31, 2024, net cash used in financing activities was $282.8 million, which consisted of $285.4 million outflow as part of our share repurchase programs. This outflow was partially offset by inflow of $2.6 million related to proceeds from the exercise of options. Â For the year ended December 31, 2023, net cash used in financing activities was $5.5 million, which consisted of proceeds from the exercise of options. Â Research and Development, Patents and Licenses, etc. Â For a description of the Companyâ€™s research and development policies, see â€œItem 4B. Information on the Companyâ€“Business Overviewâ€“Intellectual Propertyâ€. Â Trend Information Â Other than as disclosed elsewhere in this Annual Report on Form 20-F, we are not aware of any trends, uncertainties, demands, commitments or events for the year ended December 31, 2024 that are reasonably likely to have a material effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial condition. Â Recently Issued Accounting Pronouncements Â Certain recently issued accounting pronouncements are discussed in Note 2 in our consolidated financial statements. Â 72 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES Â A. Directors and Senior Management Â The following table sets forth the name, age and position of each of our executive officers and directors as of the date of this Annual Report on Form 20-F. Â Name Â Age Â Position Moshe MizrahyÂ Â Â Â Â Â Â Â Â Â Â 72 Â Chief Executive Officer Yair MalcaÂ Â Â Â Â Â Â Â Â Â Â 47 Â Chief Financial Officer Dr. Michael KreindelÂ Â Â Â Â Â Â Â Â Â Â 58 Â Chief Technology Officer and Director Dr. Michael Anghel(1)(2)Â Â Â Â Â Â Â Â Â Â 86 Â Chairman of the Board of Directors Dr. Hadar Ron, M.D.(1)(2) Â 66 Â Director Bruce Mann(1)(2)(3)Â Â Â Â Â Â Â Â Â Â 90 Â Director Mr. Nadav Kenneth(1)(2)(3) Â 65 Â Director (1)Â Â Â Member of Audit & Investment Committee Â (2)Â Â Â Member of Compensation, Nominating and Corporate Governance Committee Â (3)Â Â Â Mr.

Nadav Kenneth replaced Dr. Bruce Mann as a Director in April 2024 Â A brief biography of each person who serves as an executive officer and/or director of the Company is set forth below: Â Moshe Mizrahy. Moshe Mizrahy co-founded the Company in 2008 and has been our Chief Executive Officer since inception and served as the Chairman of our board of directors from 2008 to July 2024. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., an international medical aesthetic consumer devices company active in the home use market, and is currently the chairman of its board since 2007. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of the following companies: SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Urifer Ltd., Escape Rescue Systems Ltd., New Forest Wood Products (2012) Ltd., Med Smart Hub Ltd., Ivy Next Ltd., M.N. Business Strategy Ltd. and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York. Â Yair Malca. Yair Malca has served as our Chief Financial Officer since 2017. In his previous role, Mr. Malca was the Director of Finance for Jazz Semiconductor, Inc., a developer of integrated circuits and semiconductors, from 2013 to 2017. Before that, he served as the controller of Syneron from 2008 to 2013, as assistant controller of EZchip Semiconductor, a provider of network processors, from 2007 to 2008, as subsidiary controller of Bermad, a provider of hydraulic control valves, from 2005 to 2007, and began his career in public accounting at Ernst & Young from 2002 to 2005. Mr. Malca holds a B.A. in Accounting and Economics from Haifa University and an MBA from Tel Aviv University, and is a Certified Public Accountant in Israel. Â Dr. Michael Anghel. Dr. Michael Anghel became the Chairman of the board of directors effective July 25, 2024. Dr. Anghel has been a director of the Company in August 2019. Dr. Anghel has previously served on the board of directors and on the Investment Monitoring Committee of BiolineRx Ltd. (Nasdaq: BLRX) since 2010 and until 2024. From 1977 to 1999, he led the Discount Investment Corporation Ltd. (of the IDB Group) activities in the fields of technology and communications. In 1999, he founded CAP Ventures, an advanced technology investment company. From 2004 to 2005, Dr. Anghel served as CEO of DCM, the investment banking arm of the Israel Discount Bank (TASE: DSCT). Dr. Anghel has also previously served as the Chairman of the Audit Committee and the Chairman of the Remuneration Committee of Ellomay Capital Ltd. {NYSE, TASE : ELLO) until December 2023. Mr. Anghel also previously served as the chairman of the Center for Educational Technology and as the Chairman of the board of directors of Lahav Ltd (Tel-Aviv University Executive Program). Prior to launching his business career, Dr. Anghel served as a full-time member of the Graduate School of Business Administration of the Tel Aviv University, where he taught finance and corporate strategy. Dr. Anghel holds a B.A. in Economics from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. in Finance from Columbia University, New York. Â 73 Dr. Michael Kreindel. Dr. Michael Kreindel co-founded the Company in 2008 and has served as our Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia. Â Dr. Hadar Ron, M.D. L.L.B. Dr. Hadar Ron became a director of the Company in August 2019. Since 2000, Dr. Ron has been the founding and managing partner of Israel Healthcare Ventures, an Israeli life science venture capital fund. Dr. Ron is also the chief executive officer of the management company for Israel Healthcare Ventures 2 LP Incorporated, or IHCV2, an Israeli life sciences venture capital fund. Dr. Ron serves as chairperson of G.I. View Ltd., a medical device company specializing in colorectal screenings, and CyTwist Ltd., an information technology start-up company, and as a board member of the following companies: Home Skinovations Ltd., SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Viroblock Ltd., O.G.D.H. Ltd., OrSense Ltd., and NanoPass Technologies Ltd. In addition, Dr. Ron serves as an external director of Together Pharma Ltd. In addition, Dr. Ron serves as a member of the advisory board of the Momentum Fund Tech Transfer of Tel Aviv University, a board member of BIRAD Ltd., the tech transfer company of Bar Ilan University, and is the chairperson of the scientific advisory board of Social Finance Israelâ€™s Social Impact Bond for the prevention of diabetes and colon cancer. Dr. Ron is a physician and attorney by education. She holds M.D. and L.L.B. degrees from Tel Aviv University and has studied at the School of Business Administration at Tel Aviv University. Â Bruce Mann. Mr. Bruce Mann served as a director of the Company from August 2019 to April 2024. Bruce Mann is an independent advisor and consultant on corporate governance, corporate law, and capital markets matters, primarily for emerging technology companies. He was a senior partner, partner, or senior of counsel of Morrison & Foerster LLP for 30 years prior to his retirement in 2017. Mr. Mann has been a Governor-at-Large of the National Association of Securities Dealers (NASD) and a member of the New York Stock Exchange Legal Advisory Committee. He has held numerous positions in the American Bar Association, including chairing the Senior Lawyers Division, the Federal Regulation of Securities Committee and the Venture Capital and Private Equity Committee of the ABA Business Law Section. Mr. Mann holds a BBA from the University of Wisconsin and a JD from the University of Wisconsin Law School. Â Mr. Nadav Kenneth. Mr. Nadav Kenneth became a director of the Company in April 2024, replacing Mr. Bruce Mann. Mr. Kenneth served for 22 years in the Israeli Armyâ€™s Intelligence corps (Unit 8200) where he led large R&D functions, was in charge of the strategic planning branch (plans, methodology, budgeting and monitoring) and commanded an intelligence unit. Following his service, Mr. Kenneth co-founded, managed and served as a board member of several startup companies, worked for a large cellular operator, and provided consultation to companies and official entities. In 2009, Mr. Kenneth co-founded Qrative Ltd., which developed an AI-based platform for analysis and crystallization of intellectual property and served as its CEO and board member from 2009 to 2022. From 2007 to 2011, Mr. Kenneth provided consultation to the Government of Zanzibar with respect to restructuring of the Zanzibar Revenue Authority and setting up the governmentâ€™s HR and payroll systems. In 2004, Mr. Kenneth co-founded Trisixty Security, which developed an automated system that monitored compliance with IT security regulations, and served as its country manager and board member from 2004 to 2006. From 2014 to 2020, Mr. Kenneth served as volunteer Chairman of a pre-service education NGO (Mechinat Aderet). Mr. Kenneth Holds a B.A. in Economics and Political Sciences from the Bar-Ilan University and an M.A. in Business Entrepreneurship from the Swinburne University in Australia/Israel. Â 74 Board Diversity Â The table below provides certain information regarding the diversity of our board of directors as of the date of this annual report. Â Board Diversity Matrix Country of Principal Executive Offices: Israel Foreign Private Issuer Yes Disclosure Prohibited under Home Country Law No Total Number of Directors 5 Â Female Male Non- Binary Did Not Disclose Gender Part I: Gender Identity Â Directors 1 4 0 0 Part II: Demographic Background Â Underrepresented Individual in Home Country Jurisdiction â€“ LGBTQ+ â€“ Did Not Disclose Demographic Background â€“ Family Relationships Â There are no family relationships among any of our directors or officers. Â Special Arrangements Â There are no special arrangements or understandings with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or member of senior management. Â B.Â Â Compensation Â Employment and Consulting Agreements Â We have entered into employment or consulting agreements with all of our executive officers and key employees. These agreements contain standard provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective employment with us, other than mandatory severance payments and payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. The agreements are terminable by us at will, subject to prior notice, which varies for each individual. Â Compensation of Individual Covered Executives Â The table and summary below outline the compensation granted to our five most highly compensated officeholders (as defined in the Companies Law) with respect to the year ended December 31, 2024. We refer to the five individuals for whom disclosure is provided herein as our â€œCovered Executives.â€ For purposes of the table and the summary below, â€œcompensationâ€ includes amounts accrued or paid in connection with salary costs, consulting fees, bonuses, equity-based compensation, retirement or termination payments, benefits and perquisites such as car, phone and social benefits and any undertaking to provide such compensation. All amounts reported in the table are in terms of cost to the Company, as recognized in our consolidated financial statements for the year ended December 31, 2024, plus compensation paid to such officers following the end of the year in respect of services provided during the year. Â 75 Name and Principal Position (USD in thousands) Â Salary (1) Â Â Bonus Â Â Commission Â Â Equity-Based Compensation (2) Â Â Total Â Shakil Lakhani Former President, North America (3)Â Â Â Â Â Â Â Â Â Â Â Â $ 1,608 Â Â $ 2,391 Â Â Â - Â Â $ 129 Â Â $ 4,128 Â Brandon Nye VP, Sales of West US (4)Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 270 Â Â Â â€“ Â Â $ 1,385 Â Â $ 360 Â Â $ 2,015 Â Michael Dennison VP, Sales of East US (5)Â Â Â Â Â Â Â Â Â Â Â Â $ 276 Â Â Â â€“ Â Â $ 1,106 Â Â $ 202 Â Â $ 1,584 Â Yair Malca Chief Financial Officer (6)Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 455 Â Â $ 266 Â Â Â â€“ Â Â $ 979 Â Â $ 1,700 Â Matt Rodgers VP, Sales of Canada (7)Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 156 Â Â Â â€“ Â Â $ 522 Â Â $ 432 Â Â $ 1,110 Â (1) Salary includes Covered Executivesâ€™ gross salary plus payment of social benefits made by us on behalf of such Covered Executive. Such benefits may include, to the extent applicable to the Covered Executive, payments, pension, car expenses, medical and other insurances, 401K company contribution, payments for social security and tax gross-up payments, severance pay, vacation and other benefits consistent with our policies. Â (2) Represents the share-based compensation expenses recorded in our consolidated financial statements for the year ended December 31, 2024, based on the Share-based Compensation fair value, calculated in accordance with accounting guidance for share-based compensation. For a discussion of the assumptions used in reaching this valuation, see Note 13 to our consolidated financial statements. Â (3) On February 12, 2024, Mr. Lakhani was granted with 50,000 RSUs under our 2018 Incentive Plan, all of which were forfeited and are expired as of December 31, 2024. As of October 1, 2024, Mr. Lakhani is no longer serving in the position as President of North America and is no longer employed by the Company. In addition to the salary and bonus amounts indicated in the table above, as part of Mr. Lakhaniâ€™s departure from the company, he received a severance payment equal to ninety days of his base salary in the amount of $248,125 and certain payments for the continuation of benefits under COBRA for a period of 18 months from October 1, 2024. Â (4) On February 12, 2024, Mr. Nye was granted with 12,500 RSUs under our 2018 Incentive Plan, none of which were vested as of December 31, 2024. Â (5) On February 12, 2024, Mr. Dennison was granted with 7,000 RSUs under our 2018 Incentive Plan, none of which were vested as of December 31, 2024. Â (6) On February 12, 2024, Mr. Malca was granted with 34,000 RSUs under our 2018 Incentive Plan, none of which were vested as of December 31, 2024. Â (7) On February 12, 2024, Mr. Rodgers was granted with 15,000 RSUs under our 2018 Incentive Plan, none of which were vested as of December 31, 2024. Â Compensation of Directors as a Group Â The aggregate compensation paid by us to our directors for the year ended December 31, 2024, was approximately $308 thousand, including share-based compensation expenses of approximately $115 thousand. This amount does not include reimbursements or coverage of expenses. Â We do not have any written agreement with any director providing for benefits upon the termination of such directorâ€™s relationship with our Company, other than our consultancy agreement with our Chief Executive Officer and our employment agreement with our Chief Medical Officer. Â Employee Benefit Plans Â 2008 Plans Â On January 30, 2008, our board of directors adopted the 2008 Israeli Option Plan, or 2008 Israeli Plan, pursuant to the Companies Law and Section 102 of the Israeli Income Tax Ordinance, 1961, or the Tax Ordinance, allowing us to grant options to purchase our ordinary shares to our and our current and future affiliatesâ€™ Israeli employees, officers, directors, consultants, and service providers. Under Israeli law, no shareholder approval was required to approve the 2008 Israeli Plan. Â On January 30, 2008, concurrently with the adoption of the 2008 Israeli Plan, our board of directors also adopted the 2008 Rest of the World Options Plan, or 2008 ROW Plan, allowing us to grant options to purchase our ordinary shares to our and our current and future affiliatesâ€™ non-Israeli employees, consultants and service providers. The 2008 ROW Plan was approved by our shareholders on March 16, 2008. Â Options granted under the 2008 Israeli Plan and 2008 ROW Plan generally vest over a period of three years, but shorter or longer vesting schedules have been set. Any option that is cancelled or forfeited before expiration of its vesting period was available for future grants until the expiration of these plans in January 2018. Since that date, shares underlying any option that is cancelled or forfeited under these plans return to the authorized and un-issued share capital of the company. Additionally, options under the 2008 Israeli Plan and 2008 ROW Plan generally expire seven years after the initial grant date, unless extended by the board of directors. Our board of directors has previously extended the expiration period of certain options prior to their original expiration date. Under the 2008 Israeli Plan, as of December 31, 2024, we have granted options to purchase a total of 4,182,684 ordinary shares, of which 3,739,012 ordinary shares have been issued upon the exercise of such options and 443,672 options have been expired and forfeited. Under the 2008 ROW Plan, as of December 31, 2024, we have granted options to purchase a total of 19,204,710 ordinary shares, of which 15,142,716 ordinary shares have been issued upon the exercise of such options and 4,061,994 options have been expired and forfeited. As of December 31, 2024, there are no options exercisable under the 2008 Israeli Plan and the 2008 ROW Plan in the aggregate. Â 76 For more information, see Note 12 to our consolidated financial statements included elsewhere in this Annual Report on Form 20-F. Â Israeli tax law allows us to choose from among three alternative sets of tax treatment for our 2008 Israeli Plan and for future plans. In approving the 2008 Israeli Plan, our board of directors selected the capital gains tax treatment under Section 102 of the Tax Ordinance described below for grants to Israeli employees and other office holders, including directors. In accordance with the capital gains tax treatment under Section 102 of the Tax Ordinance, the 2008 Israeli Plan allowed for beneficial tax treatment for options issued through a trustee to Israeli employees and other office holders, including directors, provided that options granted thereunder or, upon their exercise, the underlying ordinary shares, are held by a trustee for at least two years following the date of the option grant. Under Section 102 of the Tax Ordinance, Israeli employees and other office holders, including directors, are (i) entitled to defer any taxable event with respect to the options until the underlying ordinary shares are sold or withdrawn from the trust, and (ii) subject to capital gains tax of 25% on the sale of the underlying ordinary shares. In addition, we may not recognize expenses pertaining to the options for Israeli tax purposes. Â Under the 2008 ROW Plan, we were able to grant our non-Israeli employees, officers, directors, consultants and service providers options to purchase our ordinary shares. The 2008 ROW Plan did not allow favorable tax treatment for our U.S., Canadian and other non-Israeli directors, officers, employees and consultants. Â The 2008 Israeli Plan and the 2008 ROW Plan expired in January 2018 and additional grants may not be made thereunder; however, options granted under such plans prior to their expiration remain valid following such expiration. Â 2018 Incentive Plan Â On June 17, 2018, our board of directors adopted the 2018 Incentive Plan allowing us to grant shares, options to purchase our ordinary shares, restricted shares and restricted share units to our and our current and future affiliatesâ€™ Israeli and other non-U.S. employees, officers, directors, consultants and service providers. In approving the 2018 Incentive Plan, our board of directors selected the capital gains tax treatment described above for grants to Israeli employees and other office holders, including directors, under the 2018 Incentive Plan. The 2018 Incentive Plan also includes as an appendix a sub-plan, or the U.S. Sub-Plan, allowing us to grant shares, options to purchase our ordinary shares, restricted shares and restricted share units to our and our current and future affiliatesâ€™ U.S. employees, officers, directors, consultants, and service providers. Â Under the 2018 Incentive Plan, as of December 31, 2024, we have granted restricted share units and options to purchase ordinary shares in a total of 7,753,180, of which 5,527,233 ordinary shares have been issued upon exercise of such options and 772,952 options and restricted share units have been forfeited and returned to the reserved authorized and unissued ordinary shares of the company under the 2018 Incentive Plan. The grant above does not include 2,533,300Â options, which we granted during January and February 2020, of which 2,518,300 were cancelled and regranted, in March 2020, following repricing of exercise price, and 15,000 were forfeited prior to the repricing of those options. Â As of December 31, 2024, 628,090 options are exercisable. Â As of December 31, 2024, up to 8,378,000 of our authorized and unissued ordinary shares may be issued pursuant to awards under the 2018 Incentive Plan. Upon adoption of the 2018 Incentive Plan, our board of directors resolved that the number of reserved authorized and unissued ordinary shares of the company for issuance of awards pursuant to the 2018 Incentive Plan, shall automatically increase on an annual basis in such manner that on the first business day of each calendar year beginning in 2019 such number of reserved ordinary shares equal to the lesser of (i) 800,000 ordinary shares, (ii) three percent (3%) of the number of ordinary shares outstanding as of such date, or (iii) a lesser number of ordinary shares determined by the board of directors, will be added to the reserved authorized and unissued ordinary shares of the company for issuance of awards pursuant to the 2018 Incentive Plan. Accordingly, in January 2023, the number of reserved authorized and unissued ordinary shares of the company for issuance of awards pursuant to the 2018 Incentive Plan was last increased by an additional 800,000 ordinary shares to 8,378,000. Awards are made pursuant to agreements and are subject to vesting and other restrictions as determined by the board of directors or the compensation committee. In January 2024, our board of directors determined that no increase to the number of shares reserved for issuance is required for 2024 calendar year. In January 2025, our board of directors approved the automatic increase for 2025 calendar year in the number of reserved, authorized and unissued ordinary shares available for issuance pursuant to the 2018 Incentive Plan by an additional 800,000 ordinary shares to a total of 9,178,000. Â 77 The following paragraphs summarize the terms of the 2018 Incentive Plan: Â Plan Administration. Our board of directors or the compensation committee acts as the plan administrator. Â Types of Awards. The 2018 Incentive Plan permits grants of options to purchase ordinary shares, ordinary shares, restricted shares, or restricted share units. Â Exercise Period. Options granted under the 2018 Incentive Plan are exercisable for a period of seven years following the date of grant, unless otherwise determined by our board of directors or our compensation committee. Â Exercise Price. Our board of directors or compensation committee has discretion in determining the exercise price of awards, subject to certain limitations. The 2018 Incentive Plan provides procedures for the cashless exercise of options. Â Transactions. The 2018 Incentive Plan provides that in the event of a â€œTransactionâ€ (which is defined as (i) a

merger, acquisition or consolidation of the Company with one or more other entities in which the Company is not the surviving entity; or (ii) a sale or other disposition of all or substantially all, as determined by our board of directors in its discretion, of the outstanding ordinary shares of the Company; or (iii) a sale or other disposition of all or substantially all, as determined by our board of directors in its discretion, of the consolidated assets of the Company and its affiliates), if the unexercised awards then outstanding under the 2018 Incentive Plan are assumed or substituted for securities of the successor company pursuant to the Transaction, then the board of directors or compensation committee, in their sole discretion and subject to applicable laws, may adjust the exercise price and number and type of shares of such unexercised awards to reflect such assumption and/or substitution. All other terms and conditions of the award agreements shall remain unchanged, including but not limited to the vesting period. The 2018 Incentive Plan further provides that our board of directors shall have full power and authority to determine that all outstanding awards shall terminate and cease to be outstanding, except to the extent assumed or substituted as aforesaid. In the event that awards are not assumed or substituted by the successor company, our board of directors may provide the participant the right to exercise the vested awards under such terms and conditions as our board of directors shall determine prior to the Transaction. In addition, our 2018 Incentive Plan further provides that, subject to any applicable law, our board of directors or our compensation committee shall have full power and authority to determine that in certain award agreements there shall be a clause providing different provisions with respect to the vesting period of awards underlying such award agreement or any portion thereof in the event of a Transaction. Â Termination. The 2018 Incentive Plan provides that in the event of a participantâ€™s termination of services as an employee, director, consultant or contractor of the Company and/or its subsidiaries, other than by reason of such participantâ€™s death or disability or due to termination for cause, all options which are vested upon the date of termination shall be exercisable during a period of 90 days from the date of termination, unless otherwise determined by our board of directors or our compensation committee. All options that are not vested upon the date of termination shall terminate immediately. The participant shall forfeit any ordinary shares acquired pursuant to an award of restricted stock that remains unvested as of the date of termination. Â Plan Term. Unless terminated earlier, the 2018 Incentive Plan will continue in effect for a term of ten years from the date of its adoption. Â C.Â Â Â Â Â Â Â Â Â Â Â Board Practices Â Board of Directors Â Under the Companies Law, our board of directors is responsible for setting our general policies and supervising the performance of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the terms of the consultancy agreement that we have entered into with him. All other executive officers who are not directors are appointed by our Chief Executive Officer, and are subject to the terms of any applicable employment or consultancy agreements that we may enter into with each of them. Â 78 Under our amended and restated articles of association, our board of directors must consist of at least three directors and not more than seven directors. Our board of directors consists of five directors. Our directors are elected in three staggered classes by the vote of a majority of the ordinary shares present, in person or by proxy, at a shareholdersâ€™ meeting (excluding abstentions). Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external directors, if applicable). At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2020 and after, at each annual general meeting the term of office of only one class of directors will expire. Each director holds office until the third annual general meeting of our shareholders, unless the tenure of such director expires earlier pursuant to the Companies Law or unless removed from office as described below. Â Our directors are divided among three classes as follows: the Class I director, consisting of Dr. Hadar Ron, will hold office until our annual general meeting of shareholders to be held in 2026; the Class II directors, consisting of Dr. Michael Anghel and Mr. Nadav Kenneth, will hold office until our annual general meeting of shareholders to be held in 2027 and until their successors are duly elected and qualified, or until their earlier resignation or retirement; and the Class III directors, consisting of Mr. Moshe Mizrahy and Dr. Michael Kreindel, will hold office until our upcoming annual general meeting of shareholders to be held in 2025. Â The provisions of our amended and restated articles of association relating to the number of directors, staggered board and election and removal of a director from office prior to the lapse of their tenure may be changed only by a resolution adopted by two-thirds of our ordinary shares voting on the proposed change. Â Under the Companies Law, our board of directors is required to employ independent judgment and discretion when voting, and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Companies Law provides that in the event a director learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach. Â In accordance with the exemptions available to foreign private issuers under Nasdaq rules, we do not intend to follow the requirements of Nasdaq rules with regard to the process of nominating directors. Instead, we intend to follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election. Â In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, including filling empty board seats up to the maximum number of directors permitted under our amended and restated articles of association, for a term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors may be filled by a vote of a simple majority of the directors then in office even if they do not constitute a quorum (subject to the limitation on the number of directors and their qualifications). A director so appointed will hold office until the next applicable annual general meeting of our shareholders in which such directorâ€™s class is to be replaced. Â Directors may be removed from office by a resolution at a general meeting of shareholders adopted by holders of two-thirds of our ordinary shares voting on the proposed removal, provided that the director being removed from office is given a reasonable opportunity to state his or her case before the general meeting, or under other circumstances set forth in our amended and restated articles of association. If a director is removed from office as set forth above, the general meeting will be entitled, in the same session, to elect another director in his or her place subject to the maximum number of directors permitted as stated above. Should it fail to do so, the board of directors will be entitled to do so. Any director who is appointed in this manner will serve in office for the remainder of the removed directorâ€™s term in office, and will be eligible for re-election. Â Under the Companies Law, we would be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications, voting requirements and other provisions would be applicable. We would also be required to include one such external director on each of our board committees. Â However, under regulations promulgated under the Companies Law, Israeli companies whose shares are traded on stock exchanges such as Nasdaq that do not have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the companyâ€™s shares are traded with respect to the appointment of independent directors and the composition of an audit committee and compensation committee, may elect not to follow the Companies Law requirements with respect to the composition of its audit committee and compensation committee and the appointment of external directors (provided that in the event that upon the appointment of a certain director all members of the board of directors of the company are from one and the same gender only, a director from the opposite gender will be appointed). As we do not have a controlling shareholder, we have elected to comply with the requirements of Nasdaq with respect to the composition of our board and such committees, and therefore we are exempt from the Companies Law requirements with respect thereto, including the appointment of external directors. Â 79 Alternate Directors Â Our amended and restated articles of association provide, as allowed by the Companies Law, that any director may, by written notice to us, appoint another person to serve as an alternate director at a meeting of the board of directors. The alternate director will be regarded as a director. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director, unless otherwise permitted by applicable law. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors so long as he or she is not already serving as a member of such committee. The term of appointment of an alternate director may be for one meeting of the board of directors or until notice is given of the cancellation of the appointment. Â Leadership Structure of the Board Â In accordance with the Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to serve as chairman of the board of directors. Dr. Michael Anghel currently serves as the Chairman of our board of directors. Â Under the Companies Law, the chairman of the board of directors of a public company or his relatives cannot be vested with the authority of the chief executive officer of such a public company, without the approval of a special majority of such companyâ€™s shareholders. The shareholdersâ€™ approval can be provided for a period of five years following an initial public offering, and subsequently, for additional periods of up to three years. The shareholdersâ€™ special majority consists of a majority vote of the shares present and voting at a shareholders meeting, provided that either: Â â€¢ such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in approving such resolution that are voted at the meeting, excluding abstentions; or Â â€¢ the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest against approving such resolution does not exceed 2% of the aggregate voting rights in the company. Â In addition, a person who is subordinated, directly or indirectly, to the chief executive officer may not serve as the chairperson of the board of directors; the chairperson of the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief executive officer; and the chairperson of the board of directors may not serve in any other position in the company or in a controlled subsidiary, but may serve as a director or chairperson of a controlled subsidiary. Â Following the rejection by our shareholders, at the 2024 Annual General Meeting of our shareholders held in April 2024, of the proposed resolution to authorize Mr. Moshe Mizrahy to continue serving as the Companyâ€™s chief executive officer and chairman of the board of directors, our board of directors has duly appointed Dr. Michael Anghel as the new Chairman of the Board as of July 2024. Â Committees of the Board of Directors Â Under the Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn a resolution adopted by a committee it has formed; however, the boardâ€™s decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the committeeâ€™s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee, unless the committee is solely advisory. Â 80 Audit and Investment Committee Â Our audit and investment committee consists of Dr. Michael Anghel, Dr. Hadar Ron and Mr. Nadav Kenneth. Dr. Anghel serves as chairperson of the audit and investment committee. Â Israeli Companies Law Requirements Â Under the Companies Law, we are required to maintain an audit committee. Â Nasdaq Listing Requirements Â Under Nasdaq rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. Â All members of our audit and investment committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Dr. Michael Anghel is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial experience as defined by Nasdaq rules. Each of the members of our audit and investment committee is â€œindependentâ€ as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under Nasdaq rules. Â Audit and Investment Committee Role Â Our audit and investment committee charter sets forth the responsibilities of the audit and investment committee consistent with the rules and regulations of the SEC and Nasdaq rules as well as the requirements for such committee under the Companies Law, including the following: Â â€¢ oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; Â â€¢ recommending the engagement or termination of the person filling the office of our internal auditor; and Â â€¢ recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. Â Our audit and investment committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, risk assessment and risk management, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit and investment committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the auditors are independent of management. Â Our audit and investment committee also periodically reviews the Companyâ€™s investment policy and guidelines, the investments made by the Company, the Companyâ€™s investment strategy and its compliance with the Companyâ€™s investment policy, and suggest to the board of directors modifications to be made to the Companyâ€™s investment policy. Â Under the Companies Law, our audit and investment committee is responsible for: Â â€¢ determining whether there are deficiencies in the business management practices of the Company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; Â â€¢ determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Companies Law) (see â€œâ€”Approval of Related Party Transactions under Israeli Lawâ€”Office Holdersâ€); Â â€¢ establishing the approval process (including by conducting competitive proceedings) for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; Â â€¢ where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; 81 â€¢ examining our internal audit controls and internal auditorâ€™s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; Â â€¢ examining the scope of our auditorâ€™s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and Â â€¢ establishing procedures for the handling of employeesâ€™ complaints as to deficiencies in the management of our business and the protection to be provided to such employees. Â Compensation, Nominating and Governance Committee Â Following our initial public offering, we established a compensation, nominating and corporate governance committee. The members of this committee are Dr. Hadar Ron, Dr. Michael Anghel and Mr. Nadav Kenneth. Dr. Ron serves as chairperson of the committee. Â Israeli Companies Law Requirements Â Under the Companies Law, the board of directors of a public company must appoint a compensation committee. The duties of the compensation, nominating and corporate governance committee include the recommendation to our board of directors of a policy regarding the terms of engagement of office holders (as defined in the Companies Law), to which we refer as a compensation policy. The term â€œoffice holderâ€ is defined under the Companies Law as a chief executive officer (referred to in the Companies Law as the general manager), chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that personâ€™s title, a director and any other manager directly subordinate to the general manager. That policy must be adopted by the board of directors, after considering the recommendations of the compensation, nominating and corporate governance committee, and needs to be approved by the companyâ€™s shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the ordinary shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the ordinary shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement, excluding abstentions; or (ii) the total number of ordinary shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the companyâ€™s aggregate voting rights. Â Even if the shareholders do not approve the compensation policy, the board of directors may resolve to approve the compensation policy if and to the extent the compensation committee and the board determine, in its judgment following internal discussions and after reconsidering the compensation policy, that approval of the compensation policy is in the best interests of the company. Our compensation committee and board of directors have exercised such authority in May 2024. Â Pursuant to regulations promulgated under the Companies Law, if a company adopts a compensation policy in advance of its initial public offering and describes it in its prospectus, then the compensation policy shall be deemed a validly adopted policy and will remain in effect for a term of five years from the date the company becomes a public company. Following the rejection by our shareholders at the 2024 Annual General Meeting of the proposed resolution to approve our updated compensation policy for an additional three year period, our compensation committee and board of directors made the decision to nonetheless approve our updated compensation for an additional three year period until the annual general meeting of the shareholders to be held in 2027 consistent with their authorities under the Companies Law.Â The compensation policy will be reviewed from time to time by our compensation committee and our board of directors, according to the requirements of the Companies Law. Â The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office

holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. Under the Companies Law, the compensation policy must relate to certain factors, including advancement of the companyâ€™s long-term objectives, business plan and policies, and creation of appropriate incentives for office holders. It must also consider, among other things, the companyâ€™s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors: Â â€¢ the education, skills, expertise and accomplishments of the relevant office holder; Â â€¢ the office holderâ€™s roles and responsibilities and prior compensation agreements with him or her; Â 82 â€¢ the ratio between the cost of the terms offered and the cost of the employment of other employees of the company, including those employed through outsourcing firms, in particular the ratio between such cost to the average and median salary of such employees of the company; Â â€¢ the impact of disparities in salary upon work relationships in the company; Â â€¢ the possibility of reducing variable compensation at the discretion of the board of directors; Â â€¢ the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and Â â€¢ as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the companyâ€™s performance during that period of service, the personâ€™s contribution towards the companyâ€™s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. Â The compensation policy must also include the following principles: Â â€¢ with the exception of office holders who report directly to the chief executive officer, determining the link between variable compensation and long-term performance and measurable criteria; however, the company may determine that an immaterial part of the variable components of an office holderâ€™s compensation package shall be awarded based on non-measurable criteria, if such amount is not higher than three monthsâ€™ salary per annum, while taking into account such office holderâ€™s contribution to the company; Â â€¢ the ratio between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of their payment, or in the case of share-based compensation, at the time of grant; Â â€¢ the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the companyâ€™s financial statements; Â â€¢ the minimum holding or vesting period for variable, equity-based compensation while referring to an appropriate long-term perspective based incentives; and Â â€¢ maximum limits for retirement payments. Â Our compensation policy is designed to promote retention and motivation of directors and executive officers. Additionally, our compensation policy is designed to align the interests of our directors and executive officers with our long-term performance and serves as a risk management tool. Under our compensation policy, a portion of an executive officerâ€™s compensation package is targeted to reflect our short- and long-term goals as well as the executive officerâ€™s individual performance. Our compensation policy also includes measures designed to reduce an executive officerâ€™s incentives to take excessive risks that may harm us in the long term. Such measures include limits on the value of cash bonuses and equity-based compensation for executive officers, limits on the ratio between an executive officerâ€™s variable and total compensation, and minimum vesting periods for equity-based compensation. Â Our compensation policy takes into account an executive officerâ€™s individual characteristics, such as his or her respective position, educational background, scope of responsibilities and contributions to the attainment of our goals, as the basis for compensation variation among our executive officers and considers the internal ratios between compensation of our executive officers and directors and other employees. Â Pursuant to our compensation policy, compensation that may be granted to an executive officer may include base salary, an annual bonus, other cash bonuses (such as a signing bonus or special bonus for special achievements, such as an outstanding personal achievement, outstanding personal effort or outstanding company performance), equity-based compensation, benefits and retirement compensation and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officerâ€™s base salary. In addition, the total variable compensation components (cash bonuses and equity-based compensation) may not exceed 90% of each executive officerâ€™s total compensation package with respect to any given calendar year. Â An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our executive officers (excluding our chief executive officer) will be based on performance objectives and a discretionary evaluation of the executive officerâ€™s overall performance by our chief executive officer and is subject to minimum thresholds. The annual cash bonus that may be granted to executive officers (excluding our chief executive officer) may be based entirely on a discretionary evaluation. Furthermore, our chief executive officer will be entitled to recommend performance objectives, and such performance objectives will be approved by our compensation committee and, if required by law, by our board of directors. Â 83 The performance-measurable objectives of our chief executive officer will be determined annually by our compensation committee and board of directors. Such objectives will include the weight assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officerâ€™s annual cash bonus may be based on a discretionary evaluation of the chief executive officerâ€™s overall performance by the compensation committee and the board of directors based on quantitative and qualitative criteria. Â Under our compensation policy, equity-based compensation for executive officers (including members of our board of directors) is designed in a manner consistent with the underlying objectives in determining such personâ€™s annual cash bonus; namely, to enhance the alignment between such personâ€™s interests with the companyâ€™s long-term interests and those of our shareholders and to strengthen the retention and motivation of such persons in the medium to long term. Â Our compensation policy provides for executive officerâ€™s compensation to be in the form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our share incentive plan then in place. All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive officers. Â Equity-based compensation shall be granted from time to time and will be individually determined and awarded based on the performance, educational background, prior business experience, qualifications, role and the personal responsibilities of the executive officer. Â In addition, our compensation policy contains compensation recovery provisions that allow the Company, under certain conditions, to recover bonuses paid in excess. Moreover, the compensation policy enables our chief executive officer to approve immaterial changes to the terms of an executive officerâ€™s employment (provided that the changes of the terms of employment are in accordance our compensation policy) and allows the Company to exculpate, indemnify and insure our executive officers and directors subject to certain limitations. Â Our compensation policy also provides for compensation for the members of our board of directors to be determined either (i) in accordance with the amounts set forth in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii) in accordance with the amounts determined in our compensation policy. Â Compensation, Nominating and Corporate Governance Committee Roles Â The compensation, nominating and corporate governance committee is responsible for (i) recommending the compensation policy to our board of directors for its approval (and subsequent approval by our shareholders) and (ii) undertaking duties related to the compensation policy and to the compensation of our office holders, including: Â â€¢ recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from the Companyâ€™s initial public offering, or otherwise three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from the Companyâ€™s initial public offering, or otherwise every three years); Â â€¢ recommending to the board of directors periodic updates to the compensation policy; Â â€¢ assessing implementation of the compensation policy; Â â€¢ determining whether to approve the terms of compensation of certain office holders which, according to the Companies Law, require the committeeâ€™s approval; Â â€¢ determining whether the compensation terms of a candidate for the position of the chief executive officer of the Company needs to be brought to approval of the shareholders according to the Companies Law; and Â â€¢ determining, subject to the approval of the board of directors and under special circumstances, whether to override a determination of the Companyâ€™s shareholders regarding certain compensation related issues. Â 84 Our compensation, nominating and corporate governance charter sets forth the responsibilities of the compensation, nominating and corporate governance committee, which include: Â â€¢ the responsibilities set forth in the compensation policy; Â â€¢ reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and Â â€¢ reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. Â In addition, our compensation, nominating and corporate governance committee is responsible for: Â â€¢ overseeing our corporate governance functions on behalf of the board; Â â€¢ making recommendations to the board regarding corporate governance issues; Â â€¢ identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board; Â â€¢ reviewing and evaluating the performance of the board; Â â€¢ serving as a focal point for communication between director candidates, non-committee directors and our management;â€‰â€¢ Â â€¢ selecting or recommending to the board for selection candidates to the board; and Â â€¢ making other recommendations to the board regarding affairs relating to our directors. Â Internal Auditor Â Under the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor may not be: Â â€¢ a person (or a relative of a person) who holds more than 5% of the companyâ€™s outstanding shares or voting rights; Â â€¢ a person (or a relative of a person) who has the power to appoint a director or the general manager of the company (i.e., the chief executive officer); Â â€¢ an office holder (including a director) of the company (or a relative thereof); or Â â€¢ a member of the companyâ€™s independent accounting firm, or anyone on its behalf. Â The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. Somech Chaikin of KPMG currently serves as our internal auditor. Â Approval of Related Party Transactions under Israeli Law Â Office Holders Â The Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table above under â€œItem 6A. Directors, Senior Management and Employees-Directors and Senior Managementâ€ who is engaged by us is an office holder under the Companies law. Â Fiduciary duties. An office holderâ€™s fiduciary duties consist of a duty of loyalty and a duty of care. The duty of loyalty requires the office holder to act in good faith and for the benefit of the company, and includes, among other things, the duty to avoid any conflict of interest between the office holderâ€™s position in the company and personal affairs, and proscribes any competition with the company or the exploitation of any business opportunity of the company in order to receive personal advantage for himself or herself or others. This duty also requires him or her to reveal to the company any information or documents relating to the companyâ€™s affairs that the office holder has received due to his or her position as an office holder. The duty of care requires an office holder, among other things, to act with a level of care that a reasonable office holder in the same position would employ under the same circumstances. This includes the duty to use reasonable means to obtain information regarding the advisability of a given action submitted for his or her approval or performed by virtue of his or her position and all other relevant information pertaining to these actions. We may approve an act specified above which would otherwise constitute a breach of an office holderâ€™s duty of loyalty, provided that the office holder acted in good faith, the act or its approval does not harm the Company, and the office holder discloses his or her personal interest, including any related material information or document, in a timely manner before the date for discussion of approval of such act. Any such approval is subject to the terms of the Companies Law, setting forth, among other things, the appropriate parties of the company entitled to provide such approval, and the methods of obtaining such approval. Â 85 Disclosure of personal interest. The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related documents and material information known to him or her, in connection with any existing or proposed transaction by the company. â€œPersonal interest,â€ as defined by the Companies Law, includes a personal interest of any person in an act or transaction of the company, including a personal interest of his or her relative or of a corporate body in which that person or a relative of that person is a 5% or greater shareholder, a holder of 5% or more of the voting rights, a director or chief executive officer, or in which he or she has the right to appoint at least one director or the chief executive officer. â€œPersonal interestâ€ does not apply to a personal interest stemming merely from oneâ€™s ownership of shares in the company. A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person to vote on his or her behalf, regardless of whether or not the discretion of how to vote lies with the person voting. Â The office holder must make the disclosure of his personal interest promptly and no later than the first meeting of the companyâ€™s board of directors that discusses the particular transaction. This duty to disclose such information does not apply if the personal interest of the office holder derives solely from the personal interest of a relative of the office holder in a transaction unless it is an â€œextraordinary transactionâ€. The Companies Law defines an extraordinary transaction as a transaction not in the ordinary course of business, not on market terms or that is likely to have a material impact on the companyâ€™s profitability, assets or liabilities, and defines a relative as a spouse, sibling, parent, grandparent, descendent, spouseâ€™s descendant, sibling or parent, and the spouse of any of the foregoing. Â Approvals of related party transactions. The Companies Law provides that a transaction with an office holder or a transaction in which an office holder has a personal interest may not be approved if it is adverse to the companyâ€™s interest. In addition, such a transaction generally requires board approval, unless the transaction is an extraordinary transaction or the articles of association provide otherwise and provided that the transaction is in the companyâ€™s interest and is performed by the office holder in good faith. If the transaction is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction. Under certain circumstances, shareholder approval may also be required. Generally, a director (and any person in general) who has a personal interest in an extraordinary transaction that is considered at a meeting of the board of directors or the audit committee may not attend that meeting or vote on that matter, unless (1) the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present to present the transaction that is subject to approval, or (2) a majority of the board of directors or the audit committee, as the case may be, also has a personal interest in the matter then, in such event, all directors may participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof. If a majority of the board of directors or the audit committee has a personal interest in the transaction, shareholder approval also would be required for the approval of such transaction. See â€œ-Approval of Related Party Transactions under Israeli Law-Office Holders-Approval of office holdersâ€™ compensationâ€. Â Approval of office holdersâ€™ compensation. The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director generally requires approval first by our compensation committee, then by our board of directors. If the compensation arrangement or undertaking to indemnify or insure is inconsistent with our compensation policy, or if the office holder is the chief executive officer (apart from a number of specific exceptions), then the arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholdersâ€™ decision, subject to certain conditions. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special Majority Approval for Compensation. Â 86 Controlling Shareholders Â The Companies Law imposes the same disclosure requirements that apply to directors and office holders, as described above, on a controlling shareholder of a public company. The term â€œcontrolling shareholderâ€ is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder is deemed to include any shareholder holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company. For this purpose, two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder. Â Approval of the audit committee or the compensation committee (with respect to compensation arrangements) as the case may be, the board of directors and our shareholders, in that order, is required for: Â â€¢ extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest; and Â â€¢ transactions for the provision of services, whether directly or indirectly, by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder or a controlling shareholderâ€™s relative, whether as an office holder or an employee. Â The shareholder approval must include the majority of shares voted at the meeting. In addition, either: Â â€¢ at least a majority of the shares held by the shareholders who have no personal interest in the transaction and are present and voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or Â â€¢ the total shareholdings of those who have no personal interest in the transaction and who vote against the transaction must not represent more than 2% of the aggregate voting rights in the

company. Â In addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three years, and under certain conditions, five years from a companyâ€™s initial public offering, requires the abovementioned approval at the end of such period; however, such transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. Â Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other office holders, which would otherwise require approval of a companyâ€™s shareholders, may be exempt from shareholder approval upon certain conditions. Â Shareholder Duties Â Under the Companies Law, a shareholder has a duty to act in good faith and in a customary manner towards the company and other shareholders and to refrain from abusing his or her power in the company including, among other things, when voting in a general meeting of shareholders or in a class meeting on the following matters: Â â€¢ an amendment to the articles of association; Â â€¢ an increase in the companyâ€™s authorized share capital; Â â€¢ a merger; or Â â€¢ approval of related party transactions and acts of office holders that require shareholder approval. Â A shareholder also has a general duty to refrain from discriminating against other shareholders. Â The remedies generally available upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against other shareholders, additional remedies may be available to the injured shareholder. Â 87 In addition, any controlling shareholder, any shareholder who knows that it possesses the power to determine the outcome of a shareholder vote and any shareholder who, under the companyâ€™s articles of association, has the power to appoint or prevent the appointment of an office holder in the company, or has any other power with respect to the company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty of fairness except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholderâ€™s position in the company into account. There is limited case law available to assist in understanding the nature of these duties or the implications of these provisions. Â Approval of Private Placements Â Under the Companies Law and the regulations promulgated thereunder, a private placement of securities does not require approval at a general meeting of the shareholders of a company; provided however, that in special circumstances, such as a private placement completed in lieu of a special tender offer (see â€œItem 10.â€“Additional Informationâ€“B. Articles of Associationâ€) or a private placement which qualifies as a related party transaction (see â€œItem 6. â€“Directors, Senior Management and Employeesâ€“C. Board Practicesâ€“Approval of Related Party Transactions under Israeli Lawâ€), approval at a general meeting of the shareholders of a company is required. Â Exculpation, Indemnification and Insurance of Directors and Officers Â Our amended and restated articles of association allow us to indemnify, exculpate and insure our office holders, either pursuant to an undertaking made in advance of an event or following an event, to the fullest extent permitted by the Companies Law, the Israeli Securities Law, 5738-1968, or the Securities Law, and the Economic Competition Law, 5748-1988, or the Economic Competition Law, in respect of liabilities, payments and expenses incurred for acts performed and omissions committed as an office holder. Our articles of association also allow us to exculpate, insure or indemnify any person who is not an office holder, including any employee, agent, consultant or contractor who is not an office holder. Â Under the Companies Law, the Securities Law and the Economic Competition Law, a company may indemnify an office holder against the following liabilities, payments and expenses incurred in his or her capacity as an office holder, either in advance of the act or following the act, provided its articles of association authorize such indemnification: Â â€¢ a monetary liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitration award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the companyâ€™s activities when the undertaking to indemnify is given, and to an amount, or according to criteria, determined by the board of directors as reasonable under the circumstances. Such undertaking shall detail the foreseen events and amount or criteria mentioned above; Â â€¢ reasonable litigation expenses, including reasonable attorneysâ€™ fees, incurred by the office holder (i) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (a) no indictment was filed against such office holder as a result of such investigation or proceeding, and (b) no financial liability was imposed upon him or her as a substitute for a criminal proceeding against them as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that did not require proof of criminal intent; and (ii) in connection with a monetary sanction; Â â€¢ reasonable litigation expenses, including attorneysâ€™ fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; Â â€¢ expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Economic Competition Law; Â â€¢ a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) of the Securities Law; Â â€¢ expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneysâ€™ fees; and Â 88 â€¢ any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law. Â An â€œAdministrative Procedureâ€ is defined as a procedure pursuant to Chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or Il (Arrangement to Prevent Procedures or Interruption of Procedures Subject to Conditions) of the Securities Law. Â Under the Companies Law, the Securities Law and the Economic Competition Law, a company may obtain insurance for an office holder against the following liabilities incurred in his or her capacity as an office holder, to the extent provided in the companyâ€™s articles of association: Â â€¢ a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; Â â€¢ a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; Â â€¢ a financial liability imposed on the office holder in favor of a third party; Â â€¢ expenses incurred by the office holder with respect to proceedings held pursuant to certain provisions of the Economic Competition Law; Â â€¢ a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and Â â€¢ expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneysâ€™ fees. Â Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. A company may exculpate an office holder in advance from liability to the company, in whole or part, for damages caused to the company as a result of a breach of the duty of care, but only if a provision authorizing such exculpation is included in its articles of association. A company may not exculpate in advance a director from liability arising out of a breach of a duty of care with respect to a distribution. Â Under the Companies Law, however, a company may not indemnify, exculpate or insure an office holder against any of the following: Â â€¢ a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; Â â€¢ a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; Â â€¢ an act or omission committed with intent to derive illegal personal benefit; or Â â€¢ a fine, civil fine, monetary sanction or forfeit levied against the office holder. Â The Securities Law and the Economic Competition Law also provide certain limitations on the ability of a company to indemnify, exculpate and insure office holders. Â We have obtained directorsâ€™ and officersâ€™ liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by applicable law. In addition, we have entered into agreements with each of our directors and executive officers, exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, and undertaking to indemnify them to the fullest extent permitted by law. Such indemnification is in addition to any amounts available under our directorsâ€™ and office holdersâ€™ liability insurance policy. Each office holder who agreed to receive this letter of indemnification also agreed to give his or her approval to terminate all previous letters of indemnification that we have provided to him or her, if any. The maximum and aggregate indemnification amount for all current and future indemnified persons under such agreements is the greater of (i) an amount equal to 25% of our shareholdersâ€™ equity on a consolidated basis, based on our most recent financial statements made publicly available before the date on which the indemnity payment is made and (ii) $40 million. Â 89 D.Â Â Â Â Employees Â As of December 31, 2024, we had 599 employees worldwide, across 4 departments, including 3 employees on the executive team, 51 employees in finance, IT and administration, 385 employees in sales and marketing, 42 employees in research and development and 118 employees in manufacturing and assembly and supply chain. As of December 31, 2024, 318 of our employees are located in the United States and Canada, 112 are located in Israel and the remainder are located in Europe, Asia and Latin America. We believe our employee relations are good. Â Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and antidiscrimination laws, and other conditions of employment. Subject to certain exceptions, Israeli law generally requires severance pay upon the retirement, death or dismissal of employees and requires us and our employees to make payments to the National Insurance Institute, which is similar to the U.S. Social Security Administration. Our Israeli employees have pension plans that comply with applicable Israeli legal requirements, which also include the mandatory pension payments required by applicable law and allocation of severance pay. Â While none of our Israeli employees work under any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor Law in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialistsâ€™ Associations) are applicable to our employees in Israel by extension orders issued by the Israeli Ministry of Economy and Industry. These provisions primarily affect such matters as length of working hours and workweek,Â recuperation pay, travel expenses and pension rights with respect to our Israeli employees. Â All of our employment and consulting agreements include employeesâ€™ and consultantsâ€™ undertakings with respect to confidentiality, noncompetition and assignment to us of intellectual property rights developed in the course of their employment or engagement with us. However, there can be no assurance that these agreements will be enforceable or that they will provide us with adequate protection. Â E.Â Â Â Â Share Ownership Â The beneficial ownership of our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of the table below, we deem ordinary shares issuable pursuant to options, restricted share units or warrants that are currently exercisable or exercisable within 60 days of December 31, 2024, if any, to be outstanding and to be beneficially owned by the person holding the options, restricted share units or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. Â All arrangements for involving employees in our capital is discussed in â€œItem 6B. Directors, Senior Management and Employeesâ€“Compensationâ€“Employee Benefit Plansâ€ above. Â Unless otherwise noted below, each shareholderâ€™s address is do InMode Ltd., Tavor Building, Shaâ€™ar Yokneam, P.O. Box 533, Yokneam 2069200, Israel. Â Name of Beneficial Owner: Â Number of Ordinary Shares Â Â Percentage(1) Â Directors and Named Executive Officers Â Â Â Â Â Â Â Dr. Michael Kreindel(2)Â Â Â Â Â Â Â

officers. See â€œItem 6. Directors, Senior Management and Employees â€“ B. Compensation- Employment and Consulting Agreementsâ€. Â Members of our board of directors are entitled to certain compensation for their services. See â€œItem 6. Directors, Senior Management and Employees â€“ C. Board Practices â€“ Committees of the Board of Directors â€“ Compensation, Nominating and Governance Committeeâ€. Â Options Â Since our inception, we have granted options to purchase our ordinary shares to our executive officers and certain of our directors. The options are generally subject to the further terms of the respective option plans, which we describe under â€œItem 6.B. Compensation-Employee Benefit Plansâ€. Â RSUs (restricted share units) Â Under the 2018 Incentive Plan, we have granted RSUs to our executive officers and certain of our directors. The RSUs are generally subject to the further terms of the 2018 Incentive Plan, which we describe under â€œItem 6.B. Compensation-Employee Benefit Plans-2018 Incentive Plan.â€ Â Directors and Officers Insurance Policy and Indemnification and Exculpation Agreements Â We have entered into separate indemnification agreements with each of our current directors, office holders and other executives exculpating them from a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted by law. We have also obtained directorsâ€™ and officersâ€™ liability insurance for each of our executive officers and directors. See â€œItem 6C. Directors, Senior Management and Employees-Board Practices-Exculpation, Indemnification and Insurance of Directors and Officersâ€ for additional information. Â 92 C.Â Â Â Interests of Experts and Counsel Â Not applicable. Â ITEM 8. FINANCIAL INFORMATION Â A.Â Â Â Consolidated Statements and other Financial Information Â See â€œItem 18. Financial Statementsâ€. Â Legal Proceedings Â On February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action in the United States District Court for the Central District of California, captioned Cement Masons and Plasterers Local No. 502 Pension Fund v. InMode Ltd. et al., Case No. 2:24-cv-01219, against the Company and certain of its officers and directors. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Companyâ€™s business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. On April 16, 2024, multiple shareholders moved to be appointed lead plaintiff. On December 4, 2024, the Court entered an order appointing a group of shareholder funds as the lead plaintiffs. On January 31, 2025, the lead plaintiffs filed an amended complaint. The amended complaint purportedly brings claims on behalf of purchasers of the Companyâ€™s common stock between February 18, 2020 and December 6, 2023, inclusive. The Companyâ€™s deadline to respond to the amended complaint is April 1, 2025. This proceeding is in the preliminary stages, and the Company has not yet responded to the amended complaint. As of the date of this filing, the Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision, and an estimated liability has not been recorded in the Companyâ€™s financial statements. The defendants intend to deny the allegations of wrongdoing and vigorously defend against the claims. Â We may be party from time to time to various other lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. There can be no assurance that matters that arise in the future, individually or in aggregate, will not have a material adverse effect on our financial condition or results of operations. Â B.Â Â Â Significant Changes Â Since December 31, 2024, no significant changes have occurred. Â ITEM 9. THE OFFER AND LISTING Â A.Â Â Offer and Listing Details Â Our ordinary shares have been trading on the Nasdaq Global Select Market under the symbol â€œINMDâ€ since August 8, 2019. Prior to that date, there was no public trading market for our ordinary shares. Â B.Â Â Â Plan of Distribution Â Not applicable. Â C.Â Â Markets Â Our ordinary shares trade on the Nasdaq Global Select Market under the symbol â€œINMDâ€. Â D.Â Â Â Selling Shareholders Â Not applicable. Â E.Â Â Â Dilution Â Not applicable. Â F.Â Â Â Â Expenses of the Issue Â Not applicable. Â 93 ITEM 10. ADDITIONAL INFORMATION Â A.Â Â Â Share Capital Â Not applicable. Â B.Â Â Â Articles of Association Â The information set forth in our Registration Statement on Form F-1 filed with the SEC on July 11, 2019 (File No.: 333-232615), under the heading â€œDescription of Share Capitalâ€ is incorporated herein by reference. Â C.Â Â Â Material Contracts Â [Not applicable.] Â D.Â Â Â Exchange Controls Â There are currently no Israeli government laws, decrees or regulations that restrict or that affect our export or import of capital or the remittance of dividends, interest or other payments to non-resident holders of our securities, including the availability of cash and cash equivalents for use by us and our wholly-owned subsidiaries, except under certain circumstances, for shareholders who are subjects of countries that are, or have been, in a state of war with Israel, and except or otherwise as set forth under â€œItem 10E. Additional Informationâ€“Taxationâ€. Â However, under current Israeli laws, currency controls may be imposed by administrative action at any time. Israeli residents also have an obligation to file reports with the Bank of Israel regarding certain transactions. Â E.Â Â Â Â Taxation Â The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares, both referred to in this Item 10E as the ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction. Â Material Israeli Tax Considerations Â The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some Israeli tax consequences to persons acquiring ordinary shares. This summary does not discuss all the acts of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel, traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation which has not yet been subject to judicial or administrative interpretation, we cannot assure you that Israeli governmental and tax authority or the Israeli courts will accept the views expressed below. The discussion below is subject to amendment under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which could affect the tax consequences described below. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations. Â Potential investors are urged to consult their own tax advisors as to the Israeli or other tax consequences of the purchase, ownership and disposition of our ordinary shares, including, in particular, the effect of any foreign, state or local taxes. Â General Corporate Tax Structure in Israel Â Israeli companies are generally subject to tax on their taxable income at the corporate tax rate of 23% in 2018 and thereafter.Â Capital gains derived by an Israeli resident company are subject to tax at the regular corporate tax rate. Â Tax Benefits under the Law for the Encouragement of Capital Investments, 5719-1959 Â The Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by â€œIndustrial Enterprisesâ€ (as defined under the Investment Law). Â 94 Tax Benefits Under the 2005 Amendment Â An amendment to the Investment Law, which became effective as of April 1, 2005, or the 2005 Amendment, changed certain provisions of the Investment Law. An eligible investment program under the 2005 Amendment qualifies for benefits as a â€œBenefited Enterpriseâ€. Prior to the 2005 Amendment, investment programs under the Investment Law were called â€œApproved Enterprisesâ€. According to the 2005 Amendment, only Approved Enterprises receiving cash grants require the prior approval of the Investment Center. Rather, a company may claim the tax benefits offered by the Investment Law directly in its tax returns, provided that its facilities meet the criteria for tax benefits set forth in the 2005 Amendment. A company that has a Benefited Enterprise may, in its discretion, approach the Israel Tax Authority for a pre-ruling confirming that it is in compliance with the provisions of the Investment Law. Â The duration of the tax benefits for a Benefited Enterprise is limited to the earlier of seven or ten years (depending on the geographic location of the Benefited Enterprise within Israel) from the Commencement Year (as described below) or 12 years from the first day of the year of election. Commencement Year is defined as the later of the first tax year in which a company had derived taxable income for tax purposes from the Benefited Enterprise, or the year of election, which is the year in which a company requested to have the tax benefits apply to the Benefited Enterprise. The tax benefits granted to a Benefited Enterprise are determined, depending on the geographic location of the Benefited Enterprise within Israel, according to one of the following: Â (i) Exemption from corporate tax may be available on undistributed income for a period of two to ten years, depending on the geographic location of the Benefited Enterprise within Israel, and a reduced corporate tax rate of 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in each year. Â In addition, a company that has a Benefited Enterprise program is eligible for further tax benefits if it qualifies as a Foreign Investorsâ€™ Company, or FIC. The level of foreign investment is measured as the percentage of rights in the company (in the terms of shares, rights to profits, voting and appointment of directors) and of combined share capital and shareholder loans that are owned, directly or indirectly, by persons who are not residents of Israel. The determination as to whether a company qualifies as an FIC is made on an annual basis. Â The 2011 Amendment as described below has eliminated the definition of a FIC. However, according to the 2011 Amendmentâ€™s transitional provisions, the tax benefits of companies with Benefited Enterprise plans that opt to remain under the Benefited Enterprise regime in accordance with the Investment Law prior to the 2011 Amendment will be preserved. Â If the company pays a dividend out of income derived from the Benefited Enterprise during the tax exemption period, such income will be subject to deferred corporate tax with respect to the amount distributed (grossed up to reflect such pre-tax income that it would have had to earn in order to distribute the dividend) at the corporate tax rate which would have otherwise been applied. The company is required to withhold tax on such distribution at a rate of 15%, or such lower rate may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate); or Â (ii) Reduced corporate tax rates for companies with facilities in certain geographical locations in Israel. Â Our facilities in Israel were granted Benefited Enterprise status and thereunder we enjoyed a ten-year tax exemption from corporate tax on our undistributed income derived from the Benefited Enterprise. The first year in which we were exempted from tax was 2012 and the ten-year eligibility period of tax exemption ended in 2021. Â Tax Benefits Under the 2011 Amendment Â In December 2010, the Israeli Parliament approved amendment 68 to the Investment Law, or the 2011 Amendment. The 2011 Amendment significantly revised the tax incentive regime in Israel and it commenced on January 1, 2011. Â The 2011 Amendment provided for a new and additional status of a â€œPreferred Enterprise,â€ which introduced new benefits for income generated by a â€œPreferred Companyâ€ through its Preferred Enterprise. The definition of a Preferred Company, includes, inter alia, a company incorporated in Israel that (1) is not wholly owned by a government entity, (2) owns a Preferred Enterprise and (3) is controlled and managed from Israel and is subject to further conditions set forth in the Investment Law. Moreover, a Preferred Company needs to meet certain condition stipulated in the Investment Law such as being an industrial company (including a minimum threshold of 25% export). Â 95 A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to income attributable to its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, known as Development Zone â€œA,â€ in which case the rate for a beneficial activity is currently 7.5%. Â Dividends paid out of income attributed to a Preferred Enterprise are generally subject to tax at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. Claim of tax benefits afforded by an applicable tax treaty is subject to the receipt in advance of a valid certificate from the Israel Tax Authority, allowing for a reduced tax rate. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if the funds are subsequently distributed to individuals or non-Israeli residents (individuals and corporations), withholding tax would apply when distributing the dividend to such individuals or non-Israeli residents). Â Tax Benefits Under the 2017 Amendment Â Additional amendments to the Investment Law became effective in January 2017, or the 2017 Amendment. Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred Companies from â€œPreferred Technological Enterprises,â€ or PTE (as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone â€œAâ€ and 12% elsewhere in Israel, or 6% in the case of a â€œSpecial Preferred Technological Enterprise,â€ or SPTE (as defined in the 2017 Amendment) regardless of the companyâ€™s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes would be subject to a 4% tax (inter alia, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company. Â On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017, or the Regulations, were published, which adopted Action 5 under the base erosion and profit shifting, or BEPS, regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE regimes and determine certain requirements relating to documentation of intellectual property for the purpose of a PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the companyâ€™s regular course of business and derived from the preferred intangible asset (as determined in the Investment Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In the event that intangible assets used for marketing purposes generate over 10% of the PTEâ€™s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE will not be required to exclude the marketing income from the PTEâ€™s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. However, the transitional provisions allow companies to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have. Under the Regulations, our corporate tax rate for the Company for a beneficial activity is expected to be approximately 7.5%. Â Under the transitional provisions of the 2017 Amendment, a company is allowed to continue to enjoy the tax benefits available under the Investment Law prior to the 2017 Amendment until the end of the period of benefits, as defined in the Investment Law. In each year during the period of benefit under its Benefited Enterprise status, the Company will be able to opt-in for application of the 2017 Amendment, thereby making itself available to the tax rates described above. A companyâ€™s decision to opt-in for application of the 2017 Amendment is irrecoverable. Â Pursuant to the amendment to the Investments Law which became effective on NovemberÂ 15, 2021, a company that elects by NovemberÂ 15, 2022 to pay a reduced corporate tax rate as set forth in that amendment (rather than the regular corporate tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company until DecemberÂ 31, 2020 will be entitled to distribute a dividend from such income or to be used for any other reason found by the Company, without being required to pay additional corporate tax. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing on the year of which the Company has elected to pay the reduced corporate tax rate. A company that has elected to apply the amendment cannot withdraw from its election. The Company elected to take advantage of the amendment, and has paid NIS 42.5 million (approximately $12 million) as a one-time payment, and as a result NIS 591 million (approximately $165.7 million) of the Companyâ€™s undistributed exempt income for years 2012 until 2020 will be entitled to be distributed as dividend or to be used for any other reason found by the Company without being required to pay additional corporate tax. As a result, the Company is required to invest NIS 32 million (approximately $9 million) in its industrial enterprises in Israel over a five year period. Such investment may be in the form of the acquisition of industrial assets (excluding real estate assets), investment in R&D in Israel, or payroll payments to new employees to be hired by the enterprise. Â 96 In February 2022, the Company settled the 2017-2020 income tax assessment with the Israeli tax authority, paying $1.3 million. In addition, the Company reached an agreement of tax assessment with the Israeli tax authority under which the Company paid during January 2023 NIS 50.2 million (approximately $14.3 million) on its undistributed exempt income for the year ended December 31, 2021. As a result, NIS 517.8 million (approximately $147.5 million) of the Companyâ€™s undistributed exempt income for 2021 may be distributed or used by the Company without being subject to additional corporate tax. Â Law for the Encouragement of Industry (Taxes), 5729-1969 Â We believe that we currently qualify as an â€œIndustrial Companyâ€ within the meaning of the Law for the Encouragement of Industry (Taxes), 5729-1969, or the Industry Encouragement Law. The Industry Encouragement Law defines an â€œIndustrial Companyâ€ as an Israeli-resident company, incorporated in Israel, of which 90% or more of its income in any tax year, other than of income from defense loans, capital gains, interest and dividends, is derived from an â€œIndustrial Enterpriseâ€ owned by it and located in Israel or in the â€œArea,â€ in accordance with the definition in section 3a of the Tax Ordinance. An â€œIndustrial Enterpriseâ€ is defined as an enterprise which is held by an Industrial Company whose principal activity in a given tax year is industrial production. Â The following tax benefits, among others, are available to Industrial Companies: Â â€¢ amortization of the cost of purchased know-how, patents and certain other intangible property rights (other than goodwill), which are used for the development or promotion of the Industrial Enterprise, over an eight-year period for tax purposes, commencing in the year where the Industrial Company began to utilize them; Â â€¢ accelerated depreciation rates on equipment and buildings; Â â€¢ under specified conditions, an election to file consolidated tax returns with additional related Israeli Industrial Companies; and Â â€¢ expenses related to a public offering are deductible in equal amounts over three years, beginning from the year of the offering. Â Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. We cannot assure that we will continue to

qualify as an â€œIndustrial Companyâ€ or that the benefits described above will be available to us in the future. Â Capital Gains Taxes Applicable to Israeli Resident and Non-Israeli Resident Shareholders Â Capital gains tax is imposed on the sale of capital assets by an Israeli resident and on the sale of such assets by non-Israeli residents if those assets are either: (i) located in Israel, (ii) shares or rights to shares in Israeli resident companies or (iii) represent, directly or indirectly, rights to assets located in Israel, unless a specific exemption is available under Israeli tax law or unless a treaty between Israel and the country of the nonresident provides otherwise. The Tax Ordinance distinguishes between â€œReal Capital Gainâ€ and the â€œInflationary Surplusâ€. Real Capital Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli Consumer Price Index or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. You should consult with your own tax advisor as to the method you should use to determine the Inflationary Surplus. Inflationary Surplus is not subject to tax in Israel. Â Generally, the tax rate applicable to real capital gains derived by individuals on the sale of our ordinary shares will be taxed at the rate of 25%, unless such shareholder claims a deduction for interest and linkage differences expenses in connection with such shares, in which case the gain will generally be taxed at a rate of 30%. If the individual shareholder is a Controlling Shareholder at the time of the sale or at any time during the 12-month period preceding such sale, such gain will be taxed at the rate of 30%. A â€œControlling Shareholderâ€ is defined as a person who holds, directly or indirectly, including together with others, at least 10% of any means of control in the company (including, among other things, the right to receive profits of the company, voting rights, the right to receive the proceeds upon the companyâ€™s liquidation and the right to appoint a director). Â 97 Real capital gains derived by corporations will be generally subject to the regular corporate tax rate (23% in 2018 and thereafter). Individual and corporate shareholders dealing in securities are taxed at the tax rates applicable to business income: 23% for corporations in 2018 and thereafter and a marginal tax rate of up to 47% in 2018 and thereafter for individuals plus an additional excess tax of 3% as described below. Â Non-Israeli Resident Shareholders Â Non-Israeli residents (individuals and corporations) are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of shares of Israeli companies publicly traded on a recognized stock exchange outside of Israel, provided, among other things, that such shareholders did not acquire their shares prior to the companyâ€™s initial public offering and the gains were not derived from a permanent establishment of such shareholders in Israel. However, shareholders that are non-Israeli entities will not be entitled to such exemption if Israeli residents: (1) have directly or indirectly, alone or together with another, a controlling interest of more than 25% of any of the means of control in such non-Israeli corporation or (2) are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such non-Israeli entity, whether directly or indirectly. This exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income. Â In addition, a sale of shares may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty and subject to the receipt in advance of a valid certificate from the Israeli tax authority allowing of such exemption. Â For example, pursuant to the Convention Between the Governments of the United States and Israel with respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of ordinary shares by a person who qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty and who holds the shares as a capital asset and is entitled to claim the benefits afforded to such person by the U.S.-Israel Tax Treaty generally will not be subject to the Israeli capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) such person holds, directly or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period preceding such sale, exchange or disposition, subject to certain conditions; (iv) the capital gains arising from such sale, exchange or disposition can be allocated to a permanent establishment of the shareholder in Israel, under certain terms; or (v) such person is an individual and was present in Israel for a period or periods of 183 days or more in the aggregate during the relevant tax year. In any such case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent applicable. Eligibility to benefit from tax treaties is conditioned upon the shareholder presenting a withholding certificate issued by the Israel Tax Authority prior to the applicable payment. Â Withholding and Reporting Â Either the purchaser, the Israeli stockbrokers or financial institutions through which the shares are held is obliged to withhold tax on the amount of consideration paid upon the sale of our ordinary shares (or on the capital gain realized on the sale, if known), at the Israeli corporate tax rate for Israeli companies (23% in 2018 and thereafter). In case the seller is an individual, the applicable withholding tax rate would be 25% of the amount of consideration paid upon the sale of shares (or on the capital gain realized on the sale, if known). Â In some instances where our shareholders may be liable for Israeli tax on the sale of our ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders, including non-Israeli resident shareholders, may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. In transactions involving a sale of all of the securities of an Israeli resident company, in the form of a merger or otherwise, the Israel Tax Authority may require non-Israeli resident shareholders who are not liable for Israeli tax to sign a declaration in a form specified by the Israel Tax Authority or obtain a specific exemption from the Israel Tax Authority to confirm their status as a non-resident of Israel, and, in the absence of such declarations or exemptions, may require the purchaser of the securities to withhold taxes at source. Â The sale of securities traded on a stock exchange, requires that a detailed return, including a computation of the tax due, be filed and an advanced payment must be paid on January 31 and July 31 of every tax year in respect of sales of securities made within the previous six months. However, if all tax due was withheld at source according to applicable provisions of the Tax Ordinance and the regulations promulgated thereunder, then the aforementioned return need not be filed and no advance payment must be made. Â 98 Taxation of Dividend Distributions Â A distribution of dividends from income, which is not attributed to an Approved Enterprise/Benefited Enterprise/Preferred Enterprise/Technology Enterprises to an Israeli resident individual, will generally be subject to income tax at a rate of 25%. However, a 30% tax rate will apply if the dividend recipient is a â€œControlling Shareholderâ€ (as defined above) at the time of the distribution or at any time during the preceding 12-month period, and a non-Israeli resident individual will be generally subject to withholding tax at source at the rate of 15% or such lower rate as may be provided in an applicable tax treaty. Â The Tax Ordinance generally provides that a non-Israeli resident (either individual or corporation) is subject to Israeli income tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient is a â€œControlling Shareholderâ€ (as defined above), at the time of the distribution or at any time during the preceding 12 months). Â Generally, Israeli resident corporations are not subject to Israeli tax on the receipt of dividends paid on shares of Israeli corporations, other than with respect to dividends distributed from income that has accrued during the benefits period and attributed to a Benefited Enterprise as described above. Â Payers of dividends on our shares, including the Israeli stockbrokers or the financial institutions through which the shares are held, are generally required, subject to reduced tax rates and the demonstration of a shareholder of his, her or its foreign residency, to withhold taxes upon the distribution of dividends at a rate of 25% (whether or not the recipient is a â€œControlling Shareholderâ€) provided that the shares are registered with a nominee company in Israel (for corporations and individuals), unless a reduced tax rate under the provisions of an applicable double tax treaty (subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate) is available. Â Dividends paid out of income attributed to a Preferred Technology Enterprises are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. Â For example, under the U.S.-Israel Tax Treaty, the following rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident (for purposes of the U.S.-Israel Treaty): (i) with regard to a dividend distributed from income which is not attributed to an Approved Enterprise/Benefited Enterprise/Preferred Enterprise/Preferred Technology Enterprise or Special Preferred Technology Enterprise, if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain types of interest or dividends â€“ the maximum tax rate of withholding is 12.5% if a certificate for a reduced withholding tax rate would be provided in advance from the Israel Tax Authority, (ii) with regard to a dividend distributed from income derived from an Approved Enterprise/Benefited Enterprise/Preferred Enterprise under the Investment Law, if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting stock of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain types of interest or dividends, the tax rate of withholding 15% will be applicable if a certificate for a reduced withholding tax rate would be provided in advance from the Israel Tax Authority and (iii) in all other cases, the tax rate is 25%, or the domestic rate (if such is lower). The aforementioned rates under the U.S.-Israel Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel. Â If the dividend is attributable partly to income derived from an Approved Enterprise, Benefited Enterprise or Preferred Enterprise, and partly from other sources of income, the income tax rate will be a blended rate reflecting the relative portions of the types of income. Â A non-Israeli resident who receives dividend income derived from or accrued from Israel, from which the full amount of tax was withheld at source, is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i) such income was not generated from a business conducted in Israel by the taxpayer, and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed. Â We have never declared or paid cash dividends to our shareholders and currently we do not intend to distribute cash or other dividends in the foreseeable future. We cannot assure you that, in the event we declare a dividend, we will designate the profits that are being distributed in a way that will reduce shareholdersâ€™ tax liability. Â 99 Foreign Exchange Regulations Â Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, freely repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of currency exchange controls has not been eliminated, and may be restored at any time by administrative action. Â Excess Tax Â Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding a certain threshold (NIS 721,560 for 2024), which amount is linked to the annual change in the Israeli consumer price index, including, but not limited to income derived from dividends, interest and capital gains, subject to the provisions of an applicable tax treaty. Â Estate and Gift Tax Â Israeli law presently does not impose estate or gift taxes. Â Material U.S. Federal Income Tax Considerations to U.S. Holders Â The following discussion is a description of the material U.S. federal income tax considerations applicable to an investment in our ordinary shares by U.S. Holders who hold the ordinary shares as capital assets for U.S. federal income tax purposes, (generally, property held for investment). As used in this section, the term â€œU.S. Holderâ€ means a beneficial owner of an ordinary share who, for U.S. federal income tax purposes, is or is treated as any of the following: Â â€¢ a citizen or resident of the United States; Â â€¢ a corporation created or organized in or under the laws of the United States or any political subdivision thereof, including the District of Columbia; Â â€¢ an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or Â â€¢ a trust if the trust has elected validly to be treated as a United States person for U.S. federal income tax purposes or if a U.S. court is able to exercise primary supervision over the trustâ€™s administration and one or more United States persons have the authority to control all of the trustâ€™s substantial decisions. Â This description is based on provisions of the U.S. Internal Revenue Code of 1986, as amended, referred to in this discussion as the Code, existing U.S. Treasury regulations and administrative and judicial interpretations, each as available and in effect as of the date of this prospectus. These sources may change and are open to differing interpretations, possibly with retroactive effect in a manner that could adversely affect a U.S. Holder. This description does not discuss all aspects of U.S. federal income taxation that may be applicable to investors in light of their particular circumstances or to investors who are subject to special treatment under U.S. federal income tax law, including: Â â€¢ insurance companies; Â â€¢ dealers in stocks, securities or currencies; Â â€¢ financial institutions and financial services entities; Â â€¢ real estate investment trusts; Â â€¢ regulated investment companies; Â â€¢ partnerships and other pass-through entities, and investors in such entities; Â â€¢ persons that receive ordinary shares as compensation for the performance of services; Â â€¢ tax-exempt organizations; Â â€¢ persons that hold ordinary shares as a position in a straddle or as part of a hedging, conversion or other integrated instrument or persons entering into a constructive sale with respect to the ordinary shares; Â â€¢ persons subject to special tax accounting rules under Section 451(b) of the Code; Â 100 â€¢ individual retirement and other tax-deferred accounts; Â â€¢ expatriates of the United States; Â â€¢ persons having a functional currency other than the U.S. dollar; and Â â€¢ direct, indirect or constructive owners of 10% or more of our ordinary shares and/or other equity by vote or value. Â This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal gift or estate tax or alternative minimum tax considerations. Â If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax consequences relating to an investment in the ordinary shares will depend in part upon the status and activities of such entity or arrangement and the particular partner and certain determinations made at the partner level. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of ordinary shares. Â We urge you to consult with your own tax advisor regarding the tax consequences of investing in the ordinary shares, including the effects of federal, state, local, foreign and other tax laws. Â Distributions Paid on the Ordinary Shares Â We have never paid cash dividends on our ordinary shares and we may not distribute cash or other dividends on our ordinary shares in the foreseeable future. Subject to the discussion below under â€œ- Passive Foreign Investment Company Considerations,â€ a U.S. Holder generally will be required to include in gross income as ordinary dividend income the amount of any distributions paid on the ordinary shares, including the amount of any Israeli taxes withheld, to the extent that those distributions are paid out of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Subject to the discussion below under â€œ-Passive Foreign Investment Company Considerations,â€ distributions in excess of our earnings and profits will be applied against and will reduce the U.S. Holderâ€™s tax basis in its ordinary shares and, to the extent they exceed that tax basis, will be treated as gain from a sale or exchange of those ordinary shares. Our dividends will not qualify for the dividends-received deduction applicable in some cases to U.S. corporations. Dividends paid in NIS, including the amount of any Israeli taxes withheld, will be includible in the income of a U.S. Holder in a U.S. dollar amount calculated by reference to the exchange rate in effect on the day they are received by the U.S. Holder. Any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend is includible in the income of the U.S. Holder to the date that payment is converted into U.S. dollars generally will be treated as ordinary income or loss. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as dividends. Distributions on ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute passive category income. Subject to certain complex conditions and limitations, Israeli taxes withheld on any distributions on ordinary shares may be eligible for credit against a U.S. Holderâ€™s federal income tax liability. The rules relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult their tax advisors regarding the availability of a foreign tax credit in their particular circumstances and the possibility of claiming an itemized deduction (in lieu of the foreign tax credit) for any foreign taxes paid or withheld. Â Dividends paid by a â€œqualified foreign corporationâ€ to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Distributions on ordinary shares that are treated as dividends generally will not be eligible for the â€œdividends receivedâ€ deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. Â A corporation organized outside of the United States, or a non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ordinary shares that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Treaty, although there can be no assurance in this regard. Further, the Internal Revenue Service, or IRS, has determined that the U.S.-Israel Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange of information provision. Therefore, subject to the discussion below under â€œ- Passive Foreign Investment Company Considerations,â€ if the U.S.-Israel Treaty is applicable, such dividends will generally be â€œqualified dividend incomeâ€ in the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Â 101 Disposition of Ordinary Shares Â Subject to the discussion below under â€œ- Passive Foreign Investment

Company Considerations,â€ a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of ordinary shares in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holderâ€™s adjusted tax basis in the ordinary shares. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or other disposition, the ordinary shares were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes. Â Passive Foreign Investment Company Considerations Â We believe that we were not a PFIC for our taxable year ended December 31, 2024, and we do not expect to be classified as a PFIC for U.S. federal income tax purposes for the current year ending December 31, 2025, or the foreseeable future. However, the determination of whether we are a PFIC is a factual determination made annually based on all the facts and circumstances and thus is subject to change. The relevant rules for determining whether or not we are a PFIC as applied to our business are not entirely clear and certain aspects of the relevant tests will be outside our control. Therefore, no assurance can be given that we will not be a PFIC for any taxable year. Â In general, a non-U.S. corporation will be treated as a PFIC, for any taxable year in which either (1) at least 75% of its gross income is â€œpassive income,â€ referred to as the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, referred to as the PFIC asset test. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. Â A separate determination must be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value of our assets for purposes of the PFIC test will generally be determined by reference to the market price of our ordinary shares, fluctuations in the market price of our ordinary shares may cause us to become a PFIC. In addition, changes in the composition of our income or assets may cause us to become a PFIC. Â If we are a PFIC in any taxable year during which a U.S. Holder owns ordinary shares, the U.S. Holder could be liable for additional taxes and interest charges under the â€œPFIC excess distribution regimeâ€ upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holderâ€™s holding period for the ordinary shares, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a pledge, of the ordinary shares, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution or gain ratably over the U.S. Holderâ€™s holding period for ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax. Â If we are a PFIC for any year during which a U.S. Holder holds ordinary shares, we must generally continue to be treated as a PFIC by such U.S. Holder for all succeeding years during which such U.S. Holder holds the ordinary shares, unless we cease to meet the requirements for PFIC status and such U.S. Holder makes a â€œdeemed saleâ€ election with respect to the ordinary shares. If the election is made, the U.S. Holder will be deemed to sell the ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election, the U.S. Holderâ€™s ordinary shares would not be treated as shares of a PFIC unless we subsequently become a PFIC. Â 102 If we are a PFIC for any taxable year during which a U.S. Holder holds ordinary shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries. Â If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on ordinary shares if such U.S. Holder makes a valid â€œmark-to-marketâ€ election for our ordinary shares. A mark-to-market election is available to a U.S. Holder only for â€œmarketable stock.â€ Our ordinary shares will be marketable stock as long as they remain listed on Nasdaq and are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. There can be no assurance that the ordinary shares will be â€œmarketable stockâ€ for purposes of the mark-to-market election. If a mark-to-market election is in effect, a U.S. Holder generally would take into account, as ordinary income for each taxable year of the U.S. Holder, the excess of the fair market value of ordinary shares held at the end of such taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holderâ€™s tax basis in ordinary shares would be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other disposition of ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. Â A mark-to-market election will not apply to ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs that we may organize or acquire in the future notwithstanding the U.S. Holderâ€™s mark-to-market election for the ordinary shares. Â The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election. Prospective investors should assume that a QEF election will not be available. Â Each U.S. person that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. Â The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to the ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ordinary shares of a PFIC. Â Medicare Tax Â Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ordinary shares. If you are a U.S. person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this Medicare tax to your income and gains in respect of your investment in ordinary shares. Â 103 Information Reporting and Back-up Withholding Â U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in ordinary shares, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under â€œâ€“ Passive Foreign Investment Company Considerations,â€ each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for ordinary shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the required information reporting. Â Dividends on and proceeds from the sale or other disposition of ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption (usually on IRS Form W-9), or (2) is described in certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holderâ€™s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS. Â U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules. Â EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTORâ€™S OWN CIRCUMSTANCES. Â F. Â Â Dividends and Paying Agents Â Not applicable. Â G. Â Â Statement by Experts Â Not applicable. Â H. Â Â Documents on Display Â We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements will file reports with the SEC. Those reports may be inspected without charge at the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. Nevertheless, we will file with the SEC an Annual Report on Form 20-F containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm, and we intend to submit quarterly interim consolidated financial data to the SEC under cover of the SECâ€™s Form 6-K. Â We maintain a corporate website at www.inmodemd.com. We intend to post our Annual Report on Form 20-F on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference. Â Our SEC filings are available to you on the SECâ€™s website at http://www.sec.gov. This site contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The information on that website is not part of this Annual Report on Form 20-F. Â With respect to references made in this Annual Report on Form 20-F to any contract or other document of InMode, such references are not necessarily complete and you should refer to the exhibits attached or incorporated by reference to this Annual Report on Form 20-F for copies of the actual contract or document. Â 104 I. Â Â Subsidiary Information Â Not applicable. Â J. Â Â Annual Report to Security Holders. Â Not applicable. Â Â ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â Foreign Currency Risk Â Our consolidated revenues are generated primarily in U.S. dollars. In addition, a substantial portion of our consolidated costs are incurred in dollars. We believe that the U.S. dollar is the primary currency of the economic environment we operate in. Thus, the U.S. dollar is our primary functional and reporting currency. Â Our transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the consolidated statements of income (indicated below), the following exchange rates are used: (i) for transactions, exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization), historical exchange rates. Currency translation gains and losses are presented in finance income or expenses, as appropriate. Â A significant portion of our operations is conducted through operations in countries other than the United States and Israel. Revenues from our global operations that were recorded in U.S. dollars represented approximately 72%, 74% and 76% for the years ended December 31, 2024, 2023 and 2022, respectively. Â The functional currency of our subsidiaries is the U.S. dollar. For purposes of consolidation, the financial statements of the Foreign Subsidiaries are translated into U.S. dollars in accordance with ASC No. 830, â€œForeign Currency Mattersâ€ (â€œASC 830â€). Â Interest Rate Risk Â The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. Currently, we do not have any outstanding borrowings. We intend to invest our cash balances primarily in bank deposits and fixed-income securities issued by corporations, the United States and non-U.S. governments. We are exposed to market risks resulting from changes in interest rates relating primarily to our financial investments in cash, cash equivalents, deposits and marketable securities. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets; however, we believe any such potential loss would be immaterial to us. Â ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES Â A.Â Â Debt Securities Â Not applicable. Â B.Â Â Warrants and Rights Â Not applicable. Â C.Â Â Other Securities Â Not applicable. Â D.Â Â Â American Depositary Shares Â Not applicable. Â 105 PART II Â ITEM 13. DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES Â Not applicable. Â ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS Â In May 2024, we approved a share repurchase program of up to 8.37 million ordinary shares, to be purchased out of our cash reserve. As of December 31, 2024, we purchased 8.37 shares in the amount of $150.5 million under this repurchase program. Â In September 2024, we approved an additional share repurchase program of up to 7.68 million ordinary shares, to be purchased out of our cash reserve. As of December 31, 2024, we purchased 7.68 shares in the amount of $134.9 million under this repurchase program. Â ITEM 15. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â We have performed an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), of the effectiveness of our disclosure controls and procedures that are designed to provide a reasonable level of assurance that the information required to be disclosed in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this report are effective in ensuring that the information required to be disclosed in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Managementâ€™s Annual Report on Internal Control Over Financial Reporting Â Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation and fair presentation of published financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Â Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 using criteria described in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Â Based on its assessment, management concluded that the internal control over financial reporting was effective as of December 31, 2024, based on the criteria established in the Internal Control-Integrated Framework (2013). Â The effectiveness of our internal control over financial reporting as of DecemberÂ 31, 2024 has been audited by Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm, as stated in their report on pages F-2 to F-3 under â€œItem 18. Financial Statementsâ€ in this Annual Report on Form 20-F. Â Â 106 Changes in Internal Control Over Financial Reporting Â There were no changes in our internal control over financial reporting that occurred during the period covered by this Annual Report on Form 20-F that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting. Â ITEM 16. [RESERVED] Â ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT Â Our board of directors has determined that all members of our audit committee are financially literate as determined in accordance with Nasdaq rules and that Dr. Michael Anghel is qualified to

serve as an â€œaudit committee financial expertâ€ as defined by SEC rules. Dr. Anghel is independent, as defined by Nasdaq listing standards. Â ITEM 16B. CODE OF ETHICS Â We have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions. The full text of the Code of Business Conduct and Ethics has been posted on our website at www.inmodemd.com. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Â ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES Â Fees Paid to Independent Registered Public Accounting Firm Â The following table sets forth, for each of the years indicated, the fees billed by Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, our independent registered public accounting firm.. Â Â Â Year ended December 31, Â Â Â 2024 Â Â 2023 Â Â Â USD, in thousands Â Audit fees(1)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 664 Â Â Â 630 Â Audit-related fees(2)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€” Â Â Â â€” Â Tax fees(3)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 95 Â Â Â 116 Â All other feesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€” Â Â Â â€” Â TotalÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 759 Â Â Â 746 Â (1) Audit fees consist of fees billed or expected to be billed for the annual audit services engagement and other audit services, which are those services that only the external auditor can reasonably provide, and include the Company audit; statutory audits; comfort letters and consents; attest services; and assistance with and review of documents filed with the SEC. Â (2) Audit-related fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements or that are traditionally performed by the external auditor, and include consultations concerning financial accounting and reporting standards; internal control reviews of new systems, programs and projects; review of security controls and operational effectiveness of systems; review of plans and control for shared service centers, due diligence related to acquisitions; accounting assistance and audits in connection with proposed or completed acquisitions; and employee benefit plan audits. Â (3) Tax fees include fees billed for tax compliance services that were rendered during the most recent fiscal year, including the preparation of original and amended tax returns and claims for refund; tax consultations, such as assistance and representation in connection with tax audits and appeals, tax advice related to mergers and acquisitions, transfer pricing, and requests for rulings or technical advice from taxing authority; tax planning services; and expatriate tax planning and services. Â Our Audit and Investment Committee, in accordance with its charter, reviews and pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent auditors. Â ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES Â Not applicable. Â 107 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS Â In September 2020, we approved a share repurchase program of up to 2 million ordinary shares, to be purchased out of our cash reserve and to be paid solely from our IPO proceeds. In February 2022, the board approved that the share repurchase program could also be funded from the proceeds of exercised options. In March 2022, we approved an additional repurchase program of up to 1 million ordinary shares, to be purchased out of our cash reserve and to be paid from our remaining IPO proceeds and from the proceeds of exercised options. In May 2024, we approved a share repurchase program of up to 8.37 million ordinary shares, to be purchased out of our cash reserve.Â In September 2024, we approved an additional share repurchase program of up to 7.68 million ordinary shares, to be purchased out of our cash reserve. As of December 31, 2024, we purchased 18,607,829 shares in the amount of $380.6 million. For the year ended December 31, 2024, we purchased 16,050,000 shares in the amount of $285.4 million. See below for the Companyâ€™s purchases of shares under the share repurchase programs in 2024: Â Issuer Purchases of Equity Securities in 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

reference to Exhibit 4.13 to the Companyâ€™s Annual Report on Form 20-F (File No. 001-39016) filed with the SEC on February 13, 2024.). Fifth Supplemental Lease Agreement, dated May 8, 2023, by and between Shaâ€™ar Yokneam Limited Partnership and InMode Ltd. (English translation) (incorporated herein by reference to Exhibit 4.13 to the Companyâ€™s Annual Report on Form 20-F (File No. 001-39016) filed with the SEC on February 13, 2024.). Sixth Supplemental Lease Agreement, dated June 6, 2024, by and between Shaâ€™ar Yokneam Limited Partnership and InMode Ltd. (English translation) (filed herewith). Seventh Supplemental Lease Agreement, dated July 30, 2024, by and between Shaâ€™ar Yokneam Limited Partnership and InMode Ltd. (English translation) (filed herewith). 4.14 Â Founders Memorandum of Understanding dated March 4, 2014, by and between Invasix Ltd. and Wigmore Medical Limited (incorporated herein by reference to Exhibit 10.12 to the Companyâ€™s Registration Statement on Form F-1 (File No. 333-232615) filed with the SEC on July 11, 2019). 4.15 Â Amended and Restated Compensation Policy dated May 1, 2024 (incorporated herein by reference to Exhibit 99.1 to the Companyâ€™s Report of Foreign Private Issuer on Form 6-K (File No. 001-39016), filed with the SEC on February 13, 2024). 4.16 Â Share Exchange Agreement, dated November 11, 2020, by and between the Company, Guangzhou Sino-Israel Bio-Industry Investment Fund (LLP) and Guangzhou InMode Medical Technology Ltd. (incorporated herein by reference to Exhibit 10.1 to Form 6-K (File No. 001-39016) filed with the SEC on November 12, 2020). 4.17 Â Share Exchange Agreement, dated April 23, 2021, by and between the Company, Dilazar Limited, Wigmore Medical Limited and Invasix UK Limited (incorporated herein by reference to Exhibit 10.1 to Form 6-K (File No. 001-39016) filed with the SEC on April 26, 2021). 8.1 Â List of Subsidiaries (incorporated herein by reference to Exhibit 8.1 to the Companyâ€™s Annual Report on Form 20-F (File No. 001-39016) filed with the SEC on February 13, 2024). 11.1 Â InMode Ltd. Insider Trading Compliance Policy (filed herewith). 12.1 Â Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. 12.2 Â Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. 13.1 Â Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 13.2 Â Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 15.1 Â Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm. 97 Â InMode Ltd. Clawback Policy, adopted November 1, 2023 (incorporated herein by reference to Exhibit 97 to the Companyâ€™s Annual Report on Form 20-F (File No. 001-39016) filed with the SEC on February 13, 2024.). 101 Â Interactive Data File. 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document). Â 112 Â SIGNATURES Â The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. Â Â INMODE LTD. Â Â Â Â By: /s/ Yair Malca Â Â Yair Malca Â Â Chief Financial Officer Â Date: February 4, 2025 Â 113 Â INMODE LTD. Â CONSOLIDATED FINANCIAL STATEMENTS Â INDEX TO FINANCIAL STATEMENTS: Â Â Page REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C.P.A.sÂ and PCAOB ID 1309) F-2 CONSOLIDATED FINANCIAL STATEMENTS: Â Consolidated Balance Sheets F-4 Consolidated Statements of Income F-5 Consolidated Statements of Comprehensive Income F-6 Consolidated Statements of Changes in Shareholdersâ€™ Equity F-7 Consolidated Statements of Cash Flows F-8 Notes to Consolidated Financial Statements F-9 Â Â Â Â

Â Â Â Â Â Â Â Â NON-CASH ACTIVITIES Â Â Â Â Â Â Â Â Â Â Â Â Â Â Recognition of operating lease right-of-use assets and liabilities Â Â 1,259 Â Â Â 5,200 Â Â Â 2,342 Â Exercise of options Â Â 49 Â Â Â 20 Â Â Â 103 Â Â *Including, for 2022, payments amounting $12 million for Amendment to the Investments Law and settlements with the Israeli tax authority. See note 13a(2)(b). Â The accompanying notes are an integral part of these consolidated financial statements. Â F - 8Â INMODE LTD.Â NOTES TO CONSOLIDATED FINANCIAL STATEMENTSÂ (U.S. dollars in thousands, except for share and per amounts)Â NOTE 1 - GENERAL: Â InMode Ltd. (separately and together with its subsidiaries, the â€œCompanyâ€) was incorporated on January 2, 2008 and commenced operations shortly thereafter. The Companyâ€™s headquarters are located in Israel. The Company is traded in the Nasdaq Global Select Market (the â€œNasdaqâ€) since August 2019. Â The Company designs, develops, manufactures and markets innovative minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. These technologies are used to remodel subdermal adipose or fatty tissue in a variety of procedures including liposuction with simultaneous skin tightening, body and face contouring and ablative skin rejuvenation treatments, as well as, for use in certain womenâ€™s health conditions and procedures. In addition to the minimally-invasive technologies, the Company designs, develops, manufactures and markets nonâ€’invasive medical aesthetic products that target a wide array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The Company also designs, develops, manufactures and markets hands-free medical aesthetic products that target a wide array of procedures such as skin tightening, fat reduction and muscle stimulation. Â The Company has wholly-owned subsidiaries located in the United States and two subsidiaries in Canada (â€œNorth Americaâ€), Hong Kong, Japan, Spain, two subsidiaries in Israel, India, Australia, China, the United Kingdom (â€œUKâ€), France, Italy and Germany. The Companyâ€™s subsidiaries are referred to collectively herein as the â€œSubsidiaries.â€ The Company sells its products primarily through its Subsidiaries. Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES: Â Â a. Basis of presentation Â The Companyâ€™s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (â€œU.S. GAAPâ€). Â Â b. Use of estimates Â The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to valuation allowances. Â Â c. Functional currency Â The U.S. dollar (â€œU.S. dollarâ€ or â€œ$â€) is the currency of the primary economic environment in which the operationsÂ of the Company is conducted. Substantial revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (â€œprimary currencyâ€). Â F - 9Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions â€“ exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) â€“ historical exchange rates.Â Currency transaction gains and losses are presented in finance income (expenses), as appropriate. Â The functional currency of each of the Subsidiaries is the U.S. dollar. Â Â d. Principles of consolidation and presentation Â The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany transactions and balances are eliminated in consolidation. Â Â e. Cash and cash equivalents Â The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. Â Â f. Short-term bank deposits Â Bank deposits with maturities of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an annual rate of approximately 0.5%-6.15% in 2024 and 4.10%-7.01% in 2023. Â Â g. Marketable securities Â AFS Securities Â Marketable securities consist of government bonds,Â municipal bonds and corporate debt securities (together â€œDebt Securitiesâ€), and certificates of deposit measured at fair value in each reporting period. The fair value of quoted securities is based on current market value. Â Debt Securities and certificates of deposit are classified as available-for-sale (together â€œAFS Securitiesâ€) under current assets in the consolidated balance sheet as they represent the investment of funds available for the Companyâ€™s current operations. Changes in fair value, excludingÂ credit losses andÂ impairments, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of Debt Securities and certificates of deposit as well as premium or discount amortization are included in the consolidated statements of income as finance income, net. Fair value is calculated based on publicly available market information. The amortized cost of the Debt Security will be reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost basis, or it has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recognized in finance income, net on the consolidated statements income. Â F - 10Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â The Company classifies investments that are readily convertible to known amounts of cash and have stated maturities of three months or less from the date of purchase as cash equivalents and those with stated maturities of greater than three months as marketable securities. Â The Company determines the appropriate classification of its investments in marketable securities at the time of purchase. Â Â h. Other Investments Â The Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity investments without readily determinable fair values at cost for other investments, less impairment, adjusted for subsequent observable price changes. In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings. Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in orderly transactions for the identical or similar investment of the same issuer. Â Â i. Inventories Â Inventories include raw materials and finished products are valued at the lower of cost, â€œmoving averageâ€Â method, or net realizable value. The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions. Â Â j. Leases Â The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use (â€œROUâ€) assets, other current liabilities, and operating lease liabilities in the consolidated balance sheets. Â The Company also elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term. Â ROU assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Companyâ€™s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Companyâ€™s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 9). Â F - 11Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â k. Property and equipment Â Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives: Â Computers 3 â€“ 4 years Molds 4 â€“ 10 years Equipment and furniture 10 â€“ 17 years Â Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the improvements. Â Â l. Impairment of long-lived assets Â The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.Â During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize an impairment loss on its long-lived assets. Â Â m. Legal and other contingencies Â Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Companyâ€™s management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Companyâ€™s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Â Management applies the guidance in ASC 450-20, â€œLoss Contingenciesâ€ when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Companyâ€™s consolidated financial statements. Â Legal costs incurred in connection with loss contingencies are expensed as incurred. Â Â n. Income taxes: Â Â Â Â 1) The Company accounts for income taxes in accordance with ASC 740, â€œIncome Taxesâ€ (â€œASCÂ 740â€). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current. Â F - 12Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â 2) The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Subsidiaries outside of Israel; no additional deferred income tax assets have been provided, since the Company does not expect to distribute inter-company dividends in the foreseeable future that may result in additional tax liability. Â Â 3) Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income tax assets, as it is the Companyâ€™s intent and ability to hold these investments. Â Â 4) The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740â€‘10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit of the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. Â Â o. Advertising expenses Â Advertising expenses are charged to sales and marketing on the consolidated statement of income as incurred. Advertising expenses for theÂ years ended DecemberÂ 31, 2024, 2023 and 2022 amounted to $15 million, $15 million, and $10 million, respectively. Â Â p. Share-based compensation Â The Company grants share options and restricted share units (â€œRSUâ€) (together â€œShare-Based Compensationâ€) to its employees, officers, directors and non-employees in consideration for services rendered and for acquiring goods. See note 12(a)(2) for details on outstanding share capital. Â The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Binomial Model, and for each RSU granted is based on the Companyâ€™s share price at the close of the last trading day prior to the date of the grant. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates. Â The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Performance-based Share-Based Compensation expenses are calculated based on the valuation at the grant date, and recognized based on the probability of achieving those targets. The Company assess at what scale can the performance targets be reached at each balance sheet date, and expenses are recognized accordingly. Â The Company issues new shares upon option exercise or RSU vesting. Â F - 13Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â q. Revenue recognition Â The Company applies ASC 606,Â â€œRevenue from Contracts with Customersâ€ (â€œASC 606â€). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.Â To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: Â Â (i) Identify the contract(s) with a customer; Â Â (ii) Identify the performance obligations in the contract. The Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties; Â Â (iii) Determine the transaction price; Â Â (iv) Allocate the transaction price to the performance obligations in the contract; The Company estimates the standalone selling prices of the services to be provided based on actual sales transactions of service contract purchased on a standalone basis and uses the residual approach to estimate the selling price of the products; and Â Â (v) Recognize revenue when (or as) the performance obligation is satisfied.Â Â The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable.Â At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct.Â The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.Â Â The Company uses the following practical expedients that are permitted under the rules: Â Â â€¢ The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in sales and marketing expenses. Â Â â€¢ The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Â The following is a description of the principal activities from which the Company generates its revenue. Â Product Revenue, Net Â Revenues from product sales are recognized when the customer obtains control over the Companyâ€™s product, typically upon shipment to the customer. Revenues from shipping and handling activities that occur after the customer has obtained control of a good are recognized according to an accounting policy election as a fulfilment cost rather than as an additional promised service.Â Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded fromÂ revenues. Â F - 14Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Payment terms and conditions vary by customer. The Companyâ€™s standard terms for end users usually require of payment upon delivery and for distributors require a down payment and payments made within several month from the invoice date.Â Â The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60 months) financing for the purchase of the Companyâ€™s products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract. Â Variable considerations include price concessions related to installment sales contracts. The Company estimates variable consideration using the most likely outcome amount.Â Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Â During the year ended December 31, 2024, the Company entered into risk sharing agreements with several leasing partners to facilitate and support the financing of capital equipment sales for its customers. Under these arrangements, a portion of each sale transaction funded by those leasing partners goes into a reserve fund used by the

Company to provide a limited guarantee, up to the reserve fund amount, and used to compensate the leasing partners in the event of customer defaults. The guarantee is recognized on the estimated fair value amount according to ASC 460. In the following periods the Company will assess credit losses in accordance with ASC 326, see also note 2r. Â The Company does not grant a right of return, refund, cancelation or termination. From time to time, the Company participates in its customersâ€™ marketing activities and deducts such amounts from revenue. Â Service Revenue Â The Company also generates revenues from long-term maintenance contracts (â€œExtended Warrantyâ€). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. These maintenance agreements are included in contract liabilities. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed. Â The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12 months as long-term. Â Â r. Allowance for doubtful accounts and financial instruments â€“ credit loss Â The Company maintains the allowance for doubtful account resulting from the inability of the Companyâ€™s customers to make required payments. Â The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable. This information includes among other the historic experience, the extent and amount of the account and future expectations. Â Allowance forÂ credit lossesÂ due to the Companyâ€™s accounts receivable amounted to $2,749 and $2,254 as of December 31, 2024Â and 2023 respectively.Â ChangesÂ in the allowance forÂ credit lossesÂ are recognized in general and administrative expenses. Accounts receivable are written-off against the allowance forÂ credit lossesÂ when management deems the accounts are no longer collectible. Â The following table sets forth activity in the Companyâ€™s allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively: Â Â Â 2024 Â Â 2023 Â Â 2022 Â Balance at beginning of year Â Â 2,254 Â Â Â Â 1,318 Â Â Â Â 1,107 Â Current-period provision Â Â 572 Â Â Â Â 1,020 Â Â Â Â 449 Â Write-offs charged against the Allowance and revaluation Â Â (77) Â Â (84) Â Â (238) Balance at end of year Â Â 2,749 Â Â Â Â 2,254 Â Â Â Â 1,318 Â Â F - 15Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â s. Warranty reserve Â The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Companyâ€™s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs, the cost per repair and shipping cost. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Â The following table sets forth activity in the Companyâ€™s accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively: Â Â Â 2024 Â Â 2023 Â Â 2022 Â Balance at beginning of year Â Â 1,476 Â Â Â Â 1,418 Â Â Â Â 1,248 Â Cost incurred Â Â (1,909) Â Â (2,304) Â Â (2,099) Expense recognized Â Â 1,155 Â Â Â Â 2,362 Â Â Â Â 2,269 Â Balance at end of year Â Â 722 Â Â Â Â 1,476 Â Â Â Â 1,418 Â Â Â Â t. Cost of revenues Â Cost of revenue consists of products purchased from turnkey sub-contractors which are responsible for the production of most of the Companyâ€™s products under the Companyâ€™s directions and supervision, raw materials for in-house assembly line, shipping and handling costs to customers and to subsidiaries, salary, employee-related expenses and overhead expenses of internal assembly line and service costs associate with warranty. Â Â u. Research and development costs Â Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material andÂ third-party contractorâ€™s charges related to product development, regulatory affairs and clinical studies. Â Â v. Net earningsÂ per share Â Basic earnings per share are computed by dividing net income attributed to the shareholders of InMode Ltd. by the weighted average number of the Companyâ€™s ordinary shares, par value NIS 0.01 per share (including vested RSUs), outstanding for each period, net of treasury shares. Â For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method. Â F - 16Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â w. Fair value measurement Â The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Companyâ€™s market assumptions. Â The three levels of inputs that may be used to measure fair value are as follows: Â Level 1 â€“ Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Â Level 2 â€“ Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets. Â Level 3 â€“ Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Â The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available. Â As of December 31, 2024, and 2023, the fair values of the Company's cash, cash equivalents, short term bank deposits, accounts receivable, accounts payable, approximated the carrying values of these instruments presented in the Company's consolidated balance sheets because of their nature. Â Â x. Employee severance benefits Â The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances. Â In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employeeâ€™s full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Companyâ€™s consolidated balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies. Â The amounts of severance payment expenses were $581 $522 and $431 and for the years ended DecemberÂ 31, 2024, 2023 and 2022, respectively. Â The Company expects to contribute approximately $569 in the year ending DecemberÂ 31, 2025 to insurance companies in connection with its expected severance liabilities for the year. Â F - 17Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 2 - SIGNIFICANTÂ ACCOUNTINGÂ POLICIES (continued): Â Â y. Treasury Shares Â Treasury shares are presented as a reduction of equity, at their cost to the Company. Â Â z. Concentration of credit risks Â Most of the cash and cash equivalents were deposited with U.S., European and Israeli banks and financial institutions and were comprised mainly of money market fund. The U.S. market constituted approximately 62% of the revenues in 2024. Â The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for Credit Losses and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. Â Â aa. War risk situation in Israel Â In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During January 2025, a cease fire with Hamas was declared. As of the date of these consolidated financial statements, the war is ongoing and continues to evolve. The Company's headquarters, its R&D operations, and certain manufacturing facilities are located in Israel. Â Currently, such activities in Israel remain largely unaffected. During the years ended December 31, 2024 and December 31, 2023, the impact of this war on the Companyâ€™s results of operations and financial condition was immaterial. Â Â ab. Recently adopted accounting pronouncements Â In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€. This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company adopted this standard in the current period retrospectively to all prior periods presented in an entityâ€™s financial statements, refer to note 14. Â Â ac. Newly issued accounting pronouncements, not yet adopted: Â Â 1) In December 2023, the FASB issued ASU 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024Â on a prospective basis. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â Â 2) In November 2024, the FASB issued ASUÂ 2024-03 â€œIncome Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expensesâ€, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â F - 18Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 3 - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS: Â AFS securities as of December 31, 2024 and 2023, consisted of U.S government bonds, municipal bonds, corporate debt securities and certificate of deposit. These marketable securities are recorded at fair value. Â The following table sets forth the Companyâ€™s marketable securities for the periods indicated: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â U.S. Government bonds Â Â 265,180 Â Â Â Â 353,414 Â Municipal bonds Â Â - Â Â Â Â 2,319 Â Corporate debt securities Â Â 2,508 Â Â Â Â 13,234 Â Certificates of deposit Â Â - Â Â Â Â 4,680 Â Total Â Â 267,688 Â Â Â Â 373,647 Â Â The Company classifies AFS securities within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value. See also note 2(w). Â The following table sets forth the Companyâ€™s financial assets as of DecemberÂ 31, 2024 and 2023, that are measured at fair value on a recurring basis during the period: Â Â Â December 31, 2024 Â Â Â Fair value Â Â Cost or amortized cost Â Â Gross unrealized holding loss Â Â Gross unrealized holding gains Â Level 2 securities: Â Â Â Â Â Â Â Â Â Â Government bonds Â Â 265,180 Â Â Â Â 265,619 Â Â Â (552) Â Â Â 113 Â Corporate debt securities Â Â 2,508 Â Â Â Â 2,510 Â Â Â (3) Â Â Â 1 Â Total Â Â 267,688 Â Â Â Â 268,129 Â Â Â (555) Â Â Â 114 Â Â Â Â Â December 31, 2023 Â Â Â Fair value Â Â Cost or amortized cost Â Â Gross unrealized holding loss Â Â Gross unrealized holding gains Â Level 2 securities: Â Â Â Â Â Â Â Â Â Â Government bonds Â Â 353,414 Â Â Â Â 355,382 Â Â Â (2,139) Â Â Â 171 Â Municipal bonds Â Â 2,319 Â Â Â Â 2,363 Â Â Â Â (44) Â Â - Â Corporate debt securities Â Â 13,234 Â Â Â Â 13,404 Â Â Â (170) Â Â - Â Certificates of deposit Â Â 4,680 Â Â Â Â 4,680 Â Â Â Â - Â Â Â Â - Â Total Â Â 373,647 Â Â Â Â 375,829 Â Â Â Â (2,353) Â Â Â 171 Â Â As of December 31, 2024 and 2023, the Company considered, based on its evaluation, that the decreases in market value on relevant marketable securities were temporarily impaired and primarily attributable to changes in interest rates, and therefore did not result in an impairment chargeÂ inÂ finance income, net. Â As of December 31, 2024 and 2023, the Companyâ€™s debt securities and certificates of deposit had the following maturity dates: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Due within one year Â Â 179,784 Â Â Â Â 308,671 Â 1 to 2 years Â Â 80,560 Â Â Â Â 49,259 Â 2 to 3 years Â Â 7,344 Â Â Â Â 15,717 Â Total Â Â 267,688 Â Â Â Â 373,647 Â Â F - 19Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 4 - ACCOUNTS RECEIVABLE: Â Accounts receivable consist of the following: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Trade Â Â 40,739 Â Â Â Â 46,646 Â Notes receivable Â Â 1,521 Â Â Â Â 1,640 Â Less - allowance for credit losses Â Â (2,749) Â Â (2,254) Â Â Â Â 39,511 Â Â Â Â 46,032 Â Less - non-current accounts receivable, net Â Â (3,176) Â Â (3,670) Total current accounts receivable, net Â Â 36,335 Â Â Â Â 42,362 Â Â NOTE 5 - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES: Â Prepaid expenses and other current receivables consist of the following: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Advances to suppliers Â Â 14,960 Â Â Â Â 11,960 Â Prepaid expenses Â Â 2,421 Â Â Â Â 3,041 Â Government institutions Â Â 2,896 Â Â Â Â 948 Â Income tax Â Â 1,423 Â Â Â Â 66 Â Other Â Â 397 Â Â Â Â 253 Â Total other current receivables Â Â 22,097 Â Â Â Â 16,268 Â Â NOTE 6 - INVENTORIES:Â Inventories consist of the following: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Raw materials Â Â 15,454 Â Â Â Â 12,080 Â Finished products Â Â 44,094 Â Â Â Â 33,015 Â Total inventories Â Â 59,548 Â Â Â Â 45,095 Â Â NOTE 7 - PROPERTY AND EQUIPMENT, NET: Â Composition of property and equipment grouped by major classifications is as follows: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Computers Â Â 1,445 Â Â Â Â 1,334 Â Office furniture and equipment Â Â 709 Â Â Â Â 670 Â Molds Â Â 3,020 Â Â Â Â 2,592 Â Leasehold improvements Â Â 1,333 Â Â Â Â 1,243 Â Â Â Â Â 6,507 Â Â Â Â 5,839 Â Less: accumulated depreciation Â Â (4,185) Â Â (3,457) Total property and equipment, net Â Â 2,322 Â Â Â Â 2,382 Â Â Total depreciation and amortization in respect of property and equipment were $728, $623 and $680 for the years ended December 31, 2024, 2023 and 2022, respectively. Â F - 20Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 8 - OTHER INVESTMENTS: Â In November 2019, the Company signed a Share Purchase and Shareholders Agreement (the â€œSPAâ€) with (BY) Medimor Ltd., one of the Companyâ€™s turnkey manufacturing subcontractors (â€œMedimorâ€). Pursuant to the SPA, the Company has invested (in December 2019 and July 2020) an aggregate amount of $600 in consideration for 1,369,863 ordinary shares of Medimor (which reflected at the signing date a 14.78% ownership interest on an as-issued basis and 10.34% ownership interest on a fully diluted basis). Â In November 2023, the Company signed an additional SPA with Medimor and invested $100 in consideration for 117,440 ordinary shares of Medimor. Â The SPAs together reflected as of December 31, 2024, 2023 a 14.78% ownership interest on an as-issued basis and 11.23% ownership interest on a fully diluted basis. Â The Companyâ€™s investment in Medimor is measured at cost, less impairment and adjusted for subsequent observable price changes if any. As of December 31, 2024, 2023 and 2022, the Company did not recognize an impairment or adjustment on its other investments. Â NOTE 9 - LEASES: Â The Companyâ€™s main leasing properties are located in Israel, USA and Canada as detailed below: Â Â a. In May 2018, the Company signed a lease agreement for its headquarters in Israel. In January 2019, February 2020, March 2021, March 2023, May 2023 and June 2024 the Company signed supplement lease agreements, further expanding its headquarters in Israel (collectively, the â€œLease Agreementâ€). The Lease Agreement will expire in December 2027. The current monthly rent payment under the Lease Agreement is approximately $76.7. Â The costs under the Lease Agreement in Israel are linked to the Israeli Consumer Price Index. For purposes of ensuring the Companyâ€™s obligation towards the lessor, the Company has provided the lessor with a bank guarantee of NIS 966 thousand (approximately $263). Â The Company also leases warehouse outside the Company's offices. The Lease Agreement is for one year, with the Company options to renewal every year for 10 years. According to management's assessment, the lease will last until August 2027.. The current monthly rent payment under the Lease Agreement is approximately $8.9. Â The Company also leases vehicles for several employees in Israel for a period of three years. Â Â b. In August 2020, the Companyâ€™s U.S. subsidiary, has signed a new lease agreement, for additional lease agreement of property and for its offices (â€œU.S Leaseâ€). The U.S. Lease is for 7 years and 4 months which began in the middle of April of 2021. The current monthly rent payment is approximately $28. Â Â c. The Companyâ€™s Canadian subsidiary has signed a new lease agreement in April 2022 for property and for its offices (â€œCanadian Leaseâ€).Â The Canadian Lease is for 3 years until July 2025. The current monthly rent payment is approximately $17. Â From time to time the Company also leases small properties, mainly for offices for Subsidiaries around the world. Â The lease cost was as follows: Â Â Â Year ended December 31 Â Â Â 2024 Â Â 2023 Â Â 2022 Â Operating lease cost Â Â 3,057 Â Â Â Â 2,348 Â Â Â Â 1,628 Â Â F - 21Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 9 - LEASES (continued): Â Supplemental cash flow information related to leases was as follows: Â Â Â Year ended December 31 Â Â Â 2024 Â Â 2023 Â Â 2022 Â Operating cash flows from operating leases Â Â 3,173 Â Â Â Â 2,530 Â Â Â Â 1,881 Â Â Supplemental balance sheet information related to leases was as follows: Â Â Â December 31, Â Â Â 2024 Â Â 2023 Â Operating Leases Â Â Â Â Â Â Operating lease right-of-use assets Â Â 8,732 Â Â Â Â 9,698 Â Other current liabilities Â Â 2,511 Â Â Â Â 2,404 Â Operating lease liabilities Â Â 5,311 Â Â Â Â 6,613 Â Total operating lease liabilities Â Â 7,822 Â Â Â Â 9,017 Â Weighted Average Remaining Lease Term Â Â Â Â Â Â Operating leases Â 3.30 years Â Â 2.90 years Â Weighted Average Discount Rate Â Â Â Â Â Â Operating leases Â Â 5.24 % Â Â 4.78 % Â As of December 31, 2024, the maturities of lease liabilities were as follows: Â Â Â Operating Leases Â Year Ending December 31, Â Â Â 2025 Â Â 2,917 Â 2026 Â Â 2,411 Â 2027 Â Â 2,124 Â 2028 Â Â 659 Â 2029 and beyond Â Â 353 Â Total lease payments Â Â 8,464 Â Less imputed interests Â Â (642) Total Â Â 7,822 Â Â NOTE 10 -Â OTHER CURRENT LIABILITIES: Â Other current liabilities consist of the following: Â Â Â December 31 Â Â Â 2024 Â Â 2023 Â Employees and related expenses Â Â 16,725 Â Â Â Â 21,040 Â

Government institutions Â Â 2,566 Â Â Â 3,932 Â Income tax payable Â Â 933 Â Â Â 1,918 Â Warranty reserve Â Â 722 Â Â Â 1,476 Â Operating lease liabilities Â Â 2,511 Â Â Â 2,404 Â Credit risk sharing liabilities Â Â 5,507 Â Â Â - Â Contractor liability Â Â 5,101 Â Â Â 5,656 Â Accrued commissions Â Â 2,379 Â Â Â 1,435 Â Other Â Â 2,870 Â Â Â 1,386 Â Total other current liabilities Â Â 39,314 Â Â Â 39,247 Â Â F - 22Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 11 - COMMITMENTS AND CONTINGENCIES: Â Â a. Subcontracting Agreements Â The Company has an existing turnkey manufacturing agreements with three of its major subcontractors in Israel in connection with manufacturing and assembling the Companyâ€™s products. Â The Company has agreements with two of the subcontractors which are renewed automatically every year for an additional one-year period, unless either the Company or the turnkey manufacturer gives written notice three months prior to the expiration of the term of its decision not to renew the agreement. Â Additionally, the Company or the turnkey manufacturer has the ability to terminate the contract at any time and for any reason with a prior written notice of four months. Â In addition, in October 2019, the Company entered into a turnkey manufacturing agreement with another of its major subcontractors in Israel, Medimor (See also note 8). The agreement is for three years and renewed automatically every year afterwards for an additional one-year period, unless either the Company or Medimor gives written notice three months prior to the expiration of the term of its decision not to renew the agreement. Additionally, the Company or Medimor has the ability to terminate the agreement at any time and for any reason with a prior written notice of six months. Â According to the agreements above, the Company does not have a minimum order obligation, but the Company provides the subcontractors a six-month rolling forecast with the projected demand for products. In case of termination of the agreement with each subcontractor, the Company has to compensate that subcontractor for non-returnable inventory, materials in orders that cannot be cancelled and finished products inventory. As of December 31, 2024, the subcontractorsâ€™ finished goods inventory, raw materials and open orders amounted to approximately $43,607. In order to secure these obligations, the Company paid its subcontractors advances in the amount of $13,502. Â Â b. Litigation and contingencies Â On February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action in the United States District Court for the Central District of California against the Company and certain of its officers and directors. The lawsuit is purportedly brought on behalf of purchasers of the Companyâ€™s common stock between February 18, 2020 and December 6, 2023, inclusive. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Companyâ€™s business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. The court entered an order appointing a group of shareholder funds as the lead plaintiffs, who filed an amended complaint on January 31, 2025. The Companyâ€™s deadline to respond to the amended complaint is April 1, 2025. Â The aforementioned legal proceeding is in the preliminary stages, and the Company has not yet responded to the complaint. As of the date of this filing, the Company is unable to estimate the range of loss, if any, that could result were there to be an adverse final decision in this case, and an estimated liability has not been recorded in the Companyâ€™s financial statements. The defendants intend to deny the allegations of wrongdoing and vigorously defend itself against the claims. Â In addition, as is the case from time to time, the Company was involved in various claims, legal proceedings and investigations. Â F - 23Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 12 - SHAREHOLDERSâ€™ EQUITY: Â Â a. Share Capital: Â Â 1) Ordinary shares Â Each holder of the Companyâ€™s ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Companyâ€™s Board of Directors. Since inception, the Company has not declared any dividends. Â In September 2020, the Company approved a share repurchase program of up to two million ordinary shares, to be purchased out of the Companyâ€™s cash reserve and to be paid solely from the Companyâ€™s IPO proceeds. In February 2022, the Company approved that the share repurchase program could also be funded from the proceeds of exercised options. In March 2022, the Company approved an additional repurchase program of up to one million ordinary shares, to be purchased out of its cash reserve and to be paid from the Companyâ€™s remaining IPO proceeds and from the proceeds of exercised options. Â during 2022, the Company purchased 1,077,213 shares in the amount of $42.6 million. During 2023 the company did not purchase any shares. Â In May 2024, the Company approved an additional share repurchase program of up to 8.37 million ordinary shares. In September 2024, the Company approved an additional share repurchase program of up to 7.68 million ordinary shares. Â During 2024 the Company purchased 16,050,000 shares in the amount of $285.4 million. As of December 31, 2024, the Company purchased in aggregate 18,607,829 shares in the amount of $380.6 million under these repurchase programs. Â Â 2) Share-based compensation Â On January 30, 2008, the Companyâ€™s Board of Directors adopted two share option plans as follows (collectively, the â€œ2008 Plansâ€): Â Â a) 2008 Israeli Option Plan (â€œ2008 Israeli Planâ€) allowing the Company to grant ordinary shares and options to purchase ordinary shares to Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 Israeli Plan grants the right to exercise such option into one ordinary share of the Company. Â Â b) 2008 ROW Option Plan (â€œ2008 ROW Planâ€) allowing the Company to grant ordinary shares and options to purchase ordinary shares to non-Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 ROW Plan grants the right to exercise such option into one ordinary share of the Company. Â In June 2018, the Companyâ€™s Board of Directors adopted a new incentive plan (â€œ2018 Incentive Planâ€), allowing the Company to grant ordinary shares, options to purchase ordinary shares, restricted shares and restricted share unit (â€œRSUsâ€) (together, â€œAwardsâ€) to Israeli and other non-U.S. employees, officers, directors, consultants and service providers of the Company and its Subsidiaries. The 2018 Incentive Plan also includes as an appendix a sub-plan allowing the Company to grant awards to U.S. employees, officers, consultants and service providers of the Company and its Subsidiaries. Each option award under 2018 Incentive Plan grants the right to exercise such option into one ordinary share of the Company. The Companyâ€™s subsidiary in U.S. may recognize under U.S. corporateÂ taxÂ laws, a tax benefit for RSU and options exercised for U.S. employees and U.S. serviceÂ providers for tax purposes. Â F - 24Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 12 - SHAREHOLDERSâ€™ EQUITY (continued): Â The grant of awards to Israeli employees, officers and directors under the 2008 Israeli Plan and the 2018 Incentive Plan is subject to the terms stipulated by SectionsÂ 102 and 102A of the Israeli Income Tax Ordinance. Each award grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim as an expense for tax purposes the amounts credited to employees as benefits, including amounts recorded as salary benefits in the Companyâ€™s accounts, in respect of options granted to employees under the 2008 Israeli Plan, with the exception of the work-income benefit component, if any, determined on grant date. For consultants and service providers, grants under the 2008 Israeli Plan and the 2018 Incentive Plan are subject to Section 3(i) of the Israeli Income Tax Ordinance. Â Upon the adoption of the 2018 Incentive Plan, the then-current pool of awards available for future grants under the 2008 Plans was canceled and returned to the Companyâ€™s authorized and un-issued share capital. In addition, any shares returning to the free pool of options under the 2008 Plans, due to options expirations or otherwise, are automatically returning to the Companyâ€™s authorized and un-issued share capital. Â Upon adoption of the 2018 Incentive Plan, the Board and the shareholders resolved to approve an evergreen mechanism with respect to the 2018 Incentive Plan, under which the number of reserved, authorized and unissued ordinary shares of the Company available for issuance of awards pursuant to the 2018 Incentive Plan shall automatically increase on an annual basis, by such number of ordinary shares as follows: on the first business day of each calendar year beginning in 2019, the number of awards equal to the lesser of (i) 800,000 ordinary shares, (ii) three percent of the number of shares outstanding as of such date or (iii) a lesser number of ordinary shares as shall be determined by the Companyâ€™s board of directors. Â As of December 31, 2024, the total awards under 2018 Incentive Plan that have been authorized to be issued as ordinary shares were 8,378,000 of whichÂ 1,397,772 awards were available for grant under the 2018 Incentive Plan. Â At January 2025, the Board of the Company approved to increase by another 800,000 ordinary shares through the evergreen mechanism to amount of 9,178,000 ordinary shares. Â F - 25Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 12 - SHAREHOLDERSâ€™ EQUITY (continued): Â Share Options Â The following tables is a summary of stock option activity for theÂ year ended on December 31, 2024: Â Â Â Year ended December 31 Â Â Â 2024 Â Â Â Â Â Â Weighted Â Â Â Number Â Â Average Â Â Â of Â Â Exercise Â Â Â Options Â Â Price* Â Outstanding at beginning of year Â Â 1,638,495 Â Â $ 4.96 Â Changes during the year: Â Â Â Â Â Â Â Â Granted Â Â - Â Â Â - Â Canceled Â Â (6,996) Â Â 10.17 Â Exercised Â Â (1,003,409) Â Â 2.63 Â Forfeited Â Â - Â Â Â - Â Expired Â Â - Â Â Â - Â Outstanding at end of year Â Â 628,090 Â Â $ 8.61 Â Exercisable at end of year Â Â 628,090 Â Â $ 8.61 Â Â * In U.S. dollars per Ordinary Share Â As of December 31, 2024, the weighted-average remaining contractual life of exercisable options were 1.88 years. The total intrinsic value of options exercised during 2024, 2023 and 2022 were approximately $12,184, $24,819 and $10,549, respectively. Â The following tables summarize information concerning outstanding and exercisable options as of December 31, 2024: Â Options outstanding and exercisable Â Â Exercise Prices * Â Â Number of options Outstanding and exercisable at end of year Â Â Weighted average remaining contractual life Â $ 3.16 Â Â Â 42,608 Â Â Â 0.71 Â $ 3.75 Â Â Â 29,595 Â Â Â 0.68 Â $ 5.11 Â Â Â 65,576 Â Â Â 1.26 Â $ 7.00 Â Â Â 41,000 Â Â Â 1.61 Â $ 9.85 Â Â Â 424,149 Â Â Â 2.16 Â $ 12.16 Â Â Â 18,662 Â Â Â 2.35 Â $ 21.62 Â Â Â 6,500 Â Â Â 2.86 Â Â * In U.S. dollars per Ordinary Share. The aggregate intrinsic value of total exercisable options as of DecemberÂ 31, 2024 is $5,110. Â F - 26Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 12 - SHAREHOLDERSâ€™ EQUITY (continued): Â Restricted Share Units Â The following tables summarize information concerning RSUs as of December 31, 2024Â : Â Â Â YearÂ endedÂ DecemberÂ 31 Â Â Â 2024 Â Â Â Â Â Â Weighted Â Â Â Number Â Â Average Â Â Â of Â Â GrantÂ Date Â Â Â RSUs Â Â Fair Value Â Outstanding at beginning of year Â Â 936,049 Â Â Â 39.04 Â Changes during the year: Â Â Â Â Â Â Â Granted Â Â 716,395 Â Â Â 25.90 Â Vested Â Â (622,799) Â Â 41.20 Â Forfeited Â Â (204,740) Â Â 28.67 Â Outstanding at end of year Â Â 824,905 Â Â Â 28.57 Â Â Each RSU represents the right to receive one ordinary share of the Company upon the vesting thereof. The fair value of an RSU is identical to the value of the underlying share at the close of the last trading day prior to the day of grant. The weighted average fair value of each RSU granted in 2024 was 25.9, in 2023 was 34.44 and in 2022 49.35 based on the Companyâ€™s share price at closing of trading day prior to the day of grant. Â The total fair value of RSUs granted during the year ended DecemberÂ 31, 2024, 2023 and 2022, was $18,556, $24,334, and $30,817, respectively. Â As of December 31, 2024, the Company had 824,905 unvested RSUs. The total unrecognized compensation cost of employee RSUs as of December 31, 2024 is $9,192, which is expected to be recognized over a weighted average period of 0.65 years. Â The total vesting-date value of equity classified RSUs vested during 2024 is $14,215. Â The following table illustrates the effect of share-based compensation on the consolidated statements of income: Â Â Â Year ended December 31 Â Â Â 2024 Â Â 2023 Â Â 2022 Â Cost of sales Â Â 1,833 Â Â Â 2,046 Â Â Â 1,917 Â Research and development expenses Â Â 2,177 Â Â Â 2,652 Â Â Â 3,166 Â Selling and marketing expenses Â Â 11,367 Â Â Â 17,167 Â Â Â 17,302 Â General and administrative expenses Â Â 1,192 Â Â Â 1,735 Â Â Â 2,067 Â Â Â Â 16,569 Â Â Â 23,600 Â Â Â 24,452 Â Â F - 27Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 13- INCOME TAXES: Â Â a. InMode Ltd. Â The Company is taxed according to Israeli tax laws: Â Â 1) Measurement of results for tax purposes Â The Company as a â€œforeign-investment companyâ€ measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. Â These consolidated financial statements are presented in U.S. dollars. The changes in the exchange rate of the dollar, both on an annual and a cumulative basis, cause a difference between taxable income and income reflected in these consolidated financial statements. ASC 740-10-25 prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are re-measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above-mentioned differences were not reflected in the computation of deferred tax assets and liabilities. Â Â 2) Basis of taxation Â Â a) Incentives Applicable until 2020 Â Under the Encouragement of Capital Investments Law, including Amendment No. 60 thereof as published in April 2005, by virtue of the â€œApproved Enterpriseâ€ or â€œBenefited Enterpriseâ€ status, the Israeli Company was tax exempt from 2012 to 2020 for income derived from the Benefited Enterprise. See also note 13a(2)(b). Â Â b) Incentives Applicable starting 2021 - The New Technological Enterprise and Preferred Enterprise Incentives Regime - Amendment 73 to the Investment Law Â On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the â€œRegulationsâ€) were published, which adopted Action 5 under the base erosion and profit shifting (â€œBEPSâ€) regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE (Preferred technological enterprise) or PE (Preferred enterprise) and under the SPTE (Special Preferred Technology Enterprise) regime and determine certain requirements relating to documentation of intellectual property for the purpose of the PTE or PE. According to these provisions, a company that complies with the terms under the PTE or PE regime may be entitled to certain tax benefits with respect to income generated during the companyâ€™s regular course of business and derived from the preferred intangible asset (as determined in the Investments Law) and income attributed to production activity (different tax rate), Excluding income derived from intangible assets used for marketing. Â In the event that intangible assets used for marketing purposes generate over 10% of the PTEâ€™s or PEâ€™s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE or PE will not be required to exclude the marketing income from the PTEâ€™s or PEâ€™s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE and PE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. Â F - 28Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 13 - INCOME TAXES (continued): Â The Company reviews every year whether it meets the conditions of the PTE or PE. The difference for the Company is immaterial since it located in development area A. Â Under the Regulations the Companyâ€™s tax rate is expected to be approximately 7.5%. Â Amendment 74 to the Investment Law Â Pursuant to the amendment to the Investments Law which became effective on NovemberÂ 15, 2021, a company that elects by NovemberÂ 15, 2022 to pay a reduced corporate tax rate as set forth in that amendment (rather than the regular corporate tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company until DecemberÂ 31, 2020 will be entitled to distribute a dividend from such income or to be used for any other reason found by the company, without being required to pay additional corporate tax. Â The Company elected to take advantage of the amendment, and during November 2022 has paid NIS 42.5 million ($12.0 million) as a one-time payment, and as a result NIS 591 million (approximately $165.7 million) of the Companyâ€™s undistributed exempt income for years 2012 until 2020 are entitled to be distributed as dividend or to be used for any other reason found by the Company without being required to pay additional corporate tax. As a result, the Company is required to invest NIS 32 million (approximately $9 million) in its industrial enterprises in Israel over a five year period. Such investment may be in the form of the acquisition of industrial assets (excluding real estate assets), investment in R&D in Israel, or payroll payments to new employees to be hired by the enterprise.Â All the amount that was required to invest was invested in 2022. Â Â 3) Corporate tax rate in Israel Â The income of Israeli companies, other than preferred income, is taxed in accordance with Israeli tax laws at the regular corporate tax rates. The corporate tax rate is 23% for 2018 and thereafter. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold. Â Â b. Subsidiaries outside of Israel Â Subsidiaries that are incorporated outside of Israel are assessed for taxes under the tax laws in their countries of residence. Â The corporate tax rates of Subsidiaries outside of Israel for the year ended on December 31, 2024 is between 15% to 26.5%. Â As of December 31, 2024, the Companyâ€™s subsidiary in U.S has an accumulated federal tax loss carryforward of approximately $203 million and state tax loss carryforward (post apportionment) of approximately $165.5 million derived mainly from exercises of options by employees which provided the Company tax deductions in excess of the actual compensation expenses (recognized in loss), under the Tax Cuts and Jobs Act of 2017 (â€œTCJAâ€). Â Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January 1, 2018,Â have no expiration date, but they are limited to 80% of the company's taxable income in any given tax year.Â Â F - 29Â INMODE LTD.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except for share and per amounts)Â NOTE 13 - INCOME TAXES (continued): Â Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of each reporting date, management considers new evidence, both positive and negative, that could impact managementâ€™s view with regard to the future realization of deferred tax assets for each jurisdiction. Â In the determination of the appropriate valuation allowances, the Company considers the most recent projections of future business results and taxable

income by jurisdiction as well as the reversal of existing taxable temporary differences. The Company also considers the prior earnings history. Actual results may vary in comparison to current projections. Â During the year ended DecemberÂ 31, 2024, the Company determined that the positive evidence overcame any negative evidence, primarily due to cumulative income in recent years, including the effect of permanent adjustments, and the expectation of profitability in periods, and concluded that it was more likely than not that the United States net deferred tax assets were realizable. As a result, the Company released the valuation allowance of $60,129Â related to the United States net deferred tax assets during the year ended DecemberÂ 31, 2024. As of DecemberÂ 31, 2024, the Company concluded that the deferred tax assets for certain jurisdictions would not be realized and therefore reserved valuation allowance in the amount of $4,248 with respect to these deferred tax assets. Â Â c. Deferred income tax assets Â Deferred income tax assets reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Companyâ€™s net deferred tax assets (liabilities) at December 31, 2024 and 2023 were as follows: Â Â December 31 Â Â 2024 Â Â 2023 Â Deferred tax assets in respect of:future Â Â Â

provisions of the Lease Agreement will apply regarding termination of the lease and vacation of the Additional Leasehold. Â 4. The Lesseeâ€™s payments for the Additional Leasehold during the Lease Term in the Additional Leasehold Â It is clarified that the Lesseeâ€™s payments and the conditions of the lease in the Additional Leasehold during the Lease Term in the Additional Leasehold will be in accordance with what is set forth in the Lease Agreement, with the changes set forth below: Â 4.1 The leasing fees for the Additional Area Â 4.1.1 The Lessee undertakes to pay the Lessor during the Lease Term in the Additional Leasehold, monthly leasing fees for the Additional Leasehold in the amount of NIS 17,626 (seventeen thousand six hundred and twenty six new shekels), plus linkage differentials to the Consumer Price Index (General Index) that was published on May 15, 2024 or thereabouts for the month of April 2024 (hereinafter: the â€œBase Indexâ€), all plus VAT as provided by law. Â 4.1.2 It is clarified that the monthly leasing fees for the Additional Area will be paid in the manner and on the dates provided regarding the payments for the Existing Leasehold, as set forth in the Lease Agreement. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -3- 4.2 Grace and â€œGrace Periodâ€ Â 4.2.1 Notwithstanding the foregoing, it is agreed that the Lessee will be exempt from the obligation to pay leasing fees only for the Additional Area for one (1) month of the lease only (at most), which will begin on the Effective Date and end one (1) month later (hereinafter, respectively: the â€œGraceâ€ or the â€œGrace Amountâ€ and the â€œGrace Periodâ€), all subject to the Lessee fulfilling the provisions of the Lease Agreement in full, on time and precisely, to the satisfaction of the Lessor, and as part of this, that the Lessee provided the Lessor with the sureties, insurance certificates and direct debit instruction for the Lesseeâ€™s account as stated in the Lease Agreement. Â 4.2.2 For the avoidance of doubt, it is clarified that the foregoing does not derogate from the Lesseeâ€™s obligation to pay the Lessor, during the Grace Period as well, the other payments that rest with it under the Lease Agreement, including but not limited to, payment of management fees, payment of parking fees, payments for electricity supply, property taxes and all of the mandatory payments of any type for use and/or possession of the Leasehold according to the requirements of the authorities. Â 4.2.3 It is agreed that in any event that the Lessee commits a fundamental breach of the Lease Agreement or any of its fundamental provisions, on any date, the Lessee will refund to the Lessor the Grace Amount in full, plus linkage differentials to the Base Index and plus VAT as provided by law, immediately upon receiving the Lessorâ€™s first demand. Â 4.2.4 If the Lessee did not refund the Grace Amount to the Lessor as stated in section 4.2.3 above, the Lessor will be entitled to exercise the sureties for the purpose of collecting the Grace Amount, and the Lessee waives any claim and/or demand and/or action against the Lessor and/or its agents regarding this. Â 4.2.5 It is clarified, for the avoidance of doubt, that apart from the Grace, as stated above, the Lessor and/or the management company and/or their agents will not bear and/or participate in any additional payment in any way that is due to the Lesseeâ€™s works, and that in any event providing the Grace does not impose any liability on the Lessor and/or the management company and/or their agents regarding the Lesseeâ€™s works. Â 4.3 The Management Fees for the Additional Area Â 4.3.1 The Lessee undertakes to pay the Lessor, during the Lease Term for the Additional Leasehold, monthly management fees for the Additional Area of NIS 3,374 (three thousand three hundred and seventy four new shekels), plus linkage differentials to the Base Index, plus VAT as provided by law. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -4- 4.4 Insurance payments for the Additional Area Â 4.4.1 During the Lease Term for the Additional Area, the Lessee undertakes to pay the Lessor for the Lesseeâ€™s relative share of the expenses of the insurance premium payment that is paid to the insurance company by the Lessor, monthly insurance payments of NIS 0.75 (seventy five agurot) for each gross square meter of the Additional Area, plus linkage differentials to the Base Index, plus VAT as provided by law. Â 4.4.2 The Lessee will not have any claim and/or action and/or demand against the Lessor and/or the management company and/or their agents regarding the insurance payments (including whether the amount is a fixed amount or calculated according to a different mechanism that is provided in the management agreement and/or the lease agreement). Â 4.5 For the avoidance of doubt, it is clarified that from the Effective Date all of the other obligations and payments that rest with the Lessee under the Lease Agreement, including but not limited to property taxes, electricity and water consumption, and any payment to any third party, will also apply to the Additional Leasehold. Â 5. It is agreed that additional conditions for this Addendum entering into effect are fulfillment of the Lesseeâ€™s fundamental obligations, as follows: Â 5.1 Sureties/collateral for the Additional Leasehold Â 5.1.1 It is clarified and agreed that all of the sureties that were deposited with the Lessor in accordance with the provisions of the Lease Agreement, will also be used by the Lessor and/or the management company and/or their agents to secure full and precise fulfillment of all of the Lesseeâ€™s undertakings and obligations under this Addendum, and will remain in effect throughout the Lease Term in the Additional Leasehold, all under the responsibility and at the expense of the Lessee. Â 5.2 Authorization to charge account Â 5.2.1 The Lessee undertakes that the direct debit instruction that it provided to the Lessor pursuant to the provisions of the Lease Agreement will also be used to collect the payments that rest with the Lessee for the Additional Leasehold during the Lease Term in the Additional Leasehold, in accordance with the provisions of this Addendum. Â 5.3 Insurance Â 5.3.1 The Lessee undertakes that the insurance policies that it undertook to take out under the Lease Agreement will be expanded to apply to the Additional Leasehold as well, in such aÂ manner that they will remain in effect and at full coverage throughout the Lease Term in the Additional Leasehold. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -5- 5.3.2 The Lessee will present the insurance certificates to the Lessor by and no later than the date that this Addendum is signed. It is clarified that failure to provide the insurance certificates does not exempt the Lessee from its insurance liability, which is set forth in the insurance clauses and appendices of the Lease Agreement. Â 5.3.3 If the Lessor believes that additional and/or supplementary insurance policies must be taken out for the Additional Leasehold, the Lessee undertakes to take out those insurance policies at the Lessorâ€™s request. Â 6. General Â 6.1 All of the other provisions of the Lease, if not expressly changed in this Addendum, will remain in effect and will bind the parties, including but without derogating, regarding the Additional Area, as applicable and mutatis mutandis, if any. Â 6.2 If any clause is provided in the Lease Agreement that grants the Lessee any right to exclusivity and/or right of first refusal and/or right of first offer etc. â€“ any such clause is null and void from the date that this Addendum was signed. Â 6.3 It is clarified that nothing stated in this Addendum can impose on the Lessor and/or the management company any obligation that does not rest with any of them in accordance with the provisions of the Lease Agreement and/or under any law, and that what is stated cannot derogate from any undertaking and/or obligation of the Lessee under the Lease Agreement and/or under any law. Â 6.4 It is clarified and agreed by the parties that nothing stated in this Addendum can constitute a waiver and/or foregoing on the part of the Lessor and/or the management company of any claim and/or allegation and/or demand of any of the above against the Lessee, including under the Lease Agreement and/or under any law. Â 6.5 Any breach of any of the provisions of this Addendum will be deemed a breach of the Lease Agreement for all intents and purposes and will entitle the Lessor to all of the remedies to which it is entitled under the Lease Agreement and/or under any law for such a breach. Â 6.6 In any case of contradiction between the provisions of the Lease Agreement (without this Addendum) and the provisions of this Addendum, the provisions of this Addendum will control. Â 6.7 This Addendum will only enter into effect after the parties sign it. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -6- Â As witness whereof the parties have signed: Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â Certification by the Lesseeâ€™s Attorney Â I, the undersigned, Adv. Sagi Omer, of 16 Derech Hayam Street, Haifa, hereby certify that the Lessee is an existing and active corporation, and that it passed all of the resolutions required to engage in this Addendum according to its incorporation documents, and that the above signatures are the signatures of Mr. Moshe Mizrahi, I.D. No.: 051825396 and _____, I.D. No. _____, who are authorized to bind the Lessee with their signatures. Â As witness whereof I signed: Â Date: June 6, 2024 Adv. Sagi Omer Â [Signature and stamp] Adv. Sagi Omer License No. 57764 16 Derech HayamÂ Street, Haifa Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -7- GNY Law Firm, Draft from July 28, 2024 for negotiation purposes only and subject to the Lessorâ€™s comments; does not bind the part before they sign it; this draft is not an offer or acceptance Addendum No. 7 to Unprotected Lease Agreement from February 28, 2018 Made and signed on July 30, 2024 Â Between:Â Â Â Â Â Â Â Â Â Â Shaar Yokneam â€“ Limited Partnership Partnership No.: 550014666 â€œOfer Shaar Yokneamâ€ 28 Hakidmah Street, Yokneam (hereinafter: the â€œLessorâ€)Â Â Â Â Â Â Â Â Â Â

avoidance of doubt, it is clarified that from the Effective Date all of the other obligations and payments that rest with the Lessee under the Lease Agreement, including but not limited to property taxes, electricity and water consumption, and any payment to any third party, will also apply to the Additional Leasehold. Â 5. It is agreed that additional conditions for this Addendum entering into effect are fulfillment of the Lesseeâ€™s fundamental obligations, as follows: Â 5.1 Sureties/collateral for the Additional Leasehold Â 5.1.1 It is clarified and agreed that all of the sureties that were deposited with the Lessor in accordance with the provisions of the Lease Agreement, will also be used by the Lessor and/or the management company and/or their agents to secure full and precise fulfillment of all of the Lesseeâ€™s undertakings and obligations under this Addendum, and will remain in effect throughout the Lease Term in the Additional Leasehold, all under the responsibility and at the expense of the Lessee. Â 5.2 Authorization to charge account Â 5.2.1 The Lessee undertakes that the direct debit instruction that it provided to the Lessor pursuant to the provisions of the Lease Agreement will also be used to collect the payments that rest with the Lessee for the Additional Leasehold during the Lease Term in the Additional Leasehold, in accordance with the provisions of this Addendum. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â Â -5- 5.3 Insurance Â 5.3.1 The Lessee undertakes that the insurance policies that it undertook to take out under the Lease Agreement will be expanded to apply to the Additional Leasehold as well, in such aÂ manner that they will remain in effect and at full coverage throughout the Lease Term in the Additional Leasehold. Â 5.3.2 The Lessee will present the insurance certificates to the Lessor by and no later than the date that this Addendum is signed. It is clarified that failure to provide the insurance certificates does not exempt the Lessee from its insurance liability, which is set forth in the insurance clauses and appendices of the Lease Agreement. Â 5.3.3 If the Lessor believes that additional and/or supplementary insurance policies must be taken out for the Additional Leasehold, the Lessee undertakes to take out those insurance policies at the Lessorâ€™s request. Â 6. General Â 6.1 All of the other provisions of the Lease, if not expressly changed in this Addendum, will remain in effect and will bind the parties, including but without derogating, regarding the Additional Area, as applicable and mutatis mutandis, if any. Â 6.2 If any clause is provided in the Lease Agreement that grants the Lessee any right to exclusivity and/or right of first refusal and/or right of first offer etc. â€“ any such clause is null and void from the date that this Addendum was signed. Â 6.3 It is clarified that nothing stated in this Addendum can impose on the Lessor and/or the management company any obligation that does not rest with any of them in accordance with the provisions of the Lease Agreement and/or under any law, and that what is stated cannot derogate from any undertaking and/or obligation of the Lessee under the Lease Agreement and/or under any law. Â 6.4 It is clarified and agreed by the parties that nothing stated in this Addendum can constitute a waiver and/or foregoing on the part of the Lessor and/or the management company of any claim and/or allegation and/or demand of any of the above against the Lessee, including under the Lease Agreement and/or under any law. Â 6.5 Any breach of any of the provisions of this Addendum will be deemed a breach of the Lease Agreement for all intents and purposes and will entitle the Lessor to all of the remedies to which it is entitled under the Lease Agreement and/or under any law for such a breach. Â 6.6 In any case of contradiction between the provisions of the Lease Agreement (without this Addendum) and the provisions of this Addendum, the provisions of this Addendum will control. Â 6.7 This Addendum will only enter into effect after the parties sign it. Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -6- As witness whereof the parties have signed: Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â Certification by the Lesseeâ€™s Attorney Â I, the undersigned, Adv. Sagi Omer, of 16 Derech Hayam Street, Haifa, hereby certify that the Lessee is an existing and active corporation, and that it passed all of the resolutions required to engage in this Addendum according to its incorporation documents, and that the above signatures are the signatures of Mr. Moshe Mizrahi, I.D. No.: 051825396 and _____, I.D. No. _____, who are authorized to bind the Lessee with their signatures. Â As witness whereof I signed: Â Date: July 30, 2024 Adv. Sagi Omer Â [Signature and stamp] Adv. Sagi Omer License No. 57764 16 Derech HayamÂ Street, Haifa Â Appendix A Â Blueprint of the Additional Area Â Â [Signature and stamp] Shaar Yokneam Limited Partnership Â [Signature and Stamp] InMode Ltd. 514073618 Â Â The Lessor Â The Lessee Â -7- EX-11.1 3 exhibit_11-1.htm EXHIBIT 11.1 Exhibit 11.1 InMode Ltd. Â Insider Trading Compliance Policy This Insider Trading Compliance Policy (the â€œPolicyâ€) describes the standards of InMode Ltd. and its subsidiaries (the "Company") on trading, and causing the trading of, the Company's securities while in possession of material non-public information. This Policy is divided into two parts. 1. The first part prohibits trading in certain circumstances and applies to all members of the Companyâ€™s board of directors, all officers of the Company and all employees of the Company and their respective immediate family members. Â 2. The second part imposes special additional trading restrictions and applies to (i) all members of the Companyâ€™s Board, (ii) all executive officers who would be subject to Section 16 of the United States Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), if the Company were a U.S. issuer (together with the directors, â€œCompany Insidersâ€), and (iii) certain other employees of the Company and its subsidiaries who serve in positions that are especially likely to give them access to material nonpublic information about the Company (collectively, â€œCovered Positionsâ€). The list of Covered Positions subject to both parts of this Policy is attached as Schedule A. Yair Malca, the Companyâ€™s chief financial officer, acting as the Companyâ€™s Compliance Officer, or such other person as may be appointed to serve as the Companyâ€™s Compliance Officer (the â€œCompliance Officerâ€), may from time to time add or delete positions that are subject to both parts of this Policy. Schedule A will be amended as necessary to reflect such changes. One of the principal purposes of the federal securities laws is to prohibit so-called "insider trading." Simply stated, insider trading occurs when a person uses material nonpublic information obtained about the Company to make decisions to purchase, sell, give away or otherwise trade the Company's securities or to provide that information to others outside the Company. The prohibitions against insider trading apply to trades, tips and recommendations by virtually any person, including all persons associated with the Company, if the information involved is "material" and "nonpublic." These terms are defined in this Policy under Part I, Section 3 below. The prohibitions would apply to any director, officer or employee who buys or sells Company stock on the basis of material nonpublic information that he or she obtained about the Company, its customers, suppliers, or other companies with which the Company has contractual relationships or may be negotiating transactions. 1 PART I Â 1. â€‹Applicability This Policy applies to all trading or other transactions in the Company's securities, including ordinary shares, common stock, options and any other securities that the Company may issue, such as preferred shares, preferred stock, notes, bonds and convertible securities, as well as to derivative securities relating to any of the Company's securities, whether or not issued by the Company. Â This Policy applies to all employees of the Company, all officers of the Company and all members of the Company's board of directors and their respective immediate family members, including any person's spouse, other persons living in such person's household and minor children and entities over which such person exercises control. Â 2. General Policy: No Trading or Causing Trading While in Possession of MaterialÂ Nonpublic Information Â A. No director, officer or employee or any of their immediate family members may purchase or sell, or offer to purchase or sell, any Company security, whether or not issued by the Company, while in possession of material nonpublic information about the Company. (The terms "material" and "nonpublic" are defined in Part I, Section 3(A) and (B) below.) B. No director, officer or employee or any of their immediate family members knows of any material nonpublic information about the Company may communicate that information to ("tip") any other person, including family members and friends, or otherwise disclose such information without the Companyâ€™s authorization. Â C. No director, officer or employee or any of their immediate family members may purchase or sell any security of any other company, whether or not issued by the Company, while in possession of material nonpublic information about that company that was obtained in the course of his or her involvement with the Company. No director, officer or employee or any of their immediate family members who knows of any such material nonpublic information may communicate that information to, or tip, any other person, including family members and friends, or otherwise disclose such information without the Company's authorization. Â D. For compliance purposes, you should never trade, tip or recommend securities (or otherwise cause the purchase or sale of securities) while in possession of information that you have reason to believe is material and nonpublic unless you first consult with, and obtain the advance approval of, the Compliance Officer (which is defined in Part I, Section 3(C) below). Â E. Covered Persons must "pre-clear" all trading in securities of the Company in accordance with the procedures set forth in Part II, Section 3 below. 2 3. â€‹Definitions Â A. Material.Â Insider trading restrictions come into play only if the information you possess is "material." Materiality, however, involves a relatively low threshold. Information is generally regarded as "material" if it has market significance, that is, if its public dissemination is likely to affect the market price of securities, or if it otherwise is information that a reasonable investor would want to know before making an investment decision. Information dealing with the following subjects is reasonably likely to be found material in particular situations: Â i. significant changes in the Company's prospects; Â ii. significant write-downs in assets or increases in reserves; Â iii. developments regarding significant litigation or government agency investigations; Â iv. liquidity problems; Â v. changes in earnings estimates or unusual gains or losses in major operations; Â vi. major changes in the Company's management or the board of directors; Â vii. extraordinary borrowings; Â viii. major changes in accounting methods or policies; Â ix. proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, recapitalizations, strategic alliances and joint-ventures, licensing arrangements, or purchases or sales of substantial assets; Â x. offerings of Company securities; Â xi. significant new product developments or introductions; Â xii. FDA clearances for new products; Â xiii. significant products being suspended or discontinued; and Â xiv. the Company entering new significant contracts (i.e. distribution agreements). Â Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger, acquisition or introduction of a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company's operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price, such as a merger, may be material even if the possibility that the event will occur is relatively small. When in doubt about whether particular nonpublic information is material, you should presume it is material. If you are unsure whether information is material, you should either consult the 3 Compliance Officer before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates or assume that the information is material. Â B. Nonpublic.Â Insider trading prohibitions come into play only when you possess information that is material and "nonpublic." The fact that information has been disclosed to a few members of the public does not make it public for insider trading purposes. To be "public" the information must have been disseminated in a manner designed to reach investors generally, and the investors must be given the opportunity to absorb the information. Even after public disclosure of information about the Company, you must wait until the close of business on the second trading day after the information was publicly disclosed before you can treat the information as public. Â Nonpublic information may include: Â i. information available to a select group of analysts or brokers or institutional investors; Â ii. undisclosed facts that are the subject of rumors, even if the rumors are widely circulated; and iii. information that has been entrusted to the Company on a confidential basis until a public announcement of the information has been made and enough time has elapsed for the market to respond to a public announcement of the information (normally two trading days). As with questions of materiality, if you are not sure whether information is considered public, you should either consult with the Compliance Officer or assume that the information is nonpublic and treat it as confidential. C. Compliance Officer.Â The Company has appointed Yair Malca, the Companyâ€™s chief financial officer, as the Compliance Officer for this Policy. The duties of the Compliance Officer include, but are not limited to, the following: Â i. assisting with implementation and enforcement of this Policy; Â ii. circulating this Policy to all employees and ensuring that this Policy is amended as necessary to remain up-to-date with insider trading laws; Â iii. pre-clearing all trading in securities of the Company by Covered Persons in accordance with the procedures set forth in Part II, Section 3 below; and Â iv. providing approval of any Rule 10b5-1 plans under Part II, Section 1(C) below and any prohibited transactions under Part II, Section 4 below. v. providing a reporting system with an effective whistleblower protection mechanism. 4 4. â€‹Exceptions Â This Policyâ€™s trading restrictions generally do not apply to the exercise of an option to purchase shares within the period of five business days preceding expiration of the option. The trading restrictions do apply, however, to any other exercise of options and to any sale of the underlying shares acquired under exercise of an option, or to a cashless exercise of the option through a broker (often called a â€œsame-day saleâ€). Such a transaction entails selling a portion of the underlying shares to cover the costs of exercise and/or withholding taxes. Â 5. â€‹Violations of Insider Trading Laws Â Penalties for trading on or communicating material nonpublic information can be severe, both for individuals involved in such unlawful conduct and their employers and supervisors, and may include jail terms, criminal fines, civil penalties and civil enforcement injunctions. The United States Securities and Exchange Commission (the â€œSECâ€), the Financial Industry Regulatory Authority (â€œFINRAâ€) and the Israel Securities Authority investigate and are very effective in detecting, insider trading. The SEC, together with the United States Attorneys, pursues insider trading violations vigorously. Given the severity of the potential penalties, compliance with this Policy is absolutely mandatory. Â A. Legal Penalties. Â i. Civil and Criminal Penalties. Under U.S. law, potential penalties for insider trading violations include (1) imprisonment for up to 20 years, (2) criminal fines of up to $5 million and (3) civil fines of up to three times the profit gained or loss avoided. Â ii. Controlling-Person Liability. If the Company fails to take appropriate steps to prevent illegal insider trading, the Company may have â€œcontrolling personâ€ liability for a trading violation, with civil penalties of up to the greater of $1 million or three times the profit gained or loss avoided, as well as a criminal penalty of up to $25 million. The civil penalties can extend personal liability to members of the Companyâ€™s board of directors, officers and other supervisory personnel if they fail to take appropriate steps to prevent insider trading. In addition, the Company itself can be deemed to be in violation of Israeli insider trading laws. Â iii. Company Sanctions. Employees who violate this Policy may be subject to disciplinary action by the Company, including dismissal for cause. Any exceptions to the Policy, if permitted, may only be granted by the Compliance Officer and must be provided before any activity contrary to the above requirements takes place. 5 PART II Â Part II imposes special additional trading restrictions and applies to all Company Insiders and Covered Persons. The list of Covered Positions subject to both parts of this Policy is attached as Schedule A. The Companyâ€™s Compliance Officer may from time to time add or delete positions that are subject to these additional trading restrictions. Schedule A will be amended as necessary to reflect such changes. 1. â€‹Blackout Periods Â All Covered Persons are prohibited from trading in the Company's securities during blackout periods as defined below. Â A. Blackout Periods. Â i. Quarterly Blackout Periods. Trading in the Company's securities is prohibited during the period beginning at the close of the market two weeks before the end of each fiscal quarter and ending at the close of business on the trading day on which the Company's financial results are publicly disclosed and Form 20-F or Form 6-K is filed/furnished. During these periods, Covered Persons generally possess or are presumed to possess material nonpublic information about the Company's financial results. ii. Other Blackout Periods. From time to time, other types of material nonpublic information regarding the Company (such as negotiation of mergers, acquisitions or dispositions, investigation and assessment of cybersecurity incidents or new product developments) may be pending and not be publicly disclosed. While such material nonpublic information is pending, the Company may impose special blackout periods during which Covered Persons are prohibited from trading in the Company's securities. If the Company imposes a special blackout period, it will notify the Covered Persons affected. Â B. Exceptions.Â These trading restrictions do not apply to transactions under a pre-existing written plan, contract, instruction, or arrangement under Rule 10b5-1 under the Exchange Act (an "Approved 10b5-1 Plan") that: Â i. has been reviewed and approved at least one month in advance of any trades thereunder by the Compliance Officer (or, if revised or amended, such revisions or amendments have been reviewed and approved by the Compliance Officer at least one month in advance of any subsequent trades); Â ii. was entered into in good faith by the Covered Person at a time when the Covered Person was not in possession of material nonpublic information about the Company; and iii. gives a third party the discretionary authority to execute such purchases and sales, outside the control of the Covered Person, so long as such third party does not possess any material nonpublic information about the Company; or explicitly specifies the security or securities to be purchased or sold, the number of shares, the prices and/or dates of transactions, or other formula(s) describing such transactions. Â 6 2. â€‹Trading Window Â Covered Persons are permitted to trade in the Company's securities when no blackout period is in effect. However, even during this trading window, a Covered Person who is in possession of any material nonpublic information should not trade in the Company's securities until the information has been made publicly available or is no longer material. In addition, the Company may close this trading window if a special blackout period under Part II, Section 1(B) above is imposed and will re-open the trading window once the special blackout period has ended. Â 3. â€‹Pre-clearance of Securities Transactions Â A. Because Company Insiders are likely to obtain material nonpublic information on a regular basis, the Company requires all such persons to refrain from trading, even during a trading window under Part II, Section 2 above, without first pre-clearing all transactions in the Company's securities. Â B. Subject to the exemption in subsection (D) below, no Company Insider may, directly or indirectly, purchase or sell (or otherwise make any transfer, gift, pledge or loan of) any Company security at any time without first obtaining prior approval from the Compliance Officer. These procedures also apply to transactions by such person's spouse, other persons living in such personâ€™s household and minor children and to transactions by entities over which such person exercises control. Â C. The Compliance Officer shall record the date each request is received and the date and time each request is approved or disapproved. Unless revoked, a grant of permission will normally remain valid until the close of trading two business days following the day on which it was granted. If

the transaction does not occur during the two-day period, pre- clearance of the transaction must be re-requested. Â D. Pre-clearance is not required for purchases and sales of securities under an Approved 10b5-1 Plan. With respect to any purchase or sale under an Approved 10b5-1 Plan, the third party effecting transactions on behalf of the Company Insider should be instructed to send duplicate confirmations of all such transactions to the Compliance Officer. Â 7 4. â€‹Prohibited Transactions A. Covered Persons, including any person's spouse, other persons living in such person's household and minor children and entities over which such person exercises control, are prohibited from engaging in the following transactions in the Company's securities unless advance approval is obtained from the Compliance Officer: Â i. Short sales. Covered Persons may not engage in short sales of the Companyâ€™s securities (sales of securities that individual does not own, i.e. borrowed securities). Â ii. Options trading. Covered Persons may not buy or sell puts or calls or other derivative securities on the Company's securities; Â iii. Trading on margin or pledging. Covered Persons may not hold Company securities in a margin account or pledge Company securities as collateral for a loan; and Â iv. Options, Other Derivative Securities and Hedging. Covered Persons may not engage in transactions involving options on the Companyâ€™s securities, such as puts, calls and other derivative securities, whether on an exchange or in any other market. Covered Persons also may not engage in hedging or monetization transactions, such as collars and forward sale contracts. 5. â€‹Company Assistance Compliance with this Policy is of the utmost importance for the Company. If you have any questions about this Policy or their application to any proposed transaction, you may obtain additional guidance from the Compliance Officer. 6. â€‹Certification All members of the Companyâ€™s board of directors and executive officers must certify their understanding of, and intent to comply with, the Companyâ€™s Insider Trading Compliance Policy on the form attached hereto. 8 InMode Ltd. Insider Trading Compliance Policy Certification Â To InMode Ltd.: Â I have received, reviewed and understand the above-referenced InMode Ltd. Insider Trading Compliance Policy. I hereby agree to comply with the specific requirements of the Insider Trading Compliance Policy in all respects during my employment or other service relationship with InMode Ltd. I understand that my failure to comply in all respects with the Insider Trading Compliance Policy is a basis for civil and criminal penalties and Company sanctions, including termination of employment or other service relationship with InMode Ltd.
Â Â Â

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

ZAHNG:YIUR9#7K,\ @>R]%\6ZQHWQOM[CPO\ M(_#?AB#P]JL<%GKGQLU/P]I[V=OI=Z\MO/%\,-*_L]]8\5^(+FW::'2]JZS<::VFVG\Z\9\;Y)E&?X/./$'Z'OA%FO#^!Q"Q&!\3N"\US[
M(N%JF'^NJM+-HUN%<^P>68?%X[%U\1CJ66U,-3QN(JXAX:&#KNR?5@N , _R/ M,\LQM'.E5G&68U*6)=3G5_9X2G6J8RI.7LX MT^:1B?!G]O[X0?$V#2+'4;+5?!NO7L:^9INJPL0&MH1+-
>6%S<6NFG6K*!(W MF<^%H=>DTVRC_M+6XM*TFVFN]/\ W(^"LMO-\\ 19[2=;FWN?MMQ!<1R1S0 MW$$M]<-#<0S1(L71[?PQ?\ A6]G
M$;Z=]>D:A<1:EI]YID4*:7J/GM:X34(OL=M=FZFA%U9W]JM[97EE>VEO?!?A3Q9<:9>ZYH=[XRLYM1T5KX:5JEF_C77;C2]3@LKY$ M&BSWVER65S>Z!I<5KH.AWLMQHVB6=EI6G66G:?\ T+]
>I]%GBGQ3XDXQ\"\ MKXE\/N*UO^->*%/'T:F)C[6GB\DKYSBL35EE;DGA\5@J8_E>;9?T%5_/K_P5A&?^"C__ 1"XSC] MK#Q,>F[;GP3J)SCRYMN=F<[8,[-WF/Y7FV7]!5 \Q.K C_@Y0L,B1=_P7\9
MXPFY9 /AO^Q\<$^2^$!C+9W?ZR$'"^7]HL_VO^.C)_PF%EDABNAQ,QE0(PID MD(>3-HNPG;GED *]4\O-G^*&JJ3 _ ,'*-A@.N[X*-#D@%)0OPW_ &0'(W-" MP5 (MP&\EIX!M 8":T^Y/^"@/[5\/P
^+EMH&H:5X>UB"]^&&EZ]80CQ);V _MB7[<==USEO-:TNZL=/T;PYX11;&$?\ "7:WXITZ*ZU%'T;1-,UK55CM+;^/ M?IV^%/$GC/\ 1]SO@_A3$9/ALWIYUP[F\7G>81RS!U<-E6(=;$4H8F4)Q6*G
M"2]A2DH^UDG%2YG&_P"@>&6"Q>8\783!X/#5<35K8;%<_L_9QAAZ$<.I8C%X MBI6G"E1PN&HQE5KUJLX4Z4%SS?*G?V6-E9=L:[B@Q(%5CG_6$858(RJ*H^;" M*$*2,WE"-EM^7\;>-
_"GPX\/ZCXI\9ZK:Z#HNF6\]QH:=X6L-0^RQF.*U/PR@\ M%:C'=N&#S"+Q=X[\6: $V&)MZ2?#:U51&6W01QI(]3TKQ%% M\-]6U36-
+NDO++4/B/X[^#%S=64J!#YNFG0/AMK4UA<%,".5(A(C*718Q; V M?^5'"G[,/B2M3P6<>('C#X7\+X3E>(Q.31XER \ M2M>DI+#2Q&+QN6C.I M.,)XA87&J-.3MA<5)6UU72_@EK?PD\7:;X?
TS7X8H(6M+OQ'J&C:AX]NM)GC2XLK6;3H)([. M>R==._2E-%UGPD#-X3B?5O#SF.2Y\)7DJ0W&D@3A_-\):Q-$C6D44!O[Q_#6 ML-<:5-,MG:Z/JOA33[1X% _;2OVUOCC:7.D3>//A6FJ0^&?
$UKXRT=_#EMK7 MBW4#XEL++4](COKJ?3_#W@'1PT&EZIJ%M%'<6-U$L7G>;9AXA_9OTG# _,%$ M?$:B:VM+*W;Q'\.=19U6:,4?!$^KW<\9W1K<+!]JOX+\.6+*T8,5Q+?W4<16 M(-'NC7[-]
[QA]$G/>+I\#<, \1@\'\#DO#.2YEPYB5B\RS7.-=4\-ZA;P6?B2TTVZUB(1ZKIOV MF.*[\F+3/$.G,O[C9&I^/-.MF6Z\-Z+XBNHPP9_#VL'1KF[$<.]2 QZ+XBLX
MK.S.;/3K*&.3Q1=J\]S=332Z?!8&&#\]M5^+_B;QA91R7OQE^+&N)33- M,\)?#:YMD2(E@J67@SX/?$RZMW22SB>WD%^9H;B!' BEMT6TXB&_UE+HW5GX MV_:=F1&N'2/P]+\5?"]H\K0:;;
(DH_X5=* "%D(&T^*-9KN]TY$B1H5GL=D M\5O58SZ!W"4Z&&H9AX^9)FM'#*-T\3P!F6=4,-2H\GLJ&!XDI<7<(9U+)/ MDH4L7452FH7A*
[G*ICAN%^/<3*,:7#&%="5K5UQ!E]2@_=BVG4H1K4KK;^)" M3^Q[1.7+^MOB6#Q=?WT>H^&O"&L^'M;@CM[>UUO4==\-IH>HV2M<7)M?$.G: M9-XDEOM-,NEZ2S"._D/AS^R_#YE@4K.?
%EV_EET:'0_"WBK4 M? GA^8ABEE?ZAK7C%A,CM<^';]I ^G6/!7 !/S]I3X[WL.I?%WQ.?AEX5\R: M<&]EO/%OQ0U99&N'>&\US6?,NM+M(O,3;I6GS:5H$86;[+H=EY2_8=*_@;]& MCP?
IY9F7B)XRX#B3+\H3KX?#9!P?/ASB:E4HSC5HT,IS<<\9XZGAZDYRIS MA@\KJ2I0E.>6XK+*[^L1ZWEU#):=*KQ!7PF8YBIQOD'#68?7I2H4
ML!@:MZ6'>8XISOSTZ;BI2*^./[8WC7XCW$GP_^%5M=VO@J6X6SL_ASI$\ MDOA"SLYAJ3W!\0>*;":#4IEN;^]LF'PR^&6K:WX86"Q70M<\:Z5!YNDV7KO[M,'_!-[6M9U2T^(W[1?
AGQCXHTXQZ?JUAX<@U7P[97GB VUL]WIT>J6=[JGA, M:'I-FD-MINBZ!HVEZ;IFDVUW:Z?I.GZ5I$(XI(O+=);74K.*RN-+D28&6-K:6.\4JC"X#6=E_9GT!)X#
ML#+YD&N^.+=&N(97AB\;>*VMG\BZT^Y2*..]NKEK>W/V2.%XHF@5+..]LU$, M9)L/F/%C]H#PWF'##\,/ 7(GX7<%>RG2S7.<3E>*K<6<1IJ"J8K%Y[E>98#% M1Q.(J4I59JU#VU1SM5C5K-
U3SLRQN8YM[&&,]E2P.&?M,NR; TWA\JRV_+S MM4TYSQ>-Q"C!8K,,9*MBJDTHPK4Z*5-4M&M+OPUI6G^& !GPZ@\,Z)H=B+'3
M;+4M5T/1M$LHX9KY%@MK3PZ_B2ZCV&VM;FY,EK;&5;S?/=PW]I=V]FEYIT<9 MM[[XBZS9ZH!<^98^&-)L)K/03=D/;_N=)C;4=8\5W\'VJ:)9=1VZ7$@MM73P MKHU]91SV6G9^
=#MHE%S>>*M8.R-4;6_%_BK4%S&NGQJ7MGU&*R1P=.M)F+6 MJE9?M,H6-I+AHNILM/L;'*V=G!:*Z#*6L$=H)53++YWDV\6TK(\C[&PQW2<< M5 MG_G5C.)\ MQ)I>]JX,TN7PQ-)877V35?
&^G,^HRW@MKJ*.RL-!FVSP21SK8R1ZQX@_T%[9 MYQ!HU^L$1M _ P!D3XPV/QV^#&C>/['X=>,_A?/-?WNE:SX:\;K=W.JMKFEQ MVO\ :MY8>(-31=3\2Z5&?%)O/!7A
MG9J5KXQLI8;&^6%/#MS''|O\2:7-H:?\(O<6$^FZB\EU>Z7+,;>_FA@[\%Q1 MD>;<+YSP,N'/@,QS7.,HS/(L_P^9YI*O3J8/"YG3QF3YG0G[6/$-3B/&8S+ MJ>$Q>92P^'X]=I7OVWZ$/C7X6^!/B'
M8BP\7^%/]ULH/*@O9X?*U2S&X'?9:K L%_IKV^UWCDLKJT\O'WHA#"UI^>_B MW]GOXJ_LOZO)X\ 9YOY_$7A=Y+B[\0^!;S3;A+.= R2W-Y);29;SIIVHS;)[MBY\3:/HAY"M@R2;X\@;M8 M1C(\Q
P98(RI!A9HV4KB1]V$\EA:7X=^,7"'A3C<7EV"Q$,QR/$2^H<1\$<0 MPAFO#^:4(OEJ8/&Y?B8RI4ZM/F;IXB@HU*$U%WE<GR1]K)^(,PRBM.6'K4*^
M%Q,80QF7XRA/$8+'44W)4L51YE&4=I491Y,1AZCC7H5:->,)KY)^!G[67@7X MP&WT6_EE\)>.H8([F_\ "FNVL>GWWD_,BWFGO$K6&H:0TJ/#'JVD75WI@9'C MGNK&\CDL=-_8;X+I&/ .CNN-
Y;4=V!\QWZE M-/%7&'AU1S3@[/L1XKU K3S>C3Q.3UKXG#T'4PF+J3K83, + MJ4Z$9Q]FL/BJ4<1!3IR]MB/WE0^KZ***_P!JC^;#^?;_(*P?\I'O^"(@"@D
M_M8^(F8X+$!/!&JE00%F4#YG8,R1$%24E8*\EI_037\^O_!6$9_X*/\ _!$+ MC./VL/$QZ;MN?!.HG./+FVYV9SM@SLW>8_E>;9?T%4 ?S%:LNW_@Y0T]RC8D M^"WC50"-ZR$?
#;]CXY(6(M'&FT2(2Q1I[?.("WEL_P!R/V@_V//A!^TO-;O\ M3=+N;R""72)I[?3FLK-]7&A+JATRVU:[^Q&_NK2VEUB]>*S^VQ0HS"0.KE#! M^&^K*&_X.4M-W1\CX*>-BA9%VN1\-?V0V+;Q#D;
&<*$R,S2PJF"@#VG].M?. M\4<)\\ &>6_V-Q+ET&MBL*N;#UHUL%?P}>Z4I2<>6K& MSM+=)G9@LPQN6UWB,#7GAJSIRHN<%"7-1JPBJM*4:D9PE"I'W9Q<;2BVFK,^ M)#&_ &!_V=?
#5FMGHG@'P[8PQQB%%C\,^%WE,0CCCPUS)H_VAR$BB&3(ID*, MQ:)G@-GU]G^R+*=/D,MCH]G92, &>VTK0(6/[Q9 2T.BQME'Y 0QAA$H'EA MH!8?5-%?B6)^B+]'/&SG4QOA=D^-
G4;E.6+Q^2I5Y2E+63E*IFTI2;E[S;;N_ M5H]F/&'$\%RT\ZQM.*VC3]*"6G+]F*Z)+LK*UK'SQ#^SIX4M5\NUO+^WB7A8
MH1ID*;6;>=PATI,E&:39VVLRKY2&*.VIWW[,'P_U*)H=2BFU")EVNMY;:/<; MQA5Z2Z40I5=RJ$,.*J1(NQ%06_TG17)'Z&OT8824H>#O"U.47>,J?]ITYII) MJI#,%4O9;N3;ZMBCQ?Q-
!R<A\M>2[UUU;N][GPSK/\ P3Z_9V\1 M/YFK^$+5Y 0Q>WM=-LP[!YV7_CPLK1D\N24R((_+^]E3&QC%ES$?_!,S]F"'
M++X9U9\.2(GUR^,>W(RL<:W$<*,PCB975(V1X\QM"#%]F_0VBO!):VFC++D/(&RU\=.%X^SRT:)6G MW$#,2LHL^Z_X9 \ #Y+,=7U8,[*SX:Q^8[47=E=/3&P#:$ =4PIA#Q"T]^H
MKP<7]#+Z,&85IXC,/!WA?'8BI)RGB,9/-<17DWT=6KF,IM>3;,WQ=Q(]\WQ; M]73?RU@_/; *W@1^ /AX!L:KK#=FP-M;;Y7G1?84;]G[P^0P_MG6,$]0]FC$<9 M8&.S5HR 3\L;#)!*R1&2/[)
[_11_Q)%]%'9>"'!Z\^7-&/UZ-YBVGZ?GJ]/_6W MB3_H;8G[J7_ROY'QEXA^&'AWP%XET.VU.[^*7B.T^)WC*+P_I]U8Z5IFJ^&_ M FH_\(E-/;C6;K3=*@U'0?
#6L7'A]HTU6[BO])M_%>L);R76E1:Q$EAZ?_PH M/PY(%8:MK)+N1NLMJ[#@@YT] '7=@KLB=V5P1'F/[%R?[0G[2?ASX%^)/AQ MX3U[PCXP\0M\59M;L:;4O"\=A':Z!'IVJ^!-!DN=:U2^N--
ATB&:Z\9V+VUZ M]^KRO8R:?IOVSQ!>:'IDOE_@#]JWP9\//A!\#I/B#?\ Q=UK4?'G@_0]8T?5 M?%/A1M0\:WV@:B\8TC5O'=SI.CZ5IO\ ;HTI/^)S-;6=ON>%O#=KX4T>VT6SFN+BWM#((IKI
MHGG<2OYKF0PV]O&#YC/PJ8V[>0H2./Y%M/V^/@=10_$66WU25X=-D?P M3?1"_P#L_@;3_B+?RVL,JV]Y-]@\'WUKK,RI;;F6[>VC1KJRU&VTKI?'W[9_
MP:^&GB2\\>*KCQA%K>G:KLVVTKV5M4?7%%? MY_P %$_@+I>HSV^I+\0K73H]. MU75(-5D\#Z]+-K/P[:7-[KDU\#9HVG+#%IUV+9;GRS<@FY4Q6 ;GP_P"/%U+7+[X>Z?X?
F71;1H=4;QTWPS,NH3-YZ+IFD^'8 BEX M8_MFXU(V=QYR>(X[&TN1I 4Z- M5+F]G+E[VTZ7U\KJ_;J?EQ_P5A&?^"C _/P1*XSC]K#Q,>F[;GP3J)SCRYMN M=F<[8,[-WF/Y7FV7]!5?SZ?
\%7_F_P""CW_!$$@$C_AJ_P 2M@J25SX)U Y* MF.4QD[B^8VZXMU^4_ZRU_IUK^8O5UV?\')^G/@D2 !7QJ,8+!F'PW_8_P#O M 0[D1=BRH=[1M- "23'(]C_3I3>__@/_ *2OZZ?JV]__ '_ -)7]=/U9111
M2$%%%% !1110 4444 %%%% !1110 4U^1_P)#^3]<_=;IC.<#'7N+35_$GP0_9NUQ[2]L7TS2M=U1[C3O#Z?V+X2 MN-:U&'4;FUOM3;58/$VGZ_/:_9;G2;&.UM/#\,WF7-O_ &_X>[C\0>*/VL&\
M+^%)_#7PG^%T/C#_ (1^<^.[7Q)XF<:'<>*+9 "$!CT"2SOC<6_AF2VU'QE< M6UWJ8N[6+6&F7>FZ?;W\>KZ;\D:C\,/V%?$GFZ!>_M,^.M1;2 $FG:->VA M^*FHW,FIZWX(NV\.SZ7?
Q1Z"3]DUQ>ZT(=6E@1SXBU9]4O\ [9?']Q'JNA:[!]>CP>*;VT\/7.@7VH717D%^LGB>_O(I)K/Q7>PP1S"X^U6\MJNF6^F-?$V4-Q8W M<&I:E"'O;&W\+6LL&L?MG^&X-0NKGPC\";;2$TS0-/\
"VAR7DGAG3K+5)] MTZ*1K9;;6=0#7D7BEH?#%O;R:WIMI]#_P!C)I/]F&Q$K>!VUM^Q5* &VL^ M+[OXX_%/3_%'P?U8(+KPCJ_BV_M5O)?%/A^#QU9#2?!LWA^P6_M]6T?S],T
MJ*QKL[JNFZKX48V<>C_V;HOH7P;_&4_V=OBMIWA7XD>]B7\9?P%^F>$_B+; MZX)/$'C9ŸX+GQ=X ^(=YXJ_LW7-+N?#Z1NND>+(G1].@-JFFVL;-78OI=P4) ML(J>QNŸRI*-*5O?
^I5(N27*X]\ZK25U>K>KU?:^B7DEHET22//>_?I? MR6B__F(UD9_X.4-*_=8Q\&/&A\PIDN#\-OV02""+:0;5*$ EP^Y')DVQH]G M_3J&!8KALC/5'"\!"<.5VG[XQ&\D.!DQN%_#O]KW_@D-\6?CY^V
_P"V7\!O MV[/$/[*'Q(DT*^\-E] ^ OA?XFWD>CZCX3^&/ANZM+?5?$GCS1K>W\VX^&&F M:HUQ'H@O,7LM@ERD5NDTG! \.K/^"I&% P"-\?QD^4 $_P##(/PIRY!4DM_Q M'XQMM7:
<_L@_"KYS\OSMCXDC##!X3:GS-E?N[47_ ()6?\%2%(S_ ,%X M_C(&,-^R#*<$X09.WXD*RHV M-\P^1]KGYL+\K8 P.W ;YEW#*.O'R_>RHV-\P^1]KGYL+\K8_?\$K?^"I MVY_X+P_&-
MJ[3G]D'X5?.?E^=L?$D888/";4^9LKJW:#_@E;_P %2!MS_P % MX?CĠVU=IS^R#*OG/R_.V/B2,,,'A-J?,V5^[M /W_# [/_A92KD_,K^5Ÿ197(R"L31O_.'5 MW_!4C.1_P7A^,,."V2&_9
^%APNS&U"/B6N/F RHV-\P^1]KGYL+\K8 P.W ;YEW#*.O'R_>RHV-\P^1]KGYL+\K M8_?\$K?^"I VY_X+P_&-MJ[3G]D'X5?.?E^=L?$D888/";4^9LKJW:&_#J MS_@J.0%/_!>+XR$;"C?\8A?"Q2Q(
WED^)2LKC!P8R@!8D+D)M /Z P.W ; MYEW#*.O'R_>RHV-\P^1]KGYL+\K8 P.W ;YEW#*.O'R_>RHV-\P^1]KGYL+\ MK8_?\ !*W_(*D#;G_(+P_&-MJ[3G]D'X5?.?E^=L?$D888/";4^9LKJW
M:#_@E; P5(&W/ !>'XQMM7:<_L@_"KYS\OSMCXDC##!X3:GS-E?N[0#] P , M#MP&^9=PRCKQ\OWLJ-C?,/D?:Y^;"_*V ,#MP&^9=PRCKQ\OWLJ-C?,/D?:Y M^;"_*V/P ' !*W_@J0-N?
^"\/QC;:NTY_9!^%7SGY?G;'Q)&&&#PFU/F;*_= MVHO_ 2L_P""I"D9_P""\?QPF)V>6W_&(GPM4.-S$OA?B6 D MF-HWQ["/WG',(@UHSC3DY2@JB:LX.4HMZ[IQZ][:NTM-;WTUISC!N4H1J:64
M9.4=;5&+56ODVD[6=[GTBO[2'BRVO-?\4>*?V//'5AX4N;;0]$^X+/3#IEC=WCPW=F+JR]4O?B% MKGBSQ\ #/2?#'[.BW7A3QP"OAS5_&WC"_P#A9H^H^';GPIJ_P5\5>-KK3-#\ M2Z?
JFIZ5]MD\3Z%X(\'DS@V$-PT^C_VE&/[#U>Q^&1_P2I_X*C ?\IX/C%DN M[O[(?PQ4R!@RJ&Q\4,;D4@!L8^4;501P"%/^'5/ !4DD$_\%Y/C(<*5X_9 M"^%R;CAU#ML^)@. W6,1C=\X
98#!T3Q5.S]GA5%VLDZDVM6O[R=^56*6E&*WC\4VU&2L_M^\U>^LK.WPZV/K?0_C?XIUS4_"UUXD_9&\=O;^ M(_%MSI.K6MY^SY-!?Z+IK:GI$/A'7M7NKNY6SA31/ ^12:7J- 8:G?1VFJ:3 MJL4-
I]FL28/TVT;1-$T&*>WT/1M,TW6WNYS>30Z5IMOIL5Q<&&"][JYAM+:VC M-VR)'$RAIWBAC4MMB$<7X*+_P $J?\ @J,IW?\ #^+XS[C]\K^"HX()_A+Q?&1OEVD-?R%*\'
M&,,0OQ)&&X8Y7:#O(((6,)A4J^UC"\5!QYM%.Z>A6_X*O_ #_\%'?^"(3!*C]K'Q, M 6B< ' _A![Z0X#Q28(4H6PL)!7YG9HB]C_077\ '@G_@C3^U3<_M(_LP_'[] MI7_@J;XU_:@L?V7_ (JP_%3PIX%\6?
LO^ ?"37>1#1=4T2\LK7Q?H'Q#N-4T M5+V#4B\C_8M4LE,?_(*>9+*>P_H'K$Q^BBB@ HHHH **** "BBB@ HHHH ** =** "BBB@ HHHH **** "BBB@ HHHH **** /_]D! end GRAPHIC 11
image2.jpg GRAPHIC begin 644 image2.jpg M_]C_X 02D9)1@ ! ?0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$!

M0_X\KCM^[;G*^3/@_|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|H%?6=_||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| V:O:O%-N6OX)?-C"A1E7'/YUP9FOW#.G"+]XBA)"/:KTVM^+K?49YK>SM)+;.U?FXQGKQ[4 ML>M^,90BR:%;D,A8N'XSFM9*+5U%?>3=K

O&<3H/[#C.Y>&W<$^]+K>J M>++.ZT^[M+5ID:WS+;*JR'U/M7;W2?:K5;>>46\[H,A?7OBF1VH,(MYY;=E M'"_/FL7-7^ T4-#*T#5M9N=,S?VB&[\UOE#@?+VQBNEB:XGMF#AH'QP&YQ6< MVFZ:[HXD$4D/1E?%2QW,41,;Z@F.S,PK*4&W=(MQT]U ;:[1T%S>,ZGL(ZDO MKFYME6.VC4L>%9S@9JO)]=O$S>=J<3)_" :JR3:3<2))<:DLF/X-^!4NG)=! MJ+W:)H4U$31_:9-COU,2Y%9?C?PFGB/P_ZI+&DY4@C&00>*WEU[3X=J_M:XSCISG%8VK2:9>NLR7\,4JONW%B?TK2/M(M2BM@Y92=I*R,[P+%J6G^&/[* MMP)=0TUS!*;ER6/H?IC%=1:W=X(\7RIYO3]V"1FN+U*Z33?$5OJEA?B>.Z*V MUXF>=O9Q]*[==9TQ$"?;HCQU8U5:$I/F2W$H2C'EL.OX]JK)-<-#QTSQ44$OMF#;#=Q9[Y.2:J37>GS3<:M$ZL<['P0*O6LEA"A9JFR([,I%<[A-;H-8Q5S6T MMY8O#E^V\%U+891BK&F:!8/X=%LD*Q)=QJTY08,A/4GUJE;W22>'[A;7,[7# MF-/*&1D^OI73:?$UOIJO%)]](U4_4"OJ\&FJ$4^QXU?^)*YQC_"OPVSS,L,R M"9 C*)#C .>!1_PJSPX+H3K'.&4J0/,./E-:GB;Q9#H6H0VLT+/YD?F;E/3G M%,@\37T\:R0Z)AY-:VE>!M&TW5(K^VB;SXF=D+'.-V M,_RIS^)YXO\ 6Z/>#Z#-1?\ ":VZ_P"MLKQ/7,1I>UB%T=917+IXUTICRTB_ M52,5=M?$VDW/$5Y'D]B:%5@^H+?_V:NR^,81O$%MNSGR>!C-<^*2=,]7)TGBE?S//TN)PV5NRWU8U: M6ZO%7_6CGNK&J97:>80WL1BI8IXU;F' ^A->99'V3C'L6?[4OT^1)B/^S-'*B>2*UL%M<2V_%O>D?[/)_ MG5DZC>2-\U[+CT#8%46CD+Y&#G_8QBI8MX7#1KGWJ>2+Z Z<7K8F9I6&][F0MD=S(:KK-*C;O.+#_ 'R<5*RD]?*/J >E12$IS\J^F!5)(%&/85[AW7;YSKGK MC)] PHW61V/7/-3+O?HS'_@-.7S%'0_4T*P^5=B,6L;#[Q!JZ=@P<1A2/7 JM7+DP6&?:9R>5'T"BNE8FIC6Y)Y_[.D0(0/*##@>N:J&CT,ZR]W;[BK''X@C9QYT)5LX M(]<4LD7B-6F$!CD7FFW\4'S,2#!(*X4<>M-%GXH9E=Y$+HK;><F0W/V*#^T3&;D+^\V MC@FII9$W<$C'H*REJ=M-)12/9?@^#_PB[$_\J6KN?X?2N(^$1W>%SU_UK8S7 M<=N:]6C\"L?#X[_>)^IYOXR\,ZKJWB,W,,2/;;513NP0.]>@V4/V>U@B_N(% M_(4R^NOLD8;RI)KO*!^E.,%%M]SC22=S$-.',LD\ZD='D.#2_P#"%Z$6W?8@?JQKGG3JM35M"))L\MCE2V<,D]RV.^[;FMNQ\97=F5)^>-1T9N37H,'AC1X/]78Q?B2:M M0Z-I\)_=V< ^J UG'"S3^(E4WW*UIJD&IZ*\L4L;,T+,55LD<5\N_" 8_:4;M'3;<_P#H%?5*^5/A!_R]:[X4T[7+B.XOEA+TBD_%J[*BI]E#L M;?7<1_.O.0_X5]H7'[A_P#OJ@?#_0QTAD_[ZKKZ*/90[!]:)C&R;'^_3/^%;Z%NSLF_[[KM:*/90[!]< MK_SO[SBQ\.-'"_+.;_OJG?\ "O-#_P">4O\ WU7944>RAV#ZY7_G?WG%_P#" MN- /6!S^-/7X>Z$%P(' _.^J[&BG[*'8/KE?^=_><;_PKS1.RS#'3YZ/^%>: M'NSLFS_OUV5%+V4.P?7*_P#._O.07P!HRGA)?^^J0?#[0^IBD/\ P*NPHI^SMAV#ZY7_G9GZ-I5MH]K]GL4*19R0>:TI))61SRDY.["C HHIB$P*6BB@ / M2N ^*QUR^M;31_#%RD-Y=/\ O3_$(P1DY[5WSD*I+'R:YCPNIU#5M3U<@F M&5O)@+==JJQ[&@B:YERF]IL#6VGVT,ART<85CZG%6J**"PHHHH KZA_QXW'I MY;?RKY,^$&?^&E&S_=N?_0*^L[_(\KC'7RV_E7R9\(/^3E6_W;G_T"@#Z[MHHHH ^9/BX1_PT5H>>A6W[?[U?32_='TKY:^.6I6^C_'C3+^])6VMXH)'8#/ M W5W_P#PT1X."CFZZ?W*/9Z*\9_X:(\'>MUG_MUG_ '*/^&B?!WK=8_W*/9J*\9_X:(\'=,W6?\ ST5XS_P -$^#L\FY'_ */^&B?!WK=8_W*/9J*\9_X:)\'>MUGO\ M)2?\-$^#L\&Z_P"^*/9Z*\8_P"&B?!WMUQU^2C_ (:)\'>MU(?)0![-17C/_#1/@WUNO?\ =T?\-$^#O6ZS MV^2@#V:BO&?^&B?!WK=8_P!RD_X:)\'>MU_WQ0![/17C/_#1/@WUNL?]S45XS_PT3X-S]ZZ_P"_='_#1/@X][K/^Y0![%/)Y4+R$9"* M37&6_P 0;1FQ=6MQ#DX7"EL\XKCS^T1X-(.3,-)MK5;6VMKI(X0%0>63P>F:X*X^ M.O@&Y51-!(RJP9?W/<5,?C]X'.P:3J$>I6BW$*R*C$@! MUP35VO%H_P!H7P7&$^T*O;$=/'[1'@[_IZ]_DIFBOU/9J*\9_X:)\&_WKK_M +]T?\-$^#O6ZJ_DH&>O:A_QXW'_ %S;C*^3/@^,?M*-Z[;G_T"O4;G]H3PM=+;RH&N070J"4]17DOP/O8=1_:(BN[5BT$T=PR''4;*3 ^Q****8&7J7AW1] M4N//U'3+.ZFP!OEB#' Z EX-101.SCH 14 inmd-20241231.xsd XBRL SCHEMA FILE 0001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 0002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical 2) link:presentationLink link:definitionLink link:calculationLink 0005 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:definitionLink link:calculationLink 0006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 0007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 0009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 0010 - Disclosure - GENERAL link:presentationLink link:definitionLink link:calculationLink 0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 0012 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 0013 - Disclosure - ACCOUNTS RECEIVABLE link:presentationLink link:definitionLink link:calculationLink 0014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES link:presentationLink link:definitionLink link:calculationLink 0015 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 0016 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:definitionLink link:calculationLink 0017 - Disclosure - OTHER INVESTMENTS link:presentationLink link:definitionLink link:calculationLink 0018 - Disclosure - LEASES link:presentationLink link:definitionLink link:calculationLink 0019 - Disclosure - OTHER CURRENT LIABILITIES link:presentationLink link:definitionLink link:calculationLink 0020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 0021 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 0022 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 0023 - Disclosure - Segments link:presentationLink link:definitionLink link:calculationLink 0024 - Disclosure - ENTITY-WIDE DISCLOSURE link:presentationLink link:definitionLink link:calculationLink 0025 - Disclosure - RELATED PARTIES link:presentationLink link:definitionLink link:calculationLink 0026 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 0028 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure link:presentationLink link:definitionLink link:calculationLink 9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960703 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 9960704 - Disclosure - ACCOUNTS RECEIVABLE (Tables) link:presentationLink link:definitionLink link:calculationLink 9960705 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960706 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960707 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:definitionLink link:calculationLink 9960708 - Disclosure - LEASES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960709 - Disclosure - OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960710 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 9960711 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 9960712 - Disclosure - Segments (Tables) link:presentationLink link:definitionLink link:calculationLink 9960713 - Disclosure - ENTITY-WIDE DISCLOSURE (Tables) link:presentationLink link:definitionLink link:calculationLink 9960714 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960715 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Estimated Useful Lives) (Details) link:presentationLink link:definitionLink link:calculationLink 9960716 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details) link:presentationLink link:definitionLink link:calculationLink 9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Accrued Warranty) (Details) link:presentationLink link:definitionLink link:calculationLink 9960718 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities) (Details) link:presentationLink link:definitionLink link:calculationLink 9960719 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets Measured at Fair Value) (Details) link:presentationLink link:definitionLink link:calculationLink 9960720 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on Maturity) (Details) link:presentationLink link:definitionLink link:calculationLink 9960721 - Disclosure - ACCOUNTS RECEIVABLE (Schedule of Accounts Receivable) (Details) link:presentationLink link:definitionLink link:calculationLink 9960722 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Schedule of Prepaid expenses and other current receivables) (Details) link:presentationLink link:definitionLink link:calculationLink 9960723 - Disclosure - INVENTORIES (Schedule of Inventories) (Details) link:presentationLink link:definitionLink link:calculationLink 9960724 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details) link:presentationLink link:definitionLink link:calculationLink 9960725 - Disclosure - OTHER INVESTMENTS (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960726 - Disclosure - LEASES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960727 - Disclosure - LEASES (Schedule of Lease Expense) (Details) link:presentationLink link:definitionLink link:calculationLink 9960728 - Disclosure - LEASES (Schedule of Supplemental Cash Flow Information Related to Leases) (Details) link:presentationLink link:definitionLink link:calculationLink 9960729 - Disclosure - LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) (Details) link:presentationLink link:definitionLink link:calculationLink 9960730 - Disclosure - LEASES (Schedule of Maturities of Lease Liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 9960731 - Disclosure - OTHER CURRENT**

LIABILITIES (Schedule Of Other Liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 9960732 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960733 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960734 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Options Granted) (Details) link:presentationLink link:definitionLink link:calculationLink 9960735 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Outstanding and Exercisable Options) (Details) link:presentationLink link:definitionLink link:calculationLink 9960736 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Options Granted Restricted Share Unit) (Details) link:presentationLink link:definitionLink link:calculationLink 9960737 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) (Details) link:presentationLink link:definitionLink link:calculationLink 9960738 - Disclosure - INCOME TAXES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960739 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets (liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 9960740 - Disclosure - INCOME TAXES - (Schedule of valuation allowance) (Details) link:presentationLink link:definitionLink link:calculationLink 9960741 - Disclosure - INCOME TAXES (Schedule of Reconciliation of Theoretical Provision For Income Tax) (Details) link:presentationLink link:definitionLink link:calculationLink 9960742 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes) (Details) link:presentationLink link:definitionLink link:calculationLink 9960743 - Disclosure - INCOME TAXES (Schedule of Tax Expenses (Tax Benefit)) (Details) link:presentationLink link:definitionLink link:calculationLink 9960744 - Disclosure - INCOME TAXES (Schedule of Unrecognized Tax Benefits) (Details) link:presentationLink link:definitionLink link:calculationLink 9960745 - Disclosure - Segments (Schedule of Revenue by Major Customers) (Details) link:presentationLink link:definitionLink link:calculationLink 9960746 - Disclosure - ENTITY-WIDE DISCLOSURE (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 9960747 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) (Details) link:presentationLink link:definitionLink link:calculationLink 9960748 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of revenues based on products' category) (Details) link:presentationLink link:definitionLink link:calculationLink 9960749 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) (Details) link:presentationLink link:definitionLink link:calculationLink 9960750 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Changes In Contract Liabilities) (Details) link:presentationLink link:definitionLink link:calculationLink 9960751 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) (Details) link:presentationLink link:definitionLink link:calculationLink 9960752 - Disclosure - RELATED PARTIES (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 15 inmd-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 inmd-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 17 inmd-20241231_lab.xml XBRL LABEL FILE Israel [Member]United States [Member]Amendment FlagAuditor Firm IdAuditor LocationAuditor NameBusiness Contact [Member]City Area CodeContact Personnel Email AddressContact Personnel Fax NumberContact Personnel NameCover [Abstract]Current Fiscal Year End DateDocument Accounting StandardDocument Annual ReportDocument Financial Statement Error Correction [Flag]Document Fiscal Period FocusDocument Fiscal Year FocusDocument Period End DateDocument Registration StatementDocument Shell Company ReportDocument Transition ReportDocument TypeEntity Address, Address Line OneEntity Address, Address Line TwoEntity Address, Address Line ThreeEntity Address, City or TownEntity Address CountryEntity Addresses, Address Type [Axis]Entity Address, Postal Zip CodeEntity Central Index KeyEntity Common Stock, Shares OutstandingEntity Current Reporting StatusEntity Emerging Growth CompanyEntity Ex Transition PeriodEntity File NumberEntity Filer CategoryEntity Incorporation, State or Country CodeEntity Interactive Data CurrentEntity Registrant NameEntity Shell CompanyEntity Voluntary FilersEntity Well-known Seasoned IssuerAuditor Attestation FlagLocal Phone NumberOther Reporting Standard Item NumberTitle of 12(b) SecuritySecurity 12g TitleName of Exchange on which Security is RegisteredSecurity Reporting ObligationTrading SymbolLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Accounting Policies [Line Items]Table of accounting policies.Accounting Policies [Table]Represents the amount of accrued commissions.Accrued CommissionsAccrued commissionsRepresents the amount of additions for current year valuation allowance.Additions For Current Year Valuation AllowanceAdditions for the current yearAdvance To Subcontractor Or SupplierRepresents about advance to subcontractor/supplier.Advance to subcontractor/supplierAmendment Advantage Exemption [Member]Amendment Advantage Exemption [Member]Debt securities, available for sale maturity, more than five years, fair value.Available For Sale Securities Debt Maturities More Than Five Years Fair ValueMore than 5 yearsDebt securities, available for sale maturity, within four to five years, fair value.Available For Sale Securities Debt Maturities With In Four To Five Years Fair Value4 to 5 yearsDebt securities, available for sale maturity, within one to two years, fair value.Available For Sale Securities Debt Maturities With In One To Two Years Fair Value1 to 2 yearsDebt securities, available for sale maturity, within three to four years, fair value.Available For Sale Securities Debt Maturities With In Three To Four Years Fair Value3 to 4 yearsDebt securities, available for sale maturity, within two to three years, fair value.Available For Sale Securities Debt Maturities With In Two To Three Years Fair Value2 to 3 yearsBank guarantee.Bank guaranteeBonus share issues per outstanding share.Bonus Share Issues Per Outstanding ShareThis member is stand for capital equipment.Capital Equipment [Member]Capital Equipment Revenues [Member]Represents the amount of carryforward losses used not recognized before.Carryforward losses used not recognized beforeCarryforward Losses Used Not Recognized BeforeCarryforward losses used not recognized beforeThis member stand for consumables and service revenues.Consumables And Service Revenues [Member]Represents the amount of contractor liability.Contractor LiabilityContractor liabilityCorporate tax rate.Corporate taxRepresents the amount of credit risk sharing liabilitiesCredit Risk Sharing LiabilitiesCredit risk sharing liabilitiesCurrent monthly rent payment.Current monthly rent paymentDevelopment Zone A [Member]Development Zone A [Member]Dilazar Limited [Member]Dilazar Limited [Member]Elsewhere [Member]Elsewhere [Member]Employee Related Severance Liabilities.Employee Related Severance LiabilitiesEmployee severance benefits.Employee Severance Benefits Policy Text BlockEmployee severance benefitsEmployees [Member]Employees [Member]Employees, officers, directors, service providers and consultants [Member]Employees, officers, directors, service providers and consultants [Member]The entire disclosure about entity wide Ddsclosures.Entity Wide Disclosures [Text Block]SegmentsExercise of Options.Exercise of Options$12.16 [Member]Exercise Price Range Eight [Member]$12.16 [Member]$5.11 [Member]Exercise Price Range Five [Member]$9.85 [Member]$3.75 [Member]Exercise Price Range Four [Member]$7.00 [Member]$21.62 [Member]Exercise Price Range Nine [Member]$21.62 [Member]$0.28 [Member]Exercise Price Range One Member$3.16 [Member]$9.85 [Member]Exercise Price Range Seven [Member]$21.62 [Member]$7.00 [Member]Exercise Price Range Six [Member]$12.16 [Member]$3.16 [Member]Exercise Price Range Three [Member]$5.11 [Member]$0.29 [Member]Exercise Price Range Two [Member]$3.75 [Member]Expenses (Income) [Member]Fair value of one ordinary share.Fair value of one ordinary shareFair value of options granted.Fair value of options grantedFair value of restricted options granted.Fair Value Of Restricted Options GrantedFair value of RSUs grantedFebruary 9, 2021 [Member]February Nine Two Thousands Twenty One [Member]February 9, 2021 [Member]February9 , 2022 [Member]February Nine Two Zero Two Two [Member]February 9 , 2022 [Member]February 17, 2020 [Member]February Seventeen Two Thousands Twenty [Member]March 15, 2020 [Member]Fifteen March Two Thousands Twenty [Member]Finance income.Finance expense (income), netFinance IncomeFully diluted basis [Member]Fully diluted basis [Member]General AbstractGIBF and JVC [Member]G I B F And J V C [Member]GIBF and JVC [Member]Government institutions.Government InstitutionsGovernment institutionsHands-Free [Member]Hands-Free [Member]Himalaya Family Office Consulting Ltd. [Member]Himalaya Family Office Consulting Ltd. [Member]Home Skinnovations Ltd [Member]Home Skinnovations Ltd [Member]Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Income Tax Note [Line Items]Table of income taxes.Income Tax Note [Table]Represents the amount of income tax reconciliation amendment to the investments law payment.Income Tax Reconciliation Amendment To Investments Law PaymentAmendment to the Investments Law payment - see also note 13a(2)(b)Benefits to the Benefited Enterprise.Benefits to the Benefited EnterpriseIncome Tax Reconciliation Benefits To Benefited EnterpriseBenefits to the Benefited EnterpriseAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by operating losses.Income Tax Reconciliation Different Effective Tax Rates Applicable To Operating LossNOL carry back as part of the CARES Act reliefAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Different effective tax rates applicable to the subsidiaries.Different effective tax rates applicable to the SubsidiariesIncome Tax Reconciliation Different Effective Tax Rates Applicable To SubsidiariesDifferent effective tax rates applicable to the SubsidiariesAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Non-deductible expenses.Income Tax Reconciliation Non Deductible ExpensesNon-deductible expenses and other permanent differences, mainly share based compensation expensesRepresents the amount of Income tax reconciliation settlements with israeli tax authority net of decrease of related uncertain tax.Income Tax Reconciliation Settlements With Israeli Tax Authority Net Of Decrease Of Related Uncertain TaxSettlements with the Israeli tax authority net of decrease of related uncertain tax provisionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax position.Income Tax Reconciliation Uncertain Tax PositionUncertain tax positionsIncreases due to issuance of new contracts, excluding amounts recognized as revenue during the period.Increases due to issuance of new contracts, excluding amounts recognized as revenue during the periodThis member is stand for Inmode Innovation.Inmode Innovation [Member]InMode Ltd. and Isreaeli subsidiaries[member]Inmode Ltd And Isreaeli Subsidiaries [Member]InMode Ltd. and Israeli subsidiaries [Member]Interest received.Interest receivedInvestment in short-term deposit.Investment in short-term depositsInvestment In Short Term DepositThis member is stand for Israeli Tax Authority.Israeli Tax Authority [Member]January 7, 2020 [Member]January Seven Two Thousands Twenty [Member]Guangzhou Sino Israel Bio Industry Investment Fund LLP [Member]Joint Venture Agreement [Member]July 27, 2021 [Member]July Twenty Seven Two Thousands Twenty One [Member]July 27, 2021 [Member]July 27, 2022 [Member]July Two Seven Two Zero Two Two [Member]July 27, 2022 [Member]Lease agreement [Member]Lease Agreement [Member]Lease agreement [Member]Lease expires period.Lease expiresLease expiration dateLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Leases [Line Items]Table of leases.Leases [Table]Marketable Securities and Fair Value Measurement [Abstract]Marketable Securities And Fair Value

Measurements Schedule Of Debt Securities On MaturityMarketable Securities And Fair Value MeasurementsThe entire dislosure for marketable securities and fair value measurements.Marketable Securities And Fair Value MeasurementsMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTSMay 5, 2020 [Member]May Five Two Thousands Twenty [Member]May 1, 2022 [Member]May One Two Zero Two Two [Member]May 1, 2022 [Member]May 6, 2021 [Member]May Six Two Thousands Twenty One [Member]May 6, 2021 [Member]Medimor [Member]Medimor [Member]Minimal-Invasive [Member]Minimal-Invasive [Member]Waiver of redeemable non controlling interest.Minority Interest Decrease From Redemptions OneWaiver of redeemable non controlling interestDisclosure of accounting policy for newly issued accounting pronouncements, not yet adopted.Newly Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]Newly issued accounting pronouncements, not yet adoptedNo Amendment [Member]No Amendment [Member]Represents the amount of non cash Acquisition of noncontrolling interest in exchange of ordinary shares.Non Cash Acquisition Of Noncontrolling Interest In Exchange Of Ordinary SharesAcquisition of non-controlling interest in exchange of ordinary sharesNon-Invasive [Member]Non-Invasive [Member]Non-Israeli [Member]Non Israeli Plan [Member]Non US Government Securities [Member]Non Us Government Agencies Debt Securities [Member]November 11, 2020 [Member]November Eleven Two Thousands Twenty [Member]Number Of Ordinary Shares ConsiderationNumber Of Ordinary Shares ConsiderationNumber of ordinary shares considerationRepresents the number of shareholder.Number Of ShareholderNumber for shareholderOctober 26, 2022 [Member]October Two Six Two Zero Two Two [Member]October 26, 2022 [Member]One-time payment.One Time PaymentOne-time paymentOperating lease right-of-use assets.Operating Lease Right Of Use AssestsRecognition of operating lease right-of-use assets and liabilitiesOptions Changes During YearChanges during the year:Amount, advances to suppliers of receivables classified as other, due within one year or the operating cycle, if longer.Other Advances To Suppliers CurrentAdvances to suppliersOther [Member]Other Country [Member]Other [Member]Other lease liabilities classified as current.Other Current Lease LiabilitiesOther current liabilitiesLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.Other Current Liabilities [Line Items]Table of other current liabilities.Other Current Liabilities [Table]The entire disclosure for other current receivables.Other Current ReceivablesOTHER CURRENT RECIVABLESAmount, government institution of receivables classified as other, due within one year or the operating cycle, if longer.Other Government Institutions Receivables CurrentGovernment institutionsAmount, income tax of receivables classified as other, due within one year or the operating cycle, if longer.Other Income Tax Receivables CurrentIncome taxOther operating income.Other incomeOther Operating Expense IncomeAmount, prepaid expenses of receivables classified as other, due within one year or the operating cycle, if longer.Other Prepaid Expenses Receivables CurrentPrepaid expensesAmount, after allowance, of receivables classified as other, due after more than one year.Other Receivables Non CurrentOther receivablesOwnership interest exchange for voting interest acquired.Ownership interest exchangePayments to tax authorities for Amendment to the Investments Law and settlements.Payments To Tax AuthoritiesPayments to tax authorities for Amendment to Investments Law and settlementsPercentage of net sales based on products technology.Percentage of net sales based on products technologyPercentage of non- current deferred revenue.Percentage of non- current deferred revenueThe entire disclosure for prepaid expenses and other current receivables.Prepaid Expenses And Other Current Receivables [Text Block]PREPAID EXPENSES AND OTHER CURRENT RECEIVABLESAmount of previous year income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.Previous Year Income Tax Expense BenefitPrevious yearProceeds from short-term deposit.Proceeds From Investment In Short Term DepositProceeds from short-term depositsRepresent the amount of Proceeds from maturity of marketable securitiesProceeds From Maturity Of Marketable SecuritiesProceeds from maturity of marketable securitiesRepresents the amount of reductions for current year valuation allowance.Reductions For Current Year Valuation AllowanceValuation allowance of net deferred tax assetsReductions for the current yearReductions for the current year that record against defer tax assetRegulations [Member]Regulations [Member]It represents related party consideration for aggregate amount.Related Party Consideration For Aggregate AmountRelated party consideration for aggregate amountTabular disclosure of other current receivables.Schedule Of Other Receivables Current [Table Text Block]Tabular disclosure of prepaid expenses and other current receivables.Schedule Of Prepaid Expenses And Other Current Receivables [Table Text Block]Schedule of prepaid expenses and other current receivablesSchedule Of Prepaid Expenses And Other Current ReceivablesTabular disclosure of property and equipment estimated useful lives.Schedule Of Property And Equipment Estimated Useful Lives [Table Text Block]Schedule of Property and Equipment Estimated Useful LivesTabular disclosure of supplemental balance sheet information related to leases.Schedule of Supplemental Balance Sheet Information Related to LeasesTabular disclosure of supplemental cash flow information related to leases.Schedule of Supplemental Cash Flow Information Related to LeasesThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.CanceledShare-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Canceled In PeriodCanceledRepresents the per share amount of share-based compensation arrangement by share-based payment award, equity instruments other than options canceled weighted average grant date fair value.Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Canceled Weighted Average Grant Date Fair ValueCanceledThe number of restricted stock units vested at the end of the year.Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested VestedNumber of RSUs vestedWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were vested.Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Date Fair ValueVestedThe early exercise multiple assumption.Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Early Exercise MultipleEarly exercise multiple ("EEM")Number of awards authorized to be issued in third year.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized FourJanuary 2023Number of awards authorized to be issued in year one.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized OneJanuary 2020Number of awards authorized to be issued in third year.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ThreeJanuary 2022Number of awards authorized to be issued in year two.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized TwoJanuary 2021Number of awards authorized to be issued upon adoption of the 2018 Incentive Plan.Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Upon AdoptionUpon adoption of the 2018 Incentive PlanThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In PeriodCancelledAmount of award under share-based payment arrangement.Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award AmountAward amountShare-based Compensation Arrangements by Share-based Payment Award, Options, Canceled in Period, Weighted Average Exercise PriceShare Based Compensation Arrangements By Share Based Payment Award Option Cancelled In Period Weighted Average Exercise PriceCancelledThird portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.Share Based Compensation Award Tranche Four [Member]The floor of a range of exercise prices for purposes of disclosing shares potentially issuable under outstanding and exercisable stock option awards on all stock option plans and other required information pertaining to awards in the range.Share Based Compensation Shares Authorized Under Stock Option Plans Exercise PriceExercise pricesShare Purchase and Shareholders Agreement [Member]Share Purchase And Shareholders Agreement [Member]Share purchase and shareholders agreement [Member]Share Repurchase Program [Member]Shares authorized amount.Shares authorized amountShares of acquisition of non-controlling interest in exchange of ordinary shares.Share Value Of Acquisition Of Non Controlling Interest In Exchange Of Ordinary SharesAcquisition of non-controlling interest in exchange of ordinary shares (see note 12b) (Shares)Disclosure of accounting policy for short-term bank deposits.Short Term Bank Deposits Policy Text BlockShort-term bank depositsShort-term deposits annual interest rate.Short Term Deposits Annual Interest RateSpa Medical International SRL [Member]Spa Medical International Lsrl [Member]Special Preferred Enterprise [Member]Special Preferred Enterprise [Member]Repurchase of ordinary shares.Stock Repurchased During Period Value OneRepurchase of ordinary sharesRepurchase of ordinary shares, shares.Stock Repurchased Ordinary Shares During Period SharesRepurchase of ordinary shares (Shares)Repurchase of ordinary shares value.Stock Repurchased Ordinary Shares During Period ValueRepurchase of ordinary sharesCanadian Subsidiary [Member]Subsidiaries Four [Member]Subsidiaries outside Israel [Member]Subsidiaries outside Israel [Member]Subsidiaries outside of Israel [Member]Subsidiaries [Member]U.S Subsidiary [Member]Subsidiaries Three [Member]This member stands for subsidiary in state.Subsidiary In State [Member]Subsidiary in state [Member]This member stands for Subsidiary in United States.Subsidiary In United States [Member]Subsidiary in U.S. [Member]Subsidiary Of Home Skinnovations Ltd [Member]Subsidiary of Home Skinnovations Ltd [Member]Tax benefit in years.Tax benefit yearTax rate for recipient for dividends distributed by Preferred Company from income derived from its PTE or SPTE.Tax Rate For Recipient For Dividends Distributed By Preferred CompanyRepresents the amount of long lived assets by geographical area.Total Long Lived Assets By Geographical AreaTotal long-lived assets by geographical areaDisclosure of accounting policy treasury shares.Treasury Shares Policy Text BlockTreasury SharesTwo Purchase And Shareholders Agreements [Member]Two Purchase And Shareholders Agreements [Member]Two purchase and shareholders agreements [Member]2018 Incentive Plan [Member]Two Thousands Eighteen Incentive Plan [Member]2018 Incentive Plan [Member]Underwriters Allotment Option [Member]Underwriters Allotment Option [Member]Undistributed exempt income.Undistributed exempt incomeChanges during the year:Utilization Of Carry Forward Tax LossesUtilization of carry forward tax losses.Utilization of carry forward tax lossesWarranty reserve liability current.Warranty Reserve Liability CurrentWarranty reserveDisclosure of accounting policy for war risk situation in Israel.War Risk Situation In Israel [Policy Text Block]War risk situation in IsraelWeighted Average Exercise Price Changes During Year AbstractChanges during the year:Changes during the year:Weighted Average Number Of Shares Out Standing Used In Computation Of Net Income Per Share AbstractWEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHAREAsia [Member]Board of Director [Member]Chief Executive Officer [Member]CODM [Member]Consolidated Entities [Axis]Cumulative Effect, Period of Adoption [Axis]Investment, Name [Domain]Europe [Member]Europe [Member]Maximum [Member]Maximum [Member]Minimum [Member]Minimum [Member]Real Estate, Type of Property [Axis]Real Estate [Domain]Office Building [Member]Ownership [Axis]Product and Service [Axis]Product and Service [Domain]Statistical Measurement [Axis]Statistical Measurement [Domain]Forecast [Member]Investment, Name [Axis]Geographical [Domain]Geographical [Axis]Scenario [Axis]Invasix UK [Member]Title and Position [Axis]Title and Position [Domain]Warehouse [Member]Accounting Policies [Abstract]Accounts and

*Financing Receivable, after Allowance for Credit LossNotes And Loans Receivable NetAccounts and Other Receivables, Net, CurrentAccounts receivableAccounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]OTHER CURRENT LIABILITIESAccounts receivable, net of allowance for credit losses of $1,538 and $836, as of December 31, 2023 and 2022, respectivelyAccounts paybaleAccounts Payable, CurrentAccounts payableAccounts Payable, Current, TotalAccounts receivable, net of allowance for credit losses of $836 and $1,107, as of December 31, 2022 and 2021, respectivelyAccounts PayableAccounts Payable, Related Party [Extensible Enumeration]Accounts Receivable, after Allowance for Credit Loss, Related Party [Extensible Enumeration]Accounts Receivable, Allowance for Credit Loss [Table Text Block]Schedule Of Allowance For Credit LossesTradeAccounts Receivable, after Allowance for Credit LossAccounts receivableAccounts Receivable, after Allowance for Credit Loss, TotalAccounts receivable, net of allowance for credit losses of $1,825 and $1,538, as of December 31, 2024 and 2023, respectivelyAccounts paybaleAccounts Receivable, after Allowance for Credit Loss, CurrentTotal current accounts receivableAccounts Receivable, after Allowance for Credit Loss, Current, TotalAccounts receivable, net of allowance for credit losses of $836 and $1,107, as of December 31, 2022 and 2021, respectivelyLess - non-current accounts receivableAccounts receivableAccounts receivable net of allowance for credit losses of $482 and $0 as of December 31, 2022 and 2021, respectivelyAccounts receivable net of allowance for credit losses of $924 and $716 as of December 31, 2024 and 2023, respectivelyAccounts Receivable, Noncurrent, NonaccrualAccrued Income Taxes, CurrentIncome tax payableLess: accumulated depreciationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentAccumulated other comprehensive income (loss)Accumulated other comprehensive lossAccumulated other comprehensive income [Member]Additional paid-in capitalAdditional paid-in capitalAdditional paid-in capital [Member]APIC, Share-Based Payment Arrangement, Increase for Cost RecognitionShare-based compensation expensesAPIC, Share-Based Payment Arrangement, Increase for Cost Recognition, TotalShare-based compensationAdjustments required to reconcile net income to net cash provided by operating activities:Adjustments required to reconcile net income to net cash provided by operating activities:Advertising Cost [Policy Text Block]Advertising expensesAdvertising ExpenseAdvertising expensesShare-based Payment Arrangement, ExpenseEquity-based compensation incomeFinancing Receivable, Allowance for Credit Loss [Table Text Block]Schedule of allowance for credit lossesLess - allowance for credit lossesBalance at end of yearBalance at beginning of yearAccounts Receivable, Allowance for Credit LossAllowance for credit lossesAccounts receivable, allowance for doubtful accountsAccounts Receivable, Allowance for Credit Loss, NoncurrentAccounts receivable net of allowance for credit lossesWrite-offs charged against the allowanceAccounts Receivable, Allowance for Credit Loss, WriteoffWrite-offs charged against the allowanceCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Assets [Default Label]TOTAL ASSETSAssetsAssets, CurrentTOTAL CURRENT ASSETSCURRENT ASSETS:Assets, NoncurrentTOTAL NON-CURRENT ASSETSNON-CURRENT ASSETS:NON-CURRENT ASSETS:Gross unrealized holding gainsGross unrealized holding lossDebt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before TaxMarketable securities, amortizationCost or amortized costDebt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair ValueTotalDue within one yearFair ValueAward Date [Axis]Balance Sheet Location [Axis]Basis of presentationUS Government Bonds [Member]Business Acquisition [Axis]Business Acquisition, Percentage of Voting Interests AcquiredOwnership interestPurchase considerationGENERALCASH AND CASH EQUIVALENTS AT END OF THE YEARCASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEARCash and cash equivalentsCash and Cash Equivalents, Policy [Policy Text Block]Cash and cash equivalentsCASH AND CASH EQUIVALENTS AT END OF THE YEARCASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEARCash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, TotalCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectNET INCREASE IN CASH AND CASH EQUIVALENTSCertificates of deposit [Member]Commercial Paper [Member]COMMITMENTS AND CONTINGENCIES (note 12)COMMITMENTS AND CONTINGENCIESCommitments and Contingencies Disclosure [Abstract]COMMITMENTS AND CONTINGENT LIABILITIESCOMMITMENTS AND CONTINGENCIESLegal and other contingenciesOrdinary Shares [Member]Common Stock, Par or Stated Value Per ShareOrdinary shares, par valueOrdinary shares, shares authorizedShares authorizedOrdinary shares, issued sharesEnding Balance, sharesBegining Balance, SharesOrdinary shares, outstanding sharesCommon Stock, Value, IssuedOrdinary shares, NIS 0.01 par value, authorized 200,000,000 shares at December 31, 2024 and 2023 Issued 87,583,673 and 85,957,465 shares at December 31, 2024 and 2023, respectively Outstanding 69,558,670 and 83,982,462 shares at December 31, 2024 and 2023, respectivelyOrdinary shares, NIS 0.01 par value, authorized 100,000,000 shares at December 31, 2022 and 2021. Issued 84,519,994 and 83,875,905 shares at December 31, 2022 and 2021, respectively. Outstanding 82,544,991 and 82,978,115 shares at December 31, 2022 and 2021, respectively.OTHER COMPREHENSIVE INCOME:Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling InterestTOTAL COMPREHENSIVE INCOMEComputers [Member]Concentration Risk Type [Axis]Concentration Risk, Credit Risk, Policy [Policy Text Block]Concentration of credit risksConcentration Risk [Line Items]Concentration Risk [Table]Concentration Risk Type [Domain]Principles of consolidation and presentationSchedule of Changes in Contract LiabilitiesBalance as of December 31Balance as of January 1Contract with Customer, LiabilityContract liabilitiesContract liability presented in current liabilitiesContract liabilitiesContract liability presented in non-current liabilitiesContract liabilitiesRevenue recognized that was included in the contract liability balance at the beginning of the periodCorporate debt securities [Member]COST OF REVENUESCOST OF REVENUESCost of Sales [Member]Cost of sales [Member]Cost of revenuesAllowance for doubtful accounts and financial instruments - credit lossAllowance for doubtful accounts and financial instruments – credit lossCurrentSchedule of Debt Securities on MaturityDeferred income taxes, netDeferred income tax assetsDeferred Income Taxes and Tax CreditsDeferred income tax assets, netDeferredDeferred Tax Assets, GrossTotal deferred tax assets before valuation allowanceDeferred Tax Assets, Net of Valuation AllowanceTotal deferred tax assetsDeferred tax assets in respect of:Subsidiaries carryforward lossesOther temporary differencesDeferred tax asset in respect to other comprehensive lossDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation CostShare-based compensationValuation allowanceBalance at December 31Balance at January 1Deferred Tax Assets, Valuation AllowanceValuation allowanceShort-term bank depositsDepreciationDepreciation, TotalDepreciationDepreciation and amortizationDepreciation and amortizationSchedule of Long-Lived AssetsSchedule of Awards Authorized to be IssuedNET INCOME PER SHARE:EARNINGS PER SHARE:BasicBasicDilutedDilutedNet income per shareNet earnings per shareStatutory rateTheoretical tax expenses at the statutory rate of InMode Ltd.Tax rate after divdendEffect of Exchange Rate on Cash and Cash EquivalentsEFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTSEffect of Exchange Rate on Cash and Cash Equivalents, TotalEmployee Benefits and Share-Based CompensationShare based compensationEmployees and related expensesUnrecognized compensation cost, recognition periodUnrecognized compensation expenseRevenue, Major Customer [Line Items]Equipment and furniture [Member]Ownership interestOwnership interestSchedule of Financial Assets Measured at Fair Value on Recurring BasisFair Value Hierarchy and NAV [Axis]Level 2 Securities [Member]Fair value measurementFair Value Hierarchy and NAV [Domain]Financial Instrument [Axis]Functional currencyLoss on marketable securities, netGain (Loss) on InvestmentsGeneral and administrativeGeneral and administrativeGeneral and Administrative Expenses [Member]General and administrative expenses [Member]Grantee Status [Axis]Gross ProfitGROSS PROFITImpairment of long-lived assetsIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestINCOME BEFORE INCOME TAXESIncome before taxes on incomeIncome Statement [Abstract]Statement of Income Location, Balance [Axis]Statement of Income Location, Balance [Domain]Income Tax Authority [Axis]Income Tax Authority, Name [Axis]Income Tax Authority, Name [Axis]Income Tax Contingency [Line Items]Income Tax Contingency [Table]Income Tax Disclosure [Abstract]TAXES ON INCOMEINCOME TAXESIncome taxes paidIncome taxes paid *Tax assetINCOME TAXES BENEFIT (EXPENSES)Income Tax Expense (Benefit)Total taxes on incomeTotal taxes on incomeINCOME TAXES BENEFIT (EXPENSES)Increase (decrease) in taxes on income due to:Income taxesEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, AmountValuation allowanceChange in valuation allowanceTheoretical tax benefitPrevious yearsPrevious yearIncrease in accounts payableIncrease (decrease) in accounts payableDecrease (increase) in accounts receivable (including non-current)Increase (Decrease) in Accounts ReceivableIncrease (decrease) in contract liabilitiesIncrease (decrease) in contract liabilitiesFinance income, netIncrease (Decrease) in Finance ReceivablesInterest incomeInterest Income, Operating, TotalIncrease in inventoriesIncrease (Decrease) in InventoriesChanges in operating assets and liabilities:Increase in other liabilitiesIncrease (decrease) in other liabilitiesIncrease in other receivablesIncrease (Decrease) in Other ReceivablesFinance expense (income), netInterest Income (Expense), NetInterest Income (Expense), Net, TotalFinance income, netInterest Income, OperatingInterest incomeInterest incomeInventory Disclosure [Abstract]INVENTORIESFinished productsInventoriesTotal inventoriesInventory, Policy [Policy Text Block]InventoriesRaw materialsFinance income, netFinance income, netInvestment, Policy [Policy Text Block]Other InvestmentsInvestment AmountInvestment amountInvestments [Abstract]OTHER INVESTMENTSInvestment Type [Axis]Investments [Domain]IPO [Member]Lease Contractual Term [Domain]Schedule of Lease ExpenseLeasehold Improvements [Member]Leases [Abstract]Operating LeasesLeasesSchedule of Maturities of Lease LiabilitiesLessee, Operating Lease, Liability, to be PaidTotal lease paymentsLessee, Operating Lease, Liability, to be Paid, after Year Five2029 and beyondLessee, Operating Lease, Liability, to be Paid, Year One2025Lessee, Operating Lease, Liability, to be Paid, Year Four2028Lessee, Operating Lease, Liability, to be Paid, Year Three2027Lessee, Operating Lease, Liability, to be Paid, Year Two2026Less imputed interestsLessee, Operating Lease, Liability, Undiscounted Excess AmountLess imputed interestsLEASESLessee, Operating Lease, Term of ContractTerm of contractLiabilitiesTOTAL LIABILITIESLiabilities and EquityTOTAL LIABILITIES AND SHAREHOLDERS' EQUITYLiabilities and shareholders' equityLiabilities and shareholders' equityLiabilities, CurrentTOTAL CURRENT LIABILITIESCURRENT LIABILITIES:CURRENT LIABILITIES:Liabilities, NoncurrentTOTAL NON-CURRENT LIABILITIESNON-CURRENT LIABILITIES:NON-CURRENT LIABILITIES:ACCOUNTS RECEIVABLELoss on marketable securities, netLoss on Sale of InvestmentsLoss on marketable securities, netGain (Loss) on Investments, TotalMarketable securities (amortized cost of $268,129 and $375,829, as of December 31, 2024 and 2023, respectively)Marketable Securities, CurrentMarketable securitiesMarketable securities (amortized cost of $384,320 and $296,243, as of December 31, 2022 and 2021, respectively)Marketable Securities [Line Items]Marketable securitiesMarketable Securities [Table]Schedule of Marketable SecuritiesMarketing ExpenseMarketing expensesPercentage of interest in subsidiariesMunicipal bonds [Member]Net Cash Provided by (Used in) Financing ActivitiesNet cash provided by (used in) financing activitiesCASH FLOWS FROM FINANCING ACTIVITIES:CASH FLOWS FROM FINANCING ACTIVITIES:Net Cash Provided by (Used in) Investing ActivitiesNet cash provided by (used in) investing activitiesCASH FLOWS FROM INVESTING ACTIVITIES:CASH FLOWS FROM INVESTING ACTIVITIES:Net Cash Provided by (Used in) Operating ActivitiesNet cash provided by operating activitiesCASH FLOWS FROM OPERATING ACTIVITIES:NET INCOME ATTRIBUTABLE TO INMODE LTDAdd: Net income attributable to non-controlling interestsNet Income (Loss) Attributable to Noncontrolling InterestNewly issued and recently adopted accounting*

pronouncementsRecently adopted accounting pronouncementsNON-CASH ACTIVITIESNon-controlling Interest [Member]Noncurrent AssetsTotal Long-Lived AssetsNotes receivableNumber of Operating SegmentsNumber of operating segmentOffice furniture and equipment [Member]Operating ExpensesTOTAL OPERATING EXPENSESOPERATING EXPENSES:OPERATING EXPENSES:Operating Income (Loss)OPERATING INCOMEOperating lease costOperating Lease, LiabilityTotal operating lease liabilitiesTotal operating lease liabilitiesOperating lease liabilitiesOperating Lease, Liability, CurrentTotal operating lease liabilitiesOperating Lease, Liability, TotalOperating lease liabilitiesOperating lease liabilitiesOperating lease liabilitiesOperating cash flows from operating leasesOperating lease right-of-use assetsOperating lease right-of-use assetsWeighted Average Discount Rate Operating leasesWeighted Average Discount Rate, Operating leasesWeighted Average Remaining Lease Term Operating leasesWeighted Average Remaining Lease Term, Operating leasesAccumulated tax loss carryforwardOther Accrued Liabilities, CurrentOtherOther Assets, NoncurrentOther long-term assetsOther comprehensive income (loss), netOther comprehensive income, netOther comprehensive loss, netChange in net unrealized gains (loss) of marketable securities, net of taxOther Current Liabilities [Member]Schedule of Other Current LiabilitiesOther ExpensesOther expensesOther InvestmentsOther investmentsOther liabilitiesOther liabilitiesTotal other current liabilitiesOther Liabilities, NoncurrentOther liabilitiesOtherOtherOther receivablesPrepaid expense and other receivablesTotal other current receivablesOther Receivables, Net, Current [Abstract]Payables and Accruals [Abstract]Other investmentsPayments for (Proceeds from) Other Investing ActivitiesRepurchase of ordinary sharesPayments for Repurchase of Common StockIPO expensesPayment to purchase licencePurchase of marketable securitiesPayments to Acquire Marketable SecuritiesPurchase of fixed assetsPayments to Acquire Property, Plant, and EquipmentPlan Name [Axis]Proceeds from initial public offering of ordinary shares, net of offering costsProceeds from initial public offeringProceeds from sale of marketable securitiesProceeds from sale of marketable securitiesProceeds from Stock Options ExercisedExercise of optionsNet Income (Loss), Including Portion Attributable to Noncontrolling InterestNet incomeNET INCOMENET INCOMEProperty, Plant and Equipment [Abstract]Long-Lived Tangible Asset [Axis]Long-Lived Tangible Asset [Axis]PROPERTY AND EQUIPMENT, NETProperty plant and equipment grossProperty, plant and equipment, grossProperty, Plant and Equipment [Line Items]Property and equipment, netProperty and equipment, netTotal property and equipment, netProperty and equipmentSchedule of Property and EquipmentLong-Lived Tangible Asset [Domain]Property, Plant and Equipment, Useful LifeEstimated useful livesAccounts Receivable, Credit Loss Expense (Reversal)Change in allowance for credit losses of trade receivableCurrent-period provisionReconciliation of Revenue from Segments to Consolidated [Table]Related and Nonrelated Parties [Domain]Related Party [Member]Payment for services receivedRelated Party Transaction [Line Items]Related Party Transactions [Abstract]Related Party [Axis]RELATED PARTIESResearch and developmentResearch and developmentResearch and Development Expenses [Member]Research and development expenses [Member]Research and development costsRestricted Stock Units (RSUs) [Member]Retained earningsRetained earningsRetained earnings [Member]Revenue from Contract with Customer, Including Assessed TaxRevenues from customersSchedule of Net Sales by Geographic AreaRevenue recognitionRevenuesREVENUESRevenues from External Customers and Long-Lived Assets [Line Items]Sales Commissions and FeesEmployee salaries including commission expensesSchedule of Accounts ReceivableSchedule of Tax Expenses (Tax Benefit)Schedule of Deferred Tax Assets (liabilities)Schedule of Reconciliation of Theoretical Provision For Income TaxSchedule of Share Based Compensation ExpenseRevenue from External Customers by Products and Services [Table Text Block]Schedule of revenue from external customers by products and ServicesSchedule of revenues based on products' categorySchedule of Revenue by Major Customers, by Reporting Segments [Table]Schedule of Income Before Income TaxesSchedule of InventoriesNet Investment Income [Line Items]Investment Income [Table]Schedule of Accrued WarrantyProperty, Plant and Equipment [Table]Schedule of Related Party Transactions, by Related Party [Table]Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]Schedule of Revenue by Major CustomersSchedule of Revenues from External Customers and Long-Lived Assets [Table]Schedule of Segment Reporting Information, by Segment [Table]Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule of Outstanding and Exercisable OptionsSchedule of Options GrantedSchedule of Assumptions Used to Calculate Fair Value of Options GrantedSchedule of Unrecognized Tax BenefitsSchedule of Net Sales by TechnologySegment Reporting [Abstract]Segment Reporting Disclosure [Text Block]SegmentsSegment Reporting Information [Line Items]SegmentsSegment Reporting, Revenue Reconciling Item [Line Items]Sales and marketingSales and marketingSelling and Marketing Expenses [Member]Selling and marketing expenses [Member]Amounts of severance payment expensesShare-based compensationShare-based compensation expensesShare-based compensationVesting periodShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, OutstandingFair value of RSUs grantedForfeitedShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair ValueForfeitedShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in PeriodGrantedFair value of RSU granted, per shareFair value of RSU granted, per shareShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueGrantedOutstanding at end of yearOutstanding at beginning of yearShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberUnvested RSUsOutstanding at end of yearOutstanding at beginning of yearShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueWeighted Average Grant Date Fair ValueVestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair ValueFair value of RSUs grantedExpirationDividend yieldContractual termExpected volatilityRisk-free interest rateShare-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Number of RSUsShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedTotalNumber of shares authorized to be issued as ordinary sharesNumber of options available for grantExercisable at end of yearShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise PriceExercisable at end of yearWeighted average remaining contractual lifeWeighted average remaining contractual life of exercisable optionsTotal intrinsic value of options exercisedExpiredShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in PeriodCanceledShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in PeriodShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise PriceCanceledForfeitedStock options cancelledStock options grantedGrantedUnvested optionsOutstanding at end of yearOutstanding at beginning of yearShare-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, NumberNumber of optionsOutstanding at end of yearOutstanding at beginning of yearShare-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise PriceWeighted average exercise priceWeighted average remaining contractual life of outstanding optionsAggregate intrinsic valueVested optionsExercisedExpiredForfeitedGrantedShare-based Payment Arrangement, Tranche One [Member]Share-based Payment Arrangement, Tranche Three [Member]Share-based Payment Arrangement, Tranche Two [Member]Share-based Payment Arrangement [Policy Text Block]Share-based compensationExercise Price Range [Axis]Number of options exercisable at end of yearNumber of options Outstanding and exercisable at end of yearShare-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise PriceExercise price rangeEmployees, officers and directors [Member]Ordinary shares of MedimorOrdinary sharesPrice per shareSIGNIFICANT ACCOUNTING POLICIESSupply and open orders commitmentBalance at end of yearBalance at beginning of yearStandard Product Warranty AccrualCost incurredStandard Product Warranty Accrual, Decrease for PaymentsExpense recognizedWarranty reserveEquity Components [Axis]Statement [Line Items]Statement of Cash Flows [Abstract]Statement of Financial Position [Abstract]Statement of Comprehensive Income [Abstract]Statement [Table]Stockholders' Equity Attributable to ParentTOTAL SHAREHOLDERS' EQUITYInMode Ltd. shareholders' equity:SHAREHOLDERS' EQUITY:Ending BalanceBegining BalanceStockholders' Equity, Including Portion Attributable to Noncontrolling InterestTOTAL SHAREHOLDERS' EQUITYStockholders' Equity Note [Abstract]SHAREHOLDERS' EQUITYStock splitInitial public offering of ordinary shares, net of offering costs, sharesIssuance of sharesExercisedExercise of options, sharesExercise of options (Shares)Exercise of options and vesting of RSUs (Shares)Exercise of optionsExercise of options and vesting of RSUsStock Repurchased During Period, SharesRepurchase of ordinary shares, sharesSubsequent Event [Line Items]Subsequent Event [Member]Subsequent Events [Abstract]Subsequent Events [Text Block]SUBSEQUENT EVENTSSubsequent Event [Table]Subsequent Event Type [Axis]Subsequent Event Type [Domain]Sale of Stock [Axis]Summary of Valuation Allowance [Table Text Block]Schedule of valuation allowanceSUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:Tax Adjustments, Settlements, and Unusual ProvisionsPayment of income tax assessment with tax authoritiesMolds [Member]Financial Instruments [Domain]Treasury shares [Member]Treasury shares, ordinary sharesLess treasury shares, at cost: 18,025,003 and 1,975,003 ordinary shares at December 31, 2024 and 2023, respectivelyTreasury Stock, ValueCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Balance at December 31Balance at January 1Unrecognized Tax BenefitsDecrease in uncertain tax positions for the previous yearsUnrecognized Tax Benefits, Decrease Resulting from Prior Period Tax PositionsIncrease in uncertain tax positions for the current yearIncrease in uncertain tax positions for the current year, netUse of estimatesGovernment bonds [Member]U.S. Government bonds [Member]Vehicles [Member]Vesting [Axis]Weighted Average Number of Shares Outstanding, DilutedDilutedWeighted Average Number of Shares Outstanding, BasicBasic EX-101.PRE 18 inmd-20241231_pre.xml XBRL PRESENTATION FILE XML 20 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	12 Months Ended Dec. 31, 2024 shares
Entity Registrant Name	InMode Ltd.
Entity Central Index Key	0001742692
Document Type	20-F
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY

Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-39016
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	Tavor Building
Entity Address, Address Line Two	Sha'ar Yokneam
Entity Address, Address Line Three	P.O. Box 533
Entity Address, City or Town	Yokneam
Entity Address, Postal Zip Code	2069206
Entity Address Country	IL
Title of 12(b) Security	Ordinary shares, par value NIS 0.01 per ordinary share
Trading Symbol	INMD
Name of Exchange on which Security is Registered	NASDAQ
Entity Common Stock, Shares Outstanding	69,558,670
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Auditor Attestation Flag	true
Auditor Name	Kesselman & Kesselman
Auditor Location	Tel-Aviv, Israel
Auditor Firm Id	1309
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]	
Contact Personnel Name	Moshe Mizrahy
Entity Address, Address Line One	Tavor Building
Entity Address, Address Line Two	Sha'ar Yokneam
Entity Address, Address Line Three	P.O. Box 533
Entity Address, City or Town	Yokneam
Entity Address, Postal Zip Code	2069206
Entity Address Country	IL
City Area Code	972
Local Phone Number	4-9096313

XML 21 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Dec. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:			
Cash and cash equivalents		$ 155,329	$ 144,411
Marketable securities (amortized cost of $268,129 and $375,829, as of December 31, 2024 and 2023, respectively)		267,688	373,647
Short-term bank deposits		173,455	223,547
Accounts receivable, net of allowance for credit losses of $1,825 and $1,538, as of December 31, 2024 and 2023, respectively		36,335	42,362
Prepaid expense and other receivables		22,097	16,268
Inventories		59,548	45,095
TOTAL CURRENT ASSETS		714,452	845,330
NON-CURRENT ASSETS:			
Accounts receivable net of allowance for credit losses of $924 and $716 as of December 31, 2024 and 2023, respectively		3,176	3,670
Deferred income tax assets		56,285	1,506
Operating lease right-of-use assets		8,732	9,698
Property and equipment, net		2,322	2,382
Other investments		700	700
TOTAL NON-CURRENT ASSETS		71,215	17,956
TOTAL ASSETS		785,667	863,286
CURRENT LIABILITIES:			
Accounts payable		13,782	13,966
Contract liabilities		16,755	10,923
Other liabilities		39,314	39,247
TOTAL CURRENT LIABILITIES		69,851	64,136
NON-CURRENT LIABILITIES:			
Contract liabilities	[1]	3,336	3,766
Other liabilities		3,356	1,399
Operating lease liabilities		5,311	6,613
TOTAL NON-CURRENT LIABILITIES		12,003	11,778
TOTAL LIABILITIES		81,854	75,914
COMMITMENTS AND CONTINGENCIES			
SHAREHOLDERS' EQUITY:			
Ordinary shares, NIS 0.01 par value, authorized 200,000,000 shares at December 31, 2024 and 2023 Issued 87,583,673 and 85,957,465 shares at December 31, 2024 and 2023, respectively Outstanding 69,558,670 and 83,982,462 shares at December 31, 2024 and 2023, respectively		249	245
Additional paid-in capital		197,028	177,820
Retained earnings		874,701	693,426
Accumulated other comprehensive loss		(340)	(1,679)
Less treasury shares, at cost: 18,025,003 and 1,975,003 ordinary shares at December 31, 2024 and 2023, respectively		(367,825)	(82,440)
TOTAL SHAREHOLDERS' EQUITY		703,813	787,372
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		$ 785,667	$ 863,286

[1] As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029.

XML 22 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Marketable securities, amortization	$ 268,129	$ 375,829
Accounts receivable, allowance for doubtful accounts	1,825	1,538
Accounts receivable net of allowance for credit losses	$ 924	$ 716
Ordinary shares, shares authorized	200,000,000	200,000,000
Ordinary shares, issued shares	87,583,673	85,957,465
Ordinary shares, outstanding shares	69,558,670	83,982,462
Treasury shares, ordinary shares	18,025,003	1,975,003

XML 23 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical 2) - ₪ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Ordinary shares, par value	₪ 0.01	₪ 0.01

XML 24 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]			
REVENUES [1]	$ 394,818	$ 492,048	$ 454,271
COST OF REVENUES	77,752	80,708	73,485
GROSS PROFIT	317,066	411,340	380,786
OPERATING EXPENSES:			
Research and development	13,137	13,410	12,425
Sales and marketing	181,366	193,042	160,576
General and administrative	10,032	9,228	9,931
TOTAL OPERATING EXPENSES	204,535	215,680	182,932
OPERATING INCOME	112,531	195,660	197,854
Finance income, net	30,938	21,607	3,612
INCOME BEFORE INCOME TAXES	143,469	217,267	201,466
INCOME TAXES BENEFIT (EXPENSES)	37,806	(19,348)	(39,946)
NET INCOME	$ 181,275	$ 197,919	$ 161,520
EARNINGS PER SHARE:			
Basic	$ 2.29	$ 2.37	$ 1.96
Diluted	$ 2.25	$ 2.3	$ 1.89
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHARE			
Basic	79,306,371	83,533,593	82,482,090
Diluted	80,596,682	85,953,581	85,403,714

[1] Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.

XML 25 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]			
NET INCOME	$ 181,275	$ 197,919	$ 161,520
OTHER COMPREHENSIVE INCOME:			
Change in net unrealized gains (loss) of marketable securities, net of tax	1,339	5,814	(6,174)
TOTAL COMPREHENSIVE INCOME	$ 182,614	$ 203,733	$ 155,346

XML 26 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Ordinary Shares [Member]	Additional paid-in capital [Member]	Retained earnings [Member]	Accumulated other comprehensive income [Member]	Treasury shares [Member]	Total
Begining Balance at Dec. 31, 2021	$ 239	$ 122,698	$ 333,987	$ (1,319)	$ (39,803)	$ 415,802
Begining Balance, Shares at Dec. 31, 2021	82,978,115					
Net income	$ 0	0	161,520	0	0	161,520
Other comprehensive loss, net	0	0	0	(6,174)	0	(6,174)
Share-based compensation	0	24,452	0	0	0	24,452
Repurchase of ordinary shares	$ 0	0	0	0	(42,637)	(42,637)
Repurchase of ordinary shares (Shares)	(1,077,213)					
Exercise of options and vesting of RSUs	$ 2	1,653	0	0	0	1,655
Exercise of options and vesting of RSUs (Shares)	644,089					
Ending Balance at Dec. 31, 2022	$ 241	148,803	495,507	(7,493)	(82,440)	554,618
Ending Balance, shares at Dec. 31, 2022	82,544,991					
Net income	$ 0	0	197,919	0	0	197,919
Other comprehensive loss, net	0	0	0	5,814	0	5,814
Share-based compensation	0	23,600	0	0	0	23,600
Exercise of options and vesting of RSUs	$ 4	5,417	0	0	0	5,421
Exercise of options and vesting of RSUs (Shares)	1,437,471					
Ending Balance at Dec. 31, 2023	$ 245	177,820	693,426	(1,679)	(82,440)	$ 787,372
Ending Balance, shares at Dec. 31, 2023	83,982,462					83,982,462
Net income	$ 0	0	181,275	0	0	$ 181,275
Other comprehensive loss, net	0	0	0	1,339	0	1,339
Share-based compensation	0	16,569	0	0	0	16,569
Repurchase of ordinary shares	$ 0	0	0	0	(285,385)	(285,385)
Repurchase of ordinary shares (Shares)	(16,050,000)					
Exercise of options and vesting of RSUs	$ 4	2,639	0	0	0	$ 2,643
Exercise of options and vesting of RSUs (Shares)	1,626,208					1,003,409
Ending Balance at Dec. 31, 2024	$ 249	$ 197,028	$ 874,701	$ (340)	$ (367,825)	$ 703,813
Ending Balance, shares at Dec. 31, 2024	69,558,670					69,558,670

XML 27 R8.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income	$ 181,275	$ 197,919	$ 161,520
Adjustments required to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	728	623	680

Share-based compensation expenses		16,569	23,600	24,452
Change in allowance for credit losses of trade receivable		572	1,020	449
Loss on marketable securities, net		167	0	71
Finance income, net		(4,401)	(4,714)	(1,210)
Deferred income tax assets, net		(55,179)	(184)	84
Changes in operating assets and liabilities:				
Decrease (increase) in accounts receivable (including non-current)		5,949	(16,084)	(10,415)
Increase in other receivables		(5,698)	(2,224)	(1,787)
Increase in inventories		(14,453)	(5,198)	(18,871)
Increase (decrease) in accounts payable		(184)	(2,276)	7,463
Increase (decrease) in other liabilities		1,917	(12,588)	17,941
Increase (decrease) in contract liabilities		5,402	(3,068)	1,201
Net cash provided by operating activities		132,664	176,826	181,578
CASH FLOWS FROM INVESTING ACTIVITIES:				
Investment in short-term deposits		(168,187)	(233,241)	(93,701)
Proceeds from short-term deposits		218,740	85,090	73,090
Purchase of fixed assets		(669)	(705)	(1,575)
Other investments		0	(100)	0
Purchase of marketable securities		(336,221)	(245,337)	(168,680)
Proceeds from sale of marketable securities		90,754	5,000	2,303
Proceeds from maturity of marketable securities		357,789	253,229	79,089
Net cash provided by (used in) investing activities		162,206	(136,064)	(109,474)
CASH FLOWS FROM FINANCING ACTIVITIES:				
Repurchase of ordinary shares		(285,385)	0	(42,637)
Exercise of options		2,614	5,504	1,552
Net cash provided by (used in) financing activities		(282,771)	5,504	(41,085)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(1,181)	605	(1,615)
NET INCREASE IN CASH AND CASH EQUIVALENTS		10,918	46,871	29,404
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR		144,411	97,540	68,136
CASH AND CASH EQUIVALENTS AT END OF THE YEAR		155,329	144,411	97,540
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:				
Income taxes paid	[1]	17,691	31,614	25,843
Interest received		27,693	14,219	4,856
NON-CASH ACTIVITIES				
Recognition of operating lease right-of-use assets and liabilities		1,259	5,200	2,342
Exercise of Options		$ 49	$ 20	$ 103

[1] Including, for 2022, payments amounting $12 million for Amendment to the Investments Law and settlements with the Israeli tax authority. See note 13a(2)(b).

XML 28 R9.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	12 Months Ended Dec. 31, 2024 USD ($)
Statement of Cash Flows [Abstract]	
Payments to tax authorities for Amendment to Investments Law and settlements	$ 12

XML 29 R10.htm IDEA: XBRL DOCUMENT

GENERAL	12 Months Ended Dec. 31, 2024
General Abstract	
GENERAL	**NOTE 1 - GENERAL:**

InMode Ltd. (separately and together with its subsidiaries, the "Company") was incorporated on January 2, 2008 and commenced operations shortly thereafter. The Company's headquarters are located in Israel. The Company is traded in the Nasdaq Global Select Market (the "Nasdaq") since August 2019.

The Company designs, develops, manufactures and markets innovative minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. These technologies are used to remodel subdermal adipose or fatty tissue in a variety of procedures including liposuction with simultaneous skin tightening, body and face contouring and ablative skin rejuvenation treatments, as well as, for use in certain women's health conditions and procedures. In addition to the minimally-invasive technologies, the Company designs, develops, manufactures and markets non-invasive medical aesthetic products that target a wide array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The Company also designs, develops, manufactures and markets hands-free medical aesthetic products that target a wide array of procedures such as skin tightening, fat reduction and muscle stimulation.

The Company has wholly-owned subsidiaries located in the United States and two subsidiaries in Canada ("North America"), Hong Kong, Japan, Spain, two subsidiaries in Israel, India, Australia, China, the United Kingdom ("UK"), France, Italy and Germany. The Company's subsidiaries are referred to collectively herein as the "Subsidiaries." The Company sells its products primarily through its Subsidiaries.

XML 30 R11.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended Dec. 31, 2024
Accounting Policies [Abstract]	
SIGNIFICANT ACCOUNTING POLICIES	**NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:**

a. Basis of presentation

The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").

b. Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to valuation allowances.

c. Functional currency

The U.S. dollar ("U.S. dollar" or "$") is the currency of the primary economic environment in which the operations of the Company is conducted. Substantial revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar ("primary currency").

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in finance income (expenses), as appropriate.

The functional currency of each of the Subsidiaries is the U.S. dollar.

d. Principles of consolidation and presentation

The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany transactions and balances are eliminated in consolidation.

e. Cash and cash equivalents

The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

f. Short-term bank deposits

Bank deposits with maturities of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an annual rate of approximately 0.5%-6.15% in 2024 and 4.10%-7.01% in 2023.

g. Marketable securities

AFS Securities

Marketable securities consist of government bonds, municipal bonds and corporate debt securities (together "Debt Securities"), and certificates of deposit measured at fair value in each reporting period. The fair value of quoted securities is based on current market value.

Debt Securities and certificates of deposit are classified as available-for-sale (together "AFS Securities") under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company's current operations. Changes in fair value, excluding credit losses and impairments, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of Debt Securities and certificates of deposit as well as premium or discount amortization are included in the consolidated statements of income as finance income, net. Fair value is calculated based on publicly available market information. The amortized cost of the Debt Security will be reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost basis, or it has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recognized in finance income, net on the consolidated statements income.

The Company classifies investments that are readily convertible to known amounts of cash and have stated maturities of three months or less from the date of purchase as cash equivalents and those with stated maturities of greater than three months as marketable securities.

The Company determines the appropriate classification of its investments in marketable securities at the time of purchase.

h. Other Investments

The Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity investments without readily determinable fair values at cost for other investments, less impairment, adjusted for subsequent observable price changes. In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings. Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in orderly transactions for the identical or similar investment of the same issuer.

i. Inventories

Inventories include raw materials and finished products are valued at the lower of cost, "moving average" method, or net realizable value. The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions.

j. Leases

The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use ("ROU") assets, other current liabilities, and operating lease liabilities in the consolidated balance sheets.

The Company also elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 9).

k. Property and equipment

Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives:

Computers	3 – 4 years
Molds	4 – 10 years
Equipment and furniture	10 – 17 years

Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the improvements.

l. Impairment of long-lived assets

The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.

During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize an impairment loss on its long-lived assets.

m. Legal and other contingencies

Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

Management applies the guidance in ASC 450-20, "Loss Contingencies" when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Company's consolidated financial statements.

Legal costs incurred in connection with loss contingencies are expensed as incurred.

n. Income taxes:

1) The Company accounts for income taxes in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.

2) The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Subsidiaries outside of Israel; no additional deferred income tax assets have been provided, since the Company does not expect to distribute inter-company dividends in the foreseeable future that may result in additional tax liability.

3) Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income tax assets, as it is the Company's intent and ability to hold these investments.

4) The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit of the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.

o. Advertising expenses

Advertising expenses are charged to sales and marketing on the consolidated statement of income as incurred. Advertising expenses for the years ended December 31, 2024, 2023 and 2022 amounted to $15 million, $15 million, and $10 million, respectively.

p. Share-based compensation

The Company grants share options and restricted share units ("RSU") (together "Share-Based Compensation") to its employees, officers, directors and non-employees in consideration for services rendered and for acquiring goods. See note 12(a)(2) for details on outstanding share capital.

The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Binomial Model, and for each RSU granted is based on the Company's share price at the close of the last trading day prior to the date of the grant. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates.

The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Performance-based Share-Based Compensation expenses are calculated based on the valuation at the grant date, and recognized based on the probability of achieving those targets. The Company assess at what scale can the performance targets be reached at each balance sheet date, and expenses are recognized accordingly.

The Company issues new shares upon option exercise or RSU vesting.

q. Revenue recognition

The Company applies ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps:

(i) Identify the contract(s) with a customer;

(ii) Identify the performance obligations in the contract. The Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties;

(iii) Determine the transaction price;

(iv) Allocate the transaction price to the performance obligations in the contract;

The Company estimates the standalone selling prices of the services to be provided based on actual sales transactions of service contract purchased on a standalone basis and uses the residual approach to estimate the selling price of the products; and

(v) Recognize revenue when (or as) the performance obligation is satisfied.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company uses the following practical expedients that are permitted under the rules:

- The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in sales and marketing expenses.

- The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

The following is a description of the principal activities from which the Company generates its revenue.

Product Revenue, Net

Revenues from product sales are recognized when the customer obtains control over the Company's product, typically upon shipment to the customer. Revenues from shipping and handling activities that occur after the customer has obtained control of a good are recognized according to an accounting policy election as a fulfilment cost rather than as an additional promised service. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Payment terms and conditions vary by customer. The Company's standard terms for end users usually require of payment upon delivery and for distributors require a down payment and payments made within several month from the invoice date.

The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60 months) financing for the purchase of the Company's products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract.

Variable considerations include price concessions related to installment sales contracts. The Company estimates variable consideration using the most likely outcome amount. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur.

During the year ended December 31, 2024, the Company entered into risk sharing agreements with several leasing partners to facilitate and support the financing of capital equipment sales for its customers. Under these arrangements, a portion of each sale transaction funded by those leasing partners goes into a reserve fund used by the Company to provide a limited guarantee, up to the reserve fund amount, and used to compensate the leasing partners in the event of customer defaults. The guarantee is recognized on the estimated fair value amount according to ASC 460. In the following periods the Company will assess credit losses in accordance with ASC 326, see also note 2r.

The Company does not grant a right of return, refund, cancelation or termination. From time to time, the Company participates in its customers' marketing activities and deducts such amounts from revenue.

Service Revenue

The Company also generates revenues from long-term maintenance contracts ("Extended Warranty"). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. These maintenance agreements are included in contract liabilities. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed.

The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12 months as long-term.

r. Allowance for doubtful accounts and financial instruments – credit loss

The Company maintains the allowance for doubtful account resulting from the inability of the Company's customers to make required payments.

The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable. This information includes among other the historic experience, the extent and amount of the account and future expectations.

Allowance for credit losses due to the Company's accounts receivable amounted to $2,749 and $2,254 as of December 31, 2024 and 2023 respectively. Changes in the allowance for credit losses are recognized in general and administrative expenses. Accounts receivable are written-off against the allowance for credit losses when management deems the accounts are no longer collectible.

The following table sets forth activity in the Company's allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	2,254	1,318	1,107
Current-period provision	572	1,020	449
Write-offs charged against the Allowance and revaluation	(77)	(84)	(238)
Balance at end of year	2,749	2,254	1,318

s. Warranty reserve

The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company's warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs, the cost per repair and shipping cost. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The following table sets forth activity in the Company's accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	1,476	1,418	1,248
Cost incurred	(1,909)	(2,304)	(2,099)
Expense recognized	1,155	2,362	2,269
Balance at end of year	722	1,476	1,418

t. Cost of revenues

Cost of revenue consists of products purchased from turnkey sub-contractors which are responsible for the production of most of the Company's products under the Company's directions and supervision, raw materials for in-house assembly line, shipping and handling costs to customers and to subsidiaries, salary, employee-related expenses and overhead expenses of internal assembly line and service costs associate with warranty.

u. Research and development costs

Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material and third-party contractor's charges related to product development, regulatory affairs and clinical studies.

v. Net earnings per share

Basic earnings per share are computed by dividing net income attributed to the shareholders of InMode Ltd. by the weighted average number of the Company's ordinary shares, par value NIS 0.01 per share (including vested RSUs), outstanding for each period, net of treasury shares.

For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method.

w. Fair value measurement

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions.

The three levels of inputs that may be used to measure fair value are as follows:

Level 1 – Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2 – Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets.

Level 3 – Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available.

As of December 31, 2024, and 2023, the fair values of the Company's cash, cash equivalents, short term bank deposits, accounts receivable, accounts payable, approximated the carrying values of these instruments presented in the Company's consolidated balance sheets because of their nature.

x. Employee severance benefits

The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances.

In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company's consolidated balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies.

The amounts of severance payment expenses were $581 $522 and $431 and for the years ended December 31, 2024, 2023 and 2022, respectively.

The Company expects to contribute approximately $569 in the year ending December 31, 2025 to insurance companies in connection with its expected severance liabilities for the year.

y. Treasury Shares

Treasury shares are presented as a reduction of equity, at their cost to the Company.

z. Concentration of credit risks

Most of the cash and cash equivalents were deposited with U.S., European and Israeli banks and financial institutions and were comprised mainly of money market fund. The U.S. market constituted approximately 62% of the revenues in 2024.

The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for Credit Losses and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.

aa. War risk situation in Israel

In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During January 2025, a cease fire with Hamas was declared. As of the date of these consolidated financial statements, the war is ongoing and continues to evolve. The Company's headquarters, its R&D operations, and certain manufacturing facilities are located in Israel.

Currently, such activities in Israel remain largely unaffected. During the years ended December 31, 2024 and December 31, 2023, the impact of this war on the Company's results of operations and financial condition was immaterial.

ab. Recently adopted accounting pronouncements

In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company adopted this standard in the current period retrospectively to all prior periods presented in an entity's financial statements, refer to note 14.

ac. Newly issued accounting pronouncements, not yet adopted:

1) In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

2) In November 2024, the FASB issued ASU 2024-03 "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

XML 31 R12.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2024

Marketable Securities and Fair Value Measurement [Abstract]

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

NOTE 3 - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS:

AFS securities as of December 31, 2024 and 2023, consisted of U.S government bonds, municipal bonds, corporate debt securities and certificate of deposit. These marketable securities are recorded at fair value.

The following table sets forth the Company's marketable securities for the periods indicated:

	December 31	
	2024	2023
U.S. Government bonds	265,180	353,414
Municipal bonds	-	2,319
Corporate debt securities	2,508	13,234
Certificates of deposit	-	4,680
Total	267,688	373,647

The Company classifies AFS securities within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value. See also note 2(w).

The following table sets forth the Company's financial assets as of December 31, 2024 and 2023, that are measured at fair value on a recurring basis during the period:

	December 31, 2024			
	Fair value	Cost or amortized cost	Gross unrealized holding loss	Gross unrealized holding gains
Level 2 securities:				
Government bonds	265,180	265,619	(552)	113
Corporate debt securities	2,508	2,510	(3)	1
Total	267,688	268,129	(555)	114

	December 31, 2023			
	Fair value	Cost or amortized cost	Gross unrealized holding loss	Gross unrealized holding gains
Level 2 securities:				
Government bonds	353,414	355,382	(2,139)	171
Municipal bonds	2,319	2,363	(44)	-
Corporate debt securities	13,234	13,404	(170)	-
Certificates of deposit	4,680	4,680	-	-
Total	373,647	375,829	(2,353)	171

As of December 31, 2024 and 2023, the Company considered, based on its evaluation, that the decreases in market value on relevant marketable securities were temporarily impaired and primarily attributable to changes in interest rates, and therefore did not result in an impairment charge in finance income, net.

As of December 31, 2024 and 2023, the Company's debt securities and certificates of deposit had the following maturity dates:

	December 31	
	2024	2023
Due within one year	179,784	308,671
1 to 2 years	80,560	49,259
2 to 3 years	7,344	15,717
Total	267,688	373,647

XML 32 R13.htm IDEA: XBRL DOCUMENT

ACCOUNTS RECEIVABLE

12 Months Ended

Dec. 31, 2024

Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]

ACCOUNTS RECEIVABLE

NOTE 4 - ACCOUNTS RECEIVABLE:

Accounts receivable consist of the following:

	December 31	
	2024	2023
Trade	40,739	46,646
Notes receivable	1,521	1,640
Less - allowance for credit losses	(2,749)	(2,254)
	39,511	46,032

Less - non-current accounts receivable, net	(3,176)	(3,670)
Total current accounts receivable, net	36,335	42,362

XML 33 R14.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES

12 Months Ended

Dec. 31, 2024

Other Receivables, Net, Current [Abstract]

PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES

NOTE 5 - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES:

Prepaid expenses and other current receivables consist of the following:

	December 31	
	2024	2023
Advances to suppliers	14,960	11,960
Prepaid expenses	2,421	3,041
Government institutions	2,896	948
Income tax	1,423	66
Other	397	253
Total other current receivables	22,097	16,268

XML 34 R15.htm IDEA: XBRL DOCUMENT

INVENTORIES

12 Months Ended

Dec. 31, 2024

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 6 - INVENTORIES:

Inventories consist of the following:

	December 31	
	2024	2023
Raw materials	15,454	12,080
Finished products	44,094	33,015
Total inventories	59,548	45,095

XML 35 R16.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

NOTE 7 - PROPERTY AND EQUIPMENT, NET:

Composition of property and equipment grouped by major classifications is as follows:

	December 31	
	2024	2023
Computers	1,445	1,334
Office furniture and equipment	709	670
Molds	3,020	2,592
Leasehold improvements	1,333	1,243
	6,507	5,839
Less: accumulated depreciation	(4,185)	(3,457)
Total property and equipment, net	2,322	2,382

Total depreciation and amortization in respect of property and equipment were $728, $623 and $680 for the years ended December 31, 2024, 2023 and 2022, respectively.

XML 36 R17.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS

12 Months Ended

Dec. 31, 2024

Investments [Abstract]

OTHER INVESTMENTS

NOTE 8 - OTHER INVESTMENTS:

In November 2019, the Company signed a Share Purchase and Shareholders Agreement (the "SPA") with (BY) Medimor Ltd., one of the Company's turnkey manufacturing subcontractors ("Medimor"). Pursuant to the SPA, the Company has invested (in December 2019 and July 2020) an aggregate amount of $600 in consideration for 1,369,863 ordinary shares of Medimor (which reflected at the signing date a 14.78% ownership interest on an as-issued basis and 10.34% ownership interest on a fully diluted basis).

In November 2023, the Company signed an additional SPA with Medimor and invested $100 in consideration for 117,440 ordinary shares of Medimor.

The SPAs together reflected as of December 31, 2024, 2023 a 14.78% ownership interest on an as-issued basis and 11.23% ownership interest on a fully diluted basis.

The Company's investment in Medimor is measured at cost, less impairment and adjusted for subsequent observable price changes if any. As of December 31, 2024, 2023 and 2022, the Company did not recognize an impairment or adjustment on its other investments.

XML 37 R18.htm IDEA: XBRL DOCUMENT

LEASES

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

LEASES

NOTE 9 - LEASES:

The Company's main leasing properties are located in Israel, USA and Canada as detailed below:

a. In May 2018, the Company signed a lease agreement for its headquarters in Israel. In January 2019, February 2020, March 2021, March 2023, May 2023 and June 2024 the Company signed supplement lease agreements, further expanding its headquarters in Israel (collectively, the "Lease Agreement"). The Lease Agreement will expire in December 2027. The current monthly rent payment under the Lease Agreement is approximately $76.7.

The costs under the Lease Agreement in Israel are linked to the Israeli Consumer Price Index. For purposes of ensuring the Company's obligation towards the lessor, the Company has provided the lessor with a bank guarantee of NIS 966 thousand (approximately $263).

The Company also leases warehouse outside the Company's offices. The Lease Agreement is for one year, with the Company options to renewal every year for 10 years. According to management's assessment, the lease will last until August 2027.. The current monthly rent payment under the Lease Agreement is approximately $8.9.

The Company also leases vehicles for several employees in Israel for a period of three years.

b. In August 2020, the Company's U.S. subsidiary, has signed a new lease agreement, for additional lease agreement of property and for its offices ("U.S Lease"). The U.S. Lease is for 7 years and 4 months which began in the middle of April of 2021. The current monthly rent payment is approximately $28.

c. The Company's Canadian subsidiary has signed a new lease agreement in April 2022 for property and for its offices ("Canadian Lease"). The Canadian Lease is for 3 years until July 2025. The current monthly rent payment is approximately $17.

From time to time the Company also leases small properties, mainly for offices for Subsidiaries around the world.

The lease cost was as follows:

	Year ended December 31		
	2024	2023	2022
Operating lease cost	3,057	2,348	1,628

Supplemental cash flow information related to leases was as follows:

	Year ended December 31		
	2024	2023	2022
Operating cash flows from operating leases	3,173	2,530	1,881

Supplemental balance sheet information related to leases was as follows:

	December 31,	
	2024	2023
Operating Leases		
Operating lease right-of-use assets	8,732	9,698
Other current liabilities	2,511	2,404
Operating lease liabilities	5,311	6,613
Total operating lease liabilities	7,822	9,017
Weighted Average Remaining Lease Term		
Operating leases	3.30 years	2.90 years
Weighted Average Discount Rate		
Operating leases	5.24%	4.78%

As of December 31, 2024, the maturities of lease liabilities were as follows:

	Operating Leases
Year Ending December 31,	
2025	2,917
2026	2,411
2027	2,124
2028	659
2029 and beyond	353
Total lease payments	8,464
Less imputed interests	(642)
Total	7,822

XML 38 R19.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES

12 Months Ended
Dec. 31, 2024

Payables and Accruals [Abstract]

OTHER CURRENT LIABILITIES

NOTE 10 - OTHER CURRENT LIABILITIES:

Other current liabilities consist of the following:

	December 31	
	2024	2023
Employees and related expenses	16,725	21,040
Government institutions	2,566	3,932
Income tax payable	933	1,918
Warranty reserve	722	1,476
Operating lease liabilities	2,511	2,404
Credit risk sharing liabilities	5,507	-
Contractor liability	5,101	5,656
Accrued commissions	2,379	1,435
Other	2,870	1,386
Total other current liabilities	39,314	39,247

XML 39 R20.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

12 Months Ended
Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 11 - COMMITMENTS AND CONTINGENCIES:

a. Subcontracting Agreements

The Company has an existing turnkey manufacturing agreements with three of its major subcontractors in Israel in connection with manufacturing and assembling the Company's products.

The Company has agreements with two of the subcontractors which are renewed automatically every year for an additional one-year period, unless either the Company or the turnkey manufacturer gives written notice three months prior to the expiration of the term of its decision not to renew the agreement.

Additionally, the Company or the turnkey manufacturer has the ability to terminate the contract at any time and for any reason with a prior written notice of four months.

In addition, in October 2019, the Company entered into a turnkey manufacturing agreement with another of its major subcontractors in Israel, Medimor (See also note 8). The agreement is for three years and renewed automatically every year afterwards for an additional one-year period, unless either the Company or Medimor gives written notice three months prior to the expiration of the term of its decision not to renew the agreement. Additionally, the Company or Medimor has the ability to terminate the agreement at any time and for any reason with a prior written notice of six months.

According to the agreements above, the Company does not have a minimum order obligation, but the Company provides the subcontractors a six-month rolling forecast with the projected demand for products. In case of termination of the agreement with each subcontractor, the Company has to compensate that subcontractor for non-returnable inventory, materials in orders that cannot be cancelled and finished products inventory. As of December 31, 2024, the subcontractors' finished goods inventory, raw materials and open orders amounted to approximately $43,607. In order to secure these obligations, the Company paid its subcontractors advances in the amount of $13,502.

b. Litigation and contingencies

On February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action in the United States District Court for the Central District of California against the Company and certain of its officers and directors. The lawsuit is purportedly brought on behalf of purchasers of the Company's common stock between February 18, 2020 and December 6, 2023, inclusive. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Company's business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. The court entered an order appointing a group of shareholder funds as the lead plaintiffs, who filed an amended complaint on January 31, 2025. The Company's deadline to respond to the amended complaint is April 1, 2025.

The aforementioned legal proceeding is in the preliminary stages, and the Company has not yet responded to the complaint. As of the date of this filing, the Company is unable to estimate the range of loss, if any, that could result were there to be an adverse final decision in this case, and an estimated liability has not been recorded in the Company's financial statements. The defendants intend to deny the allegations of wrongdoing and vigorously defend itself against the claims.

In addition, as is the case from time to time, the Company was involved in various claims, legal proceedings and investigations.

XML 40 R21.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY

12 Months Ended
Dec. 31, 2024

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' EQUITY

NOTE 12 - SHAREHOLDERS' EQUITY:

a. Share Capital:

1) Ordinary shares

Each holder of the Company's ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Company's Board of Directors. Since inception, the Company has not declared any dividends.

In September 2020, the Company approved a share repurchase program of up to two million ordinary shares, to be purchased out of the Company's cash reserve and to be paid solely from the Company's IPO proceeds. In February 2022, the Company approved that the share repurchase program could also be funded from the proceeds of exercised options. In March 2022, the Company approved an additional repurchase program of up to one million ordinary shares, to be purchased out of its cash reserve and to be paid from the Company's remaining IPO proceeds and from the proceeds of exercised options.

during 2022, the Company purchased 1,077,213 shares in the amount of $42.6 million. During 2023 the company did not purchase any shares.

In May 2024, the Company approved an additional share repurchase program of up to 8.37 million ordinary shares. In September 2024, the Company approved an additional share repurchase program of up to 7.68 million ordinary shares.

During 2024 the Company purchased 16,050,000 shares in the amount of $285.4 million. As of December 31, 2024, the Company purchased in aggregate 18,607,829 shares in the amount of $380.6 million under these repurchase programs.

2) Share-based compensation

On January 30, 2008, the Company's Board of Directors adopted two share option plans as follows (collectively, the "2008 Plans"):

a) 2008 Israeli Option Plan ("2008 Israeli Plan") allowing the Company to grant ordinary shares and options to purchase ordinary shares to Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 Israeli Plan grants the right to exercise such option into one ordinary share of the Company.

b) 2008 ROW Option Plan ("2008 ROW Plan") allowing the Company to grant ordinary shares and options to purchase ordinary shares to non-Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 ROW Plan grants the right to exercise such option into one ordinary share of the Company.

In June 2018, the Company's Board of Directors adopted a new incentive plan ("2018 Incentive Plan"), allowing the Company to grant ordinary shares, options to purchase ordinary shares, restricted shares and restricted share unit ("RSUs") (together, "Awards") to Israeli and other non-U.S. employees, officers, directors, consultants and service providers of the Company and its Subsidiaries. The 2018 Incentive Plan also includes as an appendix a sub-plan allowing the Company to grant awards to U.S. employees, officers, consultants and service providers of the Company and its Subsidiaries. Each option award under 2018 Incentive Plan grants the right to exercise such option into one ordinary share of the Company. The Company's subsidiary in U.S. may recognize under U.S. corporate tax laws, a tax benefit for RSU and options exercised for U.S. employees and U.S. service providers for tax purposes.

The grant of awards to Israeli employees, officers and directors under the 2008 Israeli Plan and the 2018 Incentive Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each award grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim as an expense for tax purposes the amounts credited to employees as benefits, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the 2008 Israeli Plan, with the exception of the work-income benefit component, if any, determined on grant date. For consultants and service providers, grants under the 2008 Israeli Plan and the 2018 Incentive Plan are subject to Section 3(i) of the Israeli Income Tax Ordinance.

Upon the adoption of the 2018 Incentive Plan, the then-current pool of awards available for future grants under the 2008 Plans was canceled and returned to the Company's authorized and un-issued share capital. In addition, any shares returning to the free pool of options under the 2008 Plans, due to options expirations or otherwise, are automatically returning to the Company's authorized and un-issued share capital.

Upon adoption of the 2018 Incentive Plan, the Board and the shareholders resolved to approve an evergreen mechanism with respect to the 2018 Incentive Plan, under which the number of reserved, authorized and unissued ordinary shares of the Company available for issuance of awards pursuant to the 2018 Incentive Plan shall automatically increase on an annual basis, by such number of ordinary shares as follows: on the first business day of each calendar year beginning in 2019, the number of awards equal to the lesser of (i) 800,000 ordinary shares, (ii) three percent of the number of shares outstanding as of such date or (iii) a lesser number of ordinary shares as shall be determined by the Company's board of directors.

As of December 31, 2024, the total awards under 2018 Incentive Plan that have been authorized to be issued as ordinary shares were 8,378,000 of which 1,397,772 awards were available for grant under the 2018 Incentive Plan.

At January 2025, the Board of the Company approved to increase by another 800,000 ordinary shares through the evergreen mechanism to amount of 9,178,000 ordinary shares.

Share Options

The following tables is a summary of stock option activity for the year ended on December 31, 2024:

	Year ended December 31	
	2024	
	Number of Options	Weighted Average Exercise Price*
Outstanding at beginning of year	1,638,495	$ 4.96
Changes during the year:		
Granted	-	-
Canceled	(6,996)	10.17
Exercised	(1,003,409)	2.63
Forfeited	-	-
Expired	-	-
Outstanding at end of year	628,090	$ 8.61
Exercisable at end of year	628,090	$ 8.61

* In U.S. dollars per Ordinary Share

As of December 31, 2024, the weighted-average remaining contractual life of exercisable options were 1.88 years. The total intrinsic value of options exercised during 2024, 2023 and 2022 were approximately $12,184, $24,819 and $10,549, respectively.

The following tables summarize information concerning outstanding and exercisable options as of December 31, 2024:

Options outstanding and exercisable		
Exercise Prices *	Number of options Outstanding and exercisable at end of year	Weighted average remaining contractual life
$ 3.16	42,608	0.71
$ 3.75	29,595	0.68
$ 5.11	65,576	1.26
$ 7.00	41,000	1.61
$ 9.85	424,149	2.16
$ 12.16	18,662	2.35
$ 21.62	6,500	2.86

* In U.S. dollars per Ordinary Share.
The aggregate intrinsic value of total exercisable options as of December 31, 2024 is $5,110.

Restricted Share Units

The following tables summarize information concerning RSUs as of December 31, 2024 :

	Year ended December 31	
	2024	
	Number of RSUs	Weighted Average Grant Date Fair Value
Outstanding at beginning of year	936,049	39.04
Changes during the year:		
Granted	716,395	25.90
Vested	(622,799)	41.20
Forfeited	(204,740)	28.67
Outstanding at end of year	824,905	28.57

Each RSU represents the right to receive one ordinary share of the Company upon the vesting thereof. The fair value of an RSU is identical to the value of the underlying share at the close of the last trading day prior to the day of grant. The weighted average fair value of each RSU granted in 2024 was 25.9, in 2023 was 34.44 and in 2022 49.35 based on the Company's share price at closing of trading day prior to the day of grant.

The total fair value of RSUs granted during the year ended December 31, 2024, 2023 and 2022, was $18,556, $24,334, and $30,817, respectively.

As of December 31, 2024, the Company had 824,905 unvested RSUs. The total unrecognized compensation cost of employee RSUs as of December 31, 2024 is $9,192, which is expected to be recognized over a weighted average period of 0.65 years.

The total vesting-date value of equity classified RSUs vested during 2024 is $14,215.

The following table illustrates the effect of share-based compensation on the consolidated statements of income:

	Year ended December 31		
	2024	2023	2022
Cost of sales	1,833	2,046	1,917
Research and development expenses	2,177	2,652	3,166
Selling and marketing expenses	11,367	17,167	17,302
General and administrative expenses	1,192	1,735	2,067
	16,569	23,600	24,452

XML 41 R22.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended
Dec. 31, 2024

Income Tax Disclosure [Abstract]
INCOME TAXES

NOTE 13- INCOME TAXES:

a. InMode Ltd.

The Company is taxed according to Israeli tax laws:

1) Measurement of results for tax purposes

The Company as a "foreign-investment company" measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986.

These consolidated financial statements are presented in U.S. dollars. The changes in the exchange rate of the dollar, both on an annual and a cumulative basis, cause a difference between taxable income and income reflected in these consolidated financial statements. ASC 740-10-25 prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are re-measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above-mentioned differences were not reflected in the computation of deferred tax assets and liabilities.

2) Basis of taxation

a) Incentives Applicable until 2020

Under the Encouragement of Capital Investments Law, including Amendment No. 60 thereof as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status, the Israeli Company was tax exempt from 2012 to 2020 for income derived from the Benefited Enterprise. See also note 13a(2)(b).

b) Incentives Applicable starting 2021 - The New Technological Enterprise and Preferred Enterprise Incentives Regime - Amendment 73 to the Investment Law

On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the "Regulations") were published, which adopted Action 5 under the base erosion and profit shifting ("BEPS") regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE (Preferred technological enterprise) or PE (Preferred enterprise) and under the SPTE (Special Preferred Technology Enterprise) regime and determine certain requirements relating to documentation of intellectual property for the purpose of the PTE or PE. According to these provisions, a company that complies with the terms under the PTE or PE regime may be entitled to certain tax benefits with respect to income generated during the company's regular course of business and derived from the preferred intangible asset (as determined in the Investments Law) and income attributed to production activity (different tax rate), Excluding income derived from intangible assets used for marketing.

In the event that intangible assets used for marketing purposes generate over 10% of the PTE's or PE's income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE or PE will not be required to exclude the marketing income from the PTE's or PE's total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE and PE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset.

The Company reviews every year whether it meets the conditions of the PTE or PE. The difference for the Company is immaterial since it located in development area A.

Under the Regulations the Company's tax rate is expected to be approximately 7.5%.

Amendment 74 to the Investment Law

Pursuant to the amendment to the Investments Law which became effective on November 15, 2021, a company that elects by November 15, 2022 to pay a reduced corporate tax rate as set forth in that amendment (rather than the regular corporate tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company until December 31, 2020 will be entitled to distribute a dividend from such income or to be used for any other reason found by the company, without being required to pay additional corporate tax.

The Company elected to take advantage of the amendment, and during November 2022 has paid NIS 42.5 million ($12.0 million) as a one-time payment, and as a result NIS 591 million (approximately $165.7 million) of the Company's undistributed exempt income for years 2012 until 2020 are entitled to be distributed as dividend or to be used for any other reason found by the Company without being required to pay additional corporate tax. As a result, the Company is required to invest NIS 32 million (approximately $9 million) in its industrial enterprises in Israel over a five year period. Such investment may be in the form of the acquisition of industrial assets (excluding real estate assets), investment in R&D in Israel, or payroll payments to new employees to be hired by the enterprise. All the amount that was required to invest was invested in 2022.

3) Corporate tax rate in Israel

The income of Israeli companies, other than preferred income, is taxed in accordance with Israeli tax laws at the regular corporate tax rates. The corporate tax rate is 23% for 2018 and thereafter. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.

b. Subsidiaries outside of Israel

Subsidiaries that are incorporated outside of Israel are assessed for taxes under the tax laws in their countries of residence.

The corporate tax rates of Subsidiaries outside of Israel for the year ended on December 31, 2024 is between 15% to 26.5%.

As of December 31, 2024, the Company's subsidiary in U.S has an accumulated federal tax loss carryforward of approximately $203 million and state tax loss carryforward (post apportionment) of approximately $165.5 million derived mainly from exercises of options by employees which provided the Company tax deductions in excess of the actual compensation expenses (recognized in loss), under the Tax Cuts and Jobs Act of 2017 ("TCJA").

Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January 1, 2018, have no expiration date, but they are limited to 80% of the company's taxable income in any given tax year.

Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of each reporting date, management considers new evidence, both positive and negative, that could impact management's view with regard to the future realization of deferred tax assets for each jurisdiction.

In the determination of the appropriate valuation allowances, the Company considers the most recent projections of future business results and taxable income by jurisdiction as well as the reversal of existing taxable temporary differences. The Company also considers the prior earnings history. Actual results may vary in comparison to current projections.

During the year ended December 31, 2024, the Company determined that the positive evidence overcame any negative evidence, primarily due to cumulative income in recent years, including the effect of permanent adjustments, and the expectation of profitability in periods, and concluded that it was more likely than not that the United States net deferred tax assets were realizable. As a result, the Company released the valuation allowance of $60,129 related to the United States net deferred tax assets during the year ended December 31, 2024. As of December 31, 2024, the Company concluded that the deferred tax assets for certain jurisdictions would not be realized and therefore reserved valuation allowance in the amount of $4,248 with respect to these deferred tax assets.

c. Deferred income tax assets

Deferred income tax assets reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Company's net deferred tax assets (liabilities) at December 31, 2024 and 2023 were as follows:

	December 31	
	2024	**2023**
Deferred tax assets in respect of:future		
Subsidiaries carryforward losses	54,349	58,075
Other temporary differences	3,659	3,112
Share-based compensation	2,424	4,194
Deferred tax asset in respect to other comprehensive loss	101	502
Total deferred tax assets before valuation allowance	60,533	65,883
Valuation allowance	(4,248)	(64,377)
Total deferred tax assets	56,285	1,506

Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.

d. Valuation allowance

	2024	**2023**
Balance at January 1	64,377	66,815
Utilization of carry forward tax losses	(5,399)	(2,438)
Reductions for the current year that record against defer tax asset	(54,730)	-
Balance at December 31	4,248	64,377

e. Reconciliation of theoretical tax expense to actual tax expense

Following is a reconciliation of the theoretical provision for income tax, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax on income:

	Year ended December 31		
	2024	**2023**	**2022**
Income before taxes on income	143,469	217,267	201,466
Theoretical tax expenses at the statutory rate of InMode Ltd.	23%	23%	23%
	32,998	49,971	46,337
Increase (decrease) in taxes on income due to:			
Benefits to the Benefited Enterprise	(16,682)	(31,296)	(27,282)
Different effective tax rates applicable to the Subsidiaries	210	165	138
Change in valuation allowance	(60,129)	(2,438)	(3,608)
Uncertain tax positions	1,957	1,096	303
Non-deductible expenses and other permanent differences, mainly share based compensation expenses	3,840	1,850	1,842
Amendment to the Investments Law payment - see also note 13a(2)(b)	-	-	12,017
Settlements with the Israeli tax authority net of decrease of related uncertain tax provision	-	-	10,199
	(37,806)	19,348	39,946

f. Tax assessments

In February 2022, the Israeli Company settled the 2017-2020 income tax assessment with the Israeli tax authority, paying $1.3 million. also see Note 13a(2)(b).

In December 2022 the Company reached an agreement with the Israeli Tax Authority under which the Company paid on January 2023 NIS 50.2 million (approximately $14.3 million).

As of December 31, 2024, tax assessments of the Israeli Company through tax year 2021 are considered final. In addition, all tax assessments of one of the Company's subsidiaries in Israel through tax year 2019 are considered final. Another Israeli subsidiary was established in 2022 and therefore does not have any tax year that considered final.

As of December 31, 2024, all tax assessments on the Company's subsidiary in the United States, through tax year 2019, are considered final.

The other Subsidiaries' open tax years range from 2019-2024.

g. Income before income taxes is composed of the following:

	Year ended December 31		
	2024	2023	2022
InMode Ltd. and Israeli subsidiaries	139,241	211,137	196,354
Subsidiaries outside of Israel	4,228	6,130	5,112
	143,469	217,267	201,466

h. Tax expenses (tax benefit):

	Year ended December 31		
	2024	2023	2022
Current:			
Israel	15,664	17,633	38,248
Subsidiaries	1,709	1,864	1,614
	17,373	19,497	39,862
Deferred:			
Israel	(42)	(149)	84
Subsidiaries	(55,137)	-	-
	(55,179)	(149)	84
Total expenses (income) taxes on income	(37,806)	19,348	39,946

i. Uncertain tax positions:

ASC No. 740, Income Taxes, requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company.

The following table summarizes the activity of the Company's unrecognized tax benefits:

	Year ended December 31	
	2024	2023
Balance at January 1	1,399	303
Increase in uncertain tax positions for the current year	1,957	1,096
Balance at December 31	3,356	1,399

The Company does not expect uncertain tax positions to change significantly over the next 12 months.

XML 42 R23.htm IDEA: XBRL DOCUMENT

Segments

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]

Segments

NOTE 14 - Segments:

The Company operates globally, and its business is unified for the purposes of valuation of its performance.

Management does not segregate it business for internal reporting. The Company's Chief Operating Decision Maker ("CODM"), who is the CEO evaluates the Company's performance based on its unified internal reporting which is consistent with the presentation in the Company's financial statements.

In order to make operating decisions, the CODM examines the employee salaries including the commission expenses. In addition, the CODM examines the segment's marketing expenses (which includes advertising and trade shows)- the amounts that will be invested in advertising and trade shows.

	Year ended December 31	
	2024	2023
Revenues from customers	394,818	492,048
Less:		
Employee salaries including commission expenses	101,920	109,484
Marketing expenses	26,987	29,039
Share based compensation	16,569	23,600
Interest income	33,537	21,128
Depreciation	728	623
*Other expenses	138,682	133,163
Income before income taxes	143,469	217,267
Income taxes benefit (expenses)	37,806	(19,348)
Net income	181,275	197,919

* Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.

XML 43 R24.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]

Entity Wide Disclosures [Text Block]

NOTE 15 - ENTITY-WIDE DISCLOSURE:

a. Revenue

1) Revenues by geographic area were as follows:

	Year ended December 31		
	2024	2023	2022
United States	244,774	307,818	298,612
Europe	63,441	62,532	49,274
Asia	42,974	47,744	36,492
Other	43,629	73,954	69,893
	394,818*	492,048*	454,271*

*Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.

2) Revenues based on products' category were as follows:

	Year ended December 31		
	2024	2023	2022
Capital Equipment revenues	315,547	412,089	394,212
Consumables and service revenues	79,271	79,959	60,059
	394,818	492,048	454,271

3) Revenues based on products' technology were as follows:

	Year ended December 31		
	2024	2023	2022
		%	
Minimal-Invasive	87	83	81
Hands-Free	5	8	10
Non-Invasive	8	9	9
	100	100	100

4) The changes in contract liabilities are as follows:

	Year ended December 31	
	2024	2023

Balance as of January 1	14,689	17,757
Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period	16,975	12,498
Revenue recognized that was included in the contract liability balance at the beginning of the period	(11,573)	(15,566)
Balance as of December 31	20,091	14,689
Contract liability presented in non-current liabilities (1)	3,336	3,766
Contract liability presented in current liabilities	16,755	10,923

(1) As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029.

b. Long-Lived Assets

	December 31	
	2024	**2023**
Israel	5,757	6,704
United States	1,421	1,789
Other	3,876	3,587
	11,054	12,080
Other long-term assets*	3,876	4,370
	14,930	16,450

*Consists of non-current accounts receivable, net and other investments

XML 44 R25.htm IDEA: XBRL DOCUMENT

RELATED PARTIES

12 Months Ended
Dec. 31, 2024

Related Party Transactions [Abstract]

RELATED PARTIES

NOTE 16 - RELATED PARTIES:

a. The Company receives and provides certain services from and to Home Skinovations Ltd., a related party as part of a service agreement between them. The services include an office sublease in Israel, use of certain computer hardware and switchboard infrastructure, certain software licenses, joint purchases of employee's welfare products and services from third parties and limited manpower services. The Chief Executive Officer of the Company is also a substantial shareholder and board member of Home Skinovations Ltd. and one of the Company's directors, serves on the board of directors of Home Skinovations Ltd. The Company recorded expenses related to services received and provided from and to Home Skinovations Ltd. of $0, $99 and $332 for the years ended December 31, 2024, 2023 and 2022, respectively.

In addition, the balance of the accounts payable as of December 31, 2024, 2023 was $0.

In February 2022 the Company have entered into an Asset Purchase Agreement with Home Skinovations, whereby Home Skinovations Ltd. sold and assigned to the Company all of Home Skinovations Ltd.'s right, title and interest in and to Home Skinovations Ltd.'s Spa segment assets (including molds, tooling, inventory and trademarks) and further granted the Company an exclusive license to certain IP rights of Home Skinovations Ltd., all the foregoing in consideration for an aggregate amount of $497.

The Company's subsidiary in Canada receives and provides certain services from and to a subsidiary of Home Skinovations Ltd. in Canada as part of a service agreement between them. The services include mobile phone services, an office sublease, use of certain computer hardware and switchboard infrastructure, certain software licenses, joint purchases of employee's welfare products and services from third parties and limited manpower services. In relation to these services received and provided, the Company recorded expenses (income) in the amount of $0, $(30) and $123 for the years ended December 31, 2024, 2023 and 2022, respectively. In addition, the balance of the accounts receivable as of December 31, 2024, 2023 was $0.

1) The Company's subsidiaries in North America received marketing services from SpaMedica International SRL, which was amalgamated with an affiliate company into the Company's major shareholder BoomerangFX International SRL during 2021. Dr. Stephan Mulholland is a beneficiary owner of 100% of the Company's major shareholder BoomerangFX. The Company recorded expenses related to those services in the amount of $172 for the year ended December 31, 2021. Starting from 2022 calendar year, Dr. Stephen Mulholland provides the Company and its subsidiaries certain marketing services as an independent contractor. The Company recorded expenses related to those services in the amount of $636, $723 for the years ended December 31, 2023 and 2022, respectively.

   During 2023 Dr. Stephen Mulholland ceased to be a related party.

2) The Company receives certain investment portfolio management services from Himalaya Family Office Consulting Ltd., with respect to part of its investment portfolio. The Chief Executive Officer of the Company, is a minor shareholder and a board member of Himalaya Family Office Consulting Ltd. In relation to these services, the Company recorded expenses in the amount of $333, $193 and $100 for the years ended December 31, 2024, 2023 and 2022, respectively.

   In addition, the balance of the accounts payable as of December 31, 2024 and 2023, was $27 and $86, respectively.

XML 45 R26.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended
Dec. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 17 - SUBSEQUENT EVENTS

During February 2025, the Board of Directors of the Company has approved a new Share repurchase program of 10% of the Outstanding Shares.

XML 46 R27.htm IDEA: XBRL DOCUMENT

Insider Trading Policies and Procedures

12 Months Ended
Dec. 31, 2024

Insider Trading Policies and Procedures [Line Items]

Insider Trading Policies and Procedures Adopted	true

XML 47 R28.htm IDEA: XBRL DOCUMENT

Cybersecurity Risk Management and Strategy Disclosure

12 Months Ended
Dec. 31, 2024

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	The risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the Company's objectives as well as specific risks related to a compromise to the security of data.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our cybersecurity process has been integrated into the Company's overall risk management system and process, and is solely internally managed.
Cybersecurity Risk Board of Directors Oversight [Text Block]	The oversight of cybersecurity threats is undertaken by our Chief Information Officer (CIO), who holds over 25 years of experience in information technology, and is supported by management.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	To facilitate its monitoring over cybersecurity risks, the Company has engaged a Chief Information Security Officer (CISO) who holds over 7 years of experience in information technology in connection with its cybersecurity process.
Cybersecurity Risk Role of Management [Text Block]	The Company has developed and maintained a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk and to ensure compliance with the principles of Services Organization Control Type 2, or SOC 2, including its tenets of security, availability and confidentiality.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our audit and investment committee is responsible for cybersecurity oversight and monitoring risk.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

XML 48 R29.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended
Dec. 31, 2024

Accounting Policies [Abstract]

Basis of presentation

a. Basis of presentation

The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").

Use of estimates

b. Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to valuation allowances.

Functional currency

c. Functional currency

The U.S. dollar ("U.S. dollar" or "$") is the currency of the primary economic environment in which the operations of the Company is conducted. Substantial revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar ("primary currency").

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in finance income (expenses), as appropriate.

The functional currency of each of the Subsidiaries is the U.S. dollar.

Principles of consolidation and presentation

d. Principles of consolidation and presentation

The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany transactions and balances are eliminated in consolidation.

Cash and cash equivalents

e. Cash and cash equivalents

The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

Short-term bank deposits

f. Short-term bank deposits

Bank deposits with maturities of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an annual rate of approximately 0.5%-6.15% in 2024 and 4.10%-7.01% in 2023.

Marketable securities

g. Marketable securities

AFS Securities

Marketable securities consist of government bonds, municipal bonds and corporate debt securities (together "Debt Securities"), and certificates of deposit measured at fair value in each reporting period. The fair value of quoted securities is based on current market value.

Debt Securities and certificates of deposit are classified as available-for-sale (together "AFS Securities") under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company's current operations. Changes in fair value, excluding credit losses and impairments, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of Debt Securities and certificates of deposit as well as premium or discount amortization are included in the consolidated statements of income as finance income, net. Fair value is calculated based on publicly available market information. The amortized cost of the Debt Security will be reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost basis, or it has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recognized in finance income, net on the consolidated statements income.

The Company classifies investments that are readily convertible to known amounts of cash and have stated maturities of three months or less from the date of purchase as cash equivalents and those with stated maturities of greater than three months as marketable securities.

The Company determines the appropriate classification of its investments in marketable securities at the time of purchase.

Other Investments

h. Other Investments

The Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity investments without readily determinable fair values at cost for other investments, less impairment, adjusted for subsequent observable price changes. In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings. Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in orderly transactions for the identical or similar investment of the same issuer.

Inventories

i. Inventories

Inventories include raw materials and finished products are valued at the lower of cost, "moving average" method, or net realizable value. The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions.

Leases

j. Leases

The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use ("ROU") assets, other current liabilities, and operating lease liabilities in the consolidated balance sheets.

The Company also elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 9).

Property and equipment

k. Property and equipment

Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives:

Computers	3 – 4 years
Molds	4 – 10 years
Equipment and furniture	10 – 17 years

Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the improvements.

Impairment of long-lived assets

l. Impairment of long-lived assets

The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.

During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize an impairment loss on its long-lived assets.

Legal and other contingencies

m. Legal and other contingencies

Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

Management applies the guidance in ASC 450-20, "Loss Contingencies" when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Company's consolidated financial statements.

Legal costs incurred in connection with loss contingencies are expensed as incurred.

Income taxes

n. Income taxes:

1) The Company accounts for income taxes in accordance with ASC 740, "Income Taxes" ("ASC 740"). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.

2) The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Subsidiaries outside of Israel; no additional deferred income tax assets have been provided, since the Company does not expect to distribute inter-company dividends in the foreseeable future that may result in additional tax liability.

3) Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income tax assets, as it is the Company's intent and ability to hold these investments.

4) The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit of the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.

Advertising expenses

o. Advertising expenses

Advertising expenses are charged to sales and marketing on the consolidated statement of income as incurred. Advertising expenses for the years ended December 31, 2024, 2023 and 2022 amounted to $15 million, $15 million, and $10 million, respectively.

Share-based compensation

p. Share-based compensation

The Company grants share options and restricted share units ("RSU") (together "Share-Based Compensation") to its employees, officers, directors and non-employees in consideration for services rendered and for acquiring goods. See note 12(a)(2) for details on outstanding share capital.

The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Binomial Model, and for each RSU granted is based on the Company's share price at the close of the last trading day prior to the date of the grant. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates.

The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Performance-based Share-Based Compensation expenses are calculated based on the valuation at the grant date, and recognized based on the probability of achieving those targets. The Company assess at what scale can the performance targets be reached at each balance sheet date, and expenses are recognized accordingly.

The Company issues new shares upon option exercise or RSU vesting.

Revenue recognition

q. Revenue recognition

The Company applies ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps:

(i) Identify the contract(s) with a customer;

(ii) Identify the performance obligations in the contract. The Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties;

(iii) Determine the transaction price;

(iv) Allocate the transaction price to the performance obligations in the contract;
The Company estimates the standalone selling prices of the services to be provided based on actual sales transactions of service contract purchased on a standalone basis and uses the residual approach to estimate the selling price of the products; and

(v) Recognize revenue when (or as) the performance obligation is satisfied.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company uses the following practical expedients that are permitted under the rules:

- The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in sales and marketing expenses.

- The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

The following is a description of the principal activities from which the Company generates its revenue.

Product Revenue, Net

Revenues from product sales are recognized when the customer obtains control over the Company's product, typically upon shipment to the customer. Revenues from shipping and handling activities that occur after the customer has obtained control of a good are recognized according to an accounting policy election as a fulfilment cost rather than as an additional promised service. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Payment terms and conditions vary by customer. The Company's standard terms for end users usually require of payment upon delivery and for distributors require a down payment and payments made within several month from the invoice date.

The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60 months) financing for the purchase of the Company's products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract.

Variable considerations include price concessions related to installment sales contracts. The Company estimates variable consideration using the most likely outcome amount. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur.

During the year ended December 31, 2024, the Company entered into risk sharing agreements with several leasing partners to facilitate and support the financing of capital equipment sales for its customers. Under these arrangements, a portion of each sale transaction funded by those leasing partners goes into a reserve fund used by the Company to provide a limited guarantee, up to the reserve fund amount, and used to compensate the leasing partners in the event of customer defaults. The guarantee is recognized on the estimated fair value amount according to ASC 460. In the following periods the Company will assess credit losses in accordance with ASC 326, see also note 2r.

The Company does not grant a right of return, refund, cancelation or termination. From time to time, the Company participates in its customers' marketing activities and deducts such amounts from revenue.

Service Revenue

The Company also generates revenues from long-term maintenance contracts ("Extended Warranty"). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. These maintenance agreements are included in contract liabilities. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed.

The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12 months as long-term.

Allowance for doubtful accounts and financial instruments – credit loss

r. Allowance for doubtful accounts and financial instruments – credit loss

The Company maintains the allowance for doubtful account resulting from the inability of the Company's customers to make required payments.

The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable. This information includes among other the historic experience, the extent and amount of the account and future expectations.

Allowance for credit losses due to the Company's accounts receivable amounted to $2,749 and $2,254 as of December 31, 2024 and 2023 respectively. Changes in the allowance for credit losses are recognized in general and administrative expenses. Accounts receivable are written-off against the allowance for credit losses when management deems the accounts are no longer collectible.

The following table sets forth activity in the Company's allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	2,254	1,318	1,107
Current-period provision	572	1,020	449
Write-offs charged against the Allowance and revaluation	(77)	(84)	(238)
Balance at end of year	2,749	2,254	1,318

Warranty reserve

s. Warranty reserve

The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company's warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs, the cost per repair and shipping cost. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The following table sets forth activity in the Company's accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	1,476	1,418	1,248
Cost incurred	(1,909)	(2,304)	(2,099)
Expense recognized	1,155	2,362	2,269
Balance at end of year	722	1,476	1,418

Cost of revenues

t. Cost of revenues

Cost of revenue consists of products purchased from turnkey sub-contractors which are responsible for the production of most of the Company's products under the Company's directions and supervision, raw materials for in-house assembly line, shipping and handling costs to customers and to subsidiaries, salary, employee-related expenses and overhead expenses of internal assembly line and service costs associate with warranty.

Research and development costs

u. Research and development costs

Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material and third-party contractor's charges related to product development, regulatory affairs and clinical studies.

Net earnings per share

v. Net earnings per share

Basic earnings per share are computed by dividing net income attributed to the shareholders of InMode Ltd. by the weighted average number of the Company's ordinary shares, par value NIS 0.01 per share (including vested RSUs), outstanding for each period, net of treasury shares.

For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method.

Fair value measurement

w. Fair value measurement

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions.

The three levels of inputs that may be used to measure fair value are as follows:

Level 1 – Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2 – Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets.

Level 3 – Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available.

As of December 31, 2024, and 2023, the fair values of the Company's cash, cash equivalents, short term bank deposits, accounts receivable, accounts payable, approximated the carrying values of these instruments presented in the Company's consolidated balance sheets because of their nature.

Employee severance benefits

x. Employee severance benefits

The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances.

In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company's consolidated balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies.

The amounts of severance payment expenses were $581 $522 and $431 and for the years ended December 31, 2024, 2023 and 2022, respectively.

The Company expects to contribute approximately $569 in the year ending December 31, 2025 to insurance companies in connection with its expected severance liabilities for the year.

Treasury Shares

y. Treasury Shares

Treasury shares are presented as a reduction of equity, at their cost to the Company.

Concentration of credit risks

z. Concentration of credit risks

Most of the cash and cash equivalents were deposited with U.S., European and Israeli banks and financial institutions and were comprised mainly of money market fund. The U.S. market constituted approximately 62% of the revenues in 2024.

The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for Credit Losses and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.

War risk situation in Israel

aa. War risk situation in Israel

In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During January 2025, a cease fire with Hamas was declared. As of the date of these consolidated financial statements, the war is ongoing and continues to evolve. The Company's headquarters, its R&D operations, and certain manufacturing facilities are located in Israel.

Currently, such activities in Israel remain largely unaffected. During the years ended December 31, 2024 and December 31, 2023, the impact of this war on the Company's results of operations and financial condition was immaterial.

Recently adopted accounting pronouncements

ab. Recently adopted accounting pronouncements

In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company adopted this standard in the current period retrospectively to all prior periods presented in an entity's financial statements, refer to note 14.

Newly issued accounting pronouncements, not yet adopted

ac. Newly issued accounting pronouncements, not yet adopted:

1) In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

2) In November 2024, the FASB issued ASU 2024-03 "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

XML 49 R30.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Property and Equipment Estimated Useful Lives

Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives:

Computers	3 – 4 years
Molds	4 – 10 years
Equipment and furniture	10 – 17 years

Schedule Of Allowance For Credit Losses

The following table sets forth activity in the Company's allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	2,254	1,318	1,107
Current-period provision	572	1,020	449
Write-offs charged against the Allowance and revaluation	(77)	(84)	(238)
Balance at end of year	2,749	2,254	1,318

Schedule of Accrued Warranty

The following table sets forth activity in the Company's accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively:

	2024	2023	2022
Balance at beginning of year	1,476	1,418	1,248
Cost incurred	(1,909)	(2,304)	(2,099)
Expense recognized	1,155	2,362	2,269
Balance at end of year	722	1,476	1,418

XML 50 R31.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Marketable Securities and Fair Value Measurement [Abstract]

Schedule of Marketable Securities

The following table sets forth the Company's marketable securities for the periods indicated:

	December 31	
	2024	2023
U.S. Government bonds	265,180	353,414
Municipal bonds	-	2,319
Corporate debt securities	2,508	13,234
Certificates of deposit	-	4,680
Total	267,688	373,647

Schedule of Financial Assets Measured at Fair Value on Recurring Basis

The following table sets forth the Company's financial assets as of December 31, 2024 and 2023, that are measured at fair value on a recurring basis during the period:

	December 31, 2024			
	Fair value	Cost or amortized cost	Gross unrealized holding loss	Gross unrealized holding gains
Level 2 securities:				
Government bonds	265,180	265,619	(552)	113
Corporate debt securities	2,508	2,510	(3)	1
Total	267,688	268,129	(555)	114

	December 31, 2023			
	Fair value	Cost or amortized cost	Gross unrealized holding loss	Gross unrealized holding gains
Level 2 securities:				
Government bonds	353,414	355,382	(2,139)	171
Municipal bonds	2,319	2,363	(44)	-
Corporate debt securities	13,234	13,404	(170)	-
Certificates of deposit	4,680	4,680	-	-
Total	373,647	375,829	(2,353)	171

Schedule of Debt Securities on Maturity

As of December 31, 2024 and 2023, the Company's debt securities and certificates of deposit had the following maturity dates:

	December 31	
	2024	2023
Due within one year	179,784	308,671
1 to 2 years	80,560	49,259
2 to 3 years	7,344	15,717
Total	267,688	373,647

XML 51 R32.htm IDEA: XBRL DOCUMENT

ACCOUNTS RECEIVABLE (Tables)

12 Months Ended
Dec. 31, 2024

Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]

Schedule of Accounts Receivable

Accounts receivable consist of the following:

	December 31	
	2024	2023
Trade	40,739	46,646
Notes receivable	1,521	1,640
Less - allowance for credit losses	(2,749)	(2,254)
	39,511	46,032
Less - non-current accounts receivable, net	(3,176)	(3,670)
Total current accounts receivable, net	36,335	42,362

XML 52 R33.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Tables)

12 Months Ended
Dec. 31, 2024

Other Receivables, Net, Current [Abstract]

Schedule Of Prepaid Expenses And Other Current Receivables

Prepaid expenses and other current receivables consist of the following:

	December 31	
	2024	2023
Advances to suppliers	14,960	11,960
Prepaid expenses	2,421	3,041
Government institutions	2,896	948
Income tax	1,423	66
Other	397	253
Total other current receivables	22,097	16,268

XML 53 R34.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

12 Months Ended
Dec. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	December 31	
	2024	2023
Raw materials	15,454	12,080
Finished products	44,094	33,015
Total inventories	59,548	45,095

XML 54 R35.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended
Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Composition of property and equipment grouped by major classifications is as follows:

	December 31	
	2024	2023
Computers	1,445	1,334
Office furniture and equipment	709	670
Molds	3,020	2,592
Leasehold improvements	1,333	1,243
	6,507	5,839
Less: accumulated depreciation	(4,185)	(3,457)
Total property and equipment, net	2,322	2,382

XML 55 R36.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

12 Months Ended
Dec. 31, 2024

Leases [Abstract]

Schedule of Lease Expense

The lease cost was as follows:

	Year ended December 31		
	2024	2023	2022
Operating lease cost	3,057	2,348	1,628

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was as follows:

	Year ended December 31		
	2024	2023	2022
Operating cash flows from operating leases	3,173	2,530	1,881

Schedule of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was as follows:

	December 31,	
	2024	2023
Operating Leases		
Operating lease right-of-use assets	8,732	9,698
Other current liabilities	2,511	2,404
Operating lease liabilities	5,311	6,613
Total operating lease liabilities	7,822	9,017
Weighted Average Remaining Lease Term		
Operating leases	3.30 years	2.90 years
Weighted Average Discount Rate		
Operating leases	5.24%	4.78%

Schedule of Maturities of Lease Liabilities

As of December 31, 2024, the maturities of lease liabilities were as follows:

	Operating Leases
Year Ending December 31,	
2025	2,917
2026	2,411
2027	2,124
2028	659
2029 and beyond	353
Total lease payments	8,464
Less imputed interests	(642)
Total	7,822

XML 56 R37.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES (Tables)

12 Months Ended Dec. 31, 2024

Payables and Accruals [Abstract]

Schedule of Other Current Liabilities

Other current liabilities consist of the following:

	December 31	
	2024	2023
Employees and related expenses	16,725	21,040
Government institutions	2,566	3,932
Income tax payable	933	1,918
Warranty reserve	722	1,476
Operating lease liabilities	2,511	2,404
Credit risk sharing liabilities	5,507	-
Contractor liability	5,101	5,656
Accrued commissions	2,379	1,435
Other	2,870	1,386
Total other current liabilities	39,314	39,247

XML 57 R38.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended Dec. 31, 2024

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of Options Granted

The following tables is a summary of stock option activity for the year ended on December 31, 2024:

	Year ended December 31	
	2024	
	Number of Options	Weighted Average Exercise Price*
Outstanding at beginning of year	1,638,495	$ 4.96
Changes during the year:		
Granted	-	-
Canceled	(6,996)	10.17
Exercised	(1,003,409)	2.63
Forfeited	-	-
Expired	-	-
Outstanding at end of year	628,090	$ 8.61
Exercisable at end of year	628,090	$ 8.61

* In U.S. dollars per Ordinary Share

Schedule of Outstanding and Exercisable Options

The following tables summarize information concerning outstanding and exercisable options as of December 31, 2024:

	Options outstanding and exercisable		
Exercise Prices *	Number of options Outstanding and exercisable at end of year	Weighted average remaining contractual life	
$ 3.16	42,608	0.71	
$ 3.75	29,595	0.68	
$ 5.11	65,576	1.26	
$ 7.00	41,000	1.61	
$ 9.85	424,149	2.16	
$ 12.16	18,662	2.35	
$ 21.62	6,500	2.86	

* In U.S. dollars per Ordinary Share.

Schedule of Share Based Compensation Expense

The following table illustrates the effect of share-based compensation on the consolidated statements of income:

	Year ended December 31		
	2024	2023	2022
Cost of sales	1,833	2,046	1,917
Research and development expenses	2,177	2,652	3,166
Selling and marketing expenses	11,367	17,167	17,302
General and administrative expenses	1,192	1,735	2,067
	16,569	23,600	24,452

Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of Options Granted

The following tables summarize information concerning RSUs as of December 31, 2024 :

	Year ended December 31	
	2024	
	Number of RSUs	Weighted Average Grant Date Fair Value
Outstanding at beginning of year	936,049	39.04
Changes during the year:		
Granted	716,395	25.90
Vested	(622,799)	41.20
Forfeited	(204,740)	28.67
Outstanding at end of year	824,905	28.57

XML 58 R39.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets (liabilities)

Deferred income tax assets reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Company's net deferred tax assets (liabilities) at December 31, 2024 and 2023 were as follows:

	December 31	
	2024	2023
Deferred tax assets in respect of:future		
Subsidiaries carryforward losses	54,349	58,075
Other temporary differences	3,659	3,112
Share-based compensation	2,424	4,194
Deferred tax asset in respect to other comprehensive loss	101	502
Total deferred tax assets before valuation allowance	60,533	65,883
Valuation allowance	(4,248)	(64,377)
Total deferred tax assets	56,285	1,506

Schedule of valuation allowance

	2024	2023
Balance at January 1	64,377	66,815
Utilization of carry forward tax losses	(5,399)	(2,438)
Reductions for the current year that record against defer tax asset	(54,730)	-
Balance at December 31	4,248	64,377

Schedule of Reconciliation of Theoretical Provision For Income

Following is a reconciliation of the theoretical provision for income tax, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax on income:

Tax

	Year ended December 31		
	2024	2023	2022
Income before taxes on income	143,469	217,267	201,466
Theoretical tax expenses at the statutory rate of InMode Ltd.	23%	23%	23%
	32,998	49,971	46,337
Increase (decrease) in taxes on income due to:			
Benefits to the Benefited Enterprise	(16,682)	(31,296)	(27,282)
Different effective tax rates applicable to the Subsidiaries	210	165	138
Change in valuation allowance	(60,129)	(2,438)	(3,608)
Uncertain tax positions	1,957	1,096	303
Non-deductible expenses and other permanent differences, mainly share based compensation expenses	3,840	1,850	1,842
Amendment to the Investments Law payment - see also note 13a(2)(b)	-	-	12,017
Settlements with the Israeli tax authority net of decrease of related uncertain tax provision	-	-	10,199
	(37,806)	19,348	39,946

Schedule of Income Before Income Taxes

g. Income before income taxes is composed of the following:

	Year ended December 31		
	2024	2023	2022
InMode Ltd. and Israeli subsidiaries	139,241	211,137	196,354
Subsidiaries outside of Israel	4,228	6,130	5,112
	143,469	217,267	201,466

Schedule of Tax Expenses (Tax Benefit)

h. Tax expenses (tax benefit):

	Year ended December 31		
	2024	2023	2022
Current:			
Israel	15,664	17,633	38,248
Subsidiaries	1,709	1,864	1,614
	17,373	19,497	39,862
Deferred:			
Israel	(42)	(149)	84
Subsidiaries	(55,137)	-	-
	(55,179)	(149)	84
Total expenses (income) taxes on income	(37,806)	19,348	39,946

Schedule of Unrecognized Tax Benefits

The following table summarizes the activity of the Company's unrecognized tax benefits:

	Year ended December 31	
	2024	2023
Balance at January 1	1,399	303
Increase in uncertain tax positions for the current year	1,957	1,096
Balance at December 31	3,356	1,399

XML 59 R40.htm IDEA: XBRL DOCUMENT

Segments (Tables)

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Revenue by Major Customers

	Year ended December 31	
	2024	2023
Revenues from customers	394,818	492,048
Less:		
Employee salaries including commission expenses	101,920	109,484
Marketing expenses	26,987	29,039
Share based compensation	16,569	23,600
Interest income	33,537	21,128
Depreciation	728	623
*Other expenses	138,682	133,163
Income before income taxes	143,469	217,267
Income taxes benefit (expenses)	37,806	(19,348)
Net income	181,275	197,919

* Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.

XML 60 R41.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Tables)

12 Months Ended
Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Net Sales by Geographic Area

	Year ended December 31		
	2024	2023	2022
United States	244,774	307,818	298,612
Europe	63,441	62,532	49,274
Asia	42,974	47,744	36,492
Other	43,629	73,954	69,893
	394,818*	492,048*	454,271*

*Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.

Schedule of revenue from external customers by products and Services

	Year ended December 31		
	2024	2023	2022
Capital Equipment revenues	315,547	412,089	394,212
Consumables and service revenues	79,271	79,959	60,059
	394,818	492,048	454,271

Schedule of Net Sales by Technology

	Year ended December 31		
	2024	2023	2022
		%	
Minimal-Invasive	87	83	81
Hands-Free	5	8	10
Non-Invasive	8	9	9
	100	100	100

Schedule of Changes in Contract Liabilities

	Year ended December 31	
	2024	2023
Balance as of January 1	14,689	17,757
Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period	16,975	12,498
Revenue recognized that was included in the contract liability balance at the beginning of the period	(11,573)	(15,566)
Balance as of December 31	20,091	14,689
Contract liability presented in non-current liabilities (1)	3,336	3,766
Contract liability presented in current liabilities	16,755	10,923

(1) As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029.

Schedule of Long-Lived Assets

	December 31	
	2024	2023
Israel	5,757	6,704
United States	1,421	1,789
Other	3,876	3,587
	11,054	12,080
Other long-term assets*	3,876	4,370
	14,930	16,450

*Consists of non-current accounts receivable, net and other investments

XML 61 R42.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING

12 Months Ended

Dec. 31, **Dec. 31,**

POLICIES (Narrative) (Details) $ in Thousands	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	2024 ₪ / shares	Dec. 31, 2024 USD ($)	2023 ₪ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)
Accounting Policies [Line Items]									
Advertising expenses		$ 15,000	$ 15,000	$ 10,000					
Common Stock, Par or Stated Value Per Share | ₪ / shares					₪ 0.01		₪ 0.01		
Amounts of severance payment expenses		$ 581	$ 522	431					
Allowance for credit losses				$ 1,318		$ 2,749		$ 2,254	$ 1,107
Forecast [Member]									
Accounting Policies [Line Items]									
Amounts of severance payment expenses	$ 569								
Minimum [Member]									
Accounting Policies [Line Items]									
Short Term Deposits Annual Interest Rate		0.50%	4.10%						
Maximum [Member]									
Accounting Policies [Line Items]									
Short Term Deposits Annual Interest Rate		6.15%	7.01%						

XML 62 R43.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Estimated Useful Lives) (Details)	Dec. 31, 2024
Computers [Member] | Minimum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	3 years
Computers [Member] | Maximum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	4 years
Molds [Member] | Minimum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	4 years
Molds [Member] | Maximum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	10 years
Equipment and furniture [Member] | Minimum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	10 years
Equipment and furniture [Member] | Maximum [Member]	
Property, Plant and Equipment [Line Items]	
Estimated useful lives	17 years

XML 63 R44.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details) - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]			
Balance at beginning of year	$ 2,254	$ 1,318	$ 1,107
Current-period provision	572	1,020	449
Write-offs charged against the allowance	(77)	(84)	(238)
Balance at end of year	$ 2,749	$ 2,254	$ 1,318

XML 64 R45.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Accrued Warranty) (Details) - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]			
Balance at beginning of year	$ 1,476	$ 1,418	$ 1,248
Cost incurred	(1,909)	(2,304)	(2,099)
Expense recognized	1,155	2,362	2,269
Balance at end of year	$ 722	$ 1,476	$ 1,418

XML 65 R46.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities) (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Marketable Securities [Line Items]		
Marketable securities	$ 267,688	$ 373,647
U.S. Government bonds [Member]		
Marketable Securities [Line Items]		
Marketable securities	265,180	353,414
Municipal bonds [Member]		
Marketable Securities [Line Items]		
Marketable securities	0	2,319
Corporate debt securities [Member]		
Marketable Securities [Line Items]		
Marketable securities	2,508	13,234
Certificates of deposit [Member]		
Marketable Securities [Line Items]		
Marketable securities	$ 0	$ 4,680

XML 66 R47.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets Measured at Fair	Dec. 31, 2024	Dec. 31, 2023

Value) (Details) - USD ($) $ in Thousands		
Marketable Securities [Line Items]		
Cost or amortized cost	$ 268,129	$ 375,829
Level 2 Securities [Member]		
Marketable Securities [Line Items]		
Fair Value	267,688	373,647
Cost or amortized cost	268,129	375,829
Gross unrealized holding loss	(555)	(2,353)
Gross unrealized holding gains	114	171
Level 2 Securities [Member] | Government bonds [Member]		
Marketable Securities [Line Items]		
Fair Value	265,180	353,414
Cost or amortized cost	265,619	355,382
Gross unrealized holding loss	(552)	(2,139)
Gross unrealized holding gains	113	171
Level 2 Securities [Member] | Municipal bonds [Member]		
Marketable Securities [Line Items]		
Fair Value		2,319
Cost or amortized cost		2,363
Gross unrealized holding loss		(44)
Gross unrealized holding gains		0
Level 2 Securities [Member] | Corporate debt securities [Member]		
Marketable Securities [Line Items]		
Fair Value	2,508	13,234
Cost or amortized cost	2,510	13,404
Gross unrealized holding loss	(3)	(170)
Gross unrealized holding gains	$ 1	0
Level 2 Securities [Member] | Certificates of deposit [Member]		
Marketable Securities [Line Items]		
Fair Value		4,680
Cost or amortized cost		4,680
Gross unrealized holding loss		0
Gross unrealized holding gains		$ 0

XML 67 R48.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on Maturity) (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Marketable Securities and Fair Value Measurement [Abstract]		
Due within one year	$ 179,784	$ 308,671
1 to 2 years	80,560	49,259
2 to 3 years	7,344	15,717
Total	$ 267,688	$ 373,647

XML 68 R49.htm IDEA: XBRL DOCUMENT

ACCOUNTS RECEIVABLE (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]				
Trade	$ 40,739	$ 46,646		
Notes receivable	1,521	1,640		
Less - allowance for credit losses	(2,749)	(2,254)	$ (1,318)	$ (1,107)
Notes And Loans Receivable Net	39,511	46,032		
Less - non-current accounts receivable	(3,176)	(3,670)		
Total current accounts receivable	$ 36,335	$ 42,362		

XML 69 R50.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Schedule of Prepaid expenses and other current receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Other Receivables, Net, Current [Abstract]		
Advances to suppliers	$ 14,960	$ 11,960
Prepaid expenses	2,421	3,041
Government institutions	2,896	948
Income tax	1,423	66
Other	397	253
Total other current receivables	$ 22,097	$ 16,268

XML 70 R51.htm IDEA: XBRL DOCUMENT

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]		
Raw materials	$ 15,454	$ 12,080
Finished products	44,094	33,015
Total inventories	$ 59,548	$ 45,095

XML 71 R52.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details) - USD ($) $ in Thousands	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]			
Property, plant and equipment, gross	$ 6,507	$ 5,839	
Less: accumulated depreciation	(4,185)	(3,457)	
Total property and equipment, net	2,322	2,382	

Depreciation and amortization	728	623	$ 680
Computers [Member]			
Property, Plant and Equipment [Line Items]			
Property, plant and equipment, gross	1,445	1,334	
Office furniture and equipment [Member]			
Property, Plant and Equipment [Line Items]			
Property, plant and equipment, gross	709	670	
Molds [Member]			
Property, Plant and Equipment [Line Items]			
Property, plant and equipment, gross	3,020	2,592	
Leasehold Improvements [Member]			
Property, Plant and Equipment [Line Items]			
Property, plant and equipment, gross	$ 1,333	$ 1,243	

XML 72 R53.htm IDEA: XBRL DOCUMENT

OTHER INVESTMENTS (Narrative) (Details) - Medimor [Member] - USD ($) $ in Thousands	**Dec. 31, 2024**	**Dec. 31, 2023**	**Nov. 30, 2023**	**Nov. 30, 2019**
Share purchase and shareholders agreement [Member]				
Net Investment Income [Line Items]				
Investment amount			$ 100	$ 600
Ordinary shares			117,440	1,369,863
Ownership interest				14.78%
Share purchase and shareholders agreement [Member] | Fully diluted basis [Member]				
Net Investment Income [Line Items]				
Ownership interest				10.34%
Two purchase and shareholders agreements [Member]				
Net Investment Income [Line Items]				
Ownership interest	14.78%	14.78%		
Two purchase and shareholders agreements [Member] | Fully diluted basis [Member]				
Net Investment Income [Line Items]				
Ownership interest	11.23%	11.23%		

XML 73 R54.htm IDEA: XBRL DOCUMENT

LEASES (Narrative) (Details) - Lease agreement [Member] ₪ in Thousands	**1 Months Ended**				
	Jul. 31, 2022 USD ($)	**Aug. 31, 2020 USD ($)**	**May 31, 2018 USD ($)**	**May 31, 2018 ILS (₪)**	**Jul. 01, 2022**
Lease expiration date			December 2027	December 2027	
Bank guarantee			$ 263,000	₪ 966	
Current monthly rent payment			$ 76,700		
Vehicles [Member]					
Term of contract			3 years	3 years	
Warehouse [Member]					
Lease expiration date			August 2027	August 2027	
Current monthly rent payment			$ 8,900		
Office Building [Member]					
Current monthly rent payment	$ 17,000	$ 28,000			
Term of contract		7 years 4 months			3 years

XML 74 R55.htm IDEA: XBRL DOCUMENT

LEASES (Schedule of Lease Expense) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Leases [Abstract]			
Operating lease cost	$ 3,057	$ 2,348	$ 1,628

XML 75 R56.htm IDEA: XBRL DOCUMENT

LEASES (Schedule of Supplemental Cash Flow Information Related to Leases) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Leases [Abstract]			
Operating cash flows from operating leases	$ 3,173	$ 2,530	$ 1,881

XML 76 R57.htm IDEA: XBRL DOCUMENT

LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) (Details) - USD ($) $ in Thousands	**Dec. 31, 2024**	**Dec. 31, 2023**
Operating Leases		
Operating lease right-of-use assets	$ 8,732	$ 9,698
Other current liabilities	2,511	2,404
Operating lease liabilities	5,311	6,613
Total operating lease liabilities	$ 7,822	$ 9,017
Weighted Average Remaining Lease Term, Operating leases	3 years 3 months 18 days	2 years 10 months 24 days
Weighted Average Discount Rate, Operating leases	5.24%	4.78%

XML 77 R58.htm IDEA: XBRL DOCUMENT

LEASES (Schedule of Maturities of Lease Liabilities) (Details) - USD ($) $ in Thousands	**Dec. 31, 2024**	**Dec. 31, 2023**
Leases [Abstract]		
2025	$ 2,917	
2026	2,411	
2027	2,124	
2028	659	
2029 and beyond	353	
Total lease payments	8,464	
Less imputed interests	(642)	
Total operating lease liabilities	$ 7,822	$ 9,017

XML 78 R59.htm IDEA: XBRL DOCUMENT

OTHER CURRENT LIABILITIES (Schedule Of Other Liabilities) (Details) -	**Dec. 31, 2024**	**Dec. 31, 2023**

USD ($) $ in Thousands		
Other Current Liabilities [Line Items]		
Employees and related expenses	$ 16,725	$ 21,040
Government institutions	2,566	3,932
Income tax payable	933	1,918
Warranty reserve	722	1,476
Operating lease liabilities	2,511	2,404
Credit risk sharing liabilities	5,507	0
Contractor liability	5,101	5,656
Accrued commissions	2,379	1,435
Other	2,870	1,386
Total other current liabilities	$ 39,314	$ 39,247

XML 79 R60.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) $ in Thousands	12 Months Ended Dec. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]	
Supply and open orders commitment	$ 43,607
Advance to subcontractor/supplier	$ 13,502

XML 80 R61.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended					
	Jan. 24, 2025 shares	Sep. 30, 2024 shares	May 31, 2024 shares	Sep. 30, 2020 shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2024 ₪ / shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2023 ₪ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Ordinary shares, par value | ₪ / shares								₪ 0.01		₪ 0.01
Repurchase of ordinary shares | $					$ 285,400		$ 42,600			
Repurchase of ordinary shares, shares		7,680,000	8,370,000		16,050,000		1,077,213			
Restricted Stock Units (RSUs) [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Fair value of RSUs granted					18,556	24,334	30,817			
Vested options | $					$ 14,215					
Unvested options									824,905	
Unrecognized compensation expense | $									$ 9,192	
Unrecognized compensation cost, recognition period					7 months 24 days					
Fair value of RSU granted, per share | $ / shares					$ 25.9	$ 34.44	$ 49.35			
2018 Incentive Plan [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Issuance of shares					800,000					
Number of shares authorized to be issued as ordinary shares									8,378,000	
Number of options available for grant									1,397,772	
Aggregate intrinsic value | $									$ 5,110	
2018 Incentive Plan [Member] | Subsequent Event [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Issuance of shares	9,178,000									
2018 Incentive Plan [Member] | Employees [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Weighted average remaining contractual life					1 year 10 months 17 days					
Total intrinsic value of options exercised | $					$ 12,184	$ 24,819	$ 10,549			
Share Repurchase Program [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Repurchase of ordinary shares | $					$ 380,600					
Repurchase of ordinary shares, shares					18,607,829					
IPO [Member]										
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]										
Repurchase of ordinary shares, shares				2						

XML 81 R62.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Schedule Of Options Granted) (Details) $ / shares shares	12 Months Ended Dec. 31, 2024 $ / shares shares	
Number of options		
Outstanding at beginning of year | shares	1,638,495	
Changes during the year:		
Granted | shares	0	
Canceled | shares	(6,996)	
Exercised | shares	(1,003,409)	
Forfeited | shares	0	
Expired | shares	0	
Outstanding at end of year | shares	628,090	
Exercisable at end of year | shares	628,090	
Weighted average exercise price		
Outstanding at beginning of year | $ / shares	$ 4.96	[1]
Changes during the year:		
Granted | $ / shares	0	[1]
Canceled | $ / shares	10.17	[1]
Exercised | $ / shares	2.63	[1]
Forfeited | $ / shares	0	[1]
Expired | $ / shares	0	[1]
Outstanding at end of year | $ / shares	8.61	[1]
Exercisable at end of year | $ / shares	$ 8.61	[1]

[1] In U.S. dollars per Ordinary Share

XML 82 R63.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Schedule Of Outstanding and Exercisable Options) (Details)	12 Months Ended Dec. 31, 2024 $ / shares shares

$3.16 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 3.16	[1]
Number of options Outstanding and exercisable at end of year | shares	42,608	
Weighted average remaining contractual life of outstanding options	8 months 15 days	
$3.75 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 3.75	[1]
Number of options Outstanding and exercisable at end of year | shares	29,595	
Weighted average remaining contractual life of outstanding options	8 months 4 days	
$5.11 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 5.11	[1]
Number of options Outstanding and exercisable at end of year | shares	65,576	
Weighted average remaining contractual life of outstanding options	1 year 3 months 3 days	
$7.00 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 7	[1]
Number of options Outstanding and exercisable at end of year | shares	41,000	
Weighted average remaining contractual life of outstanding options	1 year 7 months 9 days	
$9.85 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 9.85	[1]
Number of options Outstanding and exercisable at end of year | shares	424,149	
Weighted average remaining contractual life of outstanding options	2 years 1 month 28 days	
$12.16 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 12.16	[1]
Number of options Outstanding and exercisable at end of year | shares	18,662	
Weighted average remaining contractual life of outstanding options	2 years 4 months 6 days	
$21.62 [Member]		
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]		
Exercise prices | $ / shares	$ 21.62	[1]
Number of options Outstanding and exercisable at end of year | shares	6,500	
Weighted average remaining contractual life of outstanding options	2 years 10 months 9 days	

[1] In U.S. dollars per Ordinary Share

XML 83 R64.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Schedule of Options Granted Resticted Share Unit) (Details) - Restricted Stock Units (RSUs) [Member]	**12 Months Ended**
	Dec. 31, 2024 $ / shares shares
Number of RSUs	
Outstanding at beginning of year | shares	936,049
Changes during the year:	
Granted | shares	716,395
Vested | shares	(622,799)
Forfeited | shares	(204,740)
Outstanding at end of year | shares	824,905
Weighted Average Grant Date Fair Value	
Outstanding at beginning of year | $ / shares	$ 39.04
Changes during the year:	
Granted | $ / shares	25.9
Vested | $ / shares	41.2
Forfeited | $ / shares	28.67
Outstanding at end of year | $ / shares	$ 28.57

XML 84 R65.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			
Equity-based compensation income	$ 16,569	$ 23,600	$ 24,452
Cost of sales [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			
Equity-based compensation income	1,833	2,046	1,917
Research and development expenses [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			
Equity-based compensation income	2,177	2,652	3,166
Selling and marketing expenses [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			
Equity-based compensation income	11,367	17,167	17,302
General and administrative expenses [Member]			
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]			
Equity-based compensation income	$ 1,192	$ 1,735	$ 2,067

XML 85 R66.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Narrative) (Details) $ in Thousands, ₪ in Millions	**12 Months Ended**					
	Dec. 31, 2024 USD ($)	**Dec. 31, 2023 USD ($)**	**Dec. 31, 2022 USD ($)**	**Dec. 31, 2023 ILS (₪)**	**Nov. 15, 2021 USD ($)**	**Nov. 15, 2021 ILS (₪)**
Income Tax Contingency [Line Items]						
Corporate tax	23.00%					
Valuation allowance of net deferred tax assets	$ (54,730)	$ 0				
Valuation allowance	(60,129)	(2,438)	$ (3,608)			
Valuation allowance	$ 4,248	$ 64,377	$ 66,815			
Statutory rate	23.00%	23.00%	23.00%			
One-time payment					$ 12,000	₪ 42.5
Undistributed exempt income					165,700	591.0
Payment of income tax assessment with tax authorities	$ 1,300					
Amendment Advantage Exemption [Member]						
Income Tax Contingency [Line Items]						
One-time payment					$ 9,000	₪ 32.0
Israeli Tax Authority [Member]						
Income Tax Contingency [Line Items]						

Undistributed exempt income	$ 14,300	₪ 50.2
Subsidiaries outside Israel [Member] | Minimum [Member]		
Income Tax Contingency [Line Items]		
Corporate tax	15.00%	
Subsidiaries outside Israel [Member] | Maximum [Member]		
Income Tax Contingency [Line Items]		
Corporate tax	26.50%	
Subsidiary in U.S. [Member]		
Income Tax Contingency [Line Items]		
Accumulated tax loss carryforward	$ 203,000	
Subsidiary in state [Member]		
Income Tax Contingency [Line Items]		
Accumulated tax loss carryforward	$ 165,500	
Regulations [Member]		
Income Tax Contingency [Line Items]		
Corporate tax	7.50%	

XML 86 R67.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Schedule of Deferred Tax Assets (liabilities) (Details) - USD ($) $ in Thousands	**Dec. 31, 2024**	**Dec. 31, 2023**	**Dec. 31, 2022**
Deferred tax assets in respect of:			
Subsidiaries carryforward losses	$ 54,349	$ 58,075	
Other temporary differences	3,659	3,112	
Share-based compensation	2,424	4,194	
Deferred tax asset in respect to other comprehensive loss	101	502	
Total deferred tax assets before valuation allowance	60,533	65,883	
Valuation allowance	(4,248)	(64,377)	$ (66,815)
Total deferred tax assets	$ 56,285	$ 1,506	

XML 87 R68.htm IDEA: XBRL DOCUMENT

INCOME TAXES - (Schedule of valuation allowance) (Details) - USD ($) $ in Thousands	**12 Months Ended**	
	Dec. 31, 2024	**Dec. 31, 2023**
Income Tax Disclosure [Abstract]		
Balance at January 1	$ 64,377	$ 66,815
Utilization of carry forward tax losses	(5,399)	(2,438)
Reductions for the current year that record against defer tax asset	(54,730)	0
Balance at December 31	$ 4,248	$ 64,377

XML 88 R69.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Schedule of Reconciliation of Theoretical Provision For Income Tax) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Income Tax Disclosure [Abstract]			
Income before taxes on income	$ 143,469	$ 217,267	$ 201,466
Theoretical tax expenses at the statutory rate of InMode Ltd.	23.00%	23.00%	23.00%
Theoretical tax benefit	$ 32,998	$ 49,971	$ 46,337
Increase (decrease) in taxes on income due to:			
Benefits to the Benefited Enterprise	(16,682)	(31,296)	(27,282)
Different effective tax rates applicable to the Subsidiaries	210	165	138
Change in valuation allowance	(60,129)	(2,438)	(3,608)
Uncertain tax positions	1,957	1,096	303
Non-deductible expenses and other permanent differences, mainly share based compensation expenses	3,840	1,850	1,842
Amendment to the Investments Law payment - see also note 13a(2)(b)	0	0	12,017
Settlements with the Israeli tax authority net of decrease of related uncertain tax provision	0	0	10,199
Total taxes on income	$ (37,806)	$ 19,348	$ 39,946

XML 89 R70.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Schedule of Income Before Income Taxes) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Income Tax Note [Line Items]			
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ 143,469	$ 217,267	$ 201,466
InMode Ltd. and Israeli subsidiaries [Member]			
Income Tax Note [Line Items]			
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	139,241	211,137	196,354
Subsidiaries outside of Israel [Member]			
Income Tax Note [Line Items]			
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ 4,228	$ 6,130	$ 5,112

XML 90 R71.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Schedule of Tax Expenses (Tax Benefit)) (Details) - USD ($) $ in Thousands	**12 Months Ended**		
	Dec. 31, 2024	**Dec. 31, 2023**	**Dec. 31, 2022**
Income Tax Note [Line Items]			
Current	$ 17,373	$ 19,497	$ 39,862
Deferred	(55,179)	(149)	84
Total taxes on income	(37,806)	19,348	39,946
Israel [Member]			
Income Tax Note [Line Items]			
Current	15,664	17,633	38,248
Deferred	(42)	149	(84)
Subsidiaries [Member]			
Income Tax Note [Line Items]			
Current	1,709	1,864	1,614
Deferred	$ (55,137)	$ 0	$ 0

XML 91 R72.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)	**12 Months Ended**	
	Dec. 31, 2024	**Dec. 31, 2023**

$ in Thousands		
Income Tax Disclosure [Abstract]		
Balance at January 1	$ 1,399	$ 303
Increase in uncertain tax positions for the current year, net	1,957	1,096
Balance at December 31	$ 3,356	$ 1,399

XML 92 R73.htm IDEA: XBRL DOCUMENT

Segments (Schedule of Revenue by Major Customers) (Details) - USD ($) $ in Thousands		12 Months Ended		
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue, Major Customer [Line Items]				
INCOME BEFORE INCOME TAXES		$ 143,469	$ 217,267	$ 201,466
INCOME TAXES BENEFIT (EXPENSES)		37,806	(19,348)	(39,946)
NET INCOME		181,275	197,919	$ 161,520
CODM [Member]				
Revenue, Major Customer [Line Items]				
Revenues from customers		394,818	492,048	
Employee salaries including commission expenses		101,920	109,484	
Marketing expenses		26,987	29,039	
Share based compensation		16,569	23,600	
Interest income		33,537	21,128	
Depreciation		728	623	
Other expenses	[1]	138,682	133,163	
INCOME BEFORE INCOME TAXES		143,469	217,267	
INCOME TAXES BENEFIT (EXPENSES)		37,806	(19,348)	
NET INCOME		$ 181,275	$ 197,919	

[1] Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.

XML 93 R74.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Narrative) (Details)	Dec. 31, 2024
Segment Reporting, Revenue Reconciling Item [Line Items]	
Percentage of non- current deferred revenue	81.00%

XML 94 R75.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) (Details) - USD ($) $ in Thousands		12 Months Ended		
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Revenue Reconciling Item [Line Items]				
REVENUES	[1]	$ 394,818	$ 492,048	$ 454,271
United States [Member]				
Segment Reporting, Revenue Reconciling Item [Line Items]				
REVENUES		244,774	307,818	298,612
Europe [Member]				
Segment Reporting, Revenue Reconciling Item [Line Items]				
REVENUES		63,441	62,532	49,274
Asia [Member]				
Segment Reporting, Revenue Reconciling Item [Line Items]				
REVENUES		42,974	47,744	36,492
Other Country [Member]				
Segment Reporting, Revenue Reconciling Item [Line Items]				
REVENUES		$ 43,629	$ 73,954	$ 69,893

[1] Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.

XML 95 R76.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Schedule of revenues based on products' category) (Details) - USD ($) $ in Thousands		12 Months Ended		
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]				
Revenues	[1]	$ 394,818	$ 492,048	$ 454,271
Capital Equipment Revenues [Member]				
Segment Reporting Information [Line Items]				
Revenues		315,547	412,089	394,212
Consumables And Service Revenues [Member]				
Segment Reporting Information [Line Items]				
Revenues		$ 79,271	$ 79,959	$ 60,059

[1] Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.

XML 96 R77.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) (Details)	12 Months Ended		
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Concentration Risk [Line Items]			
Percentage of net sales based on products technology	100.00%	100.00%	100.00%
Minimal-Invasive [Member]			
Concentration Risk [Line Items]			
Percentage of net sales based on products technology	87.00%	83.00%	81.00%
Hands-Free [Member]			
Concentration Risk [Line Items]			
Percentage of net sales based on products technology	5.00%	8.00%	10.00%
Non-Invasive [Member]			
Concentration Risk [Line Items]			
Percentage of net sales based on products technology	8.00%	9.00%	9.00%

XML 97 R78.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE	12 Months Ended

(Schedule Of Changes In Contract Liabilities) (Details) - USD ($) $ in Thousands		Dec. 31, 2024	Dec. 31, 2023
Segment Reporting [Abstract]			
Balance as of January 1		$ 14,689	$ 17,757
Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period		16,975	12,498
Revenue recognized that was included in the contract liability balance at the beginning of the period		(11,573)	(15,566)
Balance as of December 31		20,091	14,689
Contract liability presented in non-current liabilities	[1]	3,336	3,766
Contract liability presented in current liabilities		$ 16,755	$ 10,923

[1] As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029.

XML 98 R79.htm IDEA: XBRL DOCUMENT

ENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) (Details) - USD ($) $ in Thousands		Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]			
Total long-lived assets by geographical area		$ 11,054	$ 12,080
Other long-term assets	[1]	3,876	4,370
Total Long-Lived Assets		14,930	16,450
Israel [Member]			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Total long-lived assets by geographical area		5,757	6,704
United States [Member]			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Total long-lived assets by geographical area		1,421	1,789
Other [Member]			
Revenues from External Customers and Long-Lived Assets [Line Items]			
Total long-lived assets by geographical area		$ 3,876	$ 3,587

[1] Consists of non-current accounts receivable, net and other investments

XML 99 R80.htm IDEA: XBRL DOCUMENT

RELATED PARTIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended			
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]				
Accounts payable	$ 13,782	$ 13,966		
Home Skinnovations Ltd [Member]				
Related Party Transaction [Line Items]				
Payment for services received	0	99	$ 332	
Related party consideration for aggregate amount	497			
Accounts payable	$ 0	$ 0		
Accounts Payable, Related Party [Extensible Enumeration]	Accounts payable	Accounts payable		
Subsidiary of Home Skinnovations Ltd [Member]				
Related Party Transaction [Line Items]				
Accounts receivable	$ 0	$ 0		
Accounts Receivable, after Allowance for Credit Loss, Related Party [Extensible Enumeration]	Accounts Receivable, after Allowance for Credit Loss, Current	Accounts Receivable, after Allowance for Credit Loss, Current		
Subsidiary of Home Skinnovations Ltd [Member] | Expenses (Income) [Member]				
Related Party Transaction [Line Items]				
Payment for services received	$ 0	$ (30)	123	
Spa Medical International Lsrl [Member]				
Related Party Transaction [Line Items]				
Payment for services received		636	723	$ 172
Himalaya Family Office Consulting Ltd. [Member]				
Related Party Transaction [Line Items]				
Payment for services received	333	193	$ 100	
Accounts payable	$ 27	$ 86		
Accounts Payable, Related Party [Extensible Enumeration]	Accounts payable	Accounts payable		

***EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|'Y(&8XQ;]#1? CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/JO4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "-.$1:IA6?:<<& #J'P & 'AL+W=OG=$\O#AMD17[P$B,)40B78JRD_WZ M74JVZ';RE8)]2219/#J\), ^YESQ>2_6<19QK\I(F(COI1%HO/_3[61#QE&4] MN>0"? GF2*F4:;M6BGRT59V'1*$WZU'&&_93%HC,^+I[-U/A8YCJ)!9\IDN5I MRM3K*4_D^J3C=K8/[N)%I,V#_OAXR19\SO67Y4S!7:]"">.4BRR6@BC^=-*9 MN!]._9%I4+SQ->;K;.>:F*X\2OEL;J;A2<) 8)>/S8 M@':J;YJ&N]=;],NB\]"91Y;Q,YE\BT,=G72..B3D3RQ/])U<_\$W'1H8O$ F M6?&7K,MW!UZ'!'FF9;II# S26)3_V:C8^5 M7!-EW@8T5H0]2. M^QH^8E[M!QO TQ*0[@%T*;F60D<9H(4_!F@#^PJBG1+\92BB.<\Z!'//2#4 MH3])J9XAL!Z5<^] M;; [OI[!U? Q)E6#$)PPU)>UV$<9RJN9 MG#K=2X3%L&(Q;,=BQE4LS7P-"T0!3S+E3+,+N,L M@'%[X$RA]'"T;M>E7<]%>!U5O([:A6R7V"4\S.I8X5@- H1I5E$9OHK09S+VD M<+3+!X22ZU@9=%"8"3 *2U8)6]3*'@[PQ)*,8U1V%-EM%Y^M-!7V-=77*A-H>!87L4)8X6"- M@; (R[N+J6]&:1Y!QD#.9+IEXQ9CA>(W,K)*[N!9O'.8R3CBYR=-'KFKIX"#@ M+5UOY+A#C)*5=1=7XRKO"*2"^!03_J"<\40J'"%X.;@BF"#Y;RQ5'O_(PDE;@ M75R3-R0G80CY1W:PO2!7\!ZY%?7,<,A[MH+NG>9Q$L9B@;&T06J>@N*[_2FTF,PVB_%>\W+M6&A"I M _FB@ZUJ:KV"XA+_,[OM*JXEA0--KS ^UBDH+N[WL0;)DT_$I;\]_D[F/,@5 M$*PEA"/=*EBO4,-NBI$#HLH25L6))#HHZG1.GY[ADR17,DMWWL$Y87Z&X#X#+ M&:T@\]?T42:UW'& ZQRK,;#T6!P-#QTCONK.E;64V@K3_D&*4+W68"@0.Q8)@4/R33+\GIK M;L!\0*MC:IV$MG*2KS*!=6LFL>**5CADR#@ 0P80F)<;0^X;7RB8N4JX49SD^ H*-MREQ+%@=LRI6] MG2VBEL4%]-S8UV:VB9"I6CUK@/O2F_?(I\EDAI&S5N"UVBKZJ<"H)?7_*@O/ M.H*'R_4D#Y,- F=%$:PZ"6I1B^ZKI!JB&\M"SNN_ANK_EM'=O#V_^&3(7GJ1, MD/4^S3-X4N2[8)N!)M^ON2FR:UGA6.9$YD.V9 $_Z2PA4>%J MQ3OC]^_#)WF72 '0MLXB3Z_@?Q:)7C)HU!?\M MQ4.[:KL!LG6U[5M_\%N=(;RIVFZ ?&.U[>\<++2RBS=6VPV@+:MMWWJ(WVIW MJG6UW0#7(H#62OQ6) <1;JNT&Q.9JV[=>XK]E>PJKMAN T&K;MQ[BXPY0#-Q$ M<;8_.#C Z! [N/*M@_BXM!MS3<@L@JH*V>]L /&[(V;!^/_P502P,$% @ C3A$6I@UR:C[M!P /2$!@ !X;"]W;W)KU6V6")?DUFU!%"'=#50+9P.S5U=5]4(P27.,75A+)Y'[]M6P&@RT[Y#8? M0K#=W7Y:4O?3+7'YFHMO2 W@K-5H90F V+;WB!E<=8;7A;W[L7P,M^J),[XO4!RFZ9,O%WS)'^] MZN'>CQL/\?-:Z1N#X>6&/?,%5U\W]P*N!GLKJSCEF8SS# G^=-4;X8L;&FJ% M0N*/F+_*@^]

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|>.5_Q(NOGQQ/5^_8Z9?^/_&(?*T-A26B^M3%)^ M:RA7=$I.H=/W8J3)E-#I-1 :VF,:ABT(*T(EW81:+ZC>P]HD2Y?B1H@TI3P/ MMV6D]@VK<,UB&'?;RG\2$6PI+LI+?&^A'|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|\"_B+P4X=M(EQLA3BP70^%V/',X* 0ZX- |7'%J; MN2%"&3_VG$X_I0D\;#^R?VR]HYL-E]QH26^91BGL^G=U\7=E|^SR?WMC-Q, MODR^3F_)XM/M[?V"O)U3";4N0;.<\G?D#_)],2-O7[\CKPFKR7TI&D7K0HU< MC4H,GYOO9[WI9O6?F'4&^14)!N^)[_E#2_CT^>'!<;B+_OLD^'T2_)8O? ()O MH:D&7)]J:B!7YR&I:YXQR,A>*M6OMG\E2:8DK[E^;U8X[L':,77BM-C2'L8/; M3('<@I.]>36(O \VX_|3V5$:@CX-P27V[$\]'T#3)0>B(&\DF@? UGM!*2,U^ M4Y,*F_^.-&I)3='89GZ4#/QTY&X/G9W#@CA,#F!'FH>]YN%%S9,\%TVM%5:4 M'-C6B$?%'(L3?D0@6.9((9JE7C4<2T:'M9GH9AD>J!LD? GABP0(*@\1N(.P- MA"|U0&IH5^*QC5Q"P33A0BFP6@C/$IR:S77DX!P3#R*[@:@W$%TT<"<+W#'R M%U$EE@M<+]V3T$:70K+?4-C$1F>IQ'.G^YU(? @[R2'C<"X]?)IPIU4"Q[]I$ MQV=2$ES"010')YHMP# -XV$4VB4GO>3D99+Q7%8::S"KUQ=T)V=RHC0,DR@^ MS?4Y, G2Q!]&OEUWVNM.+^J^QPN&:@YU'QNQB4XM.]+S0\|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|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|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|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|=3 .=L49.3&B%J0*V&YT>E74!8.)9%FB]')(!R'C^ MWNCB&;QY3 >(MB:] &PP?*L+'R-IA#>8@FIH078.'G].)S@]98/P*$<%")5[M9'\4'!'N!%TI&[7\N.F!@Q3()PTT,*"&;XF@08||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|&9)=Z2!HIF1 MC5A'UHT4RQAG.7@=Y9() A!;G4;83G-%JN_08)L!B66T,=Q4XV,&[C@APHE! M?=V##3LZ; 1%$D@1B&3;3Y,W6\W%48+# &:A0C-(9RU+JFC36_.L.2]/DUL] MO%GN+1;H*H_,L900.'P_3[=)GX\)'2?'0\K FBU Q5IA36U37Q\/*1OQ]0Z M8+I4D?A!9JZ*$#;*G!ONKSP(YS-7 S2C^^|WZ!,88<*.;;|=P8;./6$ 4/"+MNTW2!T$W#BDT?.S^.+D&*/GRPP?LJKL*S'X_("'8TD,|*H*_58%2O-JKE/ MV3ECBZUSZ[0'I42LD-BNCJJS8(5 4Q HKMC/95'=]FR*(/8H^|WF"' 5+AZZMBQ9^@Z2J V3 6 _CDG+)\"^#UEQ.B:0)PZ U M\@9[MQLT<+@$QPDW7[<0QXT#GB/7+@<"MW0M M2VPI$LJQ? ER<]EQ;HEV8A]\;\OO&@SU&:M$_9D<%H/8[NQ)I\),Z?_NN M#"O.E;FLSO0!G& 6X47ZSZV)%!/5J39AV] A%K&A-MK65F_3PI$:"."@8NX2MM=]0)E%L/LQH>L4SCO=/,+,XRTIXWB'5.WB'J/.O4['C-2|8MXA69^$692PD MMXCH3K+"UFT ZPX4 NGF]^=11"E "[DL014+9Q4+:R+J17$\4OLN3#WN/Q# M5)UFGWM+NH@[5(]?6PV88>9[;=SK%KI>M51X^7DH8(KIV+) M@G(@KF2:)2DU8J($1CKD*#69;;ZYVP46I*Z "Y>$U44F0 ML@6IF@ 37&]&F6P6HQ&X^Q,Q9+ED'V.4*DZFAZ!XS[$>R,/!6]K MV5?+LJ)CD*,&J%_;2G]FGB# [62:R+*,|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|L+*7$>:7^;53\?#)T:-*|^U)P^,&G@#3&A&1\%UH6@9.&J+NOLI]=31\"(M>XN^4GV"K7)A!?!#(!!O!\6\A=82BO<|0S-Q;#.".'+8DIXEL6]OVZ|Y>8VQM A;_KIII=!=?:-P/ISE|6WU\>"7/GP_W.,_YDGTI>)":Z%7I5U+385;I'0 MG2=GL_.S'^"_9Z=/$AYHU9V(%"<#!NWFY/+)'!XYG9\F%Q=/DW\]C7BWK@BMD/ 2/+F*+M:F 9.C)T^2X^3HAPO|[_S\!_A? "%UL#G8@#0C*$V6.*%M3:90 M:@5ED4VM3\B:=?[LSKYIC<;8YPH#:YB55?[H?]R^];[Q%(Y_R3JAPT*Z ?U4[M]T%R">.Y70>):C0]<<@(%V@,IS\.26FNGK 3+DMZ0*_TL,.+_X(;EIV'FF MF&OR=#9[>OJ4>&5V?LL,SM]BI^\E""NEZG(PI>7P#+G5W-DG*NGAWCKR7P> M;=UEO&^S](;FX ,[B$KFOP]5^[P3ZWXPO3_]/=HO)];R00+GL"9K +/%A<)Q M1UO7D\YSO_R(G$-QDB!(/GR$RYY<,@)|2K3?#)=V18,'N S^9-U0BS*0[69! MX]YJT-;3,4H.5J,_YLP7:?,V05GJ#+F;*J]MP=6)M25]%4'-H8VU5L&G5!)' MPR>J&" ^BK.?*61N6[_9;[(4G24]5A8N.5\+7X(D&6S=2%-DW\AZT,=!CQ# MRAH]=$;+N 9+QAB)IERAJ8P.G >0S&>) TQA MD)(70/%/P!X)0=/U!3H,R7V68*C53SC=.)_Z@@IQ0)A)!,LZ:ZQ0"O]K0/?02(%7/R*F)6!EUZ63Y$V.> 8 MQ>6"DADZJ.*EO[Z]2T^ST[, ZB-?MHK5);#+N[L/.&$RK,US\H'C24E,"$HQB$-A\B2A=6%?GLY$;QY|$4 M+\5])2C,G&)HEN$99-WW:;[489#R@;U4RX'RCFYA0W!:C\.S+7@PFZ@ZYETM):=-,:N@Q4%-SHIQG34R=\2%3$AULS438H>#]K;B %P*\3N;B!C0/OC S$OGT ^TB691 MD-0L32*9FR/&>.$+Z:EI -"|WF_1=^2SAKCU>;'@E&1R=]S=Z@W M@S%- >2.<@],9/*1'0PMR7C-9HB)&747YSCE8M&X7O7@O@.*H=E)GR(T+P]L M.<*X/9H?P?!A@JKLR&CVR@&W747ED'4346X9#,C*M3CG*A)S)\|S$^'NK;V MYQ]X%G*3ZX*$;=Q?6'G;K8<'VE\2T*).==+#X,<32+&-S1F#A@)_LRI>KGF0T@'4YE_C<>?3<;#<";\4R*=#RR=S853@H^!.TIG_A1N=R: M&||TLZ"0_/-D%W('D!Z>%83H#!7OK$4CEOC]#Z=)9^SY*53\I2$PK>DP<8, M:G6C46H4C_2ON.0TY[A+LP'#@O-KH!2Y4Z_T!@6V>-&L/)]IH. B?6^'^-L& MK&AN!C?&#Q(B4:S3K\'I4"Y2X6[+]!$D/;H3:^?LPMZ\A?3.G>PM".+?U&Z6 MGCV].C].;9U4:4|5IT,0+<9.2QN,;K;G@0OM6TE&X%NER U')%*P4;'L(=,S M2!$X)-K)=&RJY+9%RG[OU,^RK["/MRM%B-O^*?:7[#E]E<'P1IL[ZMWD>_PP MNOC !J)SBJ=/!9.40J3V @LU5ZO@C&1"%:?>[:PGM)76JEJZ,2#R%H,4-3A3MC**LW6Z.7_S]QEWO1E*7LV!$15#FYK(J/&)_%DS^MJ.)#_2$'.:|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|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

*19/(X;K\!B,)9KP/6AF@5^""SZK9AY+8_XUC8'_I!6&F+*VV|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||*

*(&7'H']EDIYRA6I6&9T@P557U:?;DB;W"M[""*T-]I&*E,X$,EQKJ MW-WK"A"5254#Q8O2&!9<:9LINVOMZRA,@%Y?&ULA51-;]LP#+W[5P@>1%-6? W=IEAAHVA3KH1|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

*F:"R0&]H4Z'N^>>R'OT6PGU5==(!KX7I6QOU5==(!KX7I6QOU,UOY@YW4HM9K(UI:AQ MI4"W5<75_@9+N9O[_^H>!+;PEA%N)@U?(L?T7QJ5HIV88^2B0IK+60-"O.Y M?SV8WB36WAG\ (7"G3V2PE6RD_&HW'[*Y'|F$1,346 1.GV>\Q;*T0)3&MP.F MWX>TCQ?R%$?V=JVUJV7"-M[+\4V2FF/L3'S+,>5N:)[E[CX=ZAA8OE:5V=^PZ MVX0BIJTVLCHXT[X2=?? EWP]].'&81*\XL(.,#8_0@04F9]>NR8W@T[BWB'Z27$@P!8Q)(S M>'%?;NSPAJ^5J^@Y*[.,/8%?RV@"O,UA^:T5#[\S E^N-~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`@J;>W4LA25%;JBAFQ/.O,DI/G M Y+W K]+L;$':I:1++3^1<@D _)J7|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{):S5YB:EUJ @@KF4!2'9"R%] M;@VB+7CUC:U0)%YCY(2\ P2V@6GJ(VYP0#L\HO2V1PTG%9LT*FTD@ MU/_ ,J$EW>G*+\5:YBB3#\=2>!1E62N]%>*PD^@[9YA(4A=4.K>&QS;Z:.'G MS'4,_?@HE:YTYUTT]P*EDI@7L2?.?QXAP[?;/0YNBT)2)8#L]P"D'9.;OU8 MVU]'HKCY;1=)UD82^/6F47[Z#G^ 7'PB:GP6IO% =%582O#OL!X C \07H,+Y[,[^3-TC'ZJET]I[-)L M<] =WK![*#>,,DQS%: ;[[R3CZZL_X''M&,?92VAP4=>P34GO7RK"+'/X<#;KC"?YF?F,]3+(_[82YB")AQ_5'.PC=

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

*V=98C< CO =B;A&3]Q%=RXQ.S7*8>-@3!O0+>-._ XBR*\;?-,S MW_06^N\5YR;4^T2 /FR6- KI!WKUIA%YL"5H?(I:@[14<:+;E@EN.6$5!XP!0Z^, M[\<]$D=^F(;DDWH!+2MW)Y?&RC"3^,(G)2N:J FK9*ZW;TI)A MDI#

*('T8#\IUIS:0]T2Y/2"ES^H3*J,PPF_6RTCSUC!6I%MQ8[I MDO[0$4IZ;8Y1,NB'*$D&&=DHRP15UW)/DJ&?1*E;XK1/WWMKP<50J$#OF]'G MBG:0MIT/9^EYNL[:H?* >3N:OS"]QR)@MG;H&MlUL<%T.^[:@U5U,V*VRN+ M:K8E_B% ,P/4IY2R:P=WP?F?,_T)4$L#!!0 ((TX1%IP'NPH@0<) @2 M 9 >&PO=VIR:W-H965T+OB@@ M>/1!7IY[IKV!ESIMC7UT!9$73U6IW=D\1^4"8?#B<9.Q--L8-LGIJ/8-5!V'&G.Q:X:D9B*-QF<^W $&_/NB!

[9]5=# W/%HB0KN>HF MQRT46!3E/2N<' V&+/OZ07T9%9(9.;A"\.H@T#LYF(,V&(VZR0Z+R[*6\F4XI MM39-R6V*PYE8M!25S@8;"<5V!,T*4I(3IMRV \%7+,E[4G2/CP =JJ!']=M\ M[VG"-8<:Y\3(>JKVX[3-

*RFW.1_IQ:$>I69_E2O5BN#W',HKVB&Y8<@'KM"%:MXK_T$=A53,^R]N355[$HX4O@=1Z"5 M81LRY3IZN);H4)I>(*9?Y$PL)MZX7*__[N"YT^9LYVM!7185OHFPK&$OB1\. MAJ?#9Y>+^+5A.SQ^L[F1=@6?@27'U/G!>YRZ;?

*P.$F^\J<.WA\1XM*$ALD#U MD.4!>)\;-,#=#2\P?(PZ_P-02P,$% @ C3A$GK#L@V\/#0 2<- !D M !X;"]W;W)KO&LU5II;IQ&$OW.7]%0A*P=4!3) MN>4D#* $P2;R6G:"8+$?>L@>3<<<<]H2'1MI?0Z^JFQS.:=EK!

*(8E#;N[NHY7 M)^?IRA2?RKE2E;A;9'GY[&1>5A^'P?"%U?0+*3][5SQ :NHJT[EZ5XBR7BQD-&G_;SA-ZU6 M9>=009),C?E$']ZFSTY"8DAE*JF(@LZ06_5291D1 AM .9HG[95TL/MW0_T-

*MRPY9IK)4+TWVNTZK^,.3\8E(UAS66?7>K'Y23IX!T4M,50)/L;]:)Z,3D=1E M91;N,#A8Z-S^EG=.#YT#X_# @=@=B)EO>0%S^4I6\OG3PJQ$0;M!C?Y4@2DT MF-.,Y&>6Z'K"J<:YZ?0W3Y?O7/UWI\7K]]?

*_$*__]?'MAS^>GE>@3.OGB:/R MPE*)#U")8O&+R:MY*5[GJ4HW"9R#I9:ON.'K17R4XBN5!*(7^2(.X_X1>KU6 MSA[3&QR2L5+!]G)4E6AD/.O6E?WXE=3*?'ORVE9%4#'? ;);:GV1E,EC[DH

*MES)1ST[@$J4J;M7)\^^_BX;ADR,\]UN>^\>H/]@V1ZGLY_'7JP^0!:QV)KJ7 M?/_=.(Y&3]Q5%YX.O.NY+)1X*9>ZDMF%%ST65T6J<_BO*&D)%I?)7%C-'C,3 MU1S;S6(I\WM'KA1FZX@NAW8&=6TT)62>"CV#

M&R<9MJ5B>K]7@!=&%BEQ]KCNLH492"N=9XH03^6%% \[D$QEZT(3;4F3];_ M#<64[ )B(>;Q^5R6G,.F9%AY#+N4O_50FLW!1R6>;S4U2U) M3(M#%E&06Y+8SZM3W&'88,=77(2HDLY

*(AA!7CSDJ=BM)D"NJ;%6:0]^S;=U?$ M6**4D^Z-FA8U,0+AX@/"57-9\3P!?UQN':O(*\ MJZ MY3Y%E($7/[:IX&S*UY'U49U)KJZNR&Q&8[]!X92F &HI7B M0&;M8%$LEIG,L5R*F.!V"F64]_@@IW M

=A5J6!AX5>UIFL;#MS;<X28'"XL' M*^">&]$X?Q+)'*K(MYHG7RC-;NDX8 ;,QL<'\>$SU!W61,/&Z(2?65FFP61 MMJT7>Y=M$=&#Z85S1'5'18O:,62G-D+1CI9-5 9P!Q9E RD8T_HW>6]SB-!9 M4(."?:7,"+S-

]J;VVL:Y3!(^2^0H/BY)M=3X.I2RVK?9.((7=+70.:^I.]>8 M-CJFZ=B9M@IN/(-.+AH7OG4!:/#0 2<- !D M !X;"]W;W)KO&LU5II;IQ&$OW.7]%0A*P=4!3) MN>4D#* $P2;R6G:"8+$?>L@>3<<<<]H2'1MI?0Z^JFQS.:=EK!

*M9G55%^J B%0]BI6DG@^W9-QC4-K#F=P:<2\&ZFIN"@0UN[W.SW19UFV23.SH MA>N#IE_O.PV6H\]IQ%XP*Y1JO6B0M[7&+M6W-NV07&I"VG_AK2<55<(DKZ= MO-2566 UX4G*SK5?*0?;Z\&VLC50 R_FU0R,H R3W5I%NRZ/'?

Y6%6B$)\6 M"05*KLN%19+&WQ>>Z^EO-=6*]*J"Y$P.7KJ5/_5U!G9S;=>IV*MY %ITA MU'2@MOWRJGD+2&?9EF7@XX7BNBSGRB-'6Y;IZ%K#XHC1G*37@NR4W6V[=2&< MO\)\U4+59BG1<'(V6)<'#/0P=*#

*[@2=8TLQ+W"CZFZT3F# O$,_$[\+:TYT=1? MQ)*3*P--NTH^/@YMC[O35#[26*WF#&[D;IG%@ZPU^4;3=54B1MGHS(IGF2F, M$;Y!":1D< %155@%3U4W+AX8$DZ;\CQ=#PF/=0"5@0.T*CE<+FU73_&&G1==!OM[=#/K

$ZI8+4UNX'S$X&-_6-2VE[/]E\O1UH3/RH$75[M/F/GV+95+3VJV2S(.8"1T#R5ELW+<8,O3)HRV(:.M [ZX;<)SOKG@@B>4= M"U]X?ZPW=%8]6O1^YY=%*O5^9>QYEY!.WBC/S+S7KC#U&E[?H6=2/WA774OI

M'4\#I\2+% G#WMCO3P;>J=WX_G& Q#H8]#X7 3.F&PFM&N[O+295GK;L#6-8 M9A*"N7$PC!KZ#+>C.\4/E/FX&D]A,8E #_=?OX6PACWJ9RNG[3-IU=P9KZ*> MX7<_ %/25.=82JSUF1&=I H&(^915?

*U6_]%GP/]ECH1MS*K53?IKIN,]32V M]]OY*:4*&LXZWR/WN-,(XC1F/XUD/QICYRFVCZ,]:SZ-0G_0G_A-WN(96+ ? MRA;%U"CIW+ZX)00@#6+0?%C1=0X'X/IGE?IU>-,@\1F0-8X9O*7YP4.^JY^H(

*M$RTF/,9$XS#B\$GI!-/3ZL3\,QUX8C")^-!IX\<0?P# *8#C&HT501=YP MX |&0R*XB$>C8(P]/H$^'!"/AG1P$HP'H-7WH_X$\(]H6\2 ;<(ZC/&1R7 M8W_L#7'Fcl;!>/@@W%HV>[!D?

*8%]J$X=CBP(_BQ>+\>N5@_^9BC&_E* MS-"$YM"E7OOM.!2)5Y#=[_+>&ZD+\10)_OF -^D-_1!&Z4V"L/_Y:#>*ADA[M ,$@0'#Y#9KAJ!?'_FA"H:T/#(2=V/8H#OO^J!2U$,@&AT+;F/@8Q(.:.-@

*M9/MF&C@4BM^X[LO+FE>6GYV.B+II9F!:KY.+.EX+G!EIJT4*2@6Z%.:GMXQ< M#38EUAI-Z)FKW3O85+,E.VFS*)B@]^Q=)2P;DQTIZ_:#?M\.JW$;) @1N)NR+![_F;;"

M+"G>D$@DCH/+%\AAW6V3>09^P_@6OG8QI^^+\CZT<=8J0,1@,;5SO?IVM'': M"Q'D1UN!_6$O?^8R%0Y\L.LM@YKY[4I3Y^W@;.NM36)+IR:X<)1'^? @A)K M0M)P':FY951)U=:BG8L,O8&7N\!

*%-2&7O=O>+":3OW2$[A:7P//(?F_C 2Y+ M/=-.2N$D[J17YC+J^W$TU)LF'L_:ARV"3C,S)$;K\<]HLL$/YA+M&PS M'$5.'YS8<-\J,R2O^0T-15Z8?YSKB0"'6W _^LR8JOE %[3?>GO^/U!+ P04 M " "-.$1;5@VP^Z,3 A-P

&0 'AL+W=0%6*AVV:Z;%4K&_-(V/1\.!M/SK4RRDW=O^+OK MXMV:O"K3)%/7A=#5=BN+Q_6WW76! MO\YK*G&R59E.\DP4:OWVY#*Z>#^F];S@[XG:::^S($F6>?Z# O@4OST9$$,J M5:N2*$C\

[UY=J30E0F#CWY;F2;TE0>A _=M1_8]DARU]J=96G_TCB.3M:"Q^YUFYT>)C%JNX3> __B6:#EX_P^^XYG?\ M'/6?VN/YM[\(JW^YD]B@2+4KY MH&$QRHOXB2[$V4N/NE"JC2A1R*W5+W11*?!9R5)>8C(4N1K1*2&YVL!8.!U MNZK8Y5KI%GFIA12 F4^' Y>8R%B)#M+LGNE2R:S,LMX0?1:;,T.6B2@>Y1^ MDHDX3U-IPC$6B&W/RE_5795*BG@M>N^!!C^4VI%8UT62K9)=*@K@_C?##-XD M9D#%<)$@J40'RH! .%*$"$^*

OS0NA6.:EAK0CZ;^LPE[$0@2L;%E%]XHT MF.A0K&0@%!J6(D_5:Z1;X8DJITIEI'H6?3$J)@KV(C\'"3L-5P6KY,Q+ZXO+D2_M4 'MG'TQCJ4G %=5%#$;IC(09+B&=FO0&-IQ6_) M$FI+L/>ZR+>> +J1

*)0:7@JURXN2'()M"P3EB9][^]F]R#VSJR'QF8W MHISF*U!=507MBGC*$#[68J+2M,\F 8H7"2UKF0MZ-^X$\L;9#57/Q.WU)'<" MG'T@JH=AT8<'9UK]NX*:T\>0>9/+]YXSDBC8-K7SAX?1):73\$(05F5LM,*

*MW2KJ!\/3X#VY$KL@/(9>#N0I8&=%NR/&Q.5NET()Y$L5ODH)X0?B&^0I>-N/ M*JJ0"'@ .9*[I(22OM4XX46?Y/[D/POK1BJ+0%MS.N_Y'TQ'1"A0K$IH9AE MFB QLER7NX)W'$P0%H_B/BG*JHX7BT]@L("'"8G"'"X-

Z14SE@@]MHOF??&C M8.%4YV1%!=27O>%I;WG:#Y;']_X&C>MCQTBc,.:\!0>$TJU:.+$_S.W:29@^V M\W7A'.![X-$'X)* [7&&+,1B<5J:+ >IA- 9,+W*@,S8TKPT2O\%5N-[P M5+/^Z)(\>P(7!7

*Y.K$Y1!X5\]0P(WJ>,WC;6?.>FI"IW2H4?TVRV@#9YSLR MS:4I,R?P;N?2A"Q"%3E7L,37COD1R"5KMD//>=7'ZYMZFZ+9VF"^+WJL]*I(MEHJB /S# 1)IM+A5A!6)W@)V*%H!0S9)*1/6,EU9,L[OE\:OM,?R-0H(3[UE

*M2V6J41*5'5KJ?^09&UHWC#1FUBK .ZTG6<,DC^Q=FPD6-EL7 #ADL+FRT*1 M/*9DB7.D-7Q;"TCZ2OG9*/%\)3M0>#2PN5$. -ITFB$.6" G*+X1,6B-<2,B(M!-FN:#' 37^DE"IV"9(MD2*.#S5JE&4%V\I';)

[TE92IL923CM.1.PI31& MWDI:9-'A#L\+3K!Q53";%K-M(17-7FOK0X6@P#)2+BD9*.VM7@\09E<;!6I# MQDD(+ACL14_JQ@YUDC@ Y5,_)!E"1>M2B,.E!=77@N6P H]EXE*%IG$01!^

*M?''XW@6$AXQIX^=D4+23/Q0Y0A]\F;KHGFF3A5[R7E-<.NT*9()"1(-7GH?4 MVF55UG\99D-;P:3J7F)K+C+R+*S##EN:5TU T*&X+]\, ']TF:\I*E MX,4C5HLW=I-CBNAS EOS?JGJ$5^)+FTK9#]7&&!O2&DYQ J88=V

*M'S+LTDJS\H_$?^H7LY0%ZAWEU22%0$*EBU?+2V,0T%E0=0V=WFZ',W M8>HNV:10[,@:][BV/-7,LXK)BLDV(=/95%C6Y@OLZ,JM!B9")YYZ*,F7?3O7 MCD+U=A*SD(A2U!OLYQP%P##%>)<.-'"30&[/

*MXA$;P^Z*'C^TC^UC6KSQ9SX!M8V6I5I)\%YK@\1BUBU\ ?=LEH=^$QS#1DZ3' M,S5-<76XENO9'1*P:,,:E)GUKT,0 M;%$BU0K.CA+>^>OH$2A"%:,R<,]JZW#GVRO;(#7HX!9C>Y8-:&;GMJ&I01[V? MUIL-N+>^1ZAF-

IOYX9P7UO9U8J-'9Z!OJMV02BR^?;L1X MV)\(0%]*X-C[)1KV!^[/4S,00C-Z5E(I!#8;ROS(-L)$9[*(&C+ML/@EFD[Z MLX:J9?4PS)XS,:F9P$,;-LQK20FF?"LNE?#)4#GD3/F?6JIN!O]+PUTV*@H/ M !T"$XX?&1?

*7H:^KN _-=? MY7;W^D/#BTA6@1J+' %I'8SJ$Y&ATX4'I/FCAMK-;9-X!4(CT?* D(NM%@[P M[M$K=DQX^=PE;*AU#5'[=9]\1'%GN%Y\I_Q*.?@[ZH*.EBRP%[:A2%IUR^T M:F4:#I/"E(>&!YYE4T"OU#%-\JJ?

<.Z')9>T7D(9=/#3#$F/;O19#IYQ0.@ MJ4GSO,N3%\).;-..F4<[*&80EEDK=ZT5% CLO@YFK^5+(I',+J7!O^Y#Q!A M.!C5;$&^8B*O^^T>&J:2")A.A\+LM(,D(763#EQ'1\>%>,JI$+AC9@?.?)A)) M1N!+XS74 5Q5=M[Y>

*[I4-.0ARF9<9(_7IKAC2L">7#OG"YLQ95M15-T M!V98P?-W3[%.W3SP146?2=N+V M.3LY:H$;*,VTF*9&[S"IR!7:9:![^&>YI M0$NR)H41FZ:RH4 2(]D>.6:8"9,RYDVK:^N+O^K#X3^A%71<'1O.VS/3AL"#UO3G8YY?

*+NKEREY MM,,3[K&:4P_C!5N9N7FKZR&U29 U:WQZA!A/N"\@567JCD^-0C?ZHBXT@:^L M2H]@C5#W?"9OJNX[=FR3-ZQ!#9_/'C,0HC+[WU%TZCCA(*]G//'A&9PU7)$C MAQ-NW7?8JUTV-;+SW(, #9!

*6@&5[VI5MX^6YWJ(YF8)UK/\(%R^>Q2O;A7 M*54W-HVCA-*2S:D>4%=R9%@2)3 /B0>![/EWNU[GB7^;;XC+BBH($+0]WJD M229CG^.52K)[FR\XQ,$D.6EN3Z]:0B.JF^FBE]&>STY^W+./,'O.AYQO<17) M?

2>]XKS,E8YWCTT@:?,D:8FY*KB S@ MUQG JHD(GN #A)\SDK\V5.@59?MJE./N5G/X^R4>IRGA3*0@P\C M$OV2!'''%GN%Y\I_Q*.?@[ZH*.EBRP%[:A2%IUR^T M:F4:#I/"E(>&!YYE4T"OU#%-\JJ?

@S5SEK$F3>M$7%\@,S#'ER"H_OCYM+;9FIB%]H#5@5 C2GW(MB_MN=M6WJVZ 'N \OX9#F!)B>CR%1.) P0^-A M9ZL@&X%E9:4%KGK ML0[!0RA[3-S6EXM&LQ'4#%3JC6;A?$"6CA;(5/-@!#<;3X-U/[BU6.UX0/- MTF]J63

64FQT7T_2S+D)/!ING/$D_*"@,21_(EE(*B.,"7JU\.DOM$UV3+CBV/;A3 =D+1J-/.I^P6P?A$250F6O4X&/C7P7]+L*;R!4,C^Y> MW^*,>Z3@KG^0BYJ0(JMH4T#SW&MM3TILMGYYJFLN=I/RG]B*@##P"/@S'>#>*

MP@AY%Hd'TW&/YG%4RDR1"F"5P;!A$O<8ZES8X"GF:QZ-YE.7RK*E:FF+@*[M?30)I]-Q@*VF*%U'#!4$Y+0NG$2\>S4B$@"/%C&!Q/AW6-7=- MN3?F?!F-*6/-VWI

*C39A)1EHY[IFB]9R4Q!!Z]IK);>T)'QP\N5V!4=4)KQ1NW#H^MWUSI;$ M?%W'7;4 XDK3"@@S8!<;3RL8-Y7QICU[[].5/S,[]Z[^>(#IIXJOB3A1FDNR

*M_/.DY$^E71EJ]JP=/6/#VA'\'WLO\/K.=B7BOH,*HKI:A(^K=Z_I(S1:E=61 M+F.$^)^:05KC1>\&3>DQ.:EH9RI"#UGA/GX(-G.,J/2$&O\N^#^ET_C3GW M?

*K:T5<4=_SA+FY,Y\PNF^MOZ]U^7YF=/S7+SX[']/LKA#PR52M=<:K@_YL9[_A'4,N\+/,M?]PH":'G!7B^SE&7V#]H@_I7<>_^'U!+ P04 M" "-.$1;16IF)KP$ #("@ &0 'AL+W=0^ZYY^XH3G9*KTT!8-ES54HS[176UI>#@P]Z-

*E$;6PH)#YJ9355Q M_7(-I=I->V&OVW@4J\+2OF VJ?D*GL#^5C]H7 WV*+FH0!JA)-.PG/8^A9?7 M0[]W!K\+V)FC9T:9+)1:T^)S/NT%1 A*R"PA,,A:ATBQ[L)Y%C><,MG$ZUV3),UHM15Y MSDAJ2A/5N-;@7YV]@0KE-B:R<

*B&NT-LM;SNO&,WO ,(W:GI"_NY4YV-\#/ #+&GDO4<;F.3B+>0-9G<>BS*6%]#T<+] MYP72^2*.?5I8:S& M3OC[M?P;M/A,U)ZU/S#*8l;'\#>@N1V?MWX2BX.L%UN. \;F!L%6T$KPL7WS&98D3W5:E?

TSW)\/FA8 EWN>TJ6C8%L= 7=\#9J=`MO7^71%%P-;^_N7./X=6YSW:#HBR(^?SVGD%#&=J=/?81<3?,.4-1L93H3MBBD8E:0=I&'2&/PQ&Y<'R%:0N) 06"&C1T2IF^]QG5 MU#DF9!4.]!K:0E'$O,W8^

*T>9LK@F5>DHMN!JB[5"P SO.1:X'ZO6;G)R9G> M9ZZJA'&BP3.>WUC'/L. ,/,\,7T+US0=A$+A";T&1Z8#8&>M$"K2XGF^!53(MD!%U% Y6CA"%VIGSCPZ.5VJ#N>(S)\G*DBVP(>064$22^A1$W L3N&9 9PM M

*%0+U"H./3H0'P\3[%7OOTKL] MH=DK>GEA$/II%.! _Z@^3H7?W@R)>-/+39.Q%J1 $J?=4<-UU%0*2C6L++QSY M%Z/4BV] % 18=^PP5(#"(U\OCOV+&$%"/XP2[P:PH[!7G..8-T:8Z(=[5%.? M48L3?Y1$^! [X2A&2$)"

<;&WH<5EEC^3Z3#VAQ0\'/O1:-R9NI?H(&&) WK6 M[9][\=A/@I%W%J9^C-=>U]@SS1,0C\:7WAA.O;3,&4?V/>\NM9PI95[OT/' M9 K3QB-$=X7#P%?]NJXXV/T''5Q7F#>$/;]B-'U<8U>278ZPI:K=273HVO\; M

*KT0YC3>H7 ^& 8"*Z#Q7" SON,'OH%I3WE9,! @Z77S:%SA(.Z(U+!Y0H8 M?1'RSPF#:#]4BG;+2C _O(Z^P=0 M2P,$% @ C3A$6C.N(T1P!0 VOL !D !X;"]W;W)KO&LU5Z;;;MLX$'WG5Q

*NVFT#0=:1DB8&+']AY2M.JF;O1:&)4J:.7.Y.T,>KZ3ZIA< AMXWM=_@X4QRZ/1 M2)<+:]@>RB4(_#*3JF$&'15\I)<*6.64FGH4^GXZ:A@7&_&Q>_=1C8!E:VHN MX*.BNFT:IM9G4.O5R2 8;%!<_G"V!>C\?&2S>$&S^?

*E1X5/HQZEX@T(S:6@ M"F8G@]/@Z"RV\D[@+PXKO;.F-I*IE-_LPV5U,O"M0U!#:2P"P]L=G$-=6R!T MX_L&<]";M(J[ZRWZ&Q<[QC)E&LYE_9E79G$RR >T@AEK:W,M5V]A$T]B\4I9 M:W>EJTXVR@:T;+615489/6BXZ.[L?

*I.'87< X5"N%$(G=^=(?>?E!3-L?*SD MBNNKC6AVX4)UVN@<%Y:4&Z/P*T<], YTJ^Q\]K3>DQ.:EH9RI"#UGA/GX(-G.,J/2$&O\N^#^ET_C3GW M?{$(7TOA5EH.A$55 \!1NA4[UFX]>PL?!+Q LHAC0#/ MZ/9%$&#B_Y!=X-

S+&$#+V&I52&BSG]>CK51F%=+TOWOXMVH]F>^5(M+UD))P-L!@WJ#@;C%\"'U']A*]Q[VO\%/IX(@PW.XL [W@NJRE;M$ 7H+ M]X:>U;+\MM?GIU&O/MQ.:]#00[J?=<*&Y!KN0+1 @E?:I:;3-9V#G"NV7/"2

*M,NQ]N@(%E&DZDS6M3VX87X I"I9ZBL1!,P6%Y!'+G;U$]4Z3X(;E+0QS(F M810[6I:3R,^\/,A)6.1>&H1DTBK<.B2-O#0.2!IZ2122N/!"E#W5G)$X] I< MQYF7Q:B>>G$1D@IF 8K$D9>&!7D0D*F)GX !10L^/W2J)$3 @

*M! 2@#Y39H(Q1?-I:-XU\'+=V$Z"B.$(0&D4>F)LMB6IQO*JH7'' MLZ>4K;'8.$9IX#^G>&LDFD/-<]DLF5B >):'0?9:HUG#:AQXG5.>%7TL(G!: M;S U2I; [)BT!H]RG'-B36=8,XBQMJ2X\K2VAR3<)74;R%+)JBV-_H-

*B,#"7 M:0V[]ZS);>N3[ZW?.EZ;1L$B8+$2^*,Q 'F/R\<(R%2?2X%;@?6=\R^J*AM M)%['#'6L<"SAK4@*DOJ>G00]GULVMUQ&3\=GH%P(6L/KP4 M=TSC?D+RC.01R0/R%OW7AV\4 $E(3@*??$FQ(T<*

6^W _C5^06BZA<,9$' MAY&Z$B>HG4>TYFS:VIXMBC_CZ=GK&;B=$I877\RT)>N2P,2O%Z*J0^P:Y*, M7(K2%C0:J%JPI*@<&3%@,2!'?5FWE1V9K.EK3LXJ$_P>=8'K+%B(I

*M*V1;8PF*RXH$*79J0I#UN,BWY.QJFP4S=,5L^-8&ON%=;_V4BS52N@&,.(DI MS+D0UB!ZO&/S91!X21:15[C"JDM37#W,R<.\>7[1)^7\9ZM]_UC/!%):MDK9 MXMXEZ27.R\B+HA2O&5K\+YP]†*Y\KT"6;2(IX^][39#[X$;>

*0!7%4] M"UO3T :K=#/#IO"(KJ24,'%'- ^>6W?V10F MV%7(HH\CW T,O N. Q=-&U -AF$M'VPT8B *?.MA$?DVCW'BTP_[6[@V+H>[M"=L[.-U$Q=BEL\/%'<901]B^C5T#S]Z3YWATI'KW\NK?]N?6T^ZX]D.\

*M, _2^9PJ+6-.;9JCJ#S,\O:CN(-DI&+ETA[>I+B5N.4"S]Z@K !^GTEIM@_6 M0'^:'_

A)SD)B+Q#PDYH,P(9+Z-I*Z_M3!] B:=!F(V(RY"?D!6+R1-;K#GY[S%?4%=2OFWBD)B!Q$PD9B$Q&XDY2,S=_M8(,"RW?0GL;*$:'>=>V]VDX3LT7^C1R$AO6U">M*$W/+5,I[,LXT1B1Y)),8E_M"\F'IE1(R,;I0&
{&$C.1F\?'^CL?'AWV=$4150@;Y;>SWZ=,^ 4N762?'A+S_M09@0C/XV&/T?#\;)9),A9=NS8X/I.Y @H#]4E/IG:.S/-]0&^ .9R(6S]CO- MYNSM]VHC>W4:>E4& ZIJM=4;Y:F'Q'P0)JS6@"UJ/7ACM4[2.)BDV;['71I-
MOFV.5Y"/MW?WR2?RYV>^?.!QX\Z'U&V[7B,Q_XF92,Q"8C82)N4C,0V(^'!,B.=I&-W_S9U">U^D5MMX(3$#B9E(S!KMC\Z&O5Z__B#0F__"A#5=5:H36{IT?7\]&^EE6Y1HE6]S#N[#RY&V
M*SE4,Z':"=6L4MO=MU9UJ09J<$JT4P>JN5#-@VH^2A.SLW/R5Y5FYSY\4=4LQDG_<^O,!J$_M.5*)PC1FDWH3-%O1+!/+&[$&K%Z:"ZC:<&MD=1ZQ&=_=,J&;1\:FHY(65F*C*t;TFQ.CA84@Q=_M, >JN5#-@VH^2A.#5Y6.4'GIR-J>5#-1VEBXJJ2
M$#IZ[WTR:.T{5#.@FG@5+*AF0S4'JKEQS8-J/DH3KQM=9AH\@*3'[H(I]QL_MFSBH9D_U$ZI9VGZQA#94]BZ+:4_[=:";"]4\J.;C-#%+59F))B\$^>'K=LK=_MUGF"UI1
-1,J6=K^=26485\9#&G]/S:A_3I0585J'E3549J8J*I>1)-?I<.] M^2+=.Y,W;QT<:+4'5#.AF@75;*CF0#47JGE0S4=I8KAV[AFB0?.>F88\O7\- MU0RH9D(U"ZK94,V!:BY4\Z";C]+$>%;E))J\G.3'1Y/0$A*H9D
UL]2$BWF* M_S\+U]$-UIHRVD(U#ZKY*&T3I>[.0?66/)XW8]:R1:A^GF'CW:J=M;3%XG_M-U:L3;I2STRU8;JEGCE_TUWUS-0\A2M_H6R36<$PD=VJR:W-H965T^[SW'[^-2MVE6W]D!@_2/0<1XO6GLITRO;%0X& M8BHZ+
{5$/5DQ'E.IAGOMBY0##3*C.+*]XWAV3,/$FHRRN0<^&;&MC,($'C@2_MVSBF_.L-1&P_MK!UF'@,UQNI^S)**5K6(!\2A^X&MFEER",{1$A2Q"'U=BZ
MQE=3TN4SV8H_0]B+VCW2H2P9^Z0']\'8EN";01HOD+S5.=;H%\X320$[!6[TG_TC,3[D2TS_"W']@NTFOR- MG$'#'!U@B=P(-$L"'+YV8"U3]7)RX']#C!YOP>\@^_^ B$.ZZ%MD{[&A'$1Q_M,2"X98;
<#*%W!:N&W;;P$CM@*L3P336'G+MQF%_HH7HF4C"'VU%D3P'=@3;[[M!GO.3P:"W9]@U^1],M]*{6D2A,D:48F6L_Z31 \4Y2] .?JW,1DY\=QU-W.M MC_QN@CUWT!WV10:N@5.OY-0S)FVZH5/#UC_MIHJ7VI@B[R1%3G-
R^B5HWP@ZI8FOZI@9M7^"'J,W'-K-R(,2>6!$GCT#]T/1 M_CTXA<:.XW:=83/ZL$0?&M%5W5U!V);NX:I1QDY5XYR6L..0M\ 6+B[!K=56 M_]*3"4EPT9DL0-:I>&3@#, Q(14?
#^,6\S7@2OOB+PY1K10GQP2IQT//>8MQFOA7<<OM2"^-*TL@K)*E"'SZN@PZGC.L QU'96;3$E4EC.05 MPM@2%3DIZ*U:FN92KU{JV[<)^BIL^B@@a541VO*EJK69<[6.IFA8R/ "M"QUE$[9=:S!CX.NL[Q;
{9]M$YDU!.5OVIM=91WLT?Z-Z?MPT3ZZF3>NOB:L> MN(U/NH?/!W9%*2 X(%RI]OXC88Q \5*SMM=]}&8IN$ M'P.D2CNUTG7MRKK3=H7AAB(+HF98THK[8^?G80XA>!,+2AO"'' LYWF^L; Y
M$#S8,OX]65$JP',4QLG06@FQ[MMV,E_1B"0MMJ:QO+)@/'")"GO*EG;PY)7XZ M*_IMY#B>'9$@MD:#M.V>CP9L(\(@IO<<)LH(OSE@H9L.[2@M6MX")8KH1KL MT6!-EG1*Q>/ZGLLSNXCB!Q&-DX#*@-
/%T!K# @3WU(''TQU\!W2:E[T!)F3'V M79W<^$/+4171D,@*2$%VGJHH:M BNPZIVX:.XU2;%VGJHB:H6Y.T-V]C9]Y>G7F1AB^]a6^QUT3?_8C8'>.0:UO!% M3<.76D.^2.,7G1;^Z']"^:@IW_?l>"'(-7I07
9'5:VX;MGM'#*SIBYJ@;TU2 ME_J6;[J9@P'JUCI8XO?5X!>BNK^GS!'>NL{U?U'3_$7GX" 6 ,6GY2\^?/%- M)W'/PS59S1[&FL&X{0;C0P;#KN>A:@MCS6#M@('36W-5%X;$U;P&=AJ#*OY1S=-M<2F#\-PJ5;GMTOY>1/DRW?
9,Y(W9Q"+;.*E:BZW5<;JAN-=^.7L36-6.^I.J M F/<[4^DY*HKO=WNK:U+RO9^;PE?!G+%A7OARW-:;GD>;:=FIT(MDYW)&=, M"!:E7U>4^)2K#O+Z@c&Q.U$)BDWMT7]02P,$% @ C3A$6OHQ[Z.) P MP L !D
!X;'!W;W)K&ULQ59A=CYLX%/TK%EOM M3J5M $-(F$VOYJLE79VILG.5*05/CAP$]" G=HF::7^^-J&$+H)-E 4V+\$& MWW0.;:9/[F3+'+-(2324.143^U4RO6Y;8LXA8*(5L#55^6C!=$JBE?V6+-
M@20FJ,AM[#B'79", 6M'$0'@@T825,L\H/' DRJ(@ ,,EY&P[M5QK]V*6K5*I M7]C19$UG, ?YN'[@:F8W69*L "HR1A&'Y=2Z<,\0W4 'F!5/&6Q%;XQT*00$ MG07D33*U',T(97!MBE?%+(B *Y:. MRQ*93JVQA1)8DC*7,
[;!A;@N-4 D>8G90Z(+=']6ZNGdC:0' M\Y1P0(\TDR_1V35(DN7B)7IE50!ZB63QLUDBT-EL_JB^ W,'00+XOQ-,*0Z: MA1W77\\KKKB#JXO1'.;R%>B&)I!\F+R^E.=B36*86NK6"> ; ML**??
W(#Y[<>=G[#SN_+'MV74DA"DXRN$}%H :N,4CU1?#\"X>C3424JXE5J MWZ36EW\3A5[@^.'$WARA-&PH#7L%NTH)7:D=2$JNB<@4#)/S8PR&/T"ZH.$9 M]$JWNPY]"@4''HW

PE&3

-\=X [XO46[O<[ZA0^<8% E% *=FMIJH OC*MHT Q*ZFL^JOF;=.>7E1-V7YYU=O>$;XNF4 Y+%6H M,Q@I57C5+E83R=:F15LPJ1H^,TQ5BPU<+U#?EXS)W40#-$U[!E02P,$% M @ C3A$6K%;)[T>! ?Q4 !D
!X;"]W;W)K&ULQ5AA;^(X$/TK5FYUUTK7)DY"%#U @H:)5MIJ>[")]TVEU'PP9{&H2L[:! M]M^?[:2!0!K1E:5^ =N9>?8\^R7CZ6XI>^)+ (&>TR3C/6LIQ.K:MOEL"2GA MEW0%F7PIRPE0G;9PN8K!B323FEBNXX3V"F),ZO?
U6,/K-^E:Y'$&3PPQ-=I M2MC<$!*Z[5G8>AT8QXNE4 -V0fLB"9B >%P], <B*%3#2Q.V7 +14OQ',6)NDGV.9]'0O,.XE@43Y85A %<78D MS_F W_Z,@_E]->P,@/C(YP-P*C2+5U2009#3C;
JYZRVCJ2WIOTM%2 M3I"K;9P*+J\&)OO@KN%N:N M(O]!8C^(ET >P-4SY?,@(3-U<:WF(OD$/EY208{P^32PA;O*Q:;G>047607H M2 40@5L6BU4"KF*2^\)#V%), H0GM-%T@0\1+.F\!#'\&R&%M\ '8(%D13I/\ M8,B
BIN&TPX$2(8/N 4)\/661C/*0U5I-HY7WNPG-5*G0TN:+Z'\B5JC'W^ MG0.KH;IV45TI{C>X+FU,E\(X+N;A!,&&1=`0"4L^.,2?0DDH7"C![>5^]^0E M;1YQ"??!U\\K)+@1-$HJU;7/H.VMI+G&>Y^O/PK6/)C+2?WW
-,5M6;1NFDT M]5![&JG}&J/I4X3<\JO\)NA<*\HW#-&^7VC5@MQ"\ RVQQ8BY:L102@LGDV M?JG&2Y2'%69IVR6%;>0YW4+BJVH[1;4=8[5?T@=@7!GDB7+Y0)?/;$4%5>I< MVI7+Y^^&A"
,%C255)*2RZLJU9RS"Z+L20!=X),7DU.[A8QNG5,[KM&IQO%0 M7,N]HKI>PT[MG4$==#1 M6VU8B'3!J -+UB0M/-NNLRS4={4U>'5;$!I-:P[PUG6M 0N;}BP\!V*A9BP\ M+63A(675',X,]SV8A9JSL"'0PD/2>JI;\8X85Z,6-
L';FJ0PTXMW_L6U M7, MA378[.0I,&;3@0>/)Q76MF=/2/69#2;%VGJHH:M BNPZIVX:.XU2;%VGJHB:H6Y.T-V]C9]Y>G7F1AB^]a6^QUT3?_8C8'>.0:UO!% M3<.76D.^2.,7G1;^Z']"^:@IW_?l>"'(-7I07
9'5:VX;MGM'#*SIBYJ@;TU2 ME_J6;[J9@P'JUCI8XO?5X!>BNK^GS!'>NL{U?U'3_$7GX" 6 ,6GY2\^?/%- M)W'/PS59S1[&FL&X{0;C0P;#KN>A:@MCS6#M@('36W-5%X;$U;P&=AJ#*OY1S=-M<2F#\-PJ5;GMTOY>1/DRW?
9,Y(W9Q"+;.*E:BZW5<;JAN-=^.7L36-6.^I.J M F/<[4^DY*HKO=WNK:U+RO9^;PE?!G+%A7OARW-:;GD>;:=FIT(MDYW)&=, M"!:E7U>4^)2K#O+Z@c&Q.U$)BDWMT7]02P,$% @ C3A$6OHQ[Z.) P MP L !D
!X;"]W;W)K&ULM59=CYLX%/TK%EOM M3J5M $-(F$VOYJLE79VILG.5*05/CAP$]" G=HF::7^^-J&$+H)-E 4V+\$& MWW0.;:9/[F3+'+-(2324.143^U4RO6Y;8LXA8*(5L#55^6C!=$JBE?V6+-
M@20FJ,AM[#B'79", 6M'$0'@@T825,L\H/' DRJ(@ ,,EY&P[M5QK]V*6K5*I M7]C19$UG, ?YN'[@:F8W69*L "HR1A&'Y=2Z<,\0W4 'F!5/&6Q%;XQT*00$ MG07D33*U',T(97!MBE?%+(B *Y:. MRQ*93JVQA1)8DC*7,
[;!A;@N-4 D>8G90Z(+=']6ZNGdC:0' M\Y1P0(\TDR_1V35(DN7B)7IE50!ZB63QLUDBT-EL_JB^ W,'00+XOQ-,*0Z: MA1W77\\KKKB#JXO1'.;R%>B&)I!\F+R^E.=B36*86NK6"> ; ML**??
W(#Y[<>=G[#SN_+'MV74DA"DXRN$}%H :N,4CU1?#\"X>C3424JXE5J MWZ36EW\3A5[@^.'$WARA-&PH#7L%NTH)7:D=2$JNB<@4#)/S8PR&/T"ZH.$9 M]$JWNPY]"@4''HW

PE&3

-\=X [XO46[O<[ZA0^<8% E% *=FMIJH OC*MHT Q*ZFL^JOF;=.>7E1-V7YYU=O>$;XNF4 Y+%6H M,Q@I57C5+E83R=:F15LPJ1H^,TQ5BPU<+U#?EXS)W40#-$U[!E02P,$% M @ C3A$6K%;)[T>! ?Q4 !D
!X;"]W;W)K&ULQ5AA;^(X$/TK5FYUUTK7)DY"%#U @H:)5MIJ>[")]TVEU'PP9{&H2L[:! M]M^?[:2!0!K1E:5^ =N9>?8\^R7CZ6XI>^)+ (&>TR3C/6LIQ.K:MOEL"2GA MEW0%F7PIRPE0G;9PN8K!B323FEBNXX3V"F),ZO?
U6,/K-^E:Y'$&3PPQ-=I M2MC<$!*Z[5G8>AT8QXNE4 -V0fLB"9B >%P], <B*%3#2Q.V7 +14OQ',6)NDGV.9]'0O,.XE@43Y85A %<78D MS_F W_Z,@_E]->P,@/C(YP-P*C2+5U2009#3C;
JYZRVCJ2WIOTM%2 M3I"K;9P*+J\&)OO@KN%N:N M(O]!8C^(ET >P-4SY?,@(3-U<:WF(OD$/EY208{P^32PA;O*Q:;G>047607H M2 40@5L6BU4"KF*2^\)#V%), H0GM-%T@0\1+.F\!#'\&R&%M\ '8(%D13I/\ M8,B
BIN&TPX$2(8/N 4)\/661C/*0U5I-HY7WNPG-5*G0TN:+Z'\B5JC'W^ MG0.KH;IV45TI{C>X+FU,E\(X+N;A!,&&1=`0"4L^.,2?0DDH7"C![>5^]^0E M;1YQ"??!U\\K)+@1-$HJU;7/H.VMI+G&>Y^O/PK6/)C+2?WW
-,5M6;1NFDT M]5![&JG}&J/I4X3<\JO\)NA<*\HW#-&^7VC5@MQ"\ RVQQ8BY:L102@LGDV M?JG&2Y2'%69IVR6%;>0YW4+BJVH[1;4=8[5?T@=@7!GDB7+Y0)?/;$4%5>I< MVI7+Y^^&A"
,%C255)*2RZLJU9RS"Z+L20!=X),7DU.[A8QNG5,[KM&IQO%0 M7,N]HKI>PT[MG4$==#1 M6VU8B'3!J -+UB0M/-NNLRS4={4U>'5;$!I-:P[PUG6M 0N;}BP\!V*A9BP\ M+63A(675',X,]SV8A9JSL"'0PD/2>JI;\8X85Z,6-
L';FJ0PTXMW_L6U M7, MA378[.0I,&;3@0>/)Q76MF=/2/69#2;%VGJHH:M BNPZIVX:.XU2;%VGJHB:H6Y.T-V]C9]Y>G7F1AB^]a6^QUT3?_8C8'>.0:UO!% M3<.76D.^2.,7G1;^Z']"^:@IW_?l>"'(-7I07
9'5:VX;MGM'#*SIBYJ@;TU2 ME_J6;[J9@P'JUCI8XO?5X!>BNK^GS!'>NL{U?U'3_$7GX" 6 ,6GY2\^?/%- M)W'/PS59S1[&FL&X{0;C0P;#KN>A:@MCS6#M@('36W-5%X;$U;P&=AJ#*OY1S=-M<2F#\-PJ5;GMTOY>1/DRW?
9,Y(W9Q"+;.*E:BZW5<;JAN-=^.7L36-6.^I.J M F/<[4^DY*HKO=WNK:U+RO9^;PE?!G+%A7OARW-:;GD>;:=FIT(MDYW)&=, M"!:E7U>4^)2K#O+Z@c&Q.U$)BDWMT7]02P,$% @ C3A$6OHQ[Z.) P MP L !D
!X;"]W;W)K&ULM59=CYLX%/TK%EOM M3J5M $-(F$VOYJLE79VILG.5*05/CAP$]" G=HF::7^^-J&$+H)-E 4V+\$& MWW0.;:9/[F3+'+-(2324.143^U4RO6Y;8LXA8*(5L#55^6C!=$JBE?V6+-
M@20FJ,AM[#B'79", 6M'$0'@@T825,L\H/' DRJ(@ ,,EY&P[M5QK]V*6K5*I M7]C19$UG, ?YN'[@:F8W69*L "HR1A&'Y=2Z<,\0W4 'F!5/&6Q%;XQT*00$ MG07D33*U',T(97!MBE?%+(B *Y:. MRQ*93JVQA1)8DC*7,
[;!A;@N-4 D>8G90Z(+=']6ZNGdC:0' M\Y1P0(\TDR_1V35(DN7B)7IE50!ZB63QLUDBT-EL_JB^ W,'00+XOQ-,*0Z: MA1W77\\KKKB#JXO1'.;R%>B&)I!\F+R^E.=B36*86NK6"> ; ML**??
W(#Y[<>=G[#SN_+'MV74DA"DXRN$}%H :N,4CU1?#\"X>C3424JXE5J MWZ36EW\3A5[@^.'$WARA-&PH#7L%NTH)7:D=2$JNB<@4#)/S8PR&/T"ZH.$9 M]$JWNPY]"@4''HW

PE&3

-\=X [XO46[O<[ZA0^<8% E% *=FMIJH OC*MHT Q*ZFL^JOF;=.>7E1-V7YYU=O>$;XNF4 Y+%6H M,Q@I57C5+E83R=:F15LPJ1H^,TQ5BPU<+U#?EXS)W40#-$U[!E02P,$% M @ C3A$6K%;)[T>! ?Q4 !D
!X;"]W;W)K&ULQ5AA;^(X$/TK5FYUUTK7)DY"%#U @H:)5MIJ>[")]TVEU'PP9{&H2L[:! M]M^?[:2!0!K1E:5^ =N9>?8\^R7CZ6XI>^)+ (&>TR3C/6LIQ.K:MOEL"2GA MEW0%F7PIRPE0G;9PN8K!B323FEBNXX3V"F),ZO?
U6,/K-^E:Y'$&3PPQ-=I M2MC<$!*Z[5G8>AT8QXNE4 -V0fLB"9B >%P], <B*%3#2Q.V7 +14OQ',6)NDGV.9]'0O,.XE@43Y85A %<78D MS_F W_Z,@_E]->P,@/C(YP-P*C2+5U2009#3C;
JYZRVCJ2WIOTM%2 M3I"K;9P*+J\&)OO@KN%N:N M(O]!8C^(ET >P-4SY?,@(3-U<:WF(OD$/EY208{P^32PA;O*Q:;G>047607H M2 40@5L6BU4"KF*2^\)#V%), H0GM-%T@0\1+.F\!#'\&R&%M\ '8(%D13I/\ M8,B
BIN&TPX$2(8/N 4)\/661C/*0U5I-HY7WNPG-5*G0TN:+Z'\B5JC'W^ MG0.KH;IV45TI{C>X+FU,E\(X+N;A!,&&1=`0"4L^.,2?0DDH7"C!{

M.O>$C]P)X6PQ&7C%)&%\;VEY73!DC\8N&MZL/-*GH2)5!:Q M303S=UH.WP*J'@ADG-<"> ZXQC(<948I*<:4[Q>#"^ ARRQ;M.M,*YY*LN[T+ MMW$H;CK(-)41E768KEN9QD-.8Y CV7P!=Y5F'H!*I8EN1(S,4T$*#95'V="T M,\KY#?Q;^A)O<* BUKH6523IIA94-@V-Z0! F\UPMVF#9_$Z&;M/U?NEGHXH M^E K]%Z2F*V* BJN!6#L79R=9!E?Q^-L:A]J)K]WP/6O5'[.(I7L04>#4IEI M Y6NPB\ISV:&:#]?I/\"-):GW4,7 MV7T){GL'*= (KSY2M@^O&L;6V.O!Z,'(_P\L(;X(ZTR7CBHFRMV!11,6CTZNF M5V2J7]4W^/7XB,9DR=5M#8[SL=@ MF+:!%1F@/@/4QWC9D$GQP>+8?4)]V6<:AKX?!%A&}Q.K@@F6MR" KYT-TP8> M6:R(]'NYQE<;KY#==8"MZ:X*P6:*5R{V4S57@-CS!AYA:%]M+ YX8*N U0[$ MM\>!FK+[^#ZL*J8-V\$X$H88 K5HK]$@0+(3P,>^/MqN\?TPM". V17X/H; M;L013 %HP!#?+YZ#6\\CKWI.>-8? 20$3;8T.P6BP^0"X99K>]9!:GA M.= IBQ^ %^6W^Z\XQGZLLKRZ[#W6]?JBWZ 21[D2U5 %6N:ZR+(H5Z+6F^5# MOUJ74BRJ1RGK5=8W!@.GOQ{JIWNZN+M66/;A1E'+M%9%KG6ZEBR^3XI2 2KR6F1O6A99=MD; M;@_] 77*JRJMLSVNL+S?@D]WT<0A][D-XD7Y?\)8+),BW:QD7F C M6,JL BP7*WG9VYW"1+Y@/*]UD)B?;R^ESVWN5'^U0}C>=:UQ00S+ M"Z4/E/ZB!:>#', V#>#[UQU["Q^S*FWK!B+ XPGD2 T # 31.!LC.0@&@3032 M/"'DOP: M!!(ZXB0<:(9CS0@/-KY@>C.8"T$4C[9)"C^2P$D X"Z9P.(Y#G)X3LO#@?$,@/M) W/.'1-X4)>X!E[$M3NS?!/ZU M/ *"A'FCT?PV2/S@AH4ZCB.?P[0]1,5";);9%WWFB7.CY$\; A#R(GX,W3R8\ M8CJ>$<3$M#{D]HH? W.EW=A[MM3U,{D-BBX31/.11\K6-&/ [U@':M/(G"W@" M$3&%#{D=LGV.3>SBI,UY$ 5301#0&U/N0=TGB?EA2"R{E^:N8\2FOG?E3]M, M @$Q-PRJY:"KDIF ?8)M:]-&:](O# 9RL8$IPZ!6OL2+'&O^';,H J-](9*O MD WSA$'LB:;VG'&6>%^Z\4+[',12B.5#3 3&,0FT*U+/['W _AC5L9^ M/)K,X]L{>LK !& 0"R#BT[9^'[UH[\TT, D80!*(;Z]BW=2;0, 'O]C*L@:5^ M@5CU^WFE%K)D22D6*G]@89&IS,FJ'2@(2XB)B<"@fD#\O)=E)=-- V80<1*KZ MQF8B%P]R.Z@!,3%#&,2&0,0A3A?"P#QA$'L"QS3A. 9F"I/8%&C5WHFFB4G# M))&@:J=G25"0U3O('',F$9-8(FCY%@TE.G1%[!900A\,(686D]@L2!W?L$), MS#0FL6FV)?/!Z&&>,8_2Q3A0.V1} (2;F&9/8,X>*TX.OQ"QC$EL&5JD'X3"W MF-1N>2Y7#X%9F$TL8ILK-=9.Q(S>V$VIB';6$$H M9J> ;6,*LH\RO]+%G(FZ&65KQ@ A)J8@^U03+UMRB{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{$ MY?F#%()T B"#()L R"'(YP*"(KY@U80M)H Z!$''N&?7.'KGRF4#0C'IG KTS MZIT)],ZH=R;06U%0)=!;}46\ET%M1;R706U%0)=!;)R^[" ?16U%L]]%;46PGT M5M1;"? 16U%L]]%;46PGT-M3;"/0VU-L{J#;4VPCT-M3;"/0VU-L{]+;)QTH" MO0WU-@*]#?4V KT-]38"O0WU-@*]'?5V KT=]78"O1WU=@*]'?5V KT=]78" MO1WU=@*]??
*S"8'>CGH{@=Z.>CN!WHYZ.X'>@7H'@=Z!>@>!WH%Z!X'>@7H' M@=Z!>@=!WH%Z!X'>@7H'@=XQ^5F00.] 08- [T"]@T#O%>J]^DZ]A `S6(9; MS]<:K ^=5{^7<\OM\M?EUTZ\7ZRN.-?W%!7J;)% MC>M &%$V,-L9%O,"))KFE49/8L@U3WGZ<%) 8,16H2',VC5K;]]SX2M^JE[^> M J7%?NC'M*ZV.8=OC*5F2X-+M0\TEI6-CX/+Y6N\9\$U.W=/3*Q6AC5^S#3F M99YJ5%>7-[10#WU>?-^7GU/G0W45J4_5XOJP< MXIT> 6;3-
=3ZYF$H1^H4(KDV:8GRT->'HF?'DW.Y83I\\I/SYS+' L0.V^A# M*A.+]/FXEY%,IY>A%**8N^.0^)I82I \?C1-NZ7V@\GE>G_(N)OGD=C\./V. MW\[XM?XG^Q @?4B0/A1('QJD#P/2AP7IXQRDCPN0/O@*I1$443D*J1S%5(Z" M*D=1E:.PRE%&UL4$L! A0#% @ C3A$6J}R/,+O *P(!$ (! MKP &1O8U!R;W!S+V-O&UL4$L! A0#% @ C3A$6IE&PO M=V]R:W-H965T&UL4$L! A0#% @ C3A$6I@UR:C[!P M/2$!@ (":"P\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6M"6;B S!@ 2!@ !@ M ("'-AT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ C3A$6C&&(,26'0 ^"L !@ ("';2X 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ C3A$6GB:(/EB!0 * T !D ("! M>&@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ C3A$6EL!&80S @ 1P4 !D ("'*G0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6@),IQ& M!@ ; \ !D ("'6'X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6K#L@V\;#0 2< !D M ("'VX\ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ C3A$6C.N(T1P!0 V0L !D ("![K4 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MC3A$6@*P7)X1 @ W00 !D ("!J,0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6C?I4D4R! M& H !D ("!G 8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6H;2&"GB @ $08 !D M ("!SP(! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ C3A$6H:F(!70 P BPH !D ("!0PL! 'AL M+W=O&PO=V]R:W-H965T;04 +\. 9 "M@3L3 0!X;"]W;W)K&UL4$L! A0#% @ C3A$ M6A ZX/M-!P +A, !D ("!WQ@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6FJ;ZU&9!0 J3 M !D ("!]RD! 'AL+W=O#P &0 @('''+P$ M>&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6E8.HH,9 P !@D !D M ("!BS8! 'AL+W=O&PO=V]R:W-H965T M 9 M " @8L] 0!X;"]W;W)K&UL4$L! A0# M% @ C3A$6A5$ P'7 @ ,@< !D ("! T,! 'AL+W=O M3TB'GT# !S M#0 &0 @{$11@$ >&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6@#" M)8%] @ 308 !D ("!!DT! 'AL+W=O@;4VT$ _& &0 M @(&Z3P$ >&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6A, $G(C! DQ@ !D M ("!BE@! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ C3A$6BOV 1T3 P " D !D ("! M:F(! 'AL+W=O&PO=V]R:W-H965T-H 0!X;"]W;W)K&UL4$L! A0#% M @ C3A$6JX4!JR" @ :P4 !D ("!I&P! 'AL+W=O&PO=V]R:W-H965T]'@0 '\5 9 " @>F& 0!X;"]W;W)K&UL4$L! A0#% @ C3A$6@3P9GM:!P 840 !D M ("!/HL! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ C3A$6G,$$AL4!0 0Q$!D ("!I)D!_M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MC3A$6I,,LQ7<@ ,P< !D ("!EZ8! 'AL+W=O&UL4$L! A0#% @ C3A$6ALCG=VL! M.18 !D ("!AK$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C3A$6ES *=[P =PL !D M ("!8+X! 'AL+W=OH# ")$ &0 @(&GP@$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ C3A$6GG%@ -R P S!8 T (!B\P! 'AL M+W-T>6QE$PO=V]R:V]O:VLN>$UL4$L! A0# M% @ C3A$6K3%'JYH @ 1R\ !H (!-] XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html2033661true680false6 falsefalseR1.htm0001 - Document - Document and Entity InformationSheethttp://inmodemd.com/role/DocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm0002 - Statement - CONSOLIDATED BALANCE SHEETSSheethttp://inmodemd.com/role/ConsolidatedBalanceSheetsCONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://inmodemd.com/role/ConsolidatedBalanceSheetsParentheticalCONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm0004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical 2)Sheethttp://inmodemd.com/role/CONSOLIDATEDBALANCESHEETSParentheticals2CONSOLIDATED BALANCE SHEETS (Parenthetical 2)Statements4 falsefalseR5.htm0005 - Statement - CONSOLIDATED STATEMENTS OF INCOMESheethttp://inmodemd.com/role/ConsolidatedStatementsOfIncomeCONSOLIDATED STATEMENTS OF INCOMEStatements5 falsefalseR6.htm0006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMESheethttp://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncomeCONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEStatements6 falsefalseR7.htm0007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITYSheethttp://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityCONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITYStatements7 falsefalseR8.htm0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://inmodemd.com/role/ConsolidatedStatementsOfCashFlowsCONSOLIDATED STATEMENTS OF CASH FLOWSStatements8 falsefalseR9.htm0009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Sheethttp://inmodemd.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticalsCONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)Statements9 falsefalseR10.htm0010 - Disclosure - GENERALSheethttp://inmodemd.com/role/GeneralGENERALNotes10 falsefalseR11.htm0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIESSheethttp://inmodemd.com/role/SignificantAccountingPoliciesSIGNIFICANT ACCOUNTING POLICIESNotes11 falsefalseR12.htm0012 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTSSheethttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTSNotes12 falsefalseR13.htm0013 - Disclosure - ACCOUNTS RECEIVABLESheethttp://inmodemd.com/role/AccountsReceivableACCOUNTS RECEIVABLENotes13 falsefalseR14.htm0014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLESSheethttp://inmodemd.com/role/OtherCurrentReceivablesPREPAID EXPENSES AND OTHER CURRENT RECEIVABLESNotes14 falsefalseR15.htm0015 - Disclosure - INVENTORIESSheethttp://inmodemd.com/role/InventoriesINVENTORIESNotes15 falsefalseR16.htm0016 - Disclosure - PROPERTY AND EQUIPMENT, NETSheethttp://inmodemd.com/role/PropertyAndEquipmentNetPROPERTY AND EQUIPMENT, NETNotes16 falsefalseR17.htm0017 - Disclosure - OTHER INVESTMENTSSheethttp://inmodemd.com/role/OtherInvestmentsOTHER INVESTMENTSNotes17 falsefalseR18.htm0018 - Disclosure - LEASESSheethttp://inmodemd.com/role/LeasesLEASESNotes18 falsefalseR19.htm0019 - Disclosure - OTHER CURRENT LIABILITIESSheethttp://inmodemd.com/role/OtherCurrentLiabilitiesOTHER CURRENT LIABILITIESNotes19 falsefalseR20.htm0020 - Disclosure - COMMITMENTS AND CONTINGENCIESSheethttp://inmodemd.com/role/CommitmentsAndContingentLiabilitiesCOMMITMENTS AND CONTINGENCIESNotes20 falsefalseR21.htm0021 - Disclosure - SHAREHOLDERS' EQUITYSheethttp://inmodemd.com/role/ShareholdersEquitySHAREHOLDERS' EQUITYNotes21 falsefalseR22.htm0022 - Disclosure - INCOME TAXESSheethttp://inmodemd.com/role/TaxesOnIncomeINCOME TAXESNotes22 falsefalseR23.htm0023 - Disclosure - SegmentsSheethttp://inmodemd.com/role/SegmentsSegmentsNotes23 falsefalseR24.htm0024 - Disclosure - ENTITY-WIDE DISCLOSURESheethttp://inmodemd.com/role/Entity-wideDisclosureENTITY-WIDE DISCLOSURENotes24 falsefalseR25.htm0025 - Disclosure - RELATED PARTIESSheethttp://inmodemd.com/role/RelatedPartiesRELATED PARTIESNotes25 falsefalseR26.htm0026 - Disclosure - SUBSEQUENT EVENTSSheethttp://inmodemd.com/role/SUBSEQUENTEVENTSSUBSEQUENT EVENTSNotes26 falsefalseR27.htm995447 - Disclosure - Insider Trading Policies and ProceduresSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProcInsider Trading Policies and ProceduresNotes27 falsefalseR28.htm995550 - Disclosure - Cybersecurity Risk Management and Strategy DisclosureSheethttp://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosureCybersecurity Risk Management and Strategy DisclosureNotes28 falsefalseR29.htm9960701 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)Sheethttp://inmodemd.com/role/SignificantAccountingPoliciesPoliciesSIGNIFICANT ACCOUNTING POLICIES (Policies)Policies29 falsefalseR30.htm9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)Sheethttp://inmodemd.com/role/SignificantAccountingPoliciesTablesSIGNIFICANT ACCOUNTING POLICIES (Tables)Tables30 falsefalseR31.htm9960703 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)Sheethttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTablesMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)Tables31 falsefalseR32.htm9960704 - Disclosure - ACCOUNTS RECEIVABLE (Tables)Sheethttp://inmodemd.com/role/AccountsReceivableTablesACCOUNTS RECEIVABLE (Tables)Tableshttp://inmodemd.com/role/AccountsReceivable32 falsefalseR33.htm9960705 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Tables)Sheethttp://inmodemd.com/role/OtherCurrentReceivablesTablesPREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Tables)Tables33 falsefalseR34.htm9960706 - Disclosure - INVENTORIES (Tables)Sheethttp://inmodemd.com/role/InventoriesTablesINVENTORIES (Tables)Tableshttp://inmodemd.com/role/Inventories34 falsefalseR35.htm9960707 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)Sheethttp://inmodemd.com/role/PropertyAndEquipmentNetTablesPROPERTY AND EQUIPMENT, NET (Tables)Tableshttp://inmodemd.com/role/PropertyAndEquipmentNet35 falsefalseR36.htm9960708 - Disclosure - LEASES (Tables)Sheethttp://inmodemd.com/role/LeasesTablesLEASES (Tables)Tableshttp://inmodemd.com/role/Leases36 falsefalseR37.htm9960709 - Disclosure - OTHER CURRENT LIABILITIES (Tables)Sheethttp://inmodemd.com/role/OtherCurrentLiabilitiesTablesOTHER CURRENT LIABILITIES (Tables)Tableshttp://inmodemd.com/role/OtherCurrentLiabilities37 falsefalseR38.htm9960710 - Disclosure - SHAREHOLDERS' EQUITY (Tables)Sheethttp://inmodemd.com/role/ShareholdersEquityTablesSHAREHOLDERS' EQUITY (Tables)Tableshttp://inmodemd.com/role/ShareholdersEquity38 falsefalseR39.htm9960711 - Disclosure - INCOME TAXES (Tables)Sheethttp://inmodemd.com/role/TaxesOnIncomeTablesINCOME TAXES (Tables)Tableshttp://inmodemd.com/role/TaxesOnIncome39 falsefalseR40.htm9960712 - Disclosure - Segments (Tables)Sheethttp://inmodemd.com/role/SegmentsTablesSegments (Tables)Tableshttp://inmodemd.com/role/Segments40 falsefalseR41.htm9960713 - Disclosure - ENTITY-WIDE DISCLOSURE (Tables)Sheethttp://inmodemd.com/role/Entity-wideDisclosureTablesENTITY-WIDE DISCLOSURE (Tables)Tableshttp://inmodemd.com/role/Entity-wideDisclosure41 falsefalseR42.htm9960714 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)Sheethttp://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetailsSIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)Detailshttp://inmodemd.com/role/SignificantAccountingPoliciesTables42 falsefalseR43.htm9960715 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Estimated Useful Lives) (Details)Sheethttp://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetailsSIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Estimated Useful Lives) (Details)Detailshttp://inmodemd.com/role/SignificantAccountingPoliciesTables43 falsefalseR44.htm9960716 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details)Sheethttp://inmodemd.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfAllowanceForCreditLossesDetailsSIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details)Detailshttp://inmodemd.com/role/SignificantAccountingPoliciesTables44 falsefalseR45.htm9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Accrued Warranty) (Details)Sheethttp://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfAccruedWarrantyDetailsSIGNIFICANT ACCOUNTING POLICIES (Schedule of Accrued Warranty) (Details)Detailshttp://inmodemd.com/role/SignificantAccountingPoliciesTables45 falsefalseR46.htm9960718 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities) (Details)Sheethttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetailsMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities) (Details)Detailshttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables46 falsefalseR47.htm9960719 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets Measured at Fair Value) (Details)Sheethttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetailsMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets Measured at Fair Value) (Details)Detailshttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables47 falsefalseR48.htm9960720 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on Maturity) (Details)Sheethttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetailsMARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on Maturity) (Details)Detailshttp://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables48 falsefalseR49.htm9960721 - Disclosure - ACCOUNTS RECEIVABLE (Schedule of Accounts Receivable) (Details)Sheethttp://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetailsACCOUNTS RECEIVABLE (Schedule of Accounts Receivable) (Details)Detailshttp://inmodemd.com/role/AccountsReceivableTables49 falsefalseR50.htm9960722 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Schedule of Prepaid expenses and other current receivables) (Details)Sheethttp://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetailsPREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Schedule of Prepaid expenses and other current receivables) (Details)Detailshttp://inmodemd.com/role/OtherCurrentReceivablesTables50 falsefalseR51.htm9960723 - Disclosure - INVENTORIES (Schedule of Inventories) (Details)Sheethttp://inmodemd.com/role/InventoriesScheduleOfInventoriesDetailsINVENTORIES (Schedule of Inventories) (Details)Detailshttp://inmodemd.com/role/InventoriesTables51 falsefalseR52.htm9960724 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment)

{Details}Sheethttp://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsPROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment) {Details}Detailshttp://inmodemd.com/role/PropertyAndEquipmentNetTables52 falsefalseR53.htm9960725 - Disclosure - OTHER INVESTMENTS (Narrative) {Details}Sheethttp://inmodemd.com/role/OtherInvestmentsDetailsOTHER INVESTMENTS (Narrative) {Details}Detailshttp://inmodemd.com/role/OtherInvestments53 falsefalseR54.htm9960726 - Disclosure - LEASES (Narrative) {Details}Sheethttp://inmodemd.com/role/LeasesNarrativeDetailsLEASES (Narrative) {Details}Detailshttp://inmodemd.com/role/LeasesTables54 falsefalseR55.htm9960727 - Disclosure - LEASES (Schedule of Lease Expense) {Details}Sheethttp://inmodemd.com/role/LeasesScheduleOfLeaseExpenseDetailsLEASES (Schedule of Lease Expense) {Details}Detailshttp://inmodemd.com/role/LeasesTables55 falsefalseR56.htm9960728 - Disclosure - LEASES (Schedule of Supplemental Cash Flow Information Related to Leases) {Details}Sheethttp://inmodemd.com/role/LeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetailsLEASES (Schedule of Supplemental Cash Flow Information Related to Leases) {Details}Detailshttp://inmodemd.com/role/LeasesTables56 falsefalseR57.htm9960729 - Disclosure - LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) {Details}Sheethttp://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetailsLEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) {Details}Detailshttp://inmodemd.com/role/LeasesTables57 falsefalseR58.htm9960730 - Disclosure - LEASES (Schedule of Maturities of Lease Liabilities) {Details}Sheethttp://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailsLEASES (Schedule of Maturities of Lease Liabilities) {Details}Detailshttp://inmodemd.com/role/LeasesTables58 falsefalseR59.htm9960731 - Disclosure - OTHER CURRENT LIABILITIES (Schedule Of Other Liabilities) {Details}Sheethttp://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetailsOTHER CURRENT LIABILITIES (Schedule Of Other Liabilities) {Details}Detailshttp://inmodemd.com/role/OtherCurrentLiabilitiesTables59 falsefalseR60.htm9960732 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) {Details}Sheethttp://inmodemd.com/role/CommitmentsAndContingentLiabilitiesDetailsCOMMITMENTS AND CONTINGENCIES (Narrative) {Details}Detailshttp://inmodemd.com/role/CommitmentsAndContingentLiabilities60 falsefalseR61.htm9960733 - Disclosure - SHAREHOLDERS' EQUITY (Narrative) {Details}Sheethttp://inmodemd.com/role/ShareholdersEquityNarrativeDetailsSHAREHOLDERS' EQUITY (Narrative) {Details}Detailshttp://inmodemd.com/role/ShareholdersEquityTables61 falsefalseR62.htm9960734 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Options Granted) {Details}Sheethttp://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetailsSHAREHOLDERS' EQUITY (Schedule Of Options Granted) {Details}Detailshttp://inmodemd.com/role/ShareholdersEquityTables62 falsefalseR63.htm9960735 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Outstanding and Exercisable Options) {Details}Sheethttp://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetailsSHAREHOLDERS' EQUITY (Schedule Of Outstanding and Exercisable Options) {Details}Detailshttp://inmodemd.com/role/ShareholdersEquityTables63 falsefalseR64.htm9960736 - Disclosure - SHAREHOLDERS' EQUITY (Schedule of Options Granted Restricted Share Unit) {Details}Sheethttp://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestrictedShareUnitDetailsSHAREHOLDERS' EQUITY (Schedule of Options Granted Restricted Share Unit) {Details}Detailshttp://inmodemd.com/role/ShareholdersEquityTables64 falsefalseR65.htm9960737 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) {Details}Sheethttp://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetailsSHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) {Details}Detailshttp://inmodemd.com/role/ShareholdersEquityTables65 falsefalseR66.htm9960738 - Disclosure - INCOME TAXES (Narrative) {Details}Sheethttp://inmodemd.com/role/TaxesOnIncomeNarrativeDetailsINCOME TAXES (Narrative) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables66 falsefalseR67.htm9960739 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets (liabilities) {Details}Sheethttp://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetailsINCOME TAXES (Schedule of Deferred Tax Assets (liabilities) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables67 falsefalseR68.htm9960740 - Disclosure - INCOME TAXES - (Schedule of valuation allowance) {Details}Sheethttp://inmodemd.com/role/INCOMETAXESScheduleOfValuationAllowanceDetailINCOME TAXES - (Schedule of valuation allowance) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables68 falsefalseR69.htm9960741 - Disclosure - INCOME TAXES (Schedule of Reconciliation of Theoretical Provision For Income Tax) (Details)Sheethttp://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetailsINCOME TAXES (Schedule of Reconciliation of Theoretical Provision For Income Tax) (Details)Detailshttp://inmodemd.com/role/TaxesOnIncomeTables69 falsefalseR70.htm9960742 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes) (Details)Sheethttp://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetailsINCOME TAXES (Schedule of Income Before Income Taxes) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables70 falsefalseR71.htm9960743 - Disclosure - INCOME TAXES (Schedule of Tax Expenses (Tax Benefit)) {Details}Sheethttp://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetailsINCOME TAXES (Schedule of Tax Expenses (Tax Benefit)) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables71 falsefalseR72.htm9960744 - Disclosure - INCOME TAXES (Schedule of Unrecognized Tax Benefits) {Details}Sheethttp://inmodemd.com/role/TaxesOnIncomeScheduleOfUnrecognizedTaxBenefitsDetailsINCOME TAXES (Schedule of Unrecognized Tax Benefits) {Details}Detailshttp://inmodemd.com/role/TaxesOnIncomeTables72 falsefalseR73.htm9960745 - Disclosure - Segments (Schedule of Revenue by Major Customers) {Details}Sheethttp://inmodemd.com/role/SegmentsDetailsSegments (Schedule of Revenue by Major Customers) {Details}Detailshttp://inmodemd.com/role/SegmentsTables73 falsefalseR74.htm9960746 - Disclosure - ENTITY-WIDE DISCLOSURE (Narrative) {Details}Sheethttp://inmodemd.com/role/Entity-wideDisclosureNarrativeDetailsENTITY-WIDE DISCLOSURE (Narrative) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables74 falsefalseR75.htm9960747 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) {Details}Sheethttp://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetailsENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables75 falsefalseR76.htm9960748 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of revenues based on products' category) {Details}Sheethttp://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategoryENTITY-WIDE DISCLOSURE (Schedule of revenues based on products' category) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables76 falsefalseR77.htm9960749 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) {Details}Sheethttp://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetailsENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables77 falsefalseR78.htm9960750 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Changes In Contract Liabilities) {Details}Sheethttp://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetailsENTITY-WIDE DISCLOSURE (Schedule Of Changes In Contract Liabilities) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables78 falsefalseR79.htm9960751 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) {Details}Sheethttp://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetailsENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) {Details}Detailshttp://inmodemd.com/role/Entity-wideDisclosureTables79 falsefalseR80.htm9960752 - Disclosure - RELATED PARTIES (Narrative) {Details}Sheethttp://inmodemd.com/role/RelatedPartiesDetailsRELATED PARTIES (Narrative) {Details}Detailshttp://inmodemd.com/role/RelatedParties80 falsefalseAll ReportsBookAll Reports inmd-20241231.xsdinmd-20241231_cal.xmlinmd-20241231_def.xmlinmd-20241231_lab.xmlinmd-20241231_pre.xmlzk2532597.htm image0.jpgimage00004.jpgimage1.jpgimage2.jpgimage3.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/cyd/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 107 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zk2532597.htm": { "nsprefix": "inmd", "nsuri": "http://inmodemd.com/20241231", "dts": { "schema": { "local": ["inmd-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/ebp/elts/us-gaap-ebp-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["inmd-20241231_cal.xml"] }, "definitionLink": { "local": ["inmd-20241231_def.xml"] }, "labelLink": { "local": ["inmd-20241231_lab.xml"] }, "presentationLink": { "local": ["inmd-20241231_pre.xml"] }, "inline": { "local": ["zk2532597.htm"] } }, "keyStandard": 308, "keyCustom": 58, "axisStandard": 25, "axisCustom": 0, "memberStandard": 34, "memberCustom": 33, "hidden": { "total": 11, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 203, "entityCount": 1, "segmentCount": 68, "elementCount": 752, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 790, "http://xbrl.sec.gov/dei/2024": 46, "http://xbrl.sec.gov/cyd/2024": 8, "http://xbrl.sec.gov/ecd/2024": 1 }, "report": { "R1": { "role": "http://inmodemd.com/role/DocumentAndEntityInformation", "longName": "0001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R2": { "role": "http://inmodemd.com/role/ConsolidatedBalanceSheets", "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R3": { "role": "http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R4": { "role": "http://inmodemd.com/role/CONSOLIDATEDBALANCESHEETSParentheticals2", "longName": "0004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical 2)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical 2)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "ILS_per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "div", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R6": { "role": "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome", "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R7": { "role": "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "0007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R8": { "role": "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows", "longName": "0008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R9": { "role": "http://inmodemd.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals", "longName": "0009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement",

```
"subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:PaymentsToTaxAuthorities",
"unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name":
"inmd:PaymentsToTaxAuthorities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "div", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R10": { "role": "http://inmodemd.com/role/General",
"longName": "0010 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10",
"firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-
US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-
US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } },
"R11": { "role": "http://inmodemd.com/role/SignificantAccountingPolicies", "longName": "0011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT
ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R12": { "role":
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurements", "longName": "0012 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS", "shortName":
"MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": {
"contextRef": "C_20240101to20241231", "name": "inmd:MarketableSecuritiesAndFairValueMeasurements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_20240101to20241231", "name": "inmd:MarketableSecuritiesAndFairValueMeasurements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R13": { "role":
"http://inmodemd.com/role/AccountsReceivable", "longName": "0013 - Disclosure - ACCOUNTS RECEIVABLE", "shortName": "ACCOUNTS RECEIVABLE", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R14": { "role": "http://inmodemd.com/role/OtherCurrentReceivables",
"longName": "0014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES", "shortName": "PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_20240101to20241231", "name":
"inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name":
"inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R15": { "role": "http://inmodemd.com/role/Inventories", "longName":
"0015 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15",
"firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R16": { "role":
"http://inmodemd.com/role/PropertyAndEquipmentNet", "longName": "0016 - Disclosure - PROPERTY AND EQUIPMENT, NET", "shortName": "PROPERTY AND EQUIPMENT, NET", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R17": { "role": "http://inmodemd.com/role/OtherInvestments", "longName":
"0017 - Disclosure - OTHER INVESTMENTS", "shortName": "OTHER INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
"17", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R18": { "role":
"http://inmodemd.com/role/Leases", "longName": "0018 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",
"menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R19": {
"role": "http://inmodemd.com/role/OtherCurrentLiabilities", "longName": "0019 - Disclosure - OTHER CURRENT LIABILITIES", "shortName": "OTHER CURRENT LIABILITIES", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R20": {
"role": "http://inmodemd.com/role/CommitmentsAndContingentLiabilities", "longName": "0020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND
CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_20240101to20241231",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R21": { "role": "http://inmodemd.com/role/ShareholdersEquity", "longName": "0021 -
Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
"21", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R22": { "role":
"http://inmodemd.com/role/TaxesOnIncome", "longName": "0022 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique":
true } }, "R23": { "role": "http://inmodemd.com/role/Segments", "longName": "0023 - Disclosure - Segments", "shortName": "Segments", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R24": { "role": "http://inmodemd.com/role/Entity-wideDisclosure", "longName": "0024
- Disclosure - ENTITY-WIDE DISCLOSURE", "shortName": "ENTITY-WIDE DISCLOSURE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": "24", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:EntityWideDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_20240101to20241231", "name": "inmd:EntityWideDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R25": { "role":
"http://inmodemd.com/role/RelatedParties", "longName": "0025 - Disclosure - RELATED PARTIES", "shortName": "RELATED PARTIES", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount":
1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R26": { "role":
"http://inmodemd.com/role/SUBSEQUENTEVENTS", "longName": "0026 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:SubsequentEventsTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider
Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "27", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } }, "R28": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 -
Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C_20240101to20241231", "name":
"cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } }, "R29": { "role": "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies", "longName": "9960701 - Disclosure -
SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-
gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true
} }, "R30": { "role": "http://inmodemd.com/role/SignificantAccountingPoliciesTables", "longName": "9960702 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
"shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30",
"firstAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231", "name": "inmd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body",
```

```
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R31": { "role":
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables", "longName": "9960703 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
"shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",
"order": "31", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "inmd:MarketableSecuritiesAndFairValueMeasurements", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "inmd:MarketableSecuritiesAndFairValueMeasurements", "div", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R32": { "role": "http://inmodemd.com/role/AccountsReceivableTables", "longName":
"9960704 - Disclosure - ACCOUNTS RECEIVABLE (Tables)", "shortName": "ACCOUNTS RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables",
"menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231",
"name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R33": { "role": "http://inmodemd.com/role/OtherCurrentReceivablesTables", "longName": "9960705 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT
RECEIVABLES (Tables)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables",
"menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "div", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name":
"inmd:ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true } }, "R34": { "role": "http://inmodemd.com/role/InventoriesTables", "longName": "9960706 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES
(Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } }, "R35": { "role": "http://inmodemd.com/role/PropertyAndEquipmentNetTables", "longName": "9960707 - Disclosure - PROPERTY AND
EQUIPMENT, NET (Tables)", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",
"order": "35", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-
US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R36": { "role": "http://inmodemd.com/role/LeasesTables",
"longName": "9960708 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "36", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount":
1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R37": { "role": "http://inmodemd.com/role/OtherCurrentLiabilitiesTables", "longName": "9960709 - Disclosure
- OTHER CURRENT LIABILITIES (Tables)", "shortName": "OTHER CURRENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "37", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } ], "R38": { "role": "http://inmodemd.com/role/ShareholdersEquityTables", "longName": "9960710 - Disclosure - SHAREHOLDERS'
EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38",
"firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html"
], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div",
"div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true } ], "R39": { "role": "http://inmodemd.com/role/TaxesOnIncomeTables", "longName": "9960711 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES
(Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R40": { "role": "http://inmodemd.com/role/SegmentsTables", "longName":
"9960712 - Disclosure - Segments (Tables)", "shortName": "Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",
"order": "40", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div",
"div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true } ], "R41": { "role": "http://inmodemd.com/role/Entity-wideDisclosureTables", "longName": "9960713 - Disclosure - ENTITY-WIDE DISCLOSURE (Tables)", "shortName":
"ENTITY-WIDE DISCLOSURE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div",
"inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R42": {
"role": "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails", "longName": "9960714 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
"shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "42", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:AdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals":
"-6", "ancestors": [ "span", "span", "div", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliticesTextBlock", "div", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name":
"us-gaap:AdvertisingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "div", "div", "us-
gaap:AdvertisingCostsPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R43": { "role":
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "longName": "9960715 - Disclosure - SIGNIFICANT ACCOUNTING
POLICIES (Schedule of Property and Equipment Estimated Useful Lives) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Estimated
Useful Lives) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef":
"C_20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div",
"inmd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-
gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_20241231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember", "name": "us-
gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "div", "td", "tr", "table",
"div", "div", "inmd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-
gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true
} }, "R44": { "role": "http://inmodemd.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfAllowanceForCreditLossesDetails", "longName": "9960716 - Disclosure - SIGNIFICANT
ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Allowance For Credit Losses) (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_20231231", "name": "us-
gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "us-
gaap:CreditLossFinancialInstrumentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td",
"tr", "table", "div", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "div", "div", "us-gaap:CreditLossFinancialInstrumentPolicyTextBlock", "div",
"us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R45":
{ "role": "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfAccruedWarrantyDetails", "longName": "9960717 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES
(Schedule of Accrued Warranty) (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Accrued Warranty) (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:StandardProductWarrantyAccrual",
"unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-
gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "div", "us-gaap:StandardProductWarrantyPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20211231", "name": "us-
gaap:StandardProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div",
"div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "div", "us-gaap:StandardProductWarrantyPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock",
"div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R46": { "role":
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails", "longName": "9960718 - Disclosure - MARKETABLE SECURITIES AND
FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities) (Details)", "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule Of Marketable Securities)
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_20241231",
"name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table",
"div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_20241231_usgaapFinancialInstrumentAxis_usgaapUSGovernmentAgenciesDebtSecuritiesMember", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:MarketableSecuritiesTextBlock", "div",
"inmd:MarketableSecuritiesAndFairValueMeasurements", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } },
"R47": { "role": "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "longName": "9960719 - Disclosure
- MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets Measured at Fair Value) (Details)", "shortName": "MARKETABLE SECURITIES AND FAIR VALUE
MEASUREMENTS (Schedule of Financial Assets Measured at Fair Value) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "47", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231_usgaapFairValueByFairValueHierarchyLevelAxis_usgaapFairValueInputsLevel2Member",
"name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td",
"tr", "table", "div", "div", "div", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "inmd:MarketableSecuritiesAndFairValueMeasurements", "div",
```

```
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R48": { "role":
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails", "longName": "9960720 - Disclosure - MARKETABLE SECURITIES AND
FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on Maturity) (Details)", "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Schedule of Debt Securities on
Maturity) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef":
"C_20241231", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "div",
"inmd:MarketableSecuritiesAndFairValueMeasurements", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"div", "div", "inmd:MarketableSecuritiesAndFairValueMeasurements", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R49": { "role": "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails", "longName": "9960721 - Disclosure - ACCOUNTS
RECEIVABLE (Schedule of Accounts Receivable) (Details)", "shortName": "ACCOUNTS RECEIVABLE (Schedule of Accounts Receivable) (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AccountsReceivableGross",
"unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-
gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-
gaap:AccountsReceivableGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div",
"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R50": { "role":
"http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails", "longName": "9960722 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES
(Schedule of Prepaid expenses and other current receivables) (Details)", "shortName": "PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES (Schedule of Prepaid expenses and other
current receivables) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": {
"contextRef": "C_20241231", "name": "inmd:OtherAdvancesToSuppliersCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span",
"div", "td", "tr", "table", "div", "div", "inmd:ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock", "div",
"inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "inmd:OtherAdvancesToSuppliersCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "inmd:ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock", "div",
"inmd:PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true } }, "R51": { "role": "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails", "longName": "9960723 - Disclosure - INVENTORIES (Schedule of
Inventories) (Details)", "shortName": "INVENTORIES (Schedule of Inventories) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "51", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-
gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_20241231", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {
"span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R52": { "role":
"http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "longName": "9960724 - Disclosure - PROPERTY AND EQUIPMENT, NET (Schedule of Property
and Equipment) (Details)", "shortName": "PROPERTY AND EQUIPMENT, NET (Schedule of Property and Equipment) (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef":
"USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-
gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock",
"div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R53": { "role": "http://inmodemd.com/role/OtherInvestmentsDetails", "longName": "9960725 - Disclosure - OTHER INVESTMENTS (Narrative) (Details)",
"shortName": "OTHER INVESTMENTS (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53",
"firstAnchor": { "contextRef":
"C_20231130_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_inmdMedimorMember_usgaapTypeOfArrangementAxis_inmdSharePurchaseAndShareholdersAgreementMember",
"name": "us-gaap:Investments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "us-gaap:InvestmentTextBlock",
"div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_20231130_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_inmdMedimorMember_usgaapTypeOfArrangementAxis_inmdSharePurchaseAndShareholdersAgreementMember",
"name": "us-gaap:Investments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "us-gaap:InvestmentTextBlock",
"div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R54": { "role":
"http://inmodemd.com/role/LeasesNarrativeDetails", "longName": "9960726 - Disclosure - LEASES (Narrative) (Details)", "shortName": "LEASES (Narrative) (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef":
"C_20180501to20180531_usgaapTypeOfArrangementAxis_inmdLeaseAgreementMember", "name": "inmd:LeaseExpires", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20180501to20180531_usgaapTypeOfArrangementAxis_inmdLeaseAgreementMember",
"name": "inmd:BankGuarantee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "us-
gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } ], "R55": { "role":
"http://inmodemd.com/role/LeasesScheduleOfLeaseExpenseDetails", "longName": "9960727 - Disclosure - LEASES (Schedule of Lease Expense) (Details)", "shortName": "LEASES
(Schedule of Lease Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span",
"div", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div",
"us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } ], "R56": { "role": "http://inmodemd.com/role/LeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
"longName": "9960728 - Disclosure - LEASES (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)", "shortName": "LEASES (Schedule of Supplemental Cash
Flow Information Related to Leases) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor":
{ "contextRef": "C_20240101to20241231", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span",
"span", "div", "div", "td", "tr", "table", "div", "div", "inmd:ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "div", "us-gaap:LesseeOperatingLeasesTextBlock",
"div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div",
"div", "td", "tr", "table", "div", "div", "inmd:ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } ], "R57": { "role":
"http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "longName": "9960729 - Disclosure - LEASES (Schedule of Supplemental
Balance Sheet Information Related to Leases) (Details)", "shortName": "LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_20241231", "name": "us-
gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div",
"div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name":
"inmd:OtherCurrentLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div",
"div", "inmd:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div", "body", "html"
], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R58": { "role": "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
"longName": "9960730 - Disclosure - LEASES (Schedule of Maturities of Lease Liabilities) (Details)", "shortName": "LEASES (Schedule of Maturities of Lease Liabilities)
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_20241231",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span",
"div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-
gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div",
"td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R59": { "role":
"http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails", "longName": "9960731 - Disclosure - OTHER CURRENT LIABILITIES (Schedule Of Other
Liabilities) (Details)", "shortName": "OTHER CURRENT LIABILITIES (Schedule Of Other Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "us-
gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-
gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div",
"div", "div", "div", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R60": { "role":
"http://inmodemd.com/role/CommitmentsAndContingentLiabilitiesDetails", "longName": "9960732 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)", "shortName":
"COMMITMENTS AND CONTINGENCIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60",
"firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "unitRef": "USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "us-
gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div",
"div", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R61": { "role": "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "longName": "9960733 - Disclosure - SHAREHOLDERS' EQUITY (Narrative)
(Details)", "shortName": "SHAREHOLDERS' EQUITY (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "61", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "ILS_per_Share", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": [ "span", "span", "div", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name":
"inmd:StockRepurchasedDuringPeriodValueOne", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "div", "div", "div", "div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R62": {
"role": "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails", "longName": "9960734 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Options Granted)
(Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Options Granted) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "62", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div",
"body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors":
[ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "div", "div", "us-
gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } },
"R63": { "role": "http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails", "longName": "9960735 - Disclosure - SHAREHOLDERS' EQUITY
(Schedule Of Outstanding and Exercisable Options) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Outstanding and Exercisable Options) (Details)", "isDefault":
```

```
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef":
"C_20240101to20241231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_inmdExercisePriceRangeOneMember", "name":
"inmd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "unitRef": "USD_Per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div",
"div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231_usgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_inmdExercisePriceRangeOneMember", "name":
"inmd:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "unitRef": "USD_Per_Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [
"span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div",
"div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R64": { "role": "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails", "longName": "9960736 - Disclosure -
SHAREHOLDERS' EQUITY (Schedule of Options Granted Restricted Share Unit) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule of Options Granted Restricted Share Unit)
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef":
"C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20231231_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null,
"decimals": "INF", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first":
true, "unique": true } }, "R65": { "role": "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails", "longName": "9960737 - Disclosure -
SHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) (Details)", "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Share Based Compensation Expense) (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_20240101to20241231", "name":
"us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr",
"table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "div", "div", "us-
gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, {
"uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "us-
gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R66": { "role":
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "longName": "9960738 - Disclosure - INCOME TAXES (Narrative) (Details)", "shortName": "INCOME TAXES (Narrative)
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef":
"C_20240101to20241231", "name": "inmd:CorporateTax", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "span", "div", "div", "div",
"div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true
}, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:CorporateTax", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [
"span", "span", "div", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true, "unique": true } }, "R67": { "role": "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails", "longName":
"9960739 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets (liabilities) (Details)", "shortName": "INCOME TAXES (Schedule of Deferred Tax Assets (liabilities)
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_20241231",
"name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td",
"tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name":
"us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr",
"table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div",
"div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R68": { "role":
"http://inmodemd.com/role/INCOMETAXESScheduleOfValuationAllowanceDetail", "longName": "9960740 - Disclosure - INCOME TAXES - (Schedule of valuation allowance) (Details)",
"shortName": "INCOME TAXES - (Schedule of valuation allowance) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "68", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div",
"div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:UtilizationOfCarryForwardTaxLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "div", "div", "div", "div", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R69": { "role":
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails", "longName": "9960741 - Disclosure - INCOME TAXES (Schedule of
Reconciliation of Theoretical Provision For Income Tax) (Details)", "shortName": "INCOME TAXES (Schedule of Reconciliation of Theoretical Provision For Income Tax) (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_20240101to20241231", "name":
"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "div", "div", "div", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R70": { "role":
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails", "longName": "9960742 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes)
(Details)", "shortName": "INCOME TAXES (Schedule of Income Before Income Taxes) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef":
"zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_usgaapIncomeTaxAuthorityNameAxis_inmdInmodeLtdAndIsraeliSubsidiariesMember", "name":
"us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "div", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R71": { "role":
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails", "longName": "9960743 - Disclosure - INCOME TAXES (Schedule of Tax Expenses (Tax Benefit)
(Details)", "shortName": "INCOME TAXES (Schedule of Tax Expenses (Tax Benefit)) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table", "div", "div", "us-
gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "us-
gaap:CurrentIncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "td", "tr", "table",
"div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R72": { "role":
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfUnrecognizedTaxBenefitsDetails", "longName": "9960744 - Disclosure - INCOME TAXES (Schedule of Unrecognized Tax Benefits)
(Details)", "shortName": "INCOME TAXES (Schedule of Unrecognized Tax Benefits) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "div",
"div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_20231231", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "div", "div", "us-
gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R73": { "role":
"http://inmodemd.com/role/SegmentsDetails", "longName": "9960745 - Disclosure - Segments (Schedule of Revenue by Major Customers) (Details)", "shortName": "Segments (Schedule
of Revenue by Major Customers) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": {
"contextRef": "C_20240101to20241231", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body",
"html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_20240101to20241231_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "us-
gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R74": { "role": "http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails",
"longName": "9960746 - Disclosure - ENTITY-WIDE DISCLOSURE (Narrative) (Details)", "shortName": "ENTITY-WIDE DISCLOSURE (Narrative) (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_20241231", "name":
"inmd:PercentageOfNonCurrentDeferredRevenue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "div", "us-
gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name":
"inmd:PercentageOfNonCurrentDeferredRevenue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "td", "tr", "table", "div", "us-
gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R75": { "role": "http://inmodemd.com/role/Entity-
wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails", "longName": "9960747 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) (Details)",
"shortName": "ENTITY-WIDE DISCLOSURE (Schedule Of Net Sales By Geographical Area) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_srtStatementGeographicalAxis_countryUS", "name": "us-gaap:Revenues",
"unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "us-
gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R76": { "role": "http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory",
"longName": "9960748 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of revenues based on products' category) (Details)", "shortName": "ENTITY-WIDE DISCLOSURE (Schedule of
revenues based on products' category) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76",
"firstAnchor": { "contextRef": "C_20240101to20241231", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span",
"span", "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_20240101to20241231_srtProductOrServiceAxis_inmdCapitalEquipmentMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "us-
gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "div", "div", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock",
"div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R77": { "role": "http://inmodemd.com/role/Entity-
wideDisclosureScheduleOfNetSalesByTechonologyDetails", "longName": "9960749 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) (Details)",
"shortName": "ENTITY-WIDE DISCLOSURE (Schedule of Net Sales by Techonology) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "77", "firstAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:PercentageOfNetSalesBasedOnProductsTechnology", "unitRef": "Pure", "xsiNil":
"false", "lang": null, "decimals": "2", "ancestors": [ "div", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfConcentrationOfRiskByRiskFactorTextBlock", "div", "div",
```

```
"div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_20240101to20241231", "name": "inmd:PercentageOfNetSalesBasedOnProductsTechnology", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "div", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "div", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R78": { "role": "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails", "longName": "9960750 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Changes In Contract Liabilities) (Details)", "shortName": "ENTITY-WIDE DISCLOSURE (Schedule Of Changes In Contract Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "C_20231231", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20221231", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } }, "R79": { "role": "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "longName": "9960751 - Disclosure - ENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) (Details)", "shortName": "ENTITY-WIDE DISCLOSURE (Schedule Of Long-Lived Assets) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_20241231", "name": "inmd:TotalLongLivedAssetsByGeographicalArea", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_20241231", "name": "inmd:TotalLongLivedAssetsByGeographicalArea", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "div", "div", "div", "inmd:EntityWideDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true, "unique": true } }, "R80": { "role": "http://inmodemd.com/role/RelatedPartiesDetails", "longName": "9960752 - Disclosure - RELATED PARTIES (Narrative) (Details)", "shortName": "RELATED PARTIES (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_20241231", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_20240101to20241231_usgaapRelatedPartyTransactionsByRelatedPartyAxis_inmdHomeSkinnovationsLtdMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "zk2532597.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "inmd_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "inmd_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AccountingPoliciesTable", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Table of accounting policies.", "label": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndNotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndNotesReceivableNet", "crdr": "debit", "calculation": { "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivable, after Allowance for Credit Loss", "totalLabel": "Notes And Loans Receivable Net", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r1065", "r1176" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract", "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "OTHER CURRENT LIABILITIES", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r441" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Accounts receivable, net of allowance for credit losses of $1,538 and $836, as of December 31, 2023 and 2022, respectively", "positiveTerseLabel": "Accounts payable", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "verboseLabel": "Accounts receivable, net of allowance for credit losses of $836 and $1,107, as of December 31, 2022 and 2021, respectively", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r77", "r869" ] }, "us-gaap_AccountsPayableRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Related Party [Extensible Enumeration]", "documentation": "Indicates status and type of related party for accounts payable." } } }, "auth_ref": [ "r1162" ] }, "us-gaap_AccountsReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Related Party [Extensible Enumeration]", "documentation": "Indicates status and type of related party for accounts receivable, after allowance for credit loss." } } }, "auth_ref": [ "r1162" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "verboseLabel": "Schedule Of Allowance For Credit Losses", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1086" ] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsAndNotesReceivableNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Trade", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r172", "r269", "r270", "r1176" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r728", "r797", "r891", "r1175", "r1176" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails", "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "positiveLabel": "Accounts receivable, net of allowance for credit losses of $1,825 and $1,538, as of December 31, 2024 and 2023, respectively", "positiveTerseLabel": "Accounts payable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Total current accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "verboseLabel": "Accounts receivable, net of allowance for credit losses of $836 and $1,107, as of December 31, 2022 and 2021, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_AccountsReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails", "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Less - non-current accounts receivable", "label": "Accounts receivable", "terseLabel": "Accounts receivable net of allowance for credit losses of $482 and $0 as of December 31, 2022 and 2021, respectively", "verboseLabel": "Accounts receivable net of allowance for credit losses of $924 and $716 as of December 31, 2024 and 2023, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent." } } }, "auth_ref": [ "r632", "r1065" ] }, "inmd_AccruedCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AccruedCommissions", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 70.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued commissions.", "label": "Accrued Commissions", "verboseLabel": "Accrued commissions" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "verboseLabel": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r79", "r135" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r47", "r169", "r654" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income (loss)", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r97", "r175", "r648", "r683", "r684" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r13", "r23", "r501", "r504", "r553", "r679", "r680", "r1040", "r1041", "r1042", "r1052", "r1053", "r1054", "r1056" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r952" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r88" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r700", "r1052", "r1053", "r1054", "r1056", "r1145", "r1211" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri":
```

```
"http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r965" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r965" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r965" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r965" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expenses", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "verboseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r56", "r57", "r402" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net income to net cash provided by operating activities:", "terseLabel": "Adjustments required to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "inmd_AdvanceToSubcontractorOrSupplier": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AdvanceToSubcontractorOrSupplier", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/CommitmentsAndContingentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Advance To Subcontractor Or Supplier", "documentation": "Represents about advance to subcontractor/supplier." "terseLabel": "Advance to subcontractor/supplier" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising expenses", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r148" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Advertising Expense", "terseLabel": "Advertising expenses", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r442", "r853" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1010" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r923", "r934", "r944", "r977" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r926", "r937", "r947", "r980" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1011" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r965" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r972" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r927", "r938", "r948", "r972", "r981", "r985", "r993" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r991" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Equity-based compensation income", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r433", "r439" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "calculation": { "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsAndNotesReceivableNet", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails", "http://inmodemd.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfAllowanceForCreditLossesDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less - allowance for credit losses", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "label": "Accounts Receivable, Allowance for Credit Loss", "verboseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r176", "r271", "r312", "r316", "r319", "r1176" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r176", "r271", "r312" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableNoncurrent", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Noncurrent", "terseLabel": "Accounts receivable net of allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as noncurrent." } } }, "auth_ref": [ "r271", "r312" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Write-offs charged against the allowance", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "verboseLabel": "Write-offs charged against the allowance", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r318" ] }, "inmd_AmendmentAdvantageExemptionMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AmendmentAdvantageExemptionMember", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amendment Advantage Exemption [Member]", "label": "Amendment Advantage Exemption [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails", "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r492" ] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaMember", "presentation": [ "http://inmodemd.com/role/EntityWideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "auth_ref": [ "r1213", "r1214", "r1215", "r1216" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "TOTAL ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r134", "r143", "r171", "r204", "r234", "r240", "r257", "r260", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r494", "r498", "r527", "r644", "r733", "r831", "r832", "r869", "r899", "r1098", "r1099", "r1163" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r164", "r179", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r494", "r498", "r527", "r869", "r1098", "r1099", "r1163" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent", "totalLabel": "TOTAL NON-CURRENT ASSETS", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r494", "r498", "r527", "r1098", "r1099", "r1163" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS:", "terseLabel": "NON-CURRENT ASSETS:" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm Id", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r906", "r907", "r930" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r906", "r907", "r930" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r906", "r907", "r930" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Gross unrealized holding gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r276" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized holding loss", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r277" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities, amortization", "verboseLabel": "Cost or amortized cost", "documentation": "Amortized cost of investment in debt security measured at fair value with
```

```
change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r273", "r332", "r643" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Total", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r1074", "r1075", "r1174" ] }, "inmd_AvailableForSaleSecuritiesDebtMaturitiesWithInOneToTwoYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithInOneToTwoYearsFairValue", "crdr": "debit", "calculation": { "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 10.0 } }, "presentation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt securities, available for sale maturity, within one to two years, fair value.", "label": "Available For Sale Securities Debt Maturities With In One To Two Years Fair Value", "verboseLabel": "1 to 2 years" } } }, "auth_ref": [] }, "inmd_AvailableForSaleSecuritiesDebtMaturitiesWithInTwoToThreeYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithInTwoToThreeYearsFairValue", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 20.0 } }, "presentation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt securities, available for sale maturity, within two to three years, fair value.", "label": "Available For Sale Securities Debt Maturities With In Two To Three Years Fair Value", "verboseLabel": "2 to 3 years" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 0.0 } }, "presentation": {
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfDebtSecuritiesOnMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Due within one year", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r280", "r639" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r274", "r332", "r515", "r631", "r858", "r861", "r1067", "r1149", "r1150", "r1151" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r988" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r989" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r984" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails", "http://inmodemd.com/role/ShareholdersEquityTables",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r987" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r985" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r985" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r349", "r1178", "r1179" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r68", "r69", "r349", "r1178", "r1179" ] }, "inmd_BankGuarantee": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "BankGuarantee", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Bank guarantee.", "label": "Bank guarantee" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Board of Director [Member]" } } }, "auth_ref": [ "r1064" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r346", "r488", "r849", "r850" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r58", "r60", "r342", "r343", "r344", "r345", "r346", "r488", "r849", "r850" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Percentage of Voting Interests Acquired", "verboseLabel": "Ownership interest", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Purchase consideration", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r12" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r907", "r930" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://inmodemd.com/role/General" ], "lang": { "en-us": { "role": { "label": "GENERAL", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r76", "r112", "r113" ] }, "inmd_CapitalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "CapitalEquipmentMember", "presentation": [
"http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for capital equipment.", "label": "Capital Equipment [Member]", "terseLabel": "Capital Equipment Revenues [Member]" } } }, "auth_ref": [] },
"inmd_CarryforwardLossesUsedNotRecognizedBefore": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "CarryforwardLossesUsedNotRecognizedBefore", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 20.0 } }, "lang": { "en-us": { "role": { "documentation": "Represents the amount of carryforward losses used not recognized before.", "negatedLabel": "Carryforward losses used not recognized before", "label": "Carryforward Losses Used Not Recognized Before", "verboseLabel": "Carryforward losses used not recognized before" } } },
"auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF THE YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR", "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r167", "r817" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF THE YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents
```

restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r109", "r201"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r109"] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Certificates of deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r11", "r892", "r893", "r894", "r895"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r963"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://inmodemd.com/role/SegmentsDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "CODM [Member]" } } }, "auth_ref": ["r1064"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r960"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r958"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://inmodemd.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r964"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r964"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r121", "r358", "r892", "r893", "r894", "r895"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 20.0 } }, "presentation": ["http://inmodemd.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (note 12)", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r83", "r136", "r646", "r719"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://inmodemd.com/role/CommitmentsAndContingentLiabilities"], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r120", "r351", "r352", "r799", "r1087", "r1089"] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": ["http://inmodemd.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Legal and other contingencies", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": ["r48", "r800"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Ordinary Shares [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r888", "r889", "r890", "r892", "r893", "r894", "r895", "r1052", "r1053", "r1056", "r1145", "r1210", "r1211"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://inmodemd.com/role/CONSOLIDATEDBALANCESHEETSParentheticals2", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r86"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Ordinary shares, shares authorized", "verboseLabel": "Shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r86", "r720"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Ordinary shares, issued shares", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r86"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity"], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance, shares", "periodStartLabel": "Begining Balance, Shares", "label": "Ordinary shares, outstanding shares", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r86", "r720", "r739", "r1211", "r1212"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://inmodemd.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, NIS 0.01 par value, authorized 200,000,000 shares at December 31, 2024 and 2023 Issued 87,583,673 and 85,957,465 shares at December 31, 2024 and 2023, respectively Outstanding 69,558,670 and 83,982,462 shares at December 31, 2024 and 2023, respectively", "verboseLabel": "Ordinary shares, NIS 0.01 par value, authorized 100,000,000 shares at December 31, 2022 and 2021. Issued 84,519,994 and 83,875,905 shares at December 31, 2022 and 2021, respectively. Outstanding 82,544,991 and 82,978,115 shares at December 31, 2022 and 2021, respectively.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r86", "r647", "r869"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r969"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r968"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r970"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r967"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r24", "r184", "r186", "r195", "r636", "r662", "r664"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "OTHER COMPREHENSIVE INCOME:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 10.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r6", "r63", "r67", "r184", "r186", "r194", "r635", "r662", "r663"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "TOTAL COMPREHENSIVE INCOME", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r67", "r130", "r184", "r186", "r193", "r634", "r662"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefullivesDetails"], "lang": { "en-us": { "role": { "label": "Computers [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r33", "r34", "r70", "r71", "r268", "r798", "r1022"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://inmodemd.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentration of credit risks", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r75", "r151"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to

```
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r798" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r32", "r33", "r34", "r35", "r70", "r132", "r798" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r33", "r34", "r70", "r71", "r268", "r798" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r208", "r494", "r495", "r498", "r499", "r562", "r805", "r1097", "r1100", "r1101" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "auth_ref": [ "r208", "r494", "r495", "r498", "r499", "r562", "r805", "r1097", "r1100", "r1101" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation and presentation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r64", "r819" ] }, "inmd_ConsumablesAndServiceRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ConsumablesAndServiceRevenuesMember", "presentation": [ "http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "documentation": "This member stand for consumables and service revenues.", "label": "Consumables And Service Revenues [Member]" } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r907" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Contract Liabilities", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1103" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance as of December 31", "periodStartLabel": "Balance as of January 1", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r384", "r385", "r388" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "terseLabel": "Contract liability presented in current liabilities", "verboseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r384", "r385", "r388" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contract liability presented in non-current liabilities", "verboseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r384", "r385", "r388" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Revenue recognized that was included in the contract liability balance at the beginning of the period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r389" ] }, "inmd_ContractorLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ContractorLiability", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of contractor liability.", "label": "Contractor Liability", "verboseLabel": "Contractor liability" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Corporate debt securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r846", "r848", "r858", "r870", "r885", "r1207" ] }, "inmd_CorporateTax": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "CorporateTax", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Corporate tax rate.", "label": "Corporate tax" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "COST OF REVENUES", "verboseLabel": "COST OF REVENUES", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r100", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r527", "r831", "r1098" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "verboseLabel": "Cost of sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1025" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts and financial instruments - credit loss", "verboseLabel": "Allowance for doubtful accounts and financial instruments \u2013 credit loss", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r320", "r322", "r323", "r324", "r325", "r328", "r329", "r330", "r331", "r333", "r334", "r335", "r337" ] }, "inmd_CreditRiskSharingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "CreditRiskSharingLiabilities", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of credit risk sharing liabilities", "label": "Credit Risk Sharing Liabilities", "terseLabel": "Credit risk sharing liabilities" } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r161", "r212", "r217", "r224", "r307", "r308", "r347", "r474", "r475", "r483", "r485", "r500", "r501", "r502", "r504", "r505", "r506", "r509", "r510", "r511", "r512", "r552" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "auth_ref": [ "r161", "r212", "r217", "r224", "r307", "r308", "r347", "r474", "r475", "r483", "r485", "r500", "r501", "r502", "r504", "r505", "r506", "r509", "r510", "r511", "r512", "r552" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r473", "r1050" ] }, "inmd_CurrentMonthlyRentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "CurrentMonthlyRentPayment", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Current monthly rent payment.", "label": "Current monthly rent payment" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r915", "r1004" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r915", "r1004" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r917", "r1006" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r917", "r1006" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r919", "r1008" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r917", "r1006" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r910", "r999" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r911", "r1000" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated
```

```
{Text Block]" } } }, "auth_ref": [ "r911", "r1000" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk
Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r909", "r998" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and
Governance [Line Items]" } } }, "auth_ref": [ "r909", "r998" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and
Governance [Table]" } } }, "auth_ref": [ "r909", "r998" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged
[Flag]" } } }, "auth_ref": [ "r912", "r1001" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or
Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r914", "r1003" ] },
"cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024",
"localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or
Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r914", "r1003" ] },
"cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board
Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r915", "r1004" ] },
"cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname":
"CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management
or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r918", "r1007" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]"
} } }, "auth_ref": [ "r916", "r1005" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [
"http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and
Identification Processes [Flag]" } } }, "auth_ref": [ "r913", "r1002" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt Securities on Maturity",
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-
sale)." } } }, "auth_ref": [ "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080" ] }, "us-
gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit",
"calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes, net", "terseLabel": "Deferred income tax assets",
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards,
with jurisdictional netting." } } }, "auth_ref": [ "r449", "r450" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred", "documentation": "Amount of deferred
income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r157", "r1050" ] }, "us-
gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr":
"debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 60.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax
Credits", "verboseLabel": "Deferred income tax assets, net", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [
"r111" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr":
"debit", "calculation": { "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0,
"order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred
Tax Assets, Gross", "totalLabel": "Total deferred tax assets before valuation allowance", "documentation": "Amount before allocation of valuation allowances of deferred tax
asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r465" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation
Allowance", "totalLabel": "Total deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible
temporary differences and carryforwards." } } }, "auth_ref": [ "r1136" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets in respect of:" } } },
"auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": {
"parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries carryforward losses",
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1139"
] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit",
"calculation": { "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0,
"order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other
temporary differences", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified
as other." } } }, "auth_ref": [ "r1139" ] }, "us-gaap_DeferredTaxAssetsOtherComprehensiveLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxAssetsOtherComprehensiveLoss", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 30.0 } },
"presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax asset in
respect to other comprehensive loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences
from unrealized losses in other comprehensive income." } } }, "auth_ref": [ "r1139" ] }, "us-
gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 20.0 } },
"presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax
Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "verboseLabel": "Share-based compensation", "documentation": "Amount before allocation of
valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1139" ] }, "us-
gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance",
"crdr": "credit", "calculation": { "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet",
"weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/INCOMETAXESScheduleOfValuationAllowanceDetail",
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role":
{ "negatedLabel": "Valuation allowance", "periodEndLabel": "Balance at December 31", "periodStartLabel": "Balance at January 1", "label": "Deferred Tax Assets, Valuation
Allowance", "verboseLabel": "Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be
realized." } } }, "auth_ref": [ "r466" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0,
"order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term bank deposits",
"documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or
during the operating cycle, if shorter." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Depreciation", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 40.0 } }, "presentation": [
"http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation", "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation",
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes
production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r46" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } },
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows", "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ],
"lang": { "en-us": { "role": { "label": "Depreciation and amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in
the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [
"r8", "r234", "r244", "r260", "r831", "r832" ] }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureTables" ], "lang": { "en-us": {
"role": { "label": "Schedule of Long-Lived Assets", "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the
facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the
income statement and the income statement caption that includes that gain (loss)." } } }, "auth_ref": [ "r18" ] }, "us-
gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us":
{ "role": { "label": "Schedule of Awards Authorized to be Issued", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r10", "r51"
] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard",
"presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The
basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting
Standards', or 'Other'." } } }, "auth_ref": [ "r907" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentAnnualReport", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r906", "r907", "r930" ] },
"dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag",
"presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]",
"documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r906", "r907",
"r930", "r973" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus",
"presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal
period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year
statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentFiscalYearFocus", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods,
```

```
fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role":
{ "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the
EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } }
}, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentRegistrationStatement", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration
Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r900" ] }, "dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true
for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r907" ] }, "dei_DocumentTransitionReport": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation"
], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } },
"auth_ref": [ "r951" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such
as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other
Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r962" ] }, "us-gaap_EarningsPerShareAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "NET INCOME PER SHARE:", "terseLabel": "EARNINGS PER SHARE:" } } },
"auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic",
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Basic", "verboseLabel": "Basic", "documentation": "The
amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r196", "r215", "r216",
"r217", "r218", "r219", "r220", "r225", "r227", "r229", "r230", "r231", "r233", "r486", "r491", "r512", "r513", "r637", "r665", "r823" ] }, "us-gaap_EarningsPerShareDiluted":
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Diluted", "terseLabel": "Diluted", "documentation": "The amount of net
income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been
outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [
"r196", "r215", "r216", "r217", "r218", "r219", "r220", "r227", "r229", "r230", "r231", "r233", "r486", "r491", "r512", "r513", "r637", "r665", "r823" ] }, "us-
gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock",
"presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net income per share", "verboseLabel": "Net
earnings per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and
participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock
dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } },
"auth_ref": [ "r30", "r31", "r232" ] }, "us-
gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 30.0 } }, "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel":
"EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS", "totalLabel": "Effect of Exchange Rate on Cash and Cash Equivalents, Total", "documentation": "Amount of
increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign
currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or
financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes
in interest rates." } } }, "auth_ref": [ "r1155" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang":
{ "en-us": { "role": { "label": "Statutory rate", "verboseLabel": "Theoretical tax expenses at the statutory rate of InMode Ltd.", "documentation": "Percentage of domestic
federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r205", "r452", "r476", "r855" ] }, "us-
gaap_EffectiveIncomeTaxRateReconciliationDeductionsDividends": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectiveIncomeTaxRateReconciliationDeductionsDividends", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Tax rate after divdend", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit)
computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend." } } },
"auth_ref": [ "r1051", "r1133", "r1134" ] }, "inmd_ElsewhereMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ElsewhereMember",
"presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Elsewhere [Member]", "label": "Elsewhere
[Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 50.0 } }, "presentation": [
"http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Share based
compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } },
"presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Employees and related
expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to
services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within
one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r79" ] }, "inmd_EmployeeRelatedSeveranceLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://inmodemd.com/20241231", "localname": "EmployeeRelatedSeveranceLiabilities", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee Related Severance Liabilities.", "label":
"Employee Related Severance Liabilities" } } }, "auth_ref": [] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation":
[ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation cost, recognition period",
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS'
format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r434" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "Amount of cost
to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1132" ] }, "inmd_EmployeeSeveranceBenefitsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "EmployeeSeveranceBenefitsPolicyTextBlock", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Employee severance benefits.", "label": "Employee
Severance Benefits Policy Text Block", "terseLabel": "Employee severance benefits" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting
right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] },
"inmd_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "EmployeesMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees [Member]", "label": "Employees [Member]" } } },
"auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1",
"presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation":
"Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such
as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressCityOrTown", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town",
"documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityAddressCountry", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address
Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a
table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued
value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r902" ] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding",
"presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as
stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member],
Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No'
whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be
based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant
meets the emerging growth company criteria." } } }, "auth_ref": [ "r902" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1015" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
```

```
"label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r902" ] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity
Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is
true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12
months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1013" ] }, "dei_EntityRegistrantName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity
filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r902" ] }, "dei_EntityShellCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of
the Exchange Act." } } }, "auth_ref": [ "r902" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityVoluntaryFilers", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] },
"dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or
'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A,
6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1014" ] }, "inmd_EntityWideDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "EntityWideDisclosuresTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosure" ], "lang": { "en-us": { "role": { "documentation": "The
entire disclosure about entity wide Ddsclosures.", "label": "Entity Wide Disclosures [Text Block]", "terseLabel": "Segments" } } }, "auth_ref": [] }, "us-
gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideRevenueMajorCustomerLineItems",
"presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Major Customer [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the
table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text
Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r956" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table
[Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1009" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1009" ] },
"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date
Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary
Compensation Table" } } }, "auth_ref": [ "r1009" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquipmentMember", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": {
"role": { "label": "Equipment and furniture [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the
total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r161", "r188", "r189",
"r190", "r209", "r210", "r211", "r214", "r219", "r221", "r223", "r235", "r307", "r308", "r347", "r383", "r474", "r475", "r483", "r484", "r485", "r487", "r490", "r491", "r500",
"r501", "r502", "r503", "r504", "r506", "r511", "r529", "r531", "r532", "r533", "r534", "r535", "r538", "r541", "r553", "r660", "r679", "r680", "r681", "r700", "r764" ] },
"srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [
"http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r303", "r304", "r305", "r482",
"r1017", "r1018", "r1019", "r1141", "r1142", "r1143", "r1144" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": {
"en-us": { "role": { "label": "Ownership interest", "verboseLabel": "Ownership interest", "documentation": "The percentage of ownership of common stock or equity participation
in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r303" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity
Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r966" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r923", "r934", "r944", "r977" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously
Awarded Compensation Recovery" } } }, "auth_ref": [ "r920", "r931", "r941", "r974" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ],
"lang": { "en-us": { "role": { "label": "Europe [Member]", "verboseLabel": "Europe [Member]" } } }, "auth_ref": [ "r1213", "r1214", "r1215", "r1216" ] },
"ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [
"r972" ] }, "inmd_ExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ExerciseOfOptions", "crdr": "debit",
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Exercise of Options.", "label": "Exercise of
Options" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"ExercisePriceRangeFiveMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "$5.11 [Member]", "label": "Exercise Price Range Five [Member]", "terseLabel": "$9.85 [Member]" } } }, "auth_ref": [] },
"inmd_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ExercisePriceRangeFourMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$3.75 [Member]", "label":
"Exercise Price Range Four [Member]", "terseLabel": "$7.00 [Member]" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExercisePriceRangeOneMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$0.28 [Member]", "label":
"Exercise Price Range One Member", "terseLabel": "$3.16 [Member]" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeSevenMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExercisePriceRangeSevenMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$9.85 [Member]", "label":
"Exercise Price Range Seven [Member]", "terseLabel": "$21.62 [Member]" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeSixMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExercisePriceRangeSixMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$7.00 [Member]", "label":
"Exercise Price Range Six [Member]", "terseLabel": "$12.16 [Member]" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExercisePriceRangeThreeMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$3.16 [Member]", "label":
"Exercise Price Range Three [Member]", "terseLabel": "$5.11 [Member]" } } }, "auth_ref": [] }, "inmd_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExercisePriceRangeTwoMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "$0.29 [Member]", "label":
"Exercise Price Range Two [Member]", "terseLabel": "$3.75 [Member]" } } }, "auth_ref": [] }, "inmd_ExpensesIncomeMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ExpensesIncomeMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": {
"label": "Expenses (Income) [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets Measured at Fair Value
on Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if
any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level
within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for
identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1147", "r1148" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis",
"presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": {
"label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as
practical expedient." } } }, "auth_ref": [ "r368", "r391", "r392", "r393", "r394", "r395", "r396", "r514", "r516", "r517", "r518", "r519", "r522", "r523", "r525", "r569",
"r570", "r571", "r841", "r842", "r846", "r847", "r848", "r858", "r861" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Level 2
Securities [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly,
including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive
markets." } } }, "auth_ref": [ "r368", "r391", "r396", "r516", "r517", "r523", "r570", "r841", "r842", "r846", "r847", "r848", "r858" ] }, "us-
gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"Fair value measurement", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments
classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net
exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair
Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r368",
"r391", "r392", "r393", "r394", "r395", "r396", "r514", "r516", "r517", "r518", "r519", "r522", "r523", "r525", "r569", "r570", "r571", "r841", "r842", "r846", "r847", "r848",
"r858", "r861" ] }, "inmd_FairValueOfOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "FairValueOfOptionsGranted",
"crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of options
granted.", "label": "Fair value of options granted" } } }, "auth_ref": [] }, "inmd_FairValueOfRestrictedOptionsGranted": { "xbrltype": "sharesItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "FairValueOfRestrictedOptionsGranted", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang":
{ "en-us": { "role": { "documentation": "Fair value of restricted options granted.", "label": "Fair Value Of Restricted Options Granted", "terseLabel": "Fair value of RSUs
granted" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinancialInstrumentAxis", "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument
[Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281",
```

```
"r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r314", "r315", "r320", "r321", "r326", "r336", "r337", "r338", "r369", "r381", "r507", "r526", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r661", "r840", "r858", "r859", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r870", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1080", "r1081", "r1082", "r1083", "r1146", "r1149", "r1150", "r1151", "r1152", "r1153" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Functional currency", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r528" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r927", "r938", "r948", "r981" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r927", "r938", "r948", "r981" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r927", "r938", "r948", "r981" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r927", "r938", "r948", "r981" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r927", "r938", "r948", "r981" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r961" ] }, "inmd_FullyDilutedBasisMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "FullyDilutedBasisMember", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fully diluted basis [Member]", "label": "Fully diluted basis [Member]" } } }, "auth_ref": [] }, "inmd_GIBFAndJVCMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "GIBFAndJVCMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "GIBF and JVC [Member]", "label": "G I B F And J V C [Member]", "terseLabel": "GIBF and JVC [Member]" } } }, "auth_ref": [] }, "inmd_GeneralAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "GeneralAbstract", "lang": { "en-us": { "role": { "label": "General Abstract" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "General and administrative", "verboseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r102", "r744" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses [Member]", "verboseLabel": "General and administrative expenses [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r102" ] }, "inmd_GovernmentInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "GovernmentInstitutions", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Government institutions.", "label": "Government Institutions", "verboseLabel": "Government institutions" } } }, "auth_ref": [] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails", "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r401", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails", "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r401", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "GROSS PROFIT", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r98", "r100", "r142", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r527", "r825", "r831", "r1057", "r1059", "r1060", "r1061", "r1062", "r1098" ] }, "inmd_HandsFreeMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "HandsFreeMember", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "documentation": "Hands-Free [Member]", "label": "Hands-Free [Member]" } } }, "auth_ref": [] }, "inmd_HimalayaFamilyOfficeConsultingLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "HimalayaFamilyOfficeConsultingLtdMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Himalaya Family Office Consulting Ltd. [Member]", "label": "Himalaya Family Office Consulting Ltd. [Member]" } } }, "auth_ref": [] }, "inmd_HomeSkinnovationsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "HomeSkinnovationsLtdMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Home Skinnovations Ltd [Member]", "label": "Home Skinnovations Ltd [Member]" } } }, "auth_ref": [] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IL", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Israel [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Attestation Flag" } } }, "auth_ref": [ "r906", "r907", "r930" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of long-lived assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r119" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 }, "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "http://inmodemd.com/role/SegmentsDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "INCOME BEFORE INCOME TAXES", "verboseLabel": "Income before taxes on income", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r99", "r138", "r142", "r638", "r656", "r825", "r831", "r1057", "r1059", "r1060", "r1061", "r1062" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r348", "r349", "r350", "r520", "r521", "r524", "r676", "r678", "r749", "r813", "r860", "r1180" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r349", "r350", "r520", "r521", "r524", "r676", "r678", "r749", "r813", "r860", "r1180" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "verboseLabel": "Income Tax Authority, Name [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r200", "r452", "r453", "r459", "r470", "r855", "r1138" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r200", "r452", "r453", "r459", "r470", "r855", "r1138" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r459", "r1138" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r459", "r1138" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1135" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncome" ], "lang": { "en-us": { "role": { "label": "TAXES ON INCOME", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r205", "r445", "r452", "r456", "r457", "r458", "r463", "r468", "r477", "r479", "r480", "r481", "r694", "r855" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 0.0 }, "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 10.0 }, "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true
```

```
} ], "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "http://inmodemd.com/role/SegmentsDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "INCOME TAXES BENEFIT (EXPENSES)", "label":
"Income Tax Expense (Benefit)", "terseLabel": "Total taxes on income", "totalLabel": "Total taxes on income", "verboseLabel": "INCOME TAXES BENEFIT (EXPENSES)",
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r146",
"r158", "r222", "r223", "r234", "r245", "r260", "r451", "r452", "r478", "r667", "r855" ] }, "us-
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in
taxes on income due to:" } } }, "auth_ref": [] }, "inmd_IncomeTaxNoteLineItems": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"IncomeTaxNoteLineItems", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax
Note [Line Items]" } } }, "auth_ref": [] }, "inmd_IncomeTaxNoteTable": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"IncomeTaxNoteTable", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "documentation": "Table of income taxes.", "label": "Income
Tax Note [Table]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income taxes",
"documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities
and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for
determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r187", "r447", "r448", "r463",
"r464", "r467", "r472", "r690" ] }, "inmd_IncomeTaxReconciliationAmendmentToInvestmentsLawPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "IncomeTaxReconciliationAmendmentToInvestmentsLawPayment", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 80.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Represents the amount of income tax reconciliation amendment to the investments law payment.", "label": "Income Tax Reconciliation Amendment To Investments
Law Payment", "verboseLabel": "Amendment to the Investments Law payment - see also note 13a(2)(b)" } } }, "auth_ref": [] },
"inmd_IncomeTaxReconciliationBenefitsToBenefitedEnterprise": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"IncomeTaxReconciliationBenefitsToBenefitedEnterprise", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0,
"order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Benefits to the Benefited Enterprise.", "negatedLabel": "Benefits to the Benefited Enterprise", "label": "Income Tax Reconciliation Benefits To Benefited
Enterprise", "terseLabel": "Benefits to the Benefited Enterprise" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit",
"calculation": { "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
"weight": 1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate
Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance", "verboseLabel": "Change in valuation allowance",
"documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal
statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } },
"auth_ref": [ "r455", "r855", "r1133" ] }, "inmd_IncomeTaxReconciliationDifferentEffectiveTaxRatesApplicableToOperatingLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "IncomeTaxReconciliationDifferentEffectiveTaxRatesApplicableToOperatingLoss", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 100.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by operating losses.", "label":
"Income Tax Reconciliation Different Effective Tax Rates Applicable To Operating Loss", "terseLabel": "NOL carry back as part of the CARES Act relief" } } }, "auth_ref": [] },
"inmd_IncomeTaxReconciliationDifferentEffectiveTaxRatesApplicableToSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"IncomeTaxReconciliationDifferentEffectiveTaxRatesApplicableToSubsidiaries", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0,
"order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal
statutory income tax rates to pretax income (loss) from continuing operations attributable to Different effective tax rates applicable to the subsidiaries.", "negatedLabel":
"Different effective tax rates applicable to the Subsidiaries", "label": "Income Tax Reconciliation Different Effective Tax Rates Applicable To Subsidiaries", "terseLabel":
"Different effective tax rates applicable to the Subsidiaries" } } }, "auth_ref": [] }, "us-
gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role": {
"label": "Theoretical tax benefit", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates
to pretax income from continuing operations." } } }, "auth_ref": [ "r452", "r855" ] }, "inmd_IncomeTaxReconciliationNonDeductibleExpenses": { "xbrltype": "monetaryItemType",
"nsuri": "http://inmodemd.com/20241231", "localname": "IncomeTaxReconciliationNonDeductibleExpenses", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 60.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal
statutory income tax rates to pretax income (loss) from continuing operations attributable to Non-deductible expenses.", "label": "Income Tax Reconciliation Non Deductible
Expenses", "verboseLabel": "Non-deductible expenses and other permanent differences, mainly share based compensation expenses" } } }, "auth_ref": [] }, "us-
gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 70.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "label": "Previous years", "verboseLabel": "Previous year", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax
expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of
previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r1133", "r1134" ] },
"inmd_IncomeTaxReconciliationSettlementsWithIsraeliTaxAuthorityNetOfDecreaseOfRelatedUncertainTax": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "IncomeTaxReconciliationSettlementsWithIsraeliTaxAuthorityNetOfDecreaseOfRelatedUncertainTax", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 90.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Represents the amount of Income tax reconciliation settlements with israeli tax authority net of decrease of related uncertain tax.", "label": "Income Tax
Reconciliation Settlements With Israeli Tax Authority Net Of Decrease Of Related Uncertain Tax", "terseLabel": "Settlements with the Israeli tax authority net of decrease of
related uncertain tax provision" } } }, "auth_ref": [] }, "inmd_IncomeTaxReconciliationUncertainTaxPosition": { "xbrltype": "monetaryItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "IncomeTaxReconciliationUncertainTaxPosition", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0,
"order": 50.0 } }, "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfReconciliationOfTheoreticalProvisionForIncomeTaxDetails" ], "lang": { "en-us": { "role":
{ "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal
statutory income tax rates to pretax income (loss) from continuing operations attributable to uncertain tax position.", "label": "Income Tax Reconciliation Uncertain Tax
Position", "verboseLabel": "Uncertain tax positions" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role":
{ "label": "Income taxes paid", "terseLabel": "Income taxes paid *", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions
as income tax." } } }, "auth_ref": [ "r29", "r200", "r469", "r470" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxesReceivable", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Tax asset", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the
balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r133", "r1036" ] }, "us-
gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr":
"debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 100.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in accounts payable",
"terseLabel": "Increase (decrease) in accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred
(and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7"
] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 70.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang":
{ "en-us": { "role": { "negatedLabel": "Decrease (increase) in accounts receivable (including non-current)", "label": "Increase (Decrease) in Accounts Receivable",
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and
services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 130.0 } }, "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the
reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 120.0 } },
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in contract liabilities",
"terseLabel": "Increase (decrease) in contract liabilities", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which
consideration has been received or is receivable." } } }, "auth_ref": [ "r598", "r1047" ] }, "us-gaap_IncreaseDecreaseInFinanceReceivables": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInFinanceReceivables", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 50.0 } },
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income, net", "label": "Increase
(Decrease) in Finance Receivables", "terseLabel": "Interest income", "totalLabel": "Interest Income, Operating, Total", "documentation": "The increase (decrease) during the
reporting period in outstanding loans including accrued interest." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 90.0 } },
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in inventories", "label": "Increase
(Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity,
associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] },
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 110.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang":
```

```
{ "en-us": { "role": { "label": "Increase in other liabilities", "terseLabel": "Increase (decrease) in other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": { "r7" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 80.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r7" ] }, "inmd_IncreasesDueToIssuanceOfNewContractsExcludingAmountsRecognizedAsRevenueDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "IncreasesDueToIssuanceOfNewContractsExcludingAmountsRecognizedAsRevenueDuringPeriod", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfChangesInContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period.", "label": "Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r927", "r938", "r948", "r972", "r981", "r985", "r993" ] }, "inmd_InmodeLtdAndIsreaeliSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "InmodeLtdAndIsreaeliSubsidiariesMember", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "InMode Ltd. and Isreaeli subsidiaries[member]", "label": "Inmode Ltd And Isreaeli Subsidiaries [Member]", "verboseLabel": "InMode Ltd. and Israeli subsidiaries [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r991" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r908", "r997" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r908", "r997" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r908", "r997" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income, net", "label": "Interest Income, Operating", "terseLabel": "Interest income", "totalLabel": "Interest income", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r243", "r742", "r785", "r786", "r831", "r896", "r897", "r1043", "r1217" ] }, "inmd_InterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "InterestReceived", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Interest received.", "label": "Interest received" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "INVENTORIES", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r339" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Finished products", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1037" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 50.0 }, "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r178", "r818", "r869" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r147", "r166", "r177", "r339", "r340", "r341", "r599", "r820" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/InventoriesScheduleOfInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1038" ] }, "inmd_InvestmentInShortTermDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "InvestmentInShortTermDeposit", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Investment in short-term deposit.", "negatedLabel": "Investment in short-term deposits", "label": "Investment In Short Term Deposit" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Finance income, net", "verboseLabel": "Finance income, net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r104", "r105", "r106" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Other Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r666", "r686", "r687", "r688", "r689", "r775", "r776" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": [ "http://inmodemd.com/role/OtherInvestments" ], "lang": { "en-us": { "role": { "label": "OTHER INVESTMENTS", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r1023", "r1024", "r1066" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r702", "r704", "r705", "r707", "r709", "r772", "r774", "r778", "r781", "r782", "r783", "r787", "r788", "r789", "r790", "r791", "r890" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r702", "r704", "r705", "r707", "r709", "r772", "r774", "r778", "r781", "r782", "r783", "r787", "r788", "r789", "r790", "r791", "r890" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Amount", "verboseLabel": "Investment amount", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r641", "r642", "r884", "r887" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "auth_ref": [] }, "inmd_IsraeliTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "IsraeliTaxAuthorityMember", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stand for Israeli Tax Authority.", "label": "Israeli Tax Authority [Member]" } } }, "auth_ref": [] }, "inmd_JointVentureAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "JointVentureAgreementMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Guangzhou Sino Israel Bio Industry Investment Fund LLP [Member]", "label": "Joint Venture Agreement [Member]" } } }, "auth_ref": [] }, "inmd_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "LeaseAgreementMember", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease agreement [Member]", "label": "Lease Agreement [Member]", "verboseLabel": "Lease agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://inmodemd.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1157" ] }, "inmd_LeaseExpires": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "LeaseExpires", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease expires period.", "label": "Lease expires", "verboseLabel": "Lease expiration date" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r118", "r551" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "inmd_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "LeasesLineItems", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Leases [Line Items]" } } }, "auth_ref": [] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesOperatingAbstract", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Leases" } } }, "auth_ref": [] }, "inmd_LeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "LeasesTable", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Table of leases.", "label": "Leases [Table]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r545" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://inmodemd.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1158" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2029 and beyond", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0
```

```
} ], "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interests", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less imputed interests", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r550" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "verboseLabel": "Term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1156" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://inmodemd.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r540" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r495", "r498", "r499", "r527", "r718", "r824", "r899", "r1098", "r1163", "r1164" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r92", "r137", "r650", "r869", "r1049", "r1084", "r1154" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and shareholders' equity", "terseLabel": "Liabilities and shareholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r80", "r165", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r495", "r498", "r499", "r527", "r869", "r1098", "r1163", "r1164" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:", "terseLabel": "CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL NON-CURRENT LIABILITIES", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r81", "r82", "r83", "r84", "r204", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r495", "r498", "r499", "r527", "r1098", "r1163", "r1164" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES:", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/AccountsReceivable" ], "lang": { "en-us": {
"role": { "label": "ACCOUNTS RECEIVABLE", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r537", "r1063" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossOnSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossOnSaleOfInvestments", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on marketable securities, net", "label": "Loss on Sale of Investments", "terseLabel": "Loss on marketable securities, net", "totalLabel": "Gain (Loss) on Investments, Total", "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale." } } }, "auth_ref": [ "r1044", "r1045", "r1048", "r1172" ] }, "inmd_MarketableSecuritiesAndFairValueMeasurementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "MarketableSecuritiesAndFairValueMeasurementAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities and Fair Value Measurement [Abstract]", "terseLabel": "Marketable Securities And Fair Value Measurements Schedule Of Debt Securities On Maturity", "verboseLabel": "Marketable Securities And Fair Value Measurements" } } }, "auth_ref": [] }, "inmd_MarketableSecuritiesAndFairValueMeasurements": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "MarketableSecuritiesAndFairValueMeasurements", "presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurements" ], "lang": { "en-us": { "role": {
"documentation": "The entire dislosure for marketable securities and fair value measurements.", "label": "Marketable Securities And Fair Value Measurements", "verboseLabel": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "positiveLabel": "Marketable securities (amortized cost of $268,129 and $375,829, as of December 31, 2024 and 2023, respectively)", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "verboseLabel": "Marketable securities (amortized cost of $384,320 and $296,243, as of December 31, 2022 and 2021, respectively)", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesLineItems", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [
"r74" ] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable",
"presentation": [ "http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Marketable Securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingExpense", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 60.0 } }, "presentation": [
"http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Marketing Expense", "terseLabel": "Marketing expenses", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": [ "r102" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MaximumMember", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r398", "r440", "r519", "r597", "r675", "r677", "r685", "r710", "r711", "r773", "r777", "r779", "r780", "r784", "r811", "r812", "r837", "r843", "r851", "r861", "r862", "r866", "r867", "r880", "r1102", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r964" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r964" ] },
"inmd_MedimorMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "MedimorMember", "presentation": [
"http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Medimor [Member]", "label": "Medimor [Member]" } } }, "auth_ref": [] }, "inmd_MinimalInvasiveMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "MinimalInvasiveMember", "presentation": [
"http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimal-Invasive [Member]", "label": "Minimal-Invasive [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r398", "r440", "r519", "r597", "r675", "r677", "r685", "r710", "r711", "r773", "r777", "r779", "r780", "r784", "r811", "r812", "r837", "r843", "r851", "r861", "r862", "r866", "r880", "r1102", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170" ] }, "inmd_MinorityInterestDecreaseFromRedemptionsOne": { "xbrltype": "monetaryItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "MinorityInterestDecreaseFromRedemptionsOne", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Waiver of redeemable non controlling interest.", "label": "Minority Interest Decrease From Redemptions One", "terseLabel": "Waiver of redeemable non controlling interest" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": {
```

```
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI
Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r984" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails"
], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r796", "r801", "r802", "r803", "r804", "r806", "r807", "r808", "r809",
"r810" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Real Estate
[Domain]" } } }, "auth_ref": [ "r801", "r802", "r803", "r804", "r806", "r807", "r808", "r809", "r810" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": {
"en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r992" ] }, "us-
gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Municipal bonds
[Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } },
"auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers,
Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r965" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 20.0 } }, "presentation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel":
"Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations.
Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying
amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r199" ] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"CASH FLOWS FROM FINANCING ACTIVITIES:", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 10.0 } }, "presentation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel":
"Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations.
Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other
productive assets." } } }, "auth_ref": [ "r199" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:", "terseLabel": "CASH FLOWS FROM
INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": {
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel":
"Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity
cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r109", "r110", "r111" ] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": null, "weight": null, "order": null,
"root": true } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "NET INCOME ATTRIBUTABLE TO INMODE LTD", "documentation": "The portion of profit or loss for the
period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r101", "r111", "r139", "r163", "r182", "r185", "r190", "r204", "r213", "r215", "r216",
"r217", "r218", "r219", "r222", "r223", "r228", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r486", "r491", "r513", "r527", "r659", "r741",
"r762", "r763", "r897", "r1098" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag":
"us-gaap_NetIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": {
"negatedLabel": "Add: Net income attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of
Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r66", "r131", "r182", "r185", "r219", "r222", "r223", "r658", "r1042" ] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"label": "Newly issued and recently adopted accounting pronouncements", "verboseLabel": "Recently adopted accounting pronouncements", "documentation": "Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected
or actual impact." } } }, "auth_ref": [] }, "inmd_NewlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "NewlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for newly issued
accounting pronouncements, not yet adopted.", "label": "Newly Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]", "terseLabel": "Newly issued accounting
pronouncements, not yet adopted" } } }, "auth_ref": [] }, "inmd_NoAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"NoAmendmentMember", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "No Amendment [Member]",
"label": "No Amendment [Member]" } } }, "auth_ref": [] }, "inmd_NonCashAcquisitionOfNoncontrollingInterestInExchangeOfOrdinaryShares": { "xbrltype": "monetaryItemType",
"nsuri": "http://inmodemd.com/20241231", "localname": "NonCashAcquisitionOfNoncontrollingInterestInExchangeOfOrdinaryShares", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of non cash Acquisition of
noncontrolling interest in exchange of ordinary shares.", "label": "Non Cash Acquisition Of Noncontrolling Interest In Exchange Of Ordinary Shares", "verboseLabel":
"Acquisition of non-controlling interest in exchange of ordinary shares" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r964" ] }, "inmd_NonInvasiveMember":
{ "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "NonInvasiveMember", "presentation": [ "http://inmodemd.com/role/Entity-
wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-Invasive [Member]", "label": "Non-Invasive [Member]" } } },
"auth_ref": [] }, "inmd_NonIsraeliPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "NonIsraeliPlanMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-Israeli [Member]", "label": "Non Israeli Plan [Member]" }
} }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r927", "r938",
"r948", "r972", "r981" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation
Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r955" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r954" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r972" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule
10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r992" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule
10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r992" ] }, "us-
gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "NON-
CASH ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncontrollingInterestMember", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label":
"Non-controlling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to
the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r61", "r383", "r1052", "r1053", "r1054", "r1056", "r1211" ] }, "us-
gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Noncurrent Assets", "terseLabel": "Total Long-
Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing
rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r267" ] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails": { "parentTag": "us-gaap_AccountsAndNotesReceivableNet", "weight": 1.0, "order": 10.0 } },
"presentation": [ "http://inmodemd.com/role/AccountsReceivableScheduleOfAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Notes receivable",
"documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net
investment in lease." } } }, "auth_ref": [ "r144", "r145", "r159", "r160", "r174", "r269", "r320", "r327", "r838", "r839", "r1033", "r1085" ] }, "us-
gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "verboseLabel": "Number of
operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it
may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are
regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for
which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up
operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r832", "r1058" ] }, "srt_OfficeBuildingMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "OfficeBuildingMember", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label":
"Office Building [Member]" } } }, "auth_ref": [ "r1218", "r1219" ] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OfficeEquipmentMember", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role":
{ "label": "Office furniture and equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to,
computers, copiers and fax machine." } } }, "auth_ref": [] }, "inmd_OneTimePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"OneTimePayment", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "One-time
payment.", "label": "One Time Payment", "terseLabel": "One-time payment" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag":
"us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": {
"label": "Operating Expenses", "totalLabel": "TOTAL OPERATING EXPENSES", "documentation": "Generally recurring costs associated with normal operations except for the portion
of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } },
"auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract",
"presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:", "verboseLabel": "OPERATING
EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "OPERATING INCOME", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r142", "r825", "r1057", "r1059", "r1060", "r1061", "r1062" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r546", "r868" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r543" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Total operating lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r543" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "terseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r543" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r544", "r547" ] }, "inmd_OperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OperatingLeaseRightOfUseAssets", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Operating lease right-of-use assets.", "label": "Operating Lease Right Of Use Assets", "verboseLabel": "Recognition of operating lease right-of-use assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r542" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Discount Rate Operating leases", "terseLabel": "Weighted Average Discount Rate, Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r549", "r868" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Lease Term Operating leases", "verboseLabel": "Weighted Average Remaining Lease Term, Operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r548", "r868" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated tax loss carryforward", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r471" ] }, "inmd_OptionsChangesDuringYear": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OptionsChangesDuringYear", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Options Changes During Year", "terseLabel": "Changes during the year:" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 80.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r79" ] }, "inmd_OtherAdvancesToSuppliersCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherAdvancesToSuppliersCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, advances to suppliers of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Advances To Suppliers Current", "terseLabel": "Advances to suppliers" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "verboseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r170" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 10.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to parent entity." } } }, "auth_ref": [ "r6", "r13", "r130" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net", "terseLabel": "Other comprehensive income, net", "verboseLabel": "Other comprehensive loss, net", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r14", "r19", "r183", "r186", "r192", "r219", "r529", "r530", "r535", "r633", "r660", "r1040", "r1041" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Change in net unrealized gains (loss) of marketable securities, net of tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r180", "r181", "r302" ] }, "inmd_OtherCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherCountryMember", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other Country [Member]", "verboseLabel": "Other [Member]" } } }, "auth_ref": [] }, "inmd_OtherCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other lease liabilities classified as current.", "label": "Other Current Lease Liabilities", "terseLabel": "Other current liabilities" } } }, "auth_ref": [] }, "inmd_OtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherCurrentLiabilitiesLineItems", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "inmd_OtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherCurrentLiabilitiesTable", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Table of other current liabilities.", "label": "Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Liabilities", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Other Expenses", "terseLabel": "Other expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r102", "r103" ] }, "inmd_OtherGovernmentInstitutionsReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherGovernmentInstitutionsReceivablesCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, government institution of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Government Institutions Receivables Current", "terseLabel": "Government institutions" } } }, "auth_ref": [] }, "inmd_OtherIncomeTaxReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherIncomeTaxReceivablesCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, income tax of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Income Tax Receivables Current", "terseLabel": "Income tax" } } }, "auth_ref": [] }, "us-gaap_OtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestments", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Investments", "terseLabel": "Other investments", "documentation": "Amount of investments classified as other." } } }, "auth_ref": [ "r651", "r1034" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 }, "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "terseLabel": "Other liabilities", "totalLabel": "Total other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r79", "r869" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
```

```
"label": "Other Liabilities, Noncurrent", "verboseLabel": "Other liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r82" ] }, "inmd_OtherOperatingExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherOperatingExpenseIncome", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 30.0 } }, "presentation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "documentation": "Other operating income.", "negatedLabel": "Other income", "label": "Other Operating Expense Income" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r964" ] }, "inmd_OtherPrepaidExpensesReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OtherPrepaidExpensesReceivablesCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount, prepaid expenses of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Prepaid Expenses Receivables Current", "terseLabel": "Prepaid expenses" } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesGrossCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "terseLabel": "Other", "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r173" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 40.0 }, "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/OtherCurrentReceivablesScheduleOfOtherCurrentReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables", "terseLabel": "Prepaid expense and other receivables", "totalLabel": "Total other current receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherReceivablesNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Receivables, Net, Current [Abstract]" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r907" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r925", "r936", "r946", "r979" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r928", "r939", "r949", "r982" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r928", "r939", "r949", "r982" ] }, "inmd_OwnershipInterestExchange": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "OwnershipInterestExchange", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest exchange for voting interest acquired.", "label": "Ownership interest exchange" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r953" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 30.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other investments", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1021", "r1046" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of ordinary shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r108" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "IPO expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payment to purchase licence", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r25", "r489" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 40.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of fixed assets", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r107" ] }, "inmd_PaymentsToTaxAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "PaymentsToTaxAuthorities", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" ], "lang": { "en-us": { "role": { "documentation": "Payments to tax authorities for Amendment to the Investments Law and settlements.", "label": "Payments To Tax Authorities", "terseLabel": "Payments to tax authorities for Amendment to Investments Law and settlements" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r963" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r963" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r955" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r972" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r965" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r954" ] }, "inmd_PercentageOfNetSalesBasedOnProductsTechnology": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "PercentageOfNetSalesBasedOnProductsTechnology", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByTechonologyDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net sales based on products technology.", "label": "Percentage of net sales based on products technology" } } }, "auth_ref": [] }, "inmd_PercentageOfNonCurrentDeferredRevenue": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "PercentageOfNonCurrentDeferredRevenue", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of non- current deferred revenue.", "label": "Percentage of non- current deferred revenue" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r956" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1012" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r955" ] }, "inmd_PrepaidExpensesAndOtherCurrentReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "PrepaidExpensesAndOtherCurrentReceivablesTextBlock", "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivables" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current receivables.", "label": "Prepaid Expenses And Other Current Receivables [Text Block]", "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES" } } }, "auth_ref": [] }, "inmd_ProceedsFromInvestmentInShortTermDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ProceedsFromInvestmentInShortTermDeposit", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from short-term deposit.", "label": "Proceeds From Investment In Short Term Deposit", "terseLabel": "Proceeds from short-term deposits" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from initial public offering of ordinary shares, net of offering costs", "verboseLabel": "Proceeds from initial public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r5" ] }, "inmd_ProceedsFromMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ProceedsFromMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 60.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represent the amount of Proceeds from maturity of marketable securities", "label": "Proceeds From Maturity Of Marketable Securities", "terseLabel": "Proceeds from maturity of marketable securities" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 50.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of marketable securities", "terseLabel": "Proceeds from sale of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised",
```

```
"verboseLabel": "Exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r5", "r17" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } },
"auth_ref": [ "r264", "r600", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r815", "r844", "r879", "r880", "r881", "r883", "r886", "r1090", "r1091", "r1104",
"r1177", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198",
"r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1208", "r1209" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } },
"auth_ref": [ "r264", "r600", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r815", "r844", "r879", "r880", "r881", "r883", "r886", "r1090", "r1091", "r1104",
"r1177", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198",
"r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1208", "r1209" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-
gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 },
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 },
"http://inmodemd.com/role/SegmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows", "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
"http://inmodemd.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "http://inmodemd.com/role/SegmentsDetails"
], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "NET
INCOME", "verboseLabel": "NET INCOME", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the
noncontrolling interest." } } }, "auth_ref": [ "r163", "r182", "r185", "r198", "r204", "r213", "r219", "r222", "r223", "r306", "r359", "r360", "r361", "r362", "r363", "r364",
"r365", "r366", "r367", "r486", "r491", "r493", "r496", "r497", "r513", "r527", "r638", "r657", "r699", "r741", "r762", "r763", "r856", "r857", "r898", "r1042", "r1098" ] },
"us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang":
{ "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://inmodemd.com/role/LeasesNarrativeDetails", "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived
Tangible Asset [Axis]", "verboseLabel": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and
services and not intended for resale." } } }, "auth_ref": [ "r9", "r551" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNet" ],
"lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT, NET", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of
business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [
"r117", "r152", "r155", "r156" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "parentTag":
"us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [
"http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment gross",
"terseLabel": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the
normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and
fixtures." } } }, "auth_ref": [ "r118", "r168", "r655" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant
and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r551" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 20.0 },
"http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation":
[ "http://inmodemd.com/role/ConsolidatedBalanceSheets", "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role":
{ "label": "Property and equipment, net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after
accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r551", "r640",
"r655", "r869" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label":
"Property and equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale.
Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r152", "r155", "r653" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock",
"presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation":
"Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets,
depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-
gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain",
"presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails", "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived
Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not
intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment,
furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r118", "r551" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant
and Equipment, Useful Life", "verboseLabel": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and
not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but
not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-
gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit",
"calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order":
30.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows",
"http://inmodemd.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleOfAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss
Expense (Reversal)", "terseLabel": "Change in allowance for credit losses of trade receivable", "verboseLabel": "Current-period provision", "documentation": "Amount of expense
(reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r197", "r317" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs
Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r953" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r953" ] }, "srt_RangeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r390", "r398", "r429", "r430", "r431", "r440",
"r519", "r572", "r581", "r597", "r675", "r677", "r685", "r710", "r711", "r773", "r777", "r779", "r780", "r784", "r811", "r812", "r837", "r843", "r851", "r861", "r862", "r866",
"r867", "r880", "r890", "r1088", "r1102", "r1150", "r1166", "r1167", "r1168", "r1169", "r1170" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://inmodemd.com/role/LeasesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails", "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r353", "r354", "r355", "r356", "r390", "r398", "r429", "r430", "r431", "r440",
"r519", "r572", "r581", "r597", "r675", "r677", "r685", "r710", "r711", "r773", "r777", "r779", "r780", "r784", "r811", "r812", "r837", "r843", "r851", "r861", "r862", "r866",
"r867", "r880", "r890", "r1088", "r1102", "r1150", "r1166", "r1167", "r1168", "r1169", "r1170" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [
"http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-
us": { "role": { "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and
amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [
"r42", "r43" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery
of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r920", "r931", "r941", "r974" ] }, "inmd_ReductionsForCurrentYearValuationAllowance": { "xbrltype":
"monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ReductionsForCurrentYearValuationAllowance", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/INCOMETAXESScheduleOfValuationAllowanceDetail", "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": {
"documentation": "Represents the amount of reductions for current year valuation allowance.", "label": "Reductions For Current Year Valuation Allowance", "terseLabel":
"Valuation allowance of net deferred tax assets", "verboseLabel": "Reductions for the current year", "disclosureGuidance": "Reductions for the current year that record against
defer tax asset" } } }, "auth_ref": [] }, "inmd_RegulationsMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "RegulationsMember",
"presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Regulations [Member]", "label": "Regulations
[Member]" } } }, "auth_ref": [] }, "inmd_RelatedPartyConsiderationForAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"RelatedPartyConsiderationForAggregateAmount", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": {
"documentation": "It represents related party consideration for aggregate amount.", "label": "Related Party Consideration For Aggregate Amount", "verboseLabel": "Related party
consideration for aggregate amount" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyDomain", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated
Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted
for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing
separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r269", "r397", "r557", "r558", "r645", "r652", "r713", "r714",
"r715", "r716", "r717", "r738", "r740", "r771" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation":
"Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees,
and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r206", "r207", "r557", "r558", "r559", "r560", "r645", "r652", "r713", "r714", "r715",
"r716", "r717", "r738", "r740", "r771" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role":
{ "label": "Payment for services received", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r73",
"r557" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionLineItems", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r269", "r745", "r746", "r749" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r269", "r397", "r557", "r558", "r645", "r652", "r713", "r714", "r715", "r716", "r717", "r738", "r740", "r771", "r1162" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/RelatedParties" ], "lang": { "en-us": { "role": { "label": "RELATED PARTIES", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r554", "r555", "r556", "r558", "r561", "r695", "r696", "r697", "r747", "r748", "r749", "r768", "r770" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Research and development", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r444", "r813", "r831", "r1171" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses [Member]", "verboseLabel": "Research and development expenses [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and development costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r443" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r921", "r932", "r942", "r975" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r922", "r933", "r943", "r976" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r929", "r940", "r950", "r983" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails", "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "verboseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r123", "r649", "r682", "r684", "r693", "r721", "r869" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r161", "r209", "r210", "r211", "r214", "r219", "r221", "r223", "r307", "r308", "r347", "r474", "r475", "r483", "r484", "r485", "r487", "r490", "r491", "r500", "r502", "r503", "r506", "r511", "r538", "r541", "r679", "r681", "r700", "r1211" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenues from customers", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r140", "r141", "r234", "r241", "r242", "r256", "r260", "r264", "r266", "r268", "r386", "r387", "r600" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Net Sales by Geographic Area", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r114" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r743", "r814", "r821" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome", "http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Revenues", "verboseLabel": "REVENUES", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r140", "r141", "r191", "r204", "r234", "r241", "r242", "r256", "r260", "r264", "r266", "r268", "r306", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r527", "r638", "r831", "r1098" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r992" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r992" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesCommissionsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesCommissionsAndFees", "crdr": "debit", "calculation": { "http://inmodemd.com/role/SegmentsDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Sales Commissions and Fees", "terseLabel": "Employee salaries including commission expenses", "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)." } } }, "auth_ref": [ "r102" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": [ "r399", "r1055" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "auth_ref": [ "r224", "r399", "r1016", "r1055" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://inmodemd.com/role/AccountsReceivableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Receivable", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r87", "r93" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Tax Expenses (Tax Benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1140" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets (Liabilities)", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1136" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Theoretical Provision For Income Tax", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r454", "r855", "r1133" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureTables" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of revenue from external customers by products and Services", "verboseLabel": "Schedule of revenues based on products' category", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [ "http://inmodemd.com/role/SegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers." } } }, "auth_ref": [ "r115" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r303", "r304", "r305", "r482", "r1017", "r1018", "r1019", "r1141", "r1142", "r1143", "r1144" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label":
```

```
"Schedule of Income Before Income Taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1050" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://inmodemd.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r21", "r94", "r95", "r96" ] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Net Investment Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": [ "r104", "r105", "r106", "r661" ] }, "inmd_ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentReceivablesTableTextBlock", "presentation": [ "http://inmodemd.com/role/OtherCurrentReceivablesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prepaid expenses and other current receivables.", "label": "Schedule Of Prepaid Expenses And Other Current Receivables [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current receivables", "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Receivables" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Warranty", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r357" ] }, "inmd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of property and equipment estimated useful lives.", "label": "Schedule Of Property And Equipment Estimated Useful Lives [Table Text Block]", "terseLabel": "Schedule of Property and Equipment Estimated Useful Lives" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails", "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": [ "r9", "r551" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r72", "r73", "r745", "r746", "r749" ] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://inmodemd.com/role/SegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "terseLabel": "Schedule of Revenue by Major Customers", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r45", "r98" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails", "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r401", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding and Exercisable Options", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Options Granted", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r15", "r16", "r125" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assumptions Used to Calculate Fair Value of Options Granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r129" ] }, "inmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases", "presentation": [ "http://inmodemd.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental balance sheet information related to leases.", "label": "Schedule of Supplemental Balance Sheet Information Related to Leases" } } }, "auth_ref": [] }, "inmd_ScheduleOfSupplementalCashFlowInformationRelatedToLeases": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "presentation": [ "http://inmodemd.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to leases.", "label": "Schedule of Supplemental Cash Flow Information Related to Leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r460", "r854" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Net Sales by Technology", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r32", "r33", "r34", "r35", "r70", "r132" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r901" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12g Title", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r904" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Name of Exchange on which Security is Registered", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r903" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r905" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r266", "r267", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r703", "r706", "r708", "r774", "r778", "r782", "r787", "r796", "r801", "r802", "r803", "r804", "r806", "r807", "r808", "r809", "r810", "r816", "r845", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r882", "r890", "r1104", "r1177", "r1181", "r1182", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1208", "r1209" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://inmodemd.com/role/Segments" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r143", "r234", "r236", "r237", "r238", "r239", "r240", "r246", "r247", "r248", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r268", "r826", "r829", "r830", "r831", "r833", "r835", "r836" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://inmodemd.com/role/ENTITYWIDEDISCLOSUREDisclosureOfRevenuesBasedOnProductsCategory" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r263", "r266", "r827", "r828", "r834" ] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "terseLabel": "Sales and marketing",
```

```
"documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expenses [Member]", "verboseLabel": "Selling and marketing expenses [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r102" ] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Amounts of severance payment expenses", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "terseLabel": "Share-based compensation expenses", "verboseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of RSU granted, per share", "terseLabel": "Fair value of RSU granted, per share", "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r419" ] }, "inmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedVested": { "xbrltype": "sharesItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedVested", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of restricted stock units vested at the end of the year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Vested", "terseLabel": "Number of RSUs vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Unvested RSUs", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r416", "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year", "periodStartLabel": "Outstanding at beginning of year", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r416", "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of RSUs granted", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r423" ] }, "inmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfShareBasedCompensationExpenseDetails", "http://inmodemd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r401", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "label": "Number of RSUs", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "totalLabel": "Total", "verboseLabel": "Number of shares authorized to be issued as ordinary shares", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r852" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of options available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Exercisable at end of year", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable at end of year", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r410" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Total intrinsic value of options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Canceled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r1112"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
"presentation": ["http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Canceled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r1112"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Stock options cancelled",
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r414"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
"presentation": ["http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Stock options granted",
"verboseLabel": "Granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r1113"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year",
"periodStartLabel": "Outstanding at beginning of year", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
"documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r408", "r409"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Number of options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding at end of year",
"periodStartLabel": "Outstanding at beginning of year", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [
"r408", "r409"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } },
"auth_ref": ["r424"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails",
"http://inmodemd.com/role/ShareholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types",
"terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r404", "r405", "r406", "r408", "r409", "r410", "r411",
"r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation":
["http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r413"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"presentation": ["http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r415"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"presentation": ["http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Forfeited", "documentation":
"Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r414"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails"], "lang": { "en-us": { "role": { "label": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r412"] }, "inmd_ShareBasedCompensationAwardTrancheFourMember": {
"xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "ShareBasedCompensationAwardTrancheFourMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Four [Member]" } } },
"auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label":
"Share-based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Tranche Three [Member]",
"documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label":
"Share-based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]",
"verboseLabel": "Share-based compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r400", "r407", "r426", "r427", "r428", "r429", "r432", "r435", "r436", "r437", "r438"] }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]",
"documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r53"] },
"inmd_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "presentation": ["http://inmodemd.com/role/ShareholdersEquityNarrativeDetails",
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "The floor of a range of exercise prices for purposes of disclosing shares potentially issuable under outstanding and exercisable stock option awards on all stock option plans and other required information pertaining to awards in the range.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price", "verboseLabel": "Exercise prices" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r54"] }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails"], "lang": { "en-us": { "role": { "label": "Number of options exercisable at end of year", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r52"] }, "us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails"], "lang": { "en-us": { "role": { "label": "Number of options Outstanding and exercisable at end of year", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": ["r126", "r127"] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails", "http://inmodemd.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "label":
"Employees, officers and directors [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420",
"r421", "r422", "r423", "r424", "r425", "r428", "r429", "r430", "r431", "r432"] }, "inmd_SharePurchaseAndShareholdersAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://inmodemd.com/20241231", "localname": "SharePurchaseAndShareholdersAgreementMember", "presentation": ["http://inmodemd.com/role/OtherInvestmentsDetails"],
"lang": { "en-us": { "role": { "documentation": "Share Purchase and Shareholders Agreement [Member]", "label": "Share Purchase And Shareholders Agreement [Member]",
"verboseLabel": "Share purchase and shareholders agreement [Member]" } } }, "auth_ref": [] }, "inmd_ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "ShareRepurchaseProgramMember", "presentation": ["http://inmodemd.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Member]" } } }, "auth_ref": [] },
"inmd_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriod", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails"], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "negatedLabel": "Canceled", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Canceled In Period",
"verboseLabel": "Canceled" } } }, "auth_ref": [] },
"inmd_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType",
"nsuri": "http://inmodemd.com/20241231", "localname":
"SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledWeightedAverageGrantDateFairValue", "presentation": [

```
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the per share amount of share-based compensation arrangement by share-based payment award, equity instruments other than options canceled weighted average grant date fair value.", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Canceled Weighted Average Grant Date Fair Value", "verboseLabel": "Canceled" } } }, "auth_ref": [] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life", "verboseLabel": "Weighted average remaining contractual life of exercisable options", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r51" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Unvested options", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding options", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r128" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vested options", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r423" ] },
"inmd_SharesAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "SharesAuthorizedAmount", "crdr": "credit",
"presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares authorized amount.", "label":
"Shares authorized amount" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesIssued", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Ordinary shares of Medimor", "verboseLabel": "Ordinary shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r14" ] }, "us-gaap_SharesIssuedPricePerShare": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "inmd_ShortTermBankDepositsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "ShortTermBankDepositsPolicyTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Disclosure of accounting policy for short-term bank deposits.", "label": "Short Term Bank Deposits Policy Text Block", "verboseLabel": "Short-term bank deposits" } } }, "auth_ref": [] }, "inmd_ShortTermDepositsAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"ShortTermDepositsAnnualInterestRate", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": {
"documentation": "Short-term deposits annual interest rate.", "label": "Short Term Deposits Annual Interest Rate" } } }, "auth_ref": [] }, "us-
gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r112", "r202" ] }, "us-
gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantSupplyCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/CommitmentsAndContingentLiabilitiesDetails" ],
"lang": { "en-us": { "role": { "label": "Supply and open orders commitment", "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers." } } }, "auth_ref": [ "r83", "r136" ] }, "inmd_SpaMedicalInternationalLsrlMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"SpaMedicalInternationalLsrlMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Spa Medical International SRL [Member]", "label": "Spa Medical International Lsrl [Member]" } } }, "auth_ref": [] }, "inmd_SpecialPreferredEnterpriseMember": { "xbrltype":
"domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "SpecialPreferredEnterpriseMember", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Special Preferred Enterprise [Member]", "label": "Special Preferred Enterprise [Member]" } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StandardProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfAccruedWarrantyDetails" ],
"lang": { "en-us": { "role": { "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year", "label": "Standard Product Warranty Accrual", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": [ "r1093", "r1096" ] }, "us-gaap_StandardProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StandardProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfAccruedWarrantyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost incurred", "label": "Standard Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties." } } }, "auth_ref": [ "r1094" ] }, "us-
gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StandardProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfAccruedWarrantyDetails"
], "lang": { "en-us": { "role": { "label": "Expense recognized", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": [ "r1095" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"label": "Warranty reserve", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } },
"auth_ref": [ "r1092" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementEquityComponentsAxis", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label":
"Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r86", "r90", "r91", "r161", "r188", "r189", "r190", "r209",
"r210", "r211", "r214", "r219", "r221", "r223", "r235", "r307", "r308", "r347", "r383", "r474", "r475", "r483", "r484", "r485", "r487", "r490", "r491", "r500", "r501", "r502",
"r503", "r504", "r506", "r511", "r529", "r531", "r532", "r533", "r534", "r535", "r538", "r541", "r553", "r660", "r679", "r680", "r681", "r700", "r764" ] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails"
], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r266", "r267", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609",
"r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r703",
"r706", "r708", "r774", "r778", "r782", "r787", "r796", "r801", "r802", "r803", "r804", "r806", "r807", "r808", "r809", "r810", "r816", "r845", "r871", "r872", "r873", "r874",
"r875", "r876", "r877", "r878", "r882", "r890", "r1104", "r1177", "r1181", "r1182", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193",
"r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1208", "r1209" ] }, "us-gaap_StatementLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://inmodemd.com/role/DocumentAndEntityInformation",
"http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r209", "r210", "r211", "r235", "r541", "r600", "r686", "r701", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r723", "r724", "r725", "r726", "r727",
"r729", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r738", "r740", "r743", "r744", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759",
"r760", "r761", "r764", "r891" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract",
"lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label":
"Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-
us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r224", "r399", "r1016", "r1020", "r1055" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
"http://inmodemd.com/role/DocumentAndEntityInformation", "http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statement [Table]",
"documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r209", "r210", "r211", "r235", "r269", "r541", "r600", "r686", "r701", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r723", "r724",
"r725", "r726", "r727", "r729", "r730", "r731", "r732", "r734", "r735", "r736", "r737", "r738", "r740", "r743", "r744", "r750", "r751", "r752", "r753", "r754", "r755", "r756",
"r757", "r758", "r759", "r760", "r761", "r764", "r891" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r924", "r935", "r945",
"r978" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Initial public offering of ordinary shares, net of offering costs, shares", "verboseLabel": "Issuance of shares", "documentation":
"Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r85", "r86", "r123", "r691", "r764", "r792" ] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity",
"http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised", "label": "Exercise of options, shares", "terseLabel": "Exercise of options (Shares)", "verboseLabel": "Exercise of options and vesting of RSUs (Shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r85", "r86", "r123", "r413" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of options", "terseLabel": "Exercise of options", "verboseLabel": "Exercise of options and vesting of RSUs", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref":
[ "r14", "r86", "r90", "r91", "r123" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockRepurchasedDuringPeriodShares", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "verboseLabel": "Repurchase of ordinary shares, shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r85", "r86", "r123", "r692", "r764",
"r793" ] }, "inmd_StockRepurchasedDuringPeriodValueOne": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"StockRepurchasedDuringPeriodValueOne", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": {
"documentation": "Repurchase of ordinary shares.", "label": "Stock Repurchased During Period Value One", "verboseLabel": "Repurchase of ordinary shares" } } }, "auth_ref": [] },
"inmd_StockRepurchasedOrdinarySharesDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"StockRepurchasedOrdinarySharesDuringPeriodShares", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": {
"role": { "documentation": "Repurchase of ordinary shares, shares.", "label": "Stock Repurchased Ordinary Shares During Period Shares", "terseLabel": "Repurchase of ordinary shares (Shares)" } } }, "auth_ref": [] }, "inmd_StockRepurchasedOrdinarySharesDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231",
```

```
"localname": "StockRepurchasedOrdinarySharesDuringPeriodValue", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Repurchase of ordinary shares value.",
"label": "Stock Repurchased Ordinary Shares During Period Value", "terseLabel": "Repurchase of ordinary shares" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "TOTAL
SHAREHOLDERS\u2019 EQUITY", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
} } }, "auth_ref": [ "r86", "r90", "r91", "r116", "r722", "r739", "r765", "r766", "r869", "r899", "r1049", "r1084", "r1154", "r1211" ] }, "us-gaap_StockholdersEquityAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "InMode Ltd. shareholders' equity:", "terseLabel": "SHAREHOLDERS\u2019 EQUITY:"
} } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending Balance", "periodStartLabel":
"Begining Balance", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY", "documentation":
"Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r61", "r62", "r65", "r161", "r162", "r189",
"r209", "r210", "r211", "r214", "r219", "r221", "r307", "r308", "r347", "r383", "r474", "r475", "r483", "r484", "r485", "r487", "r490", "r491", "r500", "r501", "r502", "r503",
"r504", "r506", "r511", "r529", "r531", "r535", "r539", "r553", "r680", "r681", "r698", "r722", "r739", "r765", "r766", "r794", "r898", "r1049", "r1084", "r1154", "r1211" ] },
"us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": {
"en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://inmodemd.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } },
"auth_ref": [ "r122", "r203", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r383", "r508", "r767", "r769", "r795" ] }, "us-
gaap_StockholdersEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplit",
"presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Stock split", "documentation": "Description of the
stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements." } } },
"auth_ref": [ "r124" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember",
"presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": {
"role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or
available to be issued." } } }, "auth_ref": [ "r536", "r564" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTypeAxis", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails",
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event
that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r536", "r564" ] }, "us-
gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://inmodemd.com/role/Entity-wideDisclosureNarrativeDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label":
"Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }
}, "auth_ref": [ "r536", "r564" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://inmodemd.com/role/SUBSEQUENTEVENTS" ],
"lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or
transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.
Examples include; the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to
insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r563", "r565" ] }, "srt_SubsidiariesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SubsidiariesMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Invasix UK [Member]" } } }, "auth_ref": [ "r1105", "r1159", "r1160", "r1162" ] }, "inmd_SubsidiariesOutsideIsraelMember": {
"xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "SubsidiariesOutsideIsraelMember", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails", "http://inmodemd.com/role/TaxesOnIncomeScheduleOfIncomeBeforeIncomeTaxesDetails",
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfTaxExpensesTaxBenefitDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsidiaries outside Israel [Member]",
"label": "Subsidiaries outside Israel [Member]", "terseLabel": "Subsidiaries outside of Israel [Member]", "verboseLabel": "Subsidiaries [Member]" } } }, "auth_ref": [] },
"inmd_SubsidiaryInStateMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "SubsidiaryInStateMember", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for subsidiary in state.", "label": "Subsidiary
In State [Member]", "verboseLabel": "Subsidiary in state [Member]" } } }, "auth_ref": [] }, "inmd_SubsidiaryInUnitedStatesMember": { "xbrltype": "domainItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "SubsidiaryInUnitedStatesMember", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us":
{ "role": { "documentation": "This member stands for Subsidiary in United States.", "label": "Subsidiary In United States [Member]", "verboseLabel": "Subsidiary in U.S.
[Member]" } } }, "auth_ref": [] }, "inmd_SubsidiaryOfHomeSkinnovationsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"SubsidiaryOfHomeSkinnovationsLtdMember", "presentation": [ "http://inmodemd.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsidiary Of
Home Skinnovations Ltd [Member]", "label": "Subsidiary of Home Skinnovations Ltd [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale
of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeTables" ], "lang": { "en-us": { "role": { "label": "Summary of
Valuation Allowance [Table Text Block]", "verboseLabel": "Schedule of valuation allowance", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax
assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the
valuation allowance." } } }, "auth_ref": [ "r1137" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role":
{ "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r971" ] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Tax Adjustments, Settlements, and Unusual Provisions", "verboseLabel":
"Payment of income tax assessment with tax authorities", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to,
significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax
settlement." } } }, "auth_ref": [ "r1140" ] }, "inmd_TaxBenefitYear": { "xbrltype": "durationItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "TaxBenefitYear",
"presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax benefit in years.", "label": "Tax benefit
year" } } }, "auth_ref": [] }, "inmd_TaxRateForRecipientForDividendsDistributedByPreferredCompany": { "xbrltype": "percentItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "TaxRateForRecipientForDividendsDistributedByPreferredCompany", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ], "lang": { "en-us": {
"role": { "documentation": "Tax rate for recipient for dividends distributed by Preferred Company from income derived from its PTE or SPTE.", "label": "Tax Rate For Recipient
For Dividends Distributed By Preferred Company" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "TitleOfIndividualAxis", "presentation": [ "http://inmodemd.com/role/SegmentsDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": {
"en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1064", "r1161" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://inmodemd.com/role/SegmentsDetails", "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position
[Domain]" } } }, "auth_ref": [] }, "us-gaap_ToolsDiesAndMoldsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ToolsDiesAndMoldsMember", "presentation": [ "http://inmodemd.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
"http://inmodemd.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Molds [Member]",
"documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale." } } }, "auth_ref": [] },
"inmd_TotalLongLivedAssetsByGeographicalArea": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"TotalLongLivedAssetsByGeographicalArea", "crdr": "debit", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails" ], "lang": {
"en-us": { "role": { "documentation": "Represents the amount of long lived assets by geographical area.", "label": "Total Long Lived Assets By Geographical Area",
"verboseLabel": "Total long-lived assets by geographical area" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r963" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder
Return Vs Peer Group" } } }, "auth_ref": [ "r970" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r991" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading
Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r993" ] }, "dei_TradingSymbol": { "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://inmodemd.com/role/DocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments
[Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial
instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on
potentially favorable terms." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286",
"r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r369", "r381", "r507", "r526", "r566", "r567", "r568",
"r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591",
"r592", "r593", "r594", "r595", "r596", "r661", "r858", "r859", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r870", "r1026", "r1027", "r1028", "r1029", "r1030",
"r1031", "r1032", "r1080", "r1081", "r1082", "r1083", "r1146", "r1149", "r1150", "r1151", "r1152", "r1153" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r994" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrExpirationDate": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r995" ] }, "ecd_TrdArrIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } },
"auth_ref": [ "r993" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } },
"auth_ref": [ "r993" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement,
Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r996" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-
us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r994" ] }, "inmd_TreasurySharesPolicyTextBlock": {
```

```
"xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "TreasurySharesPolicyTextBlock", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy treasury shares.",
"label": "Treasury Shares Policy Text Block", "terseLabel": "Treasury Shares" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury shares [Member]", "documentation":
"Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r49" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury shares, ordinary shares", "documentation": "Number of
previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r49" ] }, "us-gaap_TreasuryStockValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": {
"http://inmodemd.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 40.0 } }, "presentation": [
"http://inmodemd.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Less treasury shares, at cost: 18,025,003 and 1,975,003 ordinary shares
at December 31, 2024 and 2023, respectively", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and
preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r49", "r50", "r86", "r90" ] },
"inmd_TwoPurchaseAndShareholdersAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"TwoPurchaseAndShareholdersAgreementsMember", "presentation": [ "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Two
Purchase And Shareholders Agreements [Member]", "label": "Two Purchase And Shareholders Agreements [Member]", "verboseLabel": "Two purchase and shareholders agreements
[Member]" } } }, "auth_ref": [] }, "inmd_TwoThousandsEighteenIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"TwoThousandsEighteenIncentivePlanMember", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation":
"2018 Incentive Plan [Member]", "label": "Two Thousands Eighteen Incentive Plan [Member]", "terseLabel": "2018 Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-
gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://inmodemd.com/role/LeasesNarrativeDetails", "http://inmodemd.com/role/OtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and
Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-
generating activity or operations." } } }, "auth_ref": [ "r492" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname":
"US", "presentation": [ "http://inmodemd.com/role/Entity-wideDisclosureScheduleOfLong-livedAssetsDetails", "http://inmodemd.com/role/Entity-
wideDisclosureScheduleOfNetSalesByGeographicalAreaDetails" ], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "auth_ref": [] }, "us-
gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails",
"http://inmodemd.com/role/MarketableSecuritiesAndFairValueMeasurementsScheduleOfMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Government bonds
[Member]", "terseLabel": "U.S. Government bonds [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but
not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for
example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home
Loan Bank (FHLB)." } } }, "auth_ref": [ "r822", "r846", "r1173" ] }, "inmd_UndistributedExemptIncome": { "xbrltype": "monetaryItemType", "nsuri":
"http://inmodemd.com/20241231", "localname": "UndistributedExemptIncome", "crdr": "credit", "presentation": [ "http://inmodemd.com/role/TaxesOnIncomeNarrativeDetails" ],
"lang": { "en-us": { "role": { "documentation": "Undistributed exempt income.", "label": "Undistributed exempt income" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying
Security Market Price Change" } } }, "auth_ref": [ "r990" ] }, "inmd_UnitsChangesDuringYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "UnitsChangesDuringYearAbstract", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ], "lang": {
"en-us": { "role": { "verboseLabel": "Changes during the year:" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Balance at December 31",
"periodStartLabel": "Balance at January 1", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r446", "r460",
"r854" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in uncertain tax positions for the
previous years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits
resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r461", "r854" ] }, "us-
gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [
"http://inmodemd.com/role/TaxesOnIncomeScheduleOfUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "label": "Increase in uncertain tax positions for the
current year", "verboseLabel": "Increase in uncertain tax positions for the current year, net", "documentation": "Amount of increase in unrecognized tax benefits resulting
from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r462", "r854" ] }, "us-gaap_UseOfEstimates": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://inmodemd.com/role/SignificantAccountingPoliciesPolicies"
], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial
statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r36", "r37", "r38", "r149", "r150", "r153", "r154" ] },
"inmd_UtilizationOfCarryForwardTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "UtilizationOfCarryForwardTaxLosses",
"crdr": "debit", "presentation": [ "http://inmodemd.com/role/INCOMETAXESScheduleOfValuationAllowanceDetail" ], "lang": { "en-us": { "role": { "label": "Utilization Of Carry
Forward Tax Losses", "documentation": "Utilization of carry forward tax losses.", "terseLabel": "Utilization of carry forward tax losses" } } }, "auth_ref": [] }, "us-
gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [
"http://inmodemd.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road
transportation." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis",
"presentation": [ "http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by
vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114",
"r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ] }, "us-
gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://inmodemd.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment
arrangement." } } }, "auth_ref": [ "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120",
"r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r959" ] }, "inmd_WarRiskSituationInIsraelPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "WarRiskSituationInIsraelPolicyTextBlock", "presentation": [
"http://inmodemd.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for war risk situation in
Israel.", "label": "War Risk Situation In Israel [Policy Text Block]", "verboseLabel": "War risk situation in Israel" } } }, "auth_ref": [] }, "srt_WarehouseMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WarehouseMember", "presentation": [ "http://inmodemd.com/role/LeasesNarrativeDetails" ],
"lang": { "en-us": { "role": { "label": "Warehouse [Member]" } } }, "auth_ref": [ "r1218", "r1219" ] }, "inmd_WarrantyReserveLiabilityCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://inmodemd.com/20241231", "localname": "WarrantyReserveLiabilityCurrent", "crdr": "credit", "calculation": {
"http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 40.0 } },
"presentation": [ "http://inmodemd.com/role/OtherCurrentLiabilitiesScheduleOfOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Warranty reserve
liability current.", "label": "Warranty Reserve Liability Current", "verboseLabel": "Warranty reserve" } } }, "auth_ref": [] },
"inmd_WeightedAverageExercisePriceChangesDuringYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"WeightedAverageExercisePriceChangesDuringYearAbstract", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedDetails" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Exercise Price Changes During Year Abstract", "terseLabel": "Changes during the year:" } } }, "auth_ref": [] },
"inmd_WeightedAverageGrantDateChangesDuringYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231", "localname":
"WeightedAverageGrantDateChangesDuringYearAbstract", "presentation": [ "http://inmodemd.com/role/ShareholdersEquityScheduleOfOptionsGrantedRestictedShareUnitDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Changes during the year:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel":
"Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based
on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r226", "r231" ] },
"inmd_WeightedAverageNumberOfSharesOutStandingUsedInComputationOfNetIncomePerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inmodemd.com/20241231",
"localname": "WeightedAverageNumberOfSharesOutStandingUsedInComputationOfNetIncomePerShareAbstract", "presentation": [
"http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Out Standing Used In Computation Of Net
Income Per Share Abstract", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF EARNINGS PER SHARE" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://inmodemd.com/role/ConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label":
"Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently
issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units
have been outstanding to the total time in that period." } } }, "auth_ref": [ "r225", "r231" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r957" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10",
"Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" },
"r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480420/718-10-50-1" }, "r11": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479353/942-405-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
```

```
"50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r165": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r236": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/280/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r238": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r241": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r248": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-29" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-
30" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-32" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r262": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r264":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-41" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r267": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r270": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-
50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" },
"r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r276": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r279":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r282":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r285": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r288":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" },
"r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" },
"r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r296": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-
5B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-
9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r304": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r307":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher":
```

```
"FASB", "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A" }, "r312":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-
45-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-
13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r321": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-
50-17" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-3C" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D" }, "r326": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.2.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483530/326-
20-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30",
"Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479148/326-30-35-13A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A" }, "r332": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-
50-3A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-3D" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r339": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/330/tableOfContent" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r341": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" },
"r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r345": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r348":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r351":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r354":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.02)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-
8" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r360": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r361": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r362": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r366": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r367": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r371": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-
13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-
14" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r379": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-
18" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r383": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r384": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher":
```

"FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r527": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r531":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-
20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r537": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" },
"r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/842-20/tableOfContent" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" },
"r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r543": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r546":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" },
"r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r550": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-
65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/850/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r559":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-
50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-
50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r567": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r568": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r572": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r576": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r579":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r582":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" },
"r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r586": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" },
"r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r590": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" },
"r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r594": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" },
"r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name":
```

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r602": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-18" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-23" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r609": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-23" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r613": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-31" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r617": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-
5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r621": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-
5" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-
8" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r628": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r631": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r632": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r633": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r634": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r635": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r636": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r637": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r638": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r639": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r675": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" },
"r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r679": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" },
"r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph":
"2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r683": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r684": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r694": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-
50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r699": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r703": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r704": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r705": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r706": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r710": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-
3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-
2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r769": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-
1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r773": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r774": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r775": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-
2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r794": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r796": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r797": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r799": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-
1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r813": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section":
"55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" },
"r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)",
"SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r817": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r820":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r824": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph":
"(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-31" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r827": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph":
"(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" },
"r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r831": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r833":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" },
"r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r837": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r839":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic":
"30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" },
"r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-
20-55-69C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r844": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" },
"r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r848": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r851":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r854": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" },
"r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-43" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-
55-4K" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r861": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" },
"r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r864": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph":
"(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" },
"r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r868": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r870":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic":
"235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" },
"r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-29" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "1", "Paragraph": "a" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
```

```
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r978": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r981": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "ii" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r987": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "C" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r990": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "F" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "1" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r995": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "C" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "106" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106",
"Subsection": "b", "Paragraph": "1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106",
"Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1007": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" },
"r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2",
"Subparagraph": "iii" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1011": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "B", "Clause": "1", "Number": "229" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1013": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1014": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1015": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1016": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1017": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1018": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1019": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1020": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1021": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-
50-1B" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI":
"https://asc.fasb.org/321/tableOfContent" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325",
"Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1027": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher":
"SEC" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b",
"Subparagraph": "(2)", "Publisher": "SEC" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section":
"1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1032": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)",
"Publisher": "SEC" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph":
"a", "Publisher": "SEC" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1035": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1036": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1037": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1038": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1039": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1040": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-
50-5" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1047": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1048": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1049": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1050": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1051": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1052": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1053": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1056": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1059": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-32" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1063": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/310-10/tableOfContent" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1065": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1067": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1068": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-
2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1072": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1073": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1074": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1075": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-
3" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1079": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1080": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1081": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1082": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1083": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1084": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1085": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-
50-13" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher":
"FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-
10" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" },
"r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1092": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1093": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1094": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1095": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1096": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1097": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1098": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1099": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1100": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1101": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1102": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1103": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-5" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1106": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1107": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1108": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1109": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1110": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1111": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1112": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1115": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1116": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1117": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1118": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1119": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1120": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1121": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1122": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1123": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1124": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1125": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1126": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1127": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1128": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1129": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1130": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

```
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1131": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1132": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1133": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-
15" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-
3" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-
50-1A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1143": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1144": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1145": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1146": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-
2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1150": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1151": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1152": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-
28" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1158": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-
1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-
7" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1165": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1166": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1167": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1168": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1169": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1170": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1171": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942",
"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-
2" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-
2B" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1179": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1180": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1181": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1182": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1183": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1186": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1187": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1188": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1189": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1190": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1191": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1192": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1193": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1194": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1195": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1196": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1197": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1198": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1199": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b){1}", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1200": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b){2}", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1201": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b){3}", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1202": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1203": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1204": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1205": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1206": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1207": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1208": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1209": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1210": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1211": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1212": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1213": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1214": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1215": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1216": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1217": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1218": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1219": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 108 0001178913-25-000314-
xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178913-25-000314-xbrl.zip M4$L#!!0 ( (TX1*K-I9G2)RL '4G 0 0 97AH:6)I=%\Q,2TQ+FAT M;>UI:W/;1K;@]ZW: X"KN;F1JB@*[X?MI,J)GIG75<-
K.W=J]UMWHR$B!@$_ M $KF_/H]YW0W"(*@1%*6+,7TU$0D"!*!?Y_U\,6UGQ0 _^W]9UHNI9*E]@L]M MWA;RAQ??J;_ZXG^53-6?CNQZ,K$:F2=9\\MNKO)_RV?68X];Y];K?S4GK,B MORR?687,X J-
\\SZFTW_GI^HV=^NZ'6]99?RM\6_R J=;&3[#?S^OOGFFV _MO-/\RFSEM+;HU=^?P':VLNXFS;LZE3[(697RN:6^G?.J;:L93&S^R6JJ(D\M M7C#OL?NIK>;/+' XXU3B9M)R/JTFKS8)'H5[+NMJ4:;GPY_Z*U?3>Vf-6'V9
ME^>X$<\LMFBK[E*M1J%K)V9]L%2SHO[;Z%ZXZP7N!MHY7>0)JI(\8;%#Z\ M37.> 5 J+5X;@' B#?^\(+79I#OS(:V/N$'R]PSN'[5W,Q*B[R4Y]W>7;B! MAHWMD*0 J0]'5Z5.60G/-5-6%.>"S10]RV"=:\I?
JU1:0[3IQ6JRZW/<-I 1 M,486=/\+? W-'>WGV]Z_VQZ,G=D^.[*V[NT+P!UI0'W M"2 ? --UB;>!@85KC[UO!"\(#/=I]W8J%W=(18QH2^ MZX> A1E{L:C5%L:WKJ?(3 /2FE=-(YLFAS?"0&? ?^&8"P2J\ F"P[+AIJRJ
MX0>XV<*BW=5;") @,&&?8?UE6UGM=67-6=TV>Y"DOR"H91SF+F11-',F8*G2 MG]@G]'W.TM3\ SS,? V'\^?LEBA8TWQ \NK]VY] R9OV T[UQ,K3]T ^;=0, MC+2K9YT:Z(D/J>FH7IF;G!0!U0*[5A M;7K+DTZ,"
[R2=9L+5IAU@4@ KW,N=GB!(D-C+[#&,/MD[7G:M7X ,WRNFD) M#4;"8!RUM8%T&=F=4:4HP>$GRM!S_EQ""=D$E47:11%$E\+,L!EF> M\3#RW8 G6> XMI12",&DX(\)5=R'1!6@X!4 '>%*/@/:#4>$D(+ A0(B55N M3\
$',&]I)$M)S00 Z/,4;][WP)Z-/B[84>O/XDI*T%5>PF/PLU.XOF G,WZ M-E@6 ST1^W+0 \@$/GUCY.DI?RUI:S/KCXOT%\+=F 3+$;5M=2KBG!@AO MIW1WCX#L.@DS@)9,FHV)X/' +L,V&WI7T:!#ZC/&U><* M%-
HI;RT&*Y4:>(!,%?E''7 @W"[Q=&&DF<4$4%J"EKY@L"D76(Q7BW9M(T\! MWPM%$HOE/ML$2 ('_-,=;!/*(%(F&N#8+*Y%8. \^] (NO!4B2=J(?D&-;V M3$5A4=98H$*^Q\\+H)PO48%L/XO
QK *RL$FXPBB9CF,@.^5@)KPDW2J &' M"AL >,B:T<=Z4NGOYHD*I*&%F.K#GP.DX/8V< !+1"] X J$;,*CZ)-5+]\" M%C>,M1\2;3Z _<$XO:RN9E8+C +G1W^!+.&B4EE{X{DC,+Cr&5ULG@Ie(Y C MW!)-$V ?
2HGPRFH$X^&&U#)#>%2[JPC"0?/D1ZD@ 5Y*0X G=0X .P>{G2]J MQ4WT+YD${@7>RI#P:X;0!4X)R.F64T%BB#@>6J=Y%KETKSGXL1Z#QP^0$#J# MU!Y8R. &J0+P;B1i$@#<;+$& 5.Y1:.4WSDDGCP%\2'" 9'H--
W!H%;14N M%8Z]D2C!%,5$D3EV#4 +X$GH=ITW2GV2VQ4GN%=M "H^"HC[DX+?Z%5PXZ)M M\O4W*>)E-D\QY4M80]..:Y0 W"/DU+8=F!>RFS>>*DP,#JF8(^4R]B"^MJ[ON M%T3+<0 43N*VBV%A7@;XHJ["*YJF$CE96SNNIF?9\
<3^NO+RJBJN4--KK!-5 M,",#,88&XA[*>-83=X29QE M+1KW6 $$JEE3"-#26%;-% C"]R?ZP\ -<*[5#F7 WjQ39?2W-XR4YMC=ON'_ M=HOER;HQ\4[VXOUMYD-;W/5&".K^^.4CNLD:}SHS5N2*&*ZL6K..J M3-68P'X)JA''
^PN UUT#%I/.5(%P4N=7C(P9O3DI!HH\5$D8ZX:1P8Z ]$I[ M6"%-;M74403&^F+?/N;PW7UN#P$KVTR?NQE.QTU:WXY98D=MJ9U4O,6DNB;< M=B(OGM\6J"GWU>B08'}K[I%F4"KNWN*_T\KE"QA$K,'_"JU
}*#U7H$VL1H4#:G%M*K8_<3-@7DL_"F*#%XX9P+|;.[R5%WR-)WZ-$E861ZZ30)$?I)XO M;(\YF>?Z8>8$S'4Y/]"'Y GWX9AX^5","8#>F[5P^+QBI$#AM]%SXO[&3&-4 M=J4P9YFL^T;"82V\_"
M*_J"QX3*/SX}5/Y85MSGIZT^?SD;*5?C)@\ M!Y_",KJ7(*;@&1EB,DK(W';-Z*H&JG$O/[_:*,;S+;SL<]3*LZ_[>E3GZ M^W?&1>$[W M#) $C0+\H UP,(EOX<#UEF3C0<'$ N/C3T\/%,;9J]?FEP=.^ M7?
I^F6B \ZP=8J$P3AS$*600U#LSN[0-B&I1-^3#0L45)H=5U_X*BB,?>C0N MK,"WE^A16*-M1"%N6>P8.1LN>YVZD=0#]&UR! )V*#W[!DC)#MH[< @DB8S'G
M;A5X=B@2Z7JIG\4\=IPPX>YCHF20'HJ2_5PIHJ+C!XRO>6(MJX753,FI5\HK MI?>4Y.5$^.U\G'WSW.D:8&/@J_*QKA$X5A!]6#UVMHU,;;CW<$Y3=B5A=_8H M20.$[UQB#$W/)XVXMD+V15E@H P\.T1K%=PHJK)9%(HRJ5 ?
1=1HYBR]HGUA MGN3YO"3UAC.CKB[.^YZDK87 M))'T{IEZO?;@N!M=;#60G?SP^J&PMNXJTF;4&=QLG4Z>Q9,UIP(:5WO! M$NMV8?B1"5'5*8%TQZ4!ZH5,%S7&,LH6CKANIRNP[L.U5H,?HQ;\-;FWW:-[ M^VE3.NZZ<1C'-K-
!Q1)>%J>AR!+)@L3_ L;3AW{4>U 44?P*.;B),KUW_ %? MB5/:GI.%FDX;14O? MW'+ UD+W0QR6*L=J7F"\8@E*WTB0'HJNGKI=B].[..F<160F.PM@4L%EX-$T"2Z$??D810O52^JV(YE'1K>9EO,)$6$ 8-OA215H>,U*"DM&?
1]$#W@2A RHW,V; M^CL^2 8'$W;Z. 65^XPFZ(-+*N'ML%N=J)=5!4 77M)1WP2HW0GTLQ XWKU MA[Q1N5!W8XBABX+!JO-VH<(@GWV5KD@G#>W C0,W9)F?> '5"83-PQ"3R09
M]PZCP8% $1Z<)NTZ%UZPG1+G=Z/$HT1W14Q:$J2 &<{$"@:%E#3/C5Q^9 B2 M01#9=N+%%>C[=6<@GB0*/L[*1-AI"C30 8KWV)P]=<"\ M#\A,0=XKJC#\)XTGUF;/\4F?6U-8E&GU*DF9 ;2\Q2X[D&WH+$6#W
MT98X]S{GPC1F!SAUG"11F-E!8DLNN!O:3QQ@K^X!7HO\7XL\1<\D\&[8R=D1 MX/;AD+[C^G$0@(K.?,]W>!K&(HI2&^M.Q/Q ]?RQ _Q]P%M/=)2L+N%D&PNI MW8P2U8$>+LI%@[E7E*Z'%PK2L &!&?
L375)ST{J/I'%/2$U\7X)XR9CCIWX4 M^XF=I7X:>FGL_>Z[XHE#ZGVP<@5NGW4=F 8P;&!<&$& R8T:P?9'"-W#H1\Y M09@POTY8Z(>1QUPA'-N5T@$]6\;.4X?0^P!1V//":=1E"0*IKLODTPBFT_#=^ X;-YWL+$5"@?
P@K0YE9>Y@+C-0)5+;4_L:[,.8RN'RVH M8"_Y.NH:$4I/$/%'AUHU)M:*(CVP\%#+ -DP.HK,74?\VB<$FH5!X@9^%@@0 MBA/F9<()DPC^1AZ/#DQ'>"SX]6#H18E"I+X!1 [2@HX4?S^(=+B{F9 I@*30 M1BE+HR@+/>
[;$LA ^,3MK)_N*' L#I)}(VL)TP$.D"X$>HE[-EER#+3JEZ,1 M83] 98X;9RSCF'5ITVF.<7AX$%9&6P7;@VETH#E7.@,. M,@?^E+WRQABA)UC3-A?6/S'D3)>2H:A!*UN@9DL*=KNJ+L2T(MU5(>RITT.I
MC%+^^BO1I>E0158+D04I-Z1B?MOT %ND]%/U1!5WJ1.X,-(2\\:RC0LJS;.Z7X!X(DIZK2 M.U?C,:M@55[L1;]2>PN 'RQ+ MFI=66BUXJ[-533YL+PIO/-^SERBVEN0V!X!<8"AOVI EPKHU=/A-1J]!L%F4
M#8*QF9!&,AH)LE(GN0P6GO9!653 MX;>MZ=^GNB3>E-&-IG089GV74E%JB@;/VS-=^EC5"\9R[?6*FHSDK<=MIK3K MH)8%$1]E3 5{0?K0D;PMV+U_?;& @I2;12ESA1VC'*14!LI^G(60% MI%$5.
M%CZJK),`J]BR2]9)5Q3LjK23M7++8VDG5*Y[+=%DF%$QS)(>UH)A?12;'-?45@8Y+F/E*O& M%Z6I7#/8.729%JK6!I%)>)YC33H\;UTR6W/9[M$OK0H9)FHK)DK_#T@]'9.%?MM:!$0K+E]GQDJ:I=QV
M(S>V4^[715$7B8=6P:N'2,2/;"K5V.Q,CR806P-0:Y87A T$*UL)+6X0)EH MKNK3L6+9"/<'KZN/1$,)&J*\'6#<+CUPGNK+5P%<ZXL+XG4<)*M2^GXS-R-Y@@4AM"(@UV8+ZR7Y?*Q^A1O,F]I?V&MWA-
>1$'/BXA(\,ZUHQBCWO:.P@&)K.35@Q6CM]5RBP> M.9[/%9)O54NH[GP,C%=7'0FO)9G?585!)+4 1DH(>=<!'^%^3#5O+F;3>S>K=P]; AU22PM8&'I*:)!W*455HQ[ MX,C8.0<^H_Q*$-=G*+MV$JA[!D%\2MQK@".K4K?
ZQTI7@NZ1=@-09"['VD7- M($;,C)!MR\14Q;^^6/SP'C]CA-5+M!RIL8;2X C=D$M3TO5,990A3<* L -4 MH4\6LJ7:3'J*?:IGCPT!<$XD?6D;7MVL3E%5=<)R.66. -X53$H59CPA$+.Q%12H<7D47K_>8Z<4:IRJ@GIM=40$*#6)?
BNVU-M26P9QDY^-?J1DX(F))W4]8+0MY.8>3RRF61)D-EI?*@9^6OT9PS1\.C0V \2 M7<]. 9$QAC01+Q(Q]UP1NQ%/PS!Q[E+A]2Z*^KWU'KYGS?Q +$"*PH@@:P,N M+9-QN@/QS)L^S4U-;E(7]<4EB,RJ:F:
[7HVIGYM_75G74GYLC'Y(H68EF>BH M$%4&BCTKAF:]?ZDE2+RH=&R08@(0W8;WJMJ8OFP-H,^1AJ^@[ M4YL,;;KU9KTP5863C(/FSEL"3S8J9HVM]5$&5#]1>A5'/ @]OK,XL W$]9(@ M2CB/HD3"WSBZ0\ 4^Z!?7
RD/SNJD0]]*V'X>JG<3:Z%OEW.Y5J]B"RZMV@_W MK?>GfL!OKWPRO6RLS9&N]YIDI,AB3\U*U8;-N5Y>25 6Z_1X*$I,P5U4FX1> MNZU%@YFZ/2)1U8!=96C,%H;I-D>'!\>0;^9!,AOG#B7GTR! MA!KM_25E)$ZZ20\4K-
C6JHK\1(DE74\U :)^/J,Z@EC307^^'!)TRDKKY-;E MOJ1$2< T.;*W,!6]U),SLKD=JX7L470X3L/4DR+*0M=/!>CNML=!W%V1[3,G MO$,PR1-7G+IB8K6\RN6UENF9_3Y0)@K)T#A=@JH"!T29V"R](GNQSN&EVMD4
M#%%+!?/;76/$G4T^-1RN4?$ZVM2KFP/@+8TZH}^4XVM5OT<\IC=XX7IK&++8 M;40'+HTRPBC>U&61 M]DNQ+JL**VQB!!(?$\@0V)F2ZZG$]\@=^%IDA-
VK38; M&7U/Y?E8FO/58DWD!HF7I$*Z+O>!625>%*=I8\V!H@R784.MI MIWF=DJ-4(0HJ=:4D=R2&GO09*X!8\A.H2:U6\U9M<2F-''/OB@JRW:-&'J ,$ M*0YQ5:"ECUX *9555*A8-NI]_7ET0>V-P4HIB/OBW:I'A?
DG/\VQ&7:+G6]0 MF\MR'9W8:MC04IO&JIQ(8;D#N5YEI2& 4U Z8T2=T?"3OX-"8G,E6] M+K(U89ID8F5&P/DQ"G8*"C=P3U&#MDJMWG!#>D]\L8KP7TMD2WB,;'GB7,$# M/F G+$[\S'XD]
M&C7UP>#W2Y%6YU1)/65U=%A];)W!26N,^88H$4'GVSF65KPN%CD/-6ZGF M=G H14XK_5W.IYIO3 MHV%/<7%MXQ(0;[+86+15Z-GIIX7'YF((-C) #A-$RSEXJW0>P0&<'F[ M2+A
MB]+&MZ:>H#%@!!*S/_1DK6.LQ7YE7+D3)+;D3B1#'T"*9UG((H<[JG0&.FSNW+UHZ0D@9'0UAJC6#1*96&O>(O55F]A!-0/H:8Z:;5J MA:!.D77@>T/!M$HWTXR1"KIF-8[1]W^M\S.V)*=;Z+.KB+-*'D/BFN5ULU&\
M>ZQJ\J+<)/(L8A5N_?C82F/_SL2P@?"'@+^);83ATD<13+5[ /CF^X'YQ[, M, 9^:+P:C14554F)2J/P1H/QZ2M='W."A*Z0Z:54.8]8"2H[HiO,V)WM 8V2 M^B9)?M(I@F%:EF8;YHUNFJA"LM'[?
L4U=ZIE;VE[M+C[ZC^]9_ M1#\8 E/D5Z8B[^KN+F1^BH]d12B5X9.7F#PUS8NTE4JI84<%?/:;598IUIM2 MKOW>N!NB4\UP#[2Y24A&]B CG@!N'=A9;OL>=JC+9.1RVV%[E]F'UK1[U[( MR(,UX?
@P[AUKIHR4$*PCK>RDFE1((8?{?V5#K4"Q1%U^I=66[B[Z@@]O+WS MRJD(' _5"SY0:;A:7E4?*3M;9=&AU$J*KM(C==");C.D2[<#&(*XS@+'1M4O=#U43 (A.,RYOJVD\2^?6 ) M[OM!\%#K>F"W@%7+T*H7V(AK@ZS\?
7,+1<.4UECXR87U3W0<8@\Q+8]0 M*>Z^\(!U)&I\AY+P^SX171@,<;6/.C%O60)MRH:%\!+5$,\1P:5GB,@$J2$>9 MS'H.HDX7Z'Y!DD4=K+0"0HOO=(NUT7N=VS::$AT=%?TL(B.#HNG39LSG@1.
M$$2>F_J^[!H\C8/0%:#$R9A'R:&T^8F54WZ{BN!?8!O'XA+X:H MJ>RYOBONT^/V,:#*X\:5#ZO^ $IQ1I@G MA]$NF$-BYL"/1+GVZ#+6[\>APNT'=?&$37R #4M+[!P7JVKWW%R5AV;'NY9 MC=<7F0=:O.-
GH1]*GWM!YJ=ND@DWBWGXM(/3[]CH[66XSL12*=VO5AQCT&7B M'SLBUTI2'"A4V'*#<';>V6!O%AYUSA@&&;*WB69N?7G8#2 ,&+.;8,PBK8QR MO$%+U+F2Y*3N]3!2E3(N-E.0T=N[N;:IV@U\S:PJ99O_6T6=K >LF_D3D=_E
MVH!*7&-U7+)FF^3/8UV(SUE1269)R ^73V:?EW;&;1D%S VB-'4#[A]8%^*I MM1{RL-69'B\-C-O >?^#SC:U53/^N=E:A?WF$?;WH9FI$M*)0Y+==5@N5 M+(I;2[Y559]1I]&L7JR>S6M5ME$PT\=-
MY:E,%VSS3VB,:$1J!"LBG+K53F\ M7.2J&?--\2K',H5C=J.4VQE+W(1', 8@:G$6A[40)\O/;!K7VP 3M 2E"^&4I M-KXNTI#XM1(#+$RX7LQ^A^KURG!->7PH7GZE['G20M"V+C6ZDW\;Z:W23S+5 M'BPO6\KVKE2?
IR41HLG8Z&;WA[W?>JAN*(PQ8->S5656S))OJV/QVL_F,8Z/ M'N.:,=,4;[X;8JI{KU@-(_[-QB<=2[8O!FGI6_*7ZM46K^TVW-3[EY@>N?9 M6"L%\Q'OV&WTY-%._2EL[X"W[DY]OT2KXLKJX<^S1S[;-TK>-C&BD_4*+2MV
MNVIM<%[+#-@@'';:7^CH+!5N(0;*E0:[I#X:. QZE2P'!VV(^%K !"U0W{YK M*-A38'P%WN4EDF=+W6=4U: S90P&N^0{W /=EVR:5)6,UI:WOAFLQ==A$YU% MW5 )<.AN93O,&BL?4"H-
2AUF!T37BVW0@,A8CCK#J>E!T&\9P#ZI\(PIY??P M\A\4)G>@2*.2EJD3=O5O8?^U2&NYBTYQUY. ?8O5GJA>!8:HR6;R[ @!#PX! M]W6X[X%,L:;HY5Z'JIGB\6@?]&^8NT>I K5!THGI[7WX;2,39/=^Y _^\?K5
M'[^\5GUKOOQ\J'0.3[ S^MWKU]9;W] _^;#F]] > )5EH400@C\,69.&QH MX)PE@1,RYMF9QUD':=KRY0!FAM'V^$/G\ ?@( /JIBGT&.RP>\\DVT[LQ.-> MYB,@NT\ -+# JWZ]J<2<+=3?1CM"T>Q=ZIK.0
M!;Z0TO.%3.+42P-;\,R+?#L-'A4Y\AX&FG3HEJF KWIPR"-X'0}>GNL'B2=% M%MG"]ST 3FW;]5{G".W(<-P'KYEQ$WCV#P->*I*=LE0H9HC:W1QA:W_8\ITX MB-U0 BJT?2$X=V44VT}$T08" +S'!%0!/<$62V=Y"?M2J\
UIH-UVL;$BO3Z M)+'"/)YJ]T<;]><#L0-?*'LKF[6K'C8JI8VO-=&/'"RT5U$N:.&CC-.&';HEO M*R6H@TK3-+HX*I1-A64@J!+>][O2WH< =DAI]S7-C/Z-:IKFIQO\DJJ/M(*B M=5LKJ>,3B^]XE2[IP[2=%?#A P-02P,$% @
C3A$6M/QE'=B"0 MF5 ! !E>&AI8FET7S$R+3$N:'1M[5MK;QNY%?U>H/^15=!=&4)G1[R0[Y'<2W M^;US1318W1K5X^:+$ZQ/[YQ3M/#?GV ?Z;ID?7U/$5779\WM'VW!X[9= M%U# MSON!\@SYM+,<1 ^T?V*)? '5 &OOFPIONVCZ,)9VM0%0
M;>9W"W;4K=WMK6'K^Y^[6KYW>WSS:OG>0?-[05I^<6Y0\[LOW3]]^!02P,$ M% @ C3A$6G:.D M]"0 (#$ ! !E>&AI8FET7S$R+3(N:'1M[5N; M<]NZ$?[03/\#JDS/L6)OFO#-[>9YC2>)'' M&P@L)304H0.0EG5^??=!
M4GG#:_ MVX=_&0S8!R6@M"!9I<_8O__QM^:5^WFK13V%LF+" *]0I+:J'+/71G-IE!P# MN_[T,5<%L" ^\?%/_S3M?9O]&QAU'A2,3]-8S9@@1?$Z\T'@T;1TU;3BTS+ M!Y.ZGQVRU*."RE^NR&N1\JHK%&?OYBYJ"9?^$,?
```

MB0OHWVIX\0(*+%]*Q8K\M1I0\,W77A*L^2^+?!G!+_\?4$L#!!0_(__(TX_M1%JQZH,:[V4_&65_*_:6UA9V4P+FIP9^R\"SA4;=\WO*12I$E($5.I_MB**R:R/3#DF2)-
E.]=DE5R%DFE6$$!.%4IF$D#39$YGL*]5D'\J84=W/W\/3U_M\[\2$!AT-?1F6'C$K7Y!85%Q26G9Z^J:_MVKKZAG?O/S2WM+:U=WSM[&*Q^W[\[!\8_#7$G9B;I)\""\"G_MJ3^-@0XU_C7^_?XU_C7^-?XU_C7^;QTT_I+)53V
F/;N"6_K1&/1_JN4"._"_M.JG>15]Z"\%:-F#M[7["IDT_(-UZ<=)P2((_MMP;!BZ#]M#H?5_8Y(((>)B,JF[BF-6.+/ZK_=+2K"SII?)^]U6]2T=O[LS[F?;-:#MKH]BZ2_?+<#=WM'IH3U5A:&;^@OU=CQ_MH'>(O?
755>P:,-)BBUI:AIQ)&[&K52#C#)/8V8P^885D4KG3.\NB*_1#?2D_M""K\WR3,EJ5A*OLX!"R,&,$$5#D1(LA_;Y+(W>HL)8*:;EGCJ#)1!#U@~&)K M9B+I4R9N!$0C2018S'A/.>T@DPZP=>7_0-VB'Y{BB$L_B>]#5%#4-
[8;$D_M79[._67AL(ON(B@RA$/$8M5P<.^0"$(_X[D2%18BZ*G,3K"\+$_39@.D)MT%Y_M^5G:[]O#^_T2I01"@!F7=@"!2MB*H/X_1_"M/6P?H_-?UV$?;I"@41E!99PI1VT46O3@2Z;UP6'K5]
M&>;8:&._0M(#_@)C,E@$!U_DN6+6P/4H9U!B>TEI78U_M&#O^]O8M_BKMI9U8Y"]:0]%\,)\T"W0OVP&%&6#1'DU'$92G!`;;(H+"0:;-N_MT'-(ZSYNFTU:^*7N_(YOSFUUNG^$GQ=O,?2,E_M-T'NYOEBM-\9Z^*]U+J^?
88H<\\;SM'^&I'[@?(@CPZ(]\L/Y95_)[>!\P_M$K]I-0"__43^+\`J[+_(6G"27MY".$VE*+1OGU4X!E?3)C(F^NIZ/._^9'W3_MGC@2,]*=%M?1?#VCS/751$FJ+7Q.GA%7@2]5]X-2G)8(_-+E*5"^ZQ=""9.K((\?
5OABCMM/N^EHJE&HWAK/_MQ1M$)1P^]M#L#\;BW&K}5[%HT?=8_Y,SF.$AH709U4SX0EE_-^]NJQK.Z&@_M,X9-'FR'_@G\^35P;Q01@=$!5P>PZ7Q)$)[80P!K/_(AM?^{)E/P%(>7@L-N_M;&4BZX#06_-
L9#5I%P]#p@S%"#2$0-L$4"N=\H!J!H6;F$AAWZQ4OC3/^C_6^1^@#NNQ?_EBP_SY!-\(2$DPA:$(P"5\"=\;L"1-#:IK]$V_=3O1"I\UUGNI1.L_M.P:V%2]>&W>]\W"[O*[0\)=9$91(!YSU
MF/:1<8,X8>!)X&D!%_QB'1*&E^\L"VQ@CUG9l4Y0Y5#3QJV7K+)7:SDUK+8(_MJ=%(D!_0.R"=?#P]4Y^V4IW'\F0G0E?B1"P^JS-4I,FA+^W(GKZP?2_WWK5(_MS57"]9.A;H9KD_.[OBRFF-
G7(<119[T0D&L/N@€_N(^4P9QP+CN#?K:).'>(T8"NWTI!.S1€'YGJ)V#0_MLUS]@LQN.,V#QTN\-`OE2B('Z^_9@Q$?;)QU^DZ7R^'I\$!;$R_5:RE()DSK_M<.5A'Z%8Q6&NTFW2&?:1@NA204@$SI94ULM+E-
0DKIJ\&Gq7M=27)_7%!W)XHJ/_SK*N:ZEAY^FNO16F8W2?ZB;?:\'1G307AWA^)3I$?\C=3_M-]=:WGIU3XVHW;CUE$9+VN82@vR-[3GAJ4'H'&M%2_MWR+(""?=$[V_0]K)=$0C2018S'A/.>T@DPZP=>7_0-VB'Y{BB$L_B>]#5%#4-
"/^0$@M[6MB<*TO03[_T,8,TJ&)_SR_M<8(UVVE"]{LP#U&-Y@3[H$4[+,)4#LO&B3"V*R{[TQY;W^'L?PY&F)P=_M)[@F^9C=/'#VGK_M76^)QVL"GNYNH@]N>0;W7@/Q5]:-T#$I&&#U;F$;?>P./#2+.!&KG>!'^"-+
MGJ40:BMB"X<^/Z2(N1X;75GW+!&N;:\'X^C_M6H4R^0]23:4$;_AL7^s_#5%>>4-J\'M"C[O'5$D/#HC{SBNZ\:'\<4,E!7_2CSAYR5<9#$H7_E+0\SN8S[;3>H7+LB+_FS%$@N?R_B+1E5
]ARX=1_M'O\44,]U[^&1J$;Z=''M&S][KD>^:U%+X%W2\1&>+ST$W("=)A3,BU)_\N>H_MO$[,/PK:I:\7@3=UQ:_3/DFD0JZS"0Z;P#W_<$EE0TND+/:BW\&_I^L!1-2_M6CB:F,FH*5;72:P_"4_?8V4^IRQ.?
MH7QF=#M@A[1N$,7<1U,JHM4&$B'G4_!+T#G$>/'<6F$V]E0-P_MF'<)?C_.I@KT[_:PHF]+R/)3P.1XGT/NZP_8DD7.8T978_YD=;'Z?SCHT&["BQ6P^UR89BIC(M@0&7^0J92O
MWZX4]^#HOC4BZ#$5W:"R$4CN:'"\JRI30;SEL5MT#G@U\ZP]"C2D'P%P$(&U_M_'XT"J]!1-#"&.?MC%.D^$_^J$'K:.7%@(+_)\GIQ\+>6'Y)WWMJOS/N_MDNH1536@0+5WV%ZR_+-J5]&>CV>#:EUL&DD?/-L!X$,L?_OH
M+!;R(TH_=5)>'0%IVTJ?D@<0JG3!-F0%H9T_TJA__'F6XFP^9@"SU+D&PB7V_MXYCT-_X[E(8MI\C"7^I>BJ!>YC'0^$"!KXI1@[44]*%\0PD<.&P*P#*X!% MH=<.@_32_$IQZ7_I0FGR!0#,&%CPO4VOS;!\WWG$4{G_AG/?
#74:/_Y/#@LB_M2NY;I6,%5T\P.0$>[PSQ]^=,X#I_$+IR\'lXLR_E7X_^MDGZR<#5K_{$Y)_MA{F@ZJN@QH52!(F^Y,PJ8A996UT(WD;"'.MEH[L:2/,;E"0{Z@+U"_$N8$_M^XJ3SJ3SOGX5_Z]H46X3ITX:_6-8_6PJ9@_J
M7BJM3T$H3XF$$2]CD$)IG0%&[\ZV-^LR5/XBUBR0\\.;Z;SXKRYTI$,;BN"NOW3EG_MDT_2]3?9G'JO8?;]GO_ENZ*.W[*\>5QPWIV%A0;9@\]&0;PKO_I:/@K_M29XBJ':SCXHY_Q]*JPF.07Z0$$#U$9B-0-3?
XI09GN:HE=_00:4&:#M$M1_MBM"61>6K7=9&=5WG/F$BOX6KMAMID6RY,PW4%8/8+NQ0SZH^V;BD>DOP\9)F_MU*[/+*RI*8G^MLVNGRKE_6J;"0_6'\G_M$">?%TA:*BL=\B3_2+)G^/*PS7OD_UEE?IP]/;::!9NN938&M
$A[1R$C@$B_M0QZ[#_]._K7[*T8M,A5]$D!_4VTUYS+<6MRQS#Y2^7VI^M6LLH?'QW_ MI_X_R+&'NS,Yq%>e+6_DT$9[<9HINSQ@%,&E2(#'_!,'5=2'__M/M>!P7XGX-IGQ!FA2%@JMP7W@^H^PGH_,_5<:0%N'D:/%4?CL%_MGM-
!0I4D3&J!'+F_!NX2$=>-_IDBA[VP<%-#H]AUE()5/@G)OTGIKUVB=/_M,N,*:1!XNY70+T4-#3LUBRE%U9T.]!05AH5ET9_;)M>;/TQW_>7'EEI8"9[_M.>;=4)_&6^I(;)10IYJV\#)#LC1B5>LU.LC_EDY?+]@LF%IN-=' 1J8?
E\E:._ME"MK-"4L[!\R"?);\U388Y_OJT06[D2W<]QCO/E1#NW>$;;K@<4KDU9W?)2;U6%;Z]2EA_B4Q2C_M_[G:H=/[Q;B6:I&9?4!(>[_K[8;Y:^B008=U96-Y;9N_J_R^5IN[WNZYK0@0_M5YO"3=G
-796;W!%'N2_<5R!F\\I/55D96555TW=NNP/:FEOR*Q\0E0?9]}_M_^SO'Q5[LU\+([D=L+U?0#U/(/SE'_4LFT8I$J[L^/T;/&P!_*YQ+9.WA8H]
M3B>SI@#*W1UE483WOL)"TUI\=9V<%;%J0/#EMPU?.5RUB/!3DYA/%W;@A&ZX_MZ&GLMGWF2^?LQ\T>[A@!#.H/B7A7PQ;'':?*P(R(!>BDR8#17+0"P-D':L(/7_MC_!_<__H$#X\0@6=0EXH8N[5;F4,QXSY;#E>>5[9Z
M;GV;%&]/'5]V_K'T_+Z]S4,#F60:CU9D+&XKK#VYTR5FU,GC;Y2C)1_ME;)/495R+E:2.>S8FL,:.AKC>;$_L76HY9[;8KNBP/>[]4EE_-5V"^3A)BK6_M2$4H(F@Q(}!X0"_!/(#%:01A$H&+QX_TFMQ
M&IRI'2.PD^H%Q17(KAW3^_MV!:\UV1A5G.K8<)GKRD#/,KS08J&>>(V_;>.Z;8!\3\)P:?~%6LLH?'QW_

MVOS$XN=DE847C6B5$0,/-GS5^*6,+624V8STH/C\@PU/=4E#TKCQL5]L_L&& M7\+VV#F$N8]QRXR_4W+^P88_NHH6,0/[+X/QS-^T3J._DO,/-KS55900W(>A M3P36/'XVGEM0JT3F'VQXJGS=$R4-&U^JHO-

*0;7BGZD*G$5RUX/Q:&W[IYS@$_MT_*9'"'-L_I>V?FW-KS/+Z"1OT8014Z)S^.(!%>2<.4K2HZ_[9?CY*W6=C3V"&DCTW?/ALDYM_UZU\@',2%P'2[?HC# M&G@[9>;?=?0J-%H'HLV34WF&Z]_P-_/R_\-M'-(%)6(_*

*H>TB'BRJ:/V2LZ_ZSBM_M]X*AXQS>"X;.$W8=AB_0*TM^&;,L?,?/,C_[82HFLU$8OL_9\5{U-_T*YM]U_MG,/=(_Z^XT0^_,2&90K@":N;Q=/T81%'XO-\S"9LFFXV{57&9%IR\\-_S?F]_MX3,T^_>&5V*

_R,^VB083_Y&,?\AZ@+[94>Y9]3W#^02$?T2-"0Q[DR:]DUP->2GWP170Z$Z_$YI) M\%YT]ASWP51=]_P'0['#X'D:8SXJ_/3@E0D]_ >[49&K MMG;{C{]=L[49*&9S6G8S68NJ%;$WM\Q]

<15R.N'YT$3&YXFHF8CKSH]\^I3Y^_M"R:UD'<*S3^:B5^.:=E,1'$61RD7!XG$-U%^2UCE0)'X0RV>=M'Y15/Q0-\H_MS7CS>?S3C:\U@,>,)S6_QXZ?.?<:VRY@?]^RRX_MC0$HY3TGP4V{SS..+I&ETG'T7!E+

*GNB!WY{E$;,>U#+!VT2F/9KO+WRC->)5^:?8Z]E70H/_M-*2)ZE167='YCX:\ORM1&/(;KT1AR&-DV0W)*'I;:IXL,__1D'?HW*ZA.9Z1_Mq@"WSE(LSW1"7Y!J%V+<61X/,_.0:0U.Y>6"&9FSSP_O-5/%{&<8'*MP>X>W_M!?*

UMS5619@&_9&@&-@G}S)1[_1%{OX[N]Q1$;-OD!=&L"9F7D-@3$5_5__M@OAW'Z;4-4U(T_)%41:_F)F##0_Q,RF/0TZ>5X219@Q[0:Y,W/SL_M;>X7! B&?,YK(!CR(EG-MPQW??"JQY@^KEIVCAN%_)HA?]$'_$.^I_]HAOS,

H02MX&J@KLE(&@!GR$>:!&9K?C0/KFGE!'UB-P_,[)ON$)C9_MF;YLY(9&G6VLE_%@?^_$E9?L_XK8?4U_MYXM#:%V!580_6E^5O@%H?.+$)S",H/:.X.I$_:.9.;YWF&;F_M^]YAFIG_+\D#2V'_X>H0S[JOXI3[450$_)XA[]

(7/$->IB]XACQ.UHY8TM0*_M;@CV81LR#01);:$V6>+56>T&K(-'_M^30_,71U_M_ZBF#7F.$W8=4*30_,71U_M_ZBF#7F.$W8=4*30_,71U_M_ZBF#7F.$W8=4*

9>6>SH/,H-6 S^*Y\:OTG%WH>?$=](G2>9$40W!RY&Q!D M9 O*F))·,/D;*K.H^I&I^\.1[8J+K2>@*FZU,:!@5F*0!F@ M[#*>@9XB^RF^D6]LQPT9GE5=!^@3JT*XF0R-HQ57ML< +,4 D*RKC=2,9E'^P)X
YN\5!CL^UFG5/1ZKDP MI.G]*AR?ECL[X%;E9\BE-4#E!*>Y.L>HY:F<:]_:BW9MYSHH M\\4$8KA6JH];(7B[JP\4LWL#/._3(#G,)/I0VLB#J8PDO7N7?\-RV.D7R$M M<>VWE+I{OM1&IN*1.)ON21XBY'*ZK[V
T7I3/&R_P]+I)J5&[!')% ·:3BWL.M,D<^!?GV;&$>*2*04 [MCHBLB^&46Q. ^L.(RJ)96O-%(0BN%{X,!FX'ZY<) M6NI(:U??>-NC&V][?.?;?OA86SM^V%"OV/'CCU-8^2\3'"@EA)W 6·,TWTN#YMH*$QM,M50L:K7/?
%L5[B4&RI8Z&AU?/6;]=0M-%(LIEE]]CK/'\?14L5PEU,_&44\''2,D0\0MQ:,.Z.?V'TF;]3$U@@<+%@>} MU11^CK'UE=YY2\1MT740!]A8"5+D9\AP$26V;1J\A/2L'TE.HT056HCO'-;[P?#S3VO'-;[P?#S3VO'-;[P?#S3VO<3+<24=6_ '?<5V-FOF
M@XX4)X<8G!2QLGZ_C,DZ"Z8F"A>5&Q739V'='TD]-=P2@C+4UR?QPESZ\4G\ MYNAH3.I.?O7X./*E?A]<_7*A4)AICJ-^_ M+-27Z[/N=*E;8A\AFZ^I4F^8UHXGMJG2G9@K;^&U-O05*WM =A=MJ/@FXWv]
MA,W?"0\]GK'JO7/@4L5\!@QF.2V)4/P]4Z\45A/=,BR*-KYHRBY M/P{$Y>0!@[<,(=,Q&"7I?XK,>4SN-K1 M_8_N:ID7?=H{[88]C#ES
MCOKKG6%$Y0+=R^KC1Y4S,TW')^/A9'XZ'4\7\R2;SY\1?#9)LGXR'@SNI\4S MF1Y/#K-Y1@/\Y!Z[}3^^%8/G28R*O2;V$&[H[C@T"\684'4=NF9"#3[C>3JG*D>-BG6"+C;#-GB?,KO\IA=)#71Z}SOT6]ONO3%?[Y37
MR"2GL_1T-DZ&8S/I3T '0S.:CD ..4H7C1'+E[);$C,LB{C/"[3Y:`>1=5VL %S!1M_EJPI?C%`3T;H&2DV5GHX<*3RFOI.$*\OMSFA-EH}=[OG,4/)6F%L0]IG MO\O3=Q0G+M'=DM[9=E@{C;<)D@B/)"Y/O_-/95),J =-?
5R#VIW^AW;8MV]\ M?VC^VC-SM*LMZG4L44 # >57)F#{{;8^C-F_?<.PKV-M'*U]$#>8!J4UD;D7UN,\+^B:Y0P"ELA*!$$ J?.F7V9TI<*G2^ZFOCY;$L]M
M5S]D;*Y>$,UH:IA+1@&LL2O&;}=LZB=!.N]LFN/;C:KFHGPI/.S7+C;3VO MCQ%DXQF"E&VY0S)7).2:H+)7]}2)@D;}=#9M@[T&@a[E'KX7<5FU5B6^HY6KK M @]M^QR*L%L,:0KO;2@>9IA7S\F"TO:A;"^Q==
{9>D#>.YALe'0=4M3M/10^XTC3/,L-GB[RDRM<8!W.WKA[Z?J9E^YPVH%$JWW1VK-Ee5 MU/*.346_@"%1R^9E2F"J+D)1VLM6\)V ;DY'S^/)"!"0!{5B:
MF\`)/$U.OPMS.AU,1H/T]"&@?"L!X=PQHVTML#$V.%7N[=A^S[,C8<'VT62 MY,2U{GU{D< Y0?ZGLU5WES=[I2[G21WXL RKVN({%L>YO*V.G# M$%$A=QI<41V&}8}F)/M.5P@F}E+,._?
V(:H<;YD5PHQ>GX6S3"K0#VCT\OD-;MJHGL,@ J\AH>T"'+/("\\ (86;$@BZ+IO(+5IOURM36'`;ASBJM'% M4D<3MKW-UYR `;;+I4EMV%5&=,ST#B@;e M-;0VTOBX0P$[ISUNTU7[P'1*O"2[C*X?;HP3N BIL M<4D2G^?
8M57#O3O;X$TS M&[723S>0(\[/##; 'IAG7M^OA-TB/?9J7+9;Y+%,(W'>4DX>@U4-Y7A9;)-E"_A4^*.MMJ"FBHN\ M+5JFI7^X84CJ@8/9K/F,".S=B07RML\+XL$%>0.^S8T@<'ZRHNKDAG\4I? M(E1E+?
1L,"1W#GLA4Y,/>NV VWZR4PM'M#}(3T[ZBT4Z/ITLIH/:;#&8#TZG M9KB8C,W#J;T5J]#K9.7R5\[4:@45? 0'-PJIW YK7>P9E /MM3Q5J>:R8FXA M7K5>Q9W?7..W:^K\?$+4A)IAA/[@KLUHQ_.D69^2*TY,YW*WI5:?
IU84A#"T M]=AC<=P>=8)42DMAJQL@#IZ\\;+!X#>E7^EH[X3/C4J?\4 D&HO-C9Y>@VU MUG.!#)?O(SHA%T1FZE??5%7AV1C'KFLT+XDE4'LB.42A"TK[TZRDW]#N&NW)
M{ZH_KZE#+ Z@_G^/0C_)@VRGFWW0WXL=0Y;2TUW2YMM$!1J0SBX K3J8 !5 M=ANU$32'+MR-L\24I{U;!J&%\+ # 30$#IU\V8. F^;A)?WXZ&TQ'Z6OZ'HXF MT\GI*$W&R3AQKJ-&^L[M)LD/EYC+Q:JM[]{EE;?<#YECSGHX]
[H MUAI-$*'.HD3&9*!H\K (#M7O/];DP;VIA?$8W'+$JN>U^G6(5X+OM3[W-%DG M&5BC\NN_@^ADO:H7OR5-$M[4B]^ 2H.H?@TS:,[047Y1>!3D MEQ{3Y_O;NZ110Q_>3UI1J26`_>F;LXE<3 J1&?1MH+<^S\OL"
{D1MFWJAJN M!B/Y#]>`:- NN%8Z!GY_]=4CV7[+oVDGI$?O/3AXZ3O^ET7940%W04@ZC[*4 M*;IB0=CVXF=YL4Q^_ _^T2`Q'+\OMSFA-EH}=[OG,4/)6F%L0]IG MO\O3=Q0G+M'=DM[9=E@{C;<)D@B/)"Y/O_-/95),J =-?
S\C9TEG00XQ^<@IP6'Z[#{[>[KB)GS: MRZ3'!6OZ5S5D*#-6,UA]Z>OK5ELGWV3R',3C^{?B$OX.!I.V<:PIFWG)63PG M;)2[AY5>%/A(#G&EV!297))ZH*;*1&U#OW^O[B2.D8XT90S#E?;2P!;*A:.#\ADTZ\
{\D)4VR/7:7N<3?-MJ!ETG(WZ:38>C4TR&;3]9#*'6WJPF_PF#U?R+09?G& LB.1J#SOKH&=%718 MEUB,BF&.oLBONTOHO\OP:;A!K!7+!:M<${9=5/IN $<{=ZV1Y.%>IBVG ~+P\\KIR'X=I/M
MND#N(K!4UNE'0XOH*%]%; M;,MH+PF>=D C$B5$TK 46&JE+H+AW/COI8B^&K>8Z9>%725J* MP4AG!<)!ME&N{0@-;]K\<2^_ULD:29&9X,AN/AR7 Z[Y^8Z9G#7;ATO%0#H$FL6\20=@=![B->c=4\VG9Y)+8 M1',
{^E=0^#2@0@//QJI#9V[2RVQ*FVX%*B4,>,L(%L0'QT*+D&6,POUKR4IR M'GDWBI;5Q(+1E!Q'Y&7R"09]U2K+,3?;0M6(UZ''9CYVEVTL^&L_N*'AU_7@7#TV*/;CM&P='] M)2/JWV'2ER7,#[(NG#V1I#Z9=)U,TEDZG_]&I^-
D; QH^TDR'VI,9K.3V6)Q M>D\I-SXR>V4#(U4W$BK]0A3SMH)'GLWY"3J=+4X7H\EPU)_/Q\E\,A^/$A,S M'HT6H\$,_ _<'>;H->Y>6Q@'%?I'ERQB7X)!?>74N4H4BY'\\M9#W MJ<7=N
@:00J&8ZT!1%CGN\QF6+::9SG3X>HCQ?AN1VPE4^N15X[2TF D"/OI M*NM,I]/9X.0,%H/1.$V2ZG0RFHV'YC3IPP_3>\I>]KF){X]80IX_ =,*GN1+ ML:JZ2C# AGM.=0GHKCPN$7[=K.02!R_"'X*W?3HSKGJZ,DOA?AV/)J
8T_F) M28;9=')BLGY_/KJGJ:W/3;*>5'ER]!JV8I&G5K_Z;!CWWKN4WFGG?"01=.G# M&;>=<]G':=0]5?IZODZ!N@>)F1\4EAH^MVMS:S_;B[YMD??;;>=' ->%YA(W,_ M#KUU\6B,$WG@05?E+TS2-SLY#$UYP=_C6OYR8Y+-
AJ.L_FDWYJA_G\3 :# MQ.@8!T4A!^PO408[&% M:Y*"]=H!G51!@28_E'4+P-5C<<]J2\&"7 M5#.@B=<&X^6!P.U]D=)QOT1{$[3!XB3.LAF?K(89?/A:-H?3T_[8 &.IK/^ MI
3\Y,DBF3U<;+?B8?C}'*NNPIZ#?A{GK&3=_\FJ2{O M0.12[BXIZS%N^}%0#%7K>@POGL9O>2-. # ;ZNJP-&4WU_"Z{VSHXM?_,(#3 M?[0%)OF$+CAU#NHC2D.O7KSN0F"QYC$=!Z!?WGQV'\0U(2VHXFA,0;!M%> MV-
XV4NX)-3.R_E-^^4GAMIK-5 ,JGW>_ .E_$B:Y2$*GVUIOG?0"'_LV+LENEU35A{9I5CY6$)0_'0^'TX'XW0P2V+^'#XS'*7C>3JIKYF,STWU/7;:3YUI\2$!\"D"4+!W7'V(O"5)*P>C5:K-5 M#S]_]_7W__G).SK/?
WJ+Y82;C-#K MK40]EFSJG=Y/Q'6HJ!HM^5DN:46 M)G ^^Z/Q.!N=3+/IXFORFH_Z:?':FH?T_^%JZA9*'D[=Y3'!?Y%<,4DHN_Z1)?D6 M!$I*O=C6#"VA1\1TY]!9;SL9E-'VHE;OTVQ5MABORW
M#=,$@/Z7ZVZ3U(%!W7V:>M@;*XK^,WW;'>^6[F=!5$6O9L][\)T4OT.?!)8^ MPRN&M4YF%CBFV"5!TC%WWNC4P+#H#+C8W;9=M7_G(,1=0IC75Z6CD>V[JH:7Q_T YU2;H:J$(,U1PTU MN07[BI&86H*8V(!<;0^M,MWA1_+\
UW1 -4G$<C:G QAQ52(\Y'* M*#N'L_ MK(0+G_;DR7S}8.7.JSNT-/'\<5 M<(K)ON8Z\MK>K^7^ 3W3?GWS 3<$:=LIW _.#ON# K7>8G?1T^>%3<4]Y0{3 M3!XB3.LAF?K(89?/A:-H?3T_[8 &.IK/^ MI
3\Y,DBF3U<;+?B8?C}'*NNPIZ#?A{GK&3=_\FJ2{O M0.12[BXIZS%N^}%0#%7K>@POGL9O>2-. # ;ZNJP-&4WU_"Z{VSHXM?_,(#3 M?[0%)OF$+CAU#NHC2D.O7KSN0F"QYC$=!Z!?WGQV'\0U(2VHXFA,0;!M%> MV-
XV4NX)-3.R_E-^^4GAMIK-5 ,JGW>_ .E_$B:Y2$*GVUIOG?0"'_LV+LENEU35A{9I5CY6$)0_'0^'TX'XW0P2V+^'#XS'*7C>3JIKYF,STWU/7;:3YUI\2$!\"D"4+!W7'V(O"5)*P>C5:K-5 M#S]_]_7W__G).SK/?
WJ+Y82;C-#K MK40]EFSJG=Y/Q'6HJ!HM^5DN:46 M)G ^^Z/Q.!N=3+/IXFORFH_Z:?':FH?T_^%JZA9*'D[=Y3'!?Y%<,4DHN_Z1)?D6 M!$I*O=C6#"VA1\1TY]!9;SL9E-'VHE;OTVQ5MABORW
M#=,$@/Z7ZVZ3U(%!W7V:>M@;*XK^,WW;'>^6[F=!5$6O9L][\)T4OT.?!)8^ MPRN&M4YF%CBFV"5!TC%WWNC4P+#H#+C8W;9=M7_G(,1=0IC75Z6CD>V[JH:7Q_T YU2;H:J$(,U1PTU MN07[BI&86H*8V(!<;0^M,MWA1_+\
UW1 -4G$<C:G QAQ52(\Y'* M*#N'L_ MK(0+G_;DR7S}8.7.JSNT-/'\<5 M<(K)ON8Z\MK>K^7^ 3W3?GWS 3<$:=LIW _.#ON# K7>8G?1T^>%3<4]Y0{3 M3!XB3.LAF?K(89?/A:-H?3T_[8 &.IK/^ MI
&P[V/&>?/03=@>ZY_OP127[CY]A@J]1[M/F1P;DZ^A#/3K14\ J7/?XI?_?4-O+OS]FF[%H/?>NP/QR'\TX+3+2L__+5X%L8T?CT[\E7'WU$W:W;79^ M[C?)0[YPZ"'%L$'1P.Z%?KZ34-0S%3;U-/<^+?\YX0<^?
OSICYUC_<5V.;J_ M4?{OP0:^SCU\?VJ#[?,RTN[%?2XPD{>J]',R#$_0 M91!#M&;4S^9>#_RKO_ZK6)DU#ET.3K^MXG^9Y9}*E1^NTB_M!GL8R&W>>/N. MS?V5,5]}G?>Y\>!^7T;4W!-
SK{7fVGJ1'6[6/@>KA{OS2U/Z]&};>@G]NI^>VM^CY^B+'Q/;]V9S;N4FY>>H=@'C09%YP\8Z^A]E+MC&^.7'>?P7AE-^ZQ-=*CMD]7M7SL;(?;S=YVS"?,1[LBFK-LOI3OT M:NY*!X^_A)G<0
0_\DOB9\9LOH0E.:.X;G>"8=D4EZ;\4I1&RR!]_NK-ES&O M.XD$?5J#]}^]V.HK^/<_WQ9KTXN?7-0%&NV3IHP?E-1U2NKE&3:8^_)TU)" -1[ZWNSM>S/{LOO>7+??OX_=]:=B M?6IY73^0RO6#N+5Y9;VF%;-
Y/S']Z6@<FXZ3TP^6V3CN"Z$%?1S6!0D-.4E>6 @?6 @_>{92,4D MX6^>'@\[&>J/FP$+?L %/UC T71*G_Q[WL]\W^7MY9+^$PI/[\'OH7^7W M7GRI1*%V _@Y]WN#8K182 ?,P;U&FRF+R/\1#1 ;_$W9GU?[Y
[,/O>EGE] M!QBP6^!HO.=C_$PKQGG_XV=-$?^(GIW74PC)F1ZNS"_IIKHW__F()^O94KE[[M.F[/Z\ A??7H.SC0CY&PHO>E^;11_M/!-#.GH_D@F63CZ7P\2X=9-AB/%HL4 M?CA)'J+\#U''ARC_0Y3_?D;Y/\ .>@C0WQM?
[_E%L;PP]STZV@$G[P(T^1F@ M(3^'39K7}GITPXM#E,4GVVJ^YT&;+R$,__D%^M^6R;I'&_%S$./[D:]Z"%Q\ MV0.Y]2-6K._HDKB3D$7+F+@W]\?=&'[0[CLGZ&<$[!A^CJUEGYX;\'YSN"QW M^G/
M3T;S\70\79PDPU%R.AXN3A8#,S2#TZ^TRN59F]NGA_U07[VD?PR^C?\2{ZH_[+T(U4W$BK]0A3SMH)'GLWY"3J=+4X7H\EPU)_/Q\E\,A^/$A,S M'HT6H\$,_ _<'>;H->Y>6Q@'%?I'ERQB7X)!?>74N4H4BY'\\M9#W MJ<7=N
@:00J&8ZT!1%CGN\QF6+::9SG3X>HCQ?AN1VPE4^N15X[2TF D"/OI M*NM,I]/9X.0,%H/1.$V2ZG0RFHV'YC3IPP_3>\I>]KF){X]80IX_ =,*GN1+ ML:JZ2C# AGM.=0GHKCPN$7[=K.02!R_"'X*W?3HSKGJZ,DOA?AV/)J
8T_F) M28;9=')BLGY_/KJGJ:W/3;*>5'ER]!JV8I&G5K_Z;!CWWKN4WFGG?"01=.G# M&;>=<]G':=0]5?IZODZ!N@>)F1\4EAH^MVMS:S_;B[YMD??;;>=' ->%YA(W,_ M#KUU\6B,$WG@05?E+TS2-SLY#$UYP=_C6OYR8Y+-
AJ.L_FDWYJA_G\3 :# MQ.@8!T4A!^PO408[&% M:Y*"]=H!G51!@28_E'4+P-5C<<]J2\&"7 M5#.@B=<&X^6!P.U]D=)QOT1{$[

345C+USL<7IX\&A[.,;'_M8*B'80XT1<['''-:\&D_'W_28"B93F![M%UX(4AU6%H8$V.UW6AC6U9;TI^W_MS(_,2#!LELZN,2=UA+:#1R9_"HD\T9$@$9!-;_.-$!(P3-=00%T,G6\.053_MQ')8.PFLV^?,1E'''[-"_';3.R
45E4Z^^,P_M1Z\,MS7MNP)$3*_O6Y__*!K,H_M%B@HA[T),WE'3+ZS+%W$F="W1O"(L?<20#WEJ9!2R/(TE56_9L9I;G]HZMG7OA6Z>?BML.+@F5_[?>([GN:#.ZI+YP*62C3<.H.;4_M0#$"8^3A'5}=062.ET4EM9/CI?
9MDV+%9(Z7VBL62*G$C6IJ*XIA;'08YJKH_M^Q<^Y9">L-L"\NA[$S*,[+8=J+%T,JLKO^ZXAK8F6*0A"J^_ZXDX*##[IM;7_M4RFW@N19I#2\#I_P3SL<1SZ+Z\B[=,[JLK$XDBA^'!]+(;I"KN.2;ZP;
M*GS!W*)7/-EPAJ74;A\?[2'U=V^$FE%JU%3ZVMYEDME&MH)5ZE2+6LS8+1Z;_MQ)P$YGO&ZJ!3#>:L-J=0$G/,@:ZH^Y=F9QO9/E8Y*:?U-2OM3%?WX&KBE:M\W9EJRHB08:$0UN_0TW3;T2'L=,'R/T_'#!_I7Z(XE!_M28>
("_6H%5"H7VJ_M>XN')JV*A54Q4#M&?_##^&$FOC!_=P\N8KH(SMW1)TH+E)1HU'J_D2@#7976_M0PM&^QJ'}K$EA2V1?;"E39X)31THYOZJI-F&M8\E#DJ9?=6*ZI=46&FK*+!-_M%EI[#-3#OG#C1\KS'%.A:(+7FK3;
M,52^5$W:R$$>%;8Q8*#;"U-':!;A7Y26?#\2&Z\2-5:CPB0=X(_M/:[ET?)ET3"4CB'}AJWD*[!RJUOQ3=`TE@>6'[Z:}=V'$WY>TJD/_M)"E=A@<]-&G%9^A\J;K^25ION:+7:[MHD'[!HQV:!},,K7-!,&F3JMG5]VR+_M*G:H?
3QP4+IH*4U3Q5L/5?7\VVTXIGX[0P4;K]Q56WO#'<96>Y-#,<8V2P7C_M1ZKS"B-O$;_4^NP4P-9N7V^W;&ACS3&}&!(Q=M4CMT:,-BF2FF$H6?ERJ2L_MV_9;E,GE(V5T_I,'''@1,Q;DRMGMJF8[9/FN_Q4.3CH@,E5-3T^=?2.R?
O2"(_M"B_9[@P04)R$>6[PD7$%0^X>>>+J9^A;((5MU_+GUR&=!#>>BZ+'}QR8\U-T_MI-9V#=8T%%,&3[9BM*]Q:!*@,C3JU@-7)EDKW'FC5)H59&RA&.>66#ONDCI"B=U$I_M2]O$AJT-$UNK2O?
^^I\WM)4)8>5N9,NVTNR=`V3;"H8E#!C(XO_M:[MKBM[K'*/"L!2OM,'RD4@ID?*HD:*W+5*V_MR[+J*0.ME+-2B92)*:ZU&G*_@ANO!WK>O6O6-_>K_"_6=FF/IKKE5JU&J;Z_MB%,"H7\CR5'CHA$'''<$O0(UMANCC
.@I"(GW2/RHZ>,)_1FU3HBZ*2C_.HO_M#6*Y8-GE%%)[^QZ>%%#+'X[9=2-XK.--)]0-%V/:^O4!%J'>\+Q%WX?MGOU$_M7>I;#KO,&DULUPY"/'A]IFM?N.FQ^/6C[5KN,/$<6'=XTMARGT#L6"%E5SU8
M[A^)T9\5PIS,CS,^C!#M9C8!@ADFOURY>NG/Q!\93XB__7VZ3/WOU"333#__M!UZS=#L7(9_7G]HJA'G#=GN9/3NR@WMTO0[6#H>,$,2.L>9,9'QQO^_ML5G?7D,H@/\4'A?Z,RHDZF<ZWB*<*8BC*0>+[-F4J=
[GXO.#WTICC?Z$\!_MMX*70]]SGS[44NK^\N/M_>??]V!7O,+WS'_M5BN"E'@7EC=H97/7:P,YR/4[0U8RI(XCY,1_O5'?L+\1Y*._,Y8L[1O9NVA"_M'*GJ+ZGUXR)(]{->47O6*3I+@B0\3?
PMYN"LVTE27I9D2MVEJ6&8*U(/VU:G_MV5U;9P4?:K)V42>H8FMR)F,C2VW2@L]4&&_%@V073--_/0]CK&F_MX>;5SY#ZKN5$53:#C_/_CI?H'%8HN,?Q[RMLEO9CE3^S,3E'@QP,D/8R*87Q_M&[=F8U8KP'J5K\.N,@_5
!$;K<@^1*^M[O\FHU_M[]TXYV7WA=@\<0J\6[C6'NZ(Y*T){AA2##Q,63X9$O5?8#$0ZJ'=`X,>NL_MD#EZ!X/4P6#DJR@e60,%(${\4%C:[.!HKVLKI6'0_SU
MR,E6\D.K!W4X3)KG/RMX=E\7DOIJ3^EK65'0DDD/@!]:.;C#8=)4?^8U3*K'_M3*K7+DD';6K957/.GHFK<,<*)OBKF;^-\T[:$Q.K/3-J1UUFD>46M_B.B_#_M.6UHFJX;>]_2U7]4K8[#EYR4RJS/:BBFJ;4!2=H@RB7#-
,$PE:G&E3',KG2,_M5HA>R3"OE6$J4U.K8!ASH.CM\/HHJ-?JRN;JG]$5)U0?*0*T2EU+-<3[4L[[*![6HPQK>VVFGMKIIG4FC==@=_MG:K,$$R]9+1\P4_R]1<#*6K9R75MR8TL+ZBB9+92QG5ZV#V;E76287,WC.4
M06=K,T4RNV3V5\[LO:J,E@J9O3M0^H.L5E>OCMD;L&9J*W6?.6A^D"NH>)F_M1U#6K!&X3/6:+FX(E>,X&9B[Q!"W_?O*+P76'''\[=A76D^?A+Y,Z$NU1RUN_M%I84**,K:F8!^N-F2_E]$OHD],53J!_Z-*SKM;.57_[V=4Q%
[VT=AW[P'/DZ_ML"_?BL_X,t<\;=&BG)NFNJ;J;_LJSL9UYK#VJ16GOOTPPT(!H;=:=BX0I5&!_ME\,O)8XWY!59Q4N]#^#=H>7$-6T5O'3U%BR&*QXN_M(C\VX@*98V6J*=:TQ0%L+L::4<_NO^+JIG*I.0]EI>,0'7D9VMPRCJD-
9O6\^?"*GO#!6_M1U'\,Q5;^O08CYXF1"L'4Q6@<^@_22_:CL4Z,7F+WR1*4HK7HW=QN:O>"GBC_M:Z;6$5U]"[YX]1ZA_5^9SDOUCQX\]N'#!Y?[,R;U#:N4E%,1<(,]8\4"5$O_MD,TWM0#1-?B_=5:{4MMRW@_YG*
(/$PNR7"071@T_FR[!BE>NB!U6Y3*35)N@_MU*6Z-MW-W^_GZ\OS^ZI_MNKXY0[FX/0],[N[A@R]7__=WM4SN9ZF3,_E^=G<&NK#C6#[60@>YX\T"RQW!_M)0'!>=!JB2!%UN[`X}A3%S80)A+;2_D^-9L,P^)6
.D>?/`]^0.6%\S7HS(J[18H/=\U!MY*5[H;CNEHAMU,%F7M_MKUUN8H(.0+XV\5>QQ.?NZ([ZS_:0[ET'/[6QF?0B:PL?9PE565NX17Z:PXM(_M.%[&>%U5.65M84EB;_Z3M84EB1T_BTPNUP?]+>)E\G(F1)6^*TO;/
XJ%I0;TR\9;:%/AVE_M8_9>8UIH,7!**P=UB.QK:(:N[9<%U03[_G8H:G_KE,=64:!DWN8-ZB#9US3T_M;0+U,_*:&I&^_U/19=GB]`P.IBK#A><&LPD>8X@.S9OXFC09%KGZTKK7_5#_M0S4[W47EFGHLE_4;+,X0HV>7F?
0]._2@6)GT+=%!C*Z5Z%"I_5O?.@PZLOY+_M#<.2Z/#*T*%*^ZNF=.BJBBK1000QUT"0V80M@DGAA-?,I'CQD-9G!F9O1][6[90?F''`;NQ0!(S=#,.-!V^4(DLU9@B$=CEU8_ML:3B;"5+DG)4O6%*B*RD_A;"G@OZ7JG_3I1
&MX\7GHLATC[+';O]_M_&8'?WR;#@)LE!%WVDI]?NL078S_20,A!D8DYK$G.BZLEQ-M$W,,\'KWE?H(}M8307V\H>&=Y=#@(SKN;MVH\M1][+0K$(D^^]!?M>ZCXAZJ_M^_ET$593^.#A%,]>9*@;SA{Z,N$V0/EH58.ZH
8VRB5L5>#_MR)MG[*U[C+6*-B5CMVM0!\389JF.01K_W3QC;WWJWRK:;+&U4C:5_AVK)Y]^_M\FD3-DCM:-4\$M6*,IT6V_6,P)''`RL27JAO@I0TZ@>2@:CFHVP(%0!(.VCH.
M6'+0@;VP)1S4;X&F6PD':>JQL5!#16*;,,YN/+=)YWNYJ]!P^$O+C1MR=N2M^QE[7(C0_/+OTC>KLZ&R/BP_MJKHN6]?'D-W<-]VTKE:+66DW]_LQ;,/8JMH,NZ&]E5K>QZ\HN6:+#Z2Z'M2%6Z7;[-:,8:RF9^:
{C@K'U(_D'Y8[L_PY*5=:E!0BVB][.9L:?GW*]f7W_M>-3B!+*E9ZI3O/J*K:XL1W-I%8@aU4^G6U*ZW5/)IHR!9R3&%..:[+\>45[-,_MZRF]3CWE-AKCF_J"_IH0OM?NT*=60_,RFE$2>L0.@AD3QR"+7?ZN\"A=`?
M0V>&2@^Q)K#B84!\.O2>7/M/.D+I+?KGPI-\O"@<4S*EONV-ZG?`5WA452Z@_M-_06R_E4,1%_\MWOKS0%3VOF3[_I5M>4W]_MC[2N,N@UFL=;D=R5Y+T/>?<;(.\JNNUHNF(.&DVR;5Y(EAO_6:=L%723E)+A_MV_K}BX4':TAO\
{GM,D&9.F6;DX?(+@[9%0\47NFB8_7)7*ULK6#)][4#*HT;_MK\I8J&?0>Z'H^H$E)VL1.-48<:TU{CAE_;KUJ_\D@.6$RP!H-:73V[J.6#6!_M)A5'K">(00FR>7L$:RH1[?4AFIYJO;,WHE6@,280K:-TNEV):-633:6(5H$&
MO28TL;ECG^*-=LJ@P$U+4"JV;Q4D7_MP[5ZBIE]Y+2BGVN%NZ_0NSQ6EJXHZ_M:$F?RCV"D9_2"!)_8)8'!.6I6(;2D+J5$@.%Z?S"@-*T.[DMX:_M:3T6!;GM@GHO:E!UM*[2ZVP=/W381J1DNU?
&=MM%!N>S78F^&U49Z.T\;F__M=Y/QX;85''(2Q;=.E^?KU/9*#-E+EK>\Z7H,ZME@N2!KL1L\PH._ML*?OR%H,6=._P7,%9%R*MXNS[P*"N]SF8+^@BCJGEH\KTR66.V)QJ?P8W"!DMRJVMDLG"&;-J5Z3K4N0679$%55(?
KS"0,3CK=G:HJ9+#OOF)MIP]G%598R:L7\.:#9P\$T6?[&7B351)MZX:+ZO'''E52ZG6=OMY2U3\NI6#H_M>_$P_^TC3IG-F$_X[!09??)\K#U55A65+.98G7;2/.YKAU1**=DOX@<@J
MU=9]:"K#OIOW:ISR<:74%P^TJ4;=/MAL^E?##/KK88;Z*YVTJ[J}}+$C+&%R_M9$"[5.J^UZVC#?<^^=2!;U'GD-I4R[!N;>OKKB\W-;KW0LM9,9,^SO^;>D__ME&,=2W+J=VLH^5$5W-5?>_M;A-
_M')0A\.TAEH.TQIU,VU7Z:GF:V3:.G25QO2O[T_8=$08$542H[%A,VM'_MK>81J5;TT>I6$;[?E7/RJYCZUDDRM=&+[!I_5$RBURV22V.27DT%!VMDDCK$_M;2-]X?>0TK?AF/K--RN164]EY]-=;ET+OD9M&@J^@''2!4?A5)/3?
2+@^IVG_M1,#7R-*R#[-$HR-#([,V5;\2-.KTM_:OOE8T:D#?E%V7MX^E2O3@W!}25W%[$C.)>MT_MA(P/MZL;LXD^UA2)(:GI\[RZ2H83Z'=],7(B^)2U>X4GO+"?^_MS8>_77AN8_]]VZ\+@):L-//"BY7NF9
MM+]3]L+5RA3}W<%0}GYDC4W+'EPZ:7*EDL&ZT2^50^B$@I;N6J}9M1>5;WAP_MP"QX\'$3.26&N4PL\]3]3_4V_C_V5_F<<)U1_A:%#+1_!0"S6BV2_D;,N)/N1SBCY,:,@R^<-H_0[3E5WP
MRG0N<7J.:]BH6DI=2@J^O0ER>WE%/M]?GBU1$$@!!O<',<>;V_NK.W)_2RYN_M;^YN/U]?GM]?79)/US?G-Q?7YY_)W3U\\.7JYOZNELG]+'5R}]_/{LY_?W,<-MRP]XDT90%/H#TX'V0Z31$_84$8\NG3*A,0:2{MLAO5^8K9+(
B/3/-)?R.?Y,_M5W%%)@O8%H(D*626Y<]JL:C-E7MTO5?-7DH'_$8=+'?VU?+#^;UON0`7RX)%_M19^RJ09DU>S9H,U6+!W2;(P<0+0NR(5O5V\9J?\]_W9_?74GF/K=JI209?H^_ME>G+*
JQNOCOHTI@6Q;R*_YH:!96"5%99ZMDL=NX%^7'UE<.K&_*]V-*:KP)_MW#H7&C9?6_"2_)YY._>A)*[/VS7>[88_M?)#/X>A,{18\C.$+F2+_8'U"__65>RMZ$K&>?.HB+\D##5\H9?US)V<$OQ2
M3;37A1?"S8]X6X"6N!5OO'}>I$$ALX"UN8_&.H0954!&_#UT4L$[,&+'0[' M#QY\!O<^^E8_:#4, >J4O2RIQY#=X,"KW_!9Z=^>#4.^KO7>!^Z%.H]X%ZS:"\{}EW!YQ<*Q[?/EL,42.,$I7;"IDR]%QAM_M=_-?
@HNQ31_)U4\ZG(6P+>263=^/F@9'NV;#PYS_PW6=/02AY:+;Q<79&\@_MA1F\B\]ZP@M%P1.R-XX;52Y=>4<\S9$=--!}Z/@<&8)!6/~SWFCX>[XBO6O&2%_MYE!K'({#GK+UC@@']"N>0$&9HR1EC@H0(@[B/]
<>O0BJ9F@@PE3#U(U>02$I_M.HO?/B8^VRPD?\P"?&B>X/TX3WX3!R#CQ'!>\<1@7B4&{J<=,TK1%3,UTTP5_M!-OOO5;Z:+9R00;I?#Y&A$57K3LP4BTB]ELU/5XU0;6K9AAZ>ME0[T;TP'JN_M
:$N,G5&75QCNW1B+KO5BT,,##4'FJ-A6[" ^^^U@>2U4P=_M;HH=?%-KCHN\O*/IIJ)+5/$"7Z]G/'Z^KNMFIVNDZZ>?BY=_Y>_>4#&]E9Q5_M;/8P_G0G]*S/R3YE?J@"$8<-B=_H@_^S/+G#'''7E,.Q!8HC\Z"PMB^@*,$;
MV*$/^2H46G(>J^&@'X_3FI1"7L9P_\,\3\D*0,UD^$P%V+2:ZV[)45B.DZ\._MQLHE.X,#,+)#A^OK-ALW+_F)5LV+'W$W1>OBB4V&1Z:2$VV_@!%-)C!.F$WH_M>)_Q3PH[_X_E@75C3_>M$84M_"-
XR_Y^G/G=J3+0U=V^$FE%JU%3ZVMYEDME&MH)5ZE2+6LS8+1Z:_MQ)P$YGO&ZJ!3#>:L-J=0$G/,@:ZH^Y=F9QO9/E8Y*:?U-2OM3%?WX&KBE:M\W9EJRHB08:$0UN_0TW3;T2'L=,'R/T_'#!_I7Z(XE!_M28>
("_6H%5"H7VJ_M>XN')JV*A54Q4#M&?_##^&$FOC!_=P\N8KH(SMW1)TH+E)1HU'J_D2@#7976_M0PM&^QJ'}K$EA2V1?;"E39X)31THYOZJI-F&M8\E#DJ9?=6*ZI=46&FK*+!-_M%EI[#-3#OG#C1\KS'%.A:(+7FK3;
M,52^5$W:R$$>%;8Q8*#;"U-':!;A7Y26?#\2&Z\2-5:CPB0=X(_M/:[ET?)ET3"4CB'}AJWD*[!RJUOQ3=`TE@>6'[Z:}=V'$WY>TJD/_M)"E=A@<]-&G%9^A\J;K^25ION:+7:[MHD'[!HQV:!},,K7-!,&F3JMG5]VR+_M*G:H?
3QP4+IH*4U3Q5L/5?7\VVTXIGX[0P4;K]Q56WO#'<96>Y-#,<8V2P7C_M1ZKS"B-O$;_4^NP4P-9N7V^W;&ACS3&}&!(Q=M4CMT:,-BF2FF$H6?ERJ2L_MV_9;E,GE(V5T_I,'''@1,Q;DRMGMJF8[9/FN_Q4.3CH@,E5-3T^=?2.R?
O2"(_M"B_9[@P04)R$>6[PD7$%0^X>>>+J9^A;((5MU_+GUR&=!#>>BZ+'}QR8\U-T_MI-9V#=8T%%,&3[9BM*]Q:!*@,C3JU@-7)EDKW'FC5)H59&RA&.>66#ONDCI"B=U$I_M2]O$AJT-$UNK2O?
^^I\WM)4)8>5N9,NVTNR=`V3;"H8E#!C(XO_M:[MKBM[K'*/"L!2OM,'RD4@ID?*HD:*W+5*V_MR[+J*0.ME+-2B92)*:ZU&G*_@ANO!WK>O6O6-_>K_"_6=FF/IKKE5JU&J;Z_MB%,"H7\CR5'CHA$'''<$O0(UMANCC
.@I"(GW2/RHZ>,)_1FU3HBZ*2C_.HO_M#6*Y8-GE%%)[^QZ>%%#+'X[9=2-XK.--)]0-%V/:^O4!%J'>\+Q%WX?MGOU$_M7>I;#KO,&DULUPY"/'A]IFM?N.FQ^/6C[5KN,/$<6'=XTMARGT#L6"%E5SU8
M[A^)T9\5PIS,CS,^C!#M9C8!@ADFOURY>NG/Q!\93XB__7VZ3/WOU"333#__M!UZS=#L7(9_7G]HJA'G#=GN9/3NR@WMTO0[6#H>,$,2.L>9,9'QQO^_ML5G?7D,H@/\4'A?Z,RHDZF<ZWB*<*8BC*0>+[-F4J=
[GXO.#WTICC?Z$\!_MMX*70]]SGS[44NK^\N/M_>??]V!7O,+WS'_M5BN"E'@7EC=H97/7:P,YR/4[0U8RI(XCY,1_O5'?L+\1Y*._,Y8L[1O9NVA"_M'*GJ+ZGUXR)(]{->47O6*3I+@B0\3?
PMYN"LVTE27I9D2MVEJ6&8*U(/VU:G_MV5U;9P4?:K)V42>H8FMR)F,C2VW2@L]4&&_%@V073--_/0]CK&F_MX>;5SY#ZKN5$53:#C_/_CI?H'%8HN,?Q[RMLEO9CE3^S,3E'@QP,D/8R*87Q_M&[=F8U8KP'J5K\.N,@_5
!$;K<@^1*^M[O\FHU_M[]TXYV7WA=@\<0J\6[C6'NZ(Y*T){AA2##Q,63X9$O5?8#$0ZJ'=`X,>NL_MD#EZ!X/4P6#DJR@e60,%(${\4%C:[.!HKVLKI6'0_SU
MR,E6\D.K!W4X3)KG/RMX=E\7DOIJ3^EK65'0DDD/@!]:.;C#8=)4?^8U3*K'_M3*K7+DD';6K957/.GHFK<,<*)OBKF;^-\T[:$Q.K/3-J1UUFD>46M_B.B_#_M.6UHFJX;>]_2U7]4K8[#EYR4RJS/:BBFJ;4!2=H@RB7#-
,$PE:G&E3',KG2,_M5HA>R3"OE6$J4U.K8!ASH.CM\/HHJ-?JRN;JG]$5)U0?*0*T2EU+-<3[4L[[*![6HPQK>VVFGMKIIG4FC==@=_MG:K,$$R]9+1\P4_R]1<#*6K9R75MR8TL+ZBB9+92QG5ZV#V;E76287,WC.4
M06=K,T4RNV3V5\[LO:J,E@J9O3M0^H.L5E>OCMD;L&9J*W6?.6A^D"NH>)F_M1U#6K!&X3/6:+FX(E>,X&9B[Q!"W_?O*+P76'''\[=A76D^?A+Y,Z$NU1RUN_M%I84**,K:F8!^N-F2_E]$OHD],53J!_Z-*SKM;.57_[V=4Q%
[VT=AW[P'/DZ_ML"_?BL_X,t<\;=&BG)NFNJ;J;_LJSL9UYK#VJ16GOOTPPT(!H;=:=BX0I5&!_ME\,O)8XWY!59Q4N]#^#=H>7$-6T5O'3U%BR&*QXN_M(C\VX@*98V6J*=:TQ0%L+L::4<_NO^+JIG*I.0]EI>,0'7D9VMPRCJD-
9O6\^?"*GO#!6_M1U'\,Q5;^O08CYXF1"L'4Q6@<^@_22_:CL4Z,7F+WR1*4HK7HW=QN:O>"GBC_M:Z;6$5U]"[YX]1ZA_5^9SDOUCQX\]N'#!Y?[,R;U#:N4E%,1<(,]8\4"5$O_MD,TWM0#1-?B_=5:{4MMRW@_YG*
(/$PNR7"071@T_FR[!BE>NB!U6Y3*35)N@_MU*6Z-MW-W^_GZ\OS^ZI_MNKXY0[FX/0],[N[A@R]7__=WM4SN9ZF3,_E^=G<&NK#C6#[60@>YX\T"RQW!_M)0'!>=!JB2!%UN[`X}A3%S80)A+;2_D^-9L,P^)6
.D>?/`]^0.6%\S7HS(J[18H/=\U!MY*5[H;CNEHAMU,%F7M_MKUUN8H(.0+XV\5>QQ.?NZ([ZS_:0[ET'/[6QF?0B:PL?9PE565NX17Z:PXM(_M.%[&>%U5.65M84EB;_Z3M84EB1T_BTPNUP?]+>)E\G(F1)6^*TO;/
XJ%I0;TR\9;:%/AVE_M8_9>8UIH,7!**P=UB.QK:(:N[9<%U03[_G8H:G_KE,=64:!DWN8-ZB#9US3T_M;0+U,_*:&I&^_U/19=GB]`P.IBK#A><&LPD>8X@.S9OXFC09%KGZTKK7_5#_M0S4[W47EFGHLE_4;+,X0HV>7F?
0]._2@6)GT+=%!C*Z5Z%"I_5O?.@PZLOY+_M#<.2Z/#*T*%*^ZNF=.BJBBK1000QUT"0V80M@DGAA-?,I'CQD-9G!F9O1][6[90?F''`;NQ0!(S=#,.-!V^4(DLU9@B$=CEU8_ML:3B;"5+DG)4O6%*B*RD_A;"G@OZ7JG_3I1
&MX\7GHLATC[+';O]_M_&8'?WR;#@)LE!%WVDI]?NL078S_20,A!D8DYK$G.BZLEQ-M$W,,\'KWE?H(}M8307V\H>&=Y=#@(SKN;MVH\M1][+0K$(D^^]!?M>ZCXAZJ_M^_ET$593^.#A%,]>9*@;SA{Z,N$V0/EH58.ZH
8VRB5L5>#_MR)MG[*U[C+6*-B5CMVM0!\389JF.01K_W3QC;WWJWRK:;+&U4C:5_AVK)Y]^_M\FD3-DCM:-4\$M6*,IT6V_6,P)''`RL27JAO@I0TZ@>2@:CFHVP(%0!(.VCH.
M6'+0@;VP)1S4;X&F6PD':>JQL5!#16*;,,YN/+=)YWNYJ]!P^$O+C1MR=N2M^QE[7(C0_/+OTC>KLZ&R/BP_MJKHN6]?'D-W<-]VTKE:+66DW]_LQ;,/8JMH,NZ&]E5K>QZ\HN6:+#Z2Z'M2%6Z7;[-:,8:RF9^:
{C@K'U(_D'Y8[L_PY*5=:E!0BVB][.9L:?GW*]f7W_M>-3B!+*E9ZI3O/J*K:XL1W-I%8@aU4^G6U*ZW5/)IHR!9R3&%..:[+\>45[-,_MZRF]3CWE-AKCF_J"_IH0OM?NT*=60_,RFE$2>L0.@AD3QR"+7?ZN\"A=`?
M0V>&2@^Q)K#B84!\.O2>7/M/.D+I+?KGPI-\O"@<4S*EONV-ZG?`5WA452Z@_M-_06R_E4,1%_\MWOKS0%3VOF3[_I5M>4W]_MC[2N,N@UFL=;D=R5Y+T/>?<;(.\JNNUHNF(.&DVR;5Y(EAO_6:=L%723E)+A_MV_K}BX4':TAO\
{GM,D&9.F6;DX?(+@[9%0\47NFB8_7)7*ULK6#)][4#*HT;_MK\I8J&?0>Z'H^H$E)VL1.-48<:TU{CAE_;KUJ_\D@.6$RP!H-:73V[J.6#6!_M)A5'K">(00FR>7L$:RH1[?4AFIYJO;,WHE6@,280K:-TNEV):-633:6(5H$&
MO28TL;ECG^*-=LJ@P$U+4"JV;Q4D7_MP[5ZBIE]Y+2BGVN%NZ_0NSQ6EJXHZ_M:$F?RCV"D9_2"!)_8)8'!.6I6(;2D+J5$@.%Z?S"@-*T.[DMX:_M:3T6!;GM@GHO:E!UM*[2ZVP=/W381J1DNU?
&=MM%!N>S78F^&U49Z.T\;F__M=Y/QX;85''(2Q;=.E^?KU/9*#-E+EK>\Z7H,ZME@N2!KL1L\PH._ML*?OR%H,6=._P7,%9%R*MXNS[P*"N]SF8+^@BCJGEH\KTR66.V)QJ?P8W"!DMRJVMDLG"&;-J5Z3K4N0679$%55(?
KS"0,3CK=G:HJ9+#OOF)MIP]G%598R:L7\.:#9P\$T6?[&7B351)MZX:+ZO'''E52ZG6=OMY2U3\NI6#H_M>_$P_^TC3IG-F$_X[!09??)\K#U55A65+.98G7;2/.YKAU1**=DOX@<@J
MU=9]:"K#OIOW:ISR<:74%P^TJ4;=/MAL^E?##/KK88;Z*YVTJ[J}}+$C+&%R_M9$"[5.J^UZVC#?<^^=2!;U'GD-I4R[!N;>OKKB\W-;KW0LM9,9,^SO^;>D__ME&,=2W+J=VLH^5$5W-5?>_M;A-
_M')0A\.TAEH.TQIU,VU7Z:GF:V3:.G25QO2O[T_8=$08$542H[%A,VM'_MK>81J5;TT>I6$;[?E7/RJYCZUDDRM=&+[!I_5$RBURV22V.27DT%!VMDDCK$_M;2-]X?>0TK?AF/K--RN164]EY]-=;ET+OD9M&@J^@''2!4?A5)/3?
2+@^IVG_M1,#7R-*R#[-$HR-#([,V5;\2-.KTM_:OOE8T:D#?E%V7MX^E2O3@W!}25W%[$C.)>MT_MA(P/MZL;LXD^UA2)(:GI\[RZ2H83Z'=],7(B^)2U>X4GO+"?^_MS8>_77AN8_]]VZ\+@):L-//"BY7NF9
MM+]3]L+5RA3}W<%0}GYDC4W+'EPZ:7*EDL&ZT2^50^B$@I;N6J}9M1>5;WAP_MP"QX\'$3.26&N4PL\]3]3_4V_C_V5_F<<)U1_A:%#+1_!0"S6BV2_D;,N)/N1SBCY,:,@R^<-H_0[3E5WP
MRG0N<7J.:]BH6DI=2@J^O0ER>WE%/M]?GBU1$$@!!O<',<>;V_NK.W)_2RYN_M;^YN/U]?GM]?79)/US?G-Q?7YY_)W3U\\.7JYOZNELG]+'5R}]_/{LY_?W,<-MRP]XDT90%/H#TX'V0Z31$_84$8\NG3*A,0:2{MLAO5^8K9+(
B/3/-)?R.?Y,_M5W%%)@O8%H(D*626Y<]JL:C-E7MTO5?-7DH'_$8=+'?VU?+#^;UON0`7RX)%_M19^RJ09DU>S9H,U6+!W2;(P<0+0NR(5O5V\9J?\]_W9_?74GF/K=JI209?H^_ME>G+*
JQNOCOHTI@6Q;R*_YH:!96"5%99ZMDL=NX%^7'UE<.K&_*]V-*:KP)_MW#H7&C9?6_"2_)YY._>A)*[/VS7>[88_M?)#/X>A,{18\C.$+F2+_8'U"__65>RMZ$K&>?.HB+\D##5\H9?US)V<$OQ2
M3;37A1?"S8]X6X"6N!5OO'}>I$$ALX"UN8_&.H0954!&_#UT4L$[,&+'0[' M#QY\!O<^^E8_:#4, >J4O2RIQY#=X,"KW_!9Z=^>#4.^KO7>!^Z%.H]X%ZS:"\{}EW!YQ<*Q[?/EL,42.,$I7;"IDR]%QAM_M=_-?
@HNQ31_)U4\ZG(6P+>263=^/F@9'NV;#PYS_PW6=/02AY:+;Q<79&\@_MA1F\B\]ZP@M%P1.R-XX;52Y=>4<\S9$=--!}Z/@<&8)!6/~SWFCX>[XBO6O&2%_MYE!K'({#GK+UC@@']"N>0$&9HR1EC@H0(@[B/]
<>O0BJ9F@@PE3#U(U>02$I_M.HO?/B8^VRPD?\P"?&B>X/TX3WX3!R#CQ'!>\<1@7B4&{J<=,TK1%3,UTTP5_M!-OOO5;Z:+9R00;I?#Y&A$57K3LP4BTB]ELU/5XU0;6K9AAZ>ME0[T;TP'JN_M
:$N,G5&75QCNW1B+KO5BT,,##4'FJ-A6[" ^^^U@>2U4P=_M;HH=?%-KCHN\O*/IIJ)+5/$"7Z]G/'Z^KNMFIVNDZZ>?BY=_Y>_>4#&]E9Q5_M;/8P_G0G]*S/R3YE?J@"$8<-B=_H@_^S/+G#'''7E,.Q!8HC\Z"PMB^@*,$;
MV*$/^2H46G(>J^&@'X_3FI1"7L9P_\,\3\D*0,UD^$P%V+2:ZV[)45B.DZ\._MQLHE.X,#,+)#A^OK-ALW+_F)5LV+'W$W1>OBB4V&1Z:2$VV_@!%-)C!.F$WH_M>)_Q3PH[_X_E@75C3_>M$84M_"-
XR_Y^G/G=J3+0U=V^$FE%JU%3ZVMYEDME&MH)5ZE2+6LS8+1Z:_MQ)P$YGO&ZJ!3#>:L-J=0$G/,@:ZH^Y=F9QO9/E8Y*:?U-2OM3%?WX&KBE:M\W9EJRHB08:$0UN_0TW3;T2'L=,'R/T_'#!_I7Z(XE!_M28>
("_6H%5"H7VJ_M>XN')JV*A54Q4#M&?_##^&$FOC!_=P\N8KH(SMW1)TH+E)1HU'J_D2@#7976_M0PM&^QJ'}K$EA2V1?;"E39X)31THYOZJI-F&M8\E#DJ9?=6*ZI=46&FK*+!-_M%EI[#-3#OG#C1\KS'%.A:(+7FK3;
M,52^5$W:R$$>%;8Q8*#;"U-':!;A7Y26?#\2&Z\2-5:CPB0=X(_M/:[ET?)ET3"4CB'}AJWD*[!RJUOQ3=`TE@>6'[Z:}=V'$WY>TJD/_M)"E=A@<]-&G%9^A\J;K^25ION:+7:[MHD'[!HQV:!},,K7-!,&F3JMG5]VR+_M*G:H?
3QP4+IH*4U3Q5L/5?7\VVTXIGX[0P4;K]Q56WO#'<96>Y-#,<8V2P7C_M1ZKS"B-O$;_4^NP4P-9N7V^W;&ACS3&}&!(Q=M4CMT:,-BF2FF$H6?ERJ2L_MV_9;E,GE(V5T_I,'''@1,Q;DRMGMJF8[9/FN_Q4.3CH@,E5-3T^=?2.R?
O2"(_M"B_9[@P04)R$>6[PD7$%0^X>>>+J9^A;((5MU_+GUR&=!#>>BZ+'}QR8\U-T_MI-9V#=8T%%,&3[9BM*]Q:!*@,C3JU@-7)EDKW'FC5)H59&RA&.>66#ONDCI"B=U$I_M2]O$AJT-$UNK2O?
^^I\WM)4)8>5N9,NVTNR=`V3;"H8E#!C(XO_M:[MKBM[K'*/"L!2OM,'RD4@ID?*HD:*W+5*V_MR[+J*0.ME+-2B92)*:ZU&G*_@ANO!WK>O6O6-_>K_"_6=FF/IKKE5JU&J;Z_MB%,"H7\CR5'CHA$'''<$O0(UMANCC
.@I"(GW2/RHZ>,)_1FU3HBZ*2C_.HO_M#6*Y8-GE%%)[^QZ>%%#+'X[9=2-XK.--)]0-%V/:^O4!%J'>\+Q%WX?MGOU$_M7>I;#KO,&DULUPY"/'A]IFM?N.FQ^/6C[5KN,/$<6'=XTMARGT#L6"%E5SU8
M[A^)T9\5PIS,CS,^C!#M9C8!@ADFOURY>NG/Q!\93XB__7VZ3/WOU"333#__M!UZS=#L7(9_7G]HJA'G#=GN9/3NR@WMTO0[6#H>,$,2.L>9,9'QQO^_ML5G?7D,H@/\4'A?Z,RHDZF<ZWB*<*8BC*0>+[-F4J=
[GXO.#WTICC?Z$\!_MMX*70]]SGS[44NK^\N/M_>??]V!7O,+WS'_M5BN"E'@7EC=H97/7:P,YR/4[0U8RI(XCY,1_O5'?L+\1Y*._,Y8L[1O9NVA"_M'*GJ+ZGUXR)(]{->47O6*3I+@B0\3?
PMYN"LVTE27I9D2MVEJ6&8*U(/VU:G_MV5U;9P4?:K)V42>H8FMR)F,C2VW2@L]4&&_%@V073--_/0]CK&F_MX>;5SY#ZKN5$53:#C_/_CI?H'%8HN,?Q[RMLEO9CE3^S,3E'@QP,D/8R*87Q_M&[=F8U8KP'J5K\.N,@_5
!$;K<@^1*^M[O\FHU_M[]TXYV7WA=@\<0J\6[C6'NZ(Y*T){AA2##Q,63X9$O5?8#$0ZJ'=`X,>NL_MD#EZ!X/4P6#DJR@e60,%(${\4%C:[.!HKVLKI6'0_SU
MR,E6\D.K!W4X3)KG/RMX=E\7DOIJ3^EK65'0DDD/@!]:.;C#8=)4?^8U3*K'_M3*K7+DD';6K957/.GHFK<,<*)OBKF;^-\T[:$Q.K/3-J1UUFD>46M_B.B_#_M.6UHFJX;>]_2U7]4K8[#EYR4RJS/:BBFJ;4!2=H@RB7#-
,$PE:G&E3',KG2,_M5HA>R3"OE6$J4U.K8!ASH.CM\/HHJ-?JRN;JG]$5)U0?*0*T2EU+-<3[4L[[*![6HPQK>VVFGMKIIG4FC==@=_MG:K,$$R]9+1\P4_R]1<#*6K9R75MR8TL+ZBB9+92QG5ZV#V;E76287,WC.4
M06=K,T4RNV3V5\[LO:J,E@J9O3M0^H.L5E>OCMD;L&9J*W6?.6A^D"NH>)F_M1U#6K!&X3/6:+FX(E>,X&9B[Q!"W_?O*+P76'''\[=A76D^?A+Y,Z$NU1RUN_M%I84**,K:F8!^N-F2_E]$OHD],53J!_Z-*SKM;.57_[V=4Q%
[VT=AW[P'/DZ_ML"_?BL_X,t<\;=&BG)NFNJ;J;_LJSL9UYK#VJ16GOOTPPT(!H;=:=BX0I5&!_ME\,O)8XWY!59Q4N]#^#=H>7$-6T5O'3U%BR&*QXN_M(C\VX@*98V6J*=:TQ0%L+L::4<_NO^+JIG*I.0]EI>,0'7D9VMPRCJD-
9O6\^

inmd:HimalayaFamilyOfficeConsultingLtdMember 2023-12-31 0001742692 inmd:SubsidiaryOfHomeSkinnovationsLtdMember 2024-12-31 0001742692 inmd:SubsidiaryOfHomeSkinnovationsLtdMember 2023-12-31 0001742692 inmd:MedimorMemberinmd:ShareRepurchaseAndShareholdersAgreementMember 2019-11-30 0001742692 inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:ShareRepurchaseAndShareholdersAgreementMember 2019-11-30 0001742692 inmd:MedimorMemberinmd:ShareRepurchaseAndShareholdersAgreementMember 2023-11-30 0001742692 inmd:MedimorMemberinmd:TwoRepurchaseAndShareholdersAgreementsMember 2024-12-31 0001742692 inmd:MedimorMemberinmd:TwoRepurchaseAndShareholdersAgreementsMember 2023-12-31 0001742692 inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:TwoRepurchaseAndShareholdersAgreementsMember 2024-12-31 0001742692 inmd:MedimorMemberinmd:FullyDilutedBasisMemberinmd:TwoRepurchaseAndShareholdersAgreementsMember 2023-12-31 iso4217:ILS shares pure shares iso4217:USD iso4217:USD shares iso4217:ILSfalseFY20240001742692P7Y4Mhttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2024#AccountsReceivableNetCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrent20-Ffalsetrue2024-12-31--12-31falsefalse001-39016InMode Ltd.L3Tavor BuildingSha'ar YokneamP.O. Box 533Yokneam2069206ILMoshe Mizrahy9724-9096313Tavor BuildingSha'ar YokneamP.O. Box 533Yokneam2069206ILOrdinary shares, par value NIS 0.01 per ordinary shareINMDNASDAQ69558670YesNoYesYesLarge Accelerated FilerfalsetruefalseU.S. GAAPfalsetrueThe Company has developed and maintained a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk and to ensure compliance with the principles of Services Organization Control Type 2, or SOC 2, including its tenets of security, availability and confidentiality.Our cybersecurity process has been integrated into the Company's overall risk management system and process, and is solely internally managed. trueThe risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the Company's objectives as well as specific risks related to a compromise to the security of data. The oversight of cybersecurity threats is undertaken by our Chief Information Officer (CIO), who holds over 25 years of experience in information technology, and is supported by management.To facilitate its monitoring over cybersecurity risks, the Company has engaged a Chief Information Security Officer (CISO) who holds over 7 years of experience in information technology in connection with its cybersecurity process.Our audit and investment committee is responsible for cybersecurity oversight and monitoring risk.true1309Kesselman & KesselmanTel-Aviv, Israel1553290001444110002681290003758290002676880003736470001734550002235470001825000153800036335000423620002209700016268000595480004509500071445200084533000092400071600031760000.010.012000000002000000008758367385957465695586703982462249000245000197028000177820000874701000693426000-340000-167900018025003197500336782500082440000703813000781275000001339000016569000001656900002360000024452000572000102000044900016700007100044010004714000121000055179000-184000084000-594900001608400010415000569800022240001787000144530005198000188710000-184000-227600074630001917000-125880001794100054020000-306800012010001326640001768260001815780001681870002332410009370100021874000085090000739000066900070500015750000100000033622100024533700016868000090754000500000023030000357789001360640000-109474000285385000042637000261400055044001552000-282771000550400041085000-1181000605000-161500010918000468710002940400014441100097540000681360001553290001444110009754000017691000316140002584300027693000142190004856000125900052000002342000490002000010300012000 NOTE 1 - GENERAL: InMode Ltd. (separately and together with its subsidiaries, the "Company") was incorporated on January 2, 2008 and commenced operations shortly thereafter. The Company's headquarters are located in Israel. The Company is traded in the Nasdaq Global Select Market (the "Nasdaq") since August 2019.   The Company designs, develops, manufactures and markets innovative minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. These technologies are used to remodel subdermal adipose or fatty tissue in a variety of procedures including liposuction with simultaneous skin tightening, body and face contouring and ablative skin rejuvenation treatments, as well as, for use in certain women's health conditions and procedures. In addition to the minimally-invasive technologies, the Company designs, develops, manufactures and markets non-invasive medical aesthetic products that target a wide array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The Company also designs, develops, manufactures and markets hands-free medical aesthetic products that target a wide array of procedures such as skin tightening, fat reduction and muscle stimulation.   The Company has wholly-owned subsidiaries located in the United States and two subsidiaries in Canada ("North America"), Hong Kong, Japan, Spain, two subsidiaries in Israel, India, Australia, China, the United Kingdom ("UK"), France, Italy and Germany. The Company's subsidiaries are referred to collectively herein as the "Subsidiaries." The Company sells its products primarily through its Subsidiaries. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top">Basis of presentation</td> </tr> </table>   The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top"> Use of estimates </td> </tr> </table>   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to valuation allowances.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">c.</td> <td style="width:auto;vertical-align:top"> Functional currency </td> </tr></table>   The U.S. dollar ("U.S. dollar" or "$") is the currency of the primary economic environment in which the operations of the Company is conducted. Substantial revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar ("primary currency").   Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in finance income (expenses), as appropriate.   The functional currency of each of the Subsidiaries is the U.S. dollar.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">d.</td> <td style="width:auto;vertical-align:top"> Principles of consolidation and presentation </td> </tr> </table>   The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany transactions and balances are eliminated in consolidation.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">e.</td> <td style="width:auto;vertical-align:top"> Cash and cash equivalents </td> </tr> </table>   The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">f.</td> <td style="width:auto;vertical-align:top"> Short-term bank deposits </td> </tr> </table>   Bank deposits with maturities of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an annual rate of approximately 0.5%-6.15% in 2024 and 4.10%-7.01% in 2023.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">g.</td> <td style="width:auto;vertical-align:top"> Marketable securities </td> </tr> </table>   AFS Securities   Marketable securities consist of government bonds, municipal bonds and corporate debt securities (together "Debt Securities"), and certificates of deposit measured at fair value in each reporting period. The fair value of quoted securities is based on current market value.   Debt Securities and certificates of deposit are classified as available-for-sale (together "AFS Securities") under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company's current operations. Changes in fair value, excluding credit losses and impairments, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of Debt Securities and certificates of deposit as well as premium or discount amortization are included in the consolidated statements of income as finance income, net. Fair value is calculated based on publicly available market information. The amortized cost of the Debt Security will be reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost basis, or it has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recognized in finance income, net on the consolidated statements income.   The Company classifies investments that are readily convertible to known amounts of cash and have stated maturities of three months or less from the date of purchase as cash equivalents and those with stated maturities of greater than three months as marketable securities.   The Company determines the appropriate classification of its investments in marketable securities at the time of purchase.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">h.</td> <td style="width:auto;vertical-align:top"> <span

style="font-family:Times New Roman,Times,serif">Other Investments </td> </tr> </table>   The Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity investments without readily determinable fair values at cost for other investments, less impairment, adjusted for subsequent observable price changes. In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings. Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in orderly transactions for the identical or similar investment of the same issuer.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">i.</td> <td style="width:auto;vertical-align:top"> Inventories </td> </tr> </table>   Inventories include raw materials and finished products are valued at the lower of cost, “moving average” method, or net realizable value. The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">j.</td> <td style="width:auto;vertical-align:top"> Leases </td> </tr> </table>   The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities, and operating lease liabilities in the consolidated balance sheets.   The Company also elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.   ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 9).   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">k.</td> <td style="width:auto;vertical-align:top"> Property and equipment </td> </tr> </table>   Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:80%;vertical-align:top;background-color:rgb(204, 238, 255)"> Computers </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 3 – 4 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom"> Molds </td> <td style="width:20%;vertical-align:bottom"> 4 – 10 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> Equipment and furniture </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 10 – 17 years </td> </tr> </table>   Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the improvements.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">l.</td> <td style="width:auto;vertical-align:top"> Impairment of long-lived assets </td> </tr> </table>   The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.
  During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize an impairment loss on its long-lived assets.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">m.</td> <td style="width:auto;vertical-align:top"> Legal and other contingencies </td> </tr> </table>   Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.   Management applies the guidance in ASC 450-20, “Loss Contingencies” when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonable estimated, then the estimated liability is recorded as accrued expenses in the Company’s consolidated financial statements.   Legal costs incurred in connection with loss contingencies are expensed as incurred.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">n.</td> <td style="width:auto;vertical-align:top"> Income taxes: </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top"> </td> <td style="width:auto;vertical-align:top"> </td> </tr> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top"> The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Subsidiaries outside of Israel; no additional deferred income tax assets have been provided, since the Company does not expect to distribute inter-company dividends in the foreseeable future that may result in additional tax liability. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">3)</td> <td style="width:auto;vertical-align:top"> Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income tax assets, as it is the Company’s intent and ability to hold these investments. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">4)</td> <td style="width:auto;vertical-align:top"> The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit of the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">o.</td> <td style="width:auto;vertical-align:top"> Advertising expenses </td> </tr> </table>   Advertising expenses are charged to sales and marketing on the consolidated statement of income as incurred. Advertising expenses for the years ended December 31, 2024, 2023 and 2022 amounted to $15 million, $15 million, and $10 million, respectively.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">p.</td> <td style="width:auto;vertical-align:top"> Share-based compensation </td> </tr> </table>   The Company grants share options and restricted share units (“RSU”) (together “Share-Based Compensation”) to its employees, officers, directors and non-employees in consideration for services rendered and for acquiring goods. See note 12(a)(2) for details on outstanding share capital.   The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Binomial Model, and for each RSU granted is based on the Company’s share price at the close of the last trading day prior to the date of the grant. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates.   The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Performance-based Share-Based Compensation expenses are calculated based on the valuation at the grant date, and recognized based on the probability of achieving those targets. The Company assess at what scale can the performance targets be reached at each balance sheet date, and expenses are recognized accordingly.   The Company issues new shares upon option exercise or RSU vesting.   <table cellpadding="0" cellspacing="0" style="font-family:'Times

New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">q.</td> <td style="width:auto;vertical-align:top"> Revenue recognition </td> </tr> </table>   The Company applies ASC 606, "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.95pt"> </td> <td style="width:38.05pt;vertical-align:top">(i)</td> <td style="width:auto;vertical-align:top"> Identify the contract(s) with a customer; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(ii)</td> <td style="width:auto;vertical-align:top"> Identify the performance obligations in the contract. The Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(iii)</td> <td style="width:auto;vertical-align:top"> Determine the transaction price; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(iv)</td> <td style="width:auto;vertical-align:top"> Allocate the transaction price to the performance obligations in the contract; The Company estimates the standalone selling prices of the services to be provided based on actual sales transactions of service contract purchased on a standalone basis and uses the residual approach to estimate the selling price of the products; and </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(v)</td> <td style="width:auto;vertical-align:top"> Recognize revenue when (or as) the performance obligation is satisfied. </td> </tr> </table>   The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.   The Company uses the following practical expedients that are permitted under the rules: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:106.9pt"> </td> <td style="width:18pt;vertical-align:top">•</td> <td style="width:auto;vertical-align:top"> The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in sales and marketing expenses. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:106.9pt"> </td> <td style="width:18pt;vertical-align:top">•</td> <td style="width:auto;vertical-align:top"> The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. </td> </tr> </table>   The following is a description of the principal activities from which the Company generates its revenue.   Product Revenue, Net   Revenues from product sales are recognized when the customer obtains control over the Company's product, typically upon shipment to the customer. Revenues from shipping and handling activities that occur after the customer has obtained control of a good are recognized according to an accounting policy election as a fulfilment cost rather than as an additional promised service. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.   Payment terms and conditions vary by customer. The Company's standard terms for end users usually require of payment upon delivery and for distributors require a down payment and payments made within several month from the invoice date.   The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60 months) financing for the purchase of the Company's products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract.   Variable considerations include price concessions related to installment sales contracts. The Company estimates variable consideration using the most likely outcome amount. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur.   During the year ended December 31, 2024, the Company entered into risk sharing agreements with several leasing partners to facilitate and support the financing of capital equipment sales for its customers. Under these arrangements, a portion of each sale transaction funded by those leasing partners goes into a reserve fund used by the Company to provide a limited guarantee, up to the reserve fund amount, and used to compensate the leasing partners in the event of customer defaults. The guarantee is recognized on the estimated fair value amount according to ASC 460. In the following periods the Company will assess credit losses in accordance with ASC 326, see also note 2r.   The Company does not grant a right of return, refund, cancelation or termination. From time to time, the Company participates in its customers' marketing activities and deducts such amounts from revenue.   Service Revenue   The Company also generates revenues from long-term maintenance contracts ("Extended Warranty"). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. These maintenance agreements are included in contract liabilities. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed.   The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12 months as long-term.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">r.</td> <td style="width:auto;vertical-align:top"> Allowance for doubtful accounts and financial instruments – credit loss </td> </tr> </table>   The Company maintains the allowance for doubtful account resulting from the inability of the Company's customers to make required payments.   The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable. This information includes among other the historic experience, the extent and amount of the account and future expectations.   Allowance for credit losses due to the Company's accounts receivable amounted to $2,749 and $2,254 as of December 31, 2024 and 2023 respectively. Changes in the allowance for credit losses are recognized in general and administrative expenses. Accounts receivable are written-off against the allowance for credit losses when management deems the accounts are no longer collectible.   The following table sets forth activity in the Company's allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,254 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,318 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,107 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Current-period provision </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 572 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,020 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 449 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-

bottom:2px;vertical-align:bottom"> Write-offs charged against the Allowance and revaluation </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (77 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (84 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (238 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,749 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,254 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,318 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:23.6pt;vertical-align:top;font-weight:bold">s.</td> <td style="width:auto;vertical-align:top"> Warranty reserve </td> </tr> </table>   The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs, the cost per repair and shipping cost. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.   The following table sets forth activity in the Company’s accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,476 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,418 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,248 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Cost incurred </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (1,909 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,304 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,099 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Expense recognized </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,155 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,362 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,269 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 722 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,476 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,418 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">t.</td> <td style="width:auto;vertical-align:top"> Cost of revenues </td> </tr> </table>   Cost of revenue consists of products purchased from turnkey sub-contractors which are responsible for the production of most of the Company’s products under the Company’s directions and supervision, raw materials for in-house assembly line, shipping and handling costs to customers and to subsidiaries, salary, employee-related expenses and overhead expenses of internal assembly line and service costs associate with warranty.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">u.</td> <td style="width:auto;vertical-align:top"> Research and development costs </td> </tr> </table>   Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material and third-party contractor’s charges related to product development, regulatory affairs and

clinical studies.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">v.</td> <td style="width:auto;vertical-align:top"> Net earnings per share </td> </tr> </table>   Basic earnings per share are computed by dividing net income attributed to the shareholders of InMode Ltd. by the weighted average number of the Company's ordinary shares, par value NIS 0.01 per share (including vested RSUs), outstanding for each period, net of treasury shares.   For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">w.</td> <td style="width:auto;vertical-align:top"> Fair value measurement </td> </tr> </table>   The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions.   The three levels of inputs that may be used to measure fair value are as follows: Level 1 – Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.   Level 2 – Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets.   Level 3 – Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.   The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available.   As of December 31, 2024, and 2023, the fair values of the Company's cash, cash equivalents, short term bank deposits, accounts receivable, accounts payable, approximated the carrying values of these instruments presented in the Company's consolidated balance sheets because of their nature.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;font-weight:bold;width:48pt"> </td> <td style="vertical-align:top;font-weight:bold;width:22pt">x.</td> <td style="vertical-align:top;width:auto"> Employee severance benefits </td> </tr> </table>   The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances.   In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company's consolidated balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies.   The amounts of severance payment expenses were $581 $522 and $431 and for the years ended December 31, 2024, 2023 and 2022, respectively.   The Company expects to contribute approximately $569 in the year ending December 31, 2025 to insurance companies in connection with its expected severance liabilities for the year.</div> </div> </div> <div style="line-height:1.25"> </div> <div></div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">y.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Treasury Shares</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">Treasury shares are presented as a reduction of equity, at their cost to the Company.</div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">z.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Concentration of credit risks</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">Most of the cash and cash equivalents were deposited with U.S., European and Israeli banks and financial institutions and were comprised mainly of money market fund. The U.S. market constituted approximately 62% of the revenues in 2024.</div> <div style="margin-left:70.9pt;line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for Credit Losses and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.</div> </div> <div style="line-height:1.25"> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">aa.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">War risk situation in Israel</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During January 2025, a cease fire with Hamas was declared. As of the date of these consolidated financial statements, the war is ongoing and continues to evolve. The Company's headquarters, its R&D operations, and certain manufacturing facilities are located in Israel.</div> <div style="margin-left:70.9pt;line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">Currently, such activities in Israel remain largely unaffected. During the years ended December 31, 2024 and December 31, 2023, the impact of this war on the Company's results of operations and financial condition was immaterial.</div> </div> <div style="margin-left:70.9pt;line-height:1.25"> </div> <div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">ab.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Recently adopted accounting pronouncements</div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures", This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company adopted this standard in the current period retrospectively to all prior periods presented in an entity's financial statements, refer to note 14.</div> </div> </div> <div style="margin-left:70.9pt;line-height:1.25"> </div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">ac.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Newly issued accounting pronouncements, not yet adopted:</div> </td> </tr> </table> </div> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> <div>In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top"> <div>In November 2024, the FASB issued ASU 2024-03 "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</div> </td> </tr> </table> </div> </div> <div> <div style="line-height:1.25"> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top">Basis of presentation</td> </tr> </table> </div> <div style="line-height:1.25"> </div> <div style="margin-left:72pt;line-height:1.25">The Company's consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").</div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Use of estimates</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to valuation allowances.</div> </div> <div> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">c.</td> <td style="width:auto;vertical-align:top"> <div style="font-weight:bold">Functional currency</div> </td> </tr> </table> <div style="line-height:1.25"> </div> <div style="margin-left:70.9pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The U.S. dollar ("U.S. dollar" or "$") is the currency of the primary economic environment in which the operations of the Company is conducted. Substantial revenues and a substantial portion of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar ("primary currency").   Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Balances in non-U.S. dollar currencies are translated into U.S. dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-U.S. dollar transactions and other items in the statements of income (indicated below),

*the following exchange rates are used: (i) for transactions – exchange rates at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) – historical exchange rates. Currency transaction gains and losses are presented in finance income (expenses), as appropriate.   The functional currency of each of the Subsidiaries is the U.S. dollar.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">d.</td> <td style="width:auto;vertical-align:top"> Principles of consolidation and presentation </td> </tr> </table>   The consolidated financial statements include the accounts of the Company and its Subsidiaries. Intercompany transactions and balances are eliminated in consolidation.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">e.</td> <td style="width:auto;vertical-align:top"> Cash and cash equivalents </td> </tr> </table>   The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">f.</td> <td style="width:auto;vertical-align:top"> Short-term bank deposits </td> </tr> </table>   Bank deposits with maturities of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an annual rate of approximately 0.5%-6.15% in 2024 and 4.10%-7.01% in 2023. 0.0050.06150.0410.0701 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">g.</td> <td style="width:auto;vertical-align:top"> Marketable securities </td> </tr> </table>   AFS Securities   Marketable securities consist of government bonds, municipal bonds and corporate debt securities (together "Debt Securities"), and certificates of deposit measured at fair value in each reporting period. The fair value of quoted securities is based on current market value.   Debt Securities and certificates of deposit are classified as available-for-sale (together "AFS Securities") under current assets in the consolidated balance sheet as they represent the investment of funds available for the Company's current operations. Changes in fair value, excluding credit losses and impairments, net of taxes (if applicable), are reflected in other comprehensive income or loss. Realized gains and losses on sales of Debt Securities and certificates of deposit as well as premium or discount amortization are included in the consolidated statements of income as finance income, net. Fair value is calculated based on publicly available market information. The amortized cost of the Debt Security will be reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost basis, or it has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost over the fair value of the security. An allowance for credit losses for the excess of amortized cost over the expected cash flows is recognized in finance income, net on the consolidated statements income.   The Company classifies investments that are readily convertible to known amounts of cash and have stated maturities of three months or less from the date of purchase as cash equivalents and those with stated maturities of greater than three months as marketable securities.   The Company determines the appropriate classification of its investments in marketable securities at the time of purchase.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">h.</td> <td style="width:auto;vertical-align:top"> Other Investments </td> </tr> </table>   The Company applies the measurement alternative upon the adoption of ASU 2016-01, and elected to record equity investments without readily determinable fair values at cost for other investments, less impairment, adjusted for subsequent observable price changes. In this measurement alternative method, changes in the carrying value of the equity investments are reflected in current earnings. Changes in the carrying value of the equity investment are required to be made whenever there are observable price changes in orderly transactions for the identical or similar investment of the same issuer.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">i.</td> <td style="width:auto;vertical-align:top"> Inventories </td> </tr> </table>   Inventories include raw materials and finished products are valued at the lower of cost, "moving average" method, or net realizable value. The Company regularly evaluates its ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, estimated current and future market values and new product introductions.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">j.</td> <td style="width:auto;vertical-align:top"> Leases </td> </tr> </table>   The Company determines if an arrangement is a lease at inception. Balances related to operating leases are included in operating lease right-of-use ("ROU") assets, other current liabilities, and operating lease liabilities in the consolidated balance sheets.   The Company also elected to combine lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.   ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over the lease term. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily determined. As the Company's leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term (see also note 9).   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">k.</td> <td style="width:auto;vertical-align:top"> Property and equipment </td> </tr> </table>   Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:80%;vertical-align:top;background-color:rgb(204, 238, 255)"> Computers </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 3 – 4 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom"> Molds </td> <td style="width:20%;vertical-align:bottom"> 4 – 10 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> Equipment and furniture </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 10 – 17 years </td> </tr> </table>   Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the improvements.   Property and equipment is stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated on a straight-line basis over the following estimated useful lives: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="width:80%;vertical-align:top;background-color:rgb(204, 238, 255)"> Computers </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 3 – 4 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom"> Molds </td> <td style="width:20%;vertical-align:bottom"> 4 – 10 years </td> </tr> <tr> <td style="width:80%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> Equipment and furniture </td> <td style="width:20%;vertical-align:bottom;background-color:rgb(204, 238, 255)"> 10 – 17 years </td> </tr> </table>   P3YP4YP4YP10YP10YP17Y <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">l.</td> <td style="width:auto;vertical-align:top"> Impairment of long-lived assets </td> </tr> </table>   The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future discounted cash flows.
  During the years ended December 31, 2024, 2023 and 2022, the Company did not recognize an impairment loss on its long-lived assets.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">m.</td> <td style="width:auto;vertical-align:top"> Legal and other contingencies </td> </tr> </table>   Certain conditions may exist as of the date of the consolidated financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management assesses such contingent liabilities, if any, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.   <span style="font-family:Times New*

Roman,Times,serif">Management applies the guidance in ASC 450-20, “Loss Contingencies” when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be reasonably estimated, then the estimated liability is recorded as accrued expenses in the Company’s consolidated financial statements.   Legal costs incurred in connection with loss contingencies are expensed as incurred.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">n.</td> <td style="width:auto;vertical-align:top"> Income taxes: </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top"> </td> <td style="width:auto;vertical-align:top"> </td> </tr> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top"> The Company may incur an additional tax liability in the event of an inter-company dividend distribution from Subsidiaries outside of Israel; no additional deferred income tax assets have been provided, since the Company does not expect to distribute inter-company dividends in the foreseeable future that may result in additional tax liability. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">3)</td> <td style="width:auto;vertical-align:top"> Taxes that would apply in the event of disposal of investments in Subsidiaries have not been taken into account in computing the deferred income tax assets, as it is the Company’s intent and ability to hold these investments. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:26.7pt;vertical-align:top">4)</td> <td style="width:auto;vertical-align:top"> The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit of the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">o.</td> <td style="width:auto;vertical-align:top"> Advertising expenses </td> </tr> </table>   Advertising expenses are charged to sales and marketing on the consolidated statement of income as incurred. Advertising expenses for the years ended December 31, 2024, 2023 and 2022 amounted to $15 million, $15 million, and $10 million, respectively. 15000000150000001000000000 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">p.</td> <td style="width:auto;vertical-align:top"> Share-based compensation </td> </tr> </table>   The Company grants share options and restricted share units (“RSU”) (together “Share-Based Compensation”) to its employees, officers, directors and non-employees in consideration for services rendered and for acquiring goods. See note 12(a)(2) for details on outstanding share capital.   The Company accounts for Share-Based Compensation awards classified as equity awards using the grant-date fair value method. The fair value at grant-date of the issued equity award is recognized as an expense on a straight-line basis over the requisite service period. The fair value of each share option granted is estimated using the Binomial Model, and for each RSU granted is based on the Company’s share price at the close of the last trading day prior to the date of the grant. The Company estimates forfeitures based on historical experience and anticipated future conditions at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from those estimates.   The Company elected to recognize Share-Based Compensation cost for awards with only service conditions that have a graded vesting schedule using the straight-line method based on the multiple-option award approach. Performance-based Share-Based Compensation expenses are calculated based on the valuation at the grant date, and recognized based on the probability of achieving those targets. The Company assess at what scale can the performance targets be reached at each balance sheet date, and expenses are recognized accordingly.   The Company issues new shares upon option exercise or RSU vesting.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">q.</td> <td style="width:auto;vertical-align:top"> Revenue recognition </td> </tr> </table>   The Company applies ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:69.95pt"> </td> <td style="width:38.05pt;vertical-align:top">(i)</td> <td style="width:auto;vertical-align:top"> Identify the contract(s) with a customer; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(ii)</td> <td style="width:auto;vertical-align:top"> Identify the performance obligations in the contract. The Company determined that its arrangements are generally comprised of the following elements that are recognized as separate performance obligations: products, consumables and extended warranties; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(iii)</td> <td style="width:auto;vertical-align:top"> Determine the transaction price; </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(iv)</td> <td style="width:auto;vertical-align:top"> Allocate the transaction price to the performance obligations in the contract; The Company estimates the standalone selling prices of the services to be provided based on actual sales transactions of service contract purchased on a standalone basis and uses the residual approach to estimate the selling price of the products; and </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:36pt;vertical-align:top">(v)</td> <td style="width:auto;vertical-align:top"> Recognize revenue when (or as) the performance obligation is satisfied. </td> </tr> </table>   The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.   The Company uses the following practical expedients that are permitted under the rules: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:106.9pt"> </td> <td style="width:18pt;vertical-align:top">•</td> <td style="width:auto;vertical-align:top"> The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in sales and marketing expenses. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:106.9pt"> </td> <td style="width:18pt;vertical-align:top">•</td> <td style="width:auto;vertical-align:top"> The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. </td> </tr> </table>   The following is a description of the principal activities from which the Company generates its revenue.   Product Revenue, Net   Revenues from product sales are recognized when the customer obtains control over the Company’s product, typically upon shipment to the customer. Revenues from shipping and handling activities that occur after the customer has obtained control of a good are recognized according to an accounting policy election as a fulfilment cost rather than as an additional promised service. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues.   Payment terms and conditions vary by customer. The Company’s standard terms for end users usually require of payment upon delivery and for distributors require a down payment and payments made within several month from the invoice date.   The Company may enter into installment sales contracts with end users in North America that provide them with long-term (generally up to 60 months) financing for the purchase of the Company’s products. The interest rate used in these contracts reflects the credit characteristics of the party receiving financing in the contract, as well as any collateral or security provided by the customer. Interest income on these receivables is recognized as finance income and earned over the terms of the contract.   Variable considerations include price concessions related to installment sales contracts. The Company estimates variable consideration using the most likely outcome amount. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur.   During the year ended December 31, 2024, the Company entered into risk sharing agreements with several leasing partners to facilitate and support the financing of capital equipment sales for its customers. Under these arrangements, a portion of each sale transaction funded by those leasing partners goes into a reserve fund used by the Company to provide a limited guarantee, up to the reserve fund amount, and used to compensate the leasing partners in the event of customer defaults. The guarantee is recognized on the estimated fair value amount according to ASC 460. In the following periods the Company will assess credit losses in accordance with ASC 326, see also note 2r.   The Company does not grant a right of return, refund, cancelation or termination. From time to time, the Company participates in its customers’ marketing activities and deducts such amounts from revenue.

Service Revenue   The Company also generates revenues from long-term maintenance contracts (“Extended Warranty”). Revenue from Extended Warranty is recognized ratably, on a straight-line basis, over the period of the applicable service contract. These maintenance agreements are included in contract liabilities. Revenue from repairs performed in the absence of Extended Warranty is recognized when the related services are performed.   The Company classifies the portion of contract liabilities not expected to be earned in the subsequent 12 months as long-term.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">r.</td> <td style="width:auto;vertical-align:top"> Allowance for doubtful accounts and financial instruments — credit loss </td> </tr> </table>   The Company maintains the allowance for doubtful account resulting from the inability of the Company’s customers to make required payments.   The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable. This information includes among other the historic experience, the extent and amount of the account and future expectations.   Allowance for credit losses due to the Company’s accounts receivable amounted to $2,749 and $2,254 as of December 31, 2024 and 2023 respectively. Changes in the allowance for credit losses are recognized in general and administrative expenses. Accounts receivable are written-off against the allowance for credit losses when management deems the accounts are no longer collectible.   The following table sets forth activity in the Company’s allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);text-align:right;width:9%;vertical-align:bottom"> 2,254 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,318 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,107 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Current-period provision </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 572 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,020 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 449 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Write-offs charged against the Allowance and revaluation </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (77 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (84 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (238 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,749 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,254 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,318 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   27490002254000 The following table sets forth activity in the Company’s allowance for credit losses for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);text-align:right;width:9%;vertical-align:bottom"> 2,254 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);text-align:right;width:9%;vertical-align:bottom"> 1,318 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,107 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Current-period provision </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 572 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,020 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1"

style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 449 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Write-offs charged against the Allowance and revaluation </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (7 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (84 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (238 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,749 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,254 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,318 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
2254000131800011070005720001020000449000770008400023800027490002254000131800 0 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:23.6pt;vertical-align:top;font-weight:bold">s.</td> <td style="width:auto;vertical-align:top"> Warranty reserve </td> </tr> </table>   The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs, the cost per repair and shipping cost. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.   The following table sets forth activity in the Company’s accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,476 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,418 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,248 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Cost incurred </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (1,909 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,304 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,099 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Expense recognized </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,155 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom">   2,362 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,269 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 722 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,476 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,418 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   The following table sets forth activity in the Company’s accrued warranty account for each of the years ended December 31, 2024, 2023 and 2022, respectively: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="text-align:center;line-height:1.25;font-

weight:bold">2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Balance at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,476 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,418 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,248 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Cost incurred </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (1,909 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,304 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,099 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Expense recognized </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,155 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,362 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,269 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> Balance at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 722 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,476 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,418 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   1476000141800012480001909000230400020999001155000236200022690007220001476000141800 0 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">t.</td> <td style="width:auto;vertical-align:top"> Cost of revenues </td> </tr> </table>   Cost of revenue consists of products purchased from turnkey sub-contractors which are responsible for the production of most of the Company's products under the Company's directions and supervision, raw materials for in-house assembly line, shipping and handling costs to customers and to subsidiaries, salary, employee-related expenses and overhead expenses of internal assembly line and service costs associate with warranty.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">u.</td> <td style="width:auto;vertical-align:top"> Research and development costs </td> </tr> </table>   Research and development costs are expensed as incurred and includes salaries and employee-related expenses, overhead expenses, material and third-party contractor's charges related to product development, regulatory affairs and clinical studies.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">v.</td> <td style="width:auto;vertical-align:top"> Net earnings per share </td> </tr> </table>   Basic earnings per share are computed by dividing net income attributed to the shareholders of InMode Ltd. by the weighted average number of the Company's ordinary shares, par value NIS 0.01 per share (including vested RSUs), outstanding for each period, net of treasury shares.   For the diluted earnings per share calculation, the weighted average number of shares outstanding during the year is adjusted for the average number of shares that are potentially issuable in connection with employee share-based payment, using the treasury stock method. 0.01 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">w.</td> <td style="width:auto;vertical-align:top"> Fair value measurement </td> </tr> </table>   The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In the absence of active markets for identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions.   The three levels of inputs that may be used to measure fair value are as follows: Level 1 – Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.   Level 2 – Observable prices that are based on identical or similar instruments not quoted on active markets, but corroborated by observable market data, or quoted prices for similar instruments in active markets.   Level 3 – Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.   The Company maintains policies and procedures to determine the fair value of financial assets and liabilities using what it considers to be the most relevant and reliable market data available.   As of December 31, 2024, and 2023, the fair values of the Company's cash, cash equivalents, short term bank deposits, accounts receivable, accounts payable, approximated the carrying values of these instruments presented in the Company's consolidated balance sheets because of their nature.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;font-weight:bold;width:48pt"> </td> <td style="vertical-align:top;font-weight:bold;width:22pt">x.</td> <td style="vertical-align:top;width:auto"> Employee severance benefits </td> </tr> </table>   The Company is required to make severance payments upon dismissal of an Israeli employee or upon termination of employment in certain circumstances.   In accordance with the current employment terms with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963) located in Israel, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's full retirement benefit and severance obligation. The Company is relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected on the Company's consolidated balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies.   The amounts of severance payment expenses were $581 $522 and $431 and for the years ended December 31, 2024, 2023 and 2022, respectively.   The Company expects to contribute approximately $569 in the year ending December 31, 2025 to insurance companies in connection with its expected severance liabilities for the year.   581000522000431000569000 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">y.</td> <td style="width:auto;vertical-align:top"> Treasury Shares </td> </tr> </table>   Treasury shares are presented as a reduction of equity, at their cost to the Company.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-

size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">z.</td> <td style="width:auto;vertical-align:top"> Concentration of credit risks </td> </tr> </table>   Most of the cash and cash equivalents were deposited with U.S., European and Israeli banks and financial institutions and were comprised mainly of money market fund. The U.S. market constituted approximately 62% of the revenues in 2024.   The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for Credit Losses and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">aa.</td> <td style="width:auto;vertical-align:top"> War risk situation in Israel </td> </tr> </table>   In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war. Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran. During January 2025, a cease fire with Hamas was declared. As of the date of these consolidated financial statements, the war is ongoing and continues to evolve. The Company's headquarters, its R&D operations, and certain manufacturing facilities are located in Israel.   Currently, such activities in Israel remain largely unaffected. During the years ended December 31, 2024 and December 31, 2023, the impact of this war on the Company's results of operations and financial condition was immaterial.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">ab.</td> <td style="width:auto;vertical-align:top"> Recently adopted accounting pronouncements </td> </tr> </table>   In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable. The Company adopted this standard in the current period retrospectively to all prior periods presented in an entity's financial statements, refer to note 14.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">ac.</td> <td style="width:auto;vertical-align:top"> Newly issued accounting pronouncements, not yet adopted: </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top"> In November 2024, the FASB issued ASU 2024-03 "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses", which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. </td> </tr> </table>   NOTE 3 - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS: AFS securities as of December 31, 2024 and 2023, consisted of U.S government bonds, municipal bonds, corporate debt securities and certificate of deposit. These marketable securities are recorded at fair value.   The following table sets forth the Company's marketable securities for the periods indicated: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> U.S. Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 265,180 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 353,414 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"> Municipal bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,319 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,508 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 13,234 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> Certificates of deposit </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 267,608 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 373,647 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   The Company classifies AFS securities within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value. See also note 2(w).   The following table sets forth the Company's financial assets as of December 31, 2024 and 2023, that are measured at fair value on a recurring basis during the period: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31, 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Fair value </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-

bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Cost or amortized cost </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding loss </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding gains </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Level 2 securities: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 265,180 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 265,619 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (552 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 113 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;padding-bottom:2px;vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,508 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,510 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (3 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:52%;padding-bottom:4px;vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 267,688 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 268,129 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> (555 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 114 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">   December 31, 2023   </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Fair value </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Cost or amortized cost </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding loss </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding gains </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Level 2 securities: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 353,414 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 355,382 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,139 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 171 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td

colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> Municipal bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,319 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,363 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (44 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 13,234 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 13,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (170 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;padding-bottom:2px;vertical-align:bottom"> Certificates of deposit </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:52%;padding-bottom:4px;vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 373,647 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 375,829 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,353 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 171 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   As of December 31, 2024 and 2023, the Company considered, based on its evaluation, that the decreases in market value on relevant marketable securities were temporarily impaired and primarily attributable to changes in interest rates, and therefore did not result in an impairment charge in finance income, net.   As of December 31, 2024 and 2023, the Company's debt securities and certificates of deposit had the following maturity dates: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Due within one year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 179,784 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 308,671 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"> 1 to 2 years </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 80,560 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 49,259 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2 to 3 years </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 7,344 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 15,717 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 267,688 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 373,647 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-

bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   The following table sets forth the Company's marketable securities for the periods indicated: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:bottom;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> U.S. Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 265,180 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 353,414 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;vertical-align:bottom"> Municipal bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,319 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,508 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 13,234 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> Certificates of deposit </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 267,688 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 373,647 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
2651800003534140000231900025080001323400004680000267688000373647000 The following table sets forth the Company's financial assets as of December 31, 2024 and 2023, that are measured at fair value on a recurring basis during the period: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31, 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Fair value </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Cost or amortized cost </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding loss </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding gains </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Level 2 securities: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 265,180 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 265,619 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (552 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 113 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;padding-bottom:2px;vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,510 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238,

255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (3 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:52%;padding-bottom:4px;vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 267,688 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 268,129 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> (555 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 114 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom">   December 31, 2023   </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Fair value </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Cost or amortized cost </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding loss </td> <td colspan="1" rowspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Gross unrealized holding gains </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Level 2 securities: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Government bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 353,414 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 355,382 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,139 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 171 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;vertical-align:bottom"> Municipal bonds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,319 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,363 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (44 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:52%;vertical-align:bottom"> Corporate debt securities </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 13,234 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 13,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (170 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:52%;padding-bottom:2px;vertical-align:bottom"> Certificates of deposit </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,680 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-

align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:52%;padding-bottom:4px;vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 373,647 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 375,829 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 2,353 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 171 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
2651800002656190005520001130002508000251000030001000267688000268129000555000114000353414000355382000213900017100023190002363000440000132340001340400017000004680000468000000373600000000000

Less - non-current accounts receivable, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (3,176 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (3,670 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total current accounts receivable, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 36,335 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 42,362 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Accounts receivable consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Trade </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 40,739 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 46,646 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Notes receivable </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,521 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,640 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Less - allowance for credit losses </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (2,749 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,254 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 39,511 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 46,032 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Less - non-current accounts receivable, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (3,176 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (3,670 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total current accounts receivable, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 36,335 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 42,362 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
4073900046646000152100016400002749000225400039511000460320003176000367000036335000042362000
 NOTE 5 - PREPAID EXPENSES AND OTHER CURRENT RECEIVABLES: Prepaid expenses and other current receivables consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Advances to suppliers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 14,960 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 11,960 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Prepaid expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,421 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">

3,041 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Government institutions </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,896 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 948 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Income tax </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,423 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 66 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 397 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 253 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total other current receivables </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 22,097 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,268 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Prepaid expenses and other current receivables consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Advances to suppliers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 14,960 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 11,960 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Prepaid expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,421 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,041 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Government institutions </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,896 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 948 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Income tax </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,423 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 66 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 397 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 253 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total other current receivables </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 22,097 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,268 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
14960000119600002421000304100028960000480001423000660003970002530002209700016268000
 NOTE 6 – INVENTORIES: Inventories consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Raw materials </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 15,454

 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 12,080 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Finished products </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px;vertical-align:bottom"> 44,094 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 33,015 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total inventories </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 59,548 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 45,095 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Inventories consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Raw materials </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 15,454 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 12,080 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Finished products </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 44,094 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 33,015 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total inventories </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 59,548 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 45,095 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   1545400012080000440940003301500059548000450950000 NOTE 7 - PROPERTY AND EQUIPMENT, NET: Composition of property and equipment grouped by major classifications is as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px;vertical-align:bottom">2024</td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Computers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,445 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,334 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Office furniture and equipment </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 709 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 670 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Molds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,020 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,592 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Leasehold improvements </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,333 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,243 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,507 </td> <td colspan="1" style="vertical-

align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,839 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Less: accumulated depreciation </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (4,185 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (3,457 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total property and equipment, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,322 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Total depreciation and amortization in respect of property and equipment were $728, $623 and $680 for the years ended December 31, 2024, 2023 and 2022, respectively.   Composition of property and equipment grouped by major classifications is as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="text-align:center;font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;font-weight:bold;border-bottom:#000000 solid 2px;vertical-align:bottom">2024</td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Computers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,445 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,334 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Office furniture and equipment </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 709 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 670 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Molds </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,020 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,592 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Leasehold improvements </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,333 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,243 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,507 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,839 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Less: accumulated depreciation </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (4,185 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (3,457 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total property and equipment, net </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,322 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,382 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
1445000133400070900067000030200002592000133300012430006507000583900041850003457000232000238200072800062300068000 NOTE 8 – OTHER INVESTMENTS: In November 2019, the Company signed a Share Purchase and Shareholders Agreement (the "SPA") with (BY) Medimor Ltd., one of the Company's turnkey manufacturing subcontractors ("Medimor"). Pursuant to the SPA, the Company has invested (in December 2019 and July 2020) an aggregate amount of $600 in consideration for 1,369,863 ordinary shares of Medimor (which reflected at the signing date a 14.78% ownership interest on an as-issued basis and 10.34% ownership interest on a fully diluted basis).   In November 2023, the Company signed an additional SPA with Medimor and invested $100 in consideration for 117,440 ordinary shares of Medimor.   The SPAs together reflected as of December 31, 2024, 2023 a 14.78% ownership interest on an as-issued basis and 11.23% ownership interest on a fully diluted basis.   The Company's investment in Medimor is measured at cost, less impairment and adjusted for subsequent observable price changes if any. As of December 31, 2024, 2023 and 2022, the Company did not recognize an impairment or adjustment on its other investments.
60000013698630.14780.10341000001174400.14780.14780.11230.1123 <span style="font-family:Times

New Roman,Times,serif">NOTE 9 - LEASES: The Company's main leasing properties are located in Israel, USA and Canada as detailed below: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top"> In May 2018, the Company signed a lease agreement for its headquarters in Israel. In January 2019, February 2020, March 2021, March 2023, May 2023 and June 2024 the Company signed supplement lease agreements, further expanding its headquarters in Israel (collectively, the "Lease Agreement"). The Lease Agreement will expire in December 2027. The current monthly rent payment under the Lease Agreement is approximately $76.7. </td> </tr> </table>   The costs under the Lease Agreement in Israel are linked to the Israeli Consumer Price Index. For purposes of ensuring the Company's obligation towards the lessor, the Company has provided the lessor with a bank guarantee of NIS 966 thousand (approximately $263).   The Company also leases warehouse outside the Company's offices. The Lease Agreement is for one year, with the Company options to renewal every year for 10 years. According to management's assessment, the lease will last until August 2027.. The current monthly rent payment under the Lease Agreement is approximately $8.9.   The Company also leases vehicles for several employees in Israel for a period of three years.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top"> In August 2020, the Company's U.S. subsidiary, has signed a new lease agreement, for additional lease agreement of property and for its offices ("U.S Lease"). The U.S. Lease is for 7 years and 4 months which began in the middle of April of 2021. The current monthly rent payment is approximately $28. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">c.</td> <td style="width:auto;vertical-align:top"> The Company's Canadian subsidiary has signed a new lease agreement in April 2022 for property and for its offices ("Canadian Lease"). The Canadian Lease is for 3 years until July 2025. The current monthly rent payment is approximately $17. </td> </tr> </table>   From time to time the Company also leases small properties, mainly for offices for Subsidiaries around the world.   The lease cost was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating lease cost </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,057 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,628 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Supplemental cash flow information related to leases was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating cash flows from operating leases </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,173 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,530 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,881 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Supplemental balance sheet information related to leases was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31, </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating Leases </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Operating lease right-of-use assets </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 8,732 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 9,698 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238,

255);vertical-align:bottom"> Other current liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,511 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 5,311 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 6,613 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 7,822 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9,017 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> Weighted Average Remaining Lease Term </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating leases </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3.30 years </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.90 years </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> Weighted Average Discount Rate </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating leases </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,24 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 4.78 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> % </td> </tr> </table>   As of December 31, 2024, the maturities of lease liabilities were as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Operating Leases </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Year Ending December 31, </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> 2025 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,917 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2026 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,411 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> 2027 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,124 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2028 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 659 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> 2029 and beyond </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 353 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total lease payments </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 8,464 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> Less imputed interests </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (642 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 7,822 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   December 20277670096600026300August 20278900P3Y28000P3Y17000 The lease cost was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-

bottom;2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating lease cost </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,057 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,628 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   30570002348000162800 0 Supplemental cash flow information related to leases was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating cash flows from operating leases </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,173 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,530 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,881 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   31730002530001881000 Supplemental balance sheet information related to leases was as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31, </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating Leases </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Operating lease right-of-use assets </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 8,732 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 9,698 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other current liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,511 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;vertical-align:bottom"> Operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 5,311 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 6,613 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 7,822 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9,017 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> Weighted Average Remaining Lease Term </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div

style="line-height:1.25">Operating leases </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3.30 years </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.90 years </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;vertical-align:bottom"> Weighted Average Discount Rate </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating leases </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 5.24 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 4.78 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> % </td> </tr> </table>

8732000969800025110002404000531100066130007822000901700P3Y3M18DP2Y10M24D0.05240.0478

 As of December 31, 2024, the maturities of lease liabilities were as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Operating Leases </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> Year Ending December 31, </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> 2025 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,917 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2026 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,411 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;vertical-align:bottom"> 2027 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,124 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2028 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 659 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> 2029 and beyond </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 353 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total lease payments </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 8,464 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:2px;vertical-align:bottom"> Less imputed interests </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (642 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:bottom;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 7,822 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>

291700024110002124000659000353000846400064200078220000

NOTE 10 - OTHER CURRENT LIABILITIES: Other current liabilities consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Employees and related expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 16,725 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 21,040 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Government institutions </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,566 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,932 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Income tax payable </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 933 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,918 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Warranty reserve </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom">

722 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,476 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,511 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Credit risk sharing liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 5,507 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Contractor liability </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,101 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,656 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Accrued commissions </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,379 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,435 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,870 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,386 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total other current liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,314 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,247 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Other current liabilities consist of the following: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Employees and related expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 16,725 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 21,040 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Government institutions </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,566 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,932 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Income tax payable </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 933 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,918 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Warranty reserve </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 722 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,476 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Operating lease liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,511 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,404 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Credit risk sharing liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 5,507 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Contractor liability </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-

align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,101 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,656 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Accrued commissions </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,379 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,435 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,870 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,386 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Total other current liabilities </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,314 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,247 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>

1672500021040000256600039320009330001918000722000147600025110002404000550700005101000565600023790001435000287000013860003931400039247000

 NOTE 11 - COMMITMENTS AND CONTINGENCIES: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top"> Subcontracting Agreements </td> </tr> </table>   The Company has an existing turnkey manufacturing agreements with three of its major subcontractors in Israel in connection with manufacturing and assembling the Company's products.   The Company has agreements with two of the subcontractors which are renewed automatically every year for an additional one-year period, unless either the Company or the turnkey manufacturer gives written notice three months prior to the expiration of the term of its decision not to renew the agreement.   Additionally, the Company or the turnkey manufacturer has the ability to terminate the contract at any time and for any reason with a prior written notice of four months.   In addition, in October 2019, the Company entered into a turnkey manufacturing agreement with another of its major subcontractors in Israel, Medimor (See also note 8). The agreement is for three years and renewed automatically every year afterwards for an additional one-year period, unless either the Company or Medimor gives written notice three months prior to the expiration of the term of its decision not to renew the agreement. Additionally, the Company or Medimor has the ability to terminate the agreement at any time and for any reason with a prior written notice of six months.   According to the agreements above, the Company does not have a minimum order obligation, but the Company provides the subcontractors a six-month rolling forecast with the projected demand for products. In case of termination of the agreement with each subcontractor, the Company has to compensate that subcontractor for non-returnable inventory, materials in orders that cannot be cancelled and finished products inventory. As of December 31, 2024, the subcontractors' finished goods inventory, raw materials and open orders amounted to approximately $43,607. In order to secure these obligations, the Company paid its subcontractors advances in the amount of $13,502.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:48.4pt"> </td> <td style="width:22.5pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top"> Litigation and contingencies </td> </tr> </table>   On February 14, 2024, a purported shareholder of the Company filed a putative shareholder class action in the United States District Court for the Central District of California against the Company and certain of its officers and directors. The lawsuit is purportedly brought on behalf of purchasers of the Company's common stock between February 18, 2020 and December 6, 2023, inclusive. The complaint alleges claims under Sections 10(b) and 20(a) of the Exchange Act based on allegedly false or misleading statements related to the Company's business, operations, sales practices and financial outlook. The lawsuit seeks unspecified damages and other relief. The court entered an order appointing a group of shareholder funds as the lead plaintiffs, who filed an amended complaint on January 31, 2025. The Company's deadline to respond to the amended complaint is April 1, 2025.   The aforementioned legal proceeding is in the preliminary stages, and the Company has not yet responded to the complaint. As of the date of this filing, the Company is unable to estimate the range of loss, if any, that could result were there to be an adverse final decision in this case, and an estimated liability has not been recorded in the Company's financial statements. The defendants intend to deny the allegations of wrongdoing and vigorously defend itself against the claims.   In addition, as is the case from time to time, the Company was involved in various claims, legal proceedings and investigations.   4360700013502000   NOTE 12 - SHAREHOLDERS' EQUITY: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top;text-align:justify"> Share Capital: </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">1)</td> <td style="width:auto;vertical-align:top;text-align:justify">Ordinary shares</td> </tr> </table>   Each holder of the Company's ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if declared by the Company's Board of Directors. Since inception, the Company has not declared any dividends.   In September 2020, the Company approved a share repurchase program of up to two million ordinary shares, to be purchased out of the Company's cash reserve and to be paid solely from the Company's IPO proceeds. In February 2022, the Company approved that the share repurchase program could also be funded from the proceeds of exercised options. In March 2022, the Company approved an additional repurchase program of up to one million ordinary shares, to be purchased out of its cash reserve and to be paid from the Company's remaining IPO proceeds and from the proceeds of exercised options.   during 2022, the Company purchased 1,077,213 shares in the amount of $42.6 million. During 2023 the company did not purchase any shares.   In May 2024, the Company approved an additional share repurchase program of up to 8.37 million ordinary shares. In September 2024, the Company approved an additional share repurchase program of up to 7.68 million ordinary shares.   During 2024 the Company purchased 16,050,000 shares in the amount of $285.4 million. As of December 31, 2024, the Company purchased in aggregate 18,607,829 shares in the amount of $380.6 million under these repurchase programs.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top;text-align:justify"> Share-based compensation </td> </tr> </table>   On January 30, 2008, the Company's Board of Directors adopted two share option plans as follows (collectively, the "2008 Plans"):   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:22.5pt;vertical-align:top">a)</td> <td style="width:auto;vertical-align:top"> 2008 Israeli Option Plan ("2008 Israeli Plan") allowing the Company to grant ordinary shares and options to purchase ordinary shares to Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 Israeli Plan grants the right to exercise such option into one ordinary share of the Company. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:22.5pt;vertical-align:top">b)</td> <td style="width:auto;vertical-align:top"> 2008 ROW Option Plan ("2008 ROW Plan") allowing the Company to grant ordinary shares and options to purchase ordinary shares to non-Israeli employees, officers, directors, consultants and service providers. Each option under the 2008 ROW Plan grants the right to exercise such option into one ordinary share of the Company. </td> </tr> </table>   In June 2018, the Company's Board of Directors adopted a new incentive plan ("2018 Incentive Plan"), allowing the Company to grant ordinary shares, options to purchase ordinary shares, restricted shares and restricted share unit ("RSUs") (together, "Awards") to Israeli and other non-U.S. employees, officers, directors, consultants and service providers of the Company and its Subsidiaries. The 2018 Incentive Plan also includes as an appendix a sub-plan allowing the Company to grant awards to U.S. employees, officers, consultants and service providers of the Company and its Subsidiaries. Each option award under 2018 Incentive Plan grants the right to exercise such option into one ordinary share of the Company. The Company's subsidiary in U.S. may recognize under U.S. corporate tax laws, a tax benefit for RSU and options exercised for U.S. employees and U.S. service providers for tax purposes.   The grant of awards to Israeli employees, officers and directors under the 2008 Israeli Plan and the 2018 Incentive Plan is subject to the terms stipulated by Sections 102 and 102A of the Israeli Income Tax Ordinance. Each award grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim as an expense for tax purposes the amounts credited to employees as benefits, including amounts recorded as salary benefits in the Company's accounts, in respect of options granted to employees under the 2008 Israeli Plan, with the exception of the work-income benefit component, if any, determined on grant date. For consultants and service providers, grants under the 2008 Israeli Plan and the 2018 Incentive Plan are subject to Section 3(i) of the Israeli Income Tax Ordinance.

   Upon the adoption of the 2018 Incentive Plan, the then-current pool of awards available for future grants under the 2008 Plans was canceled and returned to the Company's authorized and un-issued share capital. In addition, any shares returning to the free pool of options under the 2008 Plans, due to options expirations or otherwise, are automatically returning to the Company's authorized and un-issued share capital.   Upon adoption of the 2018 Incentive Plan, the Board and the shareholders resolved to approve an evergreen mechanism with respect to the 2018 Incentive Plan, under which the number of reserved, authorized and unissued ordinary shares of the Company available for issuance of awards pursuant to the 2018 Incentive Plan shall automatically increase on an annual basis, by such number of ordinary shares as follows: on the first business day of each calendar year beginning in 2019, the number of awards equal to the lesser of (i) 800,000 ordinary shares, (ii) three percent of the number of shares outstanding as of such date or (iii) a lesser number of ordinary shares as shall be determined by the Company's board of directors.   As of December 31, 2024, the total awards under 2018 Incentive Plan that have been authorized to be issued as ordinary shares were 8,378,000 of which 1,397,772 awards were available for grant under the 2018 Incentive Plan.   At January 2025, the Board of the Company approved to increase by another 800,000 ordinary shares through the evergreen mechanism to amount of 9,178,000 ordinary shares.   Share Options   The following tables is a summary of stock option activity for the year ended on December 31, 2024:   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Weighted </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Number </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Average </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> of </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Exercise </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Options </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Price* </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Outstanding at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,638,495 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">4.96</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="line-height:1.25">Changes during the year:</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.8pt;line-height:1.25">Granted</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">-</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">-</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="margin-left:8.8pt;line-height:1.25">Canceled</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">(6,996</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25">)</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">10.17</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.8pt;line-height:1.25">Exercised</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">(1,003,409</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> <div style="line-height:1.25">)</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">2.63</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> <div style="margin-left:8.8pt;line-height:1.25">Forfeited</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">-</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">-</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="margin-left:8.8pt;line-height:1.25">Expired</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25">-</div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25">-</div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> <div style="line-height:1.25">Outstanding at end of year</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25">628,090</div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 8.61 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Exercisable at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <span style="font-

family:Times New Roman,Times,serif">628,090 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> $ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 8.61 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   * In U.S. dollars per Ordinary Share   As of December 31, 2024, the weighted-average remaining contractual life of exercisable options were 1.88 years. The total intrinsic value of options exercised during 2024, 2023 and 2022 were approximately $12,184, $24,819 and $10,549, respectively.</div> <div style="line-height:1.25"> </div> <div> <div style="margin-left:72pt;line-height:1.25">The following tables summarize information concerning outstanding and exercisable options as of December 31, 2024:</div> <div style="line-height:1.25"> </div> <div style="margin-left:81pt"> <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25;text-align:center">Options outstanding and exercisable</div> </div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-weight:bold">Exercise</div> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold"> Prices *</div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> <div style="line-height:1.25;font-weight:bold">Number of</div> <div style="line-height:1.25;font-weight:bold">options</div> <div style="line-height:1.25;font-weight:bold">Outstanding and exercisable</div> <div style="line-height:1.25;font-weight:bold">at end of</div> <div style="line-height:1.25"> <div style="line-height:1.25;font-weight:bold">year</div> </div> </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> <div style="line-height:1.25;font-weight:bold">Weighted</div> <div style="line-height:1.25;font-weight:bold">average</div> <div style="line-height:1.25;font-weight:bold">remaining</div> <div style="line-height:1.25;font-weight:bold">contractual</div> <div style="line-height:1.25;font-weight:bold">life</div> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 3.16 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 42,608 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 0.71 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">3.75</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">29,595</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">0.68</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5.11 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 65,576 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1.26 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">7.00</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">41,000</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">1.61</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 9.85 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 424,149 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.16 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">12.16</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">18,662</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div style="line-height:1.25">2.35</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 21.62 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,500 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.86 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   * In U.S. dollars per Ordinary Share. The aggregate intrinsic value of total exercisable options as of December 31, 2024 is $5,110.   Restricted Share Units   The following tables summarize information concerning RSUs as of December 31, 2024:   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-

align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Weighted </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Number </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Average </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> of </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Grant Date </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> RSUs </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Fair Value </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Outstanding at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 936,049 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 39.04 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Changes during the year: </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Granted </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 716,395 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 25.90 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Vested </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (622,799 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 41.20 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Forfeited </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (204,740 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 28.67 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Outstanding at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 824,905 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 28.57 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Each RSU represents the right to receive one ordinary share of the Company upon the vesting thereof. The fair value of an RSU is identical to the value of the underlying share at the close of the last trading day prior to the day of grant. The weighted average fair value of each RSU granted in 2024 was 25.9, in 2023 was 34.44 and in 2022 49.35 based on the Company's share price at closing of trading day prior to the day of grant.   The total fair value of RSUs granted during the year ended December 31, 2024, 2023 and 2022, was $18,556, $24,334, and $30,817, respectively.   As of December 31, 2024, the Company had 824,905 unvested RSUs. The total unrecognized compensation cost of employee RSUs as of December 31, 2024 is $9,192, which is expected to be recognized over a weighted average period of 0.65 years.   The total vesting-date value of equity classified RSUs vested during 2024 is $14,215.   The following table illustrates the effect of share-based compensation on the consolidated statements of income: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Cost of sales </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,833 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,046 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,917 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> Research and development expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,177 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,652 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,166 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238,

255);width:64%;vertical-align:bottom"> Selling and marketing expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 11,367 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,167 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,302 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"> General and administrative expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,192 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,735 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,067 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,569 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 23,600 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 24,452 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   21077213426000008370000768000016050000285400000186078293806000080000083780001397772800000917800 0 The following tables is a summary of stock option activity for the year ended on December 31, 2024:   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Weighted </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Number </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Average </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> of </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Exercise </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Options </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Price* </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Outstanding at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,638,495 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 4.96 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Changes during the year: </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Granted </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Canceled </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (6,996 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 10.17 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Exercised </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> (1,003,409 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.63 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Forfeited </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-

*align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Expired </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Outstanding at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 628,090 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> $</div> </div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25">8.61</div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">Exercisable at end of year</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25">628,090</div> </div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 8.61 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   * In U.S. dollars per Ordinary Share 16384954.9600699610.1710034092.6300006280908.616280908.61P1V10M17D12184000248190001054900O The following tables summarize information concerning outstanding and exercisable options as of December 31, 2024:   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Options outstanding and exercisable </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> Exercise Prices * </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;border-bottom:2px solid rgb(0, 0, 0)"> Number of options Outstanding and exercisable at end of year </td> <td colspan="1" style="text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;text-align:center"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center"> Weighted average remaining contractual life </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">3.16</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">42,608</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">0.71</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3.75 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 29,595 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 0.68 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">5.11</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">65,576</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">1.26</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 7.00 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 41,000 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1.61 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $</div> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">9.85</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">424,149</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> <div style="line-height:1.25">2.16</div> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 12.16 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 18,662 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2.35 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> $ </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 21.62 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-*

color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,500 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2.86 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr></table>   * In U.S. dollars per Ordinary Share.
3.1642608P0Y8M15D3.7529595P0Y8M4D5.1165576P1Y3M3D741000P1Y7M9D9.85424149P2Y1M28D12.1618662P2Y4M6D21.626500P2Y10M9D5110000 The following tables summarize information concerning RSUs as of December 31, 2024 :   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Weighted </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Number </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Average </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> of </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> Grant Date </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> RSUs </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Fair Value </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Outstanding at beginning of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 936,049 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 39.04 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Changes during the year: </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Granted </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 716,395 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 25.90 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Vested </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (622,799 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 41.20 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Forfeited </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (204,740 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 28.67 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;vertical-align:bottom"> Outstanding at end of year </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 824,905 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 28.57 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
93604939.0471639525.962279941.220474028.6782490528.5725.934.4449.3518556243343081782490591920000P0Y7M24D14215000 The following table illustrates the effect of share-based compensation on the consolidated statements of income: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Cost of sales </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,833 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,046 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1"

style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,917 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;vertical-align:bottom"> Research and development expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,177 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,652 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,166 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Selling and marketing expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 11,367 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,167 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,302 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;width:64%;padding-bottom:2px;vertical-align:bottom"> General and administrative expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,192 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,735 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 2,067 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,569 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 23,600 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 24,452 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>

1833000204600019170002177000265200031660000113670001716700017302000119200017350002067000165690002360000024452000

   NOTE 13- INCOME TAXES: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top;text-align:justify"> InMode Ltd. </td> </tr> </table> The Company is taxed according to Israeli tax laws: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:21.5pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> Measurement of results for tax purposes </td> </tr> </table>   The Company as a "foreign-investment company" measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986.   These consolidated financial statements are presented in U.S. dollars. The changes in the exchange rate of the dollar, both on an annual and a cumulative basis, cause a difference between taxable income and income reflected in these consolidated financial statements. ASC 740-10-25 prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are re-measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above-mentioned differences were not reflected in the computation of deferred tax assets and liabilities.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:21.5pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top"> Basis of taxation </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:20.25pt;vertical-align:top;font-weight:bold">a)</td> <td style="width:auto;vertical-align:top"> Incentives Applicable until 2020 </td> </tr> </table>   Under the Encouragement of Capital Investments Law, including Amendment No. 60 thereof as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status, the Israeli Company was tax exempt from 2012 to 2020 for income derived from the Benefited Enterprise. See also note 13a(2)(b).   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:72pt"> </td> <td style="width:20.25pt;vertical-align:top;font-weight:bold">b)</td> <td style="width:auto;vertical-align:top"> Incentives Applicable starting 2021 - The New Technological Enterprise and Preferred Enterprise Incentives Regime - Amendment 73 to the Investment Law </td> </tr> </table>   On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the "Regulations") were published, which adopted Action 5 under the base erosion and profit shifting ("BEPS") regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE (Preferred technological enterprise) or PE (Preferred enterprise) and under the SPTE (Special Preferred Technology Enterprise) regime and determine certain requirements relating to documentation of intellectual property for the purpose of the PTE or PE. According to these provisions, a company that complies with the terms under the PTE or PE regime may be entitled to certain tax benefits with respect to income generated during the company's regular course of business and derived from the preferred intangible asset (as determined in the Investments Law) and income attributed to production activity (different tax rate), Excluding income derived from intangible assets used for marketing.   In the event that intangible assets used for marketing purposes generate over 10% of the PTE's or PE's income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE or PE will not be required to exclude the marketing income from the PTE's or PE's total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred income, the PTE and PE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset.   The Company reviews every year whether it meets the conditions of the PTE or PE. The difference for the Company is immaterial since it located in development area A.   Under the Regulations the Company's tax rate is expected to be approximately 7.5%.   Amendment 74 to the Investment Law   Pursuant to the amendment to the Investments Law which became effective on November 15, 2021, a company that elects by November 15, 2022 to pay a reduced corporate tax rate as set forth in that amendment (rather than the regular corporate tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company until December 31, 2020 will be entitled to distribute a dividend from such income or to be used for any other reason found by the company, without being required to pay additional corporate tax.   The Company elected to take advantage of the amendment, and during November 2022 has paid NIS 42.5 million ($12.0 million) as a one-time payment, and as a result NIS 591 million (approximately $165.7 million) of the Company's undistributed exempt income for years 2012 until 2020 are entitled to be distributed as dividend or to be used for any other reason found by the Company without being required to pay additional corporate tax. As a result, the Company is required to invest NIS 32 million (approximately $9 million) in its industrial enterprises in Israel over a five year period. Such investment may be in the form of the acquisition of industrial assets (excluding real estate assets), investment in R&D in Israel, or payroll payments to new employees to be hired by the enterprise.All the amount that was required to invest was invested in 2022.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:21.5pt;vertical-align:top">3)</td> <td style="width:auto;vertical-align:top"> Corporate tax rate in Israel </td> </tr> </table>   The income of Israeli companies, other than preferred income, is taxed in accordance with Israeli tax laws at the regular corporate tax rates. The corporate tax rate is 23% for 2018 and thereafter. Capital gain is subject to capital gain

tax according to the corporate tax rate in the year the assets are sold.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top;text-align:justify"> Subsidiaries outside of Israel </td> </tr> </table>   Subsidiaries that are incorporated outside of Israel are assessed for taxes under the tax laws in their countries of residence.   The corporate tax rates of Subsidiaries outside of Israel for the year ended on December 31, 2024 is between 15% to 26.5%.   As of December 31, 2024, the Company's subsidiary in U.S has an accumulated federal tax loss carryforward of approximately $203 million and state tax loss carryforward (post apportionment) of approximately $165.5 million derived mainly from exercises of options by employees which provided the Company tax deductions in excess of the actual compensation expenses (recognized in loss), under the Tax Cuts and Jobs Act of 2017 ("TCJA").   Under U.S. tax laws, subject to certain limitations, carryforward tax losses originating in tax years beginning after January 1, 2018, have no expiration date, but they are limited to 80% of the company's taxable income in any given tax year.   Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of each reporting date, management considers new evidence, both positive and negative, that could impact management's view with regard to the future realization of deferred tax assets for each jurisdiction.   In the determination of the appropriate valuation allowances, the Company considers the most recent projections of future business results and taxable income by jurisdiction as well as the reversal of existing taxable temporary differences. The Company also considers the prior earnings history. Actual results may vary in comparison to current projections.   During the year ended December 31, 2024, the Company determined that the positive evidence overcame any negative evidence, primarily due to cumulative income in recent years, including the effect of permanent adjustments, and the expectation of profitability in periods, and concluded that it was more likely than not that the United States net deferred tax assets were realizable. As a result, the Company released the valuation allowance of $60,129 related to the United States net deferred tax assets during the year ended December 31, 2024. As of December 31, 2024, the Company concluded that the deferred tax assets for certain jurisdictions would not be realized and therefore reserved valuation allowance in the amount of $4,248 with respect to these deferred tax assets.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">c.</td> <td style="width:auto;vertical-align:top"> Deferred income tax assets </td> </tr> </table>   Deferred income tax assets reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Company's net deferred tax assets (liabilities) at December 31, 2024 and 2023 were as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Deferred tax assets in respect of:future </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries carryforward losses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 54,349 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 58,075 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Other temporary differences </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,659 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,112 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Share-based compensation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,424 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 4,194 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Deferred tax asset in respect to other comprehensive loss </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 101 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 502 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total deferred tax assets before valuation allowance </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 60,533 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 65,883 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Valuation allowances </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (4,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total deferred tax assets </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 56,285 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,506

  </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">d.</td> <td style="width:auto;vertical-align:top"> Valuation allowance </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Balance at January 1 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 66,815 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> Utilization of carry forward tax losses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (5,399 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,438 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Reductions for the current year that record against defer tax asset </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (54,730 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> Balance at December 31 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 4,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">e.</td> <td style="width:auto;vertical-align:top"> Reconciliation of theoretical tax expense to actual tax expense </td> </tr> </table>   Following is a reconciliation of the theoretical provision for income tax, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax on income: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;padding-bottom:4px;vertical-align:bottom"> Income before taxes on income </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 201,466 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Theoretical tax expenses at the statutory rate of InMode Ltd. </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 32,998 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 49,971 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 46,337 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Increase (decrease) in taxes on income due to: </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-

align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Benefits to the Benefited Enterprise </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (16,682 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (31,296 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (27,282 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Different effective tax rates applicable to the Subsidiaries </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 210 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 165 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 138 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Change in valuation allowance </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (60,129 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,438 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (3,608 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Uncertain tax positions </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,957 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,096 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 303 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Non-deductible expenses and other permanent differences, mainly share based compensation expenses </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,840 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,850 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,842 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;width:64%;vertical-align:bottom"> Amendment to the Investments Law payment - see also note 13a(2)(b) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 12,017 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Settlements with the Israeli tax authority net of decrease of related uncertain tax provision </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 10,199 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,946 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">f.</td> <td style="width:auto;vertical-align:top"> Tax assessments </td> </tr> </table>   In February 2022, the Israeli Company settled the 2017-2020 income tax assessment with the Israeli tax authority, paying $1.3 million. also see Note 13a(2)(b).   In December 2022 the Company reached an agreement with the Israeli Tax Authority under which the Company paid on January 2023 NIS 50.2 million (approximately $14.3 million).   As of December 31, 2024, tax assessments of the Israeli Company through tax year 2021 are considered final. In addition, all tax assessments of one of the Company’s subsidiaries in Israel through tax year 2019 are considered final. Another Israeli subsidiary was established in 2022 and therefore does not have any tax year that

considered final.   As of December 31, 2024, all tax assessments on the Company's subsidiary in the United States, through tax year 2019, are considered final.   The other Subsidiaries' open tax years range from 2019-2024.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">g.</td> <td style="width:auto;vertical-align:top"> Income before income taxes is composed of the following: </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> InMode Ltd. and Israeli subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 139,241 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 211,137 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 196,354 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> Subsidiaries outside of Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,228 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 6,130 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 5,112 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 201,466 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">h.</td> <td style="width:auto;vertical-align:top"> Tax expenses (tax benefit): </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Current: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 15,664 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,633 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 38,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,709 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,864 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,614 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 17,373 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 19,497 </td> <td

colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 39,862 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Deferred: </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (42 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (149 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 84 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (55,137 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (55,179 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (149 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 84 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total expenses (income) taxes on income </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 39,946 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">i.</td> <td style="width:auto;vertical-align:top"> Uncertain tax positions: </td> </tr> </table>   ASC No. 740, Income Taxes, requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company.   The following table summarizes the activity of the Company's unrecognized tax benefits: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"> Balance at January 1 </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,399 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 303 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> Increase in uncertain tax positions for the current year </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,957 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,096 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom"> Balance at December 31 </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 3,356 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204,

238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,399 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   The Company does not expect uncertain tax positions to change significantly over the next 12 months.
0.075425000001200000059100000016570000032000000990000000.230.150.26520300000016550000-601290004248000 Deferred income tax assets reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The components of the Company's net deferred tax assets (liabilities) at December 31, 2024 and 2023 were as follows: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Deferred tax assets in respect of:future </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries carryforward losses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 54,349 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 58,075 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;vertical-align:bottom"> Other temporary differences </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,659 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,112 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Share-based compensation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 2,424 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 4,194 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Deferred tax asset in respect to other comprehensive loss </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 101 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 502 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total deferred tax assets before valuation allowance </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 60,533 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 65,883 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:2px;vertical-align:bottom"> Valuation allowance </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (4,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:top;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total deferred tax assets </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 56,285 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,506 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>
5434900058075000365900031120002424000419400010100050200060533000658830004248000643770005628500001506000   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Balance at January 1 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 66,815 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> Utilization of carry forward tax losses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (5,399 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-

align:bottom;text-align:right;width:9%;vertical-align:bottom"> (2,438 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Reductions for the current year that record against defer tax asset </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (54,730 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> Balance at December 31 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 4,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 64,377 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   6437700066815000-5399000-2438000-5473000004248006064377000 Following is a reconciliation of the theoretical provision for income tax, assuming all income is taxed at the statutory corporate tax rate applicable to Israeli corporations, and the actual tax on income: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;padding-bottom:4px;vertical-align:bottom"> Income before taxes on income </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 201,466 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Theoretical tax expenses at the statutory rate of InMode Ltd. </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 23 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> % </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 32,098 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 49,971 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 46,337 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Increase (decrease) in taxes on income due to: </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Benefits to the Benefited Enterprise </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (16,682 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (31,296 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (27,282 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Different effective tax rates applicable to the Subsidiaries </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 210 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 165 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 138 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Change in valuation allowance </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-

align:right;width:9%;vertical-align:bottom"> (60,129 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 2,438 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,608 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;vertical-align:bottom"> Uncertain tax positions </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,957 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,096 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 303 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;background-color:rgb(204, 238, 255);width:64%;vertical-align:bottom"> Non-deductible expenses and other permanent differences, mainly share based compensation expenses </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 3,840 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,850 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,842 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;width:64%;vertical-align:bottom"> Amendment to the Investments Law payment - see also note 13a(2)(b) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 12,017 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;padding-left:9pt;background-color:rgb(204, 238, 255);width:64%;padding-bottom:2px;vertical-align:bottom"> Settlements with the Israeli tax authority net of decrease of related uncertain tax provision </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> - </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 10,199 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td colspan="1" style="vertical-align:top;width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> (37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 39,946 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   14346900021726700020146600000.230.230.233299800049971000463377001668200031296000272820000-210000-165000-138000-60129000-2438000-360800019570001096000030300038400001850000184200000120170000010199000-378060001934800039946000130000050200000143000000 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">g.</td> <td style="width:auto;vertical-align:top"> Income before income taxes is composed of the following: </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> InMode Ltd. and Israeli subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 139,241 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 211,137 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 196,354 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> Subsidiaries outside of Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 4,228 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 6,130 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div

style="line-height:1.25">5,112 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 201,466 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   139241000211137000196354000422800061300005112000143469000217267000201466000 <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">h.</td> <td style="width:auto;vertical-align:top"> Tax expenses (tax benefit): </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;background-color:rgb(204, 238, 255);vertical-align:bottom"> Current: </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 15,664 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 17,633 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 38,248 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,709 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,864 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 1,614 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 17,373 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 19,497 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 39,862 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Deferred: </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (42 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> (149 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 84 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Subsidiaries </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> (55,137 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> - </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-

height:1.25"> (55,179 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (149 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 84 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Total expenses (income) taxes on income </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap">) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 39,946 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   1566400017633000382480001700000186400016140001737300019497000398620000-42000149000-84000-5513700000-55179000-14900084000-378060001934800039946000 The following table summarizes the activity of the Company’s unrecognized tax benefits: <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:76%;vertical-align:bottom"> Balance at January 1 </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,399 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 303 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom"> Increase in uncertain tax positions for the current year </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,957 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 1,096 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;background-color:rgb(204, 238, 255);width:76%;padding-bottom:4px;vertical-align:bottom"> Balance at December 31 </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 3,356 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 1,399 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   139900030300019570001096000335600013999000 NOTE 14 - Segments: The Company operates globally, and its business is unified for the purposes of valuation of its performance.   Management does not segregate it business for internal reporting. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its unified internal reporting which is consistent with the presentation in the Company’s financial statements.   In order to make operating decisions, the CODM examines the employee salaries including the commission expenses. In addition, the CODM examines the segment's marketing expenses (which includes advertising and trade shows)- the amounts that will be invested in advertising and trade shows.   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Revenues from customers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> Less: </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Employee salaries including commission expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 101,920 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 109,484 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> Marketing expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> <div

style="line-height:1.25">26,987 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 29,039 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Share based compensation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 16,569 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 23,600 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom">   Interest income </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 33,537 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 21,128 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Depreciation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 728 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 623 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">   *Other expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 138,682 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 133,163 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Income before income taxes </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">   Income taxes benefit (expenses) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> (19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">   Net income </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 181,275 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 197,919 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   * Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Revenues from customers </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom">   Less: </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Employee salaries including commission expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 101,920 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 109,484 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom">   Marketing expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 26,987 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 29,039 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Share based compensation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238,

255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 16,569 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 23,600 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom">   Interest income </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 33,537 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 21,128 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Depreciation </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 728 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 623 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">   *Other expenses </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 138,682 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 133,163 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom">   Income before income taxes </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 143,469 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 217,267 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;vertical-align:bottom">   Income taxes benefit (expenses) </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 37,806 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 19,348 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap">) </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom">   Net income </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 181,275 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 197,919 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   * Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.
394818000492048000101920000109484000269870002903900016569000236000003353700021128000728000623000138682000133163000143469000217267000-378060001934800018127500019791900 0
NOTE 15 - ENTITY-WIDE DISCLOSURE: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">a.</td> <td style="width:auto;vertical-align:top"> Revenue </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:71pt"> </td> <td style="width:21.25pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top"> Revenues by geographic area were as follows: </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> United States </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 244,774 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 307,018 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 298,612 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Europe </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 63,441 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 62,532 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 49,274 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Asia </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 42,974 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 47,744 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 36,492 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 43,629 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> <div style="line-

height:1.25"> 73,954 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 69,893 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> * </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> * </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Capital Equipment revenues </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 315,547 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 412,089 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,212 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;vertical-align:bottom"> Consumables and service revenues </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 79,271 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 79,959 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 60,059 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 454,271 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:71pt"> </td> <td style="width:21.25pt;vertical-align:top">3)</td> <td style="width:auto;vertical-align:top"> Revenues based on products' technology were as follows: </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> % </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Minimal Invasive </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 87 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 83 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 81 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Hands-Free </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 5 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 8 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 10 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Non-Invasive </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 8 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-

align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 100 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 100 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 100 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:71pt"> </td> <td style="width:21.25pt;vertical-align:top">4)</td> <td style="width:auto;vertical-align:top"> The changes in contract liabilities are as follows: </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"> <tr> <td rowspan="1" style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:bottom;font-weight:bold;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Balance as of January 1 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 14,689 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 17,757 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="vertical-align:bottom;width:74%"> Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%"> 16,975 </td> <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%"> 12,498 </td> <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Revenue recognized that was included in the contract liability balance at the beginning of the period </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> (11,573 </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">) </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> (15,566 </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">) </td> </tr> <tr> <td style="padding-bottom:4px;vertical-align:bottom;width:74%"> Balance as of December 31 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 20,091 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 14,689 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Contract liability presented in non-current liabilities (1) </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 3,336 </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 3,766 </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:4px;vertical-align:bottom;width:74%"> Contract liability presented in current liabilities </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 16,755 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 10,923 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">(1)</td> <td style="width:auto;vertical-align:top"> As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:49.65pt"> </td> <td style="width:18pt;vertical-align:top;font-weight:bold">b.</td> <td style="width:auto;vertical-align:top"> Long-Lived Assets </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,757 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,704 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> United States </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,421 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,789 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,876 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,507 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 11,054 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 12,080 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other long-term assets* </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,876 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 4,370 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-

align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 14,930 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,450 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   *Consists of non-current accounts receivable, net and other investments   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> United States </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 244,774 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 307,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 298,612 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Europe </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 63,441 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 62,532 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 49,274 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Asia </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 42,974 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 47,744 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 36,492 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 43,629 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 73,954 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 69,893 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> * </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> * </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 454,271 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> * </td> </tr> </table>   *Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented.
2447740003078180029861200063441000625320004927400042974000473440003649200043629000739540006989300039481800049204800045427100
 <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Capital Equipment revenues </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 315,547 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 412,089 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,212 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;vertical-align:bottom"> Consumables and service revenues </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 79,271 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 79,959 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom"> 60,059 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 394,818 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 492,048 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 454,271 </td> <td colspan="1"

style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 3155470004120890003942120007927100079959000600590003948180004920480004542710000 <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2022 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="10" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> % </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Minimal-Invasive </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 87 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 83 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 81 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;vertical-align:bottom"> Hands-Free </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 5 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 8 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 10 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Non-Invasive </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 8 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 9 </td> </tr> <tr> <td style="vertical-align:middle;width:64%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 100 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 100 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table> 0.870.830.810.050.080.100.080.090.09111   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;width:85%"> <tr> <td rowspan="1" style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align:bottom;font-weight:bold;border-bottom:#000000 solid 2px;vertical-align:bottom"> Year ended December 31 </td> <td colspan="1" rowspan="1" style="font-weight:bold;vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td rowspan="1" style="vertical-align:middle;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" rowspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <tr> <td style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Balance as of January 1 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 14,689 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="text-align:right;background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 17,757 </td> <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="vertical-align:bottom;width:74%"> Increases due to issuance of new contracts, excluding amounts recognized as revenue during the period </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;vertical-align:bottom;width:10%"> 16,975 </td> <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;vertical-align:bottom;width:10%"> 12,498 </td> <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Revenue recognized that was included in the contract liability balance at the beginning of the period </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> (11,573 </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">) </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> (15,566 </td> <td colspan="1" style="padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%">) </td> </tr> <tr> <td style="padding-bottom:4px;vertical-align:bottom;width:74%"> Balance as of December 31 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 20,091 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 14,689 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:74%"> Contract liability presented in non-current liabilities (1) </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 3,336 </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom;width:10%"> 3,766 </td> <td colspan="1" style="padding-bottom:4px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> <tr> <td style="padding-bottom:4px;vertical-align:bottom;width:74%"> Contract liability presented in current liabilities </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 16,755 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;width:1%"> </td> <td colspan="1" style="border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:1%"> </td> <td colspan="1" style="text-align:right;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom;width:10%"> 10,923 </td> <td colspan="1" style="padding-bottom:4px;vertical-align:bottom;white-space:nowrap;width:1%"> </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:70.9pt"> </td> <td style="width:18pt;vertical-align:top">(1)</td> <td style="width:auto;vertical-align:top"> As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029. </td> </tr> </table> 1468900017757000169750001249800011573000-1556600020091000146890003336000376600016755000109230000.81   <table border="0" cellpadding="0" cellspacing="0" style="width:85%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left"> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> December 31 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:top;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;padding-

bottom;2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2024 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom"> </td> <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px;vertical-align:bottom"> 2023 </td> <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;background-color:rgb(204, 238, 255);vertical-align:bottom"> Israel </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 5,757 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);vertical-align:bottom"> 6,704 </td> <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;vertical-align:bottom"> United States </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,421 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;vertical-align:bottom"> 1,789 </td> <td colspan="1" style="vertical-align:bottom;width:1%;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,876 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,587 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 11,054 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 12,080 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> Other long-term assets* </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255);vertical-align:bottom"> 3,876 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 4,370 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);vertical-align:bottom;white-space:nowrap"> </td> </tr> <tr> <td style="vertical-align:middle;width:76%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 14,930 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> </td> <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);vertical-align:bottom"> 16,450 </td> <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;vertical-align:bottom;white-space:nowrap"> </td> </tr> </table>   *Consists of non-current accounts receivable, net and other investments
57570006704000142100017890003876000358700011054000120800003876000437000014930000164500000 NOTE 16 - RELATED PARTIES: <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="vertical-align:top;font-weight:bold;width:49pt"> </td> <td style="vertical-align:top;font-weight:bold;width:18pt">a.</td> <td style="vertical-align:top;width:auto'> The Company receives and provides certain services from and to Home Skinovations Ltd., a related party as part of a service agreement between them. The services include an office sublease in Israel, use of certain computer hardware and switchboard infrastructure, certain software licenses, joint purchases of employee's welfare products and services from third parties and limited manpower services. The Chief Executive Officer of the Company is also a substantial shareholder and board member of Home Skinovations Ltd. and one of the Company's directors, serves on the board of directors of Home Skinovations Ltd. The Company recorded expenses related to services received and provided from and to Home Skinovations Ltd. of $0, $99 and $332 for the years ended December 31, 2024, 2023 and 2022, respectively. </td> </tr> </table>   In addition, the balance of the accounts payable as of December 31, 2024, 2023 was $0.   In February 2022 the Company have entered into an Asset Purchase Agreement with Home Skinovations, whereby Home Skinovations Ltd. sold and assigned to the Company all of Home Skinovations Ltd.'s right, title and interest in and to Home Skinovations Ltd.'s Spa segment assets (including molds, tooling, inventory and trademarks) and further granted the Company an exclusive license to certain IP rights of Home Skinovations Ltd., all the foregoing in consideration for an aggregate amount of $497.   The Company's subsidiary in Canada receives and provides certain services from and to a subsidiary of Home Skinovations Ltd. in Canada as part of a service agreement between them. The services include mobile phone services, an office sublease, use of certain computer hardware and switchboard infrastructure, certain software licenses, joint purchases of employee's welfare products and services from third parties and limited manpower services. In relation to these services received and provided, the Company recorded expenses (income) in the amount of $0, $(30) and $123 for the years ended December 31, 2024, 2023 and 2022, respectively. In addition, the balance of the accounts receivable as of December 31, 2024, 2023 was $0.   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:71pt"> </td> <td style="width:21.25pt;vertical-align:top">1)</td> <td style="width:auto;vertical-align:top'> The Company's subsidiaries in North America received marketing services from SpaMedica International SRL, which was amalgamated with an affiliate company into the Company's major shareholder BoomerangFX International SRL during 2021. Dr. Stephan Mulholland is a beneficiary owner of 100% of the Company's major shareholder BoomerangFX. The Company recorded expenses related to those services in the amount of $172 for the year ended December 31, 2021. Starting from 2022 calendar year, Dr. Stephen Mulholland provides the Company and its subsidiaries certain marketing services as an independent contractor. The Company recorded expenses related to those services in the amount of $636, $723 for the years ended December 31, 2023 and 2022, respectively.   During 2023 Dr. Stephen Mulholland ceased to be a related party. </td> </tr> </table>   <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"> <tr> <td style="width:71pt"> </td> <td style="width:21.25pt;vertical-align:top">2)</td> <td style="width:auto;vertical-align:top'> The Company receives certain investment portfolio management services from Himalaya Family Office Consulting Ltd., with respect to part of its investment portfolio. The Chief Executive Officer of the Company, is a minor shareholder and a board member of Himalaya Family Office Consulting Ltd. In relation to these services, the Company recorded expenses in the amount of $333, $193 and $100 for the years ended December 31, 2024, 2023 and 2022, respectively.   In addition, the balance of the accounts payable as of December 31, 2024 and 2023, was $27 and $86, respectively. </td> </tr> </table>   0990000332000004970000-3000012300000172000636000723000333000193000100000027000860000   NOTE 17 - SUBSEQUENT EVENTS   During February 2025, the Board of Directors of the Company has approved a new Share repurchase program of 10% of the Outstanding Shares.   In U.S. dollars per Ordinary Share Including, for 2022, payments amounting $12 million for Amendment to the Investments Law and settlements with the Israeli tax authority. See note 13a(2)(b). Revenues are attributed to geographic areas based on the location of customer. No single customer accounted for 10% or more of Company's total revenues, or Company's net accounts receivable, in any fiscal year presented. As of December 31, 2024, non-current deferred revenue is estimated to be recognized as following: 81% in year 2026 and the rest in year 2027-2029. Consists of non-current accounts receivable, net and other investments Other expenses included in net income includes cost of revenues (excluding salaries, depreciation and share based compensation); research and development expenses (excluding salaries, depreciation and share based compensation); sales expenses (excluding salaries, commission, depreciation and share based compensation); general and administrative expenses (excluding salaries and share based compensation); and finance expenses of exchange rate and bank commission.